<SEC-DOCUMENT>0001104659-21-066196.txt : 20210709
<SEC-HEADER>0001104659-21-066196.hdr.sgml : 20210709
<ACCEPTANCE-DATETIME>20210513211128
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-21-066196
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20210514
<PUBLIC-REL-DATE>20210709
DATE AS OF CHANGE:		20210514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MAXCYTE, INC.
		CENTRAL INDEX KEY:			0001287098
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				522210438
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-04865
		FILM NUMBER:		21921638

	BUSINESS ADDRESS:	
		STREET 1:		22 FIRSTFIELD ROAD
		STREET 2:		SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		301-517-5556

	MAIL ADDRESS:	
		STREET 1:		22 FIRSTFIELD ROAD
		STREET 2:		SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MAXCYTE INC
		DATE OF NAME CHANGE:	20040415
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
  <head>
    <title>tm2113965-1_s1 - none - 22.3594964s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:center; width:541.31pt; line-height:9pt;font-size:9pt;">
          <font style="letter-spacing:-0.045pt;">As confidentially submitted to the Securities and Exchange Commission on May&#160;14, 2021. </font>
          <br >
          <font style="letter-spacing:-0.045pt;">This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information </font>
          <br >
          <font style="letter-spacing:-0.045pt;">herein remains strictly confidential.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:-2.6pt; text-align:right; width:541.31pt; line-height:7.5pt;font-size:7.5pt;">
          <font style="letter-spacing:-0.038pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>&#8203;</div>
        <div style="margin-top:0.723pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 0.723333333333329pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.2pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.2pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.2pt; text-align:center; width:541.31pt; line-height:14pt;font-size:14pt;">
          <font style="letter-spacing:-0.07pt;">UNITED STATES </font>
          <br >
          <font style="letter-spacing:-0.07pt;">SECURITIES AND EXCHANGE COMMISSION </font>
          <br >
          <font style="font-size:8.5pt;letter-spacing:-0.042pt;">WASHINGTON, D.C. 20549</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:3.233pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 38.916%; margin-right: 38.916%; margin-top: 3.23333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5.2pt; text-align:center; width:541.31pt; line-height:14pt;font-size:14pt;">
          <font style="letter-spacing:-0.07pt;">FORM S-1 </font>
        </div>
        <div style="margin-top:0.19pt; text-align:center; width:541.31pt; line-height:11pt;font-size:8.5pt;">
          <font style="letter-spacing:-0.042pt;">REGISTRATION STATEMENT </font>
          <br >
          <font style="font-style:italic;">UNDER</font><font style="letter-spacing:-0.042pt;"> </font>
          <br >
          <font style="font-style:italic;">THE SECURITIES ACT OF 1933</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;font-size:14pt;">&#8203;<font style="letter-spacing:0.28pt;"> </font></font>
        </div>
        <div style="margin-top:3.223pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 38.916%; margin-right: 38.916%; margin-top: 3.22333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5.2pt; text-align:center; width:541.31pt; line-height:14pt;font-size:14pt;">
          <font style="letter-spacing:-0.07pt;">MaxCyte, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:0.4pt; text-align:center; width:541.31pt; line-height:7.5pt;font-size:7.5pt;">
          <font style="letter-spacing:-0.038pt;">(Exact name of Registrant as specified in its charter)</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.15pt;"> </font>
        </div>
        <div style="margin-top:3.533pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 38.916%; margin-right: 38.916%; margin-top: 3.53333333333336pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541.31pt;height:25.9pt;margin-top:1.89999999999998pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
          <tr style="line-height:8.38pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.042pt;">Delaware</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.042pt;">8731 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.042pt;">52-2210438 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.68pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center; line-height:7.5pt;font-size:7.5pt;">
                <font style="letter-spacing:-0.019pt;">(State or other jurisdiction of </font>
                <br >
                <font style="letter-spacing:-0.019pt;">incorporation or organization) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center; line-height:8pt;">
                <font style="letter-spacing:-0.02pt;">(Primary Standard Industrial</font>
                <br >
                <font style="letter-spacing:-0.02pt;">Classification Code Number) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center; line-height:9pt;">
                <font style="letter-spacing:-0.02pt;">(I.R.S. Employer</font>
                <br >
                <font style="letter-spacing:-0.02pt;">Identification Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9.8pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8.5pt;">
          <font style="letter-spacing:-0.042pt;">22 Firstfield Road, Suite 110 </font>
          <br >
          <font style="letter-spacing:-0.042pt;">Gaithersburg, Maryland 20878 </font>
          <br >
          <font style="letter-spacing:-0.042pt;">(301) 944-1700 </font>
        </div>
        <div style="margin-top:0.2pt; text-align:center; width:541.31pt; line-height:8pt;font-weight:normal;font-size:7.5pt;">
          <font style="letter-spacing:-0.019pt;">(Address, including zip code, and telephone number, including </font>
          <br >
          <font style="letter-spacing:-0.019pt;">area code, of Registrant&#8217;s principal executive offices)</font><font style="font-family:Times New Roman, Times, serif ;font-size:8.5pt;">&#8203;<font style="letter-spacing:0.17pt;"> </font></font>
        </div>
        <div style="margin-top:3.733pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 38.916%; margin-right: 38.916%; margin-top: 3.73333333333335pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.2pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8.5pt;">
          <font style="letter-spacing:-0.042pt;">Doug Doerfler </font>
          <br >
          <font style="letter-spacing:-0.042pt;">President and Chief Executive Officer </font>
          <br >
          <font style="letter-spacing:-0.042pt;">MaxCyte, Inc. </font>
          <br >
          <font style="letter-spacing:-0.042pt;">22 Firstfield Road, Suite 110 </font>
          <br >
          <font style="letter-spacing:-0.042pt;">Gaithersburg, Maryland 20878 </font>
          <br >
          <font style="letter-spacing:-0.042pt;">(301) 944-1700</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.17pt;"> </font>
        </div>
        <div style="margin-top:-0.6pt; text-align:center; width:541.31pt; line-height:7.5pt;font-weight:normal;font-size:7.5pt;">
          <font style="letter-spacing:-0.019pt;">(Name, address, including zip code, and telephone number, including </font>
          <br >
          <font style="letter-spacing:-0.019pt;">area code, of agent for service)</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.15pt;"> </font>
        </div>
        <div style="margin-top:3.533pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 38.916%; margin-right: 38.916%; margin-top: 3.5333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.2pt; text-align:center; width:541.31pt; line-height:8pt;font-style:italic;font-size:8pt;">Copies to:<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font></div>
        <table style="width:541.31pt;margin-top:0.399999999999977pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
          <tr style="line-height:8.38pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center; line-height:8.39pt;">
                <font style="letter-spacing:-0.042pt;">Brian&#160;F. Leaf </font>
                <br >
                <font style="letter-spacing:-0.042pt;">Christian E. Plaza </font>
                <br >
                <font style="letter-spacing:-0.042pt;">Katie&#160;A. Kazem </font>
                <br >
                <font style="letter-spacing:-0.042pt;">Cooley LLP </font>
                <br >
                <font style="letter-spacing:-0.042pt;">One Freedom Square</font>
                <br >
                <font style="letter-spacing:-0.042pt;">Reston Town Center</font> <br ><font style="letter-spacing:-0.042pt;">11951 Freedom Drive </font><br ><font style="letter-spacing:-0.042pt;">Reston, Virginia 20190 </font><br ><font style="letter-spacing:-0.042pt;">(703) 456-8000</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center; line-height:8.39pt;">
                <font style="letter-spacing:-0.042pt;">Maher Masoud</font>
                <br >
                <font style="letter-spacing:-0.042pt;">EVP and General Counsel</font>
                <br >
                <font style="letter-spacing:-0.042pt;">MaxCyte, Inc.</font>
                <br >
                <font style="letter-spacing:-0.042pt;">22 Firstfield Road, Suite 110</font>
                <br >
                <font style="letter-spacing:-0.042pt;">Gaithersburg, Maryland 20878</font>
                <br >
                <font style="letter-spacing:-0.042pt;">(301) 944-1700 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center; line-height:8.39pt;">
                <font style="letter-spacing:-0.042pt;">Michael D. Maline</font>
                <br >
                <font style="letter-spacing:-0.042pt;">Patrick O&#8217;Malley</font>
                <br >
                <font style="letter-spacing:-0.042pt;">Kathryn Fortin</font>
                <br >
                <font style="letter-spacing:-0.042pt;">DLA Piper LLP (US)</font>
                <br >
                <font style="letter-spacing:-0.042pt;">1251 Avenue of the Americas</font>
                <br >
                <font style="letter-spacing:-0.042pt;">New York, New York 10020</font>
                <br >
                <font style="letter-spacing:-0.042pt;">(212) 335-4500</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:-0.21pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 38.916%; margin-right: 38.916%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:5.2pt; width:541.31pt; line-height:8pt;font-size:8pt;">
          <font style="font-weight:normal;letter-spacing:-0.02pt;">Approximate date of commencement of proposed sale to the public: </font><font style="letter-spacing:-0.04pt;">As soon as practicable after this registration statement is declared effective.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:8pt;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, check the following box. &#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:8pt;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:8pt;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:8pt;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:8pt;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <table style="width:501.31pt;height:26.13pt;margin-left:20pt;margin-top:2.39999999999998pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
          <tr style="line-height:8.38pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:199.42pt;">
              <div style=" float:left; line-height:8.4pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:-0.021pt;">Large accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8.4pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:-0.021pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.24pt;white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:199.42pt;">
              <div style=" float:left; line-height:8.4pt; text-align:left; width:144pt;white-space:nowrap;">
                <font style="letter-spacing:-0.021pt;">Accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8.4pt; text-align:left; margin-left:144pt;">
                <font style="letter-spacing:-0.021pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.24pt;white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.38pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.003pt 0pt 0.5pt 0pt; width:199.42pt;">
              <div style=" float:left; line-height:8.4pt; text-align:left; width:120pt;white-space:nowrap;">
                <font style="letter-spacing:-0.021pt;">Non-accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:8.4pt; text-align:left; margin-left:120pt;">
                <font style="letter-spacing:-0.021pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.24pt;white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.003pt 0pt 0.5pt 0pt; width:199.42pt;">
              <div style=" float:left; line-height:8.4pt; text-align:left; width:144pt;white-space:nowrap;">
                <font style="letter-spacing:-0.021pt;">Smaller reporting company</font>
                <br >
              </div>
              <div style=" line-height:8.4pt; text-align:left; margin-left:144pt;">
                <font style="letter-spacing:-0.021pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.24pt;white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.38pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:199.42pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.24pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.003pt 0pt 0.987pt 0pt; width:199.42pt;white-space:normal;">
              <div style=" float:left; line-height:8.4pt; text-align:left; width:144pt;white-space:nowrap;">
                <font style="letter-spacing:-0.021pt;">Emerging growth company</font>
                <br >
              </div>
              <div style=" line-height:8.4pt; text-align:left; margin-left:144pt;">
                <font style="letter-spacing:-0.021pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.24pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:4.8pt; width:541.31pt; line-height:8pt;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:3.7pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 38.916%; margin-right: 38.916%; margin-top: 3.69999999999993pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.2pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:8.5pt;">
          <font style="letter-spacing:-0.042pt;">CALCULATION OF REGISTRATION FEE</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.17pt;"> </font>
        </div>
        <table style="width:541.31pt;height:46.36pt;margin-top:-5.60000000000002pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;">
            <td style="border-bottom:3pt double #000000;padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="12">&#8203;</td>
            <td style="padding:0pt;border-bottom:3pt double #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:392.77pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Title of each Class of Securities to be Registered </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:73.05pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Proposed </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Maximum</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Offering Price(1)(2) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount of</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Registration Fee </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.4pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8.4pt;">
            <td style="border-bottom:1px solid #000000;padding:0.74pt 0pt 0.667pt 0pt; width:392.77pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.021pt;">Common stock, par value $0.01 per share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.74pt 0pt 0.667pt 0pt; width:73.05pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.021pt;">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8199;&#8199;&#8199; </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.04pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0.74pt 0pt 0.667pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.74pt 0pt 0.667pt 0pt;border-bottom:1px solid #000000; min-width:39pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:8.4pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:8.4pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">Estimated solely for the purpose of calculating the registration fee in accordance with Rule&#160;457(o) of the Securities Act of 1933, as amended.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:8.4pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:8.4pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">Includes the aggregate offering price of additional shares that the underwriters have the option to purchase, if any.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:0.8pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 38.916%; margin-right: 38.916%; margin-top: 0.800000000000068pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:4.3pt; width:541.31pt; line-height:8pt;font-size:8pt;">
          <font style="letter-spacing:-0.04pt;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</font>
        </div>
        <div style="margin-top:1.8pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.80000000000007pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.3pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.29999999999995pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow-x:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.83pt;left:48.66pt;height:30.02pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#EE536B;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">
          <font style="letter-spacing:-0.08pt;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.08pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:87.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;color:#FC0014;">
          <font style="letter-spacing:-0.025pt;">Subject to Completion, Dated&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021</font><font style="color:#000000;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-size:14pt;">
          <font style="letter-spacing:-0.035pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;Shares</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lg_maxcyte-4clr.jpg" alt="[MISSING IMAGE: lg_maxcyte-4clr.jpg]" height="40" width="261" >
        </div>
        <div style="margin-top:13pt; text-align:center; width:456pt; line-height:16pt;font-size:14pt;">
          <font style="letter-spacing:-0.035pt;">COMMON STOCK</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:19.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">This is the U.S. initial public offering of shares of common stock of MaxCyte, Inc. We are offering &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Prior to this offering, there has been no public market for our common stock in the United States. It is currently estimated that the public offering price for our common stock will be between $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. We intend to apply to list our common stock on the Nasdaq Global Market under the symbol &#8220;MXCT.&#8221; Our common stock trades on AIM, a market operated by the London Stock Exchange, under the symbols &#8220;MXCT&#8221; and &#8220;MXCN.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:16.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws and, as such, we have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:13pt;font-weight:bold;font-size:11pt;">
          <font style="letter-spacing:-0.055pt;">Investing in our common stock involves risks. See &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">12</a> to read about factors you should consider before buying our common stock.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.22pt;"> </font>
        </div>
        <div style="margin-top:16.833pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:16.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:456pt;height:53.5pt;margin-top:9.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:371.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:371.61pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.70999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.61pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Underwriting discounts and commissions</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.70999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.61pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Proceeds, before expenses, to MaxCyte, Inc. </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.70999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">See the section titled &#8220;Underwriting&#8221; for additional information regarding compensation payable to the underwriters.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have granted the underwriters an option for a period of 30&#160;days from the date of this prospectus to purchase up to an additional &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of common stock at the public offering price, less the underwriting discounts and commissions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">The underwriters expect to deliver the shares of common stock to purchasers on or about&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Joint Book-Running Managers<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:18pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.08pt;">Cowen </font><font style="margin-left:107.75pt;letter-spacing:-0.08pt;">&#8199;&#8199;&#8199;&#8199;&#8199;Stifel </font><font style="float:right;letter-spacing:-0.08pt;">William Blair</font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Co-Managers<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.07pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;BTIG </font><font style="float:right;"><font style="letter-spacing:-0.07pt;">Stephens Inc.&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
          </font>
        </div>
        <div style="margin-top:17.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Prospectus dated&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:365.5pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:435.94pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:-0.025pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tPRSU">1</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:-0.025pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tRIFA">12</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:-0.025pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tSNRF">52</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMIAO"><font style="letter-spacing:-0.025pt;">MARKET, INDUSTRY AND OTHER DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tMIAO">54</a></font> <a href="#tMIAO"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:-0.025pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tUOP">55</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIPO"><font style="letter-spacing:-0.025pt;">DIVIDEND POLICY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tDIPO">56</a></font> <a href="#tDIPO"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAP"><font style="letter-spacing:-0.025pt;">CAPITALIZATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCAP">57</a></font> <a href="#tCAP"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:-0.025pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tDIL">59</a></font> <a href="#tDIL"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSCFD"><font style="letter-spacing:-0.025pt;">SELECTED CONSOLIDATED FINANCIAL DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tSCFD">61</a></font> <a href="#tSCFD"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:435.94pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tMDAA"><font style="letter-spacing:-0.025pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tMDAA">62</a></font> <a href="#tMDAA"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBUS"><font style="letter-spacing:-0.025pt;">BUSINESS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tBUS">80</a></font> <a href="#tBUS"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAN"><font style="letter-spacing:-0.025pt;">MANAGEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tMAN">109</a></font> <a href="#tMAN"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXCO"><font style="letter-spacing:-0.025pt;">EXECUTIVE COMPENSATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tEXCO">116</a></font> <a href="#tEXCO"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCRAR"><font style="letter-spacing:-0.025pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCRAR">129</a></font> <a href="#tCRAR"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRST"><font style="letter-spacing:-0.025pt;">PRINCIPAL STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tPRST">132</a></font> <a href="#tPRST"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:-0.025pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tDOCS">134</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSEFF"><font style="letter-spacing:-0.025pt;">SHARES ELIGIBLE FOR FUTURE SALE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tSEFF">137</a></font> <a href="#tSEFF"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMUFI"><font style="letter-spacing:-0.025pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tMUFI">139</a></font> <a href="#tMUFI"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUND"><font style="letter-spacing:-0.025pt;">UNDERWRITING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tUND">143</a></font> <a href="#tUND"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:-0.025pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tLEMA">150</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:-0.025pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tEXP">150</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:-0.025pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tWYCF">150</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fIFS"><font style="letter-spacing:-0.025pt;">INDEX TO FINANCIAL STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#fIFS">F-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:19pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">None of us or any of the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. None of us nor any of the underwriters take responsibility for, or can provide any assurance as to the reliability of, any other information that others may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only under circumstances and in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For investors outside the United States: None of us or any of the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering and the possession and distribution of this prospectus outside of the United States.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Any discrepancies included in this prospectus between totals and the sums of the percentages and dollar amounts presented are due to rounding.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="text-transform:uppercase;letter-spacing:-0.05pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;font-style:italic;">This summary highlights selected information included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections titled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Business,&#8221; and our financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. Unless the context otherwise requires, all references in this prospectus to &#8220;MaxCyte,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to MaxCyte, Inc. and its consolidated subsidiary.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.05pt;">Our Mission</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">We believe in the vast potential of next-generation cell therapies to have a meaningful impact on the millions of patients worldwide who, despite medical advancement, live with unmet medical needs across a variety of diseases. Our aim is to be the premier cell engineering platform technology to support the development of advanced therapeutics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.05pt;">Overview</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty&#160;years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">With increased knowledge of cell complexity and systems biology in the scientific community, researchers have sought to leverage or repurpose cell functions or machinery for research or therapeutic purposes. The ability to engineer living cells by introducing foreign molecules, such as gene editing systems and transgenes, has led to a revolution in biological research and resulted in numerous biological discoveries. Living human cells can also be engineered </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;">, or outside the body, where they are repaired or reprogrammed to fight disease. In this case, the engineered cell itself is the drug.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">Cell therapy has emerged as one of the fastest growing and most promising treatment modalities to address a host of human diseases. Over the past few&#160;years, the success of multiple U.S. Food and Drug Administration, or FDA, approved cell therapies providing long-lasting amelioration of symptoms or even the cure of disease has catalyzed tremendous investment&#8201;&#8212;&#8201;leading to exponential growth in cell-based therapies being evaluated for therapeutic applications. According to the Alliance for Regenerative Medicine, the combination of gene, cell, and tissue-based therapeutic developers raised an aggregate of $19.9&#160;billion in 2020, up from $13.3&#160;billion in 2018. According to the American Society of Gene and Cell Therapy, or ASGCT, there are now more than 3,400 cell therapies in development globally, with genetically-modified cell therapies, such as chimeric antigen receptor T cells, or CAR-Ts, accounting for 53% of those candidates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx, STx and GTx; related single-use processing assemblies, or disposables; and software protocols. We have garnered meaningful expertise in cell engineering via our internal research and development efforts as well as our customer-focused commercial approach, which includes a growing application scientist team. The platform is also supported by a robust intellectual property portfolio with 50 granted U.S. and foreign patents and 76 pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the U.S. National Institutes of Health, or </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. As of December&#160;31, 2020, we have placed more than 400 of our electroporation instruments worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We believe our ExPERT platform offers a compelling value proposition to our academic and biopharmaceutical customers due to: (i)&#160;the ability to use our technology to deliver almost any molecule into almost any cell type, including hard-to-transfect human primary cells, while maintaining high cell viability and function; (ii)&#160;the capacity to introduce larger and more diverse payloads compared to other intracellular delivery technologies, such as viral vectors; and (iii)&#160;the flexibility to scale up from research to current good manufacturing practices, or cGMP, manufacturing on a single platform&#8201;&#8212;&#8201;enabling the engineering of cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Our ExPERT technology platform is being used in the clinic to support the development of next-generation cell therapy approaches to treat human disease. Following the successful clinical development leading to FDA approvals of CAR-T cell therapies in blood-based cancer, developers have focused on improving efficacy, lowering the cost of manufacturing and expanding engineered cell therapies into new indications, such as solid tumors. To address these goals, the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy industry has trended towards developing more complex therapies that require sophisticated engineering and gene manipulation as well as the use of different starting cell types.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We believe we are well positioned in this market given the manufacturing supply constraints and payload size limitations of other delivery methods, such as viral vectors. Given our value proposition in non-viral delivery, we have established strategic relationships in the form of Strategic Platform Licenses, or SPLs, with a growing number of leading cell therapy developers as they work to bring next-generation cell therapies into and through the clinic and advance those candidates to potential commercialization. These SPLs provide us with the ability to secure downstream program-related pre-commercial milestones and, in most cases, commercial sales-based payments. In addition, from our SPL customers, we receive both annual research and clinical license fees as well as payments from sales of our proprietary disposables as recurring revenue streams.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We have entered into 12 SPLs with commercial cell therapy developers, which include: CRISPR/</font>&#8203;<font style="letter-spacing:-0.025pt;">Casebia Therapeutics; CRISPR Therapeutics; Kite Pharma (now Gilead); Precision Biosciences; Editas Medicine; VOR Biopharma; KSQ; Allogene Therapeutics; Caribou Biosciences; Apeiron Biologics; and Myeloid Therapeutics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Under these SPLs and other license agreements with our customers, in exchange for an annual license fee per instrument, we provide our customers with non-exclusive access to our:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">cGMP-compatible platform, which enables early-optimization and scale-up from preclinical research into clinical development using our intellectual property portfolio;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">FDA Master File and equivalent foreign Technical Files, which may accelerate and streamline development and reduce regulatory risk in the creation and development of our partners&#8217; therapeutic drug candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">experienced commercial team of sales personnel and application scientists who work directly with our customers to solve cell engineering problems; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">continuous know-how and cell engineering process improvements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Including our SPLs, our clinical agreements cover:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">research and clinical licenses with academic and industry customers covering over an estimated 140 programs; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">clinical licenses with academic and industry customers covering over an estimated 100 programs being developed or intended for use in humans, over 75 of which have the potential to generate program economics for us under SPL agreements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Of the over 75 clinical program licenses associated with our existing SPLs, more than 15% are in the clinic, meaning they have at least an FDA-cleared investigational new drug application, or IND. Our 12 SPLs have the potential to generate over $950&#160;million in pre-commercial milestone payments if all of the licensed programs were to achieve regulatory approvals. In addition, under the SPLs, we typically have the potential to receive significant, sales-based commercial payments for approved products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Our current strategic partners have demonstrated success progressing next-generation cell therapies through the clinic, which has provided growing validation supporting our ability to facilitate complex cell engineering in a clinical setting. Further, our platform is supported by an FDA Master File. A Master File is a submission to the FDA with confidential detailed information about our products, methods, processes and data, which can be referenced by our customers to support their own regulatory filings, which we believe has the potential to reduce certain risks and challenges in connection with our customers&#8217; regulatory submissions and development timelines. Outside of the United States, similar Technical Files are in place or being pursued to support our customers&#8217; regulatory processes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We aim to build a large, diversified portfolio of SPLs that enable us to participate in the economics of the near-term and long-term success of our partners&#8217; drug candidates. We estimate that the total addressable market opportunity for our ExPERT platform, based on the potential for current SPLs, was approximately $9&#160;billion in 2020. We expect this market to grow to over $24&#160;billion by 2026 driven by growth in the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy pipeline and a shift to use of non-viral delivery technologies as described in more detail under &#8220;Business&#8201;&#8212;&#8201;Our Market Opportunity.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.05pt;">Our Competitive Strengths</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We believe our industry leadership position and continued growth will be driven by the following competitive strengths:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Our proprietary technology platform unlocks the significant potential of advanced therapeutics</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We have built our ExPERT platform to advance the growing demands for non-viral delivery and next-generation cell and gene engineering approaches. Our platform technology enables delivery of almost any molecule into almost any cell type. We believe our platform leads the industry in performance (measured by consistency, efficiency, viability, flexibility and scale). Our platform is further supported by a robust intellectual property portfolio with 50 issued patents and 76 pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Comprehensive, high-performance transfection platform</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We believe our ExPERT platform offers a unique value proposition given the flexibility to scale up from research to cGMP manufacturing on a single platform&#8201;&#8212;&#8201;enabling the engineering of cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less. Our long-term internal engineering expertise is supplemented by our customer focused approach&#8201;&#8212;&#8201;with a growing application scientist team working with our customers across increasingly diverse applications.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Positioned as a leader in the large and growing next</font><font style="font-style:italic;font-weight:bold;">-generation cell therapy market with the ability to capitalize on rising demand for non-viral approaches.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We believe we are well positioned to capture increased market share within the large and growing next- generation cell therapy market. Since the FDA approved the first engineered CAR-T cell therapies to treat cancer in 2017, the number of cell therapy candidates being evaluated pre-clinically and clinically has grown exponentially. We expect growth to continue given the remaining high unmet medical need in cancer and other chronic conditions and predict increased investments in cell therapy product development across a variety of human diseases. We expect to grow our market share given the high performance of our platform and regulatory support through our FDA Master File as well as the ongoing shift to non-viral delivery as the industry has trended towards developing advanced cell-based therapies with complex engineering strategies to improve efficacy, reduce time to patient treatment and expand into new indications.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Innovative partnership business model focused on value creation and shared success</font><font style="letter-spacing:-0.025pt;">. Our SPLs allow us to participate in the value creation of our customers&#8217; programs via pre-commercial milestones and in nearly all cases commercial sales-based payments. We intend </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:74pt; margin-left:12pt;width:456pt;">
          <div style="margin-left:40pt; width:416pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">to continue to build a portfolio of strategic partnerships with cell therapy developers, which provide us with a growing, diversified source of potential downstream revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">In addition to the high performance and flexibility of the ExPERT platform, we believe our partnership model further reduces clinical risk and development timelines for our cell therapy partners. By entering into an SPL with us, for example, our partners gain access to our FDA Master File to support their IND-enabling studies and potentially shorten clinical development. Our FDA Master File was originally established in 2002 and has been continuously updated as platform improvements are implemented to support different applications and cell types. The FDA Master File and equivalent Technical Files in other countries can be referenced by our partners to support their own regulatory submissions with the goal of accelerating regulatory submissions processes for our partners. To date, our FDA Master File and Technical Files have been referenced by our customers in over 30 clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">First-mover advantage has yielded broad-based adoption, with commercial model supported by top-tier customers.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our business model is supported by more than 20&#160;years of investment and experience and has enabled us to cultivate long-standing and collaborative relationships with our significant and growing customer base. From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base includes large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue. We now have 12 SPLs with commercial cell therapy developers, which together provide licenses for over 75 programs, of which currently more than 15% have advanced into clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Recurring revenue model </font><font style="font-style:italic;font-weight:bold;">provides high visibility, with </font><font style="font-style:italic;font-weight:bold;">drivers of potential long-term upside.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our business model enables us to generate substantial revenue from five sources: sales of instruments and disposables to new customers; additional sales of instruments and disposables to our existing installed base; annual instrument license fees from cell therapy customers; pre-commercial milestones under SPLs; and future potential commercial sales-based payments under SPLs. We generate high recurring revenue from our ExPERT instrumentation licenses and disposable sales, which provides visibility into future near-term revenue. Over the last three&#160;years, annual renewals of instrument licenses were greater than 80% on average&#8201;&#8212;&#8201;and for our SPLs were near 100%. In addition to recurring revenue, we have the potential to receive meaningful pre-commercial and commercial payments under SPLs if our customers are successful in advancing programs through the clinic and into the commercial stage. In aggregate, we have the potential to receive over $950&#160;million in pre-commercial milestone payments under our current SPLs, if all of the covered programs were to receive regulatory approvals.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Founder-led leadership team and workforce with deep domain knowledge.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our management team combines strong and broad subject matter expertise with a demonstrated history of commercial and operational execution. Moreover, our workforce has deep domain knowledge across a range of scientific, engineering, regulatory and business disciplines. We have supplemented our diverse technical experience by assembling a deep operational team with expertise in manufacturing, legal, sales, marketing, customer service and finance. We believe the team we have assembled with talent from multiple disciplines and a science- and customer-focused culture represents a significant competitive advantage for us. As of March 31, 2021, of our 65 full-time employees, 45 have advanced degrees, including 19 with Ph.D. degrees. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.05pt;">Our Growth Strategies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The key elements of our growth strategy include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Establish ExPERT as the standard of non-viral delivery technology in the rapidly growing cell therapy market</font><font style="font-weight:bold;letter-spacing:-0.05pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We are committed to continued investment in technology and scientific innovation to maintain our market leadership position. We believe that the adaptability of, and continuous improvement in, our single-use disposable product portfolio via recent product launches exemplifies our partnership with our customers to meet varying processing volume requirements, for example. We plan to further invest in our current platform and potentially introduce new instruments and processing assemblies, or PAs, that allow us to meet the evolving needs of customers and move into new applications to better serve high-growth segments of the cell therapy market.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Drive customer adoption and accelerate revenue growth through execution and expansion of our strategic marketing initiatives.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We aim to accelerate our revenue growth by investing in our sales and application scientist teams to fuel growth in our underlying ExPERT platform and foster and develop new customer and SPL opportunities. We also see opportunity for geographic expansion, particularly in Asia, and the potential to further penetrate non-commercial customer accounts, including translational academic centers globally, which we believe will represent &#8220;hotspots&#8221; driving innovation that favor non-viral extracellular delivery technology. Finally, we expect to continue to cultivate academic collaborations and grow our application scientist team to gain exposure to and experience with up and coming cell and gene engineering approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Increase </font><font style="font-style:italic;font-weight:bold;">our number of </font><font style="font-style:italic;font-weight:bold;">SPLs.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We plan to continue to pursue SPLs with target customers, including leading biopharmaceutical companies focused on cell therapies. We believe that there are a substantial number of potential SPL opportunities in the market and have seen a commensurate increase in our SPL discussions over the past several&#160;years. Given growth in the cell therapy pipeline and increased investment in the space, we estimate that the number of potential SPLs for us will increase from approximately 50 today, based on our estimate of the companies that are currently developing engineered cell therapies, to almost 140 by 2026, based on our estimates of growth in the cell therapy pipeline, growth in the number of therapeutic delivery entrants into the market and ongoing shift to non-viral delivery. We plan to aggressively pursue these opportunities and establish new SPLs by increasing business development activities and demonstrating our technological advantages over alternative methods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Commercialize our VLX Large-Scale Transfection System under the ExPERT brand to expand our capabilities into additional attractive market verticals, including large-scale bioprocessing and cell therapy applications.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We currently market the VLX Large-Scale Transfection System, which supports the ability to transfect up to approximately 200&#160;billion cells, or ten times the number of cells and/or volume of the GTx/STx, in less than 30 minutes. We intend to commercialize the VLX under the ExPERT brand, which includes improving ease-of-use, upgrading to state-of-the-art design and developing associated disposables and software protocols for various large-scale applications. We believe this instrument could allow our platform to enter into large-scale bioprocessing applications including viral vector production in suspension cell cultures and rapid production of proteins, including monoclonal antibodies&#8201;&#8212;&#8201;as well as facilitate further scale up in allogeneic (or donor-derived) cell therapy approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Enhance manufacturing and research and development capabilities by investing in </font><font style="font-style:italic;font-weight:bold;">capacity as well as automation and process development.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We intend to expand our manufacturing infrastructure. We plan to invest in our capacity to support increased demand for our instruments and disposables as our customers move further through the clinic and toward commercialization. We also plan to invest in the automation and final assembly of our PAs for greater control and for enhanced flexibility as our partners expand the use of our technology. Additionally, we plan to expand our research and development capabilities by investing in process development via expanding laboratory space, increasing capital investment in laboratory equipment and supplies and growing our scientific team&#8201;&#8212;&#8201;to continue to align our capabilities with the requirements of our customers and potentially support new product development.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:0.970000000000027pt; margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Opportunistically pursue strategic investments, partnerships and acquisitions.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our revenue growth to date has been organically driven by the addition of customers to our growing installed base of ExPERT users and expansion of our product offerings to those customers. We may consider opportunistic investments, partnerships and acquisitions that we believe will complement our product platform, allowing us to enter new markets and applications to enhance our growth profile. We also intend to establish new industry partnerships, enabling us to remain at the forefront of cell engineering trends and continue to collaborate with customers to accelerate the development and commercialization of new medicines.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.05pt;">Risk Factors Summary</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Our business is subject to numerous risks that you should be aware of before making an investment decision. These risks are more fully described in the section titled &#8220;Risk Factors.&#8221; These risks include, among others:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We have incurred significant losses since our inception, we expect to incur losses for the foreseeable future and we may never achieve or maintain profitability.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We are highly dependent on a limited number of product offerings that require a substantial sales cycle and as a result we are prone to quarterly fluctuations in revenue. If we fail to maintain significant market acceptance in existing markets or fail to successfully increase our penetration in new and expanding markets, we will not generate expected revenue and our prospects may be harmed.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We operate in a highly competitive market characterized by rapid technological change, evolving industry standards, changes in customer needs, emerging competition, new product introductions and strong price competition. Our success depends, in part, on our ability to maintain a competitive position in the development of technologies, enhancements and products for use by our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">Our business currently depends significantly on research and development spending by biopharmaceutical companies and academic institutions, a reduction in which could limit demand for our products and adversely affect our business and operating results.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We must develop new products, as well as enhancements to existing products, and adapt to rapid and significant technological change to remain competitive.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">If we cannot maintain and expand current partnerships and enter into new partnerships, including internationally, that generate marketed licensed products, our business could be adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">The failure of our partners to meet their contractual obligations to us could adversely affect our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, or may discontinue some or all of their programs, which could have an adverse impact on our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">In recent periods, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We depend on continued supply of components and raw materials for our ExPERT instruments and PAs from third-party suppliers, and if shortages of these components or raw materials arise, we may not be able to secure enough components to build new products to meet customer demand or we may be forced to pay higher prices for these components. As such, we must also accurately forecast customer demand for our products and manage our inventory.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">Our FDA Master File, and equivalent Technical Files in foreign jurisdictions, are an important part of our strategic offering which allows our partners to expedite their cellular therapies into and through the clinic. Delays in filing or obtaining, or our inability to obtain or retain, acceptance of such filings in individual countries could negatively impact the progress of our partners if they intend to run clinical trials in such countries, and as a result, could negatively affect our reputation and revenues or require disclosure of confidential information to our partners.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:84pt; margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We may need additional funding beyond the proceeds of this offering and may be unable to raise capital when needed, which would force us to delay, reduce, eliminate or abandon our commercialization efforts or product development programs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">The COVID-19 pandemic has had and could continue to have an adverse impact on our business, operations, and the markets and communities in which we, our partners and our customers operate.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">Upon the completion of this offering, our common stock will be traded on two separate stock markets and investors seeking to take advantage of price differences between such markets may create unexpected volatility in our share price; in addition, investors may not be able to easily move shares for trading between such markets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.05pt;">Our Corporate Information</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We were incorporated under the laws of the State of Delaware in July&#160;1998 under the name Theramed, Inc. On December&#160;31, 2001, we changed our name to MaxCyte, Inc. Our principal executive offices are located at 22 Firstfield Road, Suite 110, Gaithersburg, Maryland 20878, and our telephone number is (301) 944-1700. Our website address is www.maxcyte.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus or in deciding to purchase our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.05pt;">Trademarks and Service Marks</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We have proprietary rights to a number of trademarks used in this prospectus which are important to our business. &#8220;MaxCyte,&#8221; &#8220;ExPERT,&#8221; &#8220;CARMA,&#8221; &#8220;Flow Electroporation,&#8221; &#8220;ATx,&#8221; &#8220;STx,&#8221; &#8220;GTx,&#8221; &#8220;VLX Large-Scale Transfection System&#8221; and our other registered and common law trade names, trademarks and service marks are the property of MaxCyte, Inc. Other trade names, trademarks and service marks used in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the &#174; and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.05pt;">Implications of Being an Emerging Growth Company</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may take advantage of certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm under Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.07&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. In addition, the JOBS Act provides that an emerging growth company can delay adopting new or revised accounting standards until those standards apply to private companies. We have elected to use the extended transition period under the JOBS Act. Accordingly, our financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:66pt; margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="text-transform:uppercase;letter-spacing:-0.05pt;">THE OFFERING</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Option to purchase additional shares of common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We have granted the underwriters an option, exercisable for 30&#160;days after the date of this prospectus, to purchase up to an additional&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares from us. See the section of this prospectus titled &#8220;Underwriting.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Common stock to be outstanding after this </font>
              <br >
              <font style="letter-spacing:-0.025pt;">offering </font>
            </div>
          </div>
          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares (&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares if the option to purchase additional shares from us is exercised in full)</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Use of proceeds </font>
            </div>
          </div>
          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We estimate that our net proceeds from the sale of our common stock that we are offering will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million (or approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million if the underwriters&#8217; option to purchase additional shares of our common stock from us is exercised in full), assuming a public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font>
          </div>
          <div style="margin-left:145pt; margin-top:8pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The principal purposes of this offering are to obtain additional capital to increase our financial flexibility, to support our operations and growth, to create a public market for our common stock in the United States and to enable access to the U.S. public equity markets for us and our stockholders. However, we currently intend to use the net proceeds we receive from this offering to: (i)&#160;continue making investments in research and development efforts; (ii)&#160;continue making investments in building our business development, sales and applications teams and marketing our products to new and existing partners in attractive global markets, as well as for general corporate purposes, including working capital, operating expenses and capital expenditures; (iii)&#160;further invest to in-source and automate manufacturing to support our cell therapy customers; (iv)&#160;scale our process development capabilities via investment in laboratory space, equipment and addition of scientific resources; and (v)&#160;commercialize our VLX Large-Scale Transfection System under the ExPERT family of products to facilitate potential expansion into adjacent markets.</font>
          </div>
          <div style="margin-left:145pt; margin-top:8pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">See the section titled &#8220;Use of Proceeds&#8221; for additional information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Risk factors </font>
            </div>
          </div>
          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">You should carefully read the section titled &#8220;Risk Factors&#8221; beginning on page&#160;12 and the other information included in this prospectus for a discussion of facts that you should consider before deciding to invest in shares of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Proposed Nasdaq Global Market symbol </font>
            </div>
          </div>
          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#8220;MXCT&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">AIM trading symbols </font>
            </div>
          </div>
          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#8220;MXCT&#8221;, &#8220;MXCN&#8221;</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:328pt; margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The number of shares of common stock that will be outstanding after this offering is based on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock outstanding as of March&#160;31, 2021, and excludes:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock issuable on the exercise of outstanding stock options as of March&#160;31, 2021 under our Long-Term Incentive Plan, or our LTIP, with a weighted average exercise price of $&#8199;&#8199;&#8199;&#8199; per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock reserved for future issuance as of March&#160;31, 2021 under our LTIP;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock issuable on the exercise of an outstanding common stock warrant at an exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock reserved for future issuance under our 2021 Equity Incentive Plan, or our 2021 Plan, which will become effective upon the execution of the underwriting agreement related to this offering, as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder, and any shares underlying outstanding stock awards granted under our LTIP and 2021 Plan that expire or are repurchased, forfeited, cancelled or withheld, as more fully described in the section titled &#8220;Executive Compensation&#8201;&#8212;&#8201;Equity Incentive Plans&#8221;; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock reserved for issuance under our employee stock purchase plan, or our ESPP, which will become effective upon the execution of the underwriting agreement related to this offering, as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for future issuance thereunder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">In addition, unless we specifically state otherwise, the information in this prospectus assumes:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">the filing of our fifteenth amended and restated certificate of incorporation, which will occur immediately prior to the closing of this offering;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">no exercise of the underwriters&#8217; option to purchase additional shares of common stock from us in this offering; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">no exercise of the outstanding stock options and warrant described above. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:12pt; margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="text-transform:uppercase;letter-spacing:-0.05pt;">SUMMARY CONSOLIDATED FINANCIAL DATA</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The summary consolidated statement of operations data for the&#160;years ended December&#160;31, 2019 and 2020 and the summary consolidated balance sheet data as of December&#160;31, 2020 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. You should read the financial data set forth below in conjunction with our consolidated financial statements and the accompanying notes and the information in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results to be expected for any period in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <table style="width:416pt;height:294pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:284.2pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.04pt;">Years Ended December&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.04pt;">2019 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.04pt;">2020 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
                <font style="letter-spacing:-0.05pt;">Consolidated Statement of Operations Data:</font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Revenue </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">21,620,700</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">26,168,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Costs of goods sold </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">2,499,200</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">2,767,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Gross profit </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">19,121,500</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">23,401,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
                <font style="letter-spacing:-0.025pt;">Operating expenses: </font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Research and development </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">17,601,200</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">17,744,300</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">7,852,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">8,328,700</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">General and administrative </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">6,088,200</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">8,385,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Total operating expenses </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">31,541,500</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">34,458,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Operating loss </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,420,000<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(11,056,700<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
                <font style="letter-spacing:-0.025pt;">Other income (expense): </font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(681,100<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">(825,600<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Interest and other income </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">206,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">65,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Total other income (expense) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(475,000<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(759,700<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Net loss </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Net loss per share, basic and diluted </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(0.23<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">(0.17<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 1.5pt 0pt; width:284.2pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:-0.025pt;">Weighted-average common shares outstanding, basic and diluted </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">56,397,524</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">69,464,751</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <table style="width:416pt;height:142pt;margin-left:20pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:274.68pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.04pt;">As of December&#160;31, 2020 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:274.68pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.04pt;">Actual </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.04pt;">As Adjusted(1)(2) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:274.68pt;text-align:left;">
                <font style="letter-spacing:-0.05pt;">Consolidated Balance Sheet Data:</font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.68pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Cash and cash equivalents </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">18,755,200</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.62pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.68pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Working capital(3) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">33,639,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.68pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Total assets </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">51,780,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.68pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Total liabilities </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">18,554,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.68pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Additional paid-in capital </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">127,673,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.68pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Accumulated deficit </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">(95,222,300<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.68pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Total stockholders&#8217; equity </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">33,225,400</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:10.62pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:12.5pt; width:456pt;">
            <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:-0.025pt;">The as adjusted balance sheet data gives effect to our receipt of estimated net proceeds from the sale of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock that we are offering at an assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:536pt; margin-left:12pt;width:456pt;">
          <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">(2)</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:-0.025pt;">A $1.00 increase (decrease) in the assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, working capital, total assets, and total stockholders&#8217; equity by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same. Each increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us would increase (decrease) each of cash and cash equivalents, working capital, total assets, and total stockholders&#8217; equity by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock remains the same.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:-0.025pt;">Working capital is defined as current assets less current liabilities.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">RISK FACTORS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;font-style:italic;">An investment in our common stock involves a high degree of risk. You should consider carefully the following risks and other information contained in this prospectus before you decide whether to buy our common stock. If any of the events contemplated by the following discussion of risks should occur, our business, results of operations, financial condition and growth prospects could suffer significantly. As a result, the market price of our common stock could decline, and you may lose all or part of the money you paid to buy our common stock. The risks below are not the only ones we face. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business. Certain statements below are forward-looking statements. See &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this prospectus.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Risks Related to Our Business and Growth Strategy</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We are a cell engineering and life sciences company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have limited product offerings approved for commercial sale and may never achieve or maintain profitability.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are a cell engineering and life sciences company focused on advancing the discovery, development and commercialization of next-generation cell-based medicines. The biopharmaceutical development industry, where the majority of our customers operate, is a highly speculative undertaking and involves a substantial degree of risk. We have incurred significant losses since inception and have financed our operations principally through private financings and sales of our securities in our initial public offering on AIM, a market operated by the London Stock Exchange, in March&#160;2016. We have historically relied on sales and licensing of our ATx, STx and GTx instruments, as well as sales of our portfolio of single-use disposable processing assemblies, or PAs, for nearly all of our revenue. We may be unable to sell or license our instruments to new customers and existing customers may cease or reduce their utilization of our instruments or fail to renew licenses of our instruments. Our net losses were $12.9&#160;million and $11.8&#160;million for the&#160;years ended December&#160;31, 2019 and 2020, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $95.2&#160;million. Our losses have resulted principally from expenses incurred for the research and clinical development of our proprietary cell therapy CARMA platform clinical candidate MCY-M11 and, to a lesser extent, our </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell engineering platforms and from sales and marketing costs, manufacturing expenses, management and administrative costs and other expenses that we have incurred while building our business infrastructure.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We concluded clinical activities associated with CARMA in the first half of 2021. We expect our expenses and operating losses, excluding CARMA, will continue to increase substantially for the foreseeable future as we expand our research and development efforts, expand the capabilities of our cell engineering platforms and operate as a public company in the United States. We anticipate that our expenses will increase substantially as we:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.89pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continue to advance our </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell engineering platforms and develop new technologies related to our platform;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">acquire and license technologies aligned with our </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell engineering platforms;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">expand our operational, financial and management systems and increase personnel, including personnel to support our research and development, manufacturing and commercialization efforts;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continue to develop, perfect and defend our intellectual property portfolio; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">incur additional legal, accounting and other expenses in operating our business, including the additional costs associated with operating as a public company in the United States.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have devoted a significant portion of our financial resources and efforts to building our organization, developing our </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell engineering platforms, acquiring technology, building out our manufacturing capabilities, organizing and staffing the company, business planning, establishing our intellectual property portfolio, raising capital, securing license and partnership arrangements with customers and providing general and administrative support for these operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">To become and remain profitable, we must succeed in realizing meaningful pre-commercial milestone payments from our current SPLs and potentially secure future commercial partnership, licensing or collaboration arrangements for use of our cell engineering platforms and similar arrangements for future platforms in development that have not yet been partnered. This will require us to be successful in a range of challenging activities, including continuing to develop our technology and products, accessing, developing and advancing manufacturing capacity, advancing our sales and marketing capabilities and commercializing and selling our products. We may never succeed in any or all of these activities and, even if we do, we may never generate a level of revenue that is sufficient to achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our financial results, including profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our financial results, the value of our shares of common stock could be materially adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We are highly dependent on a limited number of product offerings. Our revenue has been primarily generated from the sale and licensing of our ATx, STx and GTx instruments, as well as sales of single-use disposable PAs, which require a substantial sales cycle and are prone to quarterly fluctuations in revenue.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT technology platform and family of instruments&#8201;&#8212;&#8201;the ATx, STx and GTx, representing next-generation technology for complex cellular engineering, was commercially launched in April&#160;2019. Sales and licensing of ExPERT technology systems and related instruments together accounted for 50% and 51% of our revenue for the&#160;years ended December&#160;31, 2019 and 2020, respectively. We expect that, for at least the foreseeable future, sales and licensing of our ExPERT technology systems will continue to account for a substantial portion of our revenue. The sales cycle for our cell engineering instruments is complex and can take up to 12&#160;months or longer to complete. Material, one-time milestones earned as Strategic Platform License, or SPL, customers achieve clinical progress may also, from time to time be a significant portion of our revenue, are not in our control, are unpredictable and because of the early-stage nature of the cell therapy clinical development, may contribute materially to the volatility of our revenue. As a result of our lengthy and unpredictable sales cycle, we will be prone to quarterly fluctuations in our revenue. Quarterly fluctuations may make it difficult for us to predict our future operating results. Consequently, comparisons of our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As a result of variability and unpredictability, we may also fail to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall short of the expectations of analysts or investors or any guidance we may provide, or if the guidance we provide falls short of the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met or exceeded any previously publicly stated guidance we may have provided.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We may be unable to successfully execute on our growth strategy.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We intend to grow our business and market opportunity by continuing to invest in technology and scientific innovation, broadening our distribution capabilities to expand our installed base of ExPERT products, pursuing SPLs with target customers, commercializing our VLX Large-Scale Transfection System under the ExPERT brand, expanding our commercial infrastructure and considering opportunistic investments, partnerships and acquisitions, among other initiatives. Each of these growth strategies will require considerable time and resources, and we may not be successful in executing on any or all of these strategies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">One of the components of our growth strategy is to develop and commercialize our novel VLX platform for large-scale bioprocessing applications including viral vector production in suspension cell cultures and rapid production of proteins. In order to do so, we will be required to invest significant time, resources and capital in the development, production and launch of the VLX platform, which could divert our resources from other parts of our business and growth strategy. In addition, the success of the VLX platform may depend in part on the availability, compatibility and capability of appropriate technologies upstream and downstream of electroporation to support potential large-scale applications enabled by the VLX platform. Further, we could encounter delays and setbacks in the launch of the VLX platform, resulting in delayed acceptance by future customers and partners of such a large-scale </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">system. In addition, sales and implementation cycles of customers for such a large-scale platform may require more time than originally assumed, which could in turn negatively impact forecasted revenues. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Another component of our growth strategy is expanding our SPL model, through which we build collaborative relationships with our customers as we facilitate their efforts to bring critical cell-based medicines to the market. Even if we are able to enter into additional future SPL arrangements and similar arrangements for future therapeutic products that have not yet been partnered, there can be no assurance that any of the therapeutic products that are being or might be developed by our partners using our technology will continue to advance through clinical development, receive regulatory approvals or be successfully developed into commercially viable products. As a result, we may suffer setbacks in increasing awareness and adoption of our products in addition to the material impact on our financial results as a result of milestones not being realized and leased instruments being returned. Further, setbacks in the clinical trials of our current or future partners, such as serious adverse events, including patient deaths, could significantly impact capital available to customers and our ability to enter into future SPL agreements with new therapeutic product companies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our growth strategy also involves expanding our international operations. In addition to risks associated with international operations in general, we will also need to navigate complex foreign regulatory requirements with which we may not be familiar or have experience. To operate successfully in or obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety, efficacy, manufacturing, clinical trials, commercial sales, pricing and distribution of our products. Although our partners have repeatedly been able to reference our FDA Master File in the United States and our Technical Files in some other countries in the course of clinical development of their therapeutic products, we cannot ensure that we will obtain or establish a regulatory Technical File in other countries. If we fail to establish a regulatory Technical File in any jurisdiction, this could make customers in such jurisdictions less likely to adopt our instruments, and the geographic market for our products could be limited.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe there are several opportunities to grow our sales and product line. However, we have limited financial and managerial resources, and we may forego or delay pursuit of growth opportunities that later prove to have greater value to our business. Our resource allocation decisions may cause us to fail to capitalize on viable opportunities, and we could spend resources on strategies that are not ultimately successful.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">The estimates of market opportunity and forecasts of market growth included in this prospectus or that we develop internally may prove to be inaccurate, and even if the markets in which we compete are as large as we estimate or achieve their forecasted growth, our business could fail to grow at projected rates, if at all.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Market opportunity estimates and growth forecasts included in this prospectus, including those we have generated ourselves, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. The variables that go into the calculation of our market opportunity are subject to change over time, and there is no guarantee that any particular number or&#160;percentage of customers covered by our market opportunity estimates will purchase our products at all or generate any particular level of revenue for us. Any expansion in our market depends on a number of factors, including the cost and perceived value associated with our products and those of our competitors. Even if the markets in which we compete meet the size estimates and growth forecast in this prospectus, our business could fail to grow at projected rates, if at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. Accordingly, the forecasts of market size and growth included in this prospectus should not be taken as indicative of our future growth.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We rely on assumptions and estimates and data to calculate certain of our key metrics, and real or perceived inaccuracies in such metrics may harm our reputation and negatively affect our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to our financial results, our management regularly reviews a number of operating and financial metrics, including a breakdown of product and leased revenue into instrument sales, PAs, and leased revenue (recurring revenue), product placements, cumulative product placements, revenue by customer market (cell therapy and drug discovery), and status or number of installed instruments, SPLs, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">program licenses (research, clinical and SPL) and potential pre-commercial milestones, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. As both the industry in which we operate and our businesses continue to evolve, so too might the metrics by which we evaluate our businesses. In addition, while the calculation of the metrics we use is based on what we believe to be reasonable estimates, our internal tools are not independently verified by a third party and have a number of limitations and, furthermore, our methodologies for tracking these metrics may change over time, for example, the industry breakdown of our customer revenue. Accordingly, investors should not place undue reliance on these metrics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our future success is dependent upon our ability to increase penetration in our existing markets and expand into adjacent markets.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our customer base includes biopharmaceutical and biotechnology companies and academic institutions focused on cell-based therapeutics. Our success will depend in part upon our ability to increase our market penetration by expanding sales to existing customers and acquiring new customers and partnerships within our existing markets, and our ability to market new products and applications to existing and new customers as we develop such products and applications. Attracting new customers and introducing new products and applications require substantial time and expense. For example, it may be difficult to identify, engage and market to customers who are unfamiliar with our current products. We cannot guarantee that we will be able to further penetrate our existing markets or that these markets will be able to sustain our current and future product and service offerings. Any failure to increase penetration in our existing markets would adversely affect our ability to improve our operating results.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our success will also depend on our ability to further expand into adjacent markets, such as penetrating non-commercial customer opportunities, including translational academic centers. Our failure to further expand in adjacent markets and attract new customers could adversely affect our ability to improve our operating results.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Due to the significant resources required to enable access in new markets, we must make strategic and operational decisions to prioritize certain markets, technology offerings and partnerships, and there can be no assurance that we will expend our resources successfully or in a way that results in meaningful revenue or capitalizes on potential new markets.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe our platform has potential applications across a wide range of markets and we have targeted certain markets in which we believe we have a higher probability of success or revenue opportunity or for which the path to commercialize products and realizing or achieving revenue is shorter. For example, we believe our products have applications in markets for engineered cell therapies in immuno-oncology and inherited disorders. We seek to continue to prioritize opportunities and allocate our resources among our programs to maintain a balance between advancing near-term opportunities and exploring additional markets for our technology. However, due to the significant resources required for the development for new markets, we must make decisions regarding which markets to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular markets or workflows may not lead to the development of any viable product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain markets may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. In particular, if we are unable to develop additional relevant products and applications for markets such as cell therapy or large-scale bio-processing, it could slow or stop our business growth and negatively impact our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our business is dependent on adoption of our products by biopharmaceutical companies and academic institutions for their research and development activities focused on cell-based therapeutics. If biopharmaceutical companies and academic institutions are unwilling to change current practices to adopt our products it will negatively affect our business, financial condition, prospects and results of operations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our primary strategy to grow our revenue is to market our products across key stakeholders in cell-based therapeutics, such as biopharmaceutical companies and academic institutions. Most of our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">potential customers already use expensive research systems in their laboratories and may be reluctant to replace those systems. While the number of customers using our products has increased in recent&#160;years, many biopharmaceutical companies and academic institutions have not yet adopted our products, and such institutions and companies may choose not to adopt our products for a number of reasons, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">inability to convince potential customers that our products are an attractive alternative to existing technologies and reluctance of potential customers to replace those existing technologies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">inadequate recruiting or training of talented sales force and field application scientists in existing and new markets to facilitate outreach and further adoption and awareness of our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">lack of experience of potential customers with our products for cell engineering;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">perceived inadequacy of evidence supporting benefits or cost-effectiveness of our products over existing alternatives or negative publicity regarding cell engineering technologies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">liability risks generally associated with the use of new products and processes;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the time and training required for potential customers to use and validate our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a decrease or delay in the research and development activities using our products as a result of the COVID-19 pandemic;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">competing products and alternatives; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">introduction of other novel alternative products for cell engineering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, our customers may experience a change of control or otherwise consolidate with other biopharmaceutical companies and academic institutions. If as a result of such change of control, our customers choose or are forced to adopt other products, or otherwise reduce their use of our products, our ability to execute our growth strategy will be impaired and it will negatively affect our business, financial condition, prospects and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe that educating notable industry key opinion leaders, or KOLs, and representatives of biopharmaceutical companies and academic institutions about the merits and benefits of our products for Flow Electroporation and cell engineering is one of the key elements of increasing the adoption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products will be slowed, our ability to execute our growth strategy will be impaired, and it will negatively affect our business, financial condition, prospects and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We may be unable to compete successfully against our existing or future competitors.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We operate in a highly competitive market characterized by rapid technological change, evolving industry standards, changes in customer needs, emerging competition, new product introductions and strong price competition. We currently compete with both established and early-stage life sciences technologies companies that design, manufacture and market electroporation and other non-viral cell engineering technology based on efficacy, price, ease of use, reimbursement and customer support services.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our success depends, in part, on our ability to maintain a competitive position in the development of technologies, enhancements and products for use by our customers. Many of the companies developing or marketing competing or alternative products have competitive advantages when compared to us, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">greater financial and human resources for product development, sales and marketing;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">greater domestic and international name recognition and more product familiarity among users;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">broader and more established relationships with pharmaceutical companies and academic institutions;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">broader product lines and the ability to offer lower prices or rebates, integrate technologies more successfully to offer better workflow solutions, bundle products to offer greater discounts or incentives or offer more attractive milestone and partnership terms;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">broader intellectual property protection for their technology and products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">broader and more established domestic and international sales and marketing and distribution networks; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">more experience in conducting research and development, manufacturing and preparing regulatory submissions, both in the United States and in foreign jurisdictions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We primarily compete against products marketed by Lonza Group AG, Thermo Fisher Scientific Inc., Miltenyi Biotec, Bio-Rad Laboratories, Inc. and Harvard Bioscience, Inc. (BTX).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to already marketed products, we also face competition from products that are or could be under development and that target the same applications as our products or applications that we may address in the future. Such product candidates may be developed by the above-mentioned entities and others, including life sciences tools companies, biotechnology companies, pharmaceutical companies, private and public research institutions and academic institutions or may come about as the result of consolidation in our industry. Our competitors may develop and patent processes or products earlier than we can, obtain regulatory clearance or approvals for competing products more rapidly than we can and develop more effective and/or less expensive products or technologies that render our technology or products obsolete or non-competitive. Despite the steps we have taken to maintain and protect our intellectual property, competitors may nevertheless attempt to, or succeed in, developing similar electroporation technology, including Flow Electroporation. We also compete with other organizations in recruiting and retaining qualified scientific and management personnel. If our competitors are more successful than us in these matters, we may be unable to compete successfully against our existing or future competitors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our business currently depends significantly on research and development spending by biopharmaceutical companies, a reduction in which could limit demand for our products and adversely affect our business and operating results.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">A portion of our revenue is derived from sales to biopharmaceutical companies and academic institutions. Much of their funding is, in turn, provided by public and private financings, including investments from venture capital funds and, for public companies, the capital markets. In the near term, we expect that a portion of our revenue will continue to be derived from sales to biopharmaceutical companies and academic institutions. Accordingly, the spending policies and practices of these customers&#8201;&#8212;&#8201;which have been impacted by the COVID-19 pandemic and may additionally be impacted by other factors&#8201;&#8212;&#8201;could have a significant effect on the demand for our products. In addition, the demand for our products may depend upon the research and development budgets of these customers, which are impacted by factors beyond our control, such as:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">macroeconomic conditions and the political climate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">investor confidence in the biopharmaceutical industry and the amount of capital such investors provide to our potential customers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reduced pricing of approved therapeutics;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">scientists&#8217; and customers&#8217; opinions of the utility of new products or services;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in the regulatory environment;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">differences in budgetary cycles;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">competitor product offerings or pricing;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">merger and acquisition activity within the industry;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">market-driven pressures to consolidate operations and reduce costs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">market acceptance of relatively new technologies, such as ours;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">clinical trial or milestone failures that impact our customers&#8217; ability to raise capital; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">inability to sustain capital requirements or bankruptcy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, while the majority of our revenues are derived from biopharmaceutical customers, various state, federal and foreign agencies that provide grants and other funding may be subject to stringent budgetary constraints that could result in spending reductions, reduced grant making, reduced allocations or budget cutbacks, which could jeopardize the ability of these customers, or the customers to whom they provide funding, to purchase our products. For example, congressional appropriations </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">to the National Institutes of Health, or NIH, have generally increased year-over-year in recent&#160;years, but the NIH also experiences occasional year-over-year decreases in appropriations. There is no guarantee that NIH appropriations will not decrease or cease in the future. A decrease in the amount of, or delay in the approval of, appropriations to NIH or other similar United States or foreign organizations, such as the Medical Research Council in the United Kingdom, could result in fewer grants benefiting life sciences research. These reductions or delays could also result in a decrease in the aggregate amount of grants awarded for life sciences research or the redirection of existing funding to other projects or priorities, any of which in turn could cause our customers and potential customers to reduce or delay purchases or licensing of our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our operating results may fluctuate substantially due to the potential changes in our customers&#39; resources as described above. Any decrease in our customers&#8217; budgets or expenditures, or in the size, scope or frequency of their capital or operating expenditures, could materially and adversely affect our business, operating results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our current research and development efforts may not produce significant revenue for several&#160;years, if at all.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Developing our products is expensive, and the investment in product development may involve a long payback cycle. Our investment in research and development may not result in the data we hope to develop to support marketing of our products or in marketable products or may result in products that take longer to generate revenue, or generate less revenue, than we anticipate. For the year ended December&#160;31, 2020, our research and development expenses were $17.7&#160;million, or approximately 68% of our total revenue, which included $11.1 million of investment in our CARMA platform including the clinical investment in our wholly-owned cell therapy candidate, MCY-M11. Our future plans include significant investments in research and development of product opportunities for expansion of our products and new application areas for our products. We believe that we must continue to dedicate a significant amount of resources to our research and development efforts to maintain our competitive position. However, we may not receive significant revenue from these investments for several&#160;years, if at all.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our international operations may raise additional risks, which could have an adverse effect on our operating results.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">International customers have typically accounted for a meaningful portion of our revenue. We expect our international revenue and operations will continue to expand in the future. Our international operations are subject to a variety of risks that we do not face in the United States, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the difficulty of increased travel, infrastructure and legal compliance costs associated with developing international revenue;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">difficulties in enforcing contracts, collecting accounts receivable and longer payment cycles, especially in emerging markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">general economic conditions in the countries in which we operate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">additional withholding taxes or other taxes on our foreign income, and tariffs or other restrictions on foreign trade or investment;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">compliance with privacy and data security requirements in foreign jurisdictions in which we operate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">imposition of, or unexpected adverse changes in, foreign laws or regulatory requirements, many of which differ from those in the United States;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">costs and delays associated with developing products or technology in multiple languages, such as the software embedded in our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">compliance with foreign technical standards;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">increased length of time for shipping and acceptance of our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">increased exposure to foreign currency exchange rate risk;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">uncertainties related to the political and economic environments, including related to the recent withdrawal of the United Kingdom from the European Union;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reduced protection for intellectual property rights in some countries, particularly China; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">political unrest, war, incidents of terrorism, or responses to such events.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As we continue to expand our business globally, our success will depend, in large part, on our ability to anticipate and effectively manage these and other risks associated with our international operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our overall success in international markets depends, in part, on our ability to succeed in differing legal, regulatory, economic, social and political conditions. We may not be successful in developing and implementing policies and strategies that will be effective in managing these risks in each country where we do business. Our failure to manage these risks successfully could harm our international operations, reduce our international sales and increase our costs, thus adversely affecting our business, operating results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If we fail to offer high-quality customer service, our business and reputation could suffer.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We differentiate ourselves from our competition through our commitment to an exceptional customer experience. Accordingly, high-quality customer service is important for the growth of our business and any failure to maintain such standards of customer service, or a related market perception, could affect our ability to sell products to existing and prospective customers. The number of our customers has grown significantly and such growth, as well as any future growth, will put additional pressure on our field application scientists and customer service organization. We may be unable to hire qualified staff quickly enough or to the extent necessary to accommodate increases in demand. Providing an exceptional customer experience requires significant time and resources from our customer service team. Therefore, failure to scale our customer service organization adequately may adversely impact our business results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Customers utilize our service teams and online content for help with a variety of topics, including how to use our products efficiently, how to integrate our products into existing workflows, and how to resolve technical, analysis and operational issues if and when they arise. While we have developed significant resources for remote training and customer service, including our virtual product demonstration process, if our customers do not adopt these resources, we may be required to increase the staffing of our customer service team, which would increase our costs. Also, as our business scales, we may need to engage third-party customer service providers, which could increase our costs and negatively impact the quality of the customer experience if such third parties are unable to provide service levels equivalent to ours.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, as we continue to grow our operations and reach a global customer base, we need to be able to provide efficient customer service that meets our customers&#8217; needs globally at scale. In geographies where we sell through distributors, we often rely on those distributors to provide customer service. If these third-party distributors do not provide a high-quality customer experience, our business operations and reputation may suffer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If we cannot maintain and expand current partnerships and enter into new partnerships that generate marketed licensed products, our business could be adversely affected.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We do not have our own pipeline of therapeutic candidates, and instead we focus our efforts on the development of our cell engineering offerings, including our ExPERT platform. Our partners then use our instruments and PAs for cell engineering to develop their own therapeutic candidates without our direct involvement. As a result, our success depends on our ability to expand the number and scope of our partnerships. Many factors may impact the success of these partnerships, including our ability to perform our obligations, our partners&#8217; satisfaction with our products, competitive offerings of other companies, our partners&#8217; ability to successfully develop, secure regulatory approval for and commercialize therapeutic candidates using our products, our partners&#8217; internal priorities (including fluctuations in research and developments budgets), our partners&#8217; resource allocation decisions and competitive opportunities, disagreements with partners, the costs required of either party to the partnerships and related financing needs, and operating, legal and other risks in any relevant jurisdiction, as well as severe adverse events in cell therapy trials regardless of association with our partners.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We engage in conversations with companies regarding potential partnerships on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, including due to factors beyond our control, such as our partners&#8217; inability to successfully develop or commercialize their therapeutic candidates. In such </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">circumstances, we would not generate any substantial revenues from such a collaboration in the form of milestone payments, royalties or otherwise. Speculation in the industry about our existing or potential partnerships can be a catalyst for adverse speculation about us which can adversely affect our reputation and our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Further, our customers are subject to the extensive risks and uncertainties that apply to product candidates in this area including those associated with preclinical and clinical research and development and related regulatory and Institutional Review Board authorization and oversight, manufacturing challenges and compliance standards, the data requirements and review process for seeking marketing authorization, and the potential for safety and efficacy concerns to emerge at any stage of product development and even after approval.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If the quality or delivery of our products does not meet our customers&#8217; expectations and needs relative to their regulatory obligations, our reputation could suffer and ultimately our sales and financial results could be negatively impacted.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our customers operate in a highly regulated industry. In the course of conducting our business, our customers will expect us to adequately address any quality issues suspected to be associated with our products, including defects in our engineering, design, manufacturing and delivery processes, as well as defects in third-party components included in our products. The occurrence of defects in our products may increase as we continue to introduce new products and as we rapidly scale up manufacturing to meet potentially increased customer demand. Although we have established internal procedures designed to reduce the risks of product quality issues that may arise, there can be no assurance that we will be able to eliminate or mitigate occurrences of these issues and associated potential liabilities. In addition, identifying the root cause of quality issues may be difficult, which increases the time needed to address quality issues as they arise and increases the risk that similar problems could recur. Finding solutions to quality issues can be expensive and we may incur significant costs or lost revenue in connection with, for example, shipment holds, product recalls or other service obligations. In addition, quality issues can impair our relationships with new or existing customers and adversely affect our brand image, and our reputation could suffer, which could adversely affect our business, financial condition, results of operations, cash flows and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">The failure of our partners to meet their contractual obligations to us could adversely affect our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our reliance on our partners poses a number of additional risks, including the risk that they may not perform their contractual obligations to us to our standards, in compliance with applicable legal or contractual requirements, in a timely manner or at all; they may not maintain the confidentiality of our proprietary information; and disagreements or disputes could arise that could cause delays in, or termination of, the research, development or commercialization of therapeutic candidates produced using our instruments and PAs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, certain of our partners are large, multinational organizations that run many programs concurrently, and we are dependent on their ability to accurately track and make milestone payments to us pursuant to the terms of our agreements with them. Any failure by them to inform us when milestones are reached and make related payments to us could adversely affect our results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Some of our partners are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, and are often subject to country-specific privacy and data security risk as well as burdensome legal and regulatory requirements. Any of these factors could adversely impact their financial condition and results of operations, which could impair their ability to meet their contractual obligations to us, which may have a material adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of their clinical developments and timelines for advancing collaborative programs, and the price of our common stock may decline as a result of announcements of unexpected results or developments.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our partners have significant discretion in determining when and whether to make announcements about the status of their programs that use our technology, including their preclinical and clinical </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">programs, such as setbacks or terminations, and timelines for advancing therapeutic candidates developed using our platform. We do not plan to disclose the development status and progress of individual therapeutic candidates of our partners. Our partners may wish to report such information more or less frequently than we prefer or may not wish to report such information at all. In addition, if partners choose to announce a collaboration with us or their progress, there is no guarantee that we will concurrently recognize any fees or that such announcement will be indicative of future fees to us, as such fees are not due to us until our partner reaches certain specific activities or clinical progress events, for example investigational new drug, or IND, submissions or start of pivotal trials. The price of our common stock may decline as a result of the public announcement of unexpected results or developments in our partnerships, or as a result of our partners withholding such information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our partners may not achieve projected development and regulatory milestones and other anticipated key events in the expected timelines or at all, or may discontinue some or all of their programs, which could have an adverse impact on our business and could cause the price of our common stock to decline.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">From time to time, we may make public statements regarding the expected timing of certain milestones and key events, as well as regarding developments and milestones under our partnerships, to the extent that our partners have publicly disclosed such information or permit us to make such disclosures. Certain of our partners have also made public statements regarding their expectations for the development of programs under partnership with us and they and other partners may in the future make additional statements about their goals and expectations for the progress of their programs and/or their partnerships with us. The actual timing of these events and any resultant revenue to us can vary dramatically due to a number of factors such as delays or failures in our or our current and future partners&#8217; therapeutic discovery and development programs and the numerous uncertainties inherent in the development of therapeutics. As a result, there can be no assurance that our partners&#8217; current and future programs will advance or be completed in the time frames we or they expect, or at all. In addition, we have very little visibility into, or advance notice of, any changes in our partners&#8217; development timelines and expectations, which means that we may not be able to swiftly react and adapt to changed expectations related to the achievement and payment of milestones under our agreements. If our partners fail to achieve one or more of these milestones or other key events as we or they expect, our business could be materially adversely affected and the price of our common stock could decline.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Biopharmaceutical drug and therapeutics development is inherently uncertain, and it is possible that none of the drug or therapeutic candidates discovered using our platform that are further developed by our partners will receive marketing approval or become viable commercial products, on a timely basis or at all.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We offer our cell engineering platform to partners who are engaged in drug and therapeutics discovery and development. These partners include large pharmaceutical companies, biotechnology companies of all sizes and non-profit and academic institutions. While we receive early payments generated through sales of our ExPERT instruments and PAs and recurring revenue through the annual licenses of the ExPERT instrument to our partners, we estimate that the vast majority of the economic value of the SPLs that we enter into with our partners is in the downstream payments that are payable if certain milestones are met or approved products are sold. As a result, our future growth is dependent on the ability of our partners to successfully develop and commercialize therapies discovered or produced using our platform. Due to our reliance on our partners, the risks relating to product development, regulatory clearance, authorization or approval and commercialization apply to us derivatively through the activities of our partners. There can be no assurance that our partners will successfully develop, secure marketing approvals for and commercialize any drug or therapeutic candidates discovered or produced with our instruments. As a result, we may not realize the intended benefits of our partnerships. Since 2017, we have entered into 12 SPLs resulting in a growing number of clinical milestone payments, but we have not yet had a licensed program receive regulatory marketing approval.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, our partners may not successfully develop any drug or therapeutic candidates with our platform, or our partners may choose to discontinue the development of these drug candidates for a variety of reasons, including due to safety, risk versus benefit profile, exclusivity, competitive landscape, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">manufacturing challenges, commercialization potential, production limitations or prioritization of their resources. For product candidates of the type expected to be developed using our technology, there is the potential they could create a safety risk to patients and can also limit product efficacy. It is possible that none of these drug or therapeutic candidates will ever receive regulatory approval and, even if approved, such drug candidates may never be successfully commercialized resulting in clinical progress milestones and commercial sales-based payments not being earned.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Regulatory authorities have substantial discretion in the review and approval process and may refuse to accept any application or may decide that our partners&#8217; data are insufficient to support progression to further stages of preclinical or clinical development or for marketing approval and require additional preclinical, clinical or other studies. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also varies depending on the product candidate (including cell therapies, for which development is inherently challenging), the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate. Application of the legal and regulatory standards for approval, and the type and amount of clinical data and data supporting Chemistry, Manufacturing and Control necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. It is possible that any product candidates our partners may seek to develop in the future will never obtain the appropriate, necessary regulatory approvals.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, even if these drug or therapeutic candidates receive regulatory approval in the United States, our partners may never obtain approval or commercialize such drugs outside of the United States, which would limit their full market potential and therefore our ability to realize their potential downstream value. Furthermore, approved drugs or therapeutics may not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited. Third-party payers may opt to implement efficacy-based payment mechanisms over a multi-year period, which could impact potential product sales in any given year. Likewise, our partners have to make decisions about which clinical stage and pre-clinical drug and therapeutic candidates to develop and advance, and our partners may not have the resources to invest in all of the drug or therapeutic candidates that are produced using our platform, or clinical data and other development considerations may not support the advancement of one or more drug candidates developed using our platform. Decision-making about which drug or therapeutic candidates to prioritize involves inherent uncertainty, and our partners&#8217; development program decision-making and resource prioritization decisions, which are outside of our control, may adversely affect the potential value of those partnerships. Additionally, subject to its contractual obligations to us, if one or more of our partners is involved in a business combination, the partner might deemphasize or terminate the development or commercialization of any drug or therapeutic candidate that utilizes our platform. If one of our SPL customers terminates its agreement with us, we may find it more difficult to attract new partners.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our partners, and therefore our potential financial outcomes under our agreements, are also subject to inherent industry-wide FDA and other regulatory risk. The number of new drug applications and biologics license applications approved by the FDA varies significantly over time and if there were to be an extended reduction in the number of new drug applications and biologics license applications approved by the FDA, the industry would contract and our business would be materially harmed. Furthermore, regulatory agencies may introduce new submission requirements or implement new regulations for cell and gene therapies which could result in extended timelines for our partners, creating uncertainty or delays in achieving milestones. Such delays in these milestones will materially affect our ability to forecast and receive milestone payments outlined in our license agreements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our partners&#8217; failure to effectively advance, market and sell suitable drug and therapeutic candidates developed using our platform could have a material adverse effect on our business, financial condition, results of operations and prospects, and cause the market price of our common stock to decline. In addition to the inherent uncertainty in drug development addressed above, our ability to forecast our future revenues may be limited.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">In recent periods, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For the year ended December&#160;31, 2020, one cell therapy company with which we have entered into an SPL accounted for 15% of our total revenue, and our six largest such customers accounted for an aggregate of approximately 40% of our total revenue for the year through a combination of instrument license fees, milestones realized and processing assembly revenue. These partnerships cover a large number of programs under contract, and therefore represent a large portion of potential downstream value. In addition, our partnership agreements are typically terminable at will. As a result, if we fail to maintain our relationships with our partners or if any of our partners discontinue their programs or transition to alternative cell engineering technologies, our future results of operations could be materially and adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Similarly, in recent periods, a portion of our revenue has been derived from milestone payments from a limited number of SPL customers. Accordingly, we are more dependent on the success of a limited number of our customers&#8217; programs than we would be if our revenue was derived more broadly from many customer contracts. The loss of any of our large customers, or significant delays or discontinuations in our customers&#8217; programs, would have an adverse effect on our ability to generate revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our customers&#8217; products or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval, which could cause our future results of operations to be materially and adversely affected.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Serious adverse events or undesirable side effects caused by our customers&#8217; products or product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the European Medicines Agency or other authorities. Results of our customers&#8217; clinical trials could reveal a high and unacceptable severity and prevalence of side effects, toxicities or unexpected characteristics, including death.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If unacceptable side effects or deaths arise in the development of our customers&#8217; product candidates, the Institutional Review Boards at the institutions in which their studies are conducted, the FDA or any comparable foreign regulatory authority could suspend or terminate our customers&#8217; clinical trials or the FDA or other regulatory authorities could order them to cease clinical trials or deny approval of their product candidates for any or all targeted indications. Undesirable side effects or deaths in clinical trials with our customers&#8217; product candidates may cause the FDA or comparable foreign regulatory authorities to place a clinical hold on the associated clinical trials, to require additional studies, or otherwise to delay or deny approval of our customers&#8217; product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. Any of these occurrences could negatively impact the availability of capital for the broader cell therapy development market, reduce the demand for our products and harm our business, financial condition and prospects significantly.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We may continue to pursue collaborations or licensing arrangements, joint ventures, strategic alliances, partnerships or other strategic investment or arrangements, which may fail to produce anticipated benefits and adversely affect our operations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We may continue to pursue opportunities for collaboration, out-license, joint ventures, acquisitions of products, assets or technology, strategic alliances, or partnerships that we believe would advance our development. We may consider pursuing growth through the acquisition of technology, assets or other businesses that may enable us to enhance our technologies and capabilities. Proposing, negotiating and implementing these opportunities may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, technology, or other business resources, may compete with us for these opportunities or arrangements. We may not be able to identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have limited experience with respect to these business development activities. Management and integration of a licensing arrangement, collaboration, joint venture or other strategic arrangement may disrupt our current operations, decrease our profitability, result in significant expenses, or divert management resources that otherwise would be available for our existing business. We may not realize the anticipated benefits of any such transaction or arrangement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Furthermore, partners, collaborators, or other parties to such transactions or arrangements may fail to fully perform their obligations or meet our expectations or cooperate with us satisfactorily for various reasons and subject us to potential risks, including the followings:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties have significant discretion in determining the efforts and resources that they will apply to a transaction or arrangement;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties could independently develop, or develop with third parties, services and products that compete directly or indirectly with our product candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties may stop, delay or discontinue clinical trials as well as repeat clinical trials or conduct new clinical trials by using our intellectual property or proprietary information;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liabilities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">disputes may arise between us and partners, collaborators, or other parties that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable services and products; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties may own or co-own intellectual properties covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual properties.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Any such transactions or arrangements may also require actions, consents, approval, waiver, participation or involvement of various degrees from third parties, such as regulators, government authorities, creditors, licensors or licensees, related individuals, suppliers, distributors, shareholders or other stakeholders or interested parties. There is no assurance that such third parties will be cooperative as we desire, or at all, in which case we may be unable to carry out the relevant transactions or arrangements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We may engage in future acquisitions that could disrupt our business, cause dilution to our stockholders and harm our financial condition and operating results.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the future, we may acquire companies, assets or technologies in an effort to complement our existing offerings to enhance our market position. We have not made any acquisitions to date and we currently have no plans, proposals or arrangements with respect to any acquisition. Should we choose to pursue an acquisition in the future, we may not be able to find suitable acquisition candidates and we may not be able to complete acquisitions on favorable terms, if at all. Any future acquisitions we make could subject us to a number of risks, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the purchase price we pay could significantly deplete our cash reserves, impair our future operating flexibility or result in dilution to our existing stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may find that the acquired company, assets or technology does not further improve our financial and strategic position as planned;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may find that we overpaid for the company, asset or technology, or that the economic conditions underlying our acquisition have changed;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may have difficulty integrating the operations and personnel of the acquired company;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may have difficulty retaining the employees with the technical skills needed to enhance and provide services with respect to the acquired assets or technologies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the acquisition may be viewed negatively by customers, financial markets, or investors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may have difficulty incorporating the acquired technologies or products with our existing products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may encounter difficulty entering and competing in new product or geographic markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may encounter a competitive response, including price competition or intellectual property litigation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may have product liability, customer liability or intellectual property liability associated with the sale of the acquired company&#8217;s products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may be subject to litigation by terminated employees or third parties;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may incur debt and restructuring charges;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may acquire goodwill and other intangible assets that are subject to impairment tests, which could result in future impairment charges;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ongoing business and management&#8217;s attention may be disrupted or diverted by transition or integration issues and the complexity of managing geographically or culturally diverse enterprises; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our due diligence process may fail to identify significant existing issues with the target company&#8217;s product quality, product architecture, financial disclosures, accounting practices, internal controls, legal contingencies, intellectual property and other matters.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Any acquisitions may not generate sufficient revenue to offset the associated costs of the transactions or may result in other adverse effects, which could have a material adverse effect on our business, operating results, and financial condition. In addition, negotiations for acquisitions, collaborations or investments that are not ultimately consummated could result in significant diversion of management time, as well as substantial out-of-pocket costs, any of which could have a material adverse effect on our business, operating results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Risks Related to the Supply and Manufacturing of Our Products</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We depend on continued supply of components and raw materials for our ExPERT instruments and PAs from third-party suppliers, and if shortages of these components or raw materials arise, we may not be able to secure enough components to build new products to meet customer demand or we may be forced to pay higher prices for these components.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We rely on a limited number of suppliers for certain key components utilized in the assembly of our ExPERT instruments and manufacture of our PAs and buffer, and in some cases, such as certain instrument components, for example CPU chips or PA electrodes, we rely on a single supplier for a particular component, subassembly or consumable. Although in many cases we use standard components in our products, in some cases, components may only be purchased from a limited number of suppliers or a single supplier. Identifying and qualifying alternate sources may take time and involve additional expense, and there is no guarantee that current suppliers or alternate sources will timely deliver materials that meet our needs. If our customers experience a shortage or delay in delivery of our ExPERT instruments, PAs or buffers our business could be materially and adversely impacted.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Neither we nor our contract manufacturers enter into long-term supply contracts for these components, and none of our third-party suppliers is obligated to supply products to us for any specific period or in any specific quantities, except as may be provided for in submitted and accepted purchase orders. We are not a major customer of many of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours. Our industry has experienced component shortages and delivery delays in the past, and we may experience shortages or delays of critical components in the future as a result of strong demand in the industry, high demand in unrelated industries (e.g. shortages of electronic components due to digitization in the automotive industry), or other factors. Many of the other components required to build our ExPERT instruments are also occasionally in short supply. Therefore, if shortages or delays arise, we may not be able to timely secure enough components at reasonable prices or of acceptable quality to build new products, resulting in an inability to meet customer demand or our own operating goals, which could adversely affect our customer relationships, business, operating results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Many of the components that we use are part of the global supply chain and may be manufactured overseas. Therefore, our access to, or ability to acquire, components may be impacted by trade disputes or importation restrictions resulting from such trade disputes between governments. These disputes may result in increased tariffs, duties or taxes that will increase the cost of the components and we may have to increase the price of our products, or incur an impact on our margins, both of which can materially affect customer demand and resulting revenues.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, damage to a manufacturing facility or other property of any of our suppliers or their distribution channels due to fire, flood or other natural disaster or casualty event may have a material adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We have limited experience manufacturing our PAs and if we move manufacturing of our PAs in-house in the future and are unable to manufacture our PAs in high-quality commercial quantities successfully and consistently to meet demand, our growth will be limited.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have limited experience manufacturing our products. We do not currently manufacture our PAs in-house but may choose to do so in the future. To manufacture our PAs in the quantities that we believe will be required to meet the currently anticipated market demand, we will need to increase manufacturing capacity, which will involve significant challenges and may require additional quality controls. We may not successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If there is a disruption to our manufacturing operations, we will have no other means of producing our products until we resolve such issues with our manufacturing facilities, develop alternative manufacturing facilities, or contract with third-party manufacturers capable of producing our PAs. Additionally, any damage to or destruction of our manufacturing facilities or equipment may significantly impair our ability to supply PAs on a timely basis. There may also be unforeseen occurrences that increase our costs, such as increased prices of the components of our PAs, changes to labor costs or less favorable terms with third-party suppliers. There can be no assurance that we will not encounter such problems in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If we are unable to manufacture PAs consistently and in sufficient quantities to meet anticipated customer demand, our business, financial condition, results of operations and prospects would be harmed. If we choose to scale the commercial production of our PA and increase our manufacturing capacity, we may encounter quality issues that could result in product defects, errors or recalls. Manufacturing delays related to quality control could negatively impact our ability to bring our PAs to market, harm our reputation and decrease our revenue. Any defects, errors or recalls could be expensive and generate negative publicity, which could impair our ability to market or sell our PAs, and adversely affect our results of operations. Our inability, or that of our suppliers, to find and retain the necessary qualified employees to achieve our manufacturing goals would also negatively impact our ability to meet customer needs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, we have historically sourced and for the foreseeable future will continue to source components for our PAs from a limited number of manufacturers and, in some cases, sole source manufacturers. With respect to our PA manufacturers, we are neither a major customer, nor do we have long-term supply contracts. These manufacturers may therefore give other customers&#8217; needs higher priority than ours, and we may not be able to obtain adequate supply in a timely manner or on commercially reasonable terms. While we are in the process of qualifying additional manufacturers, qualifications can take many&#160;months. If we were to lose one or more of our sole or single source manufacturers and suppliers, it would take significant time and effort to qualify alternative suppliers, if available. Moreover, in the event that we transition to a new manufacturer, particularly from any of our single source manufacturers, doing so could be time-consuming and expensive, may result in interruptions in our ability to supply our products to the market and could affect the performance of our PAs, resulting in increased costs and negative customer perception and could have a material adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our results of operations will be harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">To ensure adequate supply of our instruments, PAs and other products, we must forecast the inventory needs of our current and prospective customers and manufacture our products based on our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">estimates of future demand. Our ability to accurately forecast demand for our products could be negatively affected by many factors, many of which are beyond our control, including our failure to accurately manage our expansion strategy, product introductions or failures by competitors, an increase or decrease in customer demand for our products or for products of our competitors, the availability of capital for our customers, our failure to accurately forecast the success of our customers&#8217; therapeutic products, market acceptance of new products, changes in general market conditions, including as a result of the COVID-19 pandemic, seasonal demands, regulatory matters or strengthening or weakening of general economic conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We seek to maintain sufficient levels of inventory of our instruments and other products to protect ourselves from supply interruptions. We rely in part on our commercial team and distributors to supply forecasts of anticipated product orders in their respective territories. If we fail to accurately estimate customer demand for our products, our inventory forecasts may be inaccurate, resulting in shortages or excesses of inventory. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which could negatively impact our business, prospects, financial condition and results of operations. Conversely, if we underestimate customer demand for our products, we may not be able to deliver products in a timely manner or at all, and this could result in reduced revenue and damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, we may not have adequate manufacturing capacity to meet such demand, and additional supplies may not be available when required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, all of which would negatively affect our business, financial condition and results of operations. If we are unable to meet customer demand, we could lose our existing customers or lose our ability to acquire new customers, which would also negatively impact our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Risks Related to Our Product Sales</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our future success depends on our ability to develop and successfully introduce new and enhanced products that meet the needs of our customers.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our offerings include products such as instruments, single-use disposables and the provision of support services to our customers with the goal to support the advancement of our customers&#8217; cell-therapies and/or drug discovery activities. We aim to collectively provide our customers with a single, integrated platform to discover, develop and manufacture safer, more targeted and increasingly complex cell-based therapies, designed for integration into customers&#8217; current good manufacturing practices environments. We cannot guarantee that the market for our current products will continue to generate significant or consistent demand. Demand for our current products could be significantly diminished by competitive technologies or products that replace them or render them obsolete or less desirable. Accordingly, we must continue to invest in research and development to develop competitive products. Restrictions resulting from the COVID-19 pandemic have had a negative impact on the work of some of our, and our customers&#8217;, research and development programs due to limitations on in-person lab work.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our future success depends on our ability to anticipate our customers&#8217; needs and develop new products and enhance current products to address those needs. Introduction of new products and product enhancements will require that we effectively transfer production processes from research and development to manufacturing and coordinate our efforts with those of our suppliers to achieve the desired level of production. If we fail to transfer production processes effectively, develop product enhancements or introduce new products or enabling services in sufficient quantities to meet the needs of our customers, or effectively coordinate with our suppliers, our sales may be reduced and our business would be harmed.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The commercial success of all of our products will depend upon their acceptance by the life science and biopharmaceutical industries. Some of the products that we are developing are based upon new technologies or approaches. As a result, there can be no assurance that these new products, even if successfully developed and introduced, will be accepted by customers. If customers do not adopt our new products, services and technologies, our results of operations may suffer and, as a result, the market price of our common stock may decline.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If we are unable to successfully develop new products, adapt to rapid and significant technological change, respond to introductions of new products by competitors, make strategic and operational decisions to prioritize certain markets, technology offerings or partnerships, and develop and capitalize on markets, technologies or partnerships, our business could suffer.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We currently sell and license our products primarily in the cell therapy market, which is characterized by significant enhancements and evolving industry and regulatory standards and a high degree of regulatory scrutiny. As a result, our customers&#8217; needs are rapidly evolving. If we do not appropriately innovate and offer our customers comprehensive solutions and otherwise invest in new technologies, our offerings may become less desirable in the markets we serve, and our customers could move to new technologies offered by our competitors or make products themselves. Without the timely introduction of new instruments, single-use disposables software, services, enhancements and new product integrations with electroporation, our offerings may become less competitive over time, in which case our competitive position and operating results could suffer. Accordingly, we focus significant efforts and resources on the development and identification of new products and applications to further drive adoption of our platform. To the extent we fail to timely introduce new and innovative products, offer enhancements to our existing products, adequately predict our customers&#8217; needs or fail to obtain desired levels of market acceptance, our business may suffer and our operating results could be adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe our products have potential applications across a wide range of markets and we have targeted certain markets in which we believe our technology has significant advantages, or for which we believe we have a higher probability of success or significant revenue opportunity. For example, we are committed to developing our platform&#8217;s applications within the life sciences market, including research, discovery, development, and manufacturing of next-generation autologous and allogeneic cell-based therapeutics, as well as drug discovery, including protein production for biological therapeutics, viral vectors, vaccines and for the discovery of small molecule drugs. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between advancing near-term opportunities and exploring additional markets and uses for our technology. However, due to the significant resources required for the development of applications data for our products or services for new markets, we must make decisions on which markets to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular markets, products or services may not lead to the development of any viable products or services and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain markets may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. In particular, if we are unable to successfully achieve on-going adoption of our electroporation platform technology, it could slow or stop our business growth and negatively impact our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">New product development involves a lengthy and complex process and we may be unable to develop or commercialize products on a timely basis, or at all.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Products from our research and development programs will take time and considerable resources to develop, and may include improvements or changes to our current products, and we may not be able to complete development and commercialization of new or enhanced products on a timely basis, or at all. There can be no assurance that our research and development efforts will produce commercially viable products and solutions and before we can commercialize any new products, we will need to expend significant funds in order to, for example:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">conduct substantial research and development;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">in some cases, obtain necessary regulatory clearance or approval;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">further develop and scale our laboratory, engineering and manufacturing processes to accommodate different products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">source and enter into agreements with new suppliers and manufacturers; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">further develop and scale our infrastructure.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our product development processes involve a high degree of risk, and these efforts may be delayed or fail for many reasons, including failure of the product to perform as expected and failure to reliably demonstrate the advantages of the product.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Even if we are successful in developing new products, it will require us to make significant additional investments in marketing and selling resources to commercialize any such products. As a result, we may be unsuccessful in commercializing new products that we develop, which could adversely affect our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our systems are complex in design and may contain defects that are not detected until deployed by our customers, which could harm our reputation, increase our costs and reduce our sales. If our products do not perform as expected or the reliability of the technology on which our products are based is questioned, our operating results, reputation and business will suffer.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our success depends on our ability to provide reliable, high-quality products that enable high performance cell engineering through flexible, efficient and cost-effective solutions. Our systems are complex in design and involve a highly complex and precise manufacturing process. As a result of the technological complexity of our systems, changes in our suppliers&#8217; manufacturing processes or the inadvertent use of defective materials by us or our suppliers could result in a product recall, or an adverse effect on our ability to achieve acceptable manufacturing quality and product reliability. To the extent that we do not achieve and maintain our projected quality or product reliability, our reputation, business, operating results, financial condition and customer relationships would be adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our customers may discover defects in our products after the products have been fully installed and operated. In addition, some of our products include components from other vendors, which may contain defects. As a result, should problems occur, it may be difficult to identify the source of the problem. If we are unable to identify and fix defects or other problems, we could experience, among other things:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">product recalls and replacement costs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">loss of customers or orders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">damage to our brand reputation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">failure to attract new customers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">diversion of development, engineering and manufacturing resources;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">regulatory actions by governmental authorities; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">legal actions by our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe that customers in our target markets are likely to be particularly sensitive to product defects and errors. Our reputation and the image of our products, services and technologies in our target markets may be impaired if our products or services fail to perform as expected. If our products do not perform, or are perceived to not have performed, as expected or favorably in comparison to competitive products, our operating results, reputation, and business will suffer, and we may also be subject to legal claims arising from product limitations, errors, or inaccuracies. Any of the foregoing could have an adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Although our products are tested in accordance with industry standards prior to shipment, defects or errors could nonetheless occur. For example, our instruments or PAs could fail or our partners could use our technology improperly and blame a failure on our systems, resulting in customer complaints and significant resources dedicated to finding the cause of the failure and/or developing a solution. Our operating results depend on our ability to execute and, when necessary, improve our quality management strategy and systems and our ability to effectively train and maintain our employees with respect to quality management. A failure of our quality control systems could result in problems with facility operations or preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We provide a standard one-year warranty on sold instruments. Existing and future warranties place us at the risk of incurring future repair and/or replacement costs. Since a large portion of our revenue is derived from sales of our PAs, which can only be used when our instruments are functioning, if our instruments fail to function and our customers choose to use alternative cell engineering methods our financial condition and results of operations would suffer. In addition, even after any underlying concerns or problems are resolved, any lingering concerns in our target markets regarding our technology </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">or any manufacturing defects or performance errors, either actual or simply perceived, in our products or services could continue to result in lost revenue, delayed market acceptance, damage to our reputation and claims against us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If we are unable to successfully expand our commercial operations, including hiring additional qualified sales representatives, application scientists, engineers, scientific personnel, and customer support staff, our business may be adversely affected.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our future sales will depend, in large part, on our ability to develop and substantially expand our sales and applications scientist infrastructure, particularly as we enter into new markets, rollout new products and platforms and manage inbound interest from new customers. We sell our products through our direct sales force and field application scientists located in North America, the United Kingdom and Europe, and have field application scientists located in the Asia-Pacific region where sales are currently managed by distributors. Our sales and marketing efforts are targeted at pharmaceutical and biotechnology companies and academic institutions focused on cell engineering and drug discovery. To continue driving adoption of our products and to support our global brand, we will need to further expand our field sales and application scientist infrastructure by hiring additional, highly qualified sales representatives, field application scientists, engineers and scientific personnel and customer support staff, in addition to increasing our marketing efforts.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Identifying and recruiting qualified personnel globally with sufficient industry experience and training them requires significant time, expense and attention. If we provide inadequate training, fail to increase our sales and marketing capabilities or fail to develop broad brand awareness in our target markets in a cost-effective manner, our business may be harmed. In addition, if our efforts to expand do not generate a corresponding increase in revenue or result in a decrease in our operating margin, our financial results will be adversely impacted. If we are unable to hire, develop and retain talented sales personnel or if new sales personnel are unable to achieve desired productivity levels in a reasonable period of time, we may not be able to realize the expected benefits of this investment or increase our revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, our highly specialized application scientists and scientific personnel work closely with researchers, clinicians and current and prospective customers to optimize and implement cell engineering methods, processes and applications to meet their specific needs. Hiring these highly skilled application scientists and scientific personnel is competitive due to the limited number of people available with the necessary scientific and technical backgrounds and ability to understand our products at a technical level, and training such individuals requires significant time, expense and attention. Furthermore, we face intense competition in the labor market for such highly skilled specialists from competitors in our industry, our customers and companies in other industries, particularly because of the recent rapid growth in the cell therapy field. To effectively support current and potential customers, we will need to hire, maintain, train and grow globally the number of our applications scientists and add to our customer support staff. If we are unable to maintain, attract, train or retain the number of qualified support personnel that our business needs, our business and prospects will suffer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If we are unable to expand or leverage the number of peer-reviewed articles published using data generated through the use of our products or otherwise increase brand awareness in our target markets, the demand for our products and our business may be adversely affected.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We rely on a significant base of peer-reviewed publications to showcase and validate the application of our technology in academic and clinical research settings. To date, there have been multiple peer-reviewed articles published, including in prominent journals, using data generated through the use of our technology across a wide range of key scientific research areas, including research, discovery, development, and manufacturing of next-generation, cell-based therapeutics, as well as drug discovery including protein production for biological therapeutics, viral vectors, vaccines and small molecule discovery. We believe that expanding the number and breadth of these publications, and otherwise developing and maintaining awareness of our brand in our target markets in a cost-effective, manner is critical to achieving broad acceptance of our products and attracting new customers. Such publications and other brand promotion activities may not generate customer awareness or increase revenue and, even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">retain the customers necessary to realize a sufficient return on our brand-building efforts, or to achieve the reputation and widespread brand awareness that is critical for broad customer adoption of our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Risks Related to Our Regulatory Environment and Our Industry</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Changes in tariffs or other government trade policies may materially adversely affect our business and results of operations, including by reducing demand for our products.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The imposition of tariffs and trade restrictions as a result of international trade disputes or changes in trade policies may adversely affect our sales and profitability. For example, in 2018 and 2019, the U.S. government imposed and proposed, among other actions, new or higher tariffs on specified imported products originating from China in response to what it characterized as unfair trade practices, and China responded by imposing and proposing new or higher tariffs on specified U.S. products. There can be no assurance that a broader trade agreement will be successfully negotiated between the United States and China to reduce or eliminate these tariffs. These tariffs, and the related geopolitical uncertainty between the United States and China, may cause decreased demand for our products or increase cost of components used in our products, which could have a material adverse effect on our business and results of operations. For example, certain of our foreign customers may respond to the imposition of tariffs or threat of tariffs on products we produce by delaying purchase orders or purchasing products from our competitors. Ongoing international trade disputes and changes in trade policies could also impact economic activity and lead to a general contraction of customer demand. In addition, tariffs on components that we may import from China or other nations will adversely affect our profitability unless we are able to exclude such components from the tariffs or we raise prices for our products, which may result in our products becoming less attractive relative to products offered by our competitors. Future actions or escalations by either the United States or China that affect trade relations may also negatively affect our business, or that of our suppliers or customers, and we cannot provide any assurances as to whether such actions will occur or the form that they may take. To the extent that our sales or profitability are negatively affected by any such tariffs or other trade actions, our business and results of operations may be materially adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We are subject to governmental export controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Exports of our products are subject to export controls and sanctions laws and regulations imposed by the U.S. government and administered by the U.S. Departments of State, Commerce, and Treasury. U.S. export control laws may require a license or other authorization to export products to certain destinations and end users. In addition, U.S. economic sanctions laws include restrictions or prohibitions on the sale or supply of certain products to U.S. embargoed or sanctioned countries, governments, persons and entities. Obtaining export licenses can be difficult, costly and time-consuming and we may not always be successful in obtaining necessary export licenses, and our failure to obtain required export approval for our products or limitations on our ability to export or sell our products imposed by export control or sanctions laws may harm our revenues and adversely affect our business, financial condition, and results of operations. Noncompliance with these laws could have negative consequences, including government investigations, penalties and reputational harm.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The regulatory framework for the collection, use, safeguarding, retention, disclosure, transfer and other processing of personal data worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. We are, and will increasingly become as we seek to expand our business, subject to numerous foreign laws, regulations, rules and standards, as well as associated industry standards, policies and contractual or other obligations, relating to the collection, use, retention, security, disclosure, transfer and other processing of personal data in the jurisdictions in which we operate, collectively, Data Protection Requirements. If we fail, or are perceived to have failed, to address or comply with any such Data Protection Requirements, this could result in enforcement actions against us that could </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">include investigations, fines, penalties, audits and inspections, additional reporting requirements and/or oversight, temporary or permanent bans on all or some processing of personal data or orders to destroy or not use personal data. Further, individuals or other relevant stakeholders could bring a variety of claims against us for our actual or perceived failure to comply with the Data Protection Requirements. Any of these events could have a material adverse effect on our reputation, business, or financial condition, and could lead to a loss of actual or prospective customers, collaborators or partners; interrupt or stop clinical trials; result in an inability to process personal data or to operate in certain jurisdictions; limit our ability to develop or commercialize our products; or require us to revise or restructure our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For example, the European Union&#8217;s General Data Protection Regulation, or GDPR, applies to any processing operations carried out in the context of the activities of an establishment in the EEA, as well as to any other processing operations relating to the offering of goods or services to individuals in the EEA and/or the monitoring of individuals&#8217; behavior in the EEA. Also, notwithstanding the United Kingdom&#8217;s withdrawal from the EU, by operation of the so called &#8220;UK GDPR&#8221; &#8203;(i.e., the GDPR as it continues to form part of the law of the United Kingdom by virtue of section 3 of the EU (Withdrawal) Act 2018 and as subsequently amended), or UK GDPR, the GDPR continues to apply in substantially equivalent form to processing operations carried out in the context of the activities of an establishment in the United Kingdom and any other processing relating to the offering of goods or services to individuals in the United Kingdom and/or monitoring of individuals&#8217; behavior in the United Kingdom. Therefore, reference to the GDPR herein also refers to the UK GDPR in the context of the United Kingdom, unless the context requires otherwise.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Furthermore, the GDPR provides that EEA Member States may introduce specific requirements related to the processing of &#8220;special categories of personal data&#8221;, including the personal data related to health and genetic information, which we may process in connection with clinical trials or otherwise; as well as personal data related to criminal offences or convictions. In the United Kingdom, the UK Data Protection Act 2018 complements the UK GDPR in this regard. This fact may lead to greater divergence on the law that applies to the processing of such personal data across the EEA and/or United Kingdom, which may increase our costs and overall compliance risk.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The GDPR itself imposes stringent data privacy and security requirements on both processors and controllers of personal data, including personal data related to health and genetic information, which we may process in connection with clinical trials. In particular, the GDPR imposes several requirements relating to ensuring there is a lawful basis for processing personal data, extends the rights of individuals to whom the personal data relates, materially expands the definition of what is expressly noted to constitute personal data (including expanding the relevant definition to capture expressly the &#8216;pseudonymized&#8217; or key-coded data that is commonly processed in a clinical trial-related context), requires additional disclosures about how personal data is to be used, imposes limitations on retention of personal data, imposes strict rules on the transfer of personal data out of the EEA to most third countries, creates mandatory data breach notification requirements in certain circumstances and establishes onerous new obligations on service providers, or processors, who process personal data simply on behalf of others.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">A particular issue presented by certain European data protection laws, including the GDPR, is that they generally restrict transfers of personal data from Europe, including the EEA, the United Kingdom and Switzerland, to the United States and most other countries unless specific safeguards to protect the transferred personal data have been implemented. A July&#160;2020 decision of the European Union&#8217;s highest court, and subsequent regulatory guidance, have made complying with these requirements even more challenging&#8201;&#8212;&#8201;particularly in respect of transfers of personal data to the United States. Certain previously available safeguards have been invalidated, and reliance on alternative and commonly used safeguards may be complex or not possible in certain circumstances, following a recent ruling of the Court of Justice of the European Union and subsequent regulatory guidance. If we are unable to implement a valid solution for personal data transfers from Europe, we will face increased exposure to regulatory actions, substantial fines and injunctions. Inability to import/export personal data from Europe may also: restrict our activities in Europe; limit our ability to collaborate with partners as well as other service providers, contractors and other companies in Europe; and/or require us to increase our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">processing capabilities within Europe at significant expense or otherwise cause us to change the geographical location or segregation of our relevant systems and operations&#8201;&#8212;&#8201;any or all of which could adversely affect our operations or financial results. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Following the United Kingdom&#8217;s withdrawal from the EU on January&#160;31, 2020 and end of the post-Brexit transition period on December&#160;31, 2020, as noted above, the United Kingdom has introduced the UK GDPR which currently makes the privacy regimes of the EEA and United Kingdom similar, though it is possible that either the EU, and consequently those further states that make up the remainder of the EEA, or United Kingdom could elect to change their approach and create differences in legal requirements and regulation in this area. This could expose us to two parallel regimes, each of which potentially authorizes similar fines and other potentially duplicative and/or divergent enforcement actions for the same violations. Furthermore, under the post-Brexit Trade and Cooperation Agreement between the EU and the United Kingdom, the United Kingdom and EU have agreed that personal data transfers to the United Kingdom from EEA Member States will not be treated as &#8216;restricted transfers&#8217; to a non-EEA country for an initial period of up to six&#160;months from the end of the post-Brexit transition period. If the European Commission does not adopt an &#8216;adequacy decision&#8217; in respect of the United Kingdom during this period, from that point onwards the United Kingdom will be an &#8216;inadequate third country&#8217; under the GDPR and transfers of personal data from the EEA to the United Kingdom will require a valid &#8216;transfer mechanism&#8217; (such as entry into the then-current form of the European Commission-issued Standard Contractual Clauses). In general terms, the relationship between the United Kingdom and the EEA in relation to certain aspects of data protection law remains unclear, and there will now be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the United Kingdom and EEA.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">While we have taken steps to comply with the GDPR and implementing legislation in applicable Member States, and the UK GDPR and Data Protection Act 2018 in the United Kingdom, we cannot assure you that our efforts to achieve and remain in compliance have been and/or will continue to be, fully successful.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EEA Member States/the United Kingdom may result in fines of up to &euro;20,000,000 / &#163;17,500,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher. In addition to administrative fines, a wide variety of other potential enforcement powers are available to competent authorities in respect of potential and suspected violations of the GDPR, including extensive audit and inspection rights, and powers to order temporary or permanent bans on all or some processing of personal data carried out by non-compliant actors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">All of these evolving compliance and operational requirements may require us to modify our data processing practices and policies, which in turn could distract management or divert resources from other initiatives and projects and may interrupt or delay our development activities. Any failure or perceived failure by us to comply with any applicable laws and regulations relating to data privacy and security could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We are subject to U.S. and certain foreign anti-corruption and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are subject to anti-corruption and anti-money laundering laws and regulations, including Foreign Corrupt Practices Act, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;&#160;201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct or may in the future conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other third-party collaborators from authorizing, promising, offering, providing, soliciting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">or receiving, directly or indirectly, improper payments or anything else of value to or from persons in the public or private sector. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition to selling our products internationally directly through our sales teams, we currently engage third parties outside of the United States, and may engage additional third parties outside of the United States, to sell our products internationally and to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other third-party collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our customers who use our platform and we, if we develop a product, may be exposed to broadly applicable U.S. federal and state healthcare laws and regulations, including those relating to kickbacks and false claims, transparency, and health information privacy and security law. Failure to comply with such laws and regulations may result in substantial penalties.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our customers who use our platform and we, if we develop a product, may be subject to broadly applicable healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell, and distribute our products. Such laws include federal and state anti-kickback laws, false claims laws, transparency laws, and health information privacy and security laws.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Violations of such laws may result in substantial criminal, civil and administrative penalties, including imprisonment, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, and significant fines, monetary penalties, forfeiture, disgorgement and damages, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, in the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care, including the proposed modification to some of the aforementioned laws. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affected the healthcare industry. These reform initiatives may, among other things, result in modifications to the aforementioned laws and/or the implementation of new laws affecting the healthcare industry. Similarly, a significant trend in the healthcare industry is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Our ability to commercialize any of our products successfully, and our customers and collaborators&#8217; ability to commercialize their products successfully, will depend in part on the extent to which coverage and adequate reimbursement for these products and will be available from third-party payors. As such, cost containment reform efforts may result in an adverse effect on our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our business is subject to environmental regulation and regulations relating to the protection of health and safety matters that could result in compliance costs. Any violation or liability under environmental laws or health and safety regulations could harm our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are subject to environmental and safety laws and regulations governing the use, storage and disposal of hazardous substances or wastes and imposing liability for the cleanup of contamination from these substances. We handle hazardous substances in our manufacturing processes, and we could be liable for any improper use, storage, or disposal of such substances. We cannot completely eliminate the risk of contamination or injury from hazardous substances or wastes, and, in the event of such an incident, we could be held liable for any damages that result. In addition, we may be required to incur significant additional costs to comply with environmental laws and regulations in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Occupational Safety and Health Act of 1970, or OSHA, establishes certain employer responsibilities, including maintenance of a workplace free of recognized hazards likely to cause death or serious injury, compliance with standards promulgated by the Occupational Safety and Health Administration and various record keeping, disclosure and procedural requirements. Various OSHA standards may apply to our operations. We have incurred, and will continue to incur, capital and operating expenditures and other costs in the ordinary course of our business in complying with OSHA and other state and local laws and regulations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The failure to comply with these regulations could result in fines by government authorities and payment of damages to private litigants, which could harm our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our FDA Master File, and equivalent Technical Files in foreign jurisdictions, are an important part of our strategic offering which allows our partners to expedite their cellular therapies into and through the clinic. Delays in filing or obtaining (as applicable in a given jurisdiction), or our inability to obtain or retain, acceptance of such filings in individual countries could negatively impact the progress of our partners if they intend to run clinical trials in such countries, and as a result, could negatively affect our reputation and revenues or require disclosure of confidential information to our partners. Further, changes that we are required to make from time to time, or changes to regulations or negative data or adverse events for our partners, could impact references to our FDA Master File and Technical Files by our partners.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Providing our customers with an established regulatory path for use of our technology in the development of their therapeutics is an important value we provide to our customers. We have established and maintained an FDA Master File and equivalent Technical Files in certain other countries to provide that regulatory path. We may be unable in a timely manner, or at all, to provide similar filings in all countries where our customers desire to perform clinical trials, and regulators may refuse to accept such filings or may change their approach to such filings in a manner that weakens our ability to support our customers. If regulators at any point find that such filings have not been sufficiently maintained, or are insufficient to support clinical trials or drug approvals, as a result we may need to disclose confidential information to our partners to allow them to include such information in their filings. In addition, while we believe our FDA Master File and equivalent Technical Files have the potential to create certain efficiencies and reduce certain regulatory development risks for our customers, there is no guarantee that referencing our FDA Master File or Technical File, as applicable, will result in success in customers&#8217; submissions seeking authorization for clinical trials or marketing authorization. We cannot be certain that the FDA or foreign regulators will not require audits of and information on our ExPERT systems used in the clinic as our partners advance their cellular therapies from preclinical through clinical development toward marketing approval. Such additional information requests and audits of our facilities could result in delays in the development and potential regulatory approval of our partners&#8217; cellular therapy product candidates, affecting timing of milestone payments and our future ability to enter into new SPL agreements. Failure to adequately respond to any such regulatory requests could result in the regulator preventing our electroporation system from being utilized for a partner&#8217;s cellular therapy. This could result in our partners not utilizing our ExPERT system for their other clinical programs and negatively impact our ability to enter into partnership agreements with other cellular therapy developers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Risks Related to Our Financial Position and Capital Requirements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We may need additional funding beyond the proceeds of this offering and may be unable to raise capital when needed, which would force us to delay, reduce, eliminate or abandon our commercialization efforts or product development programs.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We cannot be certain that our anticipated cash flow from operations will be sufficient to meet all of our cash requirements or our growth plan. We intend to continue to make investments to support our business growth and may require additional funds to:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">expand the commercialization of our products and execute on our growth strategy;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">fund our operations and product development;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">finance the expansion into new international markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">expand our manufacturing capabilities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">defend, in litigation or otherwise, any claims that we infringe, misappropriate or otherwise violate third-party patents or other intellectual property rights;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">commercialize our new products, if any such products receive regulatory clearance or approval for commercial sale; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">acquire companies and in-license products or intellectual property.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe that the net proceeds from this offering, together with our existing cash balances and cash receipts generated from sales of our products, will be sufficient to meet our anticipated cash requirements for the foreseeable future. However, we may need additional funding sooner than expected and our business and future funding requirements can change unpredictably due to a variety of factors, including acquisitions, which could affect our funding needs or cash flows from operations. We may be unable to raise additional funds in a timely manner or on terms that are acceptable to us. If we do not have, or are not able to obtain, sufficient funds, we may have to delay the further development or commercialization of our products. We also may have to reduce marketing, customer support or other resources devoted to our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our results of operations and liquidity needs could be materially and adversely affected by market fluctuations and economic downturn.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our results of operations and liquidity could be materially and adversely affected by economic conditions generally, both in the United States and elsewhere around the world. Domestic and international equity and debt markets have experienced and may continue to experience heightened volatility and turmoil based on domestic and international economic policies, conditions and concerns. In the event the markets continue to remain volatile, our results of operations and liquidity could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may decline. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions, some of which may not be federally insured. If economic instability were to occur, we cannot be certain that we will not experience losses on these cash and cash equivalents.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the level of demand for any of our products, which may vary significantly;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the timing and cost of, and level of investment in, research, development, manufacturing, regulatory approval and commercialization activities relating to our products, which may change from time to time;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the size, seasonality and customer mix of the cell engineering market;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the start, milestone attainment and completion of programs in which our platform is utilized;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">sales and marketing efforts and expenses;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the rate at which we grow our sales force and the speed at which newly-hired salespeople become effective;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in the productivity of our sales force;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">positive or negative coverage in the media or publications of our products or competitive products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the cost of manufacturing our products, which may vary depending on the quantity of production and the terms of our arrangements with our suppliers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the degree of competition in our industry and any change in the competitive landscape of our industry, including the introduction of new products or enhancements or technologies by us or others in the cell engineering market and competition-related pricing pressures;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in governmental regulations or in the status of our regulatory approvals or applications;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">future accounting pronouncements or changes in our accounting policies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">disruptions to our business and operations or to the business and operations of our suppliers, distributors, and other third parties with whom we conduct business resulting from the COVID-19 pandemic or other widespread health crises;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">future global financial crises and economic downturns, including those caused by widespread public health crises; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our ability to use our net operating losses, business tax credits and similar tax attributes to offset future taxable income or taxes may be subject to certain limitations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As of December&#160;31, 2020, we had U.S. federal and state net operating loss carryforwards of $57.8 million and $43.0 million, respectively, and federal research credit carryforwards of $0.9 million. Under current law, U.S. federal net operating losses incurred in tax&#160;years beginning after December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of such federal net operating losses in tax&#160;years beginning after December&#160;31, 2020 is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws. In addition, under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, or the IRC, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which generally is defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss and tax credit carryforwards to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past and we may experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, including pursuant to this offering, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. Similar provisions of state law also may apply to limit the use of our state net operating loss carryforwards. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Risks Related to Our Operations</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide could adversely affect our business and the businesses of our partners. The COVID-19 pandemic has had and could continue to have an adverse impact on our business, operations, and the markets and communities in which we, our partners, and customers operate.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected, by, among other things, disrupting the research and development activities of our customers, disrupting the development of our collaboration partners&#8217; product candidates, disrupting our ability to enter into new collaborations with potential partners in a timely manner, causing disruptions in the operations of our third-party manufacturing organizations upon whom we rely for the production and supply of our products, and causing other disruptions to our operations. The COVID-19 pandemic has caused general business disruption worldwide. As a result of the COVID-19 pandemic, we temporarily closed our headquarters and other offices, and our employees and contractors who are able to perform their duties remotely continue to do so. We have also implemented travel restrictions and other significant changes in how we operate our business. The operations of our partners and customers have likewise been altered. While the duration and extent of the COVID-19 pandemic depends on future developments and potential resurgences that cannot be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">accurately predicted at this time, such as the extent and effectiveness of containment actions and available vaccines, the pandemic has had an adverse effect on the global economy and the ultimate societal and economic impact of the COVID-19 pandemic remains unknown. The potential impact and duration of the COVID-19 pandemic on the global economy and our business are difficult to assess or predict. Potential impacts, some of which we have already experienced, include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our customer prospects and our existing customers may experience slowdowns in their businesses, and our academic institution customers may experience decreases in government funding of research and development, which in turn may result in reduced demand for our products, lengthening of sales cycles, loss of customers, difficulties in collections, and inaccurate inventory forecasting;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">limitations on our business operations by local, state, provincial and/or federal governments that could impact our ability to sell products to customers, and visit customers for process optimization of their cellular therapies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">delays in negotiations with partners and potential partners;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">interruption of or delays in receiving supplies from the third parties we rely on to manufacture components to our products, which may impair our ability to sell our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">interruption of or delays in installation of our products for our customers and partners;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">interruption of or delays in the shipments of purchased products to customers or to our distribution partners;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">decreased employee productivity and morale, with increased employee attrition and risk of a cyberattack resulting from our employees working from home;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">disruptions and significant costs to our growth planning, such as for facilities and international expansion;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">costs in fully returning to work from our facilities around the world, including changes to the workplace, such as space planning, food service and amenities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">legal liability for safe workplace claims;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">loss of critical vendors or third-party partners, which may go out of business; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continued cancellation of in-person marketing events, including industry conferences, and prolonged delays in our ability to reschedule or conduct in-person marketing events and other sales and marketing activities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The impact of any of the foregoing, individually or collectively, could adversely affect our business, financial condition, and results of operations. Moreover, to the extent the COVID-19 pandemic adversely affects our business, financial condition, and results of operations, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Significant disruptions of information technology systems or breaches of information security could adversely affect our business, results of operations and financial condition.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We rely to a large extent upon sophisticated information technology systems to operate our business. In the ordinary course of business, we collect, store and transmit large amounts of information (including but not limited to, confidential information, employee data, customer information, personal data and intellectual property). We also have outsourced significant elements of our operations to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our information. The size and complexity of our information security systems, and those of our third-party vendors with whom we contract (and the large amounts of information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from malicious attacks by third parties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cyberattacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyberattacks also could include phishing attempts or e-mail fraud to cause unauthorized payments or information to be transmitted to an unintended recipient, or to permit unauthorized access to systems. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">industrial espionage and market manipulation) and expertise. While we have invested significantly in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any cyberattack or security incident that leads to unauthorized access, acquisition, use or disclosure of personal or proprietary information could harm our reputation, cause us not to comply with U.S. federal and/or state, or non-U.S., data breach notification laws, or our contractual obligations, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we have cyber-insurance coverage that may cover certain events described above, this insurance is subject to deductibles and coverage limitations and we may not be able to maintain this insurance. Also, it is possible that claims could exceed the limits of our coverage. Any interruption or breach in our systems could adversely affect our business operations and/or result in the loss of information, including confidential information, employee data, customer information, personal information or intellectual property, and could result in financial, legal, business and reputational harm to us or allow third parties to gain material, inside information that they use to trade in our securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We are highly dependent on our senior management team and key personnel and our business could be harmed if we are unable to attract and retain personnel necessary for our success.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are highly dependent on our senior management team and key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales, marketing, scientific and technical professionals, and to integrate current and additional personnel in all departments. The loss of members of our senior management, sales, marketing, scientific and technical professionals could result in lower than expected sales and delays in product development. If we are not successful in attracting and retaining highly qualified personnel, it would have a negative impact on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued, and will in the future issue, equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, they may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Many of the other cell engineering or therapeutic development companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities, better chances for career advancement and higher compensation. Some of these characteristics are more appealing to high-quality candidates than what we can offer. Further, if we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, job candidates and existing employees often consider the value of the equity awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, either because we are a public company or for other reasons, it may harm our ability to recruit and retain highly skilled employees. Many of our employees have become or will soon become vested in a substantial amount of their equity awards. Our employees may be more likely to leave us if the equity they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock, particularly after the expiration of the lock-up agreements described herein.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our future success also depends on our ability to continue to attract and retain additional executive officers and other key employees as we expand our business and operations. If we fail to attract new </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">personnel or fail to retain and motivate our current personnel, it will negatively affect our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have increased the size of our organization and expect to further increase it in the future, and we may experience difficulties in managing our growth. If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">As of March&#160;31, 2021, we had 65 full-time employees. As our sales and marketing strategies develop and as we transition into operating as a public company on a U.S. exchange, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">identifying, recruiting, integrating, maintaining and motivating additional employees;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">managing our internal development efforts effectively, while complying with our contractual obligations to contractors and other third parties; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">improving our operational, financial and management controls, reporting systems and procedures.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Since our inception, we have experienced growth and anticipate further growth in our business operations both inside and outside the United States. This future growth could strain our organizational, administrative and operational infrastructure, including quality control, operational, finance, customer service and sales organization management. We expect to continue to increase our headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, engineers, technical personnel and sales and marketing staff and improve and maintain our products to properly manage our growth. Rapid expansion in personnel could mean that less experienced people develop, market and sell our products, which could result in inefficiencies and unanticipated costs, reduced quality and disruptions to our operations. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our employees, our business may be harmed. We may not be able to maintain the quality or expected turnaround times of our products or satisfy customer demand as it grows. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a timely, efficient and effective manner could adversely affect our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our officers, employees, independent contractors, consultants and commercial partners may engage in misconduct or activities that are improper under other laws and regulations, or make significant errors, which would create liability for us.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are exposed to the risk that our officers, employees, independent contractors, consultants, commercial partners, suppliers, and third-party distributors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, which could result in regulatory sanctions and serious harm to our reputation. While we have programs in place to address this conduct, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal, and administrative penalties, including without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, and the curtailment or restructuring of our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If we were to be sued for product liability, we could face substantial liabilities that exceed our resources, limit sales of our existing products and limit commercialization of any products that we may develop.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The marketing, sale and use of our products could lead to the filing of product liability claims where someone may allege that our products identified inaccurate or incomplete information or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">otherwise failed to perform as designed. We may also be subject to liability for errors in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability claim could result in substantial damages and be costly and time-consuming for us to defend. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">substantial litigation costs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">distraction of management&#8217;s attention from our primary business;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the inability to commercialize our products or new products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">decreased demand for our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">damage to our business reputation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">product recalls or withdrawals from the market;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">loss of sales; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">termination of existing agreements by our partners and potential partners failing to partner with us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We maintain product liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability claims. Any product liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our reputation. We may not be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future and these efforts may not have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also harm our reputation with customers, which could negatively affect our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If our customers fail to safely and appropriately use our products, or if we are unable to train our customers on the safe and appropriate use of our products, our reputation may be negatively impacted and we may be unable to achieve our expected sales, growth or profitability.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">An important part of our sales process includes training our customers on how to safely and appropriately use our products. If our customers are not properly trained, they may misuse or ineffectively use our products. Any improper use of our products may result in unsatisfactory outcomes, negative publicity or lawsuits against us, any of which could harm our reputation and affect future product sales. Even if our products are used improperly by customers, we may face reputational damage if our products are associated with negative outcomes or injuries. Damage to our reputation could make it more difficult for us to sell our products and enter into new partnerships. Accordingly, if our customers fail to safely and appropriately use our products or if we are unable to train our customers on the safe and appropriate use of our products, our reputation may be negatively impacted and we may be unable to achieve our expected sales, growth or profitability.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Litigation and other legal proceedings may harm our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">While we have never been involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal or state regulatory investigations, securities class actions and other legal proceedings or investigations, we may become involved in such legal proceedings which could have a negative impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could harm our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">could damage our reputation and brand image, undermine our customers&#8217; confidence and reduce long-term demand for our products, even if the regulatory or legal action is unfounded or not material to our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our operations (including our manufacturing operations) and the operations of our distribution partners could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and pandemics, including the COVID-19 pandemic, and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. Our ability to obtain components for our products could be disrupted if the operations of our suppliers were affected by a man-made or natural disaster or other business interruption, including interruptions related to the COVID-19 pandemic. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We manufacture our ExPERT instruments at our manufacturing facilities located in Maryland, and we rely on various suppliers in the United States. Should our manufacturing facilities or the facilities of our suppliers be damaged or destroyed by natural or man-made disasters, such as earthquakes, fires or other events, or should events such as political unrest unfold, it could take&#160;months to relocate or rebuild, during which time our manufacturing and the operations of our suppliers would cease or be delayed and our products may be unavailable. The inability to perform our manufacturing activities, combined with our limited inventory of materials and components and manufactured products, or the inability of our suppliers to continue their operations, may cause us to be unable to meet customer demand or harm our reputation, and we may be unable to reestablish relationships with such customers in the future. Consequently, a catastrophic event or business interruption at our manufacturing facilities or at our suppliers&#8217; facilities could harm our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We do not carry insurance for all categories of risk that our business may encounter. Although we have general and product liability insurance that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available, coverage may not be adequate to protect us against any future product liability claims. If we are unable to obtain insurance at an acceptable cost or on acceptable terms or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could negatively affect our business, financial condition and results of operations. We do not carry specific hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. Although we carry cyber insurance, the coverage may not be sufficient to cover our losses in the event of a security incident that results in any data loss, deletion or destruction; unauthorized access to, or acquisition, disclosure or exposure of information; or compromise related to the security, confidentiality, integrity or availability of information technology, software, services, communications or data.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We also expect that operating as a public company in the United States will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, on our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would negatively affect our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">The majority of our operations are currently conducted at a single location and any disruption at our facility could negatively impact our operations and increase our expenses.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our headquarters in Maryland contains most of our corporate and administrative functions, the majority of our research, and all of our in-house manufacturing, inventory and distribution functions. A natural or other disaster, such as a fire or flood, could cause substantial delays in our operations, damage or destroy our manufacturing equipment or inventory, and cause us to incur additional expenses. The insurance we maintain against fires, floods and other natural disasters may not be adequate to cover our losses in any particular case. With or without insurance, damage to our manufacturing facility or our other property, or to any of our suppliers, due to fire, flood or other natural disaster or casualty event may have a material adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We may face exposure to foreign currency exchange rate fluctuations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the Euro and the British pound. We expect our non-U.S. operations to continue to grow in the near term and we are continually monitoring our foreign currency exposure to determine if we should consider a hedging program. Today, our non-U.S. contracts are generally denominated in U.S. dollars, while our non-U.S. operating expenses are often denominated in local currencies. Additionally, as we expand our non-U.S. operations, a larger portion of our operating expenses may be denominated in local currencies. Therefore, increases in the value of the U.S. dollar and decreases in the value of foreign currencies could result in the dollar equivalent of our revenue being lower, which would negatively affect our reported results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Risks Related to our Intellectual Property</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our ability to compete and the success of our business could be jeopardized if we are unable to protect our intellectual property adequately.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our success depends to a degree upon the protection of our proprietary technology and obtaining, maintaining and enforcing our intellectual property and other proprietary rights. We rely on a combination of trade secrets, patents, copyrights, trademarks and contractual provisions with employees, contract manufacturers, consultants, customers and other third parties to establish and protect our intellectual property rights, all of which offer only limited protection. Other parties may not comply with the terms of their agreements with us, and we may not be able to enforce our rights adequately against these parties.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Although we enter into confidentiality, assignments of proprietary rights and license agreements, as appropriate, with our employees and third parties, including our contract manufacturers, contract engineering firms, and generally control access to and distribution of our technologies, documentation and other proprietary information, we cannot be certain that the steps we take to prevent unauthorized use of our intellectual property rights are sufficient to prevent their misappropriation, particularly in foreign countries where laws or law enforcement practices may not protect our intellectual property rights as fully as in the United States. In addition, we rely on trade secrets and know-how to protect certain of our technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets and know-how are difficult to protect, as trade secrets do not protect against independent development of a technology by third parties. Although we use reasonable efforts to protect our trade secrets and know-how, our employees and third parties to whom our trade secrets and know-how are disclosed may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If competitors are able to use our technology, our ability to compete effectively could be harmed. For example, if a competitor were to gain use of certain of our proprietary technology, it might be able to develop and manufacture similarly designed solutions at a reduced cost, which would result in a decrease in demand for our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Furthermore, we have adopted a strategy of seeking limited patent protection both in the United States and in foreign countries with respect to the technologies used in or relating to our products. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Although we generally apply for patents in those countries where we expect to have material sales of our patented products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. We do not know whether any of our pending patent applications will result in the issuance of patents or whether the examination process will require us to narrow our claims, and even if patents are issued, they may be contested, circumvented, modified, revoked, found to be unenforceable, or invalidated over the course of our business. Moreover, the rights granted under any issued patents may not provide us with proprietary protection, barriers to entry or competitive advantages, and, as with any technology, competitors may be able to develop and obtain patents for technologies that are similar to or superior to our technologies. If that happens, we may need to license these technologies and we may not be able to obtain licenses on reasonable terms, if at all, thereby causing great harm to our business. Additionally, the determination that a patent application or patent claim meets all of the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the United States Patent and Trademark Office, or the USPTO, or by a court or other trier of fact in the United States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or patent applications, in our licensed patents or patent applications or in third-party patents. Moreover, patents have a limited term, and certain of our patents have recently or will expire in the near future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We rely on our trademarks, trade names, and brand names to distinguish our products from the products of our competitors and have registered or applied to register many of these trademarks. We cannot assure you that our trademark applications will be approved. Third parties may also oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources to the advertising and marketing of new brands.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Legal proceedings to assert our intellectual property rights could be costly and could impair our operations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Even in those instances where we have determined that another party is breaching our intellectual property and other proprietary rights, enforcing our legal rights with respect to such breach may be expensive and difficult. We may need to engage in litigation to enforce or defend our intellectual property and other proprietary rights, which could result in substantial costs and diversion of management resources. Further, many of our current and potential competitors are substantially larger than we are and have the ability to dedicate substantially greater resources to defending any claims by us that they have breached our intellectual property rights. If we are unsuccessful in enforcing our intellectual property rights, it could have a material adverse effect on our business, results of operations and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We may be sued by third parties for alleged infringement of their proprietary rights, which could be costly, time-consuming and limit our ability to use certain technologies in the future or to develop future products.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We may be subject to claims that our technologies infringe upon the intellectual property or other proprietary rights of third parties. Any claims, even those without merit, could be time-consuming and expensive, and could divert our management&#8217;s attention away from the execution of our business plan. Moreover, any settlement or adverse judgment resulting from the claim could require us to pay substantial amounts or obtain a license to continue to use the technology that is the subject of the claim, or otherwise restrict or prohibit our use of the technology. There can be no assurance that we would be able to obtain a license from the third party asserting the claim on commercially reasonable terms, if at all, that we would be able to develop alternative technology on a timely basis, if at all, or that we would be able to obtain a license to use a suitable alternative technology to permit us to continue offering, and our customers to continue using, our affected product.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how this and future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also harm our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We may be obligated to disclose our proprietary technology to our customers, which may limit our ability to protect our intellectual property.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Certain customer agreements contain provisions permitting the customer to become a party to, or a beneficiary of, a technology escrow agreement under which we place proprietary know-how and source code for our products in escrow with a third party. Under these escrow agreements, the know-how and source code to the applicable product may be released to the customer, typically for its use to further develop, maintain, modify and enhance the product, upon the occurrence of specified events, such as our filing for bankruptcy and breaching our representations, warranties or covenants of our agreements with our customers. Disclosing this know-how and source code may limit the intellectual property protection we can obtain or maintain for that know-how or source code or the products embodying or containing that know-how or source code and may facilitate intellectual property infringement claims against us. Each of these could harm our business, results of operations and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Risks Related to This Offering and Our Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">There has been no prior market for our common stock in the United States and an active trading market for our common stock may not develop in the United States.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Prior to this offering, there has been no public market for shares of our common stock in the United States. However, since 2016, our common stock has traded on AIM under the symbol &#8220;MXCT,&#8221; as well as other symbols, of which &#8220;MXCN&#8221; is currently active, and following this offering will continue to trade on AIM. We cannot predict when or whether investor interest in our common stock might lead to an increase in its market price or the development of a more active trading market. The U.S. initial public offering price for our common stock will be determined through negotiations with the underwriters based on a number of factors, including the historic trading prices of our common stock on AIM, that might not be indicative of prices that will prevail in the trading market for our common stock in the United States. While we intend to apply to list our shares of common stock on the Nasdaq Global Market, an active trading market for our shares in the United States may never develop or be sustained following this offering. If an active market for our common stock does not develop, it may be difficult to sell shares purchased in this offering without depressing the market price for the shares, or at all.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of listed companies. Stock prices of many newly public companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Upon the completion of this offering, our common stock will be traded on two separate stock markets and investors seeking to take advantage of price differences between such markets may create unexpected volatility in our share price; in addition, investors may not be able to easily move shares for trading between such markets.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our shares of common stock are already admitted to and traded on AIM and we intend to apply to list our common stock on The Nasdaq Global Market. Price levels for our common stock may fluctuate significantly on either market, independent of our common stock price on the other market. Investors could seek to sell or buy our common stock to take advantage of any price differences between the two markets through a practice referred to as arbitrage. Any arbitrage activity could create unexpected volatility in both our common stock prices on either exchange and the volumes of shares of our common stock available for trading on either exchange. In addition, holders of common stock on either market will not be immediately able to transfer such common stock for trading on the other market without effecting necessary procedures with our transfer agent. This could result in time delays and additional cost for our stockholders. Further, if we are unable to continue to meet the regulatory requirements for admission to AIM or listing on the Nasdaq Global Market, we may lose our admission to AIM or listing </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">on the Nasdaq Global Market, which could impair the liquidity of shares of our common stock. Investors whose source of funds for the purchase of shares of our common stock is denominated in a currency other than U.S. Dollars may also be adversely affected by fluctuations in the exchange rate between such currency and the U.S. Dollar.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Securities traded on AIM may carry a higher risk than securities traded on other exchanges, which may impact the value of your investment.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our shares of common stock are currently traded on AIM. Investment in equities traded on AIM is sometimes perceived to carry a higher risk than an investment in equities quoted on exchanges with more stringent listing requirements, such as the main market of the London Stock Exchange, New York Stock Exchange or Nasdaq. This is because AIM is less heavily regulated, imposes less stringent corporate governance and ongoing reporting requirements than those other exchanges. In addition, AIM requires only half-yearly, rather than quarterly, financial reporting. You should be aware that the value of our shares of common stock may be influenced by many factors, some of which may be specific to us and some of which may affect AIM companies generally, including the depth and liquidity of the market, our performance, a large or small volume of trading in our shares of common stock, legislative changes and general economic, political or regulatory conditions, and that the prices may be volatile and subject to extensive fluctuations. Therefore, the current market price of our shares of common stock may not reflect the underlying value of our company.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">The price of our common stock is likely to be volatile and may fluctuate due to factors beyond our control.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The market price of our common stock may be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">actual or anticipated fluctuations in our financial condition or results of operations;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">variance in our financial performance from expectations of securities analysts;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in our projected operating and financial results;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">announcements by us or our competitors of significant business developments, acquisitions, or new offerings;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">announcements by our partners on clinical development delays for products being enabled by our technology;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">announcements or concerns regarding real or perceived safety or efficacy issues with our products or similar products of our competitors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">adoption of new regulations applicable to our industry or the expectations concerning future regulatory developments;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our involvement in litigation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">future sales of our common stock by us or our stockholders, as well as the anticipation of lock-up releases;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in senior management or key personnel;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the trading volume of our common stock;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in the anticipated future size and growth rate of our market; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">general economic and market conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Broad market and industry fluctuations, as well as general economic, political, regulatory and market conditions, may also negatively impact the market price of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price of our common stock and our trading volume could decline.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If no or too few securities or industry analysts commence coverage of us, the trading price for our common stock could be negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, the price of our common stock could decline. If one or more of these analysts cease coverage of us or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">fail to publish reports on us regularly, demand for our common stock could decrease, which might cause the price of our common stock and trading volume to decline</font><font style="font-style:italic;">.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We will incur increased costs as a result of operating as a U.S.-listed public company, and our management and board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As a U.S.-listed public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company or as a company with shares traded only on AIM. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Market, and other applicable securities rules and regulations impose various requirements on public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. In addition, our shares of common stock are currently traded on AIM and will continue to be subject to AIM&#8217;s admission and compliance requirements, which differ in many respects from the requirements of the Nasdaq Global Market and U.S. securities rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our management, board of directors and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our management and board of directors. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Future sales of our common stock in the public market could cause our share price to fall.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Sales of a substantial number of shares of our common stock in the public market after this offering, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. Upon the closing of this offering, we will have &#8199;&#8199;&#8199;&#8199; shares of common stock outstanding, assuming no exercise of outstanding options or the underwriters&#8217; option to purchase additional shares.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">All of the shares of common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act of 1933, or the Securities Act, as amended, except for any shares held by our affiliates as defined in Rule&#160;144 under the Securities Act. A total of &#8199;&#8199;&#8199;&#8199; shares of common stock outstanding immediately after this offering, or&#8199;&#8199;&#8199;&#8199;%, will be restricted as a result of securities laws, lock-up agreements or other contractual restrictions that restrict transfers for 90&#160;days after the date of this prospectus. Of the remaining shares outstanding,&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares will remain freely tradeable and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares will become freely tradeable after the distribution compliance period pursuant to Regulation&#160;S under the Securities Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated and William Blair &amp; Company, L.L.C. may, in their sole discretion, release all or some portion of the shares subject to lock-up agreements with the underwriters prior to expiration of the lock-up period. See &#8220;Shares Eligible for Future Sale.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We intend to file a registration statement on Form S-8 under the Securities Act to register shares for issuance under our equity incentive plans, including our Long-Term Incentive Plan, or LTIP, 2021 Equity Incentive Plan and employee stock purchase plan. Each of these plans provides for automatic increases in the shares reserved for issuance under the plan which could result in additional dilution to our stockholders. Once we register these shares, they can be freely sold in the public market upon issuance and vesting, subject to any lock-up restrictions of the holder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Because we do not expect to pay dividends on our common stock in the foreseeable future, capital appreciation, if any, would be your sole source of gain.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have never declared or paid any dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. The decision to pay </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">future dividends to stockholders will be at the discretion of our board of directors after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. Accordingly, investors cannot rely on dividend income from our common stock and any returns on an investment in our common stock will likely depend entirely upon any future appreciation in the price of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If you purchase common stock in this offering, you will suffer immediate dilution of your investment.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The assumed initial public offering price of our common stock is substantially higher than the net tangible book value per share. Therefore, if you purchase common stock in this offering, you will pay a price per share that substantially exceeds the book value of our tangible assets, after subtracting our liabilities, after this offering. Based on the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the range set forth on the cover page of this prospectus, you will experience immediate dilution of $&#8199;&#8199;&#8199;&#8199; per share, representing the difference between our net tangible book value per share after giving effect to this offering and the assumed initial public offering price. In addition, purchasers of common stock in this offering will have contributed approximately &#8199;&#8199;&#8199;&#8199;% of the aggregate price paid by all purchasers of our common stock but will own only approximately &#8199;&#8199;&#8199;&#8199;&#8199;% of our common stock outstanding after this offering. To the extent options are exercised, you will incur further dilution. See the section of this prospectus titled &#8220;Dilution&#8221; for more information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Provisions in our bylaws will require disclosure of information about stockholders that would not otherwise be required to be disclosed under applicable U.S. state or federal laws.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In accordance with the AIM Rules for Companies published by the London Stock Exchange, or the AIM Rules, we are required to disclose information regarding the legal and beneficial owners of three&#160;percent or more of our outstanding common stock. In order to allow us to comply with the AIM Rules, our certificate of incorporation contains a provision requiring any legal or beneficial owner of three&#160;percent or more of the voting power attributable to our outstanding common stock to notify us of his, her or its holdings, as well as of any change in his, her or its legal or beneficial ownership above three&#160;percent of our outstanding common stock, which increases or decreases his, her or its holding through any single&#160;percentage. Comparatively, none of the U.S. state or federal laws that will be applicable to us after the offering or the rules of Securities and Exchange Commission, or the SEC, or the Nasdaq Global Market require stockholders to report this beneficial ownership information to us or us to disclose this information to the public or a regulatory body. We are required to make this information public in the United Kingdom under the AIM Rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. We intend to use the net proceeds from this offering to: (i)&#160;continue making investments in research and development efforts; (ii)&#160;continue making investments in building our business development, sales and applications teams and marketing our products to new and existing partners in attractive global markets, as well as for general corporate purposes, including working capital, operating expenses and capital expenditures; (iii)&#160;further invest to in-source and automate manufacturing to support our cell therapy customers; (iv)&#160;scale our process development capabilities via investment in laboratory space, equipment and addition of scientific resources; and (v)&#160;commercialize our VLX Large-Scale Transfection System under the ExPERT family of products to facilitate potential expansion into adjacent markets. The failure by our management to apply these funds effectively could result in financial losses that could have an adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; will make our common stock less attractive to investors.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain exemptions from various reporting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">requirements that are applicable to other public companies that are not &#8220;emerging growth companies,&#8221; including the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Pursuant to Section&#160;107 of the JOBS Act, as an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make our common stock less attractive to investors. In addition, if we cease to be an emerging growth company, we will no longer be able to use the extended transition period for complying with new or revised accounting standards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We will remain an emerging growth company until the earliest of: (1)&#160;the last day of the fiscal year following the fifth anniversary of this offering; (2)&#160;the last day of the first fiscal year in which our annual gross revenue is $1.07&#160;billion or more; (3)&#160;the date on which we have, during the previous rolling three-year period, issued more than $1&#160;billion in non-convertible debt securities; and (4)&#160;the last day of the fiscal year in which the market value of our common stock held by non-affiliates exceeded $700&#160;million as of June&#160;30 of such fiscal year.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. For example, if we do not adopt a new or revised accounting standard, our future results of operations may not be as comparable to the results of operations of certain other companies in our industry that adopted such standards. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&#160;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an &#8220;emerging growth company&#8221; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404. We could be an &#8220;emerging growth company&#8221; for up to five&#160;years. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Provisions in our fifteenth amended and restated certificate of incorporation and amended and restated bylaws, as they will be in effect upon the completion of this offering, and provisions of Delaware </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">law applicable to us, may have the effect of delaying or preventing a change of control or changes in our management. Our fifteenth amended and restated certificate of incorporation and amended and restated bylaws will include provisions that:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">authorize our board of directors to issue, without further action by the stockholders, shares of undesignated preferred stock with terms, rights, and preferences determined by our board of directors that may be senior to our common stock;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, or our chief executive officer;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for election to our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">establish that our board of directors is divided into three classes, with each class serving three-year staggered terms;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">prohibit cumulative voting in the election of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that our directors may be removed for cause only upon the vote of at least &#8199;&#8199;&#8199;&#8199;% of our outstanding shares of voting stock; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which generally, subject to certain exceptions, prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three&#160;years following the date on which the stockholder became an &#8220;interested&#8221; stockholder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our fifteenth amended and restated certificate of incorporation will designate the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America as the exclusive forums for substantially all disputes between us and our stockholders, which will restrict our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers, or employees.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation, as will be in effect upon the completion of this offering, will provide that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any derivative action or proceeding brought on our behalf;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any action asserting a breach of a fiduciary duty;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our fifteenth amended and restated certificate of incorporation, or our amended and restated bylaws; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any action asserting a claim against us that is governed by the internal affairs doctrine.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The provisions would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Securities Exchange Act of 1934, as amended. Furthermore, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our fifteenth amended and restated certificate of incorporation will provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:488pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees. If a court were to find either choice of forum provision contained in our fifteenth amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could seriously harm our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">This prospectus contains forward-looking statements about us and our industry that involve substantial risks, uncertainties, and assumptions, including those described in &#8220;Risk Factors&#8221; and elsewhere in this prospectus. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; or &#8220;would&#8221; or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our expected future growth and the success of our business model;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the potential payments we may receive pursuant to our SPLs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share and achieve and maintain industry leadership;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the rate and degree of market acceptance of our products within the cell engineering market;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the expected future growth of our manufacturing capabilities and sales, support and marketing capabilities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to expand our customer base and enter into additional SPLs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to accurately forecast and manufacture appropriate quantities of our products to meet commercial demand;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our expectations regarding development of the cell therapy market, including projected growth in adoption of non-viral delivery approaches and gene editing manipulation technologies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to maintain our FDA Master File and Technical Files;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our research and development for any future products, including our intention to introduce new instruments and PAs and move into new applications;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the development, regulatory approval, and commercialization of competing products and our ability to compete with the companies that develop and sell such products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to retain and hire senior management and key personnel;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">regulatory developments in the United States and foreign countries;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to develop and maintain our corporate infrastructure, including our internal controls;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our financial performance and capital requirements;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our use of the net proceeds from this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this prospectus primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this prospectus. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:396pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. And while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The forward-looking statements made in this prospectus relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this prospectus to reflect events or circumstances after the date of this prospectus or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission, or SEC, as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMIAO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:354pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">MARKET, INDUSTRY AND OTHER DATA</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">This prospectus contains estimates, projections and other information concerning our industry, our business and the markets for our products. Some market data and statistical information contained in this prospectus are also based on management&#8217;s estimates and calculations, which are derived from our review and interpretation of independent sources and our internal research and knowledge of our market. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to these estimates. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements.&#8221; These and other factors could cause results to differ materially from those expressed in the projections and estimates made by independent third parties and us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Unless otherwise expressly stated, we obtained industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">USE OF PROCEEDS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We estimate that we will receive net proceeds from this offering of approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million (or approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million if the underwriters exercise their option to purchase additional shares of our common stock from us in full) based on an assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">A $1.00 increase (decrease) in the assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same. An increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us would increase (decrease) the net proceeds to us from this offering by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock remains the same.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The principal purposes of this offering are to obtain additional capital to increase our financial flexibility, to support our operations and growth, to create a public market for our common stock in the United States and to enable access to the U.S. public equity markets for us and our stockholders.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continue making investments in research and development efforts towards deepening our technology and expertise in cell engineering and delivery to support our current markets and broaden into new cell therapy applications;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continue making investments in building our business development, sales and applications teams and marketing our products to new and existing partners in attractive global markets, as well as for general corporate purposes, including working capital, operating expenses and capital expenditures;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">further invest to in-source and automate manufacturing to support our cell therapy customers progress into commercialization and broaden our position in the bioprocessing segment;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">scale our process development capabilities via investment in laboratory space, equipment and addition of scientific resources; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">commercialize our large scale VLX platform under the ExPERT brand to facilitate potential expansion into adjacent markets, such as large-scale bioprocessing, as well as the scale of cell therapy approaches (such as allogeneic therapies).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We may also use a portion of the net proceeds from this offering for the acquisition of businesses, technologies, services or other assets that we believe are complementary to our own. However, we do not currently have agreements or commitments to enter into any acquisitions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The amount and timing of these expenditures will vary depending on a number of factors, including competitive and technological developments and the rate of growth of our business and our potential acquisition activities. Based on our current plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditure requirements for the foreseeable future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIPO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:562pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">DIVIDEND POLICY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate declaring or paying any cash dividends in the foreseeable future. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">CAPITALIZATION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table sets forth our cash and cash equivalents and capitalization as of March&#160;31, 2021:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">on an actual basis;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">on an as adjusted basis, giving effect to our receipt of estimated net proceeds of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; million from the sale of shares of common stock that we are offering at an assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The information below is illustrative only and our capitalization following this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. Cash and cash equivalents are not components of our total capitalization. You should read this table together with the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes included elsewhere in this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:176.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:334.64pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Actual </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">As Adjusted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands except share and </font>
                <br >
                <font style="letter-spacing:-0.04pt;">per share amounts) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:334.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:334.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Stockholders&#8217; equity: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:334.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Common stock, $0.01 par value, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; authorized, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares issued and outstanding, actual; &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares authorized, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares issued and outstanding, as adjusted</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:334.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:334.64pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Total stockholders&#8217; equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:334.64pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.025pt;">Total capitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.67pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">A $1.00 increase (decrease) in the assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) each of our as adjusted cash and cash equivalents, additional paid-in capital, total stockholders&#8217; equity and total capitalization by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us would increase (decrease) each of our as adjusted cash and cash equivalents, additional paid-in capital, total stockholders&#8217; equity and total capitalization by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock remains the same.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The number of shares of common stock that will be outstanding after this offering is based on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of common stock outstanding as of March&#160;31, 2021, and excludes:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock issuable on the exercise of outstanding stock options as of March&#160;31, 2021 under our LTIP with a weighted average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock reserved for future issuance as of March&#160;31, 2021 under our LTIP;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock issuable on the exercise of an outstanding common stock warrant at an exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock reserved for future issuance under our 2021 Plan, which will become effective upon the execution of the underwriting agreement related to this offering, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:518pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder, and any shares underlying outstanding stock awards granted under our LTIP and 2021 Plan that expire or are repurchased, forfeited, cancelled or withheld, as more fully described in the section titled &#8220;Executive Compensation&#8201;&#8212;&#8201;Equity Incentive Plans&#8221;; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock reserved for issuance under our ESPP, which will become effective upon the execution of the underwriting agreement related to this offering, as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for future issuance thereunder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">DILUTION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the public offering price per share of common stock and the as adjusted net tangible book value per share immediately after this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our net tangible book value as of March&#160;31, 2021 was $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock. Our net tangible book value per share represents the amount of our total tangible assets less our total liabilities, divided by the number of our shares of common stock outstanding as of March&#160;31, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">After giving effect to the sale by us of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of common stock in this offering at an assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of March&#160;31, 2021 would have been $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. This amount represents an immediate increase in net tangible book value of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to our existing stockholders and an immediate dilution of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to new investors purchasing common stock in this offering. We determine dilution by subtracting the as adjusted net tangible book value per share after this offering from the public offering price per share paid by investors purchasing common stock in this offering. The following table illustrates this dilution on a per share basis:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:83pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:364.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Assumed public offering price per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:364.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Historical net tangible book value per share as of March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:364.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Increase in net tangible book value per share attributable to new investors purchasing shares in this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:364.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">As adjusted net tangible book value per share after giving effect to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt; width:364.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Dilution per share to new investors in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.39pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The dilution information discussed above is illustrative only and may change based on the actual public offering price and other terms of this offering. A $1.00 increase (decrease) in the assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) our as adjusted net tangible book value per share after this offering by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and increase (decrease) the dilution to new investors by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, in each case assuming the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same. An increase of 1,000,000 shares in the number of shares of common stock offered by us would increase our as adjusted net tangible book value by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and decrease the dilution to new investors by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and a decrease of 1,000,000 shares in the number of shares of common stock offered by us would decrease our as adjusted net tangible book value by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and increase the dilution to new investors by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, in each case assuming the assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock remains the same.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">If the underwriters exercise their option to purchase additional shares of common stock from us in full, our as adjusted net tangible book value would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, and the dilution in net tangible book value per share to new investors in this offering would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table summarizes, as of March&#160;31, 2021, on the as adjusted basis described above, the number of shares of our common stock, the total consideration and the average price per share (1)&#160;paid to us by existing stockholders and (2)&#160;to be paid by new investors acquiring our common stock in this offering at an assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:138.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:76.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.62pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="7">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Shares Purchased </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Total Consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Average Price</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:30.21pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Percent </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Percent </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:231.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Existing stockholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:30.21pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00999999999999801pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:231.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">New investors </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:30.21pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.04pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00999999999999801pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.04pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:231.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="border-bottom:3pt double #000000;padding:0pt 0pt 2.5pt 0pt; width:30.21pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.04pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">100.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00999999999999801pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.04pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">100.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Each $1.00 increase (decrease) in the assumed public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors and total consideration paid by all stockholders by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The number of shares of common stock that will be outstanding after this offering is based on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of common stock outstanding as of March&#160;31, 2021, and excludes:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock issuable on the exercise of outstanding stock options as of March&#160;31, 2021 under our LTIP with a weighted average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock reserved for future issuance as of March&#160;31, 2021 under our LTIP;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock issuable on the exercise of an outstanding common stock warrant at an exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock reserved for future issuance under our 2021 Plan, which will become effective upon the execution of the underwriting agreement related to this offering, as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for issuance thereunder, and any shares underlying outstanding stock awards granted under our LTIP and 2021 Plan that expire or are repurchased, forfeited, cancelled or withheld, as more fully described in the section titled &#8220;Executive Compensation&#8201;&#8212;&#8201;Equity Incentive Plans&#8221;; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock reserved for issuance under our ESPP, which will become effective upon the execution of the underwriting agreement related to this offering, as well as any future increases, including annual automatic evergreen increases, in the number of shares of common stock reserved for future issuance thereunder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">To the extent that stock options or warrants are exercised, new stock options or other equity awards are issued under our equity incentive plans, or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSCFD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">SELECTED CONSOLIDATED FINANCIAL DATA</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The selected consolidated statement of operations data for the fiscal&#160;years ended December&#160;31, 2019 and 2020 and the selected consolidated balance sheet data as of December&#160;31, 2019 and 2020 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. You should read the financial data set forth below in conjunction with our consolidated financial statements and the accompanying notes and the information in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results to be expected for any period in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:294pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:284.2pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Consolidated Statement of Operations Data:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">21,620,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">26,168,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Costs of goods sold </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">2,499,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">2,767,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Gross profit </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">19,121,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">23,401,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">17,601,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">17,744,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">7,852,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">8,328,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">6,088,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">8,385,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">31,541,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">34,458,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,420,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(11,056,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Other income (expense): </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(681,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">(825,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">206,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">65,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total other income (expense) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(475,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(759,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:284.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss per share, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(0.23<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">(0.17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:284.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Weighted-average common shares outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">56,397,524</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">69,464,751</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:142pt;margin-left:20pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:281.98pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:281.98pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Consolidated Balance Sheet Data:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">15,210,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">18,755,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Working capital(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">15,108,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">33,639,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">29,985,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">51,780,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">16,383,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">18,554,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">96,433,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">127,673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(83,405,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">(95,222,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total stockholders&#8217; equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">13,601,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">33,225,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Working capital is defined as current assets less current liabilities.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</font>
          <br >
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with the section of this prospectus titled &#8220;Selected consolidated financial data&#8221; and our consolidated financial statements and related notes appearing at the end of this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and business strategy, include forward-looking statements that involve risks and uncertainties. As a result of many factors, our actual results could differ materially from those discussed in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this prospectus titled &#8220;Risk factors.&#8221; Please also see the section titled &#8220;Special note regarding forward-looking statements.&#8221;<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Overview</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty&#160;years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx, STx and GTx; related single-use processing assemblies, or disposables; and software protocols. We have garnered meaningful expertise in cell engineering via our internal research and development efforts as well as our customer-focused commercial approach, which includes a growing application scientist team. The platform is also supported by a robust intellectual property portfolio with 50 granted U.S. and foreign patents and 76 pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the U.S. National Institutes of Health, or NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. As of December&#160;31, 2020, we have placed more than 400 of our electroporation instruments worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Since our inception, we have incurred significant operating losses. Our ability to generate revenue sufficient to achieve profitability will depend on the successful further development and commercialization of our products. We generated revenue of $21.6&#160;million and $26.2&#160;million for the&#160;years ended December&#160;31, 2019 and 2020, respectively, and incurred net losses of $12.9&#160;million and $11.8&#160;million for those same&#160;years. As of December&#160;31, 2020, we had an accumulated deficit of $95.2&#160;million. We expect to continue to incur net losses as we focus on growing commercial sales of our products in both the United States and international markets, including growing our sales teams, scaling our manufacturing operations, continuing research and development efforts to develop new products and further enhance our existing products. Further, following the closing of this offering, we expect to incur additional costs associated with operating as a public company in the United States.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe we have an attractive, diversified revenue model with revenue generated from multiple sources including instrument leases with recurring license fees, sales of instruments and related </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">disposables and participation in the clinical and commercial success of some of our customers through milestone and sales-based payments under agreements that we refer to as Strategic Platform Licenses, or SPLs. In addition to our ExPERT products, we previously developed CARMA, a proprietary therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies. In the first quarter of 2021, we conducted a strategic review of our CARMA activities and made the decision to cease further research and clinical development activities with respect to the CARMA platform for our own internal purposes and instead to focus on out-licensing the CARMA platform manufacturing processes and associated intellectual property to third-party customers. During the&#160;years ended December&#160;31, 2019 and 2020, our CARMA-related expenses were $11.7&#160;million and $11.1&#160;million, respectively. As a result of our strategic decision to focus on out-licensing this platform, we will no longer incur these expenses after approximately $4.0&#160;million of expenses expected to be incurred in the first half of 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe that the net proceeds from this offering, together with our existing cash, will enable us to fund our operating expenses and capital expenditure requirements for the foreseeable future. We have based this estimate on assumptions that may prove to be wrong, however, and we could exhaust our available capital resources sooner than we expect. See &#8220;Liquidity and Capital Resources&#8221; for more information about our current capital resources.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Impact of COVID-19 on Our Business</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In December&#160;2019, a novel strain of coronavirus, which led to the disease known as COVID-19, emerged in Wuhan, Hubei Province, China. Less than four&#160;months later, in March&#160;2020, the World Health Organization declared COVID-19 a pandemic, and the virus has now spread to most other countries and regions and every state within the United States, including Maryland, where our primary offices and instrument assembly facility are located. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Impacts to our business as a result of COVID-19 have included disruptions to our manufacturing operations and supply chain caused by facility closures, reductions in operating hours, staggered shifts and other social distancing efforts, decreased productivity and unavailability of materials or components, limitations on our employees&#8217; and customers&#8217; ability to travel, and delays in product installations, demonstrations, trainings or shipments to and from affected countries and within the United States. In light of the uncertain and rapidly evolving situation relating to the spread of COVID-19, we have taken precautionary measures intended to minimize the risk of the virus to our employees, our customers and the communities in which we operate, including temporarily closing our offices to visitors and limiting the number of employees in our offices to those that are deemed essential for manufacturing and research purposes, as well as virtualizing, postponing or canceling customer, employee and industry events.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Disruptions in our customers&#8217; operations have impacted and may continue to impact our business. For example, customers have experienced delays in the progress of their clinical programs, shutdowns or slowdowns in their research laboratory operations, cessation of equipment purchases, and closing of their facilities to outsiders, which have disrupted our ability to conduct product demonstrations that are a key part of our selling process. We are focused on navigating the challenges presented by COVID-19, which includes increased focus on inventory levels of finished goods and parts to reduce the risk of COVID-related supply constraints.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We do not yet know the net impact that the COVID-19 pandemic may have on our business and cannot guarantee that it will not be materially negative. Although we continue to monitor the situation and may adjust our current policies as more information and public health guidance become available, the ongoing effects of the COVID-19 pandemic and/or the precautionary measures that we or our customers have implemented or may adopt may create operational and other challenges, any of which could harm our business and results of operations. While we maintain an inventory of finished products and raw materials used in our products, a prolonged pandemic could lead to shortages and/or extended lead times for the raw materials necessary to manufacture our products. If we experience a prolonged </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">disruption in our manufacturing, supply chains or commercial operations, or if demand for our products is significantly reduced as a result of the COVID-19 pandemic, we would expect to experience a material adverse impact on our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Historically, a significant portion of our field sales, product demonstrations and user support have been conducted in person, and the marketing of our products, sourcing of potential new customers and rollout of our new products has historically been supported by our participation at industry conferences. Currently, as a result of the work and travel restrictions related to the COVID-19 pandemic, and the precautionary measures that we have adopted, substantially all of our field sales and professional services activities are being conducted remotely, which has resulted in a decrease in our travel and conference-related marketing expenditures. However, we expect these expenditures to increase in the future, which could negatively impact our financial condition and results of operations. As of the date of this prospectus, we do not yet know the extent of the negative impact of such restrictions and precautionary measures on our ability to attract new customers or retain and expand our relationships with existing customers over the near and long term.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Key Factors Affecting Our Performance</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by the following factors. While each of these factors presents significant opportunities for our business, they also pose challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address the factors below is subject to various risks and uncertainties, including those described in this prospectus under the heading &#8220;Risk Factors.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Sales and Leases of Instruments<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our financial performance has largely been driven by, and in the future will continue to be impacted by, the rate of sales and leases of our ExPERT family of proprietary flow electroporation instruments to existing and new customers. We currently market three versions of our instruments, the ATx, the STx, and the GTx, and we plan to introduce and market a fourth version called the VLX under the EXPERT brand. While the ATx and STx are primarily sold to end users for research and drug discovery purposes, the GTx is sold, typically to academic centers, for research or clinical use as well as leased to customers for research, clinical or commercial use. We view the demand for our instruments, whether in the form of sales or leases, as an indicator of the health of our current business and as a predictor of future instrument sale and lease revenue. As described below, we separately sell proprietary single-use disposables, which we call processing assemblies, or PAs, that are necessary for our customers to use our electroporation instruments. Therefore, depending on the number of instruments that have been sold or are under active lease, we have insight into the demand for PAs that will also translate to future revenue for us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our sales model varies based on the activity of the end customer, such as whether they are a translational research center, an academic center, a company focused on drug discovery, or a company engaged in cell therapy development, and the customer&#8217;s intended use of our platform. If our customer intends to use our platform for research or drug discovery only, we typically sell the instrument outright. Each of the ATx, STx and GTx have different prices based on the instrument&#8217;s features, with the GTx being the most expensive. When we sell an instrument, we also provide a non-exclusive license to our intellectual property for the customer to use the instrument broadly for research or drug discovery, as applicable. In the case of a sale, title to the instrument conveys to the buyer, but we retain the ownership of intellectual property rights and software and protocols loaded onto the instruments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The sales cycle for our cell engineering instruments varies widely and typically ranges from approximately six to approximately 12&#160;months, with the actual period depending on project stage, budget process, equipment prioritization and the general financial status of the customer or the market in general. As a result of this lengthy and unpredictable sales cycle, we expect that we will be prone to quarterly fluctuations in our instrument sales revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For cell therapy customers who use our technology to develop engineered cells for human therapeutic use in clinical trials or, if approved by regulatory authorities, for commercial sale, we license </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">our platform on a non-exclusive basis in exchange for an annual fee per instrument licensed. This license fee varies based on whether the instrument is being used for preclinical or clinical purposes. Once we have leased an instrument to a customer, we generally have high visibility into future lease revenue from this customer. Over the last several years, approximately 80% of our installed instruments up for annual lease renewal have been renewed by our customers, and the renewal rate for instruments under SPLs has been near 100%. It is possible, however, that our future lease revenue could be impacted by failure of the customer therapeutic candidates to progress through clinical development for reasons unrelated to the successful use of our instruments, such as drug toxicity, lack of efficacy, funding constraints, changes in development priorities, patient access limitations or regulatory challenges. For any of these reasons, a customer could determine not to renew or to enter into additional instrument leases with us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our installed base of electroporation instruments has grown from over 125 instruments as of December&#160;31, 2015 to over 400 instruments as of December&#160;31, 2020. This installed base includes both instruments sold to customers and instruments licensed for research and clinical use. Because of the size of the drug discovery market and our long history in that market, the installed base of instruments is currently weighted more heavily towards instruments sold for drug discovery and research applications. However, since each licensed instrument provides us with ongoing license revenues, the share of revenues from licensed instruments may grow as a share of our total revenue mix.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We plan to further grow our installed base of ExPERT instruments through additional sales and leases to our current customers and through the sale or lease of instruments to new cell therapy, drug discovery and academic customers. To achieve this goal, we intend to further expand our commercial infrastructure, including through the expansion of our sales force and field application scientists. We have expanded our sales force and field application scientist count over the past several&#160;years and now have over 20 dedicated field sales and application scientist professionals globally. Our candidate identification and hiring process is stringent, and there can be no assurance that we will be able to continue to recruit the high level of candidates that make up our current team.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, we have numerous collaborations in place with academic and commercial institutions to further expand our capabilities and supporting data in new cell engineering applications. Recent sales efforts have also focused on expanding our presence in translational academic centers, which we view as a potentially meaningful source of installed base expansion given the increased industry focus on, and government funding allocated to, cell therapy. Academic translational centers have been a strong source of cell therapy innovation and commercial spinouts in the cell therapy sector.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect revenue from instruments leased to cell therapy customers to continue to grow as those customers move their existing drug development programs into later-stage clinical trials and advance their preclinical pipeline programs into clinical development. In addition, we expect new customers to emerge and contribute to these revenues, particularly given the underlying growth in the cell therapy pipeline among companies in this industry, availability of capital to support such companies, and in particular the switch by some of these cell therapy companies away from viral approaches to non-viral approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Sales of Processing Assemblies<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to instrument sales, our current and future revenue is dependent on sales of our proprietary PAs, as well as the sale of our proprietary electroporation buffer solution, for use with our instruments. We sell PAs that are intended either to support research use or use in current good manufacturing practices, or cGMP, clinical research applications. The PAs differ in terms of their volume capacities and the associated numbers of cells that can be processed in each electroporation sequence with a particular PA, as well as the number of transfection experiments that can be performed in a single electroporation process. Our PA pricing varies based on the volume of cells processed and the number of transfections per PA.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect that as our installed instrument base grows, our sales of PAs and electroporation buffer solutions will grow accordingly, especially as cell therapy programs continue to progress through the clinic and potentially become commercial-stage, thereby increasing the number of PAs needed by customers. We are also developing and intend to launch new PAs that target previously unserved </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">subsegments across the bioprocessing and cell therapy markets, which could further increase our PA sales. However, both the number of PAs used per instrument, as well as the specific PA used, is highly variable across our customer base and depends on several factors, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the purpose for which the customer is using the platform;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the relative pricing of our PAs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">progression of cell therapy products through preclinical and clinical development;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">whether the cell therapy customer uses a centralized or decentralized manufacturing process;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the customer&#8217;s target indication, which can result in variations in patient numbers needed for clinical trials; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">whether the cells to be processed using our platform are patient-derived, donor-derived or cell line-derived.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">With considerable variability of processes, even within the same indication, such as is the case for allogeneic genetically-modified cell therapies, such as chimeric antigen receptor T cells, or CAR-Ts, and the nascency of the cell therapy industry, we expect that it may take several&#160;years for us to gain visibility into how these factors will impact our PA revenue over time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We continuously re-evaluate our PA portfolio based on customer needs and have introduced, and intend to continue to introduce, new PAs and improvements to existing PAs. In 2019, we launched the first multi-well PAs for the ExPERT platform. Compared to single-well, multi-well PAs allow users to run multiple samples concurrently, which enables scientists to complete more experiments per run, leading to shorter overall processing time and lower per transfection cost. Introduction of new PAs, however, introduces additional uncertainty. Some new PAs may fail to be used in line with our expectations when they are launched. While we also price PAs based on the value provided to the customer, introduction of new PAs could cannibalize our existing PA portfolio more than we had anticipated as customers find the new products to be a better solution for their applications or workflows.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Strategic Platform Licenses (SPLs)<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Typically, our cell therapy customers will either purchase our ATx instrument for research purposes or obtain a research use license under lease of our GTx instrument technology in order to validate the use of our technology in their programs and to progress their preclinical work towards clinic trials. However, once a cell therapy customer using one of our ExPERT instruments advances their preclinical research to a stage where they are planning to enter clinical development, they need to enter into a licensing arrangement with us for the rights to clinical and/or commercial use of our instrument. Our customers typically negotiate the terms of those licenses during research and preclinical development.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We refer to these arrangements as SPLs, the terms of which contain not only higher annual, non-exclusive license fees for the clinical use of the instrument, but also allow us to share in the economics of the customer&#8217;s programs. Since 2017, we have entered into 12 SPLs with commercial cell therapy developers, and those licenses currently allow for over 75 clinical development programs in the aggregate. On average, our current SPLs allow for approximately six product candidates per license, although this average may change over time. SPLs include potential payments to us upon the customer&#8217;s achievement of specified clinical development or regulatory milestones, as well as potential sales-based payments to us, which could be payments based upon the achievement of specified sales levels and/</font>&#8203;<font style="letter-spacing:-0.025pt;">or royalty payments that are a&#160;percentage of the customer&#8217;s net sales. The amount of each milestone payment is typically correlated in size with value-creating, pre-commercial clinical progress events or commercial sales levels.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Of the over 75 programs associated with our current SPLs, more than 15% are in the clinic, meaning they have at least an FDA-cleared Investigational New Drug application, or IND. Our 12 current SPLs have the potential to generate over $950&#160;million in pre-commercial milestone payments, if all product candidates allowed under those agreements were to fully progress through clinical development and obtain regulatory approval. However, our actual milestone revenue from these agreements will likely be considerably lower than this amount, as not all programs covered by each agreement will become and remain active programs in a customer&#8217;s development pipeline or successfully </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">complete the clinical development process, and each agreement typically includes programs that have not been specifically identified, or for which a candidate may never be identified or developed by the customer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our strategy is to capitalize on the growth in the number of cell therapy developers by entering into new SPLs. We announced six such agreements in 2019, three in 2020 and one so far in 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our future milestone revenue under our SPLs will depend in large part on the clinical and regulatory achievements of our customers. Generally, pre-commercial milestone payments become larger as programs move through the clinic. We rely in part on our customers&#8217; public disclosures around regulatory timelines to forecast our receipt of pre-commercial milestone payments. While we expect our forecasting ability to improve over time as more of our customers&#8217; programs advance through the clinic and the number of clinical programs covered by our licenses expands, given the early nature of the cell therapy clinical market, we expect our realization of pre-commercial milestones to be somewhat unpredictable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, the potential for sales-based payments once a customer&#8217;s product is approved and in commercial use is unknown and variable based on a number of factors, including inherent clinical risk, potential changes in the customer&#8217;s strategy, the designated indication and its impact on the potential number of patients to be served and the competitive products available to patients, product pricing and reimbursement structures, our customer&#8217;s commercial manufacturing plans and the inherent unknowns in adoption of next-generation cell therapies relative to other modalities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Gross Margins<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have historically generated overall gross margins of approximately 89% over the past several years, although our margins depend on our revenue mix from instruments, PAs and potential milestones under SPLs. We price our instruments at a premium given what we believe to be the broad benefits of our platform, and the limited availability of alternative, clinically validated non-viral delivery approaches. However, the market for non-viral delivery is highly competitive, and introduction of a GMP-grade platform by a competitor that delivers similar performance across a similar diversity of cell types could negatively impact our business and lead to increased price pressure that negatively impacts our gross margins. In addition, part of our growth strategy is to expand into new regional markets, which could require the use of distributors and/or our participation in more competitive environments, which could impact our ability to price our instruments at a premium and could negatively impact our ability to enter into SPLs on terms similar to those currently in effect.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect our gross margins to benefit from realization of the economics from our SPL agreements described above, to the extent that such milestones grow to be a significant proportion of overall revenues, as there is no cost of goods sold associated with such revenue. However, realization of these potential milestone revenues is uncertain.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Key Business Metrics</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to revenue, we regularly review several key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. These key metrics include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the number of cumulative instruments that we have placed with our customers, either by sale or lease, which we refer to as our installed base and consider to be an indication of our traction within the non-viral delivery market and indicative of the future recurring revenue generated from those instruments, including disposables and annual license fees;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the number of active SPLs that we have entered into with cell therapy developers, as well as the total number of our customers&#8217; clinical programs, whether active or contemplated, that are covered by such active SPLs and the&#160;percentage of those clinical programs that are under an active IND application (or foreign equivalent), meaning that the customer is cleared to commence clinical trials;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the aggregate potential pre-commercial milestone payments under active SPLs, representing the maximum potential milestone payments to us if all programs covered by each SPL were to achieve regulatory approval;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the aggregate number of potential programs covered by our active license agreements with academic and commercial customers, whether such licenses are research-only licenses, clinical-only licenses or SPLs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the aggregate number of potential programs for licensed clinical use, whether active or contemplated, that are covered by our active clinical licenses and SPLs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the aggregate number of potential programs licensed for clinical use, whether active or contemplated, that are covered by only our SPLs; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the aggregate number of programs licensed for clinical use and covered by our SPLs that are currently in the clinic.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">With respect to the numbers of programs under license, in many cases we make estimates of such programs based on our contract terms with our customers and our knowledge about our customers&#8217; clinical progression of their programs. We rely, in part, on our customers&#8217; public disclosures around regulatory timelines to forecast our receipt of pre-commercial milestone payments. However, it is possible that some programs may have become dormant or inactive without our knowledge, some new programs may be identified and some programs may progress further in clinical development without our knowledge if the customer has not made a public announcement. While we expect our forecasting ability to improve over time as more of our customers&#8217; programs move through the clinic and the number of clinical programs covered by our licenses expands, given the early nature of the cell therapy clinical market, we expect our realization of pre-commercial milestones to be somewhat unpredictable. This number may fluctuate due to the success of our commercial partners. Additionally, the addition of a large multi-product (program) SPL may dilute the&#160;percentage of commercial programs currently in the clinic.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As of December&#160;31, 2019 and 2020, our key metrics described above were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:139pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.68pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:59.16pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:59.16pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020* </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:323.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Installed base of instruments (sold or leased) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;320 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;400 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:323.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Number of active SPLs</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">8 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">12</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:323.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total number of licensed programs (research, clinical and SPLs) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;100 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;140 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:323.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total number of licensed clinical programs (clinical and SPLs) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;70 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;100 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:323.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total number of licensed clinical programs (SPLs only) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;55 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;75 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:323.68pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Total number of licensed clinical programs under SPLs currently in the clinic </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;5% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;15% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:323.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total potential pre-commercial milestones under SPLs </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;$650&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;$950&#160;million</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7.9pt; width:456pt; line-height:10pt;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">* Amounts presented as of December&#160;31, 2020 give effect to one SPL entered into and additional INDs cleared in January&#160;2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Components of Our Results of Operations</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Revenue<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We generate revenue principally from the sale of instruments, single-use PAs and buffer, and from the lease of instruments to our customers. Our SPLs also include associated clinical progress milestones and sales-based payments to us, in addition to annual lease payments. Sales of instruments and disposables under contracts with customers are classified as product sales in our consolidated financial statements. Revenue from instrument leases, including payments that we may receive from our customers based on their achievement of specified clinical development or commercialization milestones, are classified as leased elements in our consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our business and revenue growth strategy consists of the sale or lease of instruments and the sale of disposables. We record revenue from the sale of instruments or PAs upon the shipment to a customer. Instrument leases are typically invoiced annually at the start of each instrument license period and are accounted for as monthly revenue over the lease term with the expectation of continuing customer renewals of their instrument leases. As our customers achieve clinical progress milestones </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">and/or sales-based payment milestones, we recognize the full value of the milestone as revenue. In addition, as customers use instruments they have either purchased or leased, they typically replenish their supplies of disposables through recurring purchases. Although customers are not contractually obligated to renew their instrument leases or to purchase additional disposables and may decide not to do so solely at their own discretion, leased instruments and disposables revenue streams have historically formed an important component of our future revenues, and we believe they provide insight into our future performance. We consider these sales and lease revenue streams to be recurring revenues.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">In order to evaluate how our sales are trending across key markets, as well as the contribution of program economics from our SPLs, we separately analyze revenue derived from our cell therapy customers and drug discovery customers, as well as the performance-based milestone revenues we recognize under our SPLs. Cell therapy includes revenue from instruments sold, annual license fees for instruments under lease, and sales of our proprietary disposables. Drug discovery includes revenue from instruments sold, sales of our proprietary disposables and, occasionally, instruments leased, in each case under contracts with drug discovery customers. SPL performance revenue includes pre-commercial milestones earned and recognized as revenue during the period. Once SPL customers achieve regulatory approval for and commercialize their products, in nearly all cases we will also be entitled to receive sales-based payments which may be milestone payments upon achievement of specified levels of net sales and/or royalties expressed as a&#160;percentage of net sales. We have not received any commercial payments from our SPL customers to date, and we do not expect to receive any such payments in the near term. As our customers progress their programs and achieve additional milestones, our SPL program revenue is expected to constitute a growing portion of our total revenues in future periods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We also offer our customers extended warranty and service plans. Our extended warranty and service plans are offered for periods beyond the standard no-fee, one-year warranty that customers who purchase instruments receive. These extended warranty and service plans generally have fixed fees and terms ranging from one additional year to four additional&#160;years and include an annual calibration. We recognize revenue from the sale of extended warranty and service plans over the respective coverage period, which approximates the service effort provided by us. Warranties are typically not a material revenue stream for us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Product Sales<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Revenue from contracts with customers includes revenue from the sale of instruments, PAs and buffer. Customers purchase an ATx, STx or GTx depending upon their intended use and all customers purchase PAs for use with our instruments. Commercial customers may not use a purchased instrument for clinical or commercial processes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We expect product sales revenue to increase in future periods as our market grows and we are able to generate recurring PA sales.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Leased Elements<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Revenue from leased elements consists of revenue from the leasing of instruments to customers (typically the GTx). Our leases of instruments to customers consist of fixed license/lease payments and variable milestone payments that are dependent on our customer&#39;s achievement of clinical milestones. Typically, instrument leases that provide for clinical or commercial use also include sales-based milestone payments (and/or sales-based royalties in some cases) upon the commercialization of the customer&#39;s product. Under our instrument lease arrangements we lease our instruments to customers and provide associated software licenses to allow customers non-exclusive use of our technology for research and/or specific clinical programs, typically along with rights for commercial use upon approval of the customer&#39;s products. We also provide to our clinical use licensees scientific and regulatory support to help them improve process optimization and facilitate their regulatory submission process.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We expect leased elements revenue to increase in future periods as our market grows.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Cost of Goods Sold<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cost of goods sold primarily consists of costs for raw material parts, contract manufacturer costs, salaries, overhead and other direct costs related to sales recognized as revenue in the period. Cost of goods sold associated with instrument lease revenue consists of leased equipment depreciation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect that our cost of goods sold will increase or decrease primarily to the extent that our instrument and disposables revenue increases and decreases.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Gross Profit and Gross Margin<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Gross profit is calculated as revenue less cost of goods sold. Gross profit margin is gross profit expressed as a&#160;percentage of revenue. Our gross profit in future periods will depend on a variety of factors, including sales mix among instruments, disposables and milestones, the specific mix among types of instruments or disposables, the proportion of revenues associated with instrument leases as opposed to sales, the share of revenues composed of milestones, changes in the costs to produce our various products, the launch of new products or changes in existing products, our cost structure for manufacturing including changes in production volumes, and the pricing of our products which may be impacted by market conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Operating Expenses<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Research and Development<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Research and development expenses consist primarily of costs incurred for our research activities related to advancing our technology and development of applications for our technology, including research into specific applications and associated data development, process development, product development (e.g. development of instruments and disposables, including hardware and software engineering) and design and other costs not directly charged to inventory or cost of goods sold, such as supply chain development and design and management of quality systems.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">These expenses include employee-related costs, such as salaries, benefits, incentive compensation, stock-based compensation, and travel, as well as consultant services, facilities, and other expenses, laboratory supplies and materials expenses for employees and contractors engaged in research and development. We expense research and development costs as incurred in the period in which the underlying activity is undertaken.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We previously developed CARMA, our proprietary platform technology for the development of non-viral, human messenger RNA, or mRNA-based, chimeric antigen receptor, or CAR, or T-cell receptor, or TCR, redirected immune cell therapies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the first quarter of 2021, we conducted a strategic review of our CARMA activities and made the decision to cease further pre-clinical and clinical activities with respect to the CARMA platform and associated candidates (MCY-M11 and other identified targets) for our own internal purposes and instead to focus on out-licensing the CARMA platform manufacturing processes and associated intellectual property to third-party customers. For periods through the first half of 2021, our research and development expenses include costs associated with developing the CARMA platform principally for a clinical trial that has concluded. As a result of our strategic decision to focus on out-licensing this platform, we will no longer incur these expenses in future periods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe that our continued investment in research and development is essential to our long-term competitive position. We expect to continue to incur substantial research and development expenses as we invest in research and development to support our customers, develop new uses for our existing technology and develop improved and/or new offerings to our customers and partners. As a result, we expect that our research and development expenses, excluding CARMA-related expenses, will continue to increase in absolute dollars in future periods and vary from period to period as a&#160;percentage of revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Sales and Marketing<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our sales and marketing expenses consist primarily of salaries, commissions and other variable compensation, benefits, stock-based compensation and travel costs for employees within our commercial sales and marketing functions, as well as third-party costs associated with our marketing activities. We expect our sales and marketing expenses to increase in future periods as we expand our commercial </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">sales, marketing and business development teams, increase our presence globally, and increase marketing activities to drive awareness and adoption of our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">General and Administrative<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">General and administrative expenses primarily consist of salaries, benefits, stock-based compensation and travel costs for employees in our executive, accounting and finance, legal, corporate development, human resources, and office administration functions as well as professional services fees, such as consulting, audit, tax and legal fees, general corporate costs, facilities and allocated overhead expenses and costs associated with being an AIM listed public company such as director fees, broker fees, investor relations consultants and insurance costs. We expect that our general and administrative expenses will continue to increase in absolute dollars in future periods, primarily due to increased headcount to support anticipated growth in the business and due to incremental costs associated with operating as a public company listed on two exchanges, including insurance (particularly directors and officers insurance), costs to comply with the rules and regulations applicable to companies listed on a U.S. securities exchange and costs related to compliance and reporting obligations pursuant to the rules and regulations of the SEC and stock exchange listing standards, public relations and professional services. We expect these expenses to vary from period to period as a&#160;percentage of revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Other Income (Expense)<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Interest Expense<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Interest expense consists primarily of interest related to borrowings under credit facility agreements. For the&#160;years ended December&#160;31, 2019 and 2020, we had a $5.0&#160;million outstanding term loan, or the Term Loan, under the MidCap Credit Agreement (as defined below). In March&#160;2021, we repaid the Term Loan in full prior to maturity as allowed by and in accordance with the terms of the MidCap Credit Agreement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Other Income (Expense), Net<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We classify our outstanding warrant for the purchase of shares of our common stock as a liability on our consolidated balance sheets since the warrant&#8217;s strike price is in a currency other than our functional currency. The warrant liability is initially recorded at fair value at the date of issuance and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liability are recognized as a component of other income (expense). Other income (expense), net also includes interest earned on cash balances in our cash accounts and interest earned on money market funds, commercial paper and corporate bonds as well as miscellaneous income unrelated to our core operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Provision for Income Taxes<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We did not recognize a benefit for the net operating losses we incurred for the&#160;years ended December&#160;31, 2019 and 2020. As of December&#160;31, 2020, we had U.S. net operating loss carryforwards of $57.8&#160;million, which may be available to offset future taxable income and begin to expire in 2025, as well as net operating losses in the various states in which we file. We have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date since, due to our history of net losses, we have determined that it is not currently more likely than not that our net deferred tax assets are recoverable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The use of our net operating loss carryforwards may have been restricted by changes in our ownership and may be further restricted as a result of future changes in our ownership.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Results of Operations</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Comparison of the Years Ended December&#160;31, 2019 and 2020<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The results of operations presented below should be reviewed in conjunction with the consolidated financial statements and notes included elsewhere in the prospectus. The following tables set forth our results of operations for the periods presented:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:258pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:363.1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">21,621 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">26,169 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cost of goods sold </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Gross profit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">19,122 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">23,402 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:363.1pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Operating expenses </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">17,601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">17,744</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">7,852</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">8,329</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">6,088</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">8,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">31,542 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">34,459</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">(12,420<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">(11,057<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:363.1pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Other income (expense) </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">(681<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">(826<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">66</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:363.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">475</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">760 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:363.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">(12,895<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">(11,816<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9.4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Revenue<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:120pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:304.09pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Revenue </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Products sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">12,918</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">14,850</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,932 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">15<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Leased elements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">8,364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">10,717</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,354 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">28 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15pt; text-align:right; white-space:nowrap;">77 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:304.09pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">21,621 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">26,169 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">4,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:15pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Revenue increased by $4.5&#160;million, or 21%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. Product sales accounted for 60% and 57% of our total revenue for the&#160;years ended December&#160;31, 2019 and 2020, respectively, and leased elements revenue accounted for 39% and 41% of our total revenue for the&#160;years ended December&#160;31, 2019 and 2020, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table provides additional details regarding the sources of our revenue for the&#160;years presented.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:105pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:304.09pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Cell therapy </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">11,868</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">15,769</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">3,901</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Drug discovery </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">7,321</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">7,143</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(178<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">(2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">SPL performance</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,432</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,257</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">825</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:15pt; text-align:right; white-space:nowrap;">34 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:304.09pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">21,621 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">26,169 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">4,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:15pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our overall increase in revenue primarily was driven by growth among cell therapy customers in the number of instruments and disposables that we sold, new leased instrument placements, and recurring revenues from existing instrument leases, as well as growth in the number of clinical milestone </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">events that our SPL customers achieved that resulted in payments to us. Instrument sales and leases and disposable sales increased in part due to continued high levels of capital invested in companies operating in our target markets. Milestones increased due to the clinical progress of our SPL customers. </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Costs of Goods Sold<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Change, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.56pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:315.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cost of goods sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">268</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">11<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Costs of goods sold increased by $0.3&#160;million, or 11%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by higher sales of instruments and disposables. Cost of goods sold did not increase at the same rate as revenue growth because of the growth in milestone payments, which have no associated cost of goods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Operating Expenses<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Research and Development<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:308.45pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:308.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">17,601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">17,744</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">143</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.91pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Research and development expenses increased by $0.1&#160;million, or 1%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by increased compensation expense associated with field application scientist headcount increases and applications development headcount increases which combined to add $1.4&#160;million to research and development costs, offset by reduced expenses associated with our CARMA activities of $1.1&#160;million and reduced travel expenses of $0.3&#160;million during 2020 due to the impact of the COVID-19 pandemic.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Sales and Marketing<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:319.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:319.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:319.56pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:319.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and Marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">7,852</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">8,329</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">477</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Sales and marketing expenses increased by $0.5&#160;million, or 6%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by increased compensation expense as a result of headcount increases, commissions on sales, and stock-based compensation which added $1.8&#160;million to sales and marketing costs, partially offset by COVID-19 driven reductions in travel and marketing expenses of $1.3&#160;million. As travel and in-person restrictions instituted due to COVID-19 begin to recede, we expect travel and marketing expenses to increase.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">General and Administrative<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.2pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:315.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">6,088</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">8,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2,298</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">38<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">General and administrative expense increased by $2.3&#160;million, or 38%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by increased compensation expense associated with headcount increases, salary increases, and stock-based compensation which added $1.5&#160;million within the general and administrative function as well as $0.6&#160;million of expenses associated with capital raising activities that were not eligible to be capitalized. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Interest and Other Income (Expense)<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Interest and Other Income<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:320.48pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:320.48pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">66</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(140<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">(68<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Interest and other income decreased by $0.1&#160;million, or 68%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The decrease was primarily driven by declining interest income due to lower market rates in 2020 on our short-term investments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Interest and Other Expense<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:320.48pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:320.48pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">681 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">826 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">145 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">21<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.81pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Interest and other expense increased by $0.1&#160;million, or 21%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by the fair value change of common stock warrants, partially offset by fees associated with an early prepayment of debt in 2019 and the lower interest expenses due to a lower average loan balance associated with an early repayment of debt in 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Liquidity and Capital Resources</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Since our inception, we have experienced losses and negative cash flows from operations. For the year ended December&#160;31, 2020, we incurred a net loss of $11.8&#160;million. As of December&#160;31, 2020, we had an accumulated deficit of $95.2&#160;million. To date, we have funded our operations primarily with proceeds from sales of common stock, borrowings under loan agreements and from revenues associated with sales and leasing of our products to customers. As of December&#160;31, 2020, we had cash and cash equivalents and short-term investments of $34.8&#160;million. Subsequent to year end, we raised $55.3&#160;million in gross proceeds from the sale of our common stock in a private financing.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect to incur additional operating losses in the future as we continue to invest in expanding our business through growing our sales and marketing efforts, continued research and development, product development and expanding our product offerings. Based on our current business plan, we believe the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for the foreseeable future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. Our future funding requirements will depend on many factors, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">market acceptance of our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the cost and timing of establishing additional sales, marketing and distribution capabilities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the cost of our research and development activities and successful development of data supporting use of our products for new applications, and timely launch of new features and products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to enter into additional SPLs and licenses for clinical use of our platform in the future;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in the amount of capital available to existing and emerging customers in our target markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the effect of competing technological and market developments; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the level of our selling, general and administrative expenses.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If we are unable to execute on our business plan and adequately fund operations, or if the business plan requires a level of spending in excess of cash resources, we will have to seek additional equity or debt financing. If additional financings are required from outside sources, we may not be able to raise such capital on terms acceptable to us or at all. To the extent that we raise additional capital through the sale of equity or debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making product acquisitions, making capital expenditures or declaring dividends. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us. If we are unable to raise additional capital when desired, we may have to delay development or commercialization of future products. We also may have to reduce marketing, customer support or other resources devoted to our existing products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Cash Flows<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-left:20pt; margin-top:2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table summarizes our uses and sources of cash for the periods presented:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:120pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.43pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.43pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:366.43pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.43pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Net cash provided by (used in): </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(8,803<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">(8,782<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">455</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">(16,578<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">12,311</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">28,905</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:366.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">3,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">3,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.8pt; width:456pt; line-height:12pt;font-style:italic;">Operating Activities<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Net cash used in operating activities for the year ended December&#160;31, 2020 was $8.8&#160;million, and consisted primarily of our net loss of $11.8&#160;million, offset in part by net non-cash expenses of $3.9&#160;million, including stock-based compensation of $2.5&#160;million and depreciation and amortization expenses of $1.0&#160;million. We also had net cash outflows of $0.9&#160;million due to net changes in our operating assets and liabilities. Net changes in our operating assets and liabilities consisted primarily of an increase in deferred revenue of $1.6&#160;million and an increase in accounts payable and accrued expenses of $0.4&#160;million, partially offset by a $1.8&#160;million increase in accounts receivable, a $0.9&#160;million increase in inventory, a $0.2&#160;million increase in other current and non-current assets and a $0.1&#160;million increase in the net effect of our right-of-use assets and lease liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Net cash used in operating activities for the year ended December&#160;31, 2019 was $8.8&#160;million, and consisted primarily of our net loss of $12.9&#160;million, offset in part non-cash expenses of $2.5&#160;million, including stock-based compensation of $1.8&#160;million and depreciation and amortization expenses of $0.6&#160;million. We also had net cash inflows of $1.6&#160;million due to changes in our operating assets and liabilities. Net changes in our operating assets and liabilities consisted primarily of a decrease in accounts receivable of $1.6&#160;million, an increase in accounts payable and accrued expenses of $1.2&#160;million, an increase in deferred revenue of $0.8&#160;million and a $0.5&#160;million increase in the net effect of our right-of-use assets and lease liabilities, partially offset by a $1.9&#160;million increase in inventory and a $0.7&#160;million increase in other current and non-current liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Investing Activities<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash used in investing activities during the year ended December&#160;31, 2020 was $16.6&#160;million, which was primarily attributable to net purchases of marketable securities of $14.5&#160;million and purchases of property and equipment of $2.1&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash provided by investing activities during the year ended December&#160;31, 2019 was $0.5&#160;million, which was primarily attributable to net purchases and maturities of marketable securities of $1.7&#160;million, partially offset by purchases of property and equipment of $1.3&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">Financing activities<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash provided by financing activities during the year ended December&#160;31, 2020 was $28.9&#160;million, which was primarily attributable to net proceeds from issuance of common stock of $28.6&#160;million, proceeds from the PPP loan (as defined below) in the amount of $1.4&#160;million and the proceeds of $0.4&#160;million from the exercise of stock options, partially offset by the repayment of the PPP loan of $1.4&#160;million and lease principal payments of $0.1&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash provided by financing activities during the year ended December&#160;31, 2019 was $12.3&#160;million, which was primarily attributable to net proceeds from issuance of common stock of $12.3&#160;million, proceeds from borrowing under our MidCap Credit Agreement of $5.0&#160;million and the proceeds of $0.1&#160;million from the exercise of stock options, partially offset by the repayment of our previously outstanding borrowing under the MidCap Credit Agreement of $5.1&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Long-Term Debt<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2019, we entered into a Credit and Security Agreement, or the MidCap Credit Agreement, with MidCap Financial Trust, or MidCap. The MidCap Credit Agreement provided for a $5.0&#160;million term loan, or the Term Loan, maturing on November&#160;1, 2024. The Term Loan provided for (i)&#160;an interest rate of one-month Libor plus 6.5% with a 1.5% Libor floor, (ii)&#160;monthly interest payments, (iii)&#160;30 monthly principal payments of approximately $0.2&#160;million beginning June&#160;2022 and (iv)&#160;a 3% final payment fee. The Term Loan was secured by a lien on substantially all of our assets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In conjunction with our entry into the MidCap Credit Agreement, we issued MidCap a warrant to purchase 71,168 shares of common stock at a price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance. In connection with the MidCap Credit Agreement, we also incurred expenses of $47,300. As of December&#160;31, 2020, the Term Loan had an outstanding principal balance of $5.0&#160;million and $0.1&#160;million of unamortized debt discount. On March&#160;12, 2021, we repaid all amounts outstanding under the Term Loan and terminated all remaining obligations under the MidCap Credit Agreement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In April&#160;2020, we received a loan, or the PPP loan, from Silicon Valley Bank in the amount of $1.4&#160;million under the U.S. Small Business Administration&#8217;s Paycheck Protection Program, or PPP. The PPP was established as part of the U.S. Coronavirus Aid, Relief, and Economic Security (CARES) Act and provided for potential forgiveness of the loan upon our meeting certain conditions as to the use of the proceeds. The loan provided for interest at 1% and a maturity date of April&#160;2022. In May&#160;2020, we repaid the PPP loan in full.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Contractual Obligations and Commitments</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our contractual obligations and commitments as of December&#160;31, 2020 consisted of operating lease obligations, finance lease obligations and debt obligations under the MidCap Credit Agreement. As of December&#160;31, 2020, operating lease obligations included $2.0&#160;million in payments due under our lease of office and laboratory space under operating lease agreements that expire in October&#160;2023. As of December&#160;31, 2020, our finance lease obligations consisted of $0.3&#160;million in payments due for our lease of laboratory equipment under a finance lease that expires in April&#160;2023. As of December&#160;31, 2020, debt obligations included the contractually required principal and interest payments payable under our MidCap Credit Agreement, under which borrowings bore interest at a variable rate. On March&#160;12, 2021, we repaid all amounts outstanding under the MidCap Credit Agreement in full.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Purchase orders or contracts for the purchase of supplies and other goods and services are based on our current procurement or development needs and are generally fulfilled by our vendors within short time horizons.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Qualitative and Quantitative Disclosures About Market Risk</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Interest Rate Risk<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are exposed to market risk for changes in interest rates related primarily to balances of our cash and cash equivalents and marketable securities. As of December&#160;31, 2020, we had cash and cash equivalents of $18.8&#160;million, which consisted primarily of money market funds and bank deposits. Our marketable securities are held in commercial paper and corporate bonds. The primary objective </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">of our investment is to preserve principal and provide liquidity. As of December&#160;31, 2020, we had short-term marketable securities of $16.0&#160;million. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the United States. A 10% change in the level of market interest rates would not have a material effect on our business, financial condition or results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2019, we entered into the Term Loan with MidCap, which carried a fixed interest rate of 6.5% per annum plus one-month Libor with a 1.5% Libor floor. We repaid the Term Loan in full in March&#160;2021 and no longer have any variable-rate indebtedness.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Foreign Currency Risk<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are exposed to financial risks as a result of exchange rate fluctuations between the U.S. dollar and certain foreign currencies and the volatility of these rates. In the normal course of business, we earn revenue primarily denominated in U.S. Dollars as well as in Euros and British Pounds. We incur expenses primarily in U.S. Dollars as well as in Euros, British Pounds and other currencies. Our reporting currency is the U.S. Dollar. We hold our cash primarily in U.S. Dollars as well as in Euros and British Pounds. We do not expect that foreign currency gains or losses will have a material effect on our financial position or results of operations in the foreseeable future. We have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to managing risks relating to fluctuations in currency exchange rates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Inflation Risk<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We do not believe that inflation has had a material effect on our business, financial condition or results of operations. Our operations may be subject to inflation in the future principally through the costs of components and raw materials associated with our instruments and disposables and the cost of labor.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Critical Accounting Policies and Significant Judgments and Estimates</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have prepared our consolidated financial statements in accordance with generally accepted accounting principles in the United States. Our preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements included elsewhere in this prospectus, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Revenue Recognition<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We derive revenue from two primary sources, product sales, which is comprised primarily of instrument and disposables revenue, and leased elements, which is comprised of revenue associated with instrument leases.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For revenue generated pursuant to contracts with customers, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our arrangements, we perform the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the assessment of the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when, or as, we satisfy each performance obligation. At </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">contract inception, we assess the goods or services promised within each contract, determine which goods or services are performance obligations and assess whether each promised good or service is distinct.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We enter into instrument lease and licensing arrangements that are accounted for using lease accounting rather than accounted for as pursuant to contracts with customers. Under these arrangements, we license to third parties rights to use our products and embedded software. The terms of these arrangements typically include payment to us of one or more of the following: instrument lease fees, and clinical progress milestones and may, under the terms of existing agreements, include regulatory and/or sales milestone payments and/or royalties. Revenue from instrument leases is recognized ratably over the determined contractual term of the lease agreement and revenue from associated milestones is recognized when each specific milestone event is achieved by the customer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In some product sale arrangements, products and services have been sold together representing distinct performance obligations. In such arrangements we allocate the sale price to the various performance obligations in the arrangement on a relative standalone selling price basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The standalone selling price is the price at which an entity would sell a promised good or service separately to a customer. We estimate the standalone selling price of each of the identified performance obligations in our customer contracts, maximizing the use of observable inputs. Our process for determining standalone selling price requires judgment and considers multiple factors that are reasonably available and maximizes the use of observable inputs that may vary over time depending upon the unique facts and circumstances related to each performance obligation. We believe that this method results in an estimate that represents the price we would charge for the product offerings if they were sold separately.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Taxes, such as sales, value-add and other taxes, collected from customers concurrent with revenue generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are primarily directly paid by customers as pass-through costs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Amounts received under lease arrangements prior to revenue recognition are recorded as deferred revenue in our consolidated balance sheets. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in our consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as other liabilities in our consolidated balance sheets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Stock-based Compensation<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We maintain an incentive compensation plan under which stock options are granted primarily to employees, consultants and non-employee directors. We measure stock-based compensation expense on the date of grant and recognize the corresponding compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. We record forfeitures as they occur.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We estimate the fair value of stock options granted to our employees and directors based on the closing price of our common stock on the AIM, a market operated by the London Stock Exchange, on the grant date, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The assumptions include expected volatility using publicly traded peer group companies&#8217; common stock, expected dividend yield, risk-free rate of interest and the expected term using the simplified method.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Warrants to Purchase Common Stock<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In connection with our Term Loan, we issued a stock purchase warrant to purchase 71,168 shares of common stock. Because the exercise price is denominated in British pounds, we record a liability for the fair value of the warrant at the end of each reporting period, with changes between periods reported in our consolidated statements of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:100pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The fair value of the stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to such unobservable inputs identified above may change the embedded conversion options&#8217; fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in these unobservable inputs generally result in decreases in fair value.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our annual consolidated financial statements and interim condensed consolidated financial statements appearing in this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Emerging Growth Company Status</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are an &#8220;emerging growth company,&#8221; or EGC, under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Section&#160;107 of the JOBS Act provides that an EGC can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of the delayed adoption of new and revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting standards as private entities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As an EGC, we may also take advantage of certain exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we are presenting only two&#160;years of audited financial statements and only two&#160;years of related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we will avail ourselves of the exemption from providing an auditor&#8217;s attestation report on our internal control over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we will avail ourselves of the exemption from complying with any requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we are providing reduced disclosure about our executive compensation arrangements; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we will not require nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We will remain an EGC until the earliest of (i)&#160;December&#160;31, 2026, which is the last day of the fiscal year in which the fifth anniversary of this offering occurs, (ii)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more, (iii)&#160;the date on which we have issued more than $1&#160;billion in non-convertible debt during the previous rolling three-year period, or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the Securities Exchange Act of 1934, as amended, or the Exchange Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBUS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">BUSINESS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Our Mission</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe in the vast potential of next-generation cell therapies to have a meaningful impact on the millions of patients worldwide who, despite medical advancement, live with unmet medical needs across a variety of diseases. Our aim is to be the premier cell engineering platform technology to support the development of advanced therapeutics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Overview</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty&#160;years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">With increased knowledge of cell complexity and systems biology in the scientific community, researchers have sought to leverage or repurpose cell functions or machinery for research or therapeutic purposes. The ability to engineer living cells by introducing foreign molecules, such as gene editing systems and transgenes, has led to a revolution in biological research and resulted in numerous biological discoveries. Living human cells can also be engineered </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;">, or outside the body, where they are repaired or reprogrammed to fight disease. In this case, the engineered cell itself is the drug.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Cell therapy has emerged as one of the fastest growing and most promising treatment modalities to address a host of human diseases. Over the past few&#160;years, the success of multiple U.S. Food and Drug Administration, or FDA, approved cell therapies providing long-lasting amelioration of symptoms or even the cure of disease has catalyzed tremendous investment&#8201;&#8212;&#8201;leading to exponential growth in cell-based therapies being evaluated for therapeutic applications. According to the Alliance for Regenerative Medicine, the combination of gene, cell, and tissue-based therapeutic developers raised an aggregate of $19.9&#160;billion in 2020, up from $13.3&#160;billion in 2018. According to the American Society of Gene and Cell Therapy, or ASGCT, there are now more than 3,400 cell therapies in development globally, with genetically-modified cell therapies, such as chimeric antigen receptor T cells, or CAR-Ts, accounting for 53% of those candidates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx, STx and GTx; related single-use processing assemblies, or disposables; and software protocols. We have garnered meaningful expertise in cell engineering via our internal research and development efforts as well as our customer-focused commercial approach, which includes a growing application scientist team. The platform is also supported by a robust intellectual property portfolio with 50 granted U.S. and foreign patents and 76&#160;pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the U.S. National Institutes of Health, or NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. As of December&#160;31, 2020, we have placed more than 400 of our electroporation instruments worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:72pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe our ExPERT platform offers a compelling value proposition to our academic and biopharmaceutical customers due to: (i)&#160;the ability to use our technology to deliver almost any molecule into almost any cell type, including hard-to-transfect human primary cells, while maintaining high cell viability and function: (ii)&#160;the capacity to introduce larger and more diverse payloads compared to other intracellular delivery technologies, such as viral vectors; and (iii)&#160;the flexibility to scale up from research to current good manufacturing practices, or cGMP, manufacturing on a single platform&#8201;&#8212;&#8201;enabling the engineering of cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe our ExPERT intracellular delivery platform provides value across numerous applications in the life sciences market, including the research, discovery, development, and manufacturing of next-generation, cell-based therapeutics, as well as in biomanufacturing, such as transient protein production for drug discovery and manufacturing of other proteins, including biological therapeutics, viral vectors and vaccines and small molecule drug discovery.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT technology platform is being used in the clinic to support the development of next-generation cell therapy approaches to treat human disease. Following the successful clinical development leading to FDA approvals of CAR-T cell therapies in blood-based cancer, developers have focused on improving efficacy, lowering the cost of manufacturing and expanding engineered cell therapies into new indications, such as solid tumors. To address these goals, the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy industry has trended towards developing more complex therapies that require sophisticated engineering and gene manipulation as well as the use of different starting cell types.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Often as a product candidate moves from preclinical research to clinical trials and then commercial scale up, drug developers must transition to different technologies, which can create significant financial, technical, and regulatory burdens for customers and lead to significant timeline delays due to re-optimization requirements. We believe that our ExPERT platform enables our customers to engineer cells safely, efficiently, and with high reproducibility, cell viability and potency throughout the stages of product development and commercialization. This ability to use a single platform provides significant cost and time savings for our customers and accelerates the delivery of new treatments to patients.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, we are committed to continued research and development investments in technology and scientific innovation to maintain our market leadership position. For example, we intend to introduce new instruments and processing assemblies, or PAs, under the ExPERT brand that allow us to meet the evolving needs of customers and move into new applications to better serve high growth segments of the cell therapy market, including allogeneic CAR-T, engineered stem cells for inherited disorders, engineered primary cells for treatment of solid tumors and development of personalized neoantigen approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe we are well positioned in this market given the manufacturing supply constraints and payload size limitations of other delivery methods, such as viral vectors. Given our value proposition in non-viral delivery, we have established strategic relationships, in the form of Strategic Platform Licenses, or SPLs, with a growing number of leading cell therapy developers as they work to bring next-generation cell therapies into and through the clinic and advance those candidates to potential commercialization. These SPLs provide us with the ability to secure downstream program-related pre-commercial milestones and, in most cases, commercial sales-based payments. In addition, from our SPL customers, we receive both annual research and clinical license fees as well as payments from sales of our proprietary disposables as recurring revenue streams. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have entered into 12 SPLs with commercial cell therapy developers since January&#160;1, 2017, of which 11 have been publicly announced as shown in the table below..</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:241.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;min-height:11.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.5pt 0pt; width:144pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.04pt;">Partner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.5pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Therapeutic Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.5pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Date Announced </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:31.25pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:144pt;">
              <font style="letter-spacing:-0.025pt;">CRISPR/Casebia Therapeutics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:192pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:-0.025pt;">Hemoglobin-related diseases and severe combined immunodeficiency (SCID) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">March&#160;14, 2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">CRISPR Therapeutics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Immuno-oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">November&#160;9, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Kite Pharma (now Gilead)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology (CAR-T) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">November&#160;12, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Precision Biosciences </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">November&#160;14, 2018</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:31pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:144pt;">
              <font style="letter-spacing:-0.025pt;">Editas Medicine </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:192pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:-0.025pt;">Sickle cell disease and beta-thalassemia; Immuno-oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">October&#160;7, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">VOR Biopharma </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">November&#160;21, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">KSQ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">December&#160;4, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Allogene Therapeutics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology (CAR-T) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">March&#160;24, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Caribou Biosciences </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">May&#160;7, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Apeiron Biologics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">July&#160;8, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:21pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:144pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Myeloid Therapeutics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">January&#160;11, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.51pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under these SPLs and other license agreements with our customers, in exchange for an annual license fee per instrument, we provide our customers with non-exclusive access to our:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">cGMP-compatible platform, which enables early-optimization and scale-up from preclinical research into clinical development using our intellectual property portfolio;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">FDA Master File and Technical Files, which may accelerate and streamline development and reduce regulatory risk in the creation and development of our partners&#8217; therapeutic drug candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">experienced commercial team of sales personnel and application scientists who work directly with our customers to solve cell engineering problems; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continuous know-how and cell engineering process improvements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Including our SPLs, our clinical agreements cover:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">research and clinical licenses with academic and industry customers covering over an estimated 140 programs; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">clinical licenses with academic and industry customers covering over an estimated 100 programs being developed or intended for use in humans, over 75 of which have the potential to generate program economics for us under SPL agreements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Of the over 75 clinical program licenses associated with our existing SPLs, more than 15% are in the clinic, meaning they have at least an FDA-cleared investigational new drug application, or IND. Our 12 SPLs have the potential to generate over $950&#160;million in pre-commercial milestone payments if all of the licensed programs were to achieve regulatory approvals. In addition, under the SPLs, we typically have the potential to receive significant, sales-based commercial payments for approved products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.6pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-org_prog4c.jpg" alt="[MISSING IMAGE: tm2113965d1-org_prog4c.jpg]" height="128" width="551" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our current strategic partners have demonstrated success progressing next-generation cell therapies through the clinic, which has provided growing validation supporting our ability to facilitate complex cell engineering in a clinical setting. Further, our platform is supported by an FDA Master File. A Master File is a submission to the FDA with confidential detailed information about our products, methods, processes and data, which can be referenced by our customers to support their own regulatory filings, which we believe has the potential to reduce certain risks and challenges in connection with our customers&#8217; regulatory submissions and development timelines. Outside of the United States, similar Technical Files are in place or being pursued to support our customers&#8217; regulatory processes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We aim to build a large, diversified portfolio of SPLs that enable us to participate in the economics of the near-term and long-term success of our partners&#8217; drug candidates. We estimate that the total addressable market opportunity for our ExPERT platform, based on the potential for current SPLs, was approximately $9&#160;billion in 2020. We expect this market to grow to over $24&#160;billion by 2026 driven by growth in the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy pipeline and a shift to use of non-viral delivery technologies as described in more detail under &#8220;&#8212;&#160;Our Market Opportunity.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Our Competitive Strengths</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe our industry leadership position and continued growth will be driven by the following competitive strengths:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Our proprietary technology platform unlocks the significant potential of advanced therapeutics</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We have built our ExPERT platform to advance the growing demands for non-viral delivery and next-generation cell and gene engineering approaches. Our platform technology enables delivery of almost any molecule into almost any cell type. We believe our platform leads the industry in performance (measured by consistency, efficiency, viability, flexibility, and scale). Our platform is further supported by a robust intellectual property portfolio with 50 issued U.S. and foreign patents and 76 pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Comprehensive, high-performance transfection platform</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We believe our ExPERT platform offers a unique value proposition given the flexibility to scale up from research to cGMP manufacturing on a single platform&#8201;&#8212;&#8201;enabling the engineering of cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less. Our long-term internal engineering expertise is supplemented by our customer focused approach&#8201;&#8212;&#8201;with a growing application scientist team working with our customers across increasingly diverse applications.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Positioned as a leader in the large and growing next</font><font style="font-style:italic;font-weight:bold;">-generation cell therapy market with the ability to capitalize on rising demand for non-viral approaches.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We believe we are well positioned to capture increased market share within the large and growing next-generation cell therapy market. Since the FDA approved the first engineered CAR-T cell therapies to treat cancer in 2017, the number of cell therapy candidates being evaluated pre-clinically and clinically has grown exponentially. We expect growth to continue given the remaining high unmet medical need in cancer and other chronic conditions and predict increased investments in cell therapy product development across a variety of human diseases. We expect to grow our market share given the high performance of our platform and regulatory support through our FDA Master File as well as the ongoing shift to non-viral delivery as the industry has trended towards developing advanced cell-based therapies with complex engineering strategies to improve efficacy, reduce time to patient treatment and expand into new indications.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Innovative partnership business model focused on value creation and shared success</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our SPLs allow us to participate in the value creation of our customers&#8217; programs via pre-commercial milestones and in nearly all cases commercial sales-based payments. We intend to continue to build a portfolio of strategic partnerships with cell therapy developers, which provide us with a growing, diversified source of potential downstream revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to the high performance and flexibility of the ExPERT platform, we believe our partnership model further reduces clinical risk and development timelines for our cell therapy partners. By entering into an SPL with us, for example, our partners gain access to our FDA Master File to support their IND-enabling studies and potentially shorten clinical development. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our FDA Master File was originally established in 2002 and has been continuously updated as platform improvements are implemented to support different applications and cell types. The FDA Master File and equivalent Technical Files in other countries can be referenced by our partners to support their own regulatory submissions with the goal of accelerating regulatory submissions processes for our partners. To date, our FDA Master File and Technical Files have been referenced by our customers in over 30 clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">First-mover advantage has yielded broad-based adoption, with commercial model supported by top-tier customers.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our business model is supported by more than 20&#160;years of investment and experience and has enabled us to cultivate long-standing and collaborative relationships with our significant and growing customer base. From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base includes large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue. We now have 12 SPLs with commercial cell therapy developers, which together provide licenses for over 75 programs, of which currently more than 15% have advanced into clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Recurring revenue model </font><font style="font-style:italic;font-weight:bold;">provides high visibility, with</font><font style="font-style:italic;font-weight:bold;"> drivers of potential long-term upside.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our business model enables us to generate substantial revenue from five sources: sales of instruments and disposables to new customers; additional sales of instruments and disposables to our existing installed base; annual instrument license fees from cell therapy customers; pre-commercial milestones under SPLs; and potential commercial sales-based payments under SPLs. We generate high recurring revenue from our ExPERT instrumentation licenses and disposable sales, which provides visibility into future near-term revenue. Over the last three&#160;years, annual renewals of instrument licenses were greater than 80% on average&#8201;&#8212;&#8201;and for our SPLs were near 100%. In addition to recurring revenue, we have the potential to receive meaningful pre-commercial and commercial payments under SPLs if our customers are successful in advancing programs through the clinic and into the commercial stage. In aggregate, we have the potential to receive over $950&#160;million in pre-commercial milestone payments under our current SPLs, if all of the programs were to receive regulatory approvals.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Founder-led leadership team and workforce with deep domain knowledge.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our management team combines strong and broad subject matter expertise with a demonstrated history of commercial and operational execution. Moreover, our workforce has deep domain knowledge across a range of scientific, engineering, regulatory and business disciplines. We have supplemented our diverse technical experience by assembling a deep operational team with expertise in manufacturing, legal, sales, marketing, customer service and finance. We believe the team we have assembled with talent from multiple disciplines and a science- and customer-focused culture represents a significant competitive advantage for us. As of March&#160;31, 2021, of our 65 full-time employees, 45 have advanced degrees, including 19 with Ph.D. degrees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Our Growth Strategies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The key elements of our growth strategy include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Establish ExPERT as the standard of non-viral delivery technology in the rapidly growing cell therapy market</font><font style="font-weight:bold;letter-spacing:-0.05pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We are committed to continued investment in technology and scientific innovation to maintain our market leadership position. We believe that the adaptability of, and continuous improvement in, our single-use disposable product portfolio via recent product launches exemplifies our partnership with our customers to meet varying processing volume requirements, for example. We plan to further invest in our current platform and potentially introduce new instruments and PAs that allow us to meet the evolving needs of customers and move into new applications to better serve high-growth segments of the cell therapy market.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Drive customer adoption and accelerate revenue growth through execution and expansion of our strategic marketing initiatives</font><font style="font-weight:bold;letter-spacing:-0.05pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We aim to accelerate our revenue growth by investing in our sales and application scientist teams to fuel growth in our underlying ExPERT platform and foster and develop new customer and SPL opportunities. We also see opportunity for geographic expansion, particularly in Asia, and the potential to further penetrate non-commercial customer accounts, including translational academic centers globally, which we believe will represent &#8220;hotspots&#8221; driving innovation that favor non-viral extracellular delivery technology. Finally, we expect to continue to cultivate academic collaborations and grow our application scientist team to gain exposure to and experience with up and coming cell and gene engineering approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Increase </font><font style="font-style:italic;font-weight:bold;">our number of</font><font style="font-style:italic;font-weight:bold;"> SPLs</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We plan to continue to pursue SPLs with target customers, including leading biopharmaceutical companies focused on cell therapies. We believe that there are a substantial number of potential SPL opportunities in the market and have seen a commensurate increase in our SPL discussions over the past several&#160;years. Given growth in the cell therapy pipeline and increased investment in the space, we estimate that the number of potential SPLs for us will increase from approximately 50 today, based on our estimate of the companies that are currently developing engineered cell therapies, to almost 140 by 2026, based on our estimates of growth in the cell therapy pipeline, growth in the number of therapeutic delivery entrants into the market and ongoing shift to non-viral delivery. We plan to aggressively pursue these opportunities and establish new SPLs by increasing business development activities and demonstrating our technological advantages over alternative methods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Commercialize our VLX Large-Scale Transfection System under the ExPERT brand to expand our capabilities into additional attractive market verticals, including large-scale bioprocessing and cell therapy applications</font><font style="font-weight:bold;letter-spacing:-0.05pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We currently market the VLX Large-Scale Transfection System, which supports the ability to transfect up to approximately 200&#160;billion cells, or ten times the number of cells and/or volume of the GTx/STx, in less than 30 minutes. We intend to commercialize the VLX under the ExPERT brand, which includes improving ease-of-use, upgrading to state-of-the-art design and developing associated disposables and software protocols for various large-scale applications. We believe this instrument could allow our platform to enter into large-scale bioprocessing applications including viral vector production in suspension cell cultures and rapid production of proteins, including monoclonal antibodies&#8201;&#8212;&#8201;as well as facilitate further scale up in allogeneic (or donor-derived) cell therapy approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Enhance manufacturing and research and development capabilities by investing in </font><font style="font-style:italic;font-weight:bold;">capacity as well as automation and process development.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We intend to expand our manufacturing infrastructure. We plan to invest in our capacity to support increased demand for our instruments and disposables as our customers move further through the clinic and toward commercialization. We also plan to invest in the automation and final assembly of our PAs for greater control and for enhanced flexibility as our partners expand the use of our technology. Additionally, we plan to expand our research and development capabilities by investing in process development via expanding laboratory space, increasing capital investment in laboratory equipment and supplies and growing our scientific team&#8201;&#8212;&#8201;to continue to align our capabilities with the requirements of our customers and potentially support new product development.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Opportunistically pursue strategic investments, partnerships and acquisitions</font><font style="font-weight:bold;letter-spacing:-0.05pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our revenue growth to date has been organically driven by the addition of customers to our growing installed base of ExPERT users and expansion of our product offerings to those customers. We may consider opportunistic investments, partnerships and acquisitions that we believe will complement our product platform, allowing us to enter new markets and applications to enhance our growth profile. We also intend to establish new industry partnerships, enabling us to remain at the forefront of cell engineering trends and continue to collaborate with customers to accelerate the development and commercialization of new medicines.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Our Technology Platform</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The foundation of our technology is our proprietary and patented Flow Electroporation platform, which we have developed and optimized over more than 20&#160;years. Electroporation, or electro-permeabilization, leverages the fundamental properties of cell membranes, the ability to create </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">reversible permeability in the presence of an electric charge, as a universal method to introduce foreign molecules, or transfect, eukaryotic cells. Electroporation can be applied to almost any eukaryotic cell type to deliver a broad range of molecules, including DNA, mRNA, siRNA and proteins. Our patented Flow Electroporation platform is fully scalable and can support small-scale research and development through to large-scale cell engineering for development of commercial therapeutics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.81pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-pht_expert4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_expert4clr.jpg]" height="145" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our technology platform is marketed under the ExPERT brand. The value of our ExPERT brand starts with Efficiency&#8201;&#8212;&#8201;with high delivery </font><font style="font-weight:bold;letter-spacing:-0.05pt;">Efficiency</font><font style="letter-spacing:-0.025pt;">, users can achieve </font><font style="font-weight:bold;letter-spacing:-0.05pt;">Potency</font><font style="letter-spacing:-0.025pt;">, with high Potency, users improve their chances of therapeutic </font><font style="font-weight:bold;letter-spacing:-0.05pt;">Efficacy</font><font style="letter-spacing:-0.025pt;">, and if this can be repeated, </font><font style="font-weight:bold;letter-spacing:-0.05pt;">Reproducibly</font><font style="letter-spacing:-0.025pt;"> from patient to patient, users have a successful </font><font style="font-weight:bold;letter-spacing:-0.05pt;">Therapy</font><font style="letter-spacing:-0.025pt;">. By delivering high efficiency at any scale, the ExPERT platform is designed to improve our customer&#8217;s ability to achieve the required therapeutic index, enabling accelerated, cost-efficient translation of complex cellular therapies from research to the clinic.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT platform consists of three instruments, the ATx, STx and GTx, which use a broad range of PAs, or disposables, of different volumes to enable scalable electroporation from tens of thousands to billions of cells to facilitate the translation of complex cellular therapies from concept to the clinic, in support of the intended therapeutic commercialization.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our ExPERT family of instruments and disposables supports scale-up for cell therapy<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="position:relative;margin-top:4pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-pht_scale4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_scale4clr.jpg]" height="151" width="568" >
        </div>
        <div style="margin-top:16.6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Overview of our ExPERT platform</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our Flow Electroporation Technology was designed to meet the stringent demands of clinical use&#8201;&#8212;&#8201;namely, the ability to safely and reproducibly modify a broad range of primary human cells with high efficiency, low cytotoxicity, and at the scale required to enable the treatment of patients across a diverse range of diseases.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe the current ExPERT instrument family represents the next generation of our clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality and ease of use, the ExPERT platform delivers the high-end performance that we believe is essential to enabling the next wave of biological and cellular therapeutics. The combination of the ExPERT instruments, associated disposables and universal electroporation buffer, provides researchers, production scientists, and cGMP facilities with a solution to transfect cells with high efficiency, viability and consistency, which are the three attributes that are consistently ranked by our customers as the top requirements when choosing a cellular or gene engineering platform for clinical use. We believe our ExPERT platform is seen as a critical enabling technology by many of the leading cell therapy companies, helping them to achieve their program goals </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">and milestones expeditiously. Our instruments are sold or licensed for research use and licensed for clinical use, while the associated disposables and electroporation buffer are sold to support preclinical research and development work and are compatible for integration into cGMP manufacturing environments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe that the following four components of our platform have allowed us to successfully address the increasing complexity of cellular engineering approaches in the industry:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Instrument design;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Electroporation and cell handling protocols;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">PAs (disposables); and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Universal electroporation buffer formulation (consumables).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, we have implemented a global scientific and regulatory support strategy for our customers that is designed to accelerate clinical development and streamline the regulatory submission process, thereby potentially saving time and reducing cost and development risk.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe several factors differentiate our ExPERT platform and will continue to be significant drivers of customer adoption, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">High performance electroporation</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our range of ExPERT instruments can be used to transfect almost any cell type, including hard-to-transfect human primary cells and induced Pluripotent Stem Cells, or iPSCs. Transfection efficiency using our platform has consistently been at least 90% for most cell types (using mRNA) with minimal disturbance to the cell, resulting in high cell viability of at least 90%. This performance is documented by multiple peer-reviewed publications demonstrating that transfecting cells using our platform does not significantly alter the cell phenotype, natural expression of cell surface receptors or proliferative capacity.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Scalability</font><font style="font-style:italic;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our Flow Electroporation Technology can engineer cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less, without requiring costly re-optimization or sacrificing performance on scale-up. We offer a range of PAs to support preclinical research and development work and manufacturing in cGMP environments, which allows customers to seamlessly scale-up in a sterile process format that can be integrated into their workflow.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Flexibility to deliver larger and more diverse payloads.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;While adeno-associated virus, or AAV, lentivirus and other vectors have increasingly been used in </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> and </font><font style="font-style:italic;">in vivo</font><font style="letter-spacing:-0.025pt;"> gene therapies, viral vectors carry inherent capacity limitations. For example, the most commonly used Cas9 nuclease, spCas9, and a sgRNA are approximately 4.2 kilobase, or kb, in size, but a single AAV only allows for approximately 4.5 kb to be packaged within it, making it difficult to include other elements (e.g., multiple sgRNAs if multiple edits are required or DNA templates if correction is the goal) to ensure the delivery of the required elements into the cells and meet desired gene-editing objectives. A kb is a unit of measurement in molecular biology equal to 1,000 base pairs of DNA or RNA. Our platform enables larger molecules to be delivered into the cells (or multiple different molecules to be co-loaded into cells). For comparison, we are able to deliver large molecules, including CRISPR RNPs which can be 40 nanometers or higher in diameter.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Designed for Clinical Use</font><font style="letter-spacing:-0.025pt;">&#8201;&#8212;&#8201;The ExPERT GTx platform has been specifically designed for use in a cGMP clean room setting for manufacturing of cell therapies intended for use in patients. The platform integrates features such as electronic documentation and electronic signatures designed to be consistent with the FDA expectations under 21 CFR Part&#160;11, (which may be critical to the regulatory compliance process for certain customers) and networking capability for automated transfer of electronic batch records of manufacturing runs to a centralized data management solution. As part of our global regulatory strategy, our customers have access to our FDA Master File or equivalent Technical Files with the regulatory agencies in the countries where they will seek to conduct clinical trials, potentially streamlining the regulatory submission process and helping to reduce time and cost of clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Industry Background</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">The promise of cell therapy<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The field of cell therapy has emerged as one of the fastest growing and most promising treatment modalities to address a host of human diseases. In 2017, the FDA approved the first </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> CAR-T cell therapies, Kymriah and Yescarta, developed and commercialized by Novartis and Kite Pharma (now Gilead), respectively, offering a potentially transformative option to a cohort of relapsed and refractory hematological cancer patients who had previously exhausted all other therapies. The success of these therapies has catalyzed significant investment in advanced cell therapies. According to the Alliance for Regenerative Medicine, gene, cell, and tissue-based therapeutic developers raised an aggregate of $19.9&#160;billion in 2020, up from $13.3&#160;billion in 2018. According to the ASGCT, there are now more than 3,400 cell therapies in development globally, with genetically-modified CAR-Ts accounting for 53% of those candidates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe there are several key factors driving the meaningful investment and subsequent explosion in gene and cell therapy trials globally, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">success of multiple FDA-approved cell therapies providing long-lasting amelioration of symptoms or even cure of disease;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">numerous advancements in various cell engineering systems, such as the discovery and adaption of targeted gene editing systems including CRISPR, and development of next-generation intracellular delivery approaches;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">improved understanding of how to monitor and manage impacts of adverse events (including immune response to delivery vectors) as clinicians have gained more experience in treating patients with currently approved gene and cell therapies; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">successful demonstration of proof-of-concept efficacy of next-generation </font><font style="font-style:italic;">in vivo</font><font style="letter-spacing:-0.025pt;"> and </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> gene and cell therapy-based approaches as these therapies have begun to be explored in humans.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As a result of these advancements in the industry, cellular engineering programs that deliver genetically modified cells capable of treating complex human diseases are rapidly increasing in number and complexity.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Background on cell therapy<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Cells represent the smallest discrete unit of life and are the building blocks of all living organisms, from single cell organisms&#8201;&#8212;&#8201;such as amoebas&#8201;&#8212;&#8201;to organisms as complex as humans, which are made up of over 30 trillion cells. Eukaryotic cells are characterized by three basic components: (i)&#160;the cell membrane, which controls movement of molecules into and out of the cell, (ii)&#160;a nucleus, which typically houses the cell&#8217;s DNA and is where RNA synthesis occurs, and (iii)&#160;the cytoplasm, or the fluid inside the cell.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">With increased knowledge of cell complexity and systems biology in the scientific community, researchers have been able to engineer, or manipulate, cells in order to leverage or repurpose cell functions or machinery. The ability to deliver foreign molecules into living cells&#8201;&#8212;&#8201;either isolated from an organism (</font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;">), within an organism (</font><font style="font-style:italic;">in vivo</font><font style="letter-spacing:-0.025pt;">), or to cells outside of their normal biological context, such as those grown in culture (</font><font style="font-style:italic;">in vitro</font><font style="letter-spacing:-0.025pt;">)&#8201;&#8212;&#8201;has led to a revolution in biological research and resulted in numerous biological discoveries. Cell therapy is generally used to refer to </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> manipulation of cells for therapeutic purposes. Living human cells are engineered outside the body (</font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;">) where they are repaired or reprogrammed to fight disease. In this case, the cell itself is the drug.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Both academic and commercial research has focused on novel strategies to improve efficacy, reduce time to treatment, and expand the use of cell therapies into new indications. Given the level of investment, the field is evolving rapidly to next-generation approaches with increasing complexity. For example:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Development of off-the-shelf therapies.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Efforts have focused on using allogeneic donor cells or cell lines to develop &#8220;off-the shelf&#8221; approaches for CAR-T therapies. Use of donor cells versus autologous patient cells could potentially improve time to treatment, lower cost of </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:22pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">treatment, and improve therapeutic efficacy by using healthy cells as a starting point, but may require &#8220;knock-out&#8221; or &#8220;knock-down&#8221; of additional genes to prevent patients from rejecting donor cells.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Use of next-generation chimeric receptors or engineered TCRs to expand the cell therapy toolbox.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Next-generation synthetic receptors or engineered T-cell receptors, or TCRs, have been developed and introduced into cells to improve antigen recognition and reduce the potential for antigen escape (the ability to recognize multiple antigens). Engineered TCRs, for example, enable cells to recognize intracellular proteins.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Knocking out or knocking down expression of certain genes to improve efficacy</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;A promising strategy for next-generation therapies include &#8220;knocking out&#8221; or &#8220;knocking down&#8221; genes to improve the efficacy of cell therapies. For example, cancer cells have evolved to overexpress programmed death-ligand 1, which binds to programmed cell death protein 1, or PD1, on T-cells and helps evade recognition. Therefore, knocking out the PD1 &#8220;checkpoint&#8221; on T-cells could increase the ability for engineered T-cells to recognize the cancer cells.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Use of other primary cell types</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Focus of cell therapy in immuno-oncology applications has expanded to include other immune effector cells beyond T-cells (including NK cells, T-regs and gamma delta T-cells). Similarly, the treatment of complex genetic diseases using gene correction of stem cells, such as hematopoietic stem cells, or HSCs, and their derivatives and iPSCs will also require correction of multiple mutations with increasing fidelity and improved efficiency.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Driving towards personalized cell therapy</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Another promising approach is neo-antigen-based therapies, where T-cells are engineered to target each patient&#8217;s highly specific protein expression signatures identified on their cancer cells. To achieve this, multiple unique T-cell receptors directed against the patient&#8217;s own tumor antigens are identified, cloned and inserted back into the patient&#8217;s own T-cells for reinfusion. Such neoantigen T-cell receptor engineered-T-cell approaches hold promise for the future of personalized cellular immunotherapies and could fundamentally change the cancer treatment paradigm.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, the availability of gene editing systems such as CRISPR, which allows scientists to directly alter DNA and RNA at targeted locations, has meaningfully accelerated technological advancements in cell therapy. For instance, several triple edited </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies have now entered clinical trials and some companies have demonstrated proof-of-concept with as many as six edits to a single cell. These are just a few examples of the increasing complexity of the cellular engineering required to deliver the next generation of cell therapies that show great promise for treating previously untreatable diseases. We believe that our ExPERT platform can address each of these next-generation approaches because of our ability to facilitate the evolving complexities described above.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Approaches to intracellular delivery<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At a high level, there are two methods of introducing molecules into cells: carrier (or biological) based (e.g., the use of engineered viruses, vesicles, nanocarriers and nanoparticles) and membrane-disruption based or physical approaches, such as electroporation. Both of these approaches seek to introduce &#8220;cargo&#8221; into the cell interior without damaging the cell or producing an unintended impact to cell function. Carrier-based approaches serve to package the cargo to prevent it from degradation while simultaneously gaining access to the cell in order to deliver the intended cargo. Physical approaches seek to disrupt the cell membrane, which facilitates passage of molecules across the cell membrane, or involve direct penetration of the membrane.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The type of molecules that scientists can now introduce into cells&#8201;&#8212;&#8201;also referred to as payload&#8201;&#8212;&#8201;is highly diverse. Each payload type carries unique challenges including size variability, shape, architecture, and chemical properties, which has led to an increase in the number of strategies available for intracellular delivery of molecules. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:7.61000000000001pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">The following chart compares the advantages and disadvantages of viral-mediated transfection and electroporation:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5.31pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:72pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Transfection </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Method </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Advantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Disadvantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:60pt;white-space:nowrap;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.045pt;">Biological</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:72pt;white-space:nowrap;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.045pt;">Virus mediated</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:84pt;">
              <div style="text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Delivery via a viral vector, often known as &#8220;transduction&#8221; </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:84pt;">
              <div style="text-align:center; line-height:10.8pt;">
                <font style="letter-spacing:-0.022pt;">High efficiency</font>
              </div>
              <div style="margin-top:6pt; text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Easy to use (simplicity of infection)</font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">Effective on dissociated cells</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:108pt;">
              <div style="text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Labor intensive, time consuming and significant facilities cost</font>
              </div>
              <div style="margin-top:6pt; text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Insertional mutagenesis, immunogenicity, and cytotoxicity </font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">Packaging capacity limitations </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:60pt;white-space:nowrap;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.045pt;">Physical</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:72pt;white-space:nowrap;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.045pt;">Traditional </font>
                <br >
                <font style="letter-spacing:-0.045pt;">electroporation</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Electrical pulses to produce electrically induced membrane permeability to allow for payload delivery </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.022pt;">Easy to perform</font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">All cell types</font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">High transfection efficiency</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.022pt;">Potential for low cell viability</font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">Instrument investment</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">For gene and cell therapies, engineered viral vectors have historically been the most common delivery technique. Viral-mediated gene delivery uses the inherent capacity for viruses to infect human (or other) cells and inject DNA that the virus carries into cells. Commonly used viral methods of gene transfer include retrovirus, lentivirus, adenovirus, adeno-associated virus, the herpes virus and the Epstein-Barr virus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">There are several reasons why early approaches have utilized viral vectors, including that:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">viruses are widespread in humans&#8201;&#8212;&#8201;more than 200 are known to cause disease in humans&#8201;&#8212;&#8201;and are naturally efficient at delivery of genetic information into targeted cells;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">viruses can be easily engineered to deliver the genetic material of interest, can be engineered to not self-replicate, and in the case of some viruses (such as lentivirus and wild-type AAVs), integrate their DNA into the host genome, thereby driving sustainable expression of the gene of interest; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">viruses were one of the first methods used in early gene therapy trials, with the first generation of lentiviral vectors created in the mid-1990s.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">Traditionally, first-generation approaches modified T-cells with a virus-mediated chimeric antigen receptor, or CAR. For example, Kymriah and Yescarta use lentivirus and retrovirus, respectively, for delivery of the CAR construct. While viral vectors, in particular lentivirus, have formed the bulk of delivery methods for such early cell therapies, AAV has become the viral vector of choice, particularly for </font><font style="font-style:italic;">in vivo</font><font style="letter-spacing:-0.025pt;"> gene therapy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">The following chart compares the advantages and disadvantages of the major viral vectors used in gene therapy:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;min-height:111.18pt;margin-top:10.0000000000001pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:57.5pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.04pt;">Viral Vector </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Genetic </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Material </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Insert </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Capacity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:57.5pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Host Range </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Advantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Disadvantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:57.5pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.04pt;">Adenovirus</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">dsDNA </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">&lt; 7.5 kb </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:57.5pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Broad host range; infective for many cell types </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">No integration</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">No integration</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.447pt 0pt 1.563pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Large range of cell types </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.447pt 0pt 1.563pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Relative insert capacity constraints </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.447pt 0pt 1.563pt 0pt; width:96pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">High transduction efficiency </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.447pt 0pt 1.563pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">May initiate strong inflammatory response </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:231.61pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:57.5pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.04pt;">Viral Vector </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Genetic </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Material </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Insert </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Capacity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:57.5pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Host Range </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Advantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Disadvantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:57.5pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.04pt;">AAV</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">ssDNA </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">&lt; 5kb </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:57.5pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Broad host range; infective for many cell types </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Chromosomal integration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Small packaging capacity </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Nonimmunogenic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Immune response </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Nonpathogenic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Slow expression onset </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:57.5pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.04pt;">Retrovirus</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">RNA </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">8 kb </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:57.5pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Broad host range </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Long-term expression </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.02pt;">Transduces only dividing cells </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:96pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Persistent gene transfer with dividing cells </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Integration might induce oncogenesis in some applications </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:57.5pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.04pt;">Lentivirus</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">RNA </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">8 kb </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:57.5pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Ecotropic, amphotropic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Long-term expression </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Exposure to replication competent lentiviruses </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:96pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Does not require cell division for proviral integration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Random integration could cause insertional mutagenesis </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Low cytotoxicity </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 1.573pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Mobilization of the vector by endogenous retroviruses in the genomes of patients</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:15.21pt; width:456pt; line-height:11.5pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">As the cell therapy market continues to evolve, more complex approaches are being deployed to improve efficacy, reduce time to patient and expand the application of cell therapy to additional indications. Use of viral vectors carry several challenges, however, especially given the increase in complexity of these &#8220;next-generation&#8221; </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy approaches, such as:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Viral payload limitations</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Many methods of gene manipulation require insertion of relatively large molecules, including proteins such as CAS9 RNP for CRISPR or plasmids. Viral vectors, particularly AAV, have fundamental payload capacity limitations, curtailing their utility for complex engineering systems. Additionally, the industry has continued to shift to using complexed molecules including combination of proteins and mRNA which cannot be delivered by viral means.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">The picture below shows the size ranges of various kinds of molecules that can be inserted into cells.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.11pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-pht_cellul4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_cellul4clr.jpg]" height="311" width="568" >
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Concerns around toxicity</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Given viruses used in gene therapy by default infect human cells, there continue to be questions around the safety profile associated with viruses. In </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:50.93pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">particular, there are concerns over the potential for random integration of lentivirus and the widespread presence of neutralizing antibodies against many AAV serotypes used in gene therapies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.05pt;">Costs and time to market</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Concerns exist regarding viral vector manufacturing capacity and the cost associated with viral development and manufacturing. According to BioPlan&#160;Associates, a market research firm, lead times at contract manufacturing organizations are averaging 18&#160;months to obtain a cGMP viral manufacturing slot and six to nine&#160;months for requisite viral safety testing. Additional bottlenecks arise from demand for viral approaches, which has led to subsequent demand for cGMP plasmids. The ongoing COVID-19 pandemic has further exacerbated demand, particularly for adenovirus, and suspension cells, which are difficult to engineer at high volume. Concurrently, regulatory scrutiny and product characterization requirements are increasing as more gene and cell therapy products reach the clinic, as noted by the FDA&#8217;s revised guidelines for viral vector analytics in early 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Novel intracellular delivery approaches are needed to support the increased complexity of the burgeoning cell therapy pipeline. Characteristics include reducing immunogenicity risk of viral vectors, the need to drive high efficiency of multi-molecule delivery while maintaining high cell viability and potency, reducing the risk of potential genotoxicity of multiplex editing (potential for translocations), the need to deliver a large number of molecules at scale, the ability to deliver to a large number of cell types in a time efficient matter, and the need to manufacture in a cGMP environment&#8201;&#8212;&#8201;all at a manageable cost.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Electroporation as a mechanism of non-viral delivery</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Electroporation background<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">In order to understand electroporation, it is important to understand the make-up of the cell membrane. The cell membrane is a phospholipid bilayer, which is a thin membrane made up of two layers of lipid molecules forming a continuous cell membrane around the cytoplasm and acting as a stable barrier between the intracellular and extracellular environment. The lipid membrane is fluid&#8201;&#8212;&#8201;meaning individual molecules (including lipids and proteins) are free to rotate and move laterally and transversely, which is a critical property and determined by the composition of the lipid and the cell&#8217;s thermal environment. The membrane is also selectively permeable, allowing the cell to control and maintain its internal composition, with the typical arrangement of the cellular membrane designed to impede the movement or passage of molecules into or out of the cell.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Applying electric fields above a certain threshold induces membranes to become more permeable. A key discovery in the use of electroporation to drive reversible permeability of cell membranes was the use of electric pulses&#8201;&#8212;&#8201;applying fields of adequate strength but for short durations&#8201;&#8212;&#8201; which allows the membrane to return to its normal state or reseal, and thus permeabilization is transient. If the pulse is too strong or too long, the membrane does not reseal, leading to cell death. The length of time that the membrane remains permeable is dependent on various factors, including temperature, ionic content and the presence and distribution of proteins.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">While the precise molecular mechanism of electrically-induced membrane permeability has not been fully elucidated (with a number of theories proposed), experiments and mathematical modeling have provided insights into the potential physical-chemical mechanism of cell electroporation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Overview of the electroporation process<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-left:20pt; margin-top:2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following graphic shows the steps involved in the electroporation process:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-pht_electro4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_electro4clr.jpg]" height="375" width="592" >
        </div>
        <table style="width:456pt;height:142.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.833pt 0pt; width:17.33pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Step</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.833pt 0pt; width:426.67pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.04pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:17.33pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">1</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:426.67pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Polarization of the cell membrane occurs when electrical pulses are applied to cells suspended between two electrodes, creating an electric field. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17.33pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">2</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:426.67pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">The application of electrical pulses and the resulting transmembrane voltage induce the formation of openings in the cellular membrane. The size distribution of these openings depends on the intensity of the applied electric field and duration of cell exposure. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17.33pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">3</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:426.67pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">These openings allow the entry of macromolecules such as RNA, DNA or proteins (such as Cas9/guide RNA complexes) through the cell membrane and into the cytoplasm of the cell. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17.33pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">4</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:426.67pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">The effects of electroporation on the cellular membrane are reversible. Once the electric field is removed, the membrane has the capacity to reseal, trapping the molecules that passed across the membrane within the cytoplasm.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:3.9pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Development of our proprietary flow electroporation platform<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The majority of commercial electroporation systems employ static electroporation. Generally, electroporation platforms consist of two flat plate electrodes, which are attached to the opposite sides of a cuvette (or chamber). A suspension of cells is added, in addition, to the molecule or molecules to be introduced into the cells. Electrodes are connected to electronic circuity that is able to deliver electric pulses of specified duration applied one or more times to the electrodes and thus to the cell suspension in the cuvette/chamber.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Static electroporation is limited to small volumes (typically less than 1 mL), making its use in cell therapy limited primarily to early research and development. This has proven to be a bottleneck when the goal is to scale electroporation to clinical or commercial therapeutic applications where electroporation of large volumes of cell suspension is required. Maintenance of sterility is important to applications of electroporation for large volumes, and given the limited volume of cells that could be electroporated per cuvette, electroporation of large volumes of cell suspension would require multiple cuvettes using static electroporation, making it impractical outside of early, small-scale research and development experiments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Since pioneering the development and commercialization of Flow Electroporation over 20&#160;years ago, we have focused on optimizing our Flow Electroporation platform, specifically for </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:70.15pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">applications. Flow Electroporation involves the continuous pumping of batches of a fixed volume of cells from a larger cell suspension from a sample bag into an electroporation chamber housed within our PA. Once the electroporation of the cells is completed, the electroporated cells are pumped to a collection bag and the next batch of cells to be electroporated enters the chamber. This process is repeated until the complete volume of cell suspension has been electroporated.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The key benefit of Flow Electroporation is that a large volume of cells can be electroporated, all in a closed, sterile system&#8201;&#8212;&#8201;facilitating the use of electroporation for therapeutic applications without sacrificing the viability and function of the transfected cells. The ability to electroporate cells in a closed system facilitates automating and maintaining a sterile environment for the engineering and manufacturing of larger cell volumes. Examples of applications benefiting from such scale are autologous CAR-T therapies, future allogeneic approaches using iPSCs, and manufacturing of transiently produced protein using Chinese hamster ovary or human embryonic kidney cells within the bioproduction or rapid vaccine production market segments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Our Market Opportunity</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The challenges of viral delivery methods and increase in complexity of next-generation cell therapies have driven increased adoption of non-viral delivery technologies, such as electroporation. We believe our ExPERT technology is well positioned as a non-viral delivery platform in the cell therapy market. Originally developed in 1999 for the cell therapy market, we have systematically designed and improved to deliver any molecule, into any cell at any scale, with high efficiency and under cGMP conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT platform is now the delivery backbone for a number of next-generation cell therapy programs that are in the clinic, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">CRISPR Therapeutics&#8217; CTX-001 for transfusion-dependent &beta;-thalassemia and severe sickle cell disease.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">VOR Biopharma&#8217;s VOR33, an eHSC therapy candidate for the treatment of Acute Myeloid Leukemia that received IND clearance in January&#160;2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Allogene&#8217;s Allogeneic CAR-T for cancer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Caribou&#8217;s CRISPR gene-edited allogeneic T-cell therapy program.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Editas Therapeutics&#8217; EDIT-301, an </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> gene editing cell medicine in development for the treatment of sickle cell disease that received IND clearance in January&#160;2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Precision BioSciences&#8217; lead program, PBCAR0191, a novel CD19-targeted allogeneic CAR-T therapy candidate to treat relapsed/refractory Non-Hodgkin&#8217;s lymphoma and B-cell acute lymphoblastic leukemia, and PBCAR269A, a BCMA targeted genome edited allogeneic CAR-T therapy candidate for multiple myeloma.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">While many legacy cell therapy approaches use viral delivery approaches, we believe these developers will increasingly adopt non-viral approaches. We believe we currently have the largest market share supporting customers using non-viral delivery approaches for engineered cell therapies to treat immune-oncology and inherited disorders. As shown in the graphic below, we estimate that we have captured approximately 40% to 55% of U.S. clinical programs utilizing non-viral delivery and we expect to increase our share over time as more preclinical programs reach the IND-enabling phase.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:110.37pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-pc_clinical4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pc_clinical4clr.jpg]" height="326" width="548" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Based on the current pipeline of engineered </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy candidates in development for immuno-oncology and inherited genetic disorders, we estimate that our total addressable market opportunity for our ExPERT platform, based on the potential for SPLs, was approximately $9&#160;billion in 2020. We expect this market to grow to over $24&#160;billion by 2026 driven by growth in the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy pipeline and a shift to use of non-viral delivery technologies. We calculate these market opportunities using our internal estimates of risk-adjusted potential aggregate revenue potential from SPLs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We estimate there are currently almost 700 genetically modified </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies in various phases of development that we would consider our current addressable market, which is engineered cell therapy focused on oncology and inherited disorders. Based on historical growth rates of the cell therapy landscape and ongoing investment, we expect the number of </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies to at least double over the next five&#160;years. We believe approximately 40% of current therapies are using non-viral delivery technologies. Given the benefits of non-viral approaches relative to viral delivery vectors, we expect the utilization of non-viral strategies to continue growing to approximately 60% of the total market by 2026. We expect this ongoing shift to non-viral strategies to be driven by increased adoption of gene manipulation technologies, such as CRISPR based gene editing approaches, the increased complexity of </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> therapies in the pipeline, as well as the high cost, payload limitations, and current manufacturing capacity constraints of viral approaches and advances in non-viral engineering technologies. These estimates are shown in more detail in the graphic below, which also identifies the programs that we consider to be part of our potential pipeline in terms of estimating our total addressable market:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:18.08pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-org_genet4c.jpg" alt="[MISSING IMAGE: tm2113965d1-org_genet4c.jpg]" height="421" width="559" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We have a diverse portfolio of clinical partners and licensees that mirror the overall next-generation engineered </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies. While difficult to predict given uncertainty around regulatory approvals and clinical risk, according to Evaluate Pharma, a provider of commercial intelligence and predictive analytics to the pharmaceutical industry, the first next-generation </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies using non-viral approaches could be approved in the United States as early as 2023.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our platform&#8217;s ability to engineer a diversity of cell types (including CAR-T, chimeric antigen receptor Natural Killer cells, or CAR-NK/NK, T cell receptor, or TCR, and stem cells) and cell sources (autologous and allogeneic) enhances our opportunity by potentially providing for SPL revenues regardless of which approaches advance in the coming&#160;years. Additionally, our instruments and platform are well validated, having been used in over 30 clinical trials to date and having been involved in the development of drugs to treat a variety of indications spanning from hematological malignancies to solid tumors to inherited genetic disorders. We believe that the increasing number of publications highlighting the performance of our platform compared to other electroporation and transfection approaches will help to drive acceptance of our products in the cellular engineering market segments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The following graphic depicts the variety of cell types, cell sources and target indications within the cell therapy market, as well as those represented in our cell therapy customers&#8217; current programs, which we believe to be in line with the overall market. For purposes of the graphic, all clinical gene modified cell therapies across therapeutic areas, such as oncology, inherited disorders and immune disorders, using both viral and non-viral delivery have been included, while other regenerative medicine programs that do not entail genetic modification to obtain a cell-based therapeutic product, such as tissue engineering, immune or stem cell therapies, that are not genetically modified have been excluded.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:152.47pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-pc_celltype4c.jpg" alt="[MISSING IMAGE: tm2113965d1-pc_celltype4c.jpg]" height="232" width="597" >
        </div>
        <div style="margin-top:18.69pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Our Strategic Platform Licenses (SPLs)</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe our differentiated capabilities and reliability position us as the global partner of choice for non-viral cell engineering technology. Customers are attracted to our proprietary platform because it offers a highly efficient, reproducible, scalable, non-viral cell engineering system supporting concept to commercialization. Customers are seeking more involved partnerships as they navigate new ways of cell handling and therapeutic development. We believe that our reliability in the field, combined with access to our intellectual property and the deep expertise we bring to solving cell engineering and cell handling challenges represents significant points of differentiation for our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our customer relationships may evolve to an SPL after the customer&#8217;s drug candidate optimization and verification process nears completion and the clinical process development stage begins. Specifically, if a customer wishes to use our products in the clinical phase of process development, they will need to enter into an SPL, as a customer must obtain clinical rights to perform clinical process development, including for engineering runs. Customer discussion for an SPL can take place any time during our engagement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our clinical licensees receive access to our cGMP-compatible platform&#8217;s intellectual property, our scientific team and rights to reference our FDA Master File and Technical Files. In each of our SPL agreements, we supply our technology for clinical and commercial use. In return, we receive clinical progress milestone payments and, in most cases, sales-based payments (including royalties in some cases) in addition to instrument licensing fees. Typically, the SPLs include multi-program (product) rights and, while variable, average roughly six programs per commercial agreement with variability in the progression of those programs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following graphic is an example of typical single-product revenues from a representative license deal:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-pht_typical4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_typical4clr.jpg]" height="463" width="596" >
        </div>
        <div style="margin-top:10.6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Our Products</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The ExPERT instrument family was designed to provide a single unifying technology that can be used from concept to clinic, with both the research and clinical versions of the instrument incorporating the same underlying technology and protocols. Our customers have a choice of three different instrument versions that are standardized on the same technology to deliver the same high performance&#8201;&#8212;&#8201;the ATx, STx and GTx. Customers can start with the lower to medium scale research instrument (ATx) and then scale to the clinical version (GTx), without the need for re-optimization and re-validation. The STx provides the same scale as the GTx but is used for drug discovery applications, not for human therapeutic use, and is not covered by our FDA Master File or our Technical Files.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe these systems will also be supportive of the commercial marketing of our partners&#8217; therapeutic products which we enable. By allowing our customers to perform their research and process optimization on a research platform and seamlessly scale to a clinically validated, cGMP environment and 21 CFR Part&#160;11 compatible clinical platforms, significant time and cost savings can be realized.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">All of our instruments were designed to provide customers with the key features required for a scalable high-end, high-performance transfection solution. Each of our ExPERT instruments are benchtop with the same small footprint and have integrated touch screens with an intuitive Graphical User Interface, or GUI, designed for simple training and operation. To support use in the cGMP suite for clinical manufacturing, our GTx ExPERT software is network capable to enable upload of electronic batch records to a local shared drive and has a software intermediary to facilitate integration and automated data transfer to cloud-based data management solutions. We have integrated hardware and software design solutions, manufactured under cGMP, that are tailored for use in cGMP manufacturing of clinical product for advanced cellular therapies. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following chart summarizes the features of the three ExPERT instruments:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="min-height:89pt;white-space:normal;text-align:right;vertical-align:top;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0pt 0pt; width:427pt;">
              <div style="position:relative;text-align:right;">
                <img src="tm2113965d1-pht_expsca4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_expsca4clr.jpg]" height="108" width="364" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:17pt;white-space:nowrap;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:335.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;min-height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:118pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.04pt;">Features </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:103pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">ExPERT ATx </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:103pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">ExPERT STx </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">ExPERT GTx </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:31.75pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 5.333pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Main Use </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 5.333pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Research </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 5.333pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Research/</font>&#8203;<br ><font style="letter-spacing:-0.025pt;">Development </font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Clinical </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Market segment </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">General Research </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Protein Production </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Cellular Therapy </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Scale (cells) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">75,000 to 700&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">75,000 to 20&#160;billion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">75,000 to 20&#160;billion </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:36pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:118pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Designed for Use in cGMP Suite</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Benchtop </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Touchscreen </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Static electroporation </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Flow electroporation </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Barcode reader </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:36pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:118pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Designed to Align with 21 CFR Part&#160;11 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:36pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:118pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">FDA Master File and Technical Files </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:27.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 5.333pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Network capable </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:3.5pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">ExPERT ATx: Research focused, static electroporation for small to medium scale transfection<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:14pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="min-height:171pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d1-pht_atx4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_atx4clr.jpg]" height="120" width="123" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:300pt;text-align:left;">
              <div style="line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">Our ExPERT ATx static electroporation instrument is a research focused, high performance electroporation platform for small to medium scale transfection. The ATx instrument delivers high efficiency and viability at research scale and can utilize our range of PAs capable of transfecting from 75&#160;thousand up to 700&#160;million cells. Additionally, our ATx instrument is compatible with all of our static PAs, which can also be used on our GTx instrument, allowing for a seamless transition to our clinical cGMP-compatible platform. The ATx is designed and used by our customers for early design of experiment and process optimization at small scale to minimize cell acquisition and reagent costs. Once optimized for the biological function with smaller numbers of cells, the process can be replicated and scaled before being transferred to the clinical platform (GTx) for eventual manufacturing in the cGMP suite or to </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:300pt;">
              <font style="letter-spacing:-0.025pt;">the STx platform for drug discovery.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">ExPERT STx: Flow Electroporation for protein production and drug development<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="min-height:297pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d1-pht_stx4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_stx4clr.jpg]" height="136" width="125" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:300pt;text-align:left;">
              <div style="line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">Our ExPERT STx, which is used in the field of protein production as well as other drug discovery applications, also incorporates our proprietary Flow Electroporation Technology for high yield transient expression of complex proteins, viral vectors, vaccines and biologics. Our STx instrument has high efficiency and can rapidly transfect from 75&#160;thousand up to 20&#160;billion cells. When combined with flexible media strategies, the STx allows for substantial improvement in yields of high-quality, transiently expressed proteins while enabling reduced media costs. </font>
              </div>
              <div style="margin-top:6pt; line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">Another key application area for the STx is expression of therapeutic targets for cell-based assays. Traditionally, drug screening has been performed using stable cell lines because conventional transfection technologies, such as lipofection, may induce changes to membrane composition, which does not offer the consistency and scalability that are critical for sensitive, high throughput screens. By enabling high efficiency transfection of multiple plasmids simultaneously into billions of cells, the STx provides drug developers with the ability to express complex, multi-subunit proteins, such as ion channels, in physiologically relevant cells. The high viability of our transfected cells leads to robust assay responses on multiple platforms, including automated electrophysiology and high content screening technologies. Moreover, precise control over loading efficiency gives assay developers the ability to &#8220;dial in&#8221; optimal assay windows.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.2pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">ExPERT GTx: Flow Electroporation for large scale transfection in therapeutic applications<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="min-height:225pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d1-pht_gtx4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_gtx4clr.jpg]" height="177" width="159" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:300pt;text-align:left;">
              <div style="line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">The ExPERT GTx incorporates our proprietary Flow Electroporation Technology for use in the cGMP manufacturing of cellular therapies for use in the clinic. By incorporating the Flow Electroporation Technology, larger volumes of up to 20&#160;billion cells can be electroporated within 15 to 20 minutes. With a processing potential that ranges from 75,000 to 20&#160;billion cells on a cGMP, 21 CFR Part&#160;11 compatible system, the GTx represents a platform for clinical electroporation at large scale. </font>
              </div>
              <div style="margin-top:6pt; line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">The GTx integrates several design features that are critical for use in a cGMP setting, such as barcode reading capability to maintain positive identification of patient samples, 21 CFR Part&#160;11 compatible software and networking capability for automated uploading of electronic batch records to either a central server or to a cloud-based data management platform. The GTx offers the potential for closed sample processing, on a system compatible with integration into cGMP manufacturing environments, and that has an established regulatory path supported by our FDA Master File and Technical Files.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">VLX: Designed for extremely large volume cell-engineering<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The VLX Large-Scale Transfection System is a cGMP compliant instrument specifically designed for extremely large volume cell-engineering. Using proprietary Flow Electroporation Technology, the VLX supports the ability to transfect up to 200&#160;billion cells in less than 30 minutes&#8201;&#8212;&#8201;10 times the capacity of the STx. This system is designed for the rapid and large-scale production of recombinant proteins, monoclonal antibodies, viral vectors, vaccines, virus-like particles, or VLPs, and allogeneic cell therapies. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We intend to introduce the VLX under the ExPERT brand in 2021 to provide our customers with an easier to use system that incorporates the benefits of the ExPERT platform.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Disposables&#8201;&#8212;&#8201;Processing Assemblies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our range of disposable processing assemblies, or PAs, is an important differentiator for us. We are not aware of any other company with the breadth and diversity of volume ranges and designs to enable high efficiency electroporation in single-well and multi-well formats, for use in both the research and clinical settings. We view the PA design as one of the key contributors to the high efficiency and viability of the ExPERT platform.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have designed a range of PAs, that are specially designed to hold and electroporate the chosen quantity of cells. Each PA contains two electrodes, between which a medical grade gasket is sandwiched that has a unique well design consistent with the processing volume required and to allow maximum retrieval of cells. We have designed a unique range of PA&#8217;s capable of electroporating cell volumes from small to large scale, in single and multi-well formats, for both research and clinical use. Cells are placed into the well or wells and the PA is then inserted into the instrument for processing. The instrument touch screen allows the operator to select the desired cell protocol that encodes the electroporation parameters, select the type of PA to be used and enter any sample specific information. Once the sample information has been entered, the operator will touch the &#8220;Start Processing&#8221; icon on the user interface and the sample will be rapidly processed. Larger volumes of cells are accommodated by larger capacity PAs and a set of simple software commands through the intuitive GUI.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT system uses two PA designs&#8201;&#8212;&#8201;a static cuvette used for smaller cell volume requirements (from 75,000 cells up to 200&#160;million cells) and a cartridge that is used for both static and Flow Electroporation for larger cell volumes (700&#160;million up to tens of billions of cells). The Flow Electroporation PA (CL-2) allows for processing of cellular volumes ranging from 10 mL to 100 mL and up to tens of billions of cells. The CL-2 consists of two bags and associated tubing, made from medical grade materials, that are connected to the electroporation cartridge. Users will transfer their cells and loading molecules to the sample bag, and the pump on either the GTx or STx instrument pumps a fixed volume of cells into the cartridge chamber where they are electroporated. Once the electroporation is complete, the cells are pumped to the collection bag and the chamber is filled with the next volume of cells for electroporation. This process is repeated until the entire sample volume is processed. The maximum volume of 100 mL of cells can be processed in approximately 15-20 minutes. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our two ExPERT PA designs are shown in the pictures below:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="white-space:normal;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d1-pht_cuvette4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_cuvette4clr.jpg]" height="97" width="155" >
              </div>
              <div style="margin-top:5pt; text-align:center; line-height:12pt;font-style:italic;">ExPERT cuvette design <br >(Static Processing Assembly)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;vertical-align:top;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d1-pht_flowas4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_flowas4clr.jpg]" height="160" width="245" >
              </div>
              <div style="margin-top:0.85pt; text-align:center; line-height:12pt;font-style:italic;">ExPERT Flow Electroporation design<br >(Flow Processing Assembly)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have conducted extensive end-user research over the last several&#160;years to continue to improve the design of the PAs and the range of products available. As a result, we launched the ExPERT cuvette shown above in 2020 based on customer feedback, which incorporated a new design to improve handling and ease of use. Under this new design, two new volume offerings have been launched, the R-1000 that can process up to 1 mL, or 200&#160;million cells, and the R-50x3, which is a 3-well cuvette capable of processing up to 10&#160;million cells in each well. The multi-well cuvettes reduce manual handling and improve productivity in the lab. By enabling three samples to be processed in the same </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">cuvette, a more efficient process can be achieved by users. We expect to launch an additional multi-well cuvette in the second half of 2021, and the new ExPERT PA design will also be rolled out across the entire range of cuvettes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following matrix shows our full line of currently available PAs and their respective specifications and features, including the ExPERT instruments with which they can be used:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-tbl_patype4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-tbl_patype4clr.jpg]" height="303" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are committed to continuing to strategically invest in improvements in the PA design and range of products to ensure that customers have solutions that address all of their volume and use requirements, in both the research and clinical settings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Supporting Products<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our proprietary electroporation buffer, a balanced salt solution that protects cells during transfection, is formulated for use with all our instrument platforms and PAs. This consumable is used for all cell types, eliminating the need to change buffers as users switch protocols, cell types or scale up. The buffer is made in a cGMP facility, is fully chemically defined and is free of human or animal components, and is tested to meet technical, sterility and endotoxin specifications. This buffer formulation is a key contributing factor, in combination with instrument and PA design features, to the flexibility, high efficiency and viability that can be achieved by customers across the broad range of cell types processed using our platform.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Sales and Marketing</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We follow a direct sales model in North America, United Kingdom, and Europe, while also selling through third-party distributors in some regions in Europe and Asia. As of March&#160;31, 2021, we have over 20 field sales and application scientists located in the United States, the United Kingdom, and several regions in Europe and Asia. Since the commercial launch of our first Flow Electroporation instrument, the installed base of our instruments has grown to more than 400 instruments globally.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our sales force and field application scientists and international partners inform our current and potential customers of current product offerings, new target applications and advances in our technologies and products. As our primary point of contact in the marketplace, our field teams focus on delivering a consistent marketing message and high level of customer support, while also attempting to help us better understand the evolving market and customer needs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We intend to expand our sales, support, and marketing efforts in regions with a concentrated life sciences presence, including large pharmaceutical and biopharmaceutical companies. Additionally, we believe that there is significant opportunity in Asia-Pacific countries such as Japan and China. We </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">have distributors in these regions and continuously assess the need for direct sales and local support personnel to supplement our distributors&#8217; resources.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our business model is focused on identifying new applications in cell engineering to enable our customers to develop better medicines and maximize use across our customers&#8217; value chains. This is enabled through customer partnerships that allows us to further understand the critical applications for our technology and inform our future developments and market expansion.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Research and Development</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Investment in research and development is at the core of our business strategy. Members of our research and development team specialize in many functional areas including molecular biology, cellular biology, physics, gene editing, cell culture, protein manufacturing, algorithms, mechanical engineering, cell handling processes, electroporation algorithm development and customer technical support.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our research and development teams are aligned into two teams, applications and instrumentation. The application team is responsible for developing data on key applications, including improving approaches to cell handling and cell culture; designing, developing and enhancing electroporation protocols; developing and enhancing cell engineering applications, and performing product testing and quality assurance activities. The instrumentation engineering team focuses on developing and improving electroporation instrument and PA disposables to meet our partners&#8217; large range of needs from research to commercialization in a GMP environment. The research and development functional teams work together as a core team, following a stage gate process to develop, qualify and launch new products to market.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Other research and development activities include customer technical support such as lab cell processing techniques, instrumentation training and application support. Most of our research and development operations are conducted in our Maryland facility.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have made substantial investments in product and technology development since our inception. Research and development expense totaled $17.7&#160;million in the year ended December&#160;31, 2020 and $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million in the three&#160;months ended March&#160;31, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Although our CARMA pre-clinical and clinical development will be concluded in the first half of 2021, we expect our research and development expenses outside of CARMA to increase significantly for the foreseeable future as we develop data supporting the use of our products in various applications and continue to enhance our existing products as well as develop new products for our current and new markets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Manufacturing and Supply</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We design our single use PA disposables and conduct final functional testing in our Maryland facility. In addition, we design, develop and manufacture the ExPERT instruments in-house. Our in-house manufacturing and design function is certified as ISO 9001 compliant and our manufacturing facility is located at our headquarters in Maryland. This facility includes approximately 1,000 square feet of production assembly space, plus ancillary machine shop and design spaces. Inventory is held in our Maryland facility in a 2,500 square foot controlled-access shipping, receiving and storage space.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Instruments<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our range of ExPERT instruments are manufactured, tested and shipped from our Maryland facility under cGMP. Several custom components of our ExPERT instruments are fabricated by third-party suppliers. The assembly of technology-sensitive components and the final assembly is completed in-house. Currently, our Maryland manufacturing facility can support the production of ExPERT instruments in excess of current demand, and we will continue to obtain the space and staffing necessary to meet customer demand for the foreseeable future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Processing Assemblies<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our family of ExPERT instruments incorporate a broad range of proprietary single use PAs that are specially designed to meet the needs of our customers for cell volume, single- or multi-well configuration, static or flow processing. These PAs are only available from us and are designed for use </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">only with our instruments. Accordingly, our range of PAs are designed, developed, tested and shipped from our Maryland facility. We currently outsource manufacturing of components and final clean-room disposables assembly to third parties. Over time, we plan to move the cleanroom assembly activities in-house in order to enhance operational control over quality, expand capacity, enable automation implementation and improve other areas of operations. In-addition, in-house manufacturing would be expected to allow research and development to more rapidly develop new products and enhancements when manufacturing and research and development are in the same facility.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Supply<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For both instrument and PA manufacturing, we regularly assess our supply chain to ensure availability of components, our ability to respond to customer demand for our products and to qualify multiple suppliers. We have relationships with several custom parts manufacturers and electronics suppliers that can provide components for our instruments, including components currently provided by a single source. The single source suppliers are chosen for their business stability and scalability to minimize risk. If a single source supplier has a part or process that is time-consuming to transfer to another supplier, we will hold enough inventory of that part to allow adequate time for technical transfer and qualification. Our ongoing strategy is to maintain adequate levels of inventories at all times and to qualify at least two suppliers for critical quality components, and we plan to continue the diversification of our supply chain as we scale. This inventory strategy was designed to minimize supply chain risk and as a result we are currently able to ship on demand and to date have never had a backorder for a product. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Competition</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The life sciences market is highly competitive and dynamic, reflecting rapid technological evolution and continually evolving customer requirements. There are other companies, both established and early-stage, that have or are developing electroporation and other non-viral delivery technologies that could be applicable to both bioprocessing and cell engineering. These companies include Lonza Group AG, Thermo Fisher Scientific Inc., Miltenyi Biotec, Bio-Rad Laboratories, Inc. and Harvard Biosciences Inc. (BTX) as well as several other smaller companies, including spinouts from academic labs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Some of these companies may have substantially greater financial and other resources than us, including larger research and development staff or more established sales forces. Other competitors are in the process of developing novel technologies for the life sciences market which may lead to products that rival or replace our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For further discussion of the risks we face as a result of competition, see &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Business and Growth Strategy&#8201;&#8212;&#8201;We may be unable to compete successfully against our existing or future competitors.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Intellectual Property</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our intellectual property strategy has been, and still is, to obtain patent protection in relevant jurisdictions over our instruments, methods utilizing our instruments, as well as design patents over the ExPERT system. As part of this strategy, we have focused on obtaining protection for our non-viral delivery platform to the extent possible, particularly in the United States and other key jurisdictions of commercial value. As of May&#160;4, 2021, we have 50 granted U.S. and foreign patents, including in foreign jurisdictions such as Australia, Canada, Japan, China, South Korea and certain countries in Europe, as well as 76 pending patent applications worldwide. The main focus of our patent coverage protects our Flow Electroporation, processing chambers/disposables, control and process elements, and methods of using our non-viral delivery platform. Our patent portfolio provides protection over our instruments and related methods through at least 2028 and over our electroporation applications and methods through 2034. We are also working to secure design protection of the ExPERT system, which has the potential to provide protection through at least 2036.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to our granted patents and filed applications, we maintain and protect a number of different trade secrets related to our cell processing technology and other core technology areas, such as improvements made to protocols, pulsing patterns, proprietary buffer and formulations developed by us. Our&#160;years of accumulated know-how and the technical expertise of our employees provide us with a competitive advantage. We use our know-how and technical expertise to optimize and update our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">104</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">proprietary methods and protocols, such as cell handling and preparation techniques unique to different cells and target molecules, which we confidentially share with our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We maintain the confidentiality of our trade secrets, know-how and proprietary methods and protocols to protect our intellectual property from competitors. One key element of this protection is our FDA Master File and Technical Files described in more detail below, which allow us to submit to the regulator confidential detailed information about our ExPERT system and disposables. The relevant submission can be referenced by our customers or licensees to support their own regulatory filings without the need for us to disclose the confidential information contained in the FDA Master File and Technical Files.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We also seek to protect our brand through procurement of trademark rights. As of May&#160;4, 2021, we owned 13 registered trademarks in the United States, 79 registered foreign trademarks and 15 pending U.S. trademark applications. Our registered trademarks and pending trademark applications include trademarks for MaxCyte, CARMA, a stylized version of ExPERT and our logo. In order to supplement protection of our brand, we have also registered several internet domain names.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Government Regulation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The FDA and similar governmental authorities regulate, among other things, the research, development, testing, manufacturing, clearance, approval, labeling, storage, recordkeeping, advertising, promotion, marketing, distribution, post-market monitoring and reporting, and import and export of technologies including biological drug products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our biopharmaceutical and life sciences customers are subject to extensive regulations by the FDA and equivalent regulatory authorities in other countries, regarding the conduct of preclinical studies and clinical trials, in the manufacture of product candidates and products for use in humans (i.e., &#8220;Good Manufacturing Practice&#8221; laws and regulations) and the marketing authorization and commercialization of biological drug products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The activities of sponsors, applicants and manufacturers are subject to regulation of those jurisdictions where the research or manufacturing occur, and also jurisdictions for which applications are planned or have been made and the product is intended to be marketed.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Although we are not engaged in directly regulated activities, our customers will generally assess our products for sufficiency in meeting their regulatory needs, and may impose rigorous quality or other regulatory compliance requirements on us as their supplier through supplier qualification processes and customer contracts.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have established a quality management system (under ISO 9001:2015 standards) which is designed to respond to customer expectations and needs and support customer adherence to applicable regulatory requirements. The technologies we offer for potential use by customers in a cGMP environment are produced under this ISO 9001:2015 quality management system.</font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Master and Technical Files to Support Customer Regulatory Submissions<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our core business is focused on developing our proprietary and patented electroporation technology platform is used by our customers in research and development applications as well as for manufacture of commercial cell therapies. In order to support our customers&#8217; use of our platform, we have voluntarily submitted a Master File to the FDA, Center for Biologics Evaluation and Research and Technical Files to comparable regulatory authorities in other jurisdictions, and provide nonexclusive Letters of Authorization to the Master or Technical Files under contractual agreements with our customers. In this way, the regulatory body may review information on our platform in the context of its utilization by our partners in regulated products, for example, as described in our customers&#8217; Investigational New Drug applications. We continuously update the Master and Technical Files in order to support the regulatory activities of our customers. The FDA and regulators in other countries allow Master and Technical Files, but they do not approve them.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">U.S. Healthcare Laws and Reform<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the United States, there are federal and state healthcare laws that constrain the business or financial arrangements and relationships through which our customers who use our platform and we, if </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">105</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">we develop a product, research, sell, market and distribute products. Such laws include federal and state anti-kickback laws, false claims laws, transparency laws and health information privacy and security laws. Violations of these laws can lead to significant administrative, civil and criminal penalties, including sanctions, damages, disgorgement, monetary fines, possible exclusion from participation in government healthcare programs such as Medicare and Medicaid, imprisonment, additional reporting requirements and/or oversight obligations, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, in the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care, including the proposed modification to some of the aforementioned laws. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affected the healthcare industry. These reform initiatives may, among other things, result in modifications to the aforementioned laws and/or the implementation of new laws affecting the healthcare industry. Similarly, a significant trend in the healthcare industry is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Our ability to commercialize any of our products successfully, and our customers and collaborators&#8217; ability to commercialize their products successfully, will depend in part on the extent to which coverage and adequate reimbursement for these products and will be available from third-party payors. As such, cost containment reform efforts may result in an adverse effect on our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">The Foreign Corrupt Practices Act<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Data Privacy and Security Laws and Regulations<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The collection, use, transfer, disclosure, retention, security and other processing of personal data (including, without limitation, clinical trial data and other data concerning health) may be subject to independent and overlapping data security and privacy regulatory frameworks in the various jurisdictions in which we operate. These frameworks are evolving and may impose potentially conflicting obligations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For example, in the European Economic Area, or EEA, the processing of personal data is principally governed by the provisions of the General Data Protection Regulation, or GDPR. The GDPR applies to any processing operations carried out in the context of an establishment in the EEA as well as any processing operations relating to the offering of goods or services to individuals in the EEA and/or the monitoring of their behavior in the EEA. Further notwithstanding the United Kingdom&#8217;s withdrawal from the European Union, by operation of the so-called &#8220;UK GDPR&#8221; &#8203;(i.e., the GDPR as it continues to form part of the law of the United Kingdom by virtue of section 3 of the EU (Withdrawal) Act 2018 and as subsequently amended), the GDPR continues to apply in substantially equivalent form to processing operations carried out in the context of an establishment in the United Kingdom and any processing relating to the offering of goods or services to individuals in the United Kingdom and/or monitoring of their behavior in the United Kingdom. Therefore, reference to the GDPR herein, also refers to the UK GDPR in the context of the United Kingdom, unless the context requires otherwise. In addition, the GDPR provides that EEA member states may introduce specific requirements related to the processing of &#8220;special categories of personal data&#8221;, including the personal data related to health and genetic information, which we may process in connection with clinical trials or otherwise; as well as personal data related to criminal offenses or convictions. In the United Kingdom, the UK Data Protection Act 2018 complements the UK GDPR in this regard. This fact may lead to greater divergence on the law that applies to the processing of such categories of personal data across the EEA and/or United Kingdom.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">106</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The GDPR enhances data protection obligations for controllers of personal data (such as clinical trial sponsors), including stringent requirements relating to the consent of data subjects in certain circumstances, expanded disclosures about how personal data is used, requirements to respect enhanced data subject rights in certain circumstances, requirements to conduct privacy impact assessments for &#8216;high risk&#8217; processing, limitations on retention of personal data, mandatory data breach notification and &#8216;privacy by design&#8217; requirements. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA or United Kingdom to countries that have not been judged to ensure an adequate level of protection for personal data, like the United States. Such transfers of personal data require the implementation and maintenance of a valid &#8220;transfer mechanism.&#8221; Following a recent ruling of the Court of Justice of the European Union, and subsequent regulatory guidance, certain previously available transfer mechanisms have been invalidated, and reliance on alternative transfer mechanisms may be complex or not possible in certain circumstances, for example, in many cases, such transfer mechanisms may need to be supplemented with additional, often onerous, technical, organizational and/or contractual measures.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Failure to comply with the requirements of the GDPR and related national laws may result in fines up to 20&#160;million euros/17.5&#160;million pounds sterling or 4% of a company&#8217;s global annual revenues for the preceding financial year, whichever is higher. In addition to administrative fines, a wide variety of other potential enforcement powers are available to competent supervisory authorities in respect of potential and suspected violations of the GDPR, including extensive audit and inspection rights, and powers to order temporary or permanent bans on all or some processing of personal data carried out by non-compliant actors&#8201;&#8212;&#8201;including permitting authorities to require destruction of improperly gathered or used personal data. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, following the United Kingdom&#8217;s withdrawal from the European Union on January&#160;31, 2020 and end of the post-Brexit transition period on December&#160;31, 2020, as noted above, the United Kingdom has introduced the UK GDPR which currently makes the privacy regimes of the EEA and United Kingdom similar, though it is possible that either the European Union, and consequently those further states that make up the remainder of the EEA, or United Kingdom could elect to change their approach and create differences in legal requirements and regulation in this area. Furthermore, under the post-Brexit Trade and Cooperation Agreement between the European Union and the United Kingdom, the United Kingdom and European Union have agreed that personal data transfers to the United Kingdom from EEA Member States will not be treated as &#8216;restricted transfers&#8217; to a non-EEA country for an initial period of up to four&#160;months from the end of the post-Brexit transition period, plus a potential further two&#160;months thereafter. If the European Commission does not adopt an &#8216;adequacy decision&#8217; in respect of the United Kingdom during this period, from that point onwards the United Kingdom will be an &#8216;inadequate third country&#8217; under the GDPR and transfers of personal data from the EEA to the United Kingdom will require a valid transfer mechanism (such as entry into the then-current form of the European Commission-issued Standard Contractual Clauses).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Given the breadth and depth of changes in relevant data protection obligations and regulatory frameworks, achieving and maintaining compliance with applicable data protection laws and regulations such as the GDPR and UK GDPR will require significant time, resources and expense, and we may be required to put in place new or additional mechanisms to ensure compliance with current, evolving and new data protection requirements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Failure to comply, or perception of a failure to comply with any of these laws, regulations, rules and standards could result in enforcement actions against us, including fines, public censure, claims for damages by affected individuals, damage to our reputation, and loss of goodwill, any of which could have a material adverse effect on our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Legal Proceedings</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are not subject to any material legal proceedings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">107</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:360pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Facilities</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our corporate headquarters, where our primary research and development, instrument design, development and manufacture, applications lab and distribution, sales, marketing and general and administrative activities are housed, are located in Gaithersburg, Maryland.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our headquarters facility consists of approximately 26,000 square feet of office and laboratory space under leases, which expire in October&#160;2023.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe that we will require expansion of our facilities in 2022 and have entered substantive discussions for a multi-year lease of expanded space in the general area of our existing facility.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Employees and Human Capital</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As of March&#160;31, 2021, we had 65 full-time employees, 45 of which have advanced degrees, including 19 with Ph.D. degrees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase shareholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">None of our employees is represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be good.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">108</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">MANAGEMENT</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table sets forth information for our executive officers and directors, including their ages as of April&#160;1, 2021:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:215.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:192pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.04pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:24pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:192pt;">Executive Officers:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Doug Doerfler........................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">President, Chief Executive Officer and Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Amanda Murphy....................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">44</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Chief Financial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Ron Holtz................................................. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">63 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:216pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">Senior Vice President, Chief Accounting Officer and Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Thomas M. Ross...................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">60 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Executive Vice President, Global Sales </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Maher Masoud......................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">46 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Executive Vice President and General Counsel </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">Non-Employee Directors:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">J. Stark Thompson, PhD.......................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">79 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Chairman </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Will Brooke............................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Richard Douglas, PhD............................. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">68</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Stanley C. Erck........................................ </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">72 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">John Johnston.......................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">62 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Art Mandell............................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">68 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Executive Officers</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Doug Doerfler</font><font style="letter-spacing:-0.025pt;"> has served as our president and chief executive officer and on our board of directors since July&#160;1998. Prior to cofounding MaxCyte in 1998, Mr.&#160;Doerfler served as president and chief executive officer and as a director of Immunicon Corporation. Prior to joining Immunicon, Mr.&#160;Doerfler held executive positions at life sciences company Life Technologies Corporation (now Thermo Fisher). Mr.&#160;Doerfler currently serves as chair emeritus of the Maryland Tech Council and on the executive committee of the Biotechnology Innovation Organization. Mr.&#160;Doerfler received his B.S. in finance from the University of Baltimore School of Business. We believe that Mr.&#160;Doerfler&#8217;s life science and cell therapy industry knowledge and public company management experience qualify him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Amanda L. Murphy</font><font style="letter-spacing:-0.025pt;"> has served as our chief financial officer since September&#160;2020. Before joining MaxCyte, Ms.&#160;Murphy served as a managing director of BTIG, LLC from 2018 to 2020 where she covered cell and gene therapy as an equity research analyst. Prior to BTIG, she was a partner and healthcare equity research analyst at William Blair &amp; Company from 2006 to 2018, focused on covering enabling tools and services in the life sciences. Ms.&#160;Murphy received a B.S. in biology from Boston College and an M.B.A. in finance, accounting and economics from the Kellogg Graduate School of Management at Northwestern University.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Ron Holtz</font><font style="letter-spacing:-0.025pt;"> has served as our senior vice president and chief accounting officer since September&#160;2020 and served as our chief financial officer from 2005 to September&#160;2020. He has also served on our board of directors since 2016. From 2000 to 2004, Mr.&#160;Holtz served as chief financial officer of B2eMarkets Inc., an e-sourcing and performance management provider. Mr.&#160;Holtz served as chief financial officer of RWD Technologies from 1996 to 1999 and previously spent time in Ernst &amp; Young LLP&#8217;s Financial Advisory Services Group. Mr.&#160;Holtz received his B.S. in mathematics from the University of Wisconsin, an M.B.A. from the University of Maryland and is a certified public accountant. We believe Mr.&#160;Holtz&#8217;s extensive experience in business operations and accounting standards qualifies him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Thomas M. Ross</font><font style="letter-spacing:-0.025pt;"> has served as our executive vice president of global sales since September&#160;2014. Prior to joining MaxCyte, Mr.&#160;Ross was senior vice president of commercial operations at OpGen from 2012 to 2014. Mr.&#160;Ross also served as chief commercial officer at Predictive BioScience and vice </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">109</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">president of North America medical diagnostics sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, Mr.&#160;Ross held several senior leadership roles in manufacturing operations at Life Technologies Corporation and Cambrex. Mr.&#160;Ross received his B.A. in business administration from The Citadel.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Maher Masoud</font><font style="letter-spacing:-0.025pt;"> has served as our executive vice president and general counsel since January&#160;2020 and previously as our vice president of legal from May&#160;2017 to January&#160;2020. From July&#160;2015 to May&#160;2017, Mr.&#160;Masoud served as assistant general counsel and corporate secretary for Wellstat Management Company and previously served as co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors. Previously, Mr.&#160;Masoud was a corporate attorney at Human Genome Sciences, Inc. from 2006 until 2012. Mr.&#160;Masoud received his J.D. from Michigan State University College of Law and a B.S. in cell and molecular biology genetics from the University of Maryland. Mr.&#160;Masoud is a member of the Maryland state bar.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Non-Employee Directors</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">J. Stark Thompson, PhD</font><font style="letter-spacing:-0.025pt;"> has served as the chairman of our board of directors since January&#160;2001. Dr.&#160;Thompson has nearly five decades of corporate leadership and business management experience, dating back to when he joined the DuPont Company in 1967, where he spent more than 20&#160;years. From 1988 until 2000, Dr.&#160;Thompson served as president, chief executive officer and board member of Life Technologies, Inc. Dr.&#160;Thompson has served on and led various boards of directors, including for companies such as Gene Logic, Inc. and Luminex Corporation. Dr.&#160;Thompson received his B.S. in Chemistry from Muskingum University and his M.Sc. and Ph.D. in physiological chemistry from The Ohio State University. We believe Dr.&#160;Thompson&#8217;s extensive experience in business operations qualifies him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Will Brooke</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since March&#160;2004. Mr.&#160;Brooke is a limited partner of Harbert Management Corporation, or HMC, which he co-founded in 1993, most recently serving as EVP and Managing Partner of its venture capital funds family from July&#160;2003 to December&#160;2014. Mr.&#160;Brooke has been advising and investing in early-stage and growth companies for more than 30&#160;years, and previously served on the boards of numerous pharmaceutical and medical equipment companies such as nContact, Inc., NovaMin Technology, Inc. and Emageon Corporation. Since December&#160;2018 he has also served as a board member of KPX, LLC, an environmental, social and governance advisory firm serving the investment and advisory sectors. Prior to joining HMC, Mr.&#160;Brooke practiced law for a decade. Mr.&#160;Brooke received a B.S. in Business Management and a J.D. from the University of Alabama. We believe Mr.&#160;Brooke&#8217;s extensive business experience and deep financial knowledge qualifies him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Richard Douglas, PhD</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since February 2018. Dr. Douglas formerly served as the senior vice president of corporate development of Genzyme Corporation where he worked from 1989 until 2011 when Genzyme was acquired by Sanofi. Prior to joining Genzyme, Dr.&#160;Douglas served in science and corporate development capacities at Integrated Genetics prior to its acquisition by Genzyme in 1989. Since 2011 Dr. Douglas has served as an adviser to RedSky Partners, a biotechnology-focused advisory firm and also as executive director of Labyrinth Choir, Inc. He is chairman of the board of directors of AldeyraTherapeutics which he joined in 2016 and has been a board member of Novavax, Inc. since 2010. He has a B.S. in chemistry from the University of Michigan, where he now serves as chair of the National Advisory Board for the Office of Technology Transfer, and a Ph.D. in biochemistry from the University of California, Berkeley. We believe that Dr. Douglas&#39;s significant business experience and scientific background qualify him to serve on our board of directors.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Stanley C. Erck</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since March&#160;2005. Mr.&#160;Erck has served as president and chief executive officer of Novavax, Inc. since April&#160;2011 and as a director of Novavax since June&#160;2009. Mr.&#160;Erck previously served as executive chairman of Novavax from February&#160;2010 to April&#160;2011 and interim chief financial officer from November&#160;2017 to March&#160;2018. From 2000 to 2008, Mr.&#160;Erck served as president and chief executive officer of Iomai Corporation, a developer of vaccines and immune system therapies, which was acquired in 2008 by Intercell AG. He also previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme and Baxter International. Mr.&#160;Erck also served on the board of directors of BioCryst </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">110</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Pharmaceuticals from December&#160;2008 to December&#160;2018. Mr.&#160;Erck currently serves on the board of directors of MDBio Foundation. Mr.&#160;Erck received a B.S. in economics from the University of Illinois and an M.B.A. from the University of Chicago. We believe Ms.&#160;Erck&#8217;s public company board experience and extensive knowledge and experience in biotechnology qualify him to serve on our board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">John Johnston</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since January&#160;2016. Mr.&#160;Johnston previously served on the board of directors of Midatech Pharma from December&#160;2014 to February&#160;2019, Flow Group from August&#160;2013 to October&#160;2017, Action Hotels from December&#160;2013 to December&#160;2018 and Constellation Healthcare Technologies from December&#160;2014 to January&#160;2017. From August&#160;2011 to April&#160;2013 Mr.&#160;Johnston served as managing director of institutional sales at Nomura Code, and from 2008 to 2011, he was director of sales and trading at Seymour Pierce. In 2003, Mr.&#160;Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. Mr.&#160;Johnston began his investment career at the Royal Bank of Scotland and previously held positions at Legg Mason Investors and Murray Johnston. Mr.&#160;Johnston received his B.A. in commerce from Abertay University and his M.B.A. from the University of Dundee. We believe Mr.&#160;Johnston&#8217;s executive leadership and operational experience qualify him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Art Mandell</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since May&#160;2006. Mr.&#160;Mandell served as president and chief operating officer of Prestwick Pharmaceuticals, Inc. from October&#160;2005 to August&#160;2007. Prior to Prestwick, Mr.&#160;Mandell was president and chief executive officer and a director of Cellective Therapeutics, Inc. from 2004 to 2005, when it was acquired by Astra Zeneca/MedImmune. Before Cellective, Mr.&#160;Mandell served as president and chief executive officer and director of Stemron Corporation from 2001 to 2003, and as senior vice president and chief business officer of Human Genome Sciences, Inc. from 1997 to 2001. Mr.&#160;Mandell began his healthcare career at Syntex Pharmaceutical Corporation. Mr.&#160;Mandell received his B.S. from San Jose State University and his M.B.A. from Santa Clara University. We believe Mr.&#160;Mandell&#8217;s extensive knowledge and experience in both pharmaceuticals and biotechnology qualify him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Family Relationships</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">There are no family relationships among any of our directors or executive officers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Composition of Our Board of Directors</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our business and affairs are managed under the direction of our board of directors. We currently have eight directors. Our board of directors may establish the authorized number of directors from time to time by resolution. In accordance with our fourteenth amended and restated certificate of incorporation currently in effect and our fifteenth amended and restated certificate of incorporation that will be in effect following the completion of this offering, our board of directors is and will be divided into three classes with staggered three-year terms. Each director serves until the election and qualification of successor directors at the annual meeting of stockholders, or until the director&#8217;s earlier removal, resignation or death. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors are divided among the three classes as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the Class&#160;I directors are Doug Doerfler and Ron Holtz, whose terms will expire at our 2022 annual meeting of stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the Class&#160;II directors are Art Mandell and Stanley Erck, whose terms will expire at our 2023 annual meeting of stockholders; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the Class&#160;III directors are Will Brooke, John Johnston, J. Stark Thompson and Richard Douglas, PhD, whose terms will expire at our 2024 annual meeting of stockholders.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">111</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Director Independence</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In connection with this offering, we intend to list our common stock on the Nasdaq Global Market. Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#8217;s board of directors within a specified period following the completion of this offering. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance committees be independent. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Audit committee members must also satisfy the independence criteria set forth in Rule&#160;10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In order to be considered independent for purposes of Rule&#160;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (i)&#160;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (ii)&#160;be an affiliated person of the listed company or any of its subsidiaries. We intend to satisfy the audit committee independence requirements of Rule&#160;10A-3 as of the completion of this offering. Additionally, compensation committee members must not have a relationship with us that is material to the director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning her or his background, employment and affiliations, our board of directors has determined that none of our directors, other than Messrs. Doerfler and Holtz, has any relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the Nasdaq listing standards. In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our shares by each non-employee director and the transactions described in the section titled &#8220;Certain Relationships and Related Party Transactions.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Committees of Our Board of Directors</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from time to time. Upon completion of this offering, copies of each charter will be posted on our website at www.maxcyte.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of such website address in this prospectus is an inactive textual reference only.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Audit Committee<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our audit committee consists of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;,&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;. Our board of directors has determined that&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;satisfies the independence requirements under Nasdaq listing standards and Rule&#160;10A-3(b)(1) of the Exchange Act of 1934, as amended, or the Exchange Act. The chair of our audit committee is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, whom our board of directors has determined is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, our board of directors has examined each audit committee member&#8217;s scope of experience and the nature of their employment in the corporate finance sector.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The primary purpose of the audit committee is to discharge the responsibilities of our board of directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits and to oversee our independent registered public accounting firm. Specific responsibilities of our audit committee include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">112</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:70pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">helping our board of directors oversee our corporate accounting and financial reporting processes;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing related person transactions;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">obtaining and reviewing a report by the independent registered public accounting firm at least annually that describes our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">approving or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our audit committee will operate under a written charter, to be effective prior to the completion of this offering, that satisfies the applicable Nasdaq listing standards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Compensation Committee<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our compensation committee consists of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;,&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. The chair of our compensation committee is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. Our board of directors has determined that each of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199; and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;is independent under the Nasdaq listing standards and a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The primary purpose of our compensation committee is to discharge the responsibilities of our board of directors in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. Specific responsibilities of our compensation committee include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing and approving the compensation of our chief executive officer, other executive officers and senior management;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing, evaluating and recommending to our board of directors the succession plans for our executive officers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing and recommending to our board of directors the compensation paid to our directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">administering our equity incentive plans and other benefit programs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control protections and any other compensatory arrangements for our executive officers and other senior management; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing and establishing general policies relating to compensation and benefits of our employees, including our overall compensation philosophy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our compensation committee will operate under a written charter, to be effective prior to the completion of this offering, that satisfies the applicable Nasdaq listing standards. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">113</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our nominating and corporate governance committee consists of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199; and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;. The chair of our nominating and corporate governance committee is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;. Our board of directors has determined that each member of the nominating and corporate governance committee is independent under the Nasdaq listing standards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Specific responsibilities of our nominating and corporate governance committee will include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">considering and making recommendations to our board of directors regarding the composition and chairmanship of the committees of our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">instituting plans or programs for the continuing education of our board of directors and orientation of new directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">developing and making recommendations to our board of directors regarding corporate governance guidelines and matters; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">overseeing periodic evaluations of the board of directors&#8217; performance, including committees of the board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our nominating and corporate governance committee will operate under a written charter, to be effective prior to the completion of this offering, that satisfies the applicable Nasdaq listing standards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Code of Conduct</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Prior to the completion of this offering, we intend to adopt a Code of Conduct that applies to all our employees, officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The full text of our Code of Conduct will be posted on our website at www.maxcyte.com. We intend to disclose on our website any future amendments of our Code of Conduct or waivers that exempt any principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar functions or our directors from provisions in the Code of Conduct. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Compensation Committee Interlocks and Insider Participation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">None of the members of the compensation committee are currently, or have been at any time, one of our officers or employees. None of our executive officers currently serve, or have served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Non-Employee Director Compensation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have historically provided our non-employee directors with an annual cash retainer as well as additional annual retainers for service as chair of the board and service as chair or member of the board&#8217;s committees. The fees for committee service are in addition to the annual cash retainer for board service.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:107.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:159.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:36.66pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:130.54pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 Annual Cash Retainer</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">(</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">January</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">&#160;1, 2020</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">&#8201;&#8211;&#8201;</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">March&#160;31, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:102.96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">2021 Annual Cash Retainer</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:14pt;padding-right:14pt;letter-spacing:-0.04pt;">(As of April&#160;1, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:159.84pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">Board of Directors</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$67,500 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$80,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:159.84pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$40,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$40,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.84pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">Audit Committee</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$15,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$20,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:159.84pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$8,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$10,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.84pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">Compensation Committee</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$12,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$14,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:159.84pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$6,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$6,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">114</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:63.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:59.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:159.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:36.66pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:130.54pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 Annual Cash Retainer</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">(</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">January</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">&#160;1, 2020&#8201;&#8211;&#8201;March&#160;31, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:102.96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">2021 Annual Cash Retainer</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:14pt;padding-right:14pt;letter-spacing:-0.04pt;">(As of April&#160;1, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:159.84pt;white-space:normal;">
              <div style="margin-left:10pt; text-indent:-10pt;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">Nominating &amp; Corporate Governance Committee</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$8,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$10,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:159.84pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:36.66pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:-0.025pt;">Member </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$5,000</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:16pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition to annual cash retainers, our non-employee directors have been granted options to purchase shares of our common stock under our LTIP. From time to time, our non-employee directors are also reimbursed upon request for out-of-pocket expenses incurred in connection with their attendance at meetings of our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">2020 Director Compensation Table<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table sets forth information regarding the compensation earned for service on our board of directors in 2020 by our non-employee directors. Doug Doerfler, our President and Chief Executive Officer, and Ron Holtz, our Senior Vice President and Chief Accounting Officer, are also members of our board of directors but did not receive any additional compensation for service as directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:125.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Fees Earned or</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Paid in</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Cash</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:24pt;padding-right:24pt;letter-spacing:-0.04pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Awards(1)(2)</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:19pt;padding-right:19pt;letter-spacing:-0.04pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:36.12pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:3pt;padding-right:3pt;letter-spacing:-0.04pt;">Total ($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">J. Stark Thompson, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">79,500</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">102,406</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Will Brooke </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">61,000</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">83,906</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Richard Douglas, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">40,000</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">62,906</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Stanley Erck </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">46,000</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">68,906</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">John Johnston </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">48,000</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">70,906</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Art Mandell </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">56,000</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">78,906</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">This column reflects the full grant date fair value of options granted during the year measured pursuant to Financial Accounting Standard Board Accounting Standards Codification Topic 718, or ASC 718, the basis for computing stock-based compensation in our financial statements. The assumptions we used in valuing options are described in Note 2 to our financial statements included elsewhere in this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">The following table provides information regarding the aggregate number of option awards granted to our non-employee directors that were outstanding as of December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:396pt;height:98.5pt;margin-left:30pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;letter-spacing:-0.04pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="white-space:nowrap; text-align:left;" />
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">J. Stark Thompson, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">241,333 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Will Brooke </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">142,500 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Richard Douglas, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">94,700 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Stanley Erck </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">265,067 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">John Johnston </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">108,417 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Art Mandell </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">122,000</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">115</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEXCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">EXECUTIVE COMPENSATION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our named executive officers, or NEOs, for the fiscal year ended December&#160;31, 2020, consisting of our principal executive officer and the next two most highly compensated executive officers serving as of December 31, 2020, were:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Doug Doerfler, our president and chief executive officer;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Amanda L. Murphy, our chief financial officer; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Brad Calvin, our former chief commercial officer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">2020 Summary Compensation Table</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents all of the compensation awarded to or earned by or paid to our named executive officers for the fiscal year ended December&#160;31, 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:137.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:169.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Name and Principal Position </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Salary</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.04pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Awards</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:12pt;padding-right:12pt;letter-spacing:-0.04pt;">($)(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Non-Equity </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Incentive Plan&#160;</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Compensation</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:18pt;padding-right:18pt;letter-spacing:-0.04pt;">($)(2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">All Other</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Compensation</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:18pt;letter-spacing:-0.04pt;">($)</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:18pt;letter-spacing:-0.04pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Total</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:17pt;padding-right:17pt;letter-spacing:-0.04pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Doug Doerfler </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">518,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">332,263</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">356,125</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">17,339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,223,727</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:169.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">President, Chief Executive Officer and Director</div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Amanda L. Murphy(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">125,758</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,425,826</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">222,466 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">4,245</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,778,295</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="margin-left:10pt;">Chief Financial Officer</div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Brad Calvin(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">371,667 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">368,106</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">334,800 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">17,516</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,092,089</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="margin-left:10pt;">Former Chief Commercial Officer</div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Amounts reported represent the aggregate grant date fair value of the stock options granted to our named executive officers during fiscal year 2020 under our LTIP, computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in the notes to our audited financial statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be realized by the named executive officer upon the exercise of the options or the sale of the underlying shares.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents amounts paid pursuant to our annual incentive compensation program, described below.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of matching contributions under our 401(k) plan paid by us during 2020 and de minimis incentives provided to all employees based on company-wide sales performance.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Ms. Murphy began serving as our chief financial officer in September 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Mr. Calvin ceased serving as an executive officer in May 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.72pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Narrative to the Summary Compensation Table</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Performance-Based Bonuses<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Each of our executive officers is eligible to receive performance bonus under our annual incentive compensation program.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our 2020 annual incentive compensation program, each of our named executive officers was eligible to receive a cash incentive payment equal to (1)&#160;his or her target incentive, as a&#160;percentage of annual base salary, multiplied by (2)&#160;the&#160;percentage achievement of certain 2020 corporate goals established by our compensation committee in its sole discretion, subject to the named executive officer remaining employed by us through the payment date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Mr.&#160;Doerfler&#8217;s target incentive was set at 55% of his annual base salary, Ms.&#160;Murphy&#8217;s at 40% of her annual base salary, and Mr.&#160;Calvin&#8217;s at 60% of his annual base salary. The corporate goals used for purposes of the 2020 annual incentive compensation program included revenue, EBITDA, and targets </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">116</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:80pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">related to our CARMA program and licensing. Our compensation committee determined that the&#160;percentage achievement of the applicable corporate goals was 125% for Mr.&#160;Doerfler and Ms.&#160;Murphy, and 135% for Mr.&#160;Calvin. As a result, our compensation committee approved a cash incentive payment for each named executive officer in the amounts reflected above in the &#8220;Non-Equity Incentive Plan&#160;Compensation&#8221; column of the Summary Compensation Table. Each named executive&#8217;s cash incentive payment for 2020 was paid in the first quarter of 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Outstanding Equity Awards as of December&#160;31, 2020</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents estimated information regarding outstanding equity awards held by our named executive officers as of December&#160;31, 2020. See &#8220;&#8212; Equity Incentive Plans&#8201;&#8212;&#8201;Long-Term Incentive Plan&#8221; below for additional information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:247pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:178.38pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="13">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Option Awards </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:178.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Securities</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Options</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Exercisable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Securities</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Options</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Unexercisable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Exercise</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">Price (</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">&#163;</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">)(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:7pt;padding-right:7pt;letter-spacing:-0.04pt;">($)(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Expiration</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:16pt;padding-right:16pt;letter-spacing:-0.04pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:178.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Doug Doerfler </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1,145,080 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">0.04 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">11/11/2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">296,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">0.82 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.12 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">6/13/2026 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">252,833 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">43,167(2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.42 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.31 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7/14/2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">178,833 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">117,167(3) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.32 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7/18/2028 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">170,712 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">219,488(4) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.78 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3/4/2029 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">89,421 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">300,779(5) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.36 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.86 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1/20/2030 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:178.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Amanda L. Murphy </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">71,875 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1,078,125(6) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.30 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">4.51 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">9/8/2030 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:178.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Brad Calvin </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">166,667 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">33,333(7) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.50 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.42 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7/14/2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">75,521 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">49,479(3) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.32 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7/18/2028 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">54,687 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">70,313(4) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.78 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3/4/2029 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">28,646 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">96,354(5) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.36 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.86 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1/20/2030 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7,813 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">117,187(8) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.30 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">4.51 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">9/15/2030</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Option exercise prices have historically been expressed in British pounds, other than the option for 1,145,080 shares granted to Mr.&#160;Doerfler as indicated above, and are equal to the closing price of our common stock on the AIM on the date of grant. Conversions to U.S. dollars are provided for convenience using an exchange rate of &#163;1.00 = $1.3662, which was the rate published by the U.S. Federal Reserve as of December&#160;31, 2020. Following this offering, option exercise prices for future grants will be expressed in U.S. dollars based on the closing price of our common stock on the Nasdaq Global Market on the date of grant.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on July&#160;14, 2017. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">117</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(3)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on July&#160;18, 2018. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on March 4, 2019. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on January&#160;20, 2020. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on September&#160;8, 2020. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on July&#160;14, 2017. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on September 15, 2020. The shares underlying this option vest, as follows: 1/16th of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Employment Arrangements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Severance Agreements<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have entered into severance agreements with each of the NEOs in connection with his or her employment with us, which sets forth the terms and conditions of his or her specified payments and benefits in connection with a termination of employment in certain circumstances. Our goal in providing these severance and change in control payments and benefits is to offer sufficient cash continuity protection such that the NEOs will focus their full time and attention on the requirements of the business rather than the potential implications of a qualifying employment termination or change in control for their respective positions. We prefer to have certainty regarding the potential severance amounts payable to the NEOs, rather than negotiating severance at the time that an NEO&#8217;s employment terminates. We have also determined that accelerated vesting provisions with respect to outstanding equity awards in connection with a qualifying termination of employment in certain circumstances are appropriate because they encourage our NEOs to stay focused on the business in those circumstances, rather than focusing on the potential implications of the termination of employment for them personally. The material terms of the severance agreements we have entered into with our NEOs are summarized below. </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Doug Doerfler<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We entered into a severance agreement dated March&#160;8, 2017, setting forth the terms of Mr.&#160;Doerfler&#8217;s severance eligibility. Under Mr.&#160;Doerfler&#8217;s severance agreement, if he is terminated by us other than for &#8220;cause&#8221; &#8203;(as defined in the severance agreement), or if he resigns at any time that &#8220;good reason&#8221; &#8203;(as defined in the severance agreement) exists, and if such termination or resignation occurs within 24&#160;months following a &#8220;change of control&#8221; &#8203;(as defined in the severance agreement), then Mr.&#160;Doerfler will be eligible to receive (i)&#160;payment of an amount equal to 150% of his &#8220;annual base salary&#8221; (defined as his total base salary during the 12 month period prior to his date of termination divided by 12) plus 100% of his &#8220;target bonus&#8221; &#8203;(as defined in the severance agreement), with such combined amount paid in monthly installments over the 18&#160;months following his departure, less any amounts paid to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">118</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Mr.&#160;Doerfler during such 18 month period under our Short Term or Long Term Disability Plan, and less applicable tax withholdings, (ii)&#160;reimbursement of COBRA premiums for 18&#160;months, (iii)&#160;continued coverage under our term life, accident, and short and long-term disability insurance programs for 18&#160;months following his departure to the extent still provided for senior executives during such period (provided that such qualifier will not apply following a &#8220;change of control&#8221;) , and (iv)&#160;full acceleration of the vesting of the unvested shares subject to his outstanding stock options. As a condition to receiving the foregoing severance benefits, Mr.&#160;Doerfler must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under Mr.&#160;Doerfler&#8217;s severance agreement, if he is terminated by us other than for &#8220;cause,&#8221; or if he resigns at any time that &#8220;good reason&#8221; exists, and if such termination or resignation occurs at any time other than within 24&#160;months following a &#8220;change of control,&#8221; then Mr.&#160;Doerfler will be eligible to receive (i)&#160;payment of an amount equal to 100% of his &#8220;annual base salary&#8221; &#8203;(defined as his total base salary during the 12 month period prior to his date of termination divided by 12), with such amount paid in monthly installments over the 12&#160;months following his departure, less any amounts paid to Mr.&#160;Doerfler during such 12 month period under our Short Term or Long Term Disability Plan, and less applicable tax withholdings, (ii)&#160;reimbursement of COBRA premiums for 12&#160;months, and (iii)&#160;continued coverage under our term life, accident, and short and long-term disability insurance programs for 12&#160;months following his departure to the extent still provided for senior executives during such period (provided that such qualifier will not apply following a &#8220;change of control&#8221;). As a condition to receiving the foregoing severance benefits, Mr.&#160;Doerfler must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Amanda Murphy<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We entered into a severance agreement dated January&#160;21, 2021, setting forth the terms of Ms.&#160;Murphy&#8217;s severance eligibility. Under Ms.&#160;Murphy&#8217;s severance agreement, if she is terminated by us other than for &#8220;cause&#8221; &#8203;(as defined in the severance agreement), or if she resigns for &#8220;good reason&#8221; &#8203;(as defined in the severance agreement), and if such termination or resignation occurs on the date of or within 24&#160;months following a &#8220;change of control&#8221; &#8203;(as defined in the severance agreement), then Ms.&#160;Murphy will be eligible to receive (i)&#160;payment of her monthly base salary (calculated as her total base salary during the 12 month period prior to her date of termination divided by 12) for the 9&#160;months following her departure (less applicable tax withholdings), (ii)&#160;75% of her &#8220;target bonus&#8221; &#8203;(as defined in the severance agreement) (less applicable tax withholdings) paid in monthly installments over 9&#160;months, (iii)&#160;COBRA premium coverage for up to 9&#160;months, and (iv)&#160;full acceleration of the vesting of the unvested shares subject to her outstanding stock options. As a condition to receiving the foregoing severance benefits, Ms.&#160;Murphy must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under Ms.&#160;Murphy&#8217;s severance agreement, if she is terminated by us other than for &#8220;cause,&#8221; or if she resigns for &#8220;good reason,&#8221; and if such termination or resignation occurs at any time prior to a &#8220;change of control,&#8221; then Ms.&#160;Murphy will be eligible to receive (i)&#160;payment of her monthly base salary (calculated as her total base salary during the 12 month period prior to her date of termination divided by 12) for the 9&#160;months following her departure (less any amounts paid to Ms.&#160;Murphy during such 9 month period under our Short Term or Long Term Disability Plan, and less applicable tax withholdings), (ii)&#160;COBRA premium coverage for up to 9&#160;months, and (iii)&#160;if the termination or resignation occurs within 180&#160;days prior to a &#8220;change of control,&#8221; then Ms.&#160;Murphy shall also receive full acceleration of the vesting of the unvested shares subject to her outstanding stock options. As a condition to receiving the foregoing severance benefits, Ms.&#160;Murphy must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Brad Calvin<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We entered into a severance agreement dated January&#160;11, 2021, setting forth the terms of Mr.&#160;Calvin&#8217;s severance eligibility. Under Mr.&#160;Calvin&#8217;s severance agreement, if he is terminated by us other than for &#8220;cause&#8221; &#8203;(as defined in the severance agreement), or if he resigns for &#8220;good reason&#8221; &#8203;(as defined in the severance agreement), and if such termination or resignation occurs on the date of or within 24&#160;months following a &#8220;change of control&#8221; &#8203;(as defined in the severance agreement), then Mr.&#160;Calvin will be eligible to receive (i)&#160;payment of his monthly base salary (calculated as his total base salary during the 12 month period prior to his date of termination divided by 12) for the 9&#160;months following his </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">119</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">departure (less applicable tax withholdings), (ii)&#160;75% of his &#8220;target bonus&#8221; &#8203;(as defined in the severance agreement) (less applicable tax withholdings) paid in monthly installments over 9&#160;months, (iii)&#160;COBRA premium coverage for up to 9&#160;months, and (iv)&#160;full acceleration of the vesting of the unvested shares subject to his outstanding stock options. As a condition to receiving the foregoing severance benefits, Mr.&#160;Calvin must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Under Mr.&#160;Calvin&#8217;s severance agreement, if he is terminated by us other than for &#8220;cause,&#8221; or if he resigns for &#8220;good reason,&#8221; and if such termination or resignation occurs at any time prior to a &#8220;change of control,&#8221; then Mr.&#160;Calvin will be eligible to receive (i)&#160;payment of his monthly base salary (calculated as his total base salary during the 12 month period prior to his date of termination divided by 12) for the 9&#160;months following his departure (less any amounts paid to Mr.&#160;Calvin during such 9 month period under our Short Term or Long Term Disability Plan, and less applicable tax withholdings), (ii)&#160;COBRA premium coverage for up to 9&#160;months, and (iii)&#160;if the termination or resignation occurs within 180&#160;days prior to a &#8220;change of control,&#8221; then Mr.&#160;Calvin shall also receive full acceleration of the vesting of the unvested shares subject to his outstanding stock options. As a condition to receiving the foregoing severance benefits, Mr.&#160;Calvin must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Health and Welfare and Retirement Benefits</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All of our current named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, disability and life insurance plans, in each case on the same basis as all of our other employees. We do not provide perquisites or personal benefits to our named executive officers other than those provided generally to all employees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">401(k) Plan<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We maintain a tax-qualified retirement plan, the 401(k) Plan, that provides eligible employees in the United States with an opportunity to save for retirement on a tax-advantaged basis. Under the 401(k) Plan, we may provide matching and discretionary contributions. We currently match employee contributions equal to 50% of the salary deferral contributions, with a maximum company contribution of 3% of the employee&#8217;s eligible compensation. All contributions, including employer matching and discretionary contributions, are 100% vested when contributed. Pre-tax contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. The 401(k) Plan is intended to qualify under Sections&#160;401(a) and 501(a) of the Internal Revenue Code, or Code.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Equity Incentive Plans</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Long-Term Incentive Plan<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our Board of Directors adopted our Long-Term Incentive Plan, or our LTIP, in 2000. Our LTIP was amended and restated on May&#160;17, 2016. No further awards will be granted under our LTIP after the effectiveness of our 2021 Equity Incentive Plan, or our 2021 Plan, however, any awards outstanding under our LTIP will continue to be governed by their existing terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our LTIP provides for the grant of incentive stock options, or ISOs, nonstatutory stock options, or NSOs, performance awards, restricted stock and incentive shares. ISOs may be granted only to our employees and to any of our affiliate&#8217;s employees. All other awards may be granted to our employees, directors, consultants, or independent contractors or those of our affiliates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Authorized Shares</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;As of December&#160;31, 2020, an aggregate of 4,175,737 shares of our common stock were reserved for issuance under our LTIP and stock options to purchase 7,609,667 shares of our common stock were outstanding under our LTIP.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Plan&#160;Administration</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors or one or more committees or persons appointed by our board of directors may administer our LTIP (in each case, the administrator). Subject to the terms of the LTIP, the administrator has the power to, among other things, determine who will be granted awards and the terms and conditions of such awards, and interpret, prescribe, amend and make all other determinations it deems necessary or advisable for the administration of our LTIP.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">120</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Stock Options</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Stock options have been granted under our LTIP. The administrator determines the terms and conditions of stock options, including, but not limited to, the number of shares subject to the stock option, the exercise price of the stock option, and the time(s) at which the stock option may become exercisable. The exercise price of stock options granted under our LTIP generally cannot be less than 100% of the fair market value of a share of our common stock on the grant date. The term of a stock option may not exceed ten&#160;years from the grant date. With respect to any participant who owns more than 10% of the voting power of all classes of our outstanding stock, the term of an incentive stock option granted to such participant must not exceed five&#160;years from the grant date and the per share exercise price cannot be less than 110% of the fair market value of a share of our common stock on the grant date. Subject to the terms of the LTIP and as provided for in an individual award agreement, the exercise price of a stock option may be paid by (i)&#160;a net exercise arrangement; (ii)&#160;a cashless exercise or same day sale; (iii)&#160;the tender of shares of our common stock previously owned by the participant; or (iv)&#160;a partial payment may be made by delivery of a promissory note to us. In the event a participant&#8217;s employment with us is terminated for any reason other than by us for cause (as defined in each individual award agreement), the administrator may extend the exercise period of any options held by such participant; provided however, that such extended post-termination exercise period may not extend beyond the earlier of (A)&#160;the seventh anniversary of such termination, or (B)&#160;the tenth anniversary of the date the stock option is granted.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Changes to Capital Structure</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;In the event any change is made to our common stock, such as by reason of any stock split, stock dividend, or recapitalization, appropriate adjustments shall be made to (i)&#160;the maximum number and class of securities issuable under the plan, (ii)&#160;the number and class of securities subject to outstanding awards, and (iii)&#160;the exercise price of each outstanding option.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Exchange Transactions</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;In the event of an exchange transaction (as defined in the LTIP), our board of directors may take such actions as it deems necessary, including, without limitation (i)&#160;accelerating the vesting of outstanding options, either in whole or in part; or (ii)&#160;if, as part of the exchange transaction, our stockholders are receiving stock of the acquiring company as consideration, converting outstanding options in whole or in part into options to purchase shares of the acquiring company</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Amendment or Termination</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors may amend, alter or terminate the LTIP at any time. However, our board of directors will obtain stockholder approval of any amendment to the LTIP if necessary to comply with applicable laws, and will obtain the approval of each affected participant if such amendment, alteration or termination would adversely affect such participants rights under their award. As noted above, no further awards will be granted under our LTIP after the effectiveness of our 2021 Plan; however, awards outstanding under our LTIP will continue to be governed by their existing terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">2021 Equity Incentive Plan</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Prior to the completion of this offering, we expect that our board of directors will adopt, and our stockholders will approve, our 2021 Plan. We expect our 2021 Plan will become effective on the date of the underwriting agreement related to this offering. Our 2021 Plan will come into existence upon its adoption by our board of directors, but no grants will be made under our 2021 Plan prior to its effectiveness. Once our 2021 Plan becomes effective, no further grants will be made under our LTIP.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our 2021 Plan will provide for the grant of ISOs within the meaning of Section&#160;422 of the Code, to our employees and our parent and subsidiary corporations&#8217; employees, and for the grant of NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#8217; employees and consultants.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Authorized Shares</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Initially, the maximum number of shares of our common stock that may be issued under our 2021 Plan after it becomes effective will not exceed&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our common stock, which is the sum of (i)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;new shares, plus (ii)&#160;an additional number of shares not to exceed&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares, consisting of (a)&#160;shares that remain available for the issuance of awards under our LTIP as of immediately prior to the time our 2021 Plan becomes effective and (b)&#160;any shares of our common stock subject to outstanding stock options or other stock awards granted under our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">121</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">LTIP that, on or after our 2021 Plan becomes effective, terminate or expire prior to exercise or settlement; are not issued because the award is settled in cash; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares of our common stock reserved for issuance under our 2021 Plan will automatically increase on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;of each year for a period of ten&#160;years, beginning on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2022 and continuing through&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2031, in an amount equal to (1)&#8199;&#8199;&#8199;&#8199;% of the total number of shares of our common stock outstanding on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;of the immediately preceding year, or (2)&#160;a lesser number of shares determined by our board of directors no later than&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;of the immediately preceding year. The maximum number of shares of our common stock that may be issued on the exercise of ISOs under our 2021 Plan will be&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Shares subject to stock awards granted under our 2021 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares will not reduce the number of shares available for issuance under our 2021 Plan. Shares withheld under a stock award to satisfy the exercise, strike or purchase price of a stock award or to satisfy a tax withholding obligation will not reduce the number of shares available for issuance under our 2021 Plan. If any shares of our common stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&#160;to satisfy the exercise, strike or purchase price of a stock award; or (iii)&#160;to satisfy a tax withholding obligation in connection with a stock award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under our 2021 Plan.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Plan&#160;Administration</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors, or a duly authorized committee of our board of directors, will administer our 2021 Plan. Our board of directors may delegate to one or more of our officers the authority to (i)&#160;designate employees (other than officers) to receive specified stock awards; and (ii)&#160;determine the number of shares subject to such stock awards. Under our 2021 Plan, our board of directors will have the authority to determine stock award recipients, the types of stock awards to be granted, grant dates, the number of shares subject to each stock award, the fair market value of our common stock and the provisions of each stock award, including the period of exercisability and the vesting schedule applicable to a stock award.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our 2021 Plan, our board of directors also generally will have the authority to effect, with the consent of any materially adversely affected participant, (i)&#160;the reduction of the exercise, purchase, or strike price of any outstanding option or stock appreciation right; (ii)&#160;the cancellation of any outstanding option or stock appreciation right and the grant in substitution therefore of other awards, cash, or other consideration; or (iii)&#160;any other action that is treated as a repricing under generally accepted accounting principles.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Stock Options</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;ISOs and NSOs are granted under stock option agreements adopted by the administrator. The administrator will determine the exercise price for stock options, within the terms and conditions of our 2021 Plan, except the exercise price of a stock option generally will not be less than 100% of the fair market value of our common stock on the date of grant. Options granted under our 2021 Plan will vest at the rate specified in the stock option agreement as will be determined by the administrator.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The administrator will determine the term of stock options granted under our 2021 Plan, up to a maximum of 10&#160;years. Unless the terms of an optionholder&#8217;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death, or cause, the optionholder may generally exercise any vested options for a period of three&#160;months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18&#160;months following the date of death. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12&#160;months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">122</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the administrator and may include (i)&#160;cash, check, bank draft or money order; (ii)&#160;a broker-assisted cashless exercise; (iii)&#160;the tender of shares of our common stock previously owned by the optionholder; (iv)&#160;a net exercise of the option if it is an NSO; or (v)&#160;other legal consideration approved by the administrator.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Unless the administrator provides otherwise, options or stock appreciation rights generally are not transferable except by will or the laws of descent and distribution. Subject to approval of the administrator or a duly authorized officer, an option may be transferred pursuant to a domestic relations order, official marital settlement agreement, or other divorce or separation instrument.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Tax Limitations on ISOs</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an award holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (i)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&#160;the term of the ISO does not exceed five&#160;years from the date of grant.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Restricted Stock Unit Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Restricted Stock Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Restricted stock awards are granted under restricted stock award agreements adopted by the administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past or future services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The administrator will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Stock Appreciation Rights</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Stock appreciation rights are granted under stock appreciation right agreements adopted by the administrator. The administrator will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market value of our common stock on the date of grant. A stock appreciation right granted under our 2021 Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by the administrator. Stock appreciation rights may be settled in cash or shares of our common stock or in any other form of payment as determined by our board of directors and specified in the stock appreciation right agreement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The administrator will determine the term of stock appreciation rights granted under our 2021 Plan, up to a maximum of 10&#160;years. If a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three&#160;months following the cessation of service. This period may be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant&#8217;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12&#160;months in the event of disability and 18&#160;months in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">123</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">the event of death. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. In no event may a stock appreciation right be exercised beyond the expiration of its term.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Performance Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our 2021 Plan will permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured so that the stock or cash will be issued or paid only following the achievement of certain pre-established performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The performance goals may be based on any measure of performance selected by our board of directors. The performance goals may be based on company-wide performance or performance of one or more business&#160;units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by our board of directors at the time the performance award is granted, our board will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (i)&#160;to exclude restructuring or other nonrecurring charges; (ii)&#160;to exclude exchange rate effects; (iii)&#160;to exclude the effects of changes to generally accepted accounting principles; (iv)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (vi)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&#160;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&#160;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (x)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (xi)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Other Stock Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;The administrator will be permitted to grant other awards based in whole or in part by reference to our common stock. The administrator will set the number of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Non-Employee Director Compensation Limit</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;The aggregate value of all compensation granted or paid to any non-employee director with respect to any calendar year, including awards granted and cash fees paid by us to such non-employee director, will not exceed $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;in total value, except such amount will increase to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;for the first year for newly appointed or elected non-employee directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Changes to Capital Structure</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (i)&#160;the class and maximum number of shares reserved for issuance under our 2021 Plan, (ii)&#160;the class and maximum number of shares by which the share reserve may increase automatically each year, (iii)&#160;the class and maximum number of shares that may be issued on the exercise of ISOs, and (iv)&#160;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Corporate Transactions</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#8217;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time of grant, any stock awards outstanding under our 2021 Plan may be assumed, continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i)&#160;with respect to any such stock awards that are held by participants whose </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">124</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&#160;any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, the administrator may provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&#160;the value of the property the participant would have received upon the exercise of the stock award, over (ii)&#160;any per share exercise price payable by such holder, if applicable. In addition, any escrow, holdback, earn out or similar provisions in the definitive agreement for the corporate transaction may apply to such payment to the same extent and in the same manner as such provisions apply to the holders of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our 2021 Plan, a &#8220;corporate transaction&#8221; is generally the consummation of (i)&#160;a sale or other disposition of all or substantially all of our consolidated assets; (ii)&#160;a sale or other disposition of at least 50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Change in Control</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Stock awards granted under our 2021 Plan may be subject to acceleration of vesting and exercisability upon or after a change in control (as defined below) as may be provided in the applicable stock award agreement or in any other written agreement between us or any affiliate and the participant, but in the absence of such provision, no such acceleration will automatically occur.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our 2021 Plan, a &#8220;change in control&#8221; is generally (i)&#160;the acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock; (ii)&#160;a merger, consolidation or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the same proportions as their ownership immediately prior to such transaction; (iii)&#160;stockholder approval of a complete dissolution or liquidation; (iv)&#160;a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction; or (v)&#160;when a majority of our board of directors becomes comprised of individuals who were not serving on our board of directors on the date of the underwriting agreement related to this offering, or the incumbent board, or whose nomination, appointment, or election was not approved by a majority of the incumbent board still in office.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Plan&#160;Amendment or Termination</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend, suspend, or terminate our 2021 Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our board of directors adopts our 2021 Plan. No stock awards may be granted under our 2021 Plan while it is suspended or after it is terminated.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">2021 Employee Stock Purchase Plan</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Prior to the completion of this offering, our board of directors intends to adopt, and we expect our stockholders will approve, our employee stock purchase plan, or our ESPP. Our ESPP will become </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">125</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">effective immediately prior to and contingent upon the date of the underwriting agreement related to this offering. The purpose of our ESPP will be to secure the services of new employees, to retain the services of existing employees and to provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. Our ESPP will include two components. One component will be designed to allow eligible U.S. employees to purchase our common stock in a manner that may qualify for favorable tax treatment under Section&#160;423 of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the United States while complying with applicable foreign laws.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Share Reserve</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Following this offering, our ESPP will authorize the issuance of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance will automatically increase on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;of each year for a period of ten&#160;years, beginning on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2022 and continuing through&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2031, by the lesser of (i)&#8199;&#8199;&#8199;&#8199;% of the total number of shares of our common stock outstanding on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;of the immediately preceding year; and (ii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares, except before the date of any such increase, our board of directors may determine that such increase will be less than the amount set forth in clauses (i)&#160;and (ii).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Administration</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors will administer our ESPP and may delegate its authority to administer our ESPP to our compensation committee. Our ESPP will be implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of our common stock on specified dates during such offerings. Under our ESPP, our board of directors will be permitted to specify offerings with durations of not more than 27&#160;months and to specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. Our ESPP will provide that an offering may be terminated under certain circumstances.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Payroll Deductions</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, will be eligible to participate in our ESPP and to contribute, normally through payroll deductions, up to&#8199;&#8199;&#8199;&#8199;% of their earnings (as defined in our ESPP) for the purchase of our common stock under our ESPP. Unless otherwise determined by our board of directors, common stock will be purchased for the accounts of employees participating in our ESPP at a price per share equal to the lesser of (i)&#160;85% of the fair market value of a share of our common stock on the first day of an offering; or (ii)&#160;85% of the fair market value of a share of our common stock on the date of purchase.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Limitations</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Employees may have to satisfy one or more of the following service requirements before participating in our ESPP, as determined by our board of directors: (i)&#160;being customarily employed for more than 20 hours per week; (ii)&#160;being customarily employed for more than five&#160;months per calendar year; or (iii)&#160;continuous employment with us or one of our affiliates for a period of time (not to exceed two&#160;years). No employee will be permitted to purchase shares under our ESPP at a rate in excess of $25,000 worth of our common stock (based on the fair market value per share of our common stock at the beginning of an offering) for each calendar year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under our ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value under Section&#160;424(d) of the Code.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Changes to Capital Structure</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our ESPP will provide that in the event there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, our board of directors will make appropriate adjustments to: (i)&#160;the class(es) and maximum number of shares reserved under our ESPP; (ii)&#160;the class(es) and maximum number of shares by which the share reserve may increase automatically each year; (iii)&#160;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&#160;the class(es) and number of shares that are subject to purchase limits under ongoing offerings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">126</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Corporate Transactions</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our ESPP will provide that in the event of a corporate transaction (as defined below), any then-outstanding rights to purchase our stock under our ESPP may be assumed, continued, or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then the participants&#8217; accumulated payroll contributions will be used to purchase shares of our common stock within 10 business days before such corporate transaction, and such purchase rights will terminate immediately after such purchase.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our ESPP, a &#8220;corporate transaction&#8221; is generally the consummation of (i)&#160;a sale or other disposition of all or substantially all of our consolidated assets; (ii)&#160;a sale or other disposition of at least 50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Amendment or Termination</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors will have the authority to amend or terminate our ESPP, except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#8217;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or listing requirements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Limitations on Liability and Indemnification Matters</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation that will be in effect following the completion of this offering will contain provisions that limit the liability of our directors to us or our stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">unlawful payments of dividends or unlawful stock repurchases or redemptions; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any transaction from which the director derived an improper personal benefit.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If the Delaware General Corporation Law is amended after the effective date of our certificate of incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Such limitation of liability does will not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation that will be in effect following the completion of this offering will provide for us to indemnify our directors, officers, employees and other agents to the fullest extent permitted by Delaware law. Our amended and restated bylaws that will be in effect following the completion of this offering will provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents. Our amended and restated bylaws will also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action, suit or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With certain exceptions, these agreements provide for indemnification for related expenses including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe these provisions in our fifteenth amended and restated certificate of incorporation and amended and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">127</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:344pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">restated bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#8217; and officers&#8217; liability insurance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The limitation of liability and indemnification provisions in our fifteenth amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for our directors, executive officers or persons controlling us, we have been informed that, in the opinion of the Securities and Exchange Commission, or SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Rule&#160;10b5-1 Sales Plans</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our directors and officers may adopt written plans, known as Rule&#160;10b5-1 plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule&#160;10b5-1 plan, a broker executes trades under parameters established by the director or officer when entering into the plan, without further direction from them. The director or officer may amend a Rule&#160;10b5-1 plan in some circumstances and may terminate a plan at any time. Our directors and executive officers may also buy or sell additional shares outside of a Rule&#160;10b5-1 plan when they do not possess material nonpublic information, subject to compliance with the terms of our insider trading policy. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">128</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCRAR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Other than compensation arrangements for our directors and executive officers, which are described elsewhere in this prospectus, below we describe transactions since January&#160;1, 2018 to which we were a party or will be a party, in which:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the amounts involved exceeded or will exceed $120,000; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.01pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Equity Financings</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">2019 Placement<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In February&#160;2019, we issued and sold an aggregate of 5,908,319 shares of common stock at a purchase price of &#163;1.70 per share, for an aggregate amount of &#163;10.0&#160;million (approximately $13.3&#160;million as of the issue date). The following table summarizes the shares of common stock purchased by related persons.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:41.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Shares of </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Subscription Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:30pt;letter-spacing:-0.04pt;">(</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">&#163;</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:30pt;letter-spacing:-0.04pt;">)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Gross Proceeds</font>
                <br >
                <font style="letter-spacing:-0.04pt;">to MaxCyte</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.04pt;">($)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">River and Mercantile Asset Management LLP(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">662,350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,125,995</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,488,002</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.01pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:11.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">At the time of the offering River and Mercantile Asset Management LLP was a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">2020 Placement<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In May&#160;2020, we issued and sold an aggregate of 19,181,423 shares of common stock at a purchase price of &#163;1.31 per share, for an aggregate amount of &#163;25.1&#160;million (approximately $30.5&#160;million as of the issue date), or the 2020 Placement. The following table summarizes the shares of common stock purchased by related persons.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:71.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Shares of </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Subscription Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:30pt;letter-spacing:-0.04pt;">(</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">&#163;</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:30pt;letter-spacing:-0.04pt;">)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Gross Proceeds</font>
                <br >
                <font style="letter-spacing:-0.04pt;">to MaxCyte</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.04pt;">($)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P.(1) </font> </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">9,281,334 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">12,158,547 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">14,765,097 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP(2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">4,331,289</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,673,988</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">6,890,378 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">River and Mercantile Asset Management LLP(3) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,152,156</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">2,819,324 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">3,431,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.01pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:11.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P. is a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:7.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP is a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:7.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">At the time of the offering River and Mercantile Asset Management LLP was a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">2021 Placement<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In February&#160;2021, we issued and sold an aggregate of 5,740,000 shares of common stock at a purchase price of &#163;7.00 per share, for an aggregate amount of &#163;40.2&#160;million (approximately $55.3&#160;million as of the issue date). The following table summarizes the shares of common stock purchased by related persons.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:56.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Shares of </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Subscription Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:30pt;letter-spacing:-0.04pt;">(</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">&#163;</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:30pt;letter-spacing:-0.04pt;">)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Gross Proceeds</font>
                <br >
                <font style="letter-spacing:-0.04pt;">to MaxCyte</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.04pt;">($)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P.(1) </font> </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">890,000 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,230,000 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,579,931 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP(2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">330,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,310,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">3,184,612</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">129</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:11.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P. is a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP is a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Rights to Exchange</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In April&#160;2020, in connection with the 2020 Placement, we provided Casdin and Sofinnova with certain rights to exchange their shares in certain circumstances. See the section titled &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Rights to Exchange&#8221; for additional information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Novavax Sublease</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2011, we entered into a Lease Agreement, as subsequently amended or restated, the Lease Agreement, with Novavax, Inc., or Novavax, covering the sublease of approximately 19,000 square feet of office and laboratory space. The sublease is currently set to expire in October&#160;2023. Richard Douglas, PhD, a member of our board of directors, is a member of the board of directors of Novavax and Stanley Erck, a member of our board of directors, is the chief executive officer and a director of Novavax. Under the terms of the Lease Agreement, we paid Novavax $371,600, $416,800 and $623,000 in the&#160;years ended December&#160;31, 2018, 2019 and 2020, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Equity Grants to Directors and Executive Officers</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have granted stock options to certain of our directors and executive officers. For more information regarding the stock options and stock awards granted to our directors and named executive officers, see the sections titled &#8220;Management&#8201;&#8212;&#8201;Director Compensation&#8221; and &#8220;Executive Compensation.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Indemnification Agreements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation that will be in effect following the completion of this offering will contain provisions limiting the liability of directors, and both such amended and restated certificate of incorporation and our amended and restated bylaws that will be in effect following the completion of this offering will provide that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our fifteenth amended and restated certificate of incorporation and amended and restated bylaws will also provide our board of directors with discretion to indemnify our employees and other agents when determined appropriate by the board. In addition, we have entered into an indemnification agreement with each of our directors and executive officers, which requires us to indemnify them. For more information regarding these agreements, see the section titled &#8220;Executive Compensation&#8201;&#8212; Limitations on Liability and Indemnification Matters.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Policies and Procedures for Transactions with Related Persons</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Prior to the completion of this offering, we intend to adopt a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of our board of directors or our audit committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock or any member of the immediate family of any of the foregoing persons, in which the amount involved exceeds $120,000 and such person would have a direct or indirect interest, must be presented to our board of directors or our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our board of directors or our audit committee is to consider the material facts of the transaction, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The related person transactions policy also covers related party transactions under the AIM Rules, which contains a different definition of a related party to the definition of a related person set out above for U.S. purposes. The AIM Rules require that any transaction with a related party (pursuant to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">130</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:544pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">definition in the AIM Rules) that exceeds 5% in any of the class tests set out in the AIM Rules, taking into account certain provisions relating to aggregation of transactions, should be announced without delay as soon as the terms of the transaction are agreed, and that the announcement should include certain specified information including a statement that our directors (with the exception of any director who is involved in the transaction as a related party) consider, having consulted with our nominated adviser for AIM, that the terms of the transaction are fair and reasonable insofar as our shareholders are concerned.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">131</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">PRINCIPAL STOCKHOLDERS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table sets forth information with respect to the beneficial ownership of our shares as of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 by:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">each named executive officer;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">each of our directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our directors and executive officers as a group; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">each person or entity known by us to own beneficially more than 5% of our common stock (by number or by voting power).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to applicable community property laws.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Applicable&#160;percentage ownership before this offering is based on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock outstanding as of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2021. Applicable&#160;percentage ownership after this offering is based on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of common stock outstanding immediately after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares of common stock from us. In computing the number of shares beneficially owned by a person and the&#160;percentage ownership of such person, we deemed to be outstanding all shares subject to options held by the person that are currently exercisable, or exercisable or would vest based on service-based vesting conditions within 60&#160;days of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2021. However, except as described above, we did not deem such shares outstanding for the purpose of computing the&#160;percentage ownership of any other person.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o&#160;MaxCyte, Inc. 22 Firstfield Road, Suite 110, Gaithersburg, Maryland 20878.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:292.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Percentage of Shares</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Beneficially Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:73.34pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Number of Shares </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Beneficially Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:35.04pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Before </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:35.04pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">After </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:286.58pt;text-align:left;">
              <font style="border-bottom:1px solid #000000;letter-spacing:-0.05pt;">Name of Beneficial Owner</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">5% Stockholders:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P.(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP(2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Directors and Named Executive Officers:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Doug Doerfler </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">J. Stark Thompson, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Ron Holtz </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Will Brooke </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Richard Douglas, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Stanley Erck </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">John Johnston </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Art Mandell </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Amanda Murphy </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Brad Calvin </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">All directors and executive officers as a group </font>
                <br >
                <font style="letter-spacing:-0.025pt;">(&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; persons) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:73.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.04pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">132</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:436pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents beneficial ownership of less than 1%.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Casdin Capital, LLC is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC is the general partner of Casdin Partners Master Fund&#160;L.P. Eli Casdin is the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. As such, each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin may be deemed to beneficially own the securities held by Casdin Partners Master Fund, L.P. by virtue of their shared voting and investment control over Casdin Partners Master Fund, L.P. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Mr.&#160;Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. The address of these persons and entities is 1350&#160;Avenue of the Americas, Suite 2600, New York, NY 10019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">The securities are held by Sofinnova Crossover I SLP, or Sofinnova Crossover. Sofinnova Partners SAS is the management company of Sofinnova Crossover and has voting and investment control over the securities. The address of Sofinnova Crossover is 7-11, boulevard Haussmann 75009 Paris, France. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">133</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">General</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Upon the completion of this offering and filing of our fifteenth amended and restated certificate of incorporation, our authorized capital will consist of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock, par value $0.01 per share.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Outstanding Shares<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As of December&#160;31, 2020, we had 77,382,473 shares of common stock outstanding, held of record by&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;stockholders.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Voting Rights<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Each holder of common stock is entitled to one vote for each share of common stock held by such holder on all matters submitted to a vote of the stockholders. In all matters, other than the election of directors and except as otherwise required by law, our amended and restated certificate or bylaws, including any provisions requiring a separate vote of a class or series of our shares, the affirmative vote of a majority of the voting power of the shares present or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders. Our amended and restated bylaws provide that stockholders representing a majority of the voting power of our issued and outstanding capital stock, present in person, by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. The affirmative vote of holders of at least 75% of the voting power of all of the then-outstanding shares of capital stock, entitled to vote and voting together as a single class, will be required to amend certain provisions of our fifteenth amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws and the certificate, the voting rights of our common stock, removal of directors, director liability and indemnification, vacancies on our board, special meetings, annual meetings, stockholder notices, actions by written consent and exclusive forum. Unless otherwise required by law or the fifteenth amended and restated certificate of incorporation, the amended and restated bylaws provide that the election of directors shall be decided by a plurality of the votes cast at a meeting of stockholders by the holders of stock entitled to vote in the election.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Dividends<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose. Dividends may be paid in cash, in property or in shares of our common stock. See the section titled &#8220;Dividend Policy&#8221;.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Liquidation<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Rights and Preferences<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Holders of our common stock have no conversion, subscription or other rights, and there are no redemption or sinking fund provisions or, following the filing of our fifteenth amended and restated certificate of incorporation, pre-emptive rights applicable to our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Fully Paid and Nonassessable<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All outstanding shares of our common stock are fully paid and non-assessable, and the shares of common stock to be issued upon completion of this offering will be fully paid and non-assessable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Warrants</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In connection with a credit facility we issued the lender a warrant to purchase 71,168 shares of common stock at an exercise price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance. The warrant is classified as a liability as its strike price is in a currency other than our functional currency. The warrant is recorded at fair value at the end of each reporting period with changes from the prior balance sheet date recorded on the consolidated statements of operations. See Note 6 to our financial statements included in this prospectus for more information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">134</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Stock Options</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As of December&#160;31, 2020, 7,609,667 shares of common stock were issuable upon the exercise of outstanding stock options, at a weighted-average exercise price of $1.53 per share based on exchange rates as of December 31, 2020. For additional information regarding terms of our equity incentive plans, see the section titled &#8220;Executive and Director Compensation&#8201;&#8212;&#8201;Equity Incentive Plans.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Rights to Exchange</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In April&#160;2020, we entered into subscription agreements with investors Casdin Capital, LLC and Sofinnova Crossover I SLP, which provides Casdin and Sofinnova with certain rights. Under these agreements, in the event of a U.S. listing, we must take all necessary steps, including without limitation any additional filings with the SEC necessary, to allow each of our holders of common stock who elects to do so, to exchange their common stock listed on AIM for securities listed on such U.S. exchange, and we shall advise and instruct Casdin and/or Sofinnova how to convert their common stock traded on AIM and take delivery of the underlying U.S. exchange traded common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Anti-Takeover Provisions</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws to be in Effect Following this Offering<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation and amended and restated bylaws, each to be in effect following this offering, will:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that the authorized number of directors may be changed only by resolution of our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that our board of directors will be classified into three classes of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent in lieu thereof;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that special meetings of our stockholders may be called at any time, for any purpose or purposes, only by the chairperson of our board of directors, our chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The amendment of any of these provisions would require approval by the holders of at least 75% of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The combination of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">135</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:116pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Following this offering, we will be subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three&#160;years after the date that such stockholder became an interested stockholder, subject to certain exceptions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Choice of Forum<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation, as will be in effect upon the completion of this offering, will provide that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a breach of a fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our fifteenth amended and restated certificate of incorporation, or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The provisions would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act of 1934, as amended.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, our fifteenth amended and restated certificate of incorporation will provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Limitations of Liability and Indemnification</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">See the section titled &#8220;Executive Compensation&#8201;&#8212;&#8201;Limitations on Liability and Indemnification Matters.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Exchange Listing</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our common stock is currently traded on AIM, a market operated by the London Stock Exchange, under the trading symbols &#8220;MXCT&#8221; and &#8220;MXCN&#8221;. We intend to apply to list our common stock on the Nasdaq Global Market under the symbol &#8220;MXCT.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">On the completion of this offering, the transfer agent for our common stock will be&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. The transfer agent&#8217;s address is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. Our UK registrar is Link Asset Services Limited. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">136</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSEFF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">SHARES ELIGIBLE FOR FUTURE SALE</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">Prior to this offering, there has been no public market for our common stock in the United States. Future sales of substantial amounts of our common stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or impair our ability to raise equity capital.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">Based on our shares outstanding as of March&#160;31, 2021, on the completion of this offering and assuming no exercise of the underwriters&#8217; option to purchase additional shares, a total of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock will be outstanding. Of these shares, all of the common stock sold in this offering by us, plus any shares sold by exercise of the underwriters&#8217; option to purchase additional common stock from us, will be freely tradable in the public market without restriction or further registration under the Securities Act, unless these shares are held by &#8220;affiliates,&#8221; as that term is defined in Rule&#160;144 under the Securities Act, or Rule&#160;144.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The remaining shares of common stock will be, and shares of common stock subject to stock options will be on issuance, &#8220;restricted securities,&#8221; as that term is defined in Rule&#160;144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or Rule&#160;701 under the Securities Act, or Rule&#160;701, which are summarized below. Restricted securities may also be sold outside of the United States to non-U.S. persons in accordance with Rule&#160;904 of Regulation&#160;S under the Securities Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Subject to the lock-up agreements described below and the provisions of Rule&#160;144, Rule&#160;701 or Regulation&#160;S under the Securities Act (including any applicable distribution compliance period for shares sold pursuant to Regulation&#160;S under the Securities Act), as well as our insider trading policy, these restricted securities will be available for sale in the public market after the date of this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Rule&#160;144</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In general, under Rule&#160;144 as currently in effect, once we have been subject to public company reporting requirements of Section&#160;13 or 15(d) of the Exchange Act for at least 90&#160;days, an eligible stockholder is entitled to sell such shares without complying with the manner of sale, volume limitation or notice provisions of Rule&#160;144, subject to compliance with the public information requirements of Rule&#160;144. To be an eligible stockholder under Rule&#160;144, such stockholder must not be deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90&#160;days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six&#160;months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without complying with any of the requirements of Rule&#160;144, subject to the expiration of the lock-up agreements described below.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In general, under Rule&#160;144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell shares on expiration of the lock-up agreements described below, subject, in the case of restricted securities, to such shares having been beneficially owned for at least six&#160;months. Beginning 90&#160;days after the date of this prospectus, within any three-month period, such stockholders may sell a number of shares that does not exceed the greater of:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">1% of the common stock then outstanding, which will equal approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares immediately after this offering, assuming no exercise of the underwriters&#8217; option to purchase additional shares of common stock from us; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the average weekly trading volume of our common stock on the Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Sales under Rule&#160;144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">137</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:280pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Rule&#160;701</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Rule&#160;701 generally allows a stockholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90&#160;days, to sell these shares in reliance on Rule&#160;144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule&#160;144. Rule&#160;701 also permits affiliates of our company to sell their Rule&#160;701 shares under Rule&#160;144 without complying with the holding period requirements of Rule&#160;144. All holders of Rule&#160;701 shares, however, are required by that rule to wait until 90&#160;days after the date of this prospectus before selling those shares under Rule&#160;701, subject to the expiration of the lock-up agreements described below.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Form S-8 Registration Statements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We intend to file one or more registration statements on Form S-8 under the Securities Act with the SEC to register the offer and sale of shares of our common stock to be issued under our LTIP, 2021 Plan and ESPP. These registration statements will become effective immediately on filing. Shares covered by these registration statements will then be eligible for sale in the public markets, subject to vesting restrictions, any applicable lock-up agreements described below, and Rule&#160;144 limitations applicable to affiliates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Lock-Up Arrangements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We, all of our directors, executive officers and certain holders of our common stock, representing the holders of approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of our common stock, have agreed with the underwriters that, until 90&#160;days after the date of this prospectus, we and they will not, without the prior written consent of Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated or William Blair &amp; Company, L.L.C., offer, sell, assign, transfer, pledge, contract to sell, lend or otherwise dispose of any shares of common stock, or securities convertible into or exercisable or exchangeable for common stock. These agreements are described in the section titled &#8220;Underwriting.&#8221; Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated or William Blair &amp; Company, L.L.C. may, in their sole discretion, release any of the securities subject to these lock-up agreements at any time. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">138</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following summary describes the material U.S. federal income tax consequences of the ownership and disposition of our common stock acquired in this offering by Non-U.S. Holders (as defined below). This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, does not address non-U.S., state and local tax consequences that may be relevant to Non-U.S. Holders in light of their particular circumstances, and does not address U.S. federal tax consequences other than income taxes. For example, it does not address estate and gift taxes, the alternative minimum tax, the Medicare contribution tax on net investment income, or the application of special tax accounting rules under Section&#160;451(b). Special rules different from those described below may apply to certain Non-U.S. Holders that are subject to special treatment under the Code, such as banks, regulated investment companies real estate investment trusts, financial institutions, insurance companies, tax-exempt organizations, tax-qualified retirement plans, governmental organizations, broker-dealers and traders in securities or currencies, certain former citizens or long-term residents of the United States, &#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; corporations that accumulate earnings to avoid U.S. federal income tax, corporations organized outside of the United States, any state thereof, or the District of Columbia that are nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes, persons that hold our common stock as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion transaction,&#8221; &#8220;synthetic security,&#8221; or integrated investment or other risk reduction strategy, persons deemed to sell our common stock under the constructive sale provisions of the Code, persons who acquire our common stock through the exercise of an option or otherwise as compensation, &#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds, and partnerships and other pass-through entities or arrangements and investors in such pass-through entities or arrangements. Such Non-U.S. Holders are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. If a partnership (including any entity or arrangement classified as a partnership or flow-through entity for U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner in such partnership generally will depend on the status of the partner and the activities of the partnership. Partnerships holding our common stock and partners in such partnerships should consult their own tax advisors regarding the tax consequences of the ownership and disposition of our common stock. Furthermore, the discussion below is based upon the provisions of the Code and U.S. Treasury Regulations, rulings and judicial decisions thereunder, each as of the date hereof, and such authorities may be repealed, revoked, or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the U.S. Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and conclusions. This discussion assumes that the Non-U.S. Holder holds our common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">This discussion is for informational purposes only and is not tax advice. Persons considering the purchase of our common stock pursuant to this offering should consult their own tax advisors concerning the U.S. federal income, gift, estate and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences arising under the laws of any other taxing jurisdiction, including any state, local or non-U.S. tax consequences, or under any applicable income tax treaty.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For the purposes of this discussion, a &#8220;Non-U.S. Holder&#8221; is a beneficial owner of common stock that is neither a U.S. Holder nor a partnership (or other entity treated as a partnership for U.S. federal income tax purposes regardless of its place of organization or formation). A &#8220;U.S. Holder&#8221; means a beneficial owner of our common stock that is for U.S. federal income tax purposes any of the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">an individual who is a citizen or resident of the United States;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">139</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a trust if it (1)&#160;is subject to the primary supervision of a court within the United States and one or more United States persons (within the meaning of Section&#160;7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust or (2)&#160;has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a United States person.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Distributions</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As described in the section titled &#8220;Dividend Policy,&#8221; we do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock to a Non-U.S. Holder, such distributions, to the extent made out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), generally will constitute dividends for U.S. tax purposes and will be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty, subject to the discussions below regarding effectively connected income, backup withholding and foreign accounts. To obtain a reduced rate of withholding under a treaty, a Non-U.S. Holder generally will be required to provide us or our paying agent with a properly executed IRS Form W-8BEN (in the case of individuals) or IRS Form W-8BEN-E (in the case of entities), or other appropriate form, certifying the Non-U.S. Holder&#8217;s entitlement to benefits under that treaty. We do not intend to adjust our withholding unless such certificates are provided to us or our paying agent before the payment of dividends and are updated as may be required by the IRS. In the case of a Non-U.S. Holder that is an entity, U.S. Treasury Regulations and the relevant tax treaty provide rules to determine whether, for purposes of determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on the holder&#8217;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#8217;s agent will then be required to provide certification to us or our paying agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and you do not timely provide the required certification, you may be able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We generally are not required to withhold tax on dividends paid to a Non-U.S. Holder that are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such holder maintains in the United States) if a properly executed IRS Form W-8ECI, stating that the dividends are so connected, is furnished to us or our paying agent (or, if stock is held through a financial institution or other agent, to such agent). In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates applicable to U.S. persons. A corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax,&#8221; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non-U.S. Holder&#8217;s effectively connected earnings and profits, subject to certain adjustments. Non-U.S. Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">To the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will first reduce the Non-U.S. Holder&#8217;s adjusted basis in our common stock, but not below zero, and then will be treated as gain to the extent of any excess amount distributed, and taxed in the same manner as gain realized from a sale or other disposition of common stock as described in the next section.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Gain on Disposition of Our Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Subject to the discussions below regarding backup withholding and foreign accounts, a Non-U.S. Holder generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&#160;the gain is effectively connected with a trade or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">140</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">business of such holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains in the United States), (b)&#160;the Non-U.S. Holder is a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met, or (c)&#160;we are or have been a &#8220;United States real property holding corporation&#8221; within the meaning of Code Section&#160;897(c)(2) at any time within the shorter of the five-year period preceding such disposition or such holder&#8217;s holding period in our common stock. In general, we would be a United States real property holding corporation if the fair market value of our U.S. real property interests equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business. We believe that we have not been and we are not, and do not anticipate becoming, a United States real property holding corporation. Even if we are treated as a United States real property holding corporation, gain realized by a Non-U.S. Holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1)&#160;the Non-U.S. Holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (i)&#160;the five-year period preceding the disposition or (ii)&#160;the holder&#8217;s holding period in our common stock and (2)&#160;our common stock is &#8220;regularly traded,&#8221; as defined by applicable U.S. Treasury Regulations, on an established securities market. There can be no assurance that our common stock will qualify or continue to qualify as regularly traded on an established securities market. If any gain on your disposition is taxable because we are a United States real property holding corporation and your ownership of our common stock exceeds 5%, you will be taxed on such disposition generally in the manner as gain that is effectively connected with the conduct of a U.S. trade or business (subject to the provisions under an applicable income tax treaty), except that the branch profits tax generally will not apply.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">If you are a Non-U.S. Holder described in (a)&#160;above, you will be required to pay tax on a net income basis at the U.S. federal income tax rates applicable to U.S. Holders, and corporate Non-U.S. Holders described in (a)&#160;above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. If you are a Non-U.S. Holder described in (b)&#160;above, you will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which gain may be offset by certain U.S.-source capital losses (even though you are not considered a resident of the United States), provided that the you have timely filed U.S. federal income tax returns with respect to such losses. Non-U.S. Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Information Reporting Requirements and Backup Withholding</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Generally, we must report annually to the IRS and to each Non-U.S. Holder the amount of distributions paid, the name and address of the recipient, and the amount, if any, of tax withheld. These information reporting requirements apply even if withholding was not required because the dividends were effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States or withholding was reduced by an applicable income tax treaty. Under applicable income tax treaties or other agreements, the IRS may make its reports available to the tax authorities in the Non-U.S. Holder&#8217;s country of residence or country in which the Non-U.S. Holder was established.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Dividends paid to a Non-U.S. Holder that is not an exempt recipient generally will be subject to backup withholding, currently at a rate of 24%, unless the Non-U.S. Holder certifies to the payor as to its foreign status, which certification may generally be made on an applicable IRS Form W-8.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Proceeds from the sale or other disposition of common stock by a Non-U.S. Holder effected by or through a U.S. office of a broker generally will be subject to information reporting and backup withholding, currently at a rate of 24%, unless the Non-U.S. Holder certifies to the withholding agent under penalties of perjury as to, among other things, its name, address and status as a Non-U.S. Holder or otherwise establishes an exemption. Payment of disposition proceeds effected outside the United States by or through a non-U.S. office of a non-U.S. broker generally will not be subject to information reporting or backup withholding if the payment is not received in the United States. Information reporting, but generally not backup withholding, will apply to such a payment if the broker has certain connections </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">141</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:204pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">with the United States unless the broker has documentary evidence in its records that the beneficial owner thereof is a Non-U.S. Holder and specified conditions are met or an exemption is otherwise established.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Backup withholding is not an additional tax. Any amount withheld under the backup withholding rules from a payment to a Non-U.S. Holder that results in an overpayment of taxes generally will be refunded, or credited against the holder&#8217;s U.S. federal income tax liability, if any, provided that the required information is timely furnished to the IRS</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Foreign Accounts</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Sections&#160;1471 through 1474 of the Code (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain payments paid to a foreign financial institution (as specifically defined by applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a federal withholding tax of 30% on certain payments to a non-financial foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the entity. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. The withholding tax described above will not apply if the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from the rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">FATCA withholding currently applies to payments of dividends. The U.S. Treasury Department has released proposed regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30% applicable to the gross proceeds of a disposition of our common stock. In its preamble to such proposed regulations, the U.S. Treasury Department stated that taxpayers may generally rely on the proposed regulations until final regulations are issued. Non-U.S. Holders are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW.</font><font style="font-weight:normal;letter-spacing:-0.025pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">142</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUND">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">UNDERWRITING</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We and the underwriters for the offering named below have entered into an underwriting agreement with respect to the common stock being offered. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of shares of our common stock set forth opposite its name below. Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C. are the representatives of the underwriters.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:99pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:384.61pt;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Underwriter </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt; width:69.39pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">Number of Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:384.61pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cowen and Company, LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:69.39pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384.61pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Stifel, Nicolaus &amp; Company, Incorporated. </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:69.39pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384.61pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">William Blair &amp; Company, L.L.C. </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:69.39pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384.61pt;">
              <div style="white-space:nowrap;">
                <font style="text-transform:uppercase;letter-spacing:-0.025pt;">BTIG, LLC</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:69.39pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:384.61pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Stephens Inc. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:69.39pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.25pt 0pt; width:384.61pt;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="border-bottom:3pt double #000000;padding:0pt 0pt 1.5pt 0pt; width:69.39pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.21pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The underwriting agreement provides that the obligations of the underwriters are subject to certain conditions precedent and that the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the option to purchase additional shares described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act of 1933, and to contribute to payments the underwriters may be required to make in respect thereof.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Option to Purchase Additional Shares.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We have granted to the underwriters an option to purchase up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;additional shares of common stock at the public offering price, less the underwriting discounts and commissions. This option is exercisable for a period of 30&#160;days. To the extent that the underwriters exercise this option, the underwriters will purchase additional shares from us in approximately the same proportion as shown in the table above.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Discounts and Commissions.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;The following table shows the public offering price, underwriting discounts and commissions and proceeds, before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We estimate that the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and are payable by us. We have agreed to reimburse the underwriters for up to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;for their Financial Industry Regulatory Authority, or FINRA counsel fee. In accordance with FINRA Rule&#160;5110, this reimbursed fee is deemed underwriting compensation for this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:67pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="7">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:37.05pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:57.75pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Without Option </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:45.32pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">With Option </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:37.05pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.75pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.32pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Underwriting discounts and commissions </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:37.05pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.75pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.32pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Proceeds, before expenses, to the Company </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:37.05pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.75pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.32pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.1pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The underwriters propose to offer the shares of common stock to the public at the public offering price set forth on the cover of this prospectus. The underwriters may offer the shares of common stock </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">143</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">to securities dealers at the public offering price less a concession not in excess of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. If all of the shares are not sold at the public offering price, the underwriters may change the offering price and other selling terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Discretionary Accounts.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;The underwriters do not intend to confirm sales of the shares to any accounts over which they have discretionary authority.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Market Information.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our shares of common stock are admitted to trading on AIM, a market operated by the London Stock Exchange, under the symbols &#8220;MXCT&#8221; and &#8220;MXCN.&#8221; However, prior to this offering, there has been no public market for our shares or any of our other securities on any U.S. national securities exchange. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In addition to prevailing market conditions, the factors to be considered in these negotiations will include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the history of, and prospects for, our company and the industry in which we compete;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our past and present financial information;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the trading price of our common stock on AIM;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">an assessment of our management; its past and present operations, and the prospects for, and timing of, our future revenues;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the present state of our development; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">An active trading market for the shares may not develop. It is also possible that after the offering the shares will not trade in the public market at or above the initial public offering price.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We intend to apply to list our common stock on the Nasdaq Global Market under the symbol &#8220;MXCT.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Stabilization.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;In connection with this offering, the underwriters may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Overallotment transactions involve sales by the underwriters of shares of common stock in excess of the number of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares in the option to purchase additional shares. The underwriters may close out any short position by exercising their option to purchase additional shares and/or purchasing shares in the open market.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the option to purchase additional shares. If the underwriters sell more shares than could be covered by exercise of the option to purchase additional shares and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">144</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on the Nasdaq Stock Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Stabilization transactions will also need to comply with U.K. and European laws, in particular the Market Abuse Regulation (Regulation (EU) 596/2014).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Passive Market Making.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the Nasdaq Stock Market in accordance with Rule&#160;103 of Regulation&#160;M under the Securities Exchange Act of 1934, as amended, during a period before the commencement of offers or sales of common stock and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#8217;s bid, such bid must then be lowered when specified purchase limits are exceeded. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Lock-Up Agreements.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Pursuant to certain &#8220;lock-up&#8221; agreements, we and our executive officers, directors and certain other stockholders, have agreed, subject to certain exceptions, not to and will not cause or direct any of its affiliates to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into, or announce the intention to enter into any swap, hedge or similar agreement or arrangement (including, without limitation, the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) that transfers, is designed to transfer or reasonably could be expected to transfer (whether by the stockholder or someone other than the stockholder) that transfers, in whole or in part, directly or indirectly the economic consequence of ownership of, directly or indirectly, or make any demand or request or exercise any right with respect to the registration of, or file with the SEC a registration statement under the Securities Act relating to, any common stock or securities convertible into or exchangeable or exercisable for any common stock without the prior written consent of Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C., for a period of 90&#160;days after the date of the pricing of the offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">This lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or, in some instances, acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. The exceptions permit us, among other things and subject to restrictions, to: (i)&#160;issue common stock or options pursuant to employee benefit plans, (ii)&#160;issue common stock upon exercise of outstanding options or warrants, (iii)&#160;issue securities in connection with acquisitions or similar transactions, and (iv)&#160;file registration statements on Form S-8. The exceptions permit parties to the &#8220;lock-up&#8221; agreements, among other things and subject to restrictions, to: (a)&#160;make certain gifts or transfers by will or intestate succession upon the death of the party, (b)&#160;if the party is a corporation, partnership, limited liability company or other business entity, make transfers to any shareholders, partners, members of, or owners of similar equity interests in, the party, or to an affiliate of the party, if such transfer is not for value, and (c)&#160;if the party is a corporation, partnership, limited liability company or other business entity, make transfers in connection with the sale or transfer of all of the party&#8217;s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the party&#8217;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by the &#8220;lock-up&#8221; agreement. In addition, the lock-up provision will not restrict broker-dealers from engaging in market making and similar activities conducted in the ordinary course of their business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">145</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C., in their sole discretion, may release our common stock and other securities subject to the lock-up agreements described above in whole or in part at any time. When determining whether or not to release our common stock and other securities from lock-up agreements, Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C. will consider, among other factors, the holder&#8217;s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time of the request. In the event of such a release or waiver for one of our directors or officers, Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C. shall provide us with notice of the impending release or waiver at least three business days before the effective date of such release or waiver and we will announce the impending release or waiver by issuing a press release at least two business days before the effective date of the release or waiver.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than offers made by the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further offer of shares on our behalf or on behalf of the underwriters.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Electronic Offer, Sale and Distribution of Shares.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Other Relationships.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Certain of the underwriters and their affiliates have provided, and may in the future provide, various investment banking, commercial banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary fees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Selling Restrictions</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Canada</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;The common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 </font><font style="font-style:italic;">Prospectus Exemptions</font><font style="letter-spacing:-0.025pt;"> or subsection 73.3(1) of the </font><font style="font-style:italic;">Securities Act</font><font style="letter-spacing:-0.025pt;"> (Ontario), and are permitted clients, as defined in National Instrument 31-103 </font><font style="font-style:italic;">Registration Requirements, Exemptions and Ongoing Registrant Obligations</font><font style="letter-spacing:-0.025pt;">. Any resale of the common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Pursuant to section 3A.3 of National Instrument 33-105 </font><font style="font-style:italic;">Underwriting Conflicts</font><font style="letter-spacing:-0.025pt;"> (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Switzerland.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;The securities will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">146</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">European Economic Area.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area (each, a &#8220;Relevant State&#8221;), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that shares may be offered to the public in that Relevant State at any time:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">A.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to any legal entity which is a qualified investor as defined under Article&#160;2 the Prospectus Regulation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:8.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&#160;2 the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">C.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">in any other circumstances falling within Article&#160;1(4) of the Prospectus Regulation,</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">provided that no such offer of shares shall require the Issuer or any underwriter to publish a prospectus pursuant to Article&#160;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&#160;23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Issuer that it is a &#8220;qualified investor&#8221; within the meaning of Article&#160;2(e) of the Prospectus Regulation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">United Kingdom.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">A.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to any legal entity which is a qualified investor as defined under Article&#160;2 of the UK Prospectus Regulation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&#160;2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">C.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">in any other circumstances falling within Section&#160;86 of the Financial Services and Markets Authority, or FSMA,</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">provided that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to Section&#160;85 of the FSMA or supplement a prospectus pursuant to Article&#160;23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">147</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">to decide to purchase or subscribe for any shares and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#8220;qualified investors&#8221; &#8203;(as defined in the U.K. Prospectus Regulation) (i)&#160;who have professional experience in matters relating to investments falling within Article&#160;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the &#8220;Order,&#8221; and/or (ii)&#160;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article&#160;49(2)(a) to (d)&#160;of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;). In the United Kingdom, any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. Any person in the United Kingdom who is not a relevant person must not act on or rely upon this document or any of its contents.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Hong Kong.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&#160;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#8220;SFO&#8221;) of Hong Kong and any rules made thereunder; or (b)&#160;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.&#160;32) of Hong Kong) (the &#8220;CO&#8221;), or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any rules made thereunder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Singapore.</font><font style="letter-spacing:-0.025pt;"> Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">A.</font>
          <br >
        </div>
        <div style=" margin-top:7.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to an institutional investor (as defined in Section&#160;4A of the Securities and Futures Act (Chapter&#160;289) of Singapore, as modified or amended from time to time (the &#8220;SFA&#8221;)) pursuant to Section&#160;274 of the SFA;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:7.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to a relevant person (as defined in Section&#160;275(2) of the SFA) pursuant to Section&#160;275(1) of the SFA, or any person pursuant to Section&#160;275(1A) of the SFA, and in accordance with the conditions specified in Section&#160;275 of the SFA; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">C.</font>
          <br >
        </div>
        <div style=" margin-top:7.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Where the shares are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">A.</font>
          <br >
        </div>
        <div style=" margin-top:7.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:7.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">securities or securities-based derivatives contracts (each term as defined in Section&#160;2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (however described) in that trust shall not be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">148</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:58pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">transferred within six&#160;months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&#160;275 of the SFA except:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&#160;275(1A) or Section&#160;276(4)(i)(B) of the SFA;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">where no consideration is or will be given for the transfer;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">where the transfer is by operation of law;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">as specified in Section&#160;276(7) of the SFA; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(v)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">as specified in Regulation&#160;37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations&#160;2018.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Singapore SFA Product Classification&#8201;&#8212;&#8201;In connection with Section&#160;309B of the SFA and the CMP Regulations&#160;2018, unless otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section&#160;309A(1) of the SFA), that the shares are &#8220;prescribed capital markets products&#8221; &#8203;(as defined in the CMP Regulations&#160;2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Israel.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&#160;15 of the Israeli Securities Law, 5728-1968, including, inter alia, if: (i)&#160;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#8220;Addressed Investors&#8221;); or (ii)&#160;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968, subject to certain conditions (the &#8220;Qualified Investors&#8221;). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&#160;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968; (ii)&#160;which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968 regarding Qualified Investors is applicable to it; (iii)&#160;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&#160;that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968: (a)&#160;for its own account; (b)&#160;for investment purposes only; and (c)&#160;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968; and (v)&#160;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#8217;s name, address and passport number or Israeli identification number. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">149</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:198pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">LEGAL MATTERS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Cooley LLP, Reston, Virginia. Certain legal matters in connection with this offering will be passed upon for the underwriters by DLA Piper LLP (US), New York, New York.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">EXPERTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The consolidated financial statements of MaxCyte, Inc. as of and for the&#160;years ended December&#160;31, 2019 and 2020 are included herein and in the registration statement in reliance upon the report of CohnReznick LLP, independent registered public accounting firm included herein and in the registration statement, and upon the authority of said firm as experts in accounting and auditing.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">On the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available at www.sec.gov.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We also maintain a website at www.maxcyte.com. Information contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">150</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="fIFS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:443.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">MAXCYTE, INC.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">INDEX TO FINANCIAL STATEMENTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:115.5pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:431.18pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.05pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:431.18pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Audited Financial Statements for the Years Ended December&#160;31, 2020 and 2019</font>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tROIR"><font style="letter-spacing:-0.025pt;">Report of Independent Registered Public Accounting Firm </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tROIR">F-2</a></font> <a href="#tROIR"></a></td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCBS"><font style="letter-spacing:-0.025pt;">Consolidated Balance Sheets </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCBS">F-3</a></font> <a href="#tCBS"></a></td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOO"><font style="letter-spacing:-0.025pt;">Consolidated Statements of Operations </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCSOO">F-4</a></font> <a href="#tCSOO"></a></td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOC"><font style="letter-spacing:-0.025pt;">Consolidated Statements of Changes in Stockholders&#8217; Equity </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCSOC">F-5</a></font> <a href="#tCSOC"></a></td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOC1"><font style="letter-spacing:-0.025pt;">Consolidated Statements of Cash Flows </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCSOC1">F-6</a></font> <a href="#tCSOC1"></a></td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fNOTS"><font style="letter-spacing:-0.025pt;">Notes to Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#fNOTS">F-7</a></font>
            </td>
            <td style="padding:0pt;padding-left:4.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tROIR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:94pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">Report of Independent Registered Public Accounting Firm</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Board of Directors and Stockholders</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">MaxCyte, Inc.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Opinion on the Consolidated Financial Statements</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have audited the accompanying consolidated balance sheets of MaxCyte, Inc. and Subsidiary (the &#8220;Company&#8221;) as of December&#160;31, 2020 and 2019, and the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for the&#160;years then ended and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for the&#160;years then ended in conformity with accounting principles generally accepted in the United States of America.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Basis for Opinion</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">/s/ CohnReznick LLP</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have served as the Company&#8217;s auditor since 2018.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Tysons, Virginia </font> <br ><font style="letter-spacing:-0.025pt;">April&#160;20, 2021</font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCBS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:25pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">MaxCyte, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Consolidated Balance Sheets</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:530pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:321.98pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Current assets:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">18,755,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">15,210,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments, at amortized cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">16,007,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,497,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accounts receivable, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,171,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">3,244,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,315,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">3,701,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">1,003,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">797,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Total current assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">45,253,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">24,452,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,546,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">3,280,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,728,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">2,253,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">218,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">33,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Total assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">51,780,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">29,985,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Liabilities and stockholders&#8217; equity</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Current liabilities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">890,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">2,089,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accrued expenses and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,308,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">3,551,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating lease liability, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">572,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">508,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">4,843,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">3,193,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Total current liabilities</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">11,614,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">9,343,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Note payable, net of discount and deferred fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,917,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,895,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating lease liability, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,234,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,807,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">788,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">338,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Total liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">18,554,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">16,383,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Commitments and contingencies (Note 9)</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Stockholders&#8217; equity</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:321.98pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Common stock, $0.01 par; 200,000,000 shares authorized, 77,382,473 </font>
                <br >
                <font style="letter-spacing:-0.025pt;">and 57,403,583 shares issued and outstanding at December&#160;31, 2020 </font>
                <br >
                <font style="letter-spacing:-0.025pt;">and 2019, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">773,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">574,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">127,673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">96,433,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(95,222,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(83,405,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Total stockholders&#8217; equity</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">33,225,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">13,601,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Liabilities and stockholders&#8217; equity</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">51,780,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">29,985,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">See accompanying notes to the consolidated financial statements.<font style="font-style:normal;letter-spacing:-0.025pt;"> </font><br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:275pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">MaxCyte, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Consolidated Statements of Operations </font>
          <br >
          <font style="letter-spacing:-0.05pt;">For the Years Ended December&#160;31, 2020 and 2019</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:268pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Revenue</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">26,168,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">21,620,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">Costs of goods sold</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">2,767,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">2,499,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Gross profit</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">23,401,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">19,121,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Operating expenses:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">17,744,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">17,601,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">8,328,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">7,852,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">8,385,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">6,088,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Total operating expenses</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">34,458,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">31,541,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(11,056,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(12,420,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Other income (expense):</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">(825,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">(681,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">65,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">206,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Total other income (expense)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(759,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(475,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Basic and diluted net loss per common share</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(0.17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(0.23<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Weighted average common shares outstanding, basic and diluted</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">69,464,751</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">56,397,524</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">See accompanying notes to the consolidated financial statements.<font style="font-style:normal;letter-spacing:-0.025pt;"> </font><br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:246pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">MaxCyte, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Consolidated Statements of Changes in Stockholders&#8217; Equity </font>
          <br >
          <font style="letter-spacing:-0.05pt;">For the Years Ended December&#160;31, 2020 and 2019</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:141pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:13.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:155.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.04pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Paid-in </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.04pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.04pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Stockholders&#8217; </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:155.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:155.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Balance January&#160;1, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">51,332,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">513,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">82,279,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(70,510,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">12,281,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:155.95pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Issuance of stock in public </font>
                <br >
                <font style="letter-spacing:-0.025pt;">offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,908,319</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">59,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">12,271,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">12,330,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:155.95pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,752,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,752,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:155.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">162,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">1,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">131,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">132,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:155.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:155.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Balance December&#160;31, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">57,403,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">574,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">96,433,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(83,405,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">13,601,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:141pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:13.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:150.39pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.04pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Paid-in </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.04pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.04pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Stockholders&#8217; </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:150.39pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:150.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Balance January&#160;1, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">57,403,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">574,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">96,433,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(83,405,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">13,601,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:150.39pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Issuance of stock in public offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">19,181,423</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">191,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">28,375,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">28,567,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:150.39pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">2,471,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">2,471,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:150.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">797,467</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">8,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">393,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">401,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:150.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:51pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:150.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.05pt;">Balance December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">77,382,473</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">773,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:51pt; text-align:right; white-space:nowrap;">127,673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(95,222,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">33,225,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">See accompanying notes to the consolidated financial statements.<font style="font-style:normal;letter-spacing:-0.025pt;"> </font><br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOC1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">MaxCyte, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Consolidated Statements of Cash Flows </font>
          <br >
          <font style="letter-spacing:-0.05pt;">For the Years Ended December&#160;31, 2020 and 2019</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:587.5pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Cash flows from operating activities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Adjustments to reconcile net loss to net cash used in operating activities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Depreciation and amortization on property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,047,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">613,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net book value of consigned equipment sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">79,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Loss on disposal of fixed assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">25,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Fair value adjustment of liability classified warrant </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">366,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">14,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">2,471,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,752,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Bad debt (recovery) expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(117,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">54,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Amortization of discounts on short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(3,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(32,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Noncash interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">21,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">51,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Changes in operating assets and liabilities: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(1,810,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,592,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(890,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(1,890,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(205,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">66,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">525,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">474,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;finance lease </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">83,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(33,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Accounts payable, accrued expenses and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">391,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,160,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Operating lease liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(508,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">68,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,649,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">795,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(58,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(655,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(8,782,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(8,802,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Cash flows from investing activities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Purchases of short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(22,505,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(7,424,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Maturities of short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">8,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">9,149,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(2,072,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(1,271,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net cash (used in) provided by investing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(16,578,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">454,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Cash flows from financing activities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net proceeds from sale of common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">28,567,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">12,330,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Borrowings under notes payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,440,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">4,953,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Principal payments on notes payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(1,440,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(5,105,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Proceed from exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">401,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">132,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Principal payments on finance leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(63,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">28,904,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">12,310,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">3,544,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">3,962,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents, beginning of year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">15,210,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">11,248,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 2pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents, end of year </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">18,755,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">15,210,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:7.5pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Supplemental cash flow information:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash paid for interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">421,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">669,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Supplemental noncash information:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Property and equipment purchases included in accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">70,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">399,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Issuance of warrant in conjunction with debt transaction </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">60,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">See accompanying notes to the consolidated financial statements.<font style="font-style:normal;letter-spacing:-0.025pt;"> </font><br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fNOTS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">1.</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Organization and Description of Business</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">MaxCyte, Inc. (the &#8220;Company&#8221; or &#8220;MaxCyte&#8221;) was incorporated as a majority owned subsidiary of EntreMed, Inc. (&#8220;EntreMed&#8221;) on July&#160;31, 1998, under the laws and provisions of the state of Delaware and commenced operations on July&#160;1, 1999. In November&#160;2002, MaxCyte was recapitalized and EntreMed was no longer deemed to control the Company.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">MaxCyte is a global life sciences company focused on advancing the discovery, development and commercialization of next-generation cell therapies. MaxCyte leverages its proprietary cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy, including gene editing and immuno-oncology, as well as in drug discovery and development and biomanufacturing. The Company licenses and sells its instruments and technology and sells its consumables to developers of cell therapies and to pharmaceutical and biotechnology companies for use in drug discovery and development and biomanufacturing. In early 2020, the Company established a wholly owned subsidiary, CARMA Cell Therapies, Inc. (&#8220;CCTI&#8221;), as part of its development of CARMA, MaxCyte&#8217;s proprietary, mRNA-based, clinical-stage, immuno-oncology cell therapy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The COVID-19 pandemic has disrupted economic markets and the economic impact, duration and spread of related effects is uncertain at this time and difficult to predict. As a result, it is not possible to ascertain the overall future impact of COVID-19 on the Company&#8217;s business and, depending upon the extent and severity of such effects, including, but not limited to potential slowdowns in customer operations, extension of sales cycles, shrinkage in customer capital budgets or delays in customers&#8217; clinical trials, the pandemic could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and cash flows. In 2020, the Company made adjustments to its operating, sales and marketing practices to mitigate the effects of COVID-19 restrictions which reduced planned spending, particularly on travel and marketing expenditures. In addition, COVID-19 restrictions may have delayed or slowed the research activities of some existing and prospective customers. It is not possible to quantify the impact of COVID-19 on the Company&#8217;s revenues and expenses in 2020 or its expected impact on future periods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Summary of Significant Accounting Policies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Basis of Presentation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Use of Estimates</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, revenue recognition, stock-based compensation, allowance for doubtful accounts, allowance for inventory obsolescence, accruals for contingent liabilities, accruals for clinical trials, deferred taxes and valuation allowance, and the depreciable lives of fixed assets. Actual results could differ from those estimates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Principles of Consolidation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, CCTI. All significant intercompany balances have been eliminated in consolidation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Concentration</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">During the year ended December&#160;31, 2020, one customer represented 15% of revenue, in part due to certain one-time milestone events. During the year ended December&#160;31, 2019, one customer represented 10% of revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:33pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">During the year ended December&#160;31, 2020, the Company purchased approximately 47% of its inventory from a single supplier. During the year ended December&#160;31, 2019, the Company purchased approximately 56% of its inventory from a single supplier. At December&#160;31, 2020, amounts payable to three suppliers totaled 62% of total accounts payable. At December&#160;31, 2019, amounts payable to a single supplier totaled 25% of total accounts payable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Foreign Currency</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company&#8217;s functional currency is the US dollar; transactions denominated in foreign currencies are transacted at the exchange rate in effect at the date of each transaction. Differences in exchange rates during the period between the date a transaction denominated in foreign currency is consummated and the date on which it is either settled or at the reporting date are recognized in the consolidated statements of operations as general and administrative expense. The Company recognized an $81,800 foreign currency transaction gain and a $24,700 foreign currency transaction loss for the&#160;years ended December&#160;31, 2020 and 2019, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Fair Value</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. US GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Level&#160;1&#8201;&#8212;&#8201;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Level&#160;2&#8201;&#8212;&#8201;Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Level&#160;3&#8201;&#8212;&#8201;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">See Note 6 for additional information regarding fair value.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Cash, Cash Equivalents and Short-term Investments</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Cash and cash equivalents consist of financial instruments including money market funds and commercial paper with original maturities of less than 90&#160;days. Short-term investments consist of commercial paper with original maturities greater than 90&#160;days and less than one year. All money market funds, and commercial paper are recorded at amortized cost unless they are deemed to be impaired on an other-than-temporary basis, at which time they are recorded at fair value using Level&#160;2 inputs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table summarizes the Company&#8217;s investments at December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:102pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:103.64pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.04pt;">Classification </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amortized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:20pt;padding-right:20pt;letter-spacing:-0.04pt;">cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.04pt;">unrecognized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">holding gains </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.04pt;">unrecognized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">holding losses </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Aggregate </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.04pt;">fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Money market funds </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,702,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:30.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,702,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,523,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:30.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,523,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">13,996,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.35pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:30.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">13,998,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Corporate Debt </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:103.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">2,010,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.35pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:30.44pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">2,010,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:103.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,233,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.35pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">1,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:30.44pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,234,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:13pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table summarizes the Company&#8217;s investments at December&#160;31, 2019:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:87pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.04pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:103.64pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.04pt;">Classification </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Amortized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:20pt;padding-right:20pt;letter-spacing:-0.04pt;">cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.04pt;">unrecognized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">holding gains </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.04pt;">unrecognized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.04pt;">holding losses </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Aggregate </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.04pt;">fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Money market funds </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,037,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:40.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,037,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">1,399,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:40.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">1,399,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:103.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">1,497,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.68pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:40.44pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">1,498,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:103.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,934,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.68pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:40.44pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,934,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At times the Company&#8217;s cash balances may exceed federally insured limits and cash may also be deposited in foreign bank accounts that are not covered by federal deposit insurance. The Company does not believe that this results in any significant credit risk.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Inventory</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company sells or licenses products to customers. The Company uses the average cost method of accounting for its inventory and adjustments resulting from periodic physical inventory counts are reflected in costs of goods sold in the period of the adjustment. Inventory is carried at the lower of cost or net realizable value. Inventory consisted of the following at:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:54pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Raw materials inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,771,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,318,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:297.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Finished goods inventory </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">2,544,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">2,383,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:297.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Total Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">4,315,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">3,701,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company determined no allowance for obsolescence was necessary at December&#160;31, 2020 or 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Accounts Receivable</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Accounts receivable are reduced by an allowance for doubtful accounts, if needed. The allowance for doubtful accounts reflects the best estimate of probable losses determined principally on the basis of historical experience and specific allowances for known troubled accounts. All accounts or portions thereof that are deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts. The Company determined no allowance was necessary at December&#160;31, 2020. The Company recorded an allowance of $117,200 at December&#160;31, 2019. This amount was subsequently collected and the allowance was reversed in the year ended December&#160;31, 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Property and Equipment</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Property and equipment are stated at cost. Depreciation is computed using the straight-line method. Office equipment (principally computers) is depreciated over an estimated useful life of three&#160;years. Laboratory equipment is depreciated over an estimated useful life of five&#160;years. Furniture is depreciated over a useful life of seven&#160;years. Leasehold improvements are amortized over the shorter of the estimated lease term or useful life. Instruments represent equipment held at a customer&#8217;s site that is typically leased to customers on a short-term basis and is depreciated over an estimated useful life of five&#160;years.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Property and equipment include capitalized costs to develop internal-use software. Applicable costs are capitalized during the development stage of the project and include direct internal costs, third-party costs and allocated interest expenses as appropriate. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Property and equipment consist of the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:114pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Furniture and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">3,492,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">2,311,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">1,424,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">1,223,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">641,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">635,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Internal-use software under development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">30,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Internal-use software </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">1,963,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">1,277,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:297.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accumulated depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">(2,975,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">(2,198,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:297.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">4,546,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">3,280,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.01pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For the&#160;years ended December&#160;31, 2020 and 2019, the Company transferred $276,600 and $571,000, respectively, of instruments previously classified as inventory to property and equipment leased to customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For the&#160;years ended December&#160;31, 2020 and 2019, the Company incurred depreciation and amortization expense of $1,047,700 and $613,500, respectively. Maintenance and repairs are charged to expense as incurred.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the&#160;years ended December&#160;31, 2020 and 2019, the Company capitalized approximately $16,700 and $13,800 of interest expense related to capitalized software development projects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Management reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. The Company recognized no impairment in either of the&#160;years ended December&#160;31, 2020 or 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Revenue Recognition</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i)&#160;identification of contracts with customers, (ii)&#160;identification of distinct performance obligations in the contract, (iii)&#160;determination of contract transaction price, (iv)&#160;allocation of contract transaction price to the performance obligations and (v)&#160;determination of revenue recognition based on timing of satisfaction of the performance obligations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In some arrangements, product and services have been sold together representing distinct performance obligations. In such arrangements the Company allocates the sale price to the various performance obligations in the arrangement on a relative selling price basis. Under this basis, the Company determines the estimated selling price of each performance obligation in a manner that is consistent with that used to determine the price to sell the deliverable on a standalone basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company recognizes revenue upon the satisfaction of its performance obligation (generally upon transfer of control of promised goods or services to its customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer. The Company had no material incremental costs to obtain customer contracts in any period presented.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Research and Development Costs</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Research and development costs consist of independent proprietary research and development costs and the costs associated with work performed for fees from third parties. Research and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">development costs are expensed as incurred. Research costs performed for fees paid by customers are included in cost of goods sold.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Stock-Based Compensation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company grants stock-based awards in exchange for employee, consultant and non-employee director services. The value of the award is recognized as expense on a straight-line basis over the requisite service period.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company utilizes the Black-Scholes option pricing model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the expected volatility, expected dividend yield, risk-free rate of interest and the expected life of the award. A discussion of management&#8217;s methodology for developing each of the assumptions used in the Black-Scholes model is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Expected volatility</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company does not currently have sufficient history with its own common stock to determine its actual volatility. The Company has been able to identify several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated at between 49% and 55% for the year ended December&#160;31, 2020 and between 48% and 50% for the year ended December&#160;31, 2019 using the volatility of these companies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Expected dividend yield</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has never declared or paid common stock dividends and has no plans to do so in the foreseeable future. Additionally, the Company&#8217;s long-term debt agreement restricts the payment of cash dividends.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Risk-free interest rate</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">This approximates the US Treasury rate for the day of each option grant during the year, having a term that closely resembles the expected term of the option. The risk-free interest rate was between 0.4% and 1.7% for the year ended December&#160;31, 2020 and 1.6% and 2.6% for the year ended December&#160;31, 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Expected term</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">This is the period that the options granted are expected to remain unexercised. Options granted have a maximum term of ten&#160;years. The Company estimates the expected term of the options to be approximately six&#160;years for options with a standard four-year vesting period, using the simplified method. Over time, management intends to track estimates of the expected term of the option term so that estimates will approximate actual behavior for similar options.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Expected forfeiture rate</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; margin-top:4pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company records forfeitures as they occur.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Income Taxes</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more-likely-than-not that all or a portion of the deferred tax asset will not be realized.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Management uses a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return, as well as guidance on derecognition, classification, interest and penalties and financial statement reporting disclosures. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense. The Company has not identified any uncertain income tax positions that could have a material impact to the consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company is subject to taxation in various jurisdictions in the United States and abroad and remains subject to examination by taxing jurisdictions for 2016 and all subsequent periods. The Company had a Federal Net Operating Loss (&#8220;NOL&#8221;) carry forward of $57.8&#160;million as of December&#160;31, 2020, which was generally available as a deduction against future income for US federal corporate income tax purposes, subject to applicable carryforward limitations. As a result of the March&#160;2016 public offering of common stock and listing on the AIM market of the London Stock Exchange, the Company&#8217;s NOLs are limited on an annual basis, subject to certain carryforward provisions, pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended, as a result of a greater than 50% change in ownership that occurred in the three-year period ending at the time of the AIM listing and public offering. The Company has calculated that for the period ending December&#160;31, 2022, the cumulative limitation amount exceeds the NOLs subject to the limitation. In addition, the Company&#8217;s NOLs may also be limited as a result of ownership changes subsequent to the 2016 AIM listing. The Company has not yet calculated such subsequent limitations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Leases</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. In transactions where the Company is the lessee, at the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Lease expense is recognized on a straight-line basis over the lease term.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has made certain accounting policy elections for leases where it is the lessee whereby the Company (i)&#160;does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (ii)&#160;combines lease and non-lease elements of its operating leases. See Note 9 for additional details over leases where the Company is the lessee.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All transactions where the Company is the lessor are short-term (one year or less) and have been classified as operating leases. All leases require upfront payments covering the full period of the lease and thus, there are no future payments expected to be received from existing leases. See Note 3 for details over revenue recognition related to lease agreements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Loss Per Share</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of Common Stock outstanding during the period.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of stock options and stock purchase warrants, which has been excluded from the computation of diluted loss per share, was 12.9&#160;million and 10.4&#160;million for the&#160;years ended December&#160;31, 2020 and 2019, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Recent Accounting Pronouncements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Recently Adopted</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">On January&#160;1, 2020, the Company adopted new guidance addressing the accounting for implementation, setup and other upfront costs paid by a customer in a cloud computing or hosting arrangement. The guidance aligns the accounting treatment of these costs incurred in a hosting arrangement treated as a service contract with the requirements for capitalization and amortization costs to develop or obtain internal-use software. The adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Unadopted</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In June&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued guidance with respect to measuring credit losses on financial instruments, including trade receivables. The guidance eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity&#8217;s current estimate of all future expected credit losses. Under the previous guidance, an entity only considered past events and current conditions. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2022, including interim periods within those fiscal&#160;years. Early adoption is permitted for fiscal&#160;years beginning after December&#160;15, 2018, including interim periods within those fiscal&#160;years. The adoption of certain amendments of this guidance must be applied on a modified retrospective basis and the adoption of the remaining amendments must be applied on a prospective basis. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In August&#160;2020, the FASB issued guidance with respect to (i)&#160;accounting for convertible instruments, (ii)&#160;accounting for contracts in an entity&#8217;s own equity as derivatives and (iii)&#160;earnings per share calculations. The guidance attempts to simplify the accounting for convertible instruments by eliminating the requirement to separate embedded conversion options in certain circumstances. The guidance also provides for updated disclosure requirements for convertible instruments. The guidance further updates the criteria for determining whether a contract in an entity&#8217;s own equity can be classified as equity. Lastly, the guidance specifically addresses how to account for the effect of convertible instruments and potential cash settled instruments in calculating diluted earnings per share. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2021, including interim periods within those fiscal&#160;years. Early adoption is permitted for fiscal&#160;years beginning after December&#160;15, 2020, including interim periods within those fiscal&#160;years. The adoption of this guidance may be applied on a modified retrospective basis or a full retrospective basis. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">3.&nbsp;&nbsp;&nbsp;Revenue</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue is principally from the sale or lease of instruments and processing assemblies, as well as from extended warranties. In some arrangements, product and services have been sold together representing distinct performance obligations. In such arrangements the Company allocates the sale price to the various performance obligations in the arrangement on a relative selling price basis. Under this basis, the Company determines the estimated selling price of each performance obligation in a manner that is consistent with that used to determine the price to sell the deliverable on a standalone basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue is recognized at the time control is transferred to the customer and the performance obligation is satisfied. Revenue from the sale of instruments and processing assemblies is generally recognized at the time of shipment to the customer, provided no significant vendor obligations remain and collectability is reasonably assured. Revenue from equipment leases are recognized ratably over the contractual term of the lease agreement and when specific milestones are achieved by a customer. Licensing fee revenue is recognized ratably over the license period. Revenue from fees for research services is recognized when services have been provided.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Disaggregated revenue for the year ended December&#160;31, 2020 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:87pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.3pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Revenue from </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Contracts with </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Customers </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Revenue </font>
                <br >
                <font style="letter-spacing:-0.04pt;">from Lease </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Elements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:263.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Product Sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">14,850,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">14,850,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Leased Elements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,717,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,717,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:263.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">601,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">601,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:263.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">15,451,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">10,717,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">26,168,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.5pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Disaggregated revenue for the year ended December&#160;31, 2019 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:87pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:268.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Revenue from </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Contracts with </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Customers </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Revenue </font>
                <br >
                <font style="letter-spacing:-0.04pt;">from Lease </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Elements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:268.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Product Sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">12,917,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">12,917,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:268.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Leased Elements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">8,363,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,363,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:268.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">339,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">339,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:268.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">13,257,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">8,363,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">21,620,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9.49pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Additional disclosures relating to Revenue from Contracts with Customers</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Changes in deferred revenue for the year ended December&#160;31, 2020 were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:67.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at January&#160;1, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,452,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:403.99pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Revenue recognized in the current period from amounts included in the beginning</font>
                <br >
                <font style="letter-spacing:-0.025pt;">balance </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,191,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Current period deferrals, net of amounts recognized in the current period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">4,752,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:403.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">5,014,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.5pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Changes in deferred revenue for the year ended December&#160;31, 2019 were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:67.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at January&#160;1, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,770,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:403.99pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Revenue recognized in the current period from amounts included in the beginning </font>
                <br >
                <font style="letter-spacing:-0.025pt;">balance </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,435,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Current period deferrals, net of amounts recognized in the current period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">3,117,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">3,452,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Remaining contract consideration for which revenue has not been recognized due to unsatisfied performance obligations with a duration greater than one year was approximately $227,500 at December&#160;31, 2020 of which the Company expects to recognize approximately $56,200 in 2021, $56,200 in 2022, $41,900 in 2023 $22,000 in 2024 and $51,200 thereafter.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In the&#160;years ended December&#160;31, 2020 and 2019, the Company did not incur, and therefore did not defer, any material incremental costs to obtain contracts or costs to fulfil contracts.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">4.</font>
          <br >
        </div>
        <div style=" margin-top:8.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Debt</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company originally entered into a credit facility with Midcap Financial SBIC, LP (&#8220;MidCap&#8221;) in March&#160;2014. In February&#160;2019, the Company paid off the MidCap credit facility in full in accordance with its terms and conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2019, the Company entered into a new credit facility with MidCap. The credit facility provided for a $5&#160;million term loan maturing on November&#160;1, 2024. The term loan provides for (i)&#160;an interest rate of one-month Libor plus 6.5% with a 1.5% Libor floor, (ii)&#160;monthly interest payments, (iii)&#160;30 monthly principal payments of approximately $166,700 beginning June&#160;2022 and (iv)&#160;a 3% final </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">payment fee. The Company used the proceeds from the credit facility for general operating purposes. The debt is collateralized by substantially all assets of the Company.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In conjunction with the credit facility the Company issued the lender a warrant to purchase 71,168 shares of common stock at a price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance (see Note 5). In connection with the credit facility, the Company also incurred expenses of approximately $47,300. The warrant and expenses resulted in recording a debt discount which is amortized as interest expense over the term of the loan. At December&#160;31, 2020, the term loan had an outstanding principal balance of $5&#160;million and $83,000 of unamortized debt discount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In April&#160;2020, the Company received a loan from Silicon Valley Bank in the amount of $1,440,000 under the US Small Business Administration&#8217;s Paycheck Protection Program (&#8220;PPP&#8221;). The PPP was established as part of the US Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act and provides for potential forgiveness of the loan upon the Company meeting certain conditions as to the use of the proceeds. The loan provided for interest at 1% and a maturity date of April&#160;2022. In May&#160;2020, subsequent to the Company&#8217;s 2020 equity raise (see Note 5), the Company repaid the loan in full.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">5.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Stockholders&#8217; Equity</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In March&#160;2019, the Company completed an equity capital raise issuing approximately 5.9&#160;million shares of Common Stock at a price of &#163;1.70 (or approximately $2.25) per share. The transaction generated gross proceeds of approximately &#163;10&#160;million (or approximately $13.3&#160;million). In conjunction with the transaction, the Company incurred costs of approximately $1.0&#160;million which resulted in the Company receiving net proceeds of approximately $12.3&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In May&#160;2020, the Company completed an equity capital raise issuing 19,181,423 shares of its common stock at a price of &#163;1.31 (or approximately $1.60) per share in an unregistered offering. The transaction generated gross proceeds of approximately &#163;25.1&#160;million (or $30.5&#160;million). In conjunction with the transaction, the Company incurred costs of approximately $1.9&#160;million which resulted in the Company receiving net proceeds of approximately $28.6&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">During the year ended December&#160;31, 2020, the Company issued 797,467 shares of Common Stock as a result of stock option exercises, receiving gross proceeds of $401,000. During the year ended December&#160;31, 2019, the Company issued 162,500 shares of Common Stock as a result of stock option exercises, receiving gross proceeds of $132,700.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Warrant</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In connection with the November&#160;2019 credit facility the Company issued the lender a warrant to purchase 71,168 shares of Common Stock at an exercise price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance. The warrant is classified as a liability as its strike price is in a currency other than the Company&#8217;s functional currency. The warrant is recorded at fair value at the end of each reporting period with changes from the prior balance sheet date recorded on the consolidated statements of operations (see Note 6).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Stock Options</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company adopted the MaxCyte, Inc. Long-Term Incentive Plan (the &#8220;Plan&#8221;) in January&#160;2016 to amend and restate the MaxCyte 2000 Long-Term Incentive Plan to provide for the awarding of (i)&#160;stock options, (ii)&#160;restricted stock, (iii)&#160;incentive shares, and (iv)&#160;performance awards to employees, officers, and Directors of the Company and to other individuals as determined by the Board of Directors. Under the Plan, as amended, the maximum number of shares of Common Stock of the Company that the Company may issue is increased by ten&#160;percent (10%) of the shares that are issued and outstanding at the time awards are made under the Plan. On December&#160;10, 2019 and October&#160;27, 2020, the Company&#8217;s Board resolved to increase the number of stock options under the Plan by 3,000,000 and 1,500,000, respectively to provide sufficient shares to allow competitive equity compensation in its primary markets for staff and consistent with practices of comparable companies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:35.5pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020 there were 4,175,737 awards available to be issued under the Plan.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has not issued any restricted stock, incentive shares, or performance awards under the Plan. Stock options granted under the Plan may be either incentive stock options as defined by the Internal Revenue Code or non-qualified stock options. The Board of Directors determines who will receive options under the Plan and determines the vesting period. The options can have a maximum term of no more than ten&#160;years. The exercise price of options granted under the Plan is determined by the Board of Directors and must be at least equal to the fair market value of the Common Stock of the Company on the date of grant.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">A summary of stock option activity for the&#160;years ended December&#160;31, 2020 and 2019 is as follows</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:197.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:197.23pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Exercise Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Remaining </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Contractual Life </font>
                <br >
                <font style="letter-spacing:-0.04pt;">(in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.04pt;">Intrinsic Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at January&#160;1, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,388,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.49</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,354,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,538,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.17</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(162,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.82</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">217,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(465,215<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">2.48</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,299,285</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.63</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,471,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">3,849,448</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(797,467<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.52</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,198,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(487,036<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">2.59</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,864,230</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.11</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:42pt; text-align:right; white-space:nowrap;">65,576,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2.25pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercisable at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">7,609,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.53</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:12.75pt; text-align:right; white-space:nowrap;">5.9</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:42pt; text-align:right; white-space:nowrap;">43,196,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The weighted-average fair value of the options granted during the&#160;years ended December&#160;31, 2020 and 2019 was estimated to be $1.39 and $1.08, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As of December&#160;31, 2020, total unrecognized compensation expense was $7,130,900 which will be recognized over the next 2.9&#160;years.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Stock-based compensation expense for the&#160;years ended December&#160;31, 2020 and 2019 was classified as follows on the consolidated statements of operations:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:69pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.98pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,230,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">827,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">484,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">325,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">756,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">598,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">2,471,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">1,752,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">6.</font>
          <br >
        </div>
        <div style=" margin-top:13pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Fair Value</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company&#8217;s consolidated balance sheets include various financial instruments (primarily cash and cash equivalents, short-term investments, accounts receivable and accounts payable) that are carried at cost, which approximates fair value due to the short-term nature of the instruments. Notes payable are reflective of fair value based on market comparable instruments with similar terms. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has an outstanding warrant originally issued in connection with the November&#160;2019 debt financing (see Note 4) that is accounted for as a liability whose fair value is determined using Level&#160;3 inputs. The following table identifies the carrying amounts of this warrant at December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:54pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:281.23pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:281.23pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Liabilities </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:281.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Liability classified warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:281.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.79pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table identifies the carrying amounts of this warrant at December&#160;31, 2019:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:54pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:292.35pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:292.35pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Liabilities </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:292.35pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Liability classified warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:292.35pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.71pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents the activity for those items measured at fair value on a recurring basis using Level&#160;3 inputs for the year ended December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:63pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:378.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Mark-to-market </font>
                <br >
                <font style="letter-spacing:-0.04pt;">liabilities&#8201;&#8212;&#8201;warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Change in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.07pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">366,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.07pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.79pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents the activity for those items measured at fair value on a recurring basis using Level&#160;3 inputs for the year ended December&#160;31, 2019:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:78pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:378.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Mark-to-market </font>
                <br >
                <font style="letter-spacing:-0.04pt;">liabilities&#8201;&#8212;&#8201;warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Issuance </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">60,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Change in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.63pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">14,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.63pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The gains and losses resulting from the changes in the fair value of the liability classified warrant are classified as other income or expense in the accompanying consolidated statements of operations. The fair value of the Common Stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to such unobservable inputs identified above may change the embedded conversion options&#8217; fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in these unobservable inputs generally result in decreases in fair value.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has no other financial assets or liabilities measured at fair value on a recurring basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Money market funds and commercial paper classified as held-to-maturity are measured at fair value on a non-recurring basis when they are deemed to be impaired on an other-than-temporary basis. No such fair value impairment was recognized during the&#160;years ended December&#160;31, 2020 or 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:16.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has no non-financial assets and liabilities that are measured at fair value on a recurring basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company measures its long-lived assets, including property and equipment, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be impaired. No such fair value impairment was recognized during the&#160;years ended December&#160;31, 2020 or 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">7.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Retirement Plan</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company sponsors a defined-contribution 401(k) retirement plan covering eligible employees. Participating employees may voluntarily contribute up to limits provided by the Internal Revenue Code. The Company matches employee contributions equal to 50% of the salary deferral contributions, with a maximum Company contribution of 3% of the employees&#8217; eligible compensation. In the&#160;years ended December&#160;31, 2020 and 2019, Company matching contributions amounted to $351,500 and $277,700, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">8.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Income Taxes</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company did not recognize a provision (benefit) for income taxes in 2020 or 2019. Based on the Company&#8217;s historical operating performance, the Company has provided a full valuation allowance against its net deferred tax assets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Net deferred tax assets as of December&#160;31, 2020 and 2019 are presented in the table below:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:204.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Deferred tax assets:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net operating loss carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">14,998,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">12,842,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development credits </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">875,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">875,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,662,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,146,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,387,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">965,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Lease liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">566,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">647,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accruals and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">971,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">652,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.05pt;">Deferred tax liabilities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">ROU asset </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(538,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(630,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(25,300<font style="position:absolute;">) </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">19,923,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">16,474,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(19,923,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(16,474,500<font style="position:absolute;">) </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">Net deferred tax assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $57.8&#160;million as of December&#160;31, 2020 will begin to expire in various&#160;years beginning in 2025. The use of NOL carryforwards is limited on an annual basis under Internal Revenue Code Section&#160;382 when there is a change in ownership (as defined by this code section). Based on changes in Company ownership in the past, the Company believes that the use of its NOL carryforwards generated prior to the date of the change is limited on an annual basis; NOL carryforwards generated subsequent to the date of change in ownership can be used without limitation. The use of the Company&#8217;s NOL carryforwards may be restricted further if there are future changes in Company ownership. Additionally, despite the net operating loss carryforwards, the Company may have a future tax liability due to state tax requirements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:34pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Income tax expense reconciled to the tax computed at statutory rates for the&#160;years ended December&#160;31, 2020 and 2019 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:99pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:335.32pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Federal income taxes (benefit) at statutory rates </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(2,481,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(2,707,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">State income taxes (benefit), net of Federal benefit </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(787,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(898,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Windfall tax benefits </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(556,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(40,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Permanent differences, rate changes and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">377,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(29,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Change in valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">3,448,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">3,676,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">Total Income Tax Expense</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">9.&nbsp;&nbsp;&nbsp;Commitments and Contingencies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Operating Leases</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">From 2009 through September&#160;2019 the Company entered into various new and amended leases for office and laboratory space. A member of the Company&#8217;s Board of Directors is the CEO and Board member of the lessor of certain of these leases for which the rent payments totaled $623,000 and $416,800 in 2020 and 2019, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All the Company&#8217;s long-term office and laboratory leases expire in October&#160;2023 and provide for annual increases to the base rent of between 3% and 5%. The current monthly base lease payment for all office and laboratory leases is approximately $56,100. In addition to base rent, the Company pays a pro-rated share of common area maintenance (&#8220;CAM&#8221;) costs for the entire building, which is adjusted annually based on actual expenses incurred. None of the Company&#8217;s current operating leases contain any renewal provisions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All the Company&#8217;s long-term office and laboratory leases are classified as operating leases. The Company used a discount rate of 8% in calculating its lease liability under its operating leases. The September&#160;2019 lease agreements and modifications resulted in the Company establishing approximately $2,209,200 of ROU assets and $2,247,400 of lease liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020, the Company had a $1,728,300 ROU asset, a $572,500 short-term lease liability and $1,234,600 long-term lease liability related to its operating leases.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In July&#160;2020, the Company commenced a one-year office lease providing for monthly payments of $2,900. The Company applied the practical expedient and consequently, no ROU asset or lease liability was recognized for this short-term lease.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020 the weighted average remaining lease term for the Company&#8217;s operating leases was 2.8&#160;years.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Finance Leases</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In 2020, the Company entered into a three-year laboratory equipment lease that expires in April&#160;2023. The lease provides for monthly payments of approximately $9,200 per month and includes an end of lease bargain purchase option. The lease is classified as a finance lease. The Company used a discount rate of 5.5% in calculating its lease liability under this finance lease resulting in the establishment of approximately a $301,700 ROU asset and offsetting lease liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020, the Company had a $218,300 ROU asset, a $100,000 short-term lease liability included in &#8220;Accrued expenses and other&#8221; and $142,200 long-term lease liability included in &#8216;Other liabilities&#8217; related to its finance lease. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:166.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">All Leases</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Lease costs for the&#160;years ended December&#160;31, 2020 and 2019 are as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:114pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:350.31pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Finance lease cost </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Amortization of ROU asset </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">83,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Interest on expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">14,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">551,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">19,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Variable lease cost </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">289,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">217,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:350.31pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.05pt;">Total lease cost</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">1,080,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">768,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Maturities of lease liabilities as of December&#160;31, 2020 were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:99.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.27pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Operating Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Finance Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">696,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">110,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">717,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">110,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">614,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">36,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total lease payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,028,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">258,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Discount factor </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">(221,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(16,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Present value of lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">1,807,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">242,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">10.&nbsp;&nbsp;&nbsp;Subsequent Events</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In preparing these consolidated financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through April&#160;20, 2021, the date the consolidated financial statements were available to be issued.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In February&#160;2021, the Company completed a private placement offering of 5,740,000 shares of its Common Stock. The shares were sold at a price of &#163;7.00 (or approximately $9.64) per share generating approximately &#163;40.2&#160;million (or approximately $55.3&#160;million) of gross proceeds.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In March&#160;2021, the Company paid off, in full, all amounts due under its $5&#160;million Midcap term loan in accordance with its terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In the first quarter of 2021, the Company elected to conclude all pre-clinical and clinical activities related to the CARMA platform which were substantially completed by March&#160;2021.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.8pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:70.22pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:14pt;">
          <font style="letter-spacing:-0.07pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;Shares</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:48pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:18pt;">
          <font style="letter-spacing:-0.09pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:75.5pt; text-align:justify; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 75.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #63D05A; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:17.51pt; text-align:center; width:456pt;">
          <img src="lg_maxcyte-4clr.jpg" alt="[MISSING IMAGE: lg_maxcyte-4clr.jpg]" height="40" width="261" >
        </div>
        <div style="margin-top:12.7pt; text-align:justify; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 12.7pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #63D05A; ">&#8203;</div>
        </div>
        <div style="margin-top:47.32pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">Joint Book-Running Managers<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-top:50pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:16pt;">
          <tr style="line-height:16pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:16pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">
              <font style="letter-spacing:-0.08pt;">Cowen </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.08pt;">Stifel </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 1pt 0pt; width:144pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:-0.08pt;">William Blair</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:68.12pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">Co-Managers<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-top:19.9999999999999pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:14pt;">
          <tr style="line-height:14pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:14pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.07pt;">BTIG </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.07pt;">Stephens Inc.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:45.32pt; text-align:justify; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">Through and including &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 (the 25th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in our initial public offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#8217;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </font>
        </div>
        <div style="margin-top:70.52pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 70.52pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.80000000000007pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="mrll_PB1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">PART II</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Item&#160;13.</font>
          <br >
        </div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:48pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Other Expenses of Issuance and Distribution.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table sets forth all expenses to be paid by us, other than underwriting discounts and commissions, in connection with this offering. All amounts shown are estimates except for the Securities and Exchange Commission, or the SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq Global Market initial listing fee.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:100.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:9.99999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:411.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">FINRA registration fee</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Nasdaq Global Market initial listing fee</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Legal fees and expenses</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accounting fees and expenses</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:411.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Printing and miscellaneous expenses</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:411.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.4pt; text-align:justify; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">To be filed by amendment.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:11.9pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Item&#160;14.</font>
          <br >
        </div>
        <div style=" margin-top:11.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:48pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Indemnification of Directors and Officers.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Section&#160;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. Our fifteenth amended and restated certificate of incorporation that will be in effect on the completion of this offering permits indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and our amended and restated bylaws that will be in effect on the completion of this offering provide that we will indemnify our directors and officers and permit us to indemnify our employees and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have entered into indemnification agreements with our directors and officers, whereby we have agreed to indemnify our directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of MaxCyte, Inc., provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of MaxCyte, Inc. At present, there is no pending litigation or proceeding involving a director or officer of MaxCyte, Inc. regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his capacity as such.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The underwriters are obligated, under certain circumstances, under the underwriting agreement to be filed as Exhibit&#160;1.1 hereto, to indemnify us and our officers and directors against liabilities under the Securities Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Item&#160;15.</font>
          <br >
        </div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:48pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Recent Sales of Unregistered Securities.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following list sets forth information regarding all unregistered securities sold by us since January&#160;1, 2018 through the date of the prospectus that forms a part of this registration statement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="mrll_PB2">&#8203;</a><a name="mrll_Temp2">&#8203;</a><a name="mrll_TocPage2">&#8203;</a><a name="tI1EA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Issuances of Common Stock in Private Placements<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In February&#160;2019, we issued and sold an aggregate of 5,908,319 shares of our common stock to 19 investors at a purchase price of &#163;1.70 per share ($2.25 per share based on the exchange rate as of the purchase date) for aggregate consideration of&#8201;$13.3&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In May&#160;2020, we issued and sold an aggregate of 19,181,423 shares of our common stock to 21 investors at a purchase price of &#163;1.31 per share ($1.59 per share based on the exchange rate as of the purchase date) for aggregate consideration of&#8201;$30.5&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In February&#160;2021, we issued and sold an aggregate of 5,740,000 shares of our common stock to seven investors at a purchase price of &#163;7.00 per share ($9.64 per share based on the exchange rate as of the purchase date) for aggregate consideration of&#8201;$55.3&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The sales of securities described above were deemed to be exempt from registration pursuant to Regulation&#160;S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All of the purchasers in these transactions represented to us in connection with their purchase that they were acquiring the securities for investment and not distribution, that they could bear the risks of the investment and could hold the securities for an indefinite period of time. Such purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such registration. All of the foregoing securities are deemed restricted securities for the purposes of the Securities Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Stock Option Grants and Exercises<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">From January&#160;1, 2018 through the date of the prospectus that forms a part of this registration statement, we have granted options to purchase an aggregate of 10,418,005 shares of common stock to our employees, directors and consultants, at exercise prices ranging from &#163;1.075 to &#163;10.40 per share, under our LTIP. From January&#160;1, 2018 through the date of the prospectus that forms a part of this registration statement, we have issued an aggregate of 2,963,441 shares of common stock upon the exercise of stock options upon the payment of &#163;2,045,600 in aggregate exercise price (approximately $2.9&#160;million based on the exchange rate as of May&#160;7, 2021).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The offers, sales and issuances of the securities described in the preceding paragraph were deemed to be exempt from registration under Rule&#160;701, in that the transactions were under compensatory benefit plans. The recipients of such securities were our employees, directors or consultants and received the securities under our equity incentive plans. Appropriate legends were affixed to the securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Issuance of Common Stock Warrant<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2019, in connection with a credit facility, we issued to the lender a warrant to purchase 71,168 shares of common stock at an exercise price of &#163;1.09081 per share. The issuance of the warrant was deemed to be exempt from registration under the Securities Act in reliance on Section&#160;4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. The lender acquired the warrant for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were affixed to the securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">All certificates representing the securities issued in the transactions described in this Item&#160;15 included appropriate legends setting forth that the securities had not been offered or sold pursuant to a registration statement and describing the applicable restrictions on transfer of the securities. There were no underwriters employed in connection with any of the transactions set forth in this Item&#160;15.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:10.51pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Item&#160;16.</font>
          <br >
        </div>
        <div style=" margin-top:10.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:48pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Exhibits and Financial Statement Schedules.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:4pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">(a) Exhibits.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following exhibits are included herein or incorporated herein by reference:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:32.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:408pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:36pt;">
              <font style="margin-left:5.56pt;letter-spacing:-0.025pt;">1.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Form of Underwriting Agreement. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:443.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.04pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.04pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:408pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.04pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:36pt;">
              <font style="margin-left:5.56pt;letter-spacing:-0.025pt;">3.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:408pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">Fourteenth Amended and Restated Certificate of Incorporation of Registrant, as amended, as currently in effect. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36pt;">
              <font style="margin-left:5.56pt;letter-spacing:-0.025pt;">3.2* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:408pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">Form of Fifteenth Amended and Restated Certificate of Incorporation of Registrant, to be in effect on the completion of this offering. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="margin-left:5.56pt;letter-spacing:-0.025pt;">3.3* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Amended and Restated Bylaws of Registrant, as amended, as currently in effect. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36pt;">
              <font style="margin-left:5.56pt;letter-spacing:-0.025pt;">3.4* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:408pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">Form of Amended and Restated Bylaws of Registrant, to be in effect on the completion of this offering. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="margin-left:5.56pt;letter-spacing:-0.025pt;">4.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Form of Common Stock Certificate. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="margin-left:5.56pt;letter-spacing:-0.025pt;">5.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Opinion of Cooley LLP. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.1*+ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">MaxCyte, Inc. Long-Term Incentive Plan. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.2*+ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Form of Stock Option Agreements under the MaxCyte, Inc. Long-Term Incentive Plan. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.3*+ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">2021 Equity Incentive Plan. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.4*+ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:408pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the 2021 Equity Incentive Plan. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.5*+ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Forms of Director Grant Notice and Award Agreement under the 2021 Equity Incentive Plan. </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.6*+ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">2021 Employee Stock Purchase Plan. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.7* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:408pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">Form of Indemnity Agreement by and between the Registrant and each director and executive officer. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.8*</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:408pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">Eighth Amendment to Lease Agreement, dated as of September 27, 2019, between ARE-20/22/1300 Firstfield Quince Orchard, LLC and the Registrant.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.9*</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Sublease, dated as of September 9, 2019, between Novavax, Inc. and the Registrant.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.10*</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:408pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">First Amendment to Sublease, dated as of September 9, 2019, between Novavax, Inc. and the Registrant.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.11*</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:408pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">First Amendment to Sublease, dated as of September 9, 2019, between Novavax, Inc. and the Registrant.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">10.12*+ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Non-Employee Director Compensation Plan. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">21.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">List of Subsidiaries of Registrant. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">23.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Consent of CohnReznick LLP, independent registered public accounting firm. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">23.2* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Consent of Cooley LLP (included in Exhibit&#160;5.1). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">
              <font style="letter-spacing:-0.025pt;">24.1*</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:408pt;">
              <font style="letter-spacing:-0.025pt;">Power of Attorney (included on signature page to this registration statement).</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20.7pt; text-align:justify; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">To be submitted by amendment.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">+</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Indicates management contract or compensatory plan.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">(b) Financial Statement Schedules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or the notes thereto.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:12.1pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Item&#160;17.</font>
          <br >
        </div>
        <div style=" margin-top:12.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:48pt;font-weight:bold;">
          <font style="letter-spacing:-0.05pt;">Undertakings.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant under the foregoing provisions or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:388pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The undersigned registrant hereby undertakes that:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">(1)&nbsp;&nbsp;&nbsp;For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance on Rule&#160;430A and contained in a form of prospectus filed by the registrant under Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities Act will be deemed to be part of this registration statement as of the time it was declared effective.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">(2)&nbsp;&nbsp;&nbsp;For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus will be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time will be deemed to be the initial bona fide offering thereof.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">SIGNATURES</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Columbia, Maryland, on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:80pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt; width:240pt;">
              <font style="letter-spacing:-0.05pt;">MAXCYTE, INC.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:240pt;white-space:normal;">
              <div>
                <font style="letter-spacing:-0.025pt;">By:&#8199;</font>
                <br >
                <font style="letter-spacing:-0.025pt;">&#8199;</font>
              </div>
              <div style="margin-left:36pt; margin-top:-9.5pt;">
                <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 1.833pt 0pt; width:240pt;white-space:normal;">
              <div style=" float:left; margin-left:40pt; line-height:10pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Name:</font>
                <br >
              </div>
              <div style=" line-height:10pt; text-align:left; margin-left:76pt;">
                <font style="letter-spacing:-0.025pt;">Doug Doerfler </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:240pt;white-space:normal;">
              <div style=" float:left; margin-left:40pt; line-height:12pt; text-align:left; width:36pt;white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Title:</font>
                <br >
              </div>
              <div style=" line-height:12pt; text-align:left; margin-left:76pt;">
                <font style="letter-spacing:-0.025pt;">President and Chief Executive Officer</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.05pt;">POWER OF ATTORNEY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Doug Doerfler and Maher Masoud, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule&#160;462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:232.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;">
                <font style="letter-spacing:-0.04pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;">
                <font style="letter-spacing:-0.04pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;">
                <font style="letter-spacing:-0.04pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:24.167pt 0pt 1.833pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199; </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:-0.025pt;">Doug Doerfler </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:24.167pt 0pt 1.833pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">President, Chief Executive Officer and Director (Principal Executive Officer) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:24.167pt 0pt 1.833pt 0pt; width:96pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199; </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:-0.025pt;">Amanda Murphy </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Chief Financial Officer </font>
              <br >
              <font style="letter-spacing:-0.025pt;">(Principal Financial Officer)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:144pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199; </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:-0.025pt;">Ron Holtz </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Senior Vice President, Chief Accounting Officer, and Director</font>
              <br >
              <font style="letter-spacing:-0.025pt;">(Principal Accounting Officer)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 0.5pt 0pt; width:96pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199; </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:-0.025pt;">J. Stark Thompson, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Chairman of the Board of Directors</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199; </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:-0.025pt;">Will Brooke </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:181.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;">
                <font style="letter-spacing:-0.04pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;">
                <font style="letter-spacing:-0.04pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;">
                <font style="letter-spacing:-0.04pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:24.167pt 0pt 1.833pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199; </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:-0.025pt;">Richard Douglas, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:24.167pt 0pt 1.833pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:24.167pt 0pt 1.833pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199; </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:-0.025pt;">Stanley C. Erck</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199; </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:-0.025pt;">John Johnston </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:144pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199; </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:-0.025pt;">Art Mandell </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1.833pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_maxcyte-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_maxcyte-4clr.jpg
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M!$!0\$%1<=$3,Q21H;'!X6"!4K(C)#0@(F(%%1,!  (" 0,"!@,! 0$!
M 0 1(3%!$%%A<8$@\)&AL=$PP?'A0%!@_]H # ,!  (1 Q$   &_P0C5OT_G
M:G]_X5(WG:.DRMZ)[)9OR?COE8TW:NBS4]>^T(6()IK!3.=V JWP''>.XMJ]
M::YB$(0A".)UBLVRJ1G;"[*;EJ?40A'PBHVYL&:?$Y"$8(]1$M+%JV1<'0Y.
M.'G=^F>%S\#'=O\ 7>\\'YGXZ-[=;[R/C])\QUQG.Y^J+B/G+ZXA&@?6N*6S
M1AV>0=BXIBN;[)N_+.H16-620/575T]TDQ+$ZSTUA58.S>.\B;9LJDN"Q,\G
M0)J+X!#Q'#41K7%=+G=YC7$@JGL$X5B>042UB5U*XD-_8'K^/7:NK_#?&T'9
M^A.[UWMO9_-Y14U/8^DO-U_L5GWI+WY"-!+M<<N)J74M3&LRGEL$5QRAJYE_
M-0<N;>I; YH9_7&2YGD&.UQEEYY!M-8NUKX_0GS'M?CO)SG]$_1GD*&'KC+T
MSN*B4):R1=G8O6N.7DT57-BK:X]7-,)T2DUYWSKZ'&F [7TNM;W)Z1R/?U7O
M6J?N_"VWG>I*QX^M=RZKF=[P/GI\>L/9T)$$IO&6'.01O7&03-P527BUCW-\
MF=VBJ.A<?%"-)R#F7%+ER0K-WA9T$[OC)$Y..!OUI\6[?X[RE[?RO]B?>:%\
MN=_2.-3AS;]6@F+QDW-<)10=<=U$VWL4]:P<5GD<]>1JO[O&4G?3GQBW_EO
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M=\?35+/XSZ<@3?\ #6YLS!*&Y;[NW\5"DI*2XO=ZY3YPU-Y&98DP;8!"F02
M%BKSJD$FN9V_%!)@36MA_P!35A;(BG',V;W!(Z(-KLJB\N]:2_?F 5*]AL8Q
M,UHVOQ:YJG[,^.XXFAF5X5/ED@S?CV+.T3S! )JX\ZD.;\;1=UBN8(--7/9_
M,1T-;(W&7Z9O$8TS;[461M1'-F11UQDL7D3+EI&D@:;8C%"I24<6>4\O3:P-
MG_I#$E2S+\1A\:FSLD?93AK8:!0R"MJ\AS;G%U;6A,][.8J9KXYL?BR1')U2
M=81E.*N[Q:V0AX=COQ9-QF\HM./\VC'#MV7I;CC(VXW,J/S:\X I=::O58V3
M=N55L1^IHV! ONP..K(#-<7;#%QG$[8VN\RD.P,4985--)?OM1EY;'BHU%9'
M-W9=K#E9"A<_=TM^E_+\NV.P^3.X['WUXA4B<MAV=-B"P'>4O6"\4H\:1/.#
M\?(LGZFPI$R0:<Y5>G!TQOE)U!U1X[A*)VR7$$LP@[@C4-#G@:86S+&NW<O]
MIA&,8L;,IUL%C%^F4&=VI8R.4/P)D*5MK887%X9F3,K[DE^B6#LC3-'-,7S;
M'MVN&<%\8>N7HGTJ+C[;<XC??8K$R];'3FL5192)/Y_.O.HIA4V-GA5!TO;D
M%;$?J:/?YS-6.",B8\5I3T2K4W%'A)-L/VMI+]\Y.2ATRGJC&&YIQS]ZW&BB
M!O>]+?[</^H[4X@3L2ON&=&JV'"42,*R@B-;L@:UN21\P_(F-:PNL"8%KY)+
M.0!6U>._Q>8:?37VV3;+S(99DK3B$\,G_P![UH_4VR[B>W8G95B1 ZI]R;T9
M,RVH(FD<"\;#8<X'.D8#@\.J1E;I-*5<B=O+OK$D2,<CY4F QTE+_P"Y./E7
MUCN-J94\R]'8!/@C462]MWK8<?\ J:/?YQ)R\7*.N9S]E=N0)6M%MA^U])?O
ML=&5$<RGJSF1B;F51*HTE3[*Y209"E&EW]M6K4S>EV!R\IR/)38G("8YK-F>
M^(NUE]IENW&-5#>^X5S$XXJ>&Z>XDR*@FF;,8XO:T6P>3TLDQR]R*1Q3.<'L
MG6.F1Y=H=( \Z2/6,8H5"H-63_[WK(^-!V+L\QY1*<8,=S8F>HYAC765H)GB
MC7*#->/X!K;D4IK;4S0W\,KR5T?U?L[Q49ACR_O#:W)6I#F!W7E6@S/( ACC
M\O5PZ+)HFS/B2Y37M1E-2"\A96?$BM?B]DA,P*=T8"";_< K9^,2-VR?IPQ/
M+-=FK#C=E5DDN,YS#EB1--7L9%A6>1IOU C[XSRO9B>2E:5CK"\LF<I6XNBZ
MZ!2/%4ZB[[KCD"1.C0],;7(F[)NK,IC:I4T/[,:S0V6291A?5OV=39;;8 A;
M<&Q$021#)FKL&_*LA\,_XBDL=F;"MD+6X1D!.B^;=87&YP.;YE%C4K-,Y:IP
M'K<LCJ_CV2:[)-6EEV\!++N'LDT!10#Z;K;;@\9/Z+B2;QL+++X')DZ@"6MN
M3C<47?5A11="G(N&THJSA<23>-I)-@\#VAL4BG0(DO%W<D[.U9!DQ\OF6KL(
M&*8\X&DE'6^Q,W5: 6A1[6W*J3MK>E^D9F0$../B(5@8#FOP/!^)_]H " $"
M  $% N)=@WCVKJ[1E.3=X""VT;A FX*[5U6MEQ31])MM&^XM-T6]JFE %QDI
M'J+3I1LL[-(6_P H]^&WVSZ2W(AMM[= 3U"!@6VK2_)O[5=JBAM)+>#.I#\F
M =0M;"F)(>6(@2/DFI *LX".0=KE5BL#J+&XV_L\J[-7JK.]W:<3.:7Y,N[H
MO2*BU1#JK+2HQ'F/R"=.8J.1(2D:?H"I"X 38DOZ2FY'V".V%/"RQ F1F#U=
MZE9G43\H0K4I:.4'J1^1841*0OR4]+7).D3GG&*#8\F+NO\ )3T:L2EEN2^]
MP4E7]%=^KS>JWZ/U75U75S$>',:ZKJZA_CW_V@ ( 0,  04"XWWA97=M&NX7
M32Z>XN=UW2 F@-!?:-&.]ACY])NN"RTQ1UW=VI"ZB45"0N Y0IZK^]3JZBWI
M(R!MSWZ1^/R^5<%H#?WJN4=(7)NN]L'P[.]7>Y4I+N5GL:<"W#B/H#X@CTVN
MTB5J#V*0J;5'H'X(>EX<[$)(K $?* :%%<2!_0G*\RT:\NVB$MXI^S3<5TJO
M4-!Z!H/0' :,M[A:Q(:B/9T9BQ< <@XCQ'[\>=<_2K5%(D[DYJ'!5W3*B;9>
MH,56!<:^N8JU7=,J/MYSFM5E6A;VJ2E])WJ&@X!P&@] <!X*4*-92=*F26^L
M?A29<>X&^$HI SJ5JE,G*2$R56;:3X2FBFU4:8T-A;4D,LZJ[-6%]-WR?+UA
MZN7KZ+*Z+*"VT.'3:-=%M=-O\>__V@ ( 0("!C\"_HNB%<3F5+/_ "'.B?>H
M!715Y*J;[<1SNAE&$6_7DK*V:A9ZNMH;I[U3A^+O43JL@_R6S[D\##\PY*\9
M\S9#H0:W2$PF3;<C$X=GQ'"0"#]RW-7/;WH[C:C+4;>9W\'F/E-5TE$HEF@%
M>&V=IH,FV=A'.?"!W44*U,W$)Y?,B[@FT:8BXIM%LX7]MGI*/F&> 4!.*S/\
MYT[##SG23WNU$]]A'"_H/<U9JSBXX\%ZFNYOCNE@.<5J;[4:N8%W1VHU:AB\
MKU6Y< QLABM;4:A>V 1K'3T#"V')$RIE7VS^S_\ _]H " $# @8_ K<5?!7P
M#1/ =:K!G\=C?[?:%$J]7 15+_7;>&01S0C/*[Z<E9C)1L_Y^WOJ.UWR'5]\
M?<JI=^'YA0;ILS4S^Y=<W#'W)CW_ .7Y7<E>"R0LB)HU*GF.3\MQ=]++Y(U:
MGW8)KNWX'A,QDBS:OR[8=E^,OFF[;>'/2<8"5WNX/)']5T8*^:@)H>)K(7C5
M--HW#Y.E8#SEPA9UA&A5%X3&4Y W]BAP+MS6,&M3MP_3&X8=%GK]QY+98E%S
MM('N7ATOX[)=]@S1].S4?E\$QC=+1W6 \+^YIM?VA9=NQK!AP7I=NUWI63Q=
MS@M+O8FT TAO2>H)M"B(4VH[3:@YW:CASC%>6Y"FUCLQP0H-US)ZS;'DB04@
MKK+U(*7V>__:  @! 0$&/P+T\XZA\!C^WP^;&9BLR\2*"SGZ"C&9P@%C&MK"
M@M*UQ[1SYN0QC?)KP*]JI5.A2 8..KI95DWLUE/GUL*.0\,$UDY1$<(]<S.4
M1]O$D8K/C.F"@O+GRCVHQI%*9F>'(_\ KXV?MG:Y7-6J%MFY6%"R.K:]QW'Z
MC4<Z"6$*67")XSS]'<ST--35T[!"8<XF*=J8\)P)1NUKR%!1YAYQ.<?>X0BZ
M]?Q[9!31OKB&0QJP0N%WIUR0E[PR#Y3][RC'[<\7^X-X=":-!?49[4D7[Q8@
M)F9SSRB)GAC<-]L[DY+;S=?13Y5)'P4N#EIP$3QXE//'?OOUQUF%?HU(0R1R
MC7^D>K+A'M:(_L><S$1X^'TS/"(PW:MHR[BWA81U00-CW.NS68Z3?()2_P H
M9_5MGG@SJ*V&@C.>FM-7<X+3GPUR6\LB9RP/QW;=DW.GPUPFON"[?/CH8S>"
M3GE^]Q_(]SH;FJ)FQM5D7*LKTZ<Y W(2FQ'GC\')?:G]G=VEVP;BQE,@ BA@
MQ$R:ENC[SU,Q3[DIUFU$V\HA3>)C/22V>.7J=^RKS4I3NN^;H[W;9MKB='O3
M5Z6VF&PS2I2:=&&.+6Q>H5S$3JRC%>SW+6V6_P!OV-QK;=NMG9 LKL=LV;=F
M$+*VNQN=UERD$R>HZZF!I1,ZN(S/^TC_ #;\7]D_YO\ _4^S[/R>U\GI8]Q0
M"UC)3,S$<HSRX^.#=)<.0#KS@8CU>'''/_"Q\#HG/7M1/O[09YEID,NA,#Q\
MXM]<>SRQN^K((BK,Y^SPZM7QQTD'^+*\L2)^5A9E.OAPY3'T8Y_X6)97F)OV
M/J:HZ_,O."*7Y927"5Y?9YXV\SDB*??",RSDCF=NN1J(IXS/H[I_(;7YE;]&
MV[GU"C:[EA-/>%=:5)*HZ3K^\.X$L_<ALDR-4<XYQSQ4W*BX'U+U9-JLU9"<
M&IZQ:HHD9F)S L?H%L]K/;=J;6L[FVM<U*L7HKW(Z)"GR,7[ON YYE/F'T?K
M!_JO_P R\L<9^GEAE9^^U]RM*RU(VA];<,IU9:2FLYLB41QRRY8&LVS=VV#F
M(BQ=5T41)9^VQW1 !CQG/&UW-P[AI'5WE)OH/IV:EI307T]?UB[&B"&6QG\N
M+-#MG= O6JE?WIZHE6H4]1:M>0-.=.ML<<6=DWW=IV_<*LS#$V 6K4.LUPQ?
M5:N341+G(HX8+:M@WZI:OPJ716E]86F D S*PAY&S(CCE'CZ'[+NW<516X5>
M%A*WU62@\RCI._&(E3HTYZ9XY3&/A';FY%N-SIRTX2 ,6H!^^:Q3&0O/*<L^
M>4X3VGV]9)._[II9;MU+<J?M]#HNF1^HCJJL,-B2'S!.G"-IV2E;W*_:/*>D
MI]CIQI(NI8-8,E89!/$L SNGN-K+QQ$LJTJ,@I$Z8S&+(;J4.R+QTCANZ=E;
MFW?(2#6LV@MO,+>@ U1%=@W[C;32RX#"HF<\5K.Q_$ZF^4GR(HJ1;5<(LIAB
M"2C2\H()GAEC:>[>_:5SM5UF%HMU[Z&((;/3JZCTVTT9!1MLY#Y?#%>JKN6M
MU++E(7K;5$-;3%8ZBFSD,:BPMRB@U-6#5G$Q(D!C! 43'"8(9Q;WC=K2J>W4
M0$[-IS 4I<&P$AFQA $2;60,<>,SEC_B5/\ &K?_ "<;7W5N;+,[5O5H*E$U
M)DC,V*N-&9B,\AD:)XW?=J.OW2XY)IUQD6054*G./X:YQL_;>Z3?C<$DM;H4
M@B"#)-5$E!Y>SJ#%'<JV<UK].M=1)<Y3:2#U9_+H/!W-UOTMMJK]JS?M(IHC
MYW6#6O.?GQTQWGXF43E,[9*;B^>6<-KM<,X57#?4;8YS%*7&[.K;>N3:6@?K
M+3E1''"[-1Z;5=T:E/K-!Z6#G,9K:J2 XSCPG&S=P=NP-C>>VF6V+VX^"]RJ
M;C4=M=U M\W2:%&ZXQGILU3$1EXX=L6Q=H=P]OT^Y'4?TPW3N3XATJ%))M&U
M4V*+VWT@>#D7K$1TF+B(!?"<XR_#%_PK^BWL_P#EO^V_">U\GV_3\+JL^J0?
MUY#(3##T!,1RF<AUS$\<>U]S!%$YEE.B.'M>'T3ACF^9K2DC*<\YX\!_O8QN
M"E1H9=\G5\87FDLLBB?%6/:^YC.2X1Q\..#L.\W(5!/(!B!CAEE''3BD67WM
MG\RM>CNG\AL_F5O&UC95#T%<6#53,Q!@?EF,XRGQP[X=5]WV#>A/<-JT2\U*
M%CW3-3JO-I$RNK1GYIYXWS9-QNE/<.T5V)[9AGNFITO&\Q41!AF2ZLBH.(LP
MG;Z<'<W;>;4POJ29D;3S+SD(F>41&7+&W]O;%6]WK4NVZ</\[S]XM_%-X$[&
M=A]@_,D0CVOO<?K!_JO_ ,RX3V/V[=94W*S*G[O:3*.JFH55AQ3\RVL23O>4
MLU#(%D/JG [9L-&WNNX-S,^F#GR P!G+'D L,1TKGCB;T[95LZ52TJU0[C;>
M4#!2,)]P'S_9Q\(W6;2SVQC4^YVM>JH>O)JX!G%?G'ECN><N/Z/E\_\ ..V\
M,-WS:*BX[EV5#GB0B[JWJH2#F(F%'I)@K ]&8%,D7.,5-WH&VENNSW8F0R$2
MAM5T2==P-6P)CJJR(2&8X<L5.^:[@+>KL?#%;=U*TO7NP3>&2>$B0@IP[89Q
M]7/ HX8 -3MRWC=K(CJF-;7O/AJ* 'P&,YRCE&*PV*R9[DW2O3L[U:R;U%MZ
M$L]Q#K&6@:C++1S$5Z_OHX1EW5?<PCB+=>JJ)TZ0&EMU*ED,! C'&OBQW992
ML]QWFXYJK)"6I6V!3V^5)'46B,K$-G.!B?-SQ8J[+<*EME<R4O0%4R?I9/UW
M4FN3(U#$<-<QBKL^_62NU+K 0AQ!665=K&P,:I6A9,"=7B7#+%K?ZW;VWQNE
MXX:ZT0L;F72!>:T-8RLKR+CV '&_[":%R3-NL,ICT_8N(7+JNCIR!1]>L?W)
MQ<H.U+M;;=?59S&1=4>2BF,^,><,;!>)A'<JI?0NP>C4)5+URK7]C*.-:N,\
MHPCMA#I&QW"^O+UQT\_=:MVO<7,YQ+,I=1F.&6.VMB%<,38W;;RO"6O+X<-Z
MM%WBO(_]G*?&/GC';O;?:56L3-JW6@T@835@%6MM6ZU2D>FBP6?5LC]//%K:
MKXPNW3(0<$:IB)-8-C+4(S[!QX8V[N':*55FW66)8HF,LP>CZINJ1"FP?8/U
MXVLMX8%<-A[<V\=Q9,Q )^'[>E=@LST1I&5SSRP_I6K53MZJ<*V_;@-8#DO5
M$L::%*8Z3893YR/[F W+:=C:%!L02;=U=I*'B0ZXE+ K.$XD9CZ<)9W%M-BH
MAIE"+ZUV/=#8J5\ L,2GSQ+!Q7[3[DO.L]N;CK34988G^3+9O6Z&DYBXL2G1
MUN$MT^:.'++]A-=;(]_OK>M,93,@.@1-OJB1ZT3&",SS,IU%/C,SQSP*PXD9
M0(Q'RX2JS,%88D&L&)_!26?DY1RF,'8=P&. Q_='E,Q$?1C//'/%/<[/ ;^H
MJR_'IC"RAD\.1BZ,<L5"^1_YJ_T=U?D-G\RMXVK\M1_CQBQ7!?\ *^UTSW#:
MFQ.DX8H56&HC.)&?>QJP''U^&+%.R$JL57-KO7/,&I.5L'U>4QP7ZP]W1^,W
MDVJ>T*.>57WBB?O>G+,6#8I&//E/+#/]QU/Z3W?'ZP?ZK?\ ,N.[;-@Y,O>Z
MB1S\!K[70KC'#]ZK"]Y6D9W'>KKK+K,\3%4T]O 4#X"(DJ9_OO1L7<E-*TV-
MV595?T9QUCK!24@Y'V8D0B>7//'<_P#^?+^D-MQE/+]N>?R8_3_9!!5+=+72
MW6IU(^KNL5K%R *-6E\I:1\9XSPQT]9].)U=/5.C5QXZ<\L^.*_ZQ][6IUVQ
MUO@">IU(K5G5(0=H@#R]5HV7!D4SEE$Y1SQ^W]N>.ZJKHF&#NK&3G_<V5KLA
M_@-C%"BAD2S;B?M-F(X2#PJ4W\?L6AQ;V^XHQ)+60!\Q:$&0PP2C^ZTXVU==
M9=*O90^PWD*T@T-99^N,\0&J)D!&)RGC&41''T+[EI)T;9W0=IF0SG"K5-.V
M>]$6?L^\6+I3'&<;GVA99E6W>DRY4U<IW!5K;T+4/'AJ2YD\O#%U*6D=+8JR
M]H2.40.I-F[:ED>,YC=R^QC?.]K2YX>Z4=J.<N/\Y#N'#+_1>CN'\HK?F%3&
MP_8_,J.-[E!R'OI?#V9>*K-*]KCY/8Q2N7JD7JM=W5=5F2B'1$3I&=+%%P/*
M?:CEA=:KVA42A0P"EB#(@1&,HC*-S]6-U[>W3L^JQ.X4+E939%NNK8?6:E-I
M1?$^!US/5'..'&)QU%9AD4R'K'U?:QLNX6"U.M4A:9<LRUG'*.'*/3:W&XT5
M)K+UYD66HIF 6$?*;"B/LXM;BXYT&UONRM19*K]0I4OS3S%>43RY8YX_2'<5
MYTZ\F--9C$BYV0QU/-GFN!(O#VHYX8TY@5KKP3#GD*@EI$<S_!P:Z\_B-(B5
M7B)GZPAR$VSX3J(,XX>..?V\*UP4;;3*67'9>7RK(EJB2X%)-T9QQX3C:JZ1
M@55EN4L8CV0$:H+&,O"!#'CA!>J&_P#@-CT=U?D-G\RMXVK\M1_CQA'[Y0_1
MEC9]SVFN0]N]P6QL=PDD5 -"%G3"T<<LV6Y:QG*>7CBMM])0)K5%"E2EC  ,
M1XP,91YIX_/AG^XZO]);OC]8/]5_^9<;_)B?NNYS2N4G2N0%HSM6W]?1/(NG
M8DA^Q@^QNY;U?;GJNML;3;M,Z59E<JE0(JFQOU*C$JK"SDXSU1&6?,[ECN#9
M5UEKEDN+<Z6C0(ZLQGKY3PY>O%:ELC)=L_;\6*ZK4$>BXYT5NL8@0AY5-041
M/&"B<XQW/_\ GR_I#;<6;UQP5JE1++%AS#@%K4H)8PBDLHR@1PVC0?(]L[,]
MU>@I9LT6V#H4VXW/(&:F*F5S \!/QYXK]V,VVP.P6KGN*-PTSTCL_C>8_-'N
M+./+RX5V;O\ 9_\ KV[6&35L.:<#METJD0'"=0=&P51:XCRY$>>>!8!B8,B#
M PF" Q+B) 4<"@HGGXX']8.WUV,H;R=6KNLJ7JBM<1M\5T$>CS"HJVUYR4QI
MU3EG@YD)N;#N!_RE1EACE.C3[PC+6(.^K#.=!9B.6%6CW;MY^D1F%;N^I4M(
MU1!2(KW"4L^?RXLJV%NU[CNDC(U]NV5BC4UHK(@E]FFNP@//.7'+GBYOM?>G
M-/<G1JVMS+;=NC@I8 JK%H<BTJCQYXV_=^Z-L#:=TN +IJ!PR0Q*3 B7,D:B
MDR*) O-&6-\H0N3O[?3N[KMFB!ZA7*-5MA%<9+D-ER@&?7BMNVW'[MNVS6SE
M9%J^K>F264'H,"X3\L87!ZGW]VNI5,C!&1->8*U99R7#';>P OINK;50G<.
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M 3U>[1B6?9+JIP01A-UYWZ0UT=+FO3VDJBT^\X>ZD!,:["XJ-) ((Z23$>!
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MV!#72S9Z%:"G9#EPV^?W>S[$@"ZHKH0[D%&-P\M3-RDUE6,- SGL8,"&XO,
M'U+E;>2OWADZ[\ J@IA*TEG,?,5+42YW&E8\+"?F3^H(%&;L= .188 F6":E
MS'7H%RXXV@6 .$:(\4B.7C7/_5F!MHXO@_V./IM>-TT5V$*Q4+?"? +U7O%0
MS<$%4>HJ+N#K'?"/[&S-$.B_=;=NPP.R5U;DZI?**Z98S@Y78<0*F5V(>@K'
M04)PJP$Q.:;@H@%,"LQJ*1#@MHREY$U;02-S-@%O;34,X2TXN!.EH;LOBZ!Y
M3,V$*@*7EF]8HGUH6,*HKDCRTDD7<@;&44'C![\]3F HR[&'06J$7+84)K
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M%9Z)24ZAGX$[0^\<ROK,RH1E/2H.*Z83,S Z<1@ZI,PC.3TE+ [_  ?X!/\
M )D #Z='( OI/\0@38+]/_<P*_\ HF_YO__:  P# 0 "$0,1   0 %*M@1,<
M#$    E*^  &=@ CY$S:7\X#L)'J^[Y@)G?FP_@^LJ$--"-DURONH%QO%%2X
MW*.%I/,'R<53$RSFR4)!U]RG(X41="K :Q\G[XSV"*IP4&ML&1U-$PFK@-OA
MT.@1UJPM4<,OTJA.W*@["@[P6HA   $D#$D  2<CD E K(           C@
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2Q :,Q16JZD*]^C/2-_#_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2113965d1-org_prog4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-org_prog4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-  !+L@  _GP  6N8  'FY?_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@ U@.6 P$1
M  (1 0,1 ?_$ 44  0 !!0$! 0$            &! 4'" D# @$* 0$  04!
M 0$             !0$#! 8' @@)$  !! ( ! 4"! 4$ P$!   $ 0(#!0 &
M(!$3!Q P$A050!8A,2(74"0U-@A@(S0E,C=',R81  $# @0# P4("0T," 4%
M  (! P01!0 A$A,Q% 9!(A5188$R(Q @,'%"4F(D\)&ADC/3-18'0+'!T>%R
M@M)#-"65-E#QHE-C@Y.S1(34M7-4=)2T586E8*-DU2:R=<5VAA(  0(# P<'
M"04&!@(!!0$! 1$" !(#(3$$05%A<2(R$R P@9&AL=$0\,%"4B,S% 5 X6)R
MDH*BLL(D-%#QTD-3%6!S8X.C1'0EDP83 0 " @$# @8# 0$! 0    $1(0 Q
M05%A<2"!$##PD:&Q0,'1X?%08/_:  P# 0 "$0,1   ![^   ^2@+?ZI;O7G
MPJ'O1<//JX^:UQ]@          ^2A+?ZI;O5*>M/P]Z+AY]7&E:^C[
M  !ABE+Z7FJ8J@#X*"J@KYI*^?&M/T]J>JWSZKZ5K3Z
M!^%KJC=SQ@><US3C<= P%/ZO L^,_%)Y@2F?('9]Q]-W_/4'LDDM^KK2OZ
M      #\+;5'/?C"TQ!:9;GH&OFPZMCV0BO.M)O@R.>(+9MP=/WS8G7MGDEO
MW=J5^@       :V4ILG6H ^2TUI9/=O$.Q<YUYW+C&+-@Y[&LV#^Z>I?';+E
MS7.D;&Z5VW(L/N%]\W+C1^@               'D1KWYU_G-=Y6=4XIJMM6D
M?@  !M'J^Z=5>5=MV$@MCDWCUZ@       ^".>J83EX3E?U/B^GFXZ%\5H
M!LAK>V]5N5=KV4UW:)1X]>P      !K92FR=:@>!'/?C#&Q\XT4ZQ\CX<V;F
M0  'W3UL1I?:]Z>3_6N2(K:Y!Y]?8              !Y$4]^=#]YYQR.ZYP
MFTW;     NEJ_P!:N2]TWWT7I,MM^O4      'P1;WYTTV_1N.78^!QO)Q
M  !6>+G57E7:^B7/>H2ZW[]P      :V4ILG6H\"+^[>H/1?G+17K/R/3^[(
M    O>+*]%.+?;&Q&H=@DOGU]@      'AZM:R;KQ/5[=^'8AV'GL?RHF\X\
MCE>!WW9G2^V;5:+W:NM90 'X1;WYT)WGG''[L'!/&OD     ?=*]>>1=YZ :
M'TJ5>/7Z      1OU33+;]'XK=I^>J&Y;      ZN<H[;T>YWU.6>/7T
M  :V4ILG6OR1;WXTZZ/\W:(]:^1/P&7-?Z!G;5^IXCG^?2O!GJGQ?U5WKA
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MSPO[9\]=E^0=UP_+P=GNV,_P6R<<^N<.R]$S> YW7 !GV V?O9P;Z7G=FYZ
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MT+OL#E-5L&7%?5*W_%E:^UEVZ[AUEO(U)W_@%-[L@#:30?H#H#R+Z_C\KJ
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M'$EJ&[C2G!G,;S.FY#A]OLV3&S".V+TI[J[>1%,^ Q//:%UL^=OT<RW$;97
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M/3;IGS%^5H!/8K:J?W:LV1'7S&DX/)ZP!6VLKH!Q[[)VGT3O,G\>_0
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M5H#GQ8GN!*9[@-GW%T_?]K]4W63VKEYI7[ !&LR%@4KJOW3U,X[8Y9@3X
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M7"CT          !8[V/A^6A+=<M9'CY3%$I#9LAI_!,WKM%<MYTA-BR!@20
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M58N90W+<8R<3(<?)Q;)PY=BYT>OXLDQ\K&$E$S7#SQ#LS!O5B_M)K.W_ &J
M     ->Z4G1<B<5J ,?9\9A:8@=I=9V_6+9-2R/'RL@Q\G%4I#R3'RK7<LPG
M-P(IE8>PD!LMUM7KG;O37#S\$S>NW:U>C63BSW D;5=LW*W>]J5N%N[9+V/"
MLW E&+E_JL=R,6?8,E#LO!O=F_%\G$H_?C8"!V3 D[KECO8^:X:>E>+FZP;+
MJ-[LY&Q^O;2                 !%,K#PI,P$MQ,V_6,G\4QK)14FQLNQWL
M?(&!)8WD8OQ]>;[8R/"OF<X4CCN0B[M:O9W@]B^E0
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M>>^<*O+L)S*HX)L5392R31/@ESMNBKM>V*B:UQB"$G$Z-HX^K#=YV*M/X4S
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M?$LE!89RRG#Q3I%(RS(56&,'1"39$K(BHH^#WR?-95D>W+\"6JZ-\2]98>3
MF2-5P\O3EAE<4Z&;JMB>V.$=78Z'],$"0S+')[MHKV0BL8TCPM2.N9D$;9%Z
M#\Z#\FB;'Y <_MR/SX71NZ;87->R&3)^;9%5TSD%<X9T:^LB*14':K>&X(ZQ
MGA!&V1>@_.@_)HVQ^52D=$Q>:H@$_,@)TLA39.;@YUQ@3T'ECDDC8-)U989E
MD4.9&PQK&CA97OB'D9(@,ZR. D=DB2)*P:>'/_%ID_N2/+HB^L+XV$$DT,OR
M!D:AS\Y!IE%<$3R'D-FFX+8OVH?@F5A7NA?"2;TN]RS.M%Z^O%RZT74]PSH*
M[DJ3P.3KP>A9X&IU8D>V6)[O"R*]J*O@URL=TVD-2)L"/>KW<:93%=<;@ED2
M*-SO3B30JJ3P*Q2($8LT37=:+U03L(CX#R4$&<O/Q8Y6.6-L[4B; CWJ]WDM
M544 I"QLD=Z(XRY%7WJ-B<9,KD-CY*<UJ13I*L4JOB0Q%1#HE7WT?I]XWTJ=
M%XW9?0&7S BG!D12,FC\MRHU+,U3B/&N,]G.BHY,?U8II82)<0=W*,>:*-("
M>OT94 E9,1CX)I8X1I$E>+-Z/:S]4>":.?%5&I9&^[G\!X_6^5>ID7^WA+$:
M[R BG"3QR,E9XE,=(.[JS8HTSAV#2K)(-+C@R%QL$R%(B)PVIONY_$=B/?+_
M +F1?[>$,1CO*J3O:3X]OK8V)&QOK$>B#<I/8_ID%21&Q\I6#RLQHCF(RO8Q
M5&YY\:SE( CXD3DDLC(8S2G%S^;56:A.:YKV^5<6O7X47*BRZ7GV]EU,5?$5
MR(]\<,:L9 ]2E3GY"956/MG>=<66*O *Y$<^."-61P/4IR>KRDRFLTY<+Y)G
MQ+,J1)),F3/6->!51$MK+W3_ #ZZUF!48N MG'-/".RRN)"^-%RMM^GB*BIY
M2JB)96_KQ5X$Y\^:-C16JQW-%\E%RMME'QKFO;Y=E;XJ\*<^:JC8T5',7GS\
MM%RLN4X?;(K6BL3)8FS-Z"\#WMC;9VRE?11RR0O&V&5N0VX$V->Q_@YS6Y+:
M 0X3L2KDT\Q#O(1<"LYP\%L!B_)*L!A,-LYR\5>$5/U.EB>K98FJ4B>6BX'8
M3AJ)9C%^22<,(AUK,5BKQ"I^ITL3E;+$U2D3GYH-M.)@IPQ:>07:BB8;83FN
M^F];\Y\_.1V#VYD&17T#L99@OQ"1EQ21DQ]F"S);X=N$6Y<^*[C@DZ;Y.HF1
M]1V$2>MWF<\'M2Q\BOX5QEH _$*&7%)'3'V0+,EOAFX1<ES8KE5>."3IODZB
M9'U'9/)U'^<CE11[LR'(M@%=C+,!^(2,N*6*F/M:^/)MAB3";8PG.?T[86J.
M\'TL]M&Q)HFQXX2=N-'=U_;2^AX,K9.A*C/)YYSSGG/.><_)8Q7N5Z0(V1)D
MD8L;O.YYSSGG/.><_*C8LCE>D*(])DD8L;OH.><\YYSSGG/ZF-4;)[S];R1Y
M4DG]4B%PQR0R=)ZFQ=-#F)DTW5;]/#+TEZ\N=>7)9>K]=#+TLZ\N=>7)9>K_
M *<B:,Z+V:*K!8^I[9?6P1GIDK9&82/[=RUS_2T:.1[PNDY:QSY&AM]/LU7)
M61MSXYV((UR$Q1QI](UKGJ4%*'BTQ*-:U7N^&?S8-,^/P8/*^'P8WUOE9TI,
M$ <6PBND@A+%>))B5Y'NB86CR\$ KR(VIS6>+HR^0T.5T:T[\%KW$PSULL+2
MAW"S^W>H_P#!6N]#O=2>M#'IC3'M3WC_ $.*5RRSK+BGR*J&*W%,<Y5->YWN
M'\D+E3))O7GR$GJC(?&V:99OI89Y!WVKG+'&R8!@Z2+/ZX"#!Y911'%/#K ^
MI&^">2&M]48N0^@>!ZK)#R2*8V:<AE9T?83&"M$G;(MC82_R;R9?FXI'*U5]
MR,XISK=A3WQ63UG"K/\ BQ-=U7-:VQC?*?*1-'(UY,@L7.(8Z:%""B)HY&PS
M-5L[%CF+25"V.'++&;!'7.,&]%PURV-=^(W\%@C;))TQO0@8Z.0<=R.&@5%!
M@]?3%]*#1^HR%L">V'ZT(\3D]I%R8./+CH!U8\"%KHAA9?IWDS29\S99^6?,
M6'H'-)%60B:6-+4]&PGE0.BLC88J\B.)3CFJQAI3)R"IRG,(ECBQ+$Q)ICBB
M&+9FJL)1$$DQI,[_ '9'N$*G:CR)9(ARR!,ELSIF^^*0B<TDATUD9/&\F9Z-
ML#&S3F$D.FLC)XX[0Z*-55RS$I*.MO8.8A$K8456K\S98A?(7^"P]7J_]AU/
MYSUM]QTU]QR?\CS']YTX_?X1[CFOR/)?D?6[WV2>^]7\QR=\AR@][Z?] ?_:
M  @! P !!0+R>><\YYS^MYYSSGG/Z_GGJ3/5GJSFG\*YX5:A"9/M*9)L5F_%
MN+-<2XLTR/8K-F0;3@MJ"7G/Z?GA5B()D^T,3)-BLGXMQ9KGR]DF1[!9LR':
M%P6W!*SG]5ZLLMIIJW#.XS\FW?89<7:=@56[5L+%@WR_BP/N+ [*Z]J[3.?\
M&.LA@&G7IA?D@WA@F V8Q[?I##APHSM@*)S\_("N3 \ M1CT^F5>67>RUU*V
MWVRVMO(15:M/O%D!E7< VT'\#M[MH>2223/\J.1\3ZB\:7]':W$8"3SRDR>4
MUSF.J+U",1?I%7-HW) EDDDE?Y09I5?/K>TCW;$7G]"][(VV>^U 2F;]>D9-
M>W4^>^-R*ZMX,$WK8!EK>X-:3D,T)$?'=V_LVJJJOF?EE';^[;]!<6J 1/>Z
M1WFT5OUT^B5>6;EM*A\&OZ_-?S?ML;FP:M/00U.CF6M?9:(76@\,,TH\NK;&
MR[&\^]V("BAN=BLKM_'5W5C3RZ]M05XWALCF@#22/FD\Z.1\3ZP]IXWG&%1B
M0$$2%3><USF.J;!#QOH=GO$I:][W2/\ $*R.K7:<3>6I&RWDEY83UMJVBV$;
M;ZX4>EMBX=SIYB*\H,H*3QKSR*PNKL8+0+S=FV2&A&)*(-G\F.22&34MI2XB
M\5R].]V9XB!D&R1U(X-9E+6^_)V448;*>O$A 0>LO U145*LE0."C.]F8GFK
MFQ&]8CQ&&G+D IX0A&M5[GPU=&-=5PK@Z*M'?!"VHNXI8G0RP59) G!4&^Q,
M3Z!R\LV6W6XM.&T;]O:0.R62?8;#;Q4J")K+3:O=+2I!VG8#*0.XN";LO@T.
MX44Y/,M+&"I!L#R+,SRQR)A9]?N8[RN\+4KV@7 !8S5^5DLDU)!#(1+/-'5-
MVS#/TZQJ>05,!YB5L25=O505\?!4%>[!\PPA!1G.5[O$ ^6ODH9I2 *Q$6PV
MO_SB_5K(WZ=9U;_EOK83[@6NB' M*:  ;@I"O<@>?N-E\?2\,2L;+M>T#7\*
M*K5%W:K-#V'<XS@L*LK UG#%(^&2K-;8 ^7O]O[H_P 1 BCY'L?$\?72I*BI
MI!C@HJ:OD.^ ;\HO+GXZ7;_&6_AM,_%4?T"K-: 7'L(<\]^;",.'RM*"E#?5
M"RR=65M@&FO<.K3_ *O) M!+%_ALT_H%X=;_ *8/+T"+L&6SAL>5=14CFFT]
M%63UZG3H277V <--PZQ/Z9_*K[02S3Q7\NXABR'_ $7;TSJUG&):"&$^!A+
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MZ])\K:P]5RP'-W3R.(BN5 ,Y,5J6(IR.X1((-D3H2]N#:;^S[XI.JTI</5(
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MA>G1Z(I\,J',5?VG#T?996A70P5=YX5(WJ?&19%VD@,;O$QPQ5I'$^PML/J
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M?&=%K@[6!Z$A,32Z6GT'QA*;T?F=8?/5]L+*]8.K#U6;1\!TD0F PX3/4/\
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MQ4+0:96^TBPWV6Q5>M-Q$H5FZ4:!]WE^J5,S<..NL/#R/.1P![$]');5%[7
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M;350V@RK,ASD)DO@&M4J-KNI![2:?NG*V:5KYE)2Q94FLNVH+6R.:*5-Y,[
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M9\CV#?;M#H^Y1Y276#A5.VFX#M@>\:,+PG!S,I?M)9E*H0[(,MB1Q>+M\&D
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MGJ4F/.3.XIHSP^:I1I;;PQKW%72%"CI9="OX8<;H6:F:@EF;M*R<@"96RWD
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M<)O38-Q1/DS;='%%3R*L!(1_=K@0OM@44^5)M4C53XH<O3_K\ W;+RQS1Y)
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M47Y,>''^X3X/FGV\5\:EY^3;%/M"VB)BJ7J4O[]&7$^]<:(<)NNPYO\ VB(
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M8*9(G#X)N1'<-E]DQ<:=;)0<;<!:B8$F8D*X\-N1B%ZCA6OJC<& 3-\$]49
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M;D9Q>"\17)?/B8"+0I\B)"1>VBN\RXB?OFHRI\2^_<!J1(:;?% D--/NM-2
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M,5\N'>J+&Q6Y,MUNT(,BG,LC_.V1IWIC+8T(?Y0$R[R=[X9KJF_1U&>X-;/
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M&]-V;GX9OEN,;@^%1(,*/M+R^D=;5O!3JA5)5I3*DQA;K>PMDPKH[X.U)B!
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M8>>>>EM,/%[*0?=H6:\4I1?#;B=^<6\_I%EPHMJZ?>8C2+V\J1*6V7(D)1J
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MNR-)-N"NMW%P4!R4S*.4<IHB!***%HIV8&X66U<E.2"5O.2,R>92(QO\T?-
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MS/?]'ZPP\KZAZ/\ \![[9RN Q)V+P'J]OWD20 F$[ 4!&Z<"V2,[=6Z9P(
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M/;T51DC.H8DVAT9(0<H67L0W %<"E)EZ=#OQ_I\V'$>>^!& "$I@,LO<"[J
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MM^#]XT;N'CX@QPQ(>4Q'?M29>JGJ2DX6.8#,R]QX$OY^2T2I1K0*])22H(R
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MSFDA'G9N\G^';L8DB:-+A(>SFCW_ #_P^'Z?C/\ .:'M\#1\/#..:F<K]24
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M0*XR;E/T' AA) 1!L?P_X)/A"!U0C'!0^TY-P2;2B1$V)Z[-FS9LV1*Q9/\
M *),&!4!.  /@54,D+TQ< ,80HH)2 VX>O0+KT% 1.A>5&\ )@"66")>KWP)
M$7L@O,)Q!(01V-CD#(!B)@F#1/3 #0$LL$2NWSBX232A2>BZRLH-0((U!JLA
M>EJ#Q)7HM2#,$./0!T5DX= >0C&=D =K@EL+\5J)!\5N[\4N)T[FOZ_<'%!(
M-U3P2##5I@ !DR/K-8K3;EIHB0$DI#;AQ-5Z*?I\A%#@.+1*5#+^TK)\QY %
M/C'UFL5IMRTT1(#X4.GQ\,0Q=G=<C3UGY3Y+'+^("!,*:LZD?"S]GOI(_@8V
MLB5APH/EUW_2@<#BMRT) 4 L"RN"N> ^5L1S#/58*6AU4-*<_7_# A_"8@O(
M6*17'AD)@*FH6#641O5[./*(2$"-:FPNK!?L'0H7A[-F3X?7^H-OJQ8],Z(1
MT8T1)X73-3H3_)_9\HVR6],L5"C(:#XWGU6HR! [D3XR .M/>WYG%@1H^^=?
M P"@!58 M5T!RN0#I#T D<,M<P."TP!T^:QK -8MAX4S<]IXT HEIZ&A"6IQ
MMWF,*^5A;M,,D.&/\R.W!Y"IQSL,PMEE.[O\E8G5$@1C;U)\3D9)J4]P: "3
M3EEC#D'DAV(00 C:,@D*CZBP>(+2-A$#^2J@8FU#VRNY$D8 9DJJ;ZVOA+\8
M)*8V-+9? VSC$K(U^X%"(.KBJ$QB?Z@.T> D(V.0M75-AZ,Z1M[#.Q#'E_YZ
MP.L(P,@0P?90!\&JL<135-L-WBDJ_),741] 51EF>Y1L41$A08+4(07)1RE%
M(A9<JJ?!(@:01SDI43@+Q$1CX@?.@S48DDE2A#;3P:<X>"6P"!LB(=>*ZJ(0
MPY])SK 4$%THZ!'1D@N</C_"?G$&".MFPG&17\4RCB6N =@QBW)00RVY7*+$
M4_-4\-=DWU-.,--#E5_$X'6 R0:O_11T#>K+!C#'O%Z;6^AMY&Q(F.J,RIQE
M5.I8'W.$R<T%8G0LY!+>XG);:AY-ZRBC-YL('\9A]P"8G:9==J;=::(M X$4
MO_5B]F#G#/8VJP \9#C]8H_'BGXEL+@"K8^M$'7(>-ONOXQ4S=L.=0;IP%?@
M"/A)'!D *" -JI &)4=ZC!-"U#UJ-M?9IR32RT*E1!1L;8FBT3=$0]$=/I@O
M6I+-6!9%3C'%+<+:'5"^Z3#M,ES)J.;&Q3R9^G;.S8!B\+/DGB2K#B.@XA3P
MR-D7CNSI(7M#.;)4;._&*A2RF ?1NKS?N:8@@-#)9/I?E$)L\J2.'62(BZ>
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M'!]6^EI#1FI"E*!)7899GU"HB)?BH_?@GZK[M5,?T$;W&#=(KHGP\ST8<?+
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MY^D-A*:#D>K)SQP*KFK& ,H,.[%A*<GN'&*0B4B[&L=FS-H+-WJ],X'$# Q
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MXH@?AJ6O"$CC\9TH9F)S204!AAK3!CB$::O2 <;C\8A$8RG8@12$V;P$U!"
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MC\TS:+[Z'*^#_,">#^_5>[M^>_ 0A'D<0=17;IYT^SSC_ ,!=4.W]OTEXPR
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MQPG;^\9Z;T.;.(6HUU[XEZ,:BG2:K;3XPS%'!7JG0S<7J\G-9&;4LJ0L:O'
MBZI$21LBHX,48EZ,:BG2:K;3XP+C@W?4Z-O);DWA= B:(>JXZ3<;RV)TN6T\
M6>[WQL9LK=RHBGK#/6YRHI2PDD!--_C)'\L$F0T2=/MK>/2#LS/_ +\+\O\
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M8+@M!X;X'E\H2WIMM]X=>QOL.L8\J<3ROST>#(G"9%X#P!_3OLK8_/ULE'/
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MB03"12H$!&('"<G#Z46_SAQ3*E-H:ES_ -I_S/\ VG_,_P#:?\S_ -I_S/\
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M8$QR8_=B>SX.7DO=O'E^X^*GD#?49Y4!W< X"8V"2MBN8HA@AW](@ N85AR
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M;W"J['T( 4 !*K0 ;7@RJO$W/Q?>7&M"X$'SV<5 %1T!IP'BT367WR!UTC_
M#7R.) 0H.OW$!C"%OJ_/[H(XFWU2><%C&VL_4ZC7"'#T%$(TCT3Y9@U; &W.
M[$_&_2]SAB#SZ(D(ESJ.^=0!9@_X=E?ZR?-^OZ=1V0Y![TFH^4DY"$WC7]!W
MZ?NQT#(1I'Y8*P;Q)[LW[&2#TP<P&9U'.>8,(_\ #HE_K)NWW/Z>G81R)"E1
MJ/F3X:9.1+.H\G+N=15%0TGH5*%D$$DK%&A*40:H!'9%6HP3& - )GDJ0@2=
MTX(&!>V![,ZZA<HGT(]6BE.QD!5'4FZ/1[-CGA[C^#N3B8>;TG"6<..HCK>
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M#00<00'SN?5;9!24F4FN^'D %*B1$=(J,/KK[05CJE5ZGADW%UHNO1>L8_\
MH+4SO-'AOK$8#01 *(1 =HDR3[B@#!"^+^^<)SY+!43;A(9J(Q'F7L$KI$:T
M3&^<7OM41Q))0\M/$2<NZS0H8NAF$0^XX9#R2HYF[UYP@:':-4KN&8W<]0Q,
M)*K8-'-]WCJ.%"Q#8XFXO4^^ PD*""*H'2U?M&2T2X 7RG3YAF8P(#>>8VB[
M"NY)B:Q!$/(BN:C3X[\8O;83K&4PJ(G\# V@JJ?"JDC,;9.F*DM)I0 XCN_H
MK\I<S/*B%" $19.1Z'65H5B;_M@F<0AHED(=P7NR7D6(78=#/XPY('JB!FD,
M2WTZ&#!>4M-SN]6.1MBRT@B%M!M(J9"ZO&QDH0@#(T-UQO!('@PTF+@['D+;
M@P7E+3<[O5CD;8@H&U89V!#AIQ",1],,92%P@[HJ=5FKX:2*" NRC@CMA_X,
M.RD@3MT#LX1DAUPG 9HPF0K6\ 00JD1=H+SQSO6 Q=PP]K4[3\?_ (T7UQ$(
MK"X)F.=5./>J5ZO<5"9#;!YHZRE. D&R$)M349=& @SRLP>&$\U0$E"Y(*:,
M3,M9#RC9(*-6":6G48W0DA7(- &]I4# %R^@ ="3H*XT!/H 9260??WP.OBN
MF0+(4FA(8"0>%*A312*01<+$-F043:<@<%".)RS<+B 4Y ?!%\A0S2@,A" N
M]L=9(OBA;(H4QBZA>6#,*;/2T$V9VDP1)-?QON@)!+OJ>$<?!Q $K.&3,Q_B
M/;7;) IPK=$A(JBNV0[G+*F$45"#H'?"KLLE,NT*+N1'$8T?0.D(B$DKE7OO
M&$G@ 0Z"#]KYG)S+2T?2 !PG8KH#M[3&QR#D9E583ATYEW$K>_G(BURI5.Z*
M_HOKEH-6#J4,/N/P0OIUH]BAXF.V=5X=LN2"GD3WC-8FU="L< :C4:K"YQ>4
MPH@,/O?.#2$ET#):>IYKC/&<=)/W"\3NOM"'7@.64@U8NA2P>P9/ICP4[]AS
MG)%"6A+;+'$4"DDE"K(3!E;GF-5@]($3+/14UVUAV/S 2W!(?49&T2>8OJUM
MX8<.138J4<U9W'V,- <^7QA)DW6K:O#L?F EN"0^HRU-S!1U -WWYP^0" *
M-!VQ,02#%*1N1VHX<@$M,*_<A[,G;+P;D44R1/4[,LR)'P_!R<YH)F61-K!K
MM]W_ ,;ML[&Z]YB(N8B\:9Y_SWE69Z9TS\R!MX*B:1>YXRY3>\+X:GMUS\H!
M_I=7JCC.]=T;DVJT3_4SLE?=8XK3'][*-#B[OWWU7;.B=#_QW'MO.R=[E<O7
M[L3>=%O;S'GW::^&5ZM']KQ@>8K/$?87N14XVS%$^%'O3'6'Z%OIN>R1YO!;
M\O?_ / __]H # ,!  (1 Q$  !    84"S0          ":02H         !
M^@  5TQ*                   "DKH^4         2/NO\ $[@       #
M E)AW@#$                $K1;;;Y5         W\   !70       0 UC
MDDDAWH               $7+;;;;>P        KH    $CP      " VUDDD
MDDNT       %R*;@   O#;;;;;?A       1X     $Z       0%!D:YLDD
MB(      "\DDDY  JC;;;;;;;1      G8      'O      "#.DGWGK$D50
M      \DDDD2 $C;[8M5;;?D     EH ZNOI( !       4%DDD3)!DDJ@
M  ",DDDDDO ';=@F%K;;>@    &;  Y!H?( %      "EDDCX>BDDG*
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M    FU     7F "ZP   0"ZTD,QDB@        8/G9X   6G;;;;2F %-X
M  %L    $*  ?P   " "=,DDDF[          98     C\U;7"\  :Y
MC>NE7@H  '5(   0 $WZX2Q)          %_0]'   $%!H,   !+P     $A
M!HU0   5H   "   5=;*D           6VZ]@     D     ),        @
M    #)X   0     @                                   Z-0T2/JB
MH      "   5]8$ 2!='0 %)    _0-                  #?L<.GK[L
M     0  +_$>A@ZE7D/B$6SEU+GH0                  "O$KG^VOP
M  '_   *Z[M?8^@Z'\5P] K)1GF0                 ! MS>\3]3P
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MO6%"G'[BY$& B 9",?$\"3H3A,D"("089(&YF""CZ)1A:(R9,3Z>WN?%U%;
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M@O()H@KH ZUC*9,22@8[C)Y+1DMG/51_N<[^3F'D>]%3(9+1M&+OU3;F ,Y
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M#2K"HIJGR3N4F-L75,<DP@/AI!0%0/>C[T<21\-+EX0?DC6I",PD>KDBTG.
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MCB[K&C&E4SW"ZN.IV^/F!(QA\#0EU;4[C"Z.[X(EH$<;](]5A0Z*Y*_3(R@
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M<[-4E(-5CT2(,Y("$8Y"213A;ZP.F"G$1U7?4(E[OQ>JI)!4 N)=DVC!X:A
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M>#2=!,3^0)/T, $(V/H+A?TL[ Y*,:9*BC^[E0C83.\*0#Z,Q6BF3'B3$?"
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MV&!/'Q4=?OE_$=@N.I[$UX# 2!SEM&ADA2039'&H(,>X%MW5/PT 7Q88Y!:
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MQ $@(1'8E)@$+.R]K;RC+E%(P(WOYQ\!/G"22"P3*@FE(+D 7!#0P" $ !0
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M%HF0E82MIOL5(9)5(1&(H](\&(X$\':;[WGX!EY3\$ +V%^WQ%)3P)3P*<.
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M$[ 9H,BPR B3+T/1$I#UP8/I:'1&[^-_0Y*.,!VA;RT)U6?%&U2O-* &TJ-
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MD@6;<"OT$9Y,B000"1EI_P!&)")4"1=TQZYPP%IP[6>.>./:Q;;CB?7M[;>
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M EH QA86@,$IP21*8H0V"7:9)QT")1J#9+  63!=*+R5)EU/.-\!9< $<H8
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MLD6"2RD2P3CI!,^PYKF5&-C%5EM?7JS>+G&ER7>FJB"-%O-VR0.YLDO/8"F
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MK@ E0 M<F562@P:35XA 31(4\.@B/AWP$T#>*E7CR!,281)*&-? 9#R2**"
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MXOV,N$1"HD407 2<D'0BTBFP S GIG(H7L<!@ZT+27 R"@ FZ1*] X @"
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MU.$($96#A!H90 (-.M;DC0*R@E #BB<;>L&CF@RH##62=+XP^FD1 "#HJN2
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M9'@56 3<668" N/4(**,04)&/:I2G"!'\4 QO@OR(!%J$W*9A:)HA WVP8'
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MB)1!^6L_8Z6<J<,%):B4K'EE]!@U; %JN@.5Q0.=PA/V*O6"Q,""#XLVHD;
MEPY2!V22PPFC[DG0!&G.QFX@%>]R+/8 0>NE0Q(M\CM=F,^Q(=H%E5^1S\ "
MM.0SA,!)!EY0#=!)/'YJ$1(1*1&Q&D=88$*3 IDPQ-)AB9AQB4#!OVT-2 D!
MCC&-*:)-69TA)?D>R=ZH]:()BEGB+[K5@5"\HL#<E-\ 5M@ST2$K]Y<@(L6
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MATC=A1G@V'T%J+5PT7:HC?7 ZMZ!+:K _#C#7!GAA(43<!/44BZ.W:;%$40
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MPZI4C;@?F(@.@@3"*$]+;S5);Q'3HM-8PCH0F L'*B Y7+R\7[:]D.Z9S\E
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M;*0"L&1\(4W):RQ0;R1;@.,$%B($J<GX:@+VY0%GT90Y%8#;),4\2W.2I%8
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JH/:]ZCQ,?42HO&&V#]*\/Z(B;G/^G>MVN^6>K.W#[%]*G,B*U_\ @/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2113965d1-pht_expert4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_expert4clr.jpg
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M8I*R,W.SE'46,%#PL7*"HN)#-$1TM+5V8/%38R5%PH.C9,-4A,15I:1EQ1(
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M/8NP)3BF)Z)1')7(            \-(JRQ-/KF0)"()P
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M5ZQ1<_"N'$S[:57E3*2%)QIP5ETW/#)":X3$P!BOI>%R'S_85&UE
M      #71/S#*OIX4\A!)$$2(RHG0;W;XIWR\9^N+ZP-[&F=9NN\LTW]1\!]
M2? ?LS4OT+R76?N_,;!W.E]0?!?I_,.AZF:8U/[7A<,=)S7EIY+['Z!33ZPS
M3, =5'QYLCZK5GY&5WZHEFXTB!$E1?B/&97L@GU94 #PU7,KJ/7-$*5C9NMI
MFSTN3=#U@&F*-.44B9X(>F^_YS47TKQB_L#:=.FJQMUSDE.74J+=<U6SM[:8
M=)R,'-7@_P!+82NL1S-^VF/*)ZV4[5$=BB;PNT[@T3MFD#%?2\-D/G^PJ-K)
M              '7/DT5^U2GTI0!AH\957OU33K/W/D& >O\D]#/&_KC$&ZX
MKSL]Q^2_5#YY^W,4='Q?D[]%_('L'\R?;?:HJ\LO>_FWUJ^>/J2YL7.\=OH7
MYL]/?%O=? +1=-KDCZKU.0")(>0ROSG/J/4?..NY[6_<!$P+23X&JOH)4>%J
MK8]5ZLK8 \-%S+*GUR4PI6-F:VF;32Y-T/6 =(HAV$8K,P68I-_%EJCEJB28
MGM7^2NF2Y-,IL=VBY6,;,Z-Z)$U!'3M54RN*I5'3B:U5'-$]P Q7TO#9#Y_L
M*C:R0             ! UO/F07?0E&[ZWKJGR/5>V*CU@AQ33Y\>P_*-LY^E
MPYU7$;^>(?6F+.HXO6;O/+M[/'OHKSW]C^>=R_-/<J?8O:;^I>4UG7[O:[AN
M_P!X_-O4?FA7LL31I:GU51DTT+3I,CZE%.<S&2?F$5;''HNC%IY&KOH I]XU
MGP?5[&J_5A: 'AK#+,O7$A2L7,UM-VFER;H>L EAYWV:^+(M\<QT[4[8W)P5
M2H$*A6[2G'V/-S9M%^4,#VKFU%=.D=B_FV_8K*<G8U>G^58RQ9OV?>HW/H9P
MF0!BOI>&R'S_ &%1M9(               L,\JTZGJ\PTQZA3&SLT@=13@CJ
MO-M:>_\ %Z!?QLX\IZEM;P'K_?L95I;#5ZA^B^.X:WFNO##V>WGG7I^:.?Z6
M=/S.S=]<E&;D>543AJ&TDO5F:;_(@HAY=3.E%,WC5'IG$;H$YYS15E:*=OB:
M4\N.'G[1%[UMSIE2L3-UM+V.GR9H.J A#%MJNS+]%'1==,WO4P@<=N<G5,9S
M'3L3;V9;S[:JQM$Y#F+&L5W;D44M-2LU8YOV\CVKED5TW[#-4@!BWI.+R!H.
MKJU.2               !:&PTF&-US59LUYQY;O>Y=        ?,RN^NZC>]
M3@3H>&I-W#REINLOS"W$Z0!2[56N/9>75C%S]AN6]!Y+T# 74<';]_"V"Y/T
M.K6[W)+IX\ZY=QYEW;&;L9RG?PJBV,C$TKZ_@>WCWH C)$P(D!( $(05101%
M,)1B$D"0(3 1*1'#<L;Q\3Z15JJP               *+=P]<>N\ZROI.NR=
MI^BG2       !\S:YZZJ-[T8JVO.8QV7.; <YW5>HS.6  ZMBK6OO?*[MTG0
MYLT78\M08;WG'V)L]+LIR/I'9B8IZ%J==>R\RKVNVF>M%V\9F"$3&8@1! $2
M  3%$  ") B  0  !+$CDD               !PHP?TO!9PY;ON:X
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M=                 #B4XDZ3C,D<_UE7M9,9      $8HZ+BLEZ+L.Y:O
M    "6&'NHXC,/+]O-(      #!?1\3G+F^VFD          !A7I.)S1S';3
M5@                !Q*<2=)QF2-!UE7LY,9      $8HZ+B\EZ+KNY:O@
M    "6&'NGXC,/,]O,       8+Z/B<Y\WVT9           85Z3BLT<QVLU
M8                 <2G$G2<9DCG^LJ]K)C(      C%'1<7DO1==W+5\
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MU;>^I:!B9]P.TL%=5O=M;<K8?8DL])F0S?[A-OL*=H/NW3:Y+N/G,;;O$?\
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M'G5 \ZH'G5 \ZH'G5 \ZH'G5 \VJ'G5(\ZH'G5 \ZH'G5 \ZH'G5 \ZH'G5
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M60YC,',IXYI/'-9HYM-'-YPYM8#F]@.;V YM8#FU@.;6 YM8#FU@.;6 YM8
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M#,B;,^'*HQ=Q/9>9;1<\X*<EK G,G"%P!$(U0CY.\IC'@^[!@LT" .0Q5O\
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M7(N[9K[@64V+&;-%,;7*\*NEQDGU$Q@BW :3&*;*^&M;9$UXF8J#1:R07O\
M/:W/W:VWS2='#'AX$UT.5 \&#A&PZ8'0&$8U($WGN$88L6Q:%3'@]U!YYHV;
MV9[;=N3N8@I=U,MK;F;RPUGE.#' 1BA/OQ+9S9HL1KK,<D(*\S96=][ST(MA
M&S ?2XE>IESY%Y!8,!,;0CDJ)CBJP(ONW\F;K*,:(QA&81@C4GW._1-XF2VN
MP4$1KAA,:46RA!C>3T>3'?AL15N;H:H95*D.TC6C8N\[R YS8XK0$.\K#G%Q
MFU?/?4$+(!<#&E3RYHF7@W.:(4X9C<4%*GYCW><)C0"+7!27!.;*>7-'Q  Y
M!9$1N)Y^$'UGO,P3*JK- ,?)BF"5:=&:;6:LPC&FT78,04S_ % Y>?F!\*Q3
MR0<E<4[WJ F75YF<GRHQ<6\([J<#&U'OT]S8B% "ET.^F2W8&J&%2+Q", 1P
MJJ!*DNFRF3VC.1C$$-C3"$*2K4ML+H+F3(#:XQ;1RO*!M5T15W:6NS]AT;<+
M1Q1 @I#OB#(7T3G#_P#%FSW+=2M7<_OL\;6.Q8$-ZU%3/=A__4+66X0WX;\8
M\2F2BRU?G7651N0[M::PL_?MNO)W>."GF_Q$TRABC7ARP[D%-E3[0^'F2(&B
M%NPVS##%3;A %TUK;,<+PUO^-I&S3=A0P9 $)+6QB11OIK<3=I9I@H^2O>&&
M#E8FO)&P&X%9&TO0FBA\C_)GC4)4P-<;Z=VSFVY%>)MT;.]X=.IL6(V?[L"O
M4X>KG@2XQI-,8DV:(G#!!LTO?=9DB-3;%+8T>42?^%=PR/N) MFBS9M&,<-2
M%YLBS='.L[D39[O<3B</=V/5<E[L*DME4O)=:/\ :>SQ1+Z&!&6.:H"O8HVE
M)5O K.'9I&3>4RR#35P)V:Y+SC4"]KW[A7UH[RY#@'T*V7Q:X&.^GW.6*"1'
MZ]F,.#PJ$($-'>\&Q[S? YMTK\[Q<"@*MAUWF\QP3FMBZY5@XLG>5".."DEF
M!W*7*I9B5(IQY$?I1[BY%9F$G@")=SJ8*+&,S]B%HQH..M>LA:V6WN_VFR)=
M(;](Y<FRZZ3^8Y'/1?(:>0[C[BIK1KAD1 812.\G"=3RZ!D@GN80,049&DLM
M'VJ>XN2(XTUN*K(O=932*=)CIC#YA6'TM%1W=@-,3,)P4]Y-OGQ)MFR8M;AW
MUEV#=YE&569[39M4.P%.>XNI95C0S L/%62FM.F L=1 5X1!/<VU:.%2IH!S
ML#:X"K(L"[8J8KD%HD4[J!#O5032\-=+AW:(*+R&PC0-VC&G,E:0#D/. _2\
M":U@,<2]\OE#QS6^$[&]LT5J+C J#ZER=B.!6FJC8HK7)/*"BZ%C-]V*<;/K
M+4!CA1XTU\2"WYQ*A28NCPIKG-$98@(5UQ3I(%B)B<O_  HJE9F[ NG%&?,-
MJ^3*\F3LM2J52@JES0N8%3+!6A:J9#%$7=D5H&+0,6@:M"U:%G M#+X%H)?
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MFTZ2"E5WA[4 1':M<L=6+KC -%\-:9Z."P\BUJJ(YJT(J;##&_BENI;2(,R
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MA$ Z*]*?WJ.1WGQV(%$;JG?9XB2M!-=9C,2-V??-[YH7-!?;!JIC@G]&W?\
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M;'E*7X,?6QY2E^#'UL>4I?@QQY2E^#'!0YUQE%%D"K;XJ ])LLB3DPT-$J
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MM#;&.Z)"K3VA:*IEG1<\L=$;?I7EZOR]OI8_[?\ F_\ .Q_8/S?V<9I;U_\
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MEF0K3)?=47EHN65<=+_=]9.Q7#$UHB&.3C8SFDV.L$: 2Z=BDTA5'FP#@EJ
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MZ[_^ LZRO95'TJVO"&\JM-=-7>]1!7UN8U3JZX"U@I!(""6*Y$^"SJ>\06[
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M+*NQ;=YIB-#P>J;94Q*I47+S58W\^$)1;0,-MQ34.5*1SQ@=@+44LV":3+J
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MV/0]Q1;->3U$\SW3S/9GF>S&AWKJB_  >6Y$N#-C,L=RAMX RP (\*[1:SB
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MVOZ9G^K/F5-.V9-VS=^W;MF[=\[;MFM#IKO??$Z4)2^NV'VF1/9[7_Q?I/\
MA,;MQ1H^!0_T/FW23G_9S\O-]_\ B_2?\)C\N"-'P*'^A\VZ2<_[,OEYOO\
M\7Z#_A(?EP1H^!0_T;ISY_[-_EYO^GGQOPLZGO.Q]_VE''U8_MQ?3)?3!\C^
M3^H_4$<T=;O[DK^*'=OQ=T*W!ML+>6>X6K6,6R=B];G"(#<16VA$3@JF6!5%
MVO![JOPN6KJ#.)A^351V&SN-/P.H7S] 3S7+\$7(J=2G>2,9S40: J3*C39,
M4Y][-6BIP+,1WC-:K ("WEF7+C07I'0(]A_,(L."^E'CTBY:QW0/U+ZOVQZ/
M)-MGTE^"E90-77)R:Q*I&I:QLW$NU4;N6X4F+BLQY!9P$W5*KHE.'MX9<CR+
ME,BOH\Z'U9LR..M^-K5O&IIEQA/S4+[?+)[PNS/V\1! 6J@\RX)0HI-V!UT6
M"4-RY'*]<VXIJK!E)+Z/Y\-,->ES/7[(7G/93]PU#';CXK.LOO"HS[3'+W"#
MQ3[/WFNOEOZ7/4>94=[>A"[V]O!KHT6:7GAEM9P\HI(3 ]WEP>L, L$@[\D6
MZX+5AD,RY<6,4]!E];YN\M7"F[:^D.6?D_PL?=<XKY]I;8X[^?ZAFUW?_)29
M_7_R?NA@BL:8MSK-5;TW"MC; )@!Y>['92E=.A;-+P6R0Z$8;7P'D Z,HD$#
M((1A,587&H]:15SDEGF^7IX/S0>K/YE_I,3#0.\O.B0T-K>7Z=!F \-5N%W<
MD$(72<E$.5(,K66]!_4$MZR*HS@K$R<P:U_&BXVE2L%;CE4 2F5<AQ$,3*F
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M1QKI*J&V]298BE6],YIUQ&DJ)4(()!2PAAD+&!;\C"E.3W@E"F*5)0)3TJ"
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M.=UXE:F[.W,5-H- I!)>8Q4ZME@MN#GP$_T$_P!5/]1/]1/]1/\ 53_4>!2
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M-C9]@_\ ACPF\?\  !X#?I_BO?/=Y\_Z1W_W=N)B8E2I4J5!+1EB5<QS1?\
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M?!]87W_SYF9F9F9F9F9S#/Y'^'__V@ , P$  A$#$0  $
M                       "(;(
M                     R&O
M)*0+=P            /  (                              !)9) %H,
M-18KA(!"  4) *=\ SS))))(!))))))))(B               #=%X+[*/&W
MP(@.EZ(\P:)S6;DW9"89)FA;K/1]!)-8P              #Z X?(G*W#O\
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MPVVTTDDVWVR                !#         2"F8 !"X#P 4W@
M                         &P              "X $@ %D
M                  ;/220Y@ #FI==__P A0 GZYJ F).X+:W:639;9*2]
M                 J7M!BO  &?>22<.[<GN&;2(%$P[&D(! 0!-TD$Q8
M              &N@      /       'G       #@           Y
M            UD      !A       ^H       ;           $(
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M]Z'1\[')$3XW!AVY4PQV4_,=;.'I P&=-O5-<9]Z   #J4PO?7@BF[07)F#
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M!EU_&%HCGB/8%*ARL)P=U C4218QO:V*VE-2'%6#-]7-&"/%V>Q[_P# Z)A
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M)# -T%!OAO*JE@HE8SI9KH0:]+B#LUD\Y6*QZ)Z@@P(!4=07W<S^<_4^1/Q
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MQBD,!5)4?$4I%!Z])- 5@'0N7Y5%2414=A@-LO:KMJRXE%*=;F:U".HVU93
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M58>0065P=^_Q\3?N7\S=\W[_ /LR\SZ"1F[#]:_,U^OW):W=4/T#'O#(BJP
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M*VHKM0P"+<:**NCJF6+L0(ONX[DTJ?1CX1:M*C;+HICDJ@S-KCH<*AH78CF
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ML+!*(@*(U+ 52VKTH4A>)3=(B;'(]ZEB]:YM/F6+MU !FK0JT4;1H! &")#
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M<?-7K>)\V)\V)\^)\^/"?/B?/B=WE[H\G#V_:>]3M#GQ#,Z]7D\LZ_P?_]H
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M_=_:?W?VG]W]I_=_:?W_ -I_?_:?W?VG]_\ :?W_ -I_?_:?V_VG]_\ :.*
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M!'+:<::(12M SL0(NG+Z)4DO!E( Q#? #T@4RYC0NR=PA?1KL&GZ322]\_\
MOW^#N_6=P]YW#PG=!?6H/KW#]RGD:><":4J/$/I"S"S/65U3"RLK4PI2 JUH
MT=SF"U3"W>#I'5=H)L R@6F,^2A1B1!LQNNJ=R/"SJ#W_P#(98*]'WE4Y?X&
MX/8ATY2=)2;*&0S0=!8/E/)7-]5U[9E8W>@L5?5C#N2#:BVAR/E%N?Y(X9UQ
M^XU]WD?N4=W?)S$/R7O#,^2]X;L_)S/F ^L_#6?E@IM+X#'$P3?0^HOI&RL
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M_2)(9E3T-=)96J[TW576^W2*>3;DL5YJFKRI,:80XX#5H8X069MZJYAL1%(
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M_*VF6 J<Z'VZ39&)>#9YY'..>\H]"HBAVEF%NC[STT-1#3*2U-76TR*.!?)
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M0;C'G&JNA4W?7%PU/=_6 ,Q7RSZ3^_(6OK_I%_F/IX =.!U8'SA^)U?D.WB
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M[$L:37G_ ,)0).6D/<3Z3'H7["VNFPS=(&:(MIM16L&NU<?Z853\_/SJ(6_
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MS]E/V4_92]O/V\_:SWNTZ3JPW&!ET=I<U6&TLL1)OCI_Q?HO#W\NZ(:_S.O
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M)E-B=JF>C/1E])' M=*]?I AP@CHA-9@TN4"SQK"]+HM2FQ)YW#B Q63Z?\
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MK>2N;J)]7:$-5F=:;0O1CUU^V/SO(8#$FGE&:3@!O3L41""Q$JW^5I38<C)
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MAL/@ A=+.SA43WDV8"+4=07>;RIOO_.FQPN37/$ C(Q  $F"II2VX[H;26(
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2113965d1-pht_scale4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_scale4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ >@'* P$1  (1 0,1 ?_$ /8  0 !! ,! 0$
M       '!08("0,$"@(!"P$!  $% 0$!              $" P0%!@<("1
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MM\\E?L\A[2F](SRH#@')$B,0.2,4N27/CG'@/'D=:<,57#.4*O58\Y+DWO\
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MRLNZ7*EUK*J*F,<VVL>.W#FQK"XIVNLM<9G8LU.WFS.69R0+D#%F8R "B<E
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MT3\+YI[Q7;I]95UHD(_TW=X93.'_ )S /Y&KR_HXJ7;$M\\X\)+A=RH;&+U
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MFXF1,/2;<!*8W)ZSHU73*N99M:,>JW-^2W3^'YP.VT'7J.KT<K26]4=9>?\
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MC>:WBAW2UST:^>OCA]0&3_@5I\<Q7OO3O+I'I&\UO%#NEKGHU\]?'#Z@,G_
MK3XYBO?>G>72/2-YK>*'=+7/1KYZ^.'U 9/^!6GQS%>^].\ND>D;S6\4.Z6N
M>C7SU\</J R?\"M/CF*]]Z=Y=(](WFMXH=TM<]&OGKXX?4!D_P"!6GQS%>^]
M.\ND>D;S6\4.Z6N>C7SU\</J R?\"M/CF*]]Z=Y=(](WFMXH=TM<]&OGKXX?
M4!D_X%:?',5[[T[RZ1Z1O-;Q0[I:YZ-?/7QP^H#)_P "M/CF*]]Z=Y=(](WF
MMXH=TM<]&OGKXX?4!D_X%:?',5[[T[RZ1Z1O-;Q0[I:YZ-?/7QP^H#)_P*T^
M.8KWWIWETCTC>:WBAW2UST:^>OCB%>2>!\CMN.N?'#R';$:-\*Y36=&++1JA
MBMTJ-.G7,5,CDQSB"11$  !$?8UC7F\.E5K2K2INQ=J; =5MI4@<D9FG;KZS
M;ZA0KU*:BFE9&/778&!/+S"/-GPH0 V-YY ?2C>9 WH#<"JP5=$-OV3$'7GO
M:98]999F(8\SF.%I#X,D0()07>Y"8B<0V*)TTJ@Y33 ?9,)#', >T CKIJ1:
MMN->D8BEJUD? *EO?"9YA.F!X<(Y6X I[]67)VFDWH\)2XL2!X9.3X 8TSOZ
M*QM=NC26 LF2CS!(R-NSV 38O[ Q@O%O$["YBH=[*PX/WK: 4%1$!<(("<NR
MBR10,<,/4[*^U?=NTJ;O/8-J]K9UJ797-W1M0:WM%Q6I9C6=2:3+60%Z2N5R
MO-00,W1)42A=.+E:O8NX,U1GZN55/D@R,P<&ER2BKUNJMZ-:K(C$N7RE3:+R
M<34W$XG',9]U7$I(GJ%S,1L7)S+*.?+1+=(RR)7;D$U3"4JJA0!0V(NC:I9Z
M)3_FHMFUFJ:+.EK5%S30K3?M@*M,92@J,H0ME9@)Y1C%/M]HUR0C9:(! S]0
MF9$NJTC.0QPD-DX]W7EK85RC.<&N.TP-<.U2DZ?(O69)%XTCW2T:XM=A4BWO
MA7BR3@K:1CC).$#B4"JH*D.7<I@$>TM-<TZSLZ-K<LRUTHTP1E;#J+T1YCJ6
M[FJ7VHU[NU16MWK.5.91,9CSF,Y/J R?\"M/CF*]]ZR.\ND>D;S6\487=+7/
M1KYZ^.'U 9/^!6GQS%>^].\ND>D;S6\4.Z6N>C7SU\</J R?\"M/CF*]]Z=Y
M=(](WFMXH=TM<]&OGKXX?4!D_P"!6GQS%>^].\ND>D;S6\4.Z6N>C7SU\</J
M R?\"M/CF*]]Z=Y=(](WFMXH=TM<]&OGKXX?4!D_X%:?',5[[T[RZ1Z1O-;Q
M0[I:YZ-?/7QP^H#)_P "M/CF*]]Z=Y=(](WFMXH=TM<]&OGKXX?4!D_X%:?'
M,5[[T[RZ1Z1O-;Q0[I:YZ-?/7QP^H#)_P*T^.8KWWIWETCTC>:WBAW2UST:^
M>OCA]0&3_@5I\<Q7OO3O+I'I&\UO%#NEKGHU\]?'#Z@,G_ K3XYBO?>G>72/
M2-YK>*'=+7/1KYZ^.'U 9/\ @5I\<Q7OO3O+I'I&\UO%#NEKGHU\]?'#Z@,G
M_ K3XYBO?>G>72/2-YK>*'=+7/1KYZ^.'U 9/^!6GQS%>^].\ND>D;S6\4.Z
M6N>C7SU\<6M:\97"EM&KVP1R35N]=@R;BB^9O#J.3)*+ GW;594X;D3'M$-M
M^S699:O8W[FG;,2RK,S!&&SE$8%_HFHZ936K=H%1FRB3 XRGR$\T9,X2P\I7
MQ;7"S)'3FSI&-%19A,08M%PD9,SAZ4! 3/UD5! $A[$2F'J#O!V3Y+>#71=3
ML;0SMY]9OK$<@_)!Y>7DPV]ONQNXUG+4;X$71'57ZH(VM^41R<@VX[//5Y]+
M<$N6G$R3V$.[IC4.OV/XEDM1P';^Y[_?]O7)@RCNZ>((BRZ\Q [YF'2)OXPB
M&P!O_1E[/V]#5PPBH)SQY8+Y%[RV0*V;H2,$K<8$@*B8I$5DWLG'H=]T@)BE
M25*43; (@ >@?1KT+6ZM"SXHZG4OSV=M7O[T%B&DJ77;*E0@#,4E55YJ"2F*
M@X \;N7-^'^DI2DSTM.M5(!'E4::*ZSV!@R%2#*3"1E$;#C"KGIRTXX6LK3+
M[>PMF33I_50^/QQDHW!60.O,_K"M/&LJ]H(B3N$HTR!&B9C OWAP G'#<W>Q
MM9 2KI!W:]F)9Q<.]QV^<2RTZ=)T-$4YS.?M"Y R2&/2-K&EI2Z[.+K-L(4+
MEZ2S SGT2ERQN^\AA&6=^8YQW:PK9:::U:NY4<VES%D.\:P4*;#-Y@V\I)JI
M=0,8]2>DF30BBO24[ARDF'NSE ;UY:U:-U>5.SJ):MFRLR,@([5"" P!QVRV
M@;1@8MFZH5EH+3J4WJ!\0K!I=1YSD3LY]D?T#-:>,N&D(:0AI"&D(:0AI"+%
MR;?&.,:!;+Z_CWTRG689U(-*_$F:!-6B8$ ;P%1KY'SAJT7L=MG%V\;'(J*I
ME6?.DD^H.K?2$06SY/I+W^NPSNIQT;C&TXU@\J0^55KFDX0-5[$S;C&J/:XR
MK[@K$YI5QW2BQY#P:;4OB17V$$]9MAIU[J=?V:PIFK<92<H(F9<B@D%FQ$E6
M;$[ 8U>JZSINB6PO-5JBC9EPN=@Q4$SD6(!"*)$EVDBC%F$9+P,[%V6*;34,
MLLXCG9G)6ZR[)]'*'%HZ79+[M))LT>)E*X;G HF3 #E #%W*("-N[M*]C<-:
MW("UUE,!E88@,,5)4X$;#AL.((C)L+ZUU*U6]LV+6SSD2K(3E8J>JX5AB#M
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MLCM$Q(QXI.(%_I];93M5L4XSA9&3G&\A%^LE!:LWA5&2315(K]4"LD7!%&Q
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MEYG(F1G[?>82"82[ZP2DY.)12<$P<2<F987BQ4P28LRJ+NDP6(43)B4Q#[
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M0TA#2$?AO0/[ _Z&H.R$>8*)LS^M#<4(\XD&W556HOC 80 (MU/5N?=%Z=A
MPK*5Q-/?L$"G-V["(#2NR,ML2.B+V89DL#*1K,B!3&5K6);'B1N4JQB[PTQ$
M7&+CEDS= ]T,0K9TERI[" BU H" & 2U8Q1E_#.,V/+*#:PYK_WJQ_\ ^\6[
M4?C135V"-N&JHLQIJYL3ZE2Y3T.V);]Y68NCSY +OU",/8GDAT@'9OU^'VV]
MG?;5/XT9""=,^&+9O><U7<!RLBDGXD7L6;J?(U=1%;K[YO$3<F)5R](B!TT8
MVAQW:4=A$0[=@#>J<0$F0.B*)?K\VR7S5QC9V IC&JY+P0V8"F;K#NB.ZHNX
M*)P[#]$DY7 !]H U#;/E$5!9(0>8QO6U,8T-(1I.PSE.(Q/R]R?*V-^G&UN<
MG\L0DP\7/TMVW=3\C/QRI@]E=>2A4FJ0AV]3G;T"(ZA=D7V6:"6V0B"\6947
MA.0]>RQ,. ;>.O[J7L3@QQZ4(VVO'C6Q*F'^C(A'3"Y@ 0[>D/1J8DKU9#FC
M)"G7IMDCS X6U,'2;V)5MEEBH1TB?O&SB(@<=6:&9.VA@[!;OTV/B2C[/?"/
MLZ@G$1&65,\\;E=3%B-9OF0!O#XL_P#:+EV>GV:CJ#M$7:0G.,8.&V7(K$]X
MM:]A?H1\'.4F6 5'2G=(J3D$ 2T,EN.P'6=)D<MTB>DZJY2E[1V&9Q6Z3 EM
MG&),LY<2!I20>*"L[?&>O'2QM^I9RZ%59=4P^R914XB/[.J#LBYE CT=X5_R
M.8F_ZLZ'_@M%:J&R,5O*/AB3-3%,:%>,1?\ ^F,<C_\ /'_^#LKJA=D7W&$^
MB-SF;?\ (SES_JQOO^"LMJH[(LKY0\,:J.!(?\O:@_\ 1[: _MI5]!%^L)+\
ML;I=3&/&,F0O^T]QV'Y,9E_^D5[5!\L16/(/A$9-ZKBB($Y1?]GS+/\ ^H/O
M_31U#;#%2^4/#%ZX>[,1XM_ZN:1_@S&:D;(AO*/AB1M(B/.+D1)9SF[/*293
M*JFS=DHI0W[0(G87@^Z,80 B21 $1$1 I2@(CL :0$5BMO8*$;/BRB7\84*5
M["V)F0#2$=.QH+^!+&I'V\5"N3J'2>*'Z>D_=JH?E&X%61,3_P"7'+N)WEOS
M F':31%W)8=XO.WA63<K5!5T-KY(I*.12(([KN.ZZE#B(F4.(F$1$=(IY3&Z
M/2)B(9R9/3+],V.2A9Y]"S]5H%<8O82--*@6:8VFZI&8ND6ZG?MCN%;<R*B8
MQ.A0RA@ ?<&V0CXJEJK%"IM/@;O8Z_4YU*NQZZ\//3D4PD$"*@J4.\05>=H%
M52.F)BB8@J)G ##TCI$3C\E+_6A<QN0(1X%QJ4-"7:)F)>E*-;.C%O2.ZK(+
M)/0C'*QDO#-H9P*OI%(Q2@8 $Q=T(N/'39\E$2[I]'O(LTO;K7,M6<BD5!\1
MA(S3I=D=TW*=06ZBR&Q^@P]92F#J ![-(F+_ -(0TA#2$-(0TA#2$-(0TA#2
M$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1^#V@(>V Z0CS_O>%?*87;CN<
M5H+(@J8J2Y;Y0B%5(4>DJA2*6$BI2G -P P 8-^T-4"8&R,GM$/+' '"KE2
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MGR'ABH15PDZ='WEA(,IB5BXYDD6QI0+5+OTY":@UW!56S=<2"@KN0Y $^P"
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M3] YHR_-BR^" @$%_;.&]O\ WPUAQD1PCBJ^[#_M#[ __%(;^Z.D(XOJHO\
M\ ?VTA?[HZ0BD2^/+A!L',K*0_A6#44N_7]81:_1WZZ;=+\DW>K+&ZEEBAV%
M';?<>S<=(1(&*L<.7SMG:Y?OFK!L<KB*0(=1!P^6(;=-T8Z9B*),DQ#<O: K
M#^X_&0C*/2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-
M(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA
M#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(18N2?\ @=)?H?Z7!?[H_H'_
M  @BOTW_ &)_JG[C?2$7HW_1T/S/YE+]'_1_Q"_F/ZS_ $O[G;2$<VD(:0AI
3"&D(:0AI"&D(:0AI"&D(:0C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2113965d1-pht_cellul4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_cellul4clr.jpg
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MR\>7RI>5N/S^E)S^=+R^>9L)G-GM7V4
M      #@PQLNHV3N=&@^WPJ_A]]AM/WSD        '4Q3E\+?.OV.MOCRX4O
M.7'Y?2DY\*?E\Y%U>[+NIVP                                (_P!K
MJ0O)XJ_=3NTW/YS_ !67&/LO@XGDL1FK5]QH?OU]?-PT.=8?/Y:U_9P
M    .II[.<9-O[QE:                                  #"6RZQI%Z
M9Y+FG6]GN'R^VZ/F_J@PAL^FW[X=K(^$V*D^OPP[LNI6KG\MC--W\
M  #@Q^L=,MI[@Y                                 !9_OUOC'^CORY
MD?#YSZ&>1^V9AU[9! \KA=?MQT'-VL[A2?3Y8,VC3<\ZCO65,#LH
M  &(<QA\-9G#=UFG1[VQFN;$        !1\N):B/24
M    =4^+OZ0_+6+\Y@?OG^4_V)R 89V34L&[5I7AS^>8M;V[/>I;OV4
M     >9IONFE[EZ7N@U[V+79KT>_E#%Y,       #$&8P6"]I\ZJY.W'EM-I
M/J\@Z_:                      LO8ZOQB_1_Y;R1A<[]#/(_;<QZ]LG4P
M5.64+/)/9;''J3JSN        =34'<=/FG2[<+[W2L_V^.TFJ;9-.EW!XV:C
M[AI6WVG;L       .II;Z!X[/\7M,RQV:U[V[S'(.(V#:;3?30
M           ,';-JVE/I/E.;=;VGF<=V?-?6.AH]/I*TBDL:K.;C8ERQ>.6T
M        ZGS:]2\:RIB<Q*?GCO?ETZCI;=LSJ6^<FJ^UZKG3 YZ:]+N
M  #@TE]&\-Z_/-; ZUN6L6Y>790PNP[4Z5ZL                     !&>
MYT\>Y;"2;I9"D^GRR9ALX.#7J<M.5J%VM<=E[Q'(        -=-T\;MGWZF>
M-2]5DO1S49[/6UHV?5^4S-A<YE;$Y;D        @N2PWSW]6_.$A^'UI;\M^
M_*?TQ,.GD                     !U--9SA"218VOT!OS[ \CJ=3L>X
M     !P6<K"J+<5Y9R\G)R=@        >9A[-8++N'S=1QY
M        #J82G*J*@IK*:7+3C<:]            >9\P)SRLMB2-+L<XZM.6
M4H[V;3N.2K        ,)2X=6^U:HV0O&;@              ZIR<'90   !X
M&E,YVL]#J4<LOO'9-)S8           .     <@       L!;X@[E2662<LI
M.,YL[              MWVZ?S5]T_#T:[^#MOVZ6WGFWZ.VU\Y_1'(   !P
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M,)N@'4P3G]>A_>Z&;L!LDYZ/<Y -+O4?S%@[;/)@H(4!E?4_T=O7Y;[0
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M+%9D4H%DSC>EQ8=9?>VW3C*:WNO #@UVG*RD<7,SCAI?5:Y/-=FKPOH
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MB#'N3(A911D&K*16,B59R*RY!LX.3D X .0#@ Y !U!V !P#B.U #@X.P !
M)9]8. <D;)%'-<G4Y.2D*DY!R=3&ADXZ@')B8RQ'-#J<G) R='<'0[G!YGJ#
MR/4'E'K0\SL=C $9_KJ8!ER+9.S#!01G:L)1&+=E$Q(8U7:5(:8$EVJL[@
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MGB^U;C@\(N]682W:SDH2RDD$6<J%O5EIBA6^6"/E67<[D?+M+S9YF&S+$H
M          '!>+*DU;G*Q$ALK9:5+6MN):EX6*%S*8FJ9ILL\M.
M    =$P]69)0   +P8EK5F<LZ)<:AD0I<CI-",%D+V;+WC:9:4   \C4:\=L
M5EH              ,?2X.64)XU?"PR]R8):JL<M_+2DH,OV
M  >9#B:@    @IAB<KB7^R(R]R^$F3"JW GQG:\0   /,Q 9C
M,<9C7/GUZ7IOTV\B]1NGQ^GS]]-T+,6&^><=*]!L/TXP7/Z[A;.X/.^O[!GO
M ;   .IV.#!FSZEG/6-MY     .",IJQOOA>O&B^W[@_3K;)?#O=E
M        ZG)P=@                6O[]'03US\P8Q^GK61L5E[;EO'=U/,
MO:L<8[:OBC[_ /GRLQF4B69PE9W^C^E[\P_J+D  '4TL]*\HF^+S.SVD[\
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M\?I\^-E^.DVX:GC;9]6^HOF'J?U2\H]:  &/\MA]4-]\UW*\Y]2DO2R
M &G7IOYJT7]:_)GUA_.O]$,F8+>-.O3/S9HOZW^2OKY^:?Z2S'';&    !K?
M%*N8+(/.6(4V,LO2:KK<Y=A[QQW.6$C-5F:#"4N*3/9)K-7IRG*9KLL*X?G*
MZN.1[,:+!XV8LNY@:7JN;+QM*914 4G+A&.YU(CDL;/,5DX9V^OD/']_".=P
M6:<)FXOW>A(NIV]=-DU[8#6]CE75[0   ZFC>[:QX&].D[/Z L7W^'P@]]_/
MF)\OA_N?X-^@-A==V(  1_M=32GTKRC=_P R]9N_P[(     &/\ ,:C\G/T7
M_.Z>XC;\YZCZSJYZ#X#D7![M]4/SY^_^0   >!ZQS6/N7R].'UDE6I8VDV*D
MQ_'NLULL<19959*")Q'UEQ<;(!+=K)24A&I:FR]185M1/+*DAYQ+*[*=)"H
MC/9ZV,<KB,XX'8(5DL9-<;D\;YG Y'PV>AV1Q\RQV0Q?G->R?@]A['8   '!
M\PO7?.HIW>I]:/%?4.2-%WBR58%JB8)7   P_L&MX4V76-O_ #[T>L^?T
M  '!KUN?CFB7KOY+BV0P.7M;]%^AOBO[-F.-V,   #'4:WV[0I(OMU;E\>T
M                !#NWU,=93$SSI]STX_6C^O5L7*T/U^4WZG<H?IUX-V_A
MDW%928=/N@  #H<'(.3!DY:H+/%I4OB[:WYR$  '4PQLNJX&VC4=X?,O6.0
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M:K;_ *?.78//>&/[]\Y<//:/,!D_ ;[?>IEJ?EQ^??K7C&]7EWKLBZG<
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MJ93*. W\               #P-29RK3;"\0 +1]^OIMZ+YEM!I&^Y Q68
M                &$2PRUEE.2.*0NBW:S#D1.V4)Y&V0
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M                                             &$)=/7TRJX[N7@
M                                               !PG"]A'%#@'8
M                                               '":Y;;YS\F?5=
M C/;Z O'P^_U8\K]&VJTWT@
M            <)A;8M*T)WG5Z;Z?$=I=WM)VO8G5]X
M                               '"8BSVF_/K?M8L_VZXK>'/>O1MJV#
MUG=0                                                 ('D<1K5
MLNO@5''EL/K^6R%B\^
M        !J/.=I-R[P[@
M           ^0$^OTW<,D7B
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MRTF/#QT1(MR\5S+WV5]X(/U516,XZ:^A*&T,8IC+#QH@<BQ'P,+%/R,1%2U
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M$HOIL\R.;QY,#J5*RDWIQFB,VCNAS&0E(F"QS4O(I<R1U%+ ;@Y'C$/J7(R
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M+8Y%S0/V#T[K[!Z=U]@].Z9T'TY:=&Q6 $9^)S\TGQ7IC+<VC!4WO>WQ1/\
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MFW>NN)D4)8QTQU!T:2!?H=R;M%=,%!+*9O;9=#3COP,TXMEQQ;QZ947?8S'
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M$8 Z9&@2%"!"@-DP\6:ZTTVPWT^S_P!Y/TO^?5/U^%/TO^?5/UY;=1_7M_\
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MKV:<]@B;B,$P.D)QES6U@T9OD":SEM*QQG!D[(3O9=^/?3&@Y+=JN-:B2P$
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MHOAS=5E^KE+L9; 4U#0XR2X$FHT @44@5FBE?*AH#Z7!110BW:R1XV:JDI5
M!()(6@@VFT$CMMLU\R<S$CR0*,EL,^*X=;]ZX\Y:*"19]8[?Z93K=;=S(G<:
MBV+I-'?1HM2I:>P98']0Z<"/-I;^(PUSJG!1H4C?!CEGF;Z9]=<R<FU%Y5/8
M?.2J:P;CU\'8NM-'?WIEIBFSML%CY ;]HRUW:8$G$73-G35")R4%-%!LV^W^
MBK[[6KL)W)" */:O9<L-O^*U-TFG;[) Y!K%A[\M8LAAXH! 7C6WT2NJ[3X8
MEEG*+.-IO.VJ$W^VPQ@)>;(&)^+GWM;90I)\[-N69HUTW8%@&3M]7L:77S6!
MFCFY?HB.;E^B(E:MK6\JH)D[NA[9?%(RMX8YKUF\,:K$-NO1;/!V$%<<WZS>
M&.;]9O#!E3@DP=A!7 ;AV7OBKQ2Z@ZO,,^_74@@F>IFVKW U<O#OF-O&D+[)
MCJ<W=]B.IS=WV(9_336W5L)K3[(CFIOHF.:F>B>".:F>B>".:F>B>".:F^B8
MYJ;Z)X(YJ;Z)X(YJ;Z)CFIGHG@CFIOHF.:F^B>".:F^B>".:F^B8YJ;Z)CFI
MOHF.:F^B8YJ;Z)X(YJ9Z)X(YJ;Z)CFIOHF.:F^B8YJ;Z)CFIOHG@CFIGHG@C
MFIOHF.:F^B8YJ;Z)CFIOHF-7JWZQ%2Z53+W DL9QJ '5B[5FIV(:)7':336+
MHR\FF!,PY5@E@;IR]AKC4"(:)7&832:1=V+M,-$OC,)I-(N[E,.G2:9=&]V)
M%ZK6MWXFZ]T_6WRJ-;[4'47C*SU[G<#[Y\'<#_X7\_<F\WE".F8%.F-'O):!
M3]IJJ=CPBDNF<O:[@:J0]&+D'A$<YZK>".<]5O!'.>JW@CG/5;P1SGJMX(YS
MU6\$<YZK>".<]5O!'.>JW@CG/5;P1SGJMX(YSU6\$<YZK>".<]5O!'.>JW@C
MG/5;P1SGJMX(YSU6\$<YZK>".<]5O!'.>JW@CG/5;P1SGJMX(YSU6\$<YZK>
M".<]5O!'.>JW@CG/5;P1SGJMX(YSU6\$<YZK>".D7_?7;JHVI5R9>Y0F2B6S
M!:(U/Q))6-\6:*CF=WID2#AYXXPW1E'T8U4AI=,S1S+MR.9=N09 ENUS:Q'-
M.C5S CQ&LE2W%D7GRR&C1%Z2PN:(.H87)"F2Z*HI^4)>IP[DM<Q3MPR=,U;<
M7+F(@HXB6!5R;OT8F>5JO".SB&O+3,NRZ@F7.<W8FK_XCM^)2>3X8F^;$X,Y
M7'_##_*UG@'UQ108>6%67S3L_2 3Y!2:(Y8]%O!'+'HMX(=B6O\ ?.K-&]5'
M.>JW@C6SBLPQJI#T9H!WXNO>"WS6\$'H[KJZ#OP72'7;U=6]%QTRCS6\$((I
M_P"#5DC"ZJXY.4UA*IQEO NK6JC)%QIPR>:1O)%>&VG^U%>&VG^U!>786C+>
M VUB\X8>_50);OQ7C])FRY$LS+P%.<A3F"54P6OP +OYHX:-B/\ ;A^L(_VX
M?K"+Q^'!!_JQ?E84R[MG&/!])FJ^8,0@/$;E"A#>!J.2/>8C'7OO> .WXZQC
MO6]B.L8[UO8@W\1C;GWO8@/PCYKDIJ%>FA/1^DS7M2\VI0#%;=J*V[45MVH2
M\!L"%+RO_!)__]H " $# @8_ NT;C'%ARB&3SB9MYS&'Q?&V(8SI,WC3;OB^
M079,T ])FTL<?%L3-GA[.DS4;,#?%M:'9,\=9FU3/)\0IDCK,VMGD^,1F@-Z
M3-I>\>+XNQ"])F\F6?%\=R9(>Z9->\!Q:A3-30/H7T;!H7VNR:,IW!GL6<][
MCI,7I3W@Z3 P^-M-#]X'AV\O:K9%[DL:WT8;,7DS+WJ%B;JP M3"-M."'O7E
M3 [::&IN178_URNY%=K?5(@.6ISCZ4(OBL'H%=V'?:>OT$=/FT2FA3!?A'+=
M--A@XC$%)0V8U^%=>EJFSV2]G.&@;/!7\E'\XPW3GR'OM^D&(_E&)[,K6[B\
M,,8M+IHV@#X4@N=4^:2-" ;X/9E_S1^%WR9V2\/#]('2)G-O:0=!"1J9A "N
MEN[_ #@(EX9A4RFE=+DHV@(DR'!'!E.DTG=/9=*;RZQI'#5%UU#A\CC\\XJ>
M_1NKVP#,Y;N2T5N.:+TQ[</+\EHO.V2?!%^1B+Y\E[0AV13M1T7$MU>+%EA&
M5I[4IA35W1.HYRZ+_G?PKB6?B5]+]*^59>S+7\G723<Q&X[3P[ABZ^6X^;QM
M[PQ=9*F+G%W?2-?BT=.L%@^OOS]LN^*3*0I$K,T4+I=;;X>Q>;1B9?&8<A%,
M,Q'E-W;=WM+7W;U*9!LE#_&-5A&7,&'+>/*=0154!3G7-%V9B9AS%*=S9@87
MXA+XK6@-<W-Y2U:1M0V:* X+W.=.F<AC23H%,7\0 YBNF/![Z>,10;(EXE@0
MS6E=+4IVB-J),]Q5Q93I%!W1VX]TF4^9(EGC.")124II@.UK:4SFG,%,%TB0
M] M+T8**\IHR(L"7.F2V-+BTW6K9>H+LHM2&R&<AH3Y#2>27.3;X5[2'PEM"
MS>-36UN;.;NQIAC,+,U9'?9O5&&XMU[6,VC77MYHF-G2BP"I;=O?JIB5@IE[
MI#06K9Q52U5NA:ME>YV(_E&,0[,WPPUWDSAO.'AAS3XLX[S3OKVX<-B$U:G5
M.6DVTM%)NK30FBB)70IC9LIUZ67#RG"_2,R (:0L XF>QC_=N<U07<=MQ[;H
M4BZ.,;8!P."Q,QP$OC.24UQ8JN5YO(]I3DQJ?C#9,ILSFKA+M+7N('&JI  [
M/0L+3C)E'FBUQR450V0WDM:G:6'N_P"5>:[2\,(WMT9X/Q%[G*B)M"&JX<:K
M/$SI*75HJ\%F[#YG_J'S2\T4@'BC8(8OU]SG8>=3+>$,.;AKROK)--%606Y-
M,'"XA=6<D='PRW54K63E_@@[<E_%<5+F3/AYPIE@M:7ZM]Z\J 4**%\ C$_$
MIN'=+^'/NAC77F7R.4]TL%,PO::#']+)E2_-:!V-7.:',SQ_18@H/%F<8:+U
M8$?U$]DMN26*]EU(CB4S#6XTN.D]IOEXA@<TMV=C.+,\).E/F8->5=6KRM&4
M@#)#2Y"\5?5$N5BQ,DX-YKJ<ZSB@YT4[-,7,,QK&YLWTIF36%Q+\ME9HHSVK
M"FS_ +=78B>;LE@4G,(U>&+Y6#7BL::3YR5D^34*J:S?&%FTY:#M&F!/FMG8
M=?&!(W6G<@?#/B?6_$?Y:>*?M6K4:J"E[N09)DX@N!-3:*+135GCF<3Z ]J*
M9&)J\CZX(,G$T5\3_%!&IQ*C[ ]J#[G$T5\04>M!]SB:/L#VHYC$T%.0*_2C
MF,31]BWTL\<QB:TY K]*.8Q/H?XHYC%>A]<";=<U;'!#M=TF2991LV;QLX )
M3;0[$3?B4QMZ>'W&KXM )3.5%.;3V#)G-#I3A2#2#$V3AS==)FJPBP<IFRB0
MV9Y30?F9>#=STT.+?NI>WQ']K1VOU.M7Q;MZ[E55S;,33*#AJISY17*R@I2:
M,F]']ZNOZ+J[Z(+R;:+LQ)OAWOY@8W26N=334C<\-^'D.USY;GYD:0-*TY(G
M2& WI+@T[+&OHV'#9B9\41^HEZQ11>]T7!R4IXI2F&8B:MR8Y@&57T-[7OV#
M#S/RP9OB]$6)TXK<&&!_%&,G.Y D,_YD8EYJN2M]T8J8ZK72=W5B,5,=5KI-
M6?5B)SC4<5*&WJ&Q-<ZW%RAMZD0;UN, W!%-N*.\8DM-;Y\P;DP^#NGA_P"=
M^4Q._P"H/X&=G$Z6_@;$OS&[WRP_$/:QI<&A2E)J$=*P;GC$2':RZ#S@;RI;
MLH<-HH8^'_'I);JVXAO&-"2YS2Q_@)\V#B.DR-1_;PV]K&W;VM)1514I2,7K
M<3AVWL?/<%F,"M+J"*:0;#'1#/D]*Z,1<OMO*IHNJJQ@+F)PYN8II=[QM U4
MP*:: I V8DSAB</J1A9@O:QB+?90JUQCGNQ6'#73V)[QE/N)0HIII!&D)&)P
MYQ$C7N;BD;?;>-Y\R[0JTJ$RQ\,P$A\J:QKM:ZZ\&Z94OB IE>[U8&'D.<,#
MA*9B%+\T\EBBL-'&<%0J&N!AN'>]HGO6ZU:7)6@M3M5[Y6-E-D.OAHU0H8XU
M+;0E,7.G2;NKN<T.3#I,S&R;CV73[JRGAB8R9C9*36W7>ZLISYX<78V1QT7W
M7DU6P]K\;)1[FD^ZM8B6_9$/;,QLE'N:3[JUB);]D00[&R*7M?S5K+I%OV1!
M#L;(IF-?S5K;J6_9$4XV1SE_FO&VX'];(H??YJW;ACSC,/>EO+A[JUP<#;]H
MPUN+<U^)M(" ['S)FSG!LIH4DT 0)^&>U\EU1:5'<C#_ ,[\L3O^H/X&=G$^
M<W\#8E^8W>^7,P@=*GMJ>Q0=L:8&&PLP39,QGNY;RKY61RUNEV!KK: Y&I'O
M7* J"H!2INM%#0IJ  ^86V'8,&7=G/6^\<ESG"],<12^A5O*:J4%TNQ^+F:S
M&%GO)[T%&;Q6,MNBC*L:["/;,E*BBD4=R9F%GTRGM(,2),@(S5AVR[C'=/R+
M[R P6F':QS)-QS:9A0.:5I9EJ,3&2\3(OZYK6K0+INJ5.2FG-!\5E^Z"2$>?
MLFW)I[@X?^=^6)W_ %!_ SLXG2W\#8E^8W>^7?Q$INN'CMXK_2:CK:E2)S;\
MQ[&3',;?<7&ZTD"DP_$8Q>A2T""MSC9F MTA(#&X62@RA3ME3!PTN3A3/;6$
M:L=4D>B(ZI(]$1U21Z(B]T231]B.DR\%*:V\12P0^;\.8)., 4)R7)8E07-L
M]AF)QS7SITEYEI,<7L""BZPFZ@:X"D5U1=E@!N;N._!B8^47^,VL4@[M1S0V
M7//2< QO+JFA3:"4>%-8((%"%%-P>[DY :=DV[FB+@-Z3D/@R;T&7AAJ,*]A
M#IBJ]:B)8&3RW'[EL-P;IKYQ:O&=73X-D]B=>,M[)3./+<H+E2Z ZRDCOJU^
M+<7.LR-&0=ZFMQ)4]B5A)YOX0O1H<3=EO=0'IFR;(IB^QP>102*KPK[@8?\
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M[?/PCB]%Z+K/M7KR5K5L=Q[R4COV[%R=ALU?<-DN:?.):[\(.>F'-;6PH=*
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M@CDQ^IW*@]/^JOZM<G19>;>3YI\U\OE^=?._0Z.&GK>HY?\ /:^_\IS-J H
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M8^C4_I3,M+NSUO#L[,-5=Q5BZ)?7)_5B?TC)R:NSLR<O#$8JW]5KB2)$H/\
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MHN>+Z%>"JF6:=N-O@K$A3BVXEL)"G8<K(U4_R<62U &#J=(D([),W<!.X=F
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M]Q*,9[]<F.+GV\]O,$J$0QTC$&CN"H]47%O0N*_2SFQV']:]0R!:PD5K<O7
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M]0F<S-..ERIV+@@?,M1RC2DFF%YMAZ"S$3))9&\K)\I$5?*+W_5QSS1(ICY
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M?[7+BD_9W='OEM#!OVPW'^_]IA_V,7^4;&U_IP^\%ABU]Q*#V_N7&Q?P>O\
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MYF\SHJDQK.7RF<PO30-LU,H_*9FW63E"7),^. PESYYX\J4/AW>5#)#$;-?
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M9^C.N?CPT;6V>EHXHT^__!#B3X0?YGMY-D3/U<L+H;:<8YHW&?GY,\6/$?\
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ML:_0A$B=0U"<G/$+<);:Z7H3)-#2NE@-2,LFU=A2I8 #)AFGP2K6V1!O'&D
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M!KQ\EGE\]JMX_.7%>5KY"K7"B" BN'WFPH=E"%S<AIFJBM'J[++O(WLXHM#
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MA_TA:?EN/0_Z0M/RW'H?](6GY;CT/^D+3\MQZ'_2%I^6X]#_ *0M/RW'H?\
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M'JC2),BO3[Y$ZOGP\EU/8B#)81H@"JKV9=URI\['.B[6Z>\-NV;M./1V=[&
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M[U4S09CT*A(ZS''Z2&".%T7DL\6H> H"#EWZMP(_\);ZU,0F9: )0#!6K/G
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M>#1"1-Y9A2XOE97@!)R'\)N<GGVN]&XU&QDT0H9R:,E(=Y&)!Q8P6X?<08J
M3R)N#QW-_!-<388&'C%G"1V)$_QTJ:8:1F@0I6YI9$&R5\^?:9B&)\43#9WB
M(@Y";3+;1]#"+\52GPE*-Y%!R2@B18E6$L-^^EJJ2T[RBTXP:@.BA$^+G!3C
M,.$%#09A">89M 0&W'ONC",DBPRVET?X5CMAGT'IIG?HY_A*$XB[HE$?%"0
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M%T']WJ!D_P#GL-?NW6H9DG4,2**Z6<@4J=2UEL3E30R<M"M8:KVA4@!'\'@
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M5 5]$R4B(C*0I&YR3IEWWLQ7B:!ZI/R;D0UN0(>JX;/QK3KD5;4H1_Q+)?\
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MK*-[%F3R-<5DH6C0AYQTV7?<\P=4* 1E-IYR_NX@P[62 N@7*A!I45O.T?\
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MTFZ8V"H)SRR8_?X)#ZHK\<5JX79WA^R_BK@'K8/2/N_!/F=$7TPLR1,PQO\
MD@5$,H@4 L@OS0)V*0A>E ;;,5N^L8F'L!J+0[@G;T*8D>ME07K"UKU9**[>
MI1,IA,AU)49B7 A+3DMJTZ'-2[RSC36KEFTX ZFG1D1#+;Z>!V'<W#BO"VOS
M<!@6T"!MEPRM(P(M1"9 P&>2@&AN2T!,0%5!B3Z/Z2HNT:-5.K-I6'5*C17B
M(W-1>#&D)R<!>M;(VH"$HH,8K^3:;(J7<= A&$+#HMWRJS=6H8F=Q6%;38\Z
M4PBA;;J1YF,KIDU$#3B)Z2$@Q G5\'^SP&7[+Y"=!'/09VD:L/?Y!!"L:J8\
M+>/5^=BS*IMZ-@J"<]<F/W^"T_.*_'%:O5VZX?LOXJFI[V#T[[OP/ZL!%],+
M,D3D,;_D@5$<H@0 NFOS0)V*1@,E ;9,)NT9FDXKJ07:;Y=:\38TGW"OM9/&
M@BND>*,XKWR6G?>%$&OT)SV" NM_Z@=B^08[%ZX3=W8@@*8A4AY<61C.#2 6
M,[Z/JKF#AB9(KDOP[NQ)D^OFK6K[N>)^/*,Z(Q+.BL3G#V]Y4++FB7"+9.@&
M@R#9_H7 -"7PFVV_U,HK:SJ5CI2Y<YKARV"G(,4#B1S.'9JMZ9YQ78ESDT[3
M*S6_U=&LNX5[7([>H).+:4EGMP8\TXD^GH"GOT&EZ2<H.F-.O\W3NR->10?[
MUC$=,<,B2+67T1X2(9P^P;]>6'8C\6"'T0K[UW7:N8/I^/BB-YW18OJ,.R^W
M:^Y@LE8$^EY$3TB);MGZUE/F\(OKX%ONSEZ]#+O$Y-L8Z)OV0^NJFWC+J$$]
M<J5GL*#:\.8N)Q#FAG. 2]C373/6P'] GOI*%SAY;1&^I\L8%GNB56(*9B63
MLP10"K6T6V()OD/JMNRN&O62B/LB>;D@!V $2A*OTO=GU7./(H"C01:MT)Q+
MXS@11IM0Y"]X5A4;TNF!1H.C+N,0X$PX*M7BA*5$S.T=/#>"%PZ$"E,)70)S
MGWK"J?YWT$.,F1*OS5KZ*]+>$#>%*18(8&QTP_1=3KHOB%D,$8LE NDHSNV3
M@,C8L5CHVO-L&E G!$P=X#O@D-N!B B 3@.=C8!TP%DX!.<A$<;^\_G RWK!
M!F2$(GF>V']MWD XBWCWP%+(LS[0,QYDZ8'#>MD?;&O6\OPX5#X&9H/.,#5B
M0*=N"I2A=<6#4]^IH^C *69+$?&A)SS)TP/&4(_,O WJ]' N,W[H\31T#IAE
M( S0F-NW[X':? 2#; "6-X<C*A!S+,2-"VPK72 9:%)W, 0>^-[:,G.%EKP7
MW/UP\'#!41./8H:#PY3RX:J":D":K4+"U4<$*<\A? 8CS0=[MSLD.7 \WKH+
M1D(=!X"<T5L0H!Q:RW@72DC](>ZS@[I>^[9+.L) <8)L,$>)<#WT/&=::-&%
M,[.-?C@RVUA.!@B<W-V1J$[ R2YN@BP]&8O2^N0 *ANI"^YX:LH[%XG"1P3K
M*VP<W*]9<,Q#M(DB?NV]\;!?4L S&EM^(>N0S]1*,$UQYG3&*M)*B\C_ +@I
M$.-'O'\,%YA4B73,#@X"O$$WJ7*IVO1AV71*$C-!L.9.F5@FU*L"<L1T]B3(
MTF F,'M#F1*-.R<#!"[&2KW[^@,"!O[+&@?7U,#[D5!,&=G-1ZX8C.DE''(/
M/-.,)@ KF<FB8+ZN>\OH]A<?N8S*L 5H[$PI"_YC'CQXV./'CQX\>/'C8X\>
M/'CQX\>/'CQN3);O(T#"H8B*\$07CL.+^\+E4XQ3B,6XPBHYY@)>C !<"$9<
MR9XVI'W ,AXT4NF!>M@]$<4\1S$ -7;99.R="Z1![0'B$+&=TO#[H7D"'6;_
M '8IE8N< SB$H%B5"5H;C08$0/.=#T$[VD0HU;F&NQE5M*6:#H]C9$/,(BO!
MI!P2C)9(J&/YF/'SXX\>/'CQX\>/&QXX\>/'CQX\>/&QC]7?"=8VPV$ WH&-
MC$F5#Y./&QQX\>/'C:(1P0D88D1A,VI:P"X3Y <,'$:Z'4^Q^"7 F>0D&(C(
MK)@E3K&R1(WQ8)'"%OX]Q33Y2"A5T=3.:*2IHX'_ %UX_++R?C--$C$%>BDF
MV(PY6JK;W;H14#@[=(R0$D:!%LB.[P& #"+08<+MV8@&@TOM\CCCQX\>/&,3
MDI](0 VM'@VXWWU#.,EQ6-&&%01_.D#G'SJPA4L*<A_((-:V.P[3RA&\\4X%
M59#!@?<R,U1FZW8X8!EY)I""6 T=Z"RT\%Y'#*7TI&*4'5+(Z&O2P9*]89\,
M3IUXZ0XG\9CRV-OS E\#Z)3E(^M5.$<1BZ:&UX)+"'!TH,:PW$H)K;8EB'V]
MJ)1"/B'^=M *7/9#A4Z?G([CE!4S)\I$)#_AR6X [65![NBXHL[[]7$!BDCC
MP)A#N4%9K+4R?9P<J.FOL,@?G@]H%UE0!9F_42\SIZ.0<!@ W>A&3=MA0J!^
M,,2)H][)PM#RN8[#_=:L'T[J6"$ED=7/9O7^5J2 IDZ:9W'\E=_$\*0Z&J%[
M,R(M0-: :?<=0X$V<I.;GQ^JBR(0@R8M;\SA)>>5SE73 D>&CDS=" [XZ8MB
M/Y7!M6YD44O6.!F(L3$*T[."]9&_ET/D@9146&P&=7CRTBVQB($(L6I6>SPC
M"MLZ7XD-OA)BLFTB(QQPPDTQ\S6#*N4=Q-'WCTL6AT"JK&D1%$1%F:1Q &")
M'(BKR8L<U51&S6)$BZ0'_ 0F?V_C61&63%V_7?\ @P):)GGW"D5A)9@370,&
M;:V)0!QFZU>I=$:R@)P TA-EAD+5(&$PI-O1\MJV]Q)^1A20NE"""BE1K%4*
M*$KB^%4!!!9(E<=((HP-5$M)?XQ02%0I$H&RHX(6ZA,W .2940*&1>- D\TZ
M&8)( !GSYOX],ACW+4C,%"!P8%8J@VWD FE?FH8T,1H@G=AH.6LE9_BU"H<C
M]U%DB74FH$JEFBG& M2N&V/$E=SDGU(\":=C#>1OV<10<&"54]_S=SF!]E@/
ML>*@MA!VA/TAF_"$QU8.]3^OE 9.F_Z]?%-NLNJH]D_7Q9#N8.J"_@P9!ZD^
M"*PQN@)3V Q0GQ[22#PCKZ^-EKGZM'S4G7)-3?RVVPY*@KA'&6-&()HG#9T,
M"9DF3H$U5(T=%A.P%@:@3=9<@C61\)+F:&3>&1<B[1SNCG:Q$4H=-8<GMR!@
M[&1-@D2L(;-@-E0L0ZEA,'XQJ_S1D?D"=B85 U'Y/(&)L0FN^,U&,20&H7:^
M:# S8RO&,>A&*O[F)7D';*FX=L6G2\(8#&ZP4R5G)7R$H1 C1Q4#*LK,Q1.P
M94S?I.@FH0B9]L[>U%QA'#'/S#46U"%2%R/ )R<^A*8HHHV[#1G%M 83P%9K
MRZ),CMP#* V43[[3>))AM0=!(/\ 8H%&2]6JH@I0TGI!-XD!$B(D1!1Z8@ZE
M-?&?L&R[1 S/*_)*627U6.^N:A!!$0/OG13Q.G P?8F8DQ-;()<4QF&F!/22
MG?VSCV[D-8 D"P"DNS'7!0 D*GT+U1,HTL9S)O=89>JR0<?E[& <* 6G%XGL
M.26YMT"7O@=I\\-%:@7L1+\@/Q'-@[J1YPZXC37'4[]$IGT9=E4WHNZHQ];0
M\N"(?65#6(B?;+4-II%(IE"]8M@DSI!X0XN2=$-URECIWC"ZXEX,4H(8)Q;0
MO16@PE+U$$'$-GI8+B]]LZN4!(AUEB>78$I@J%:![@V&08*' WEE4EQ!V)3G
M)FVQ&V9U\QHY%LGSZ^>[K02<#K$ %F!3[T,?+&LEVR#44$*2L\2+<_"GT6"0
M]X ^2-DL%]D7=.</PI]LSEF?T_;83^^*C*3T6GE4Y6>"5$IA:(!&6="]0#[%
M+LCC&YA$+"6RZ1C<'9\<7=AYQP0T1$#)'Q98F#&<942,0"6T1+R8\C6CYTAS
ME6<.#:V=O@+\JR#?J*.@Z(/"0&(U2XPM86G&WAI04B,)1.#B/F36[/TY3OG,
MSUCZ?3>"[L:X61UAC#@\VW><]O@.F>L1EOU$7]7 AP_O,U#%FBI]JLNI\S^L
M.)3I/_:?2<YWA:+Z#7.>Z<1W4X,9S^T[[#?3);HE)B6=TLY=:H/;+H.K7[>^
M1V/D'O.<GR1!&S7& TGI]C[SEHS[1R?VSFPCX1)SNQ&77VL1..-$<0QTC/ZW
MYG6HVY%8V?1/3/Z$];ZY[6NL^?[L2W]G.1_N@G>?@W[&='PTI7FIB>#R9RXZ
MM\(@EZP_2X4.(:9**34T$F490Q=HHX"RH T8:N!SC1I%IXH 9S@J\<@[HT<:
MT/+BEO@F75RS>U$X(,DR!6,:7L#>U1HC'Y!:)@]&6283(TTRO01QUO@=;IUB
M6( T5,F1-Y(#'R-' T)]!X9?1+HTDVSG-= )%A<^467//MW8\0+O[ A.-O1V
M8+#*U!HD8IVFD9L+._#_ (*O%2"T9LWA9!+*.'9?XQ=TW!1O2$&F[F\AXMD4
MWQ:&<;!PB^MK+R-@+M'YSL[A&).N#E2().@ 0!Q0</$Y+2LXKZK"!42B$)BD
MUQ8[^Q4 ELQ[&+U9Z,AH8 #(&",WS3 #HC*^4<R!=<@"<62SM#G))$3[=<$=
M,^?]8Z&N5^CXR,Q+D1@=Y&,6=+8M$1RC1MX/5(8]D;&L)=$C*LR(=)1P&\BF
M0(T$:MF:@J-$DZ!1H'4TL"T* ]"7<.=W*X.^+I LMNX>07 +*M1%).FVV:DQ
M>'L&M; I# 3.!9LA26Z@79K)B?C$C](Z7--P92(JS%@%)+=*SQ94O<] 7^3$
M8GS#'W/9+" 87\H5.W36,$; \;.6\(A0" .1!B)BG.#FD@(N+9XP=SD<UT0>
M0LYAGZ$3=; IYL0(@LFH,SGL4".FK+>:>-XMY!7@^A!8C$ FRF,VE(P&3'DV
M,"A(F!'*]T 9YX"P8O-1D<Q8A7!!U*)#!<6^T*Q2HW!@R*\.D2\((XI(;9AQ
M42M0@G>74#Z%YOYF& @68L@0)E7,HJ8<I[FH P-E&6#ZR*R(%T9U4[-[UZ29
MWF/A*[:J1LY8KM8P1PM)UI%NFC0^K'&73,/XD"DVXO\ 7Y^N7C-EZL<-C3F$
MN>O[?G&.Q!;1*U-"&&'J^W^\3L-:@_L90@"2N^D^O/,WA#_D?*DH$6+Z)I/-
M2")VX?F4*JQ!P,!'@*$2LZR%QOQ<8)=I_HXNMD".3_FZN)F"R(LKSUR"3Z$-
M2= 6PRG%&]!!L5I+; #C1)X+9)R,/QLU%#ARU($Z,@8*^+ZEU3@IZAA7%51,
M144(GS6\<3D'A0F4P"-&LK?^M,;V3S2\GUA):22UO4PF$3UV6H."D\NK DVU
M'I(:A! T ?*+0/.;OPWHI5A:Z)6VJ5/7%II"(X9VITR'!) B5 @>%HZD$_PR
MG !,]#*%A"&1$P'3B=A]*7K!FG%5R*_?%B MIVPY%RG!,;8*JIY3$0N!.292
M-O(9J((F(&1)A<6IG!R0N')=HY8,2EF-<BD7IXC]4&),R:8Z,QJ?+IH8<H%=
M,D,U?TT(TA^3=$WK3G?^H^O3OG?^STG-5[U3_58)0SE?\[**%S5D9/&Z1OC9
M^NS]/5XGEH\=X'J<JNK/XZ2M2+@,&[Y]B,M&DHX&..3[#H9;'$1OX],HMWHD
M<Y2W;@Q9K$L<;5(3@$2/F]077G;AW88<%%+RXB^,QO##G].O]9 2U*8((B2A
MG6+31\C- IT: GRI?S$9]HE8P6N34TG;%0R@FU92XCLM0GR"S8./"(;MI'E_
MEGG_  TAUSI@H)R1-/(Y7^9:R>(KB<.LK)A1&$*A2<9=6[F+9MFLK7*$&1;^
MWKDKY$G#$21C-X3$')LAX7!A)(RL?P%8N?F%4<AIG+,_U SGY%?IRM05?WR$
M!>"%X<IA9F,2Y9\O.Y:)"PH 8.U?H0X<_!C?E]NW,"BE8/(!9J-"?!0 ,TI&
M46XU\0?(8-*,&VT*Y39C92,*( 6G#%59$)QEY%O0$1@TWI'R)IG$;$+J#I@2
M-F-CZ>B5,4IL)0+\Y8$T31.!2U@DJ9BCB1%W^$LB-FX0.VCR14^1O%62X]N)
MW,2H<5Q33%IH"$1\E9<&,&4$GK1TY%,MQW(M*2=' 28(CCTD.2M 5CCW-?T$
MB;[K_$.GTP:)V&+'!T;S;E8/ONUV"YF$!!T\(^X L,HL+QJ"!J)B1HU,I4A7
M%8[/'_Z69+Y520=/$B?0X%@5QN@@?&(Q_P"U)=X96 835>;/MN80L2Y- B,R
M:D;I2*S'E[<U0V'H,'R!&AONV+84 R313!>L22LE+(MB08-;71&H0NU^= L7
M4_8.&;'%+,&Y#>I1095AP"K'5P NB?'RA(YG>Q,4=>@YYXI%#6]LPDX+!"8O
M421C)#,/<"@BU^S=,9X"QI_51_@+8ECQ^_02;A-79N,Q$P=/\(\T:J$@R&",
MVDFC!).QFB:8&B,$K6 "E"2,L..)(I51>1<*=C!D$TDGOBL;A16,%$RFC(X$
M?P%@Q8#]&NIC.9A2_ &/^W6H0Q<"H2K.YPTE*C576K710+GE?W/!.6LXC'$3
M%,[U#X3CVHBH1(4H"7.(I?5<'F2DC.*'ZE-*_EAJTG^!.&,<[Z^P2@Q# 5&[
MT9,@Q@%BI$C,KH""S9J?RH#O6T@(&<#9B].TB,T<5I;G-.F3^8=(SO<YDNK5
M1 ,   5B+[_]@O\ &G4\>'GE/'?::E_[$3_-E4*%"Q1H2J-"A8L2)4JA0E6+
M$JA0E2I4KSD:7^O6CXP1:9 INN+QD#@%0&CRS9!TX8IPDFPD79X5^:OXT4@*
MUN216/3A(<]QA64," \LL].Q(L1$RJ"C2 G5X&H0C;8*9*&$"LSR8,_\#3*^
M;*\!+JH380I?1#J#R42PG@*"J;DD_HCD@7&)4J#3V0 0?UU-26;BRC1':%A&
M#T^($0KE0339<""%D-KAB/KBT .<X0*!A,#OX2=":',1"6A<ZPNS?JF4<P.B
M$.)C;6#.=H74)"0'^; >Q^8D+DZ FYM&(-<A(0Y3O*W0*.8<E80ESZ*7W'_#
MBA:1T_&FL_!''ITP!UR'?[5!'3 J)/-7'&<''3CZ9Y/K_>$//GC^"WAV9-6"
M!&H+F1"CRND4@J 4%$.B/5TNS@C"+HN(QLFTZ0WS#W8I^F3'E' *LT@;Q+D@
MA%C)*02L,UN7$>SQ\ &#7GI!X'WFY"<R FH1AQ?P$^(GR@TJ\0M<"@\47 D"
ME51_-@1KT\\XY467,!$Z>:K7!TF\]^!?+G2W9Y?\ FFFFFGFFFFFFFFFFFFF
MGFFFFGFFFFFGY8B?^CGD_P $T6R'!H;( +9J<;-EF%\48NK,$/PFIL57=$/B
MW";\( $0P*0$0QN,G'ESG;1FHL\ H;,$\(0$8#_$" ,N?07Q#=B<]<4HJB8D
MZR*9C#I+FG=2:0.<32(_$/B_I'5Q,CQ[2. !$Q+N#EA%<GB976\PE&]DOO*,
MI]\IO.5)F.A<1E*BG  UMF?T'CT!3F!E2,&?-"%Q:3'!-XK<_P R4EE+'#.U
MK2A#_P )>^6OL@END&$P5G_'_MRY%@(!/IQ4AL'TY:5!8(UC%CT"4*8@'&KJ
M9R5 JFQ=2R7R%E_E!)\(O02<G4TPL0?6<V4:P);/"C&Z1J<$M]9-M2$6T 6L
M9&)J9 \7M8A<0F'@XU*53$:$F.31\#K%D7:^('JBRYQUK<KO[P%7),X-7_B(
MEW7\G)IS5O&8:3]F?Y+.5IV1HZ69U=KH$WG7%PP)&!>78<[N"R&'93<R91X"
M-#36 189ET8U&"DJ>5_U%U)P^<3,N?5)>@J!84@PF/P==ZRMK61V"!?VU(.0
M:=C1)YQ#&> BSXN?\)T 4]J3 GUTN8%\!IZ&O$QO>&."#L;Y)\QGE$O/3IVG
MO1DBIO!D%QE"D[9#JT3LQ;Z3BC08%QFVY+U&&+$JS9&0I&MX%A!PM;!RE/JR
M#RX5%>UM)&G'%>U![9EP;ABMX5K"X=C?W7L='H?CQA#(<]1KU4 W65%/2M(%
M[&YALLX>W!"C/B1BH.)HF2@S9.LO_F.(#(V@4T=X3P;%7>("'C-,:H4C-A,3
M;9.0&/+]<&&\MH$X0 3$P=LGGN#3],O0$/J.9.K$3SHP]&VI%U,(,'$.224J
M&>5A#^LF@[-P(-/'"@HR4?T5#'U K,!,QFX49*I*[7V@&3Q=5/VZBM-$L<.1
M#9_(K>+#<RB:$[T7Q:<-K8$4$C[2[&=/;9B$IY?^<<YS+$S06@B4,AS3J<]@
M$\#P!8$2^*@V%)_](29,AU^"GSYZYV&HT:Z>F0Z'T_\ 22)L4"&%NT;67.5Z
MZG%#M:"9)7P]R)L;_/$YI+91%381@7K#TZJ*$K$_]*<7H<"=8G(LT0P0M.S"
M2FEC)#)P\X_IX0X90R2C-8+H6M-XA'LEJ35%$$?^E<FSY@!D.Q10$T#*J U8
MQ]040W#_ '/@<2TE%R)PI:-Q@#*(I%C>=D"",$E_Z:8G$+#=RU !,QG4\AV\
M113>.48EME5DIR/)>EB0"$.H%!1_ZBG?P-.QZ'QQ>$)_6]M[LAD(&$-H@HP*
MU*555_\ .D#</__:  @! @,!/R'^";;STF3MTWEW6R>"?OBREYG8?O.>Y-_5
M>V"%-L.A?I+% YCO_A8*AN??(?>,[VJO)&(][7#/K.7]#A-PVXY]O_%P+HK/
M9ZK:?4,C15_3X?=B7WSWZ(/ZKVP2(0GLA;.^_NZ/XH*B1T]$1,<??#M75>I^
MT??(>\'[7O\ AGNN3=A[4]IP5/6[_ _T[X$1X'OH'V^K"]>%Y7]L ?4CHPUT
M3W[9Q\<K,Q-_^$-Z@&KP'I8AE1LGJ5)W.N!6 ML &U7-.0$,B/(_4]1\>:$[
MA:/='NG'F*KCF#TZY$8($4' ^MP:$_C^G_B7,@B>[1]5C#>;]&#EXKG.!8_J
M4]\8&^W%\6M/F>3R<<VXL,KU/W_^@4U^O0)]S#J8&>EZWH=[Q)4+U$_1 ]ND
M96J5<(A3L@CMXA_RL%]M]XCG#6M"1+$=(\CBCBSK&1BN8E5S&WWE?9_(41!F
MIUR_@VP\"CN>[@^C8>A]'C!5CY7U-O>?1R- P.M?<.)UZ2'\1Z![%Y')7@Q$
MIW_D/JM)GZN+>CM& A'&H]+6SHF/A\J6SZ.[V;9(0CAS_"?:<G3'</Z3?K63
M8J;T[5-+IMY@G^0WDHX!BZ8"\AB(K7)7@_7T6FJ?4+[223CR2E,[E<N\C^%)
M\SI)L("S<MZ%PM#))6@>3IT]\TZZD$C38U.L;;3$B958GLKPZ ID:IC_ !WW
MX$E!]W';+7*2MUJ("<QCL(?H-CT'H)C4&&O:C@$(=@@?S&1>F7(IZA]?K62"
MOHJ*.10]#IQ0O6%'I)V$S@)/@8G78;AVLYR-I(8F/:5?OXDK!O&<0%UA9^B?
MPG$.CC0[&;A!U&*0.&F&1[+/0XVX?2951A(#%AH;'MB: -$K718F=K(O=4Q@
MA?#+JDTBW,1'^.(+T?87(_\ 7 ,2SQ?<;].%3"E[OZ@?S + (+81T@:+3<+.
M6T@$^LBBJD*/KE:80SR4024==<FAJ[D!B @FL$/3%+9 0CB0ZJ5IQ%^"MRV>
M'W&DP-5SD4PMCIT/8K^%6NX>8;-1M@N:6(B2:*L[# KUC;P2E=7$I/XXF?73
MJ<7$/WJH+=T]B,B:.X)8@TJ-WSJ/\<A02B2?MD206# 4E:BPVQ5!>5))*2([
M'_2/?)>: $ E@V[5E5O<1_,(.(0'%)=PW'$'*9(&-<9I"SRR(UJ,US/43Z3'
M@?,>5YD[-9H2^_WA'=W>;/4,,?5#UP%,Z*'I^S?\,$>NE=Z8:CK6LB9C*(1*
ME1HPT*QO8KR >X\[R%T)B9"#["8I+4G"PLTGOOZ^=?XZ?\V2HYAE0$R7@X"5
MK0 ""P[[\W[_ .0K_ WX7D?^)X_\PA1<!U<CE'I4=@Z#3L[8("3:NC/W),GX
M=:HIJ?<W&)!8_P"NZZ$;-V3_ (DIHR%R(D#7L[/3.2N8[W3N[80(26"UO3OP
M<0PH+6FPY[/KE;:(M<;CE'/3.!'*+7&XY1S@LB,,6N-QRCF-9HY"2UA,IT$-
M]G-'(26L)E[2&7LY'OF;:Z]O?6.L*G;77M[ZR"9K!;:=/:R1ZXS3.9+4TU/]
M_P 2/YP$3[,J$^L2>^-2I;N@GL0UJ[FHP*I$B,)@F$"72_A6<[SA]'Y,+49U
M;Z=X<JSDKO0TB(AZ[XQ$I0\3U09"^NSNXA+R:6V]VC%YV)NA0K<C<5S@K9-+
MF0O2(@Z^V,7+P="[[K4UC]E(,NE2J:A-==Y.B5M!&[^/ZB3[#]Y/N/Z93O\
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M,@D 'J7E-<G94C-LU/+KJ2TFB'I%'!%[VQ' !$029A/V#UX1;VF*E-!UH+_
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MT^]ULYA:621QG\]C2B/^V7UNW*BQW!@QY9$;14F@KY_K&5$3@%JK !U<7M
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MID+&A""X.42>\2>%GT&RTD,0!720"+%3 A=GF"2/5%-%B2-T+BF,.,R66@$
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M5-E1#>9@D5%!;)Q)A#$ZFIEGWWSC<%X/'/X"GP;=LFH_\Z93SZ9!T\Q_]/N
MQ"I**UZI@P#J_-9?O'NKD8U&-- * D'L&(J[8V3E$+J!TBO_ $MBO4.^^>1D
M-RPH+DX$G8%RFPF5WX+IF]02H/=8@N9=)5QB^F61!$%_^F[K,Y, #TQG AJ#
MJ-O:-*F%9(F1?3.;[.7_ "L"CT."?4@Y=/S@!92RA0P-Z[DY.O\ Z4'#7'2
MJ!* *BL$_    E*+H_I1^^?\_P#]2@_]4<>?)G'O_P"0_]H # ,!  (1 Q$
M !         %7?"_                                     &A@
M    "/\ !?>                                 &,H!V&(
M F4                                   !< _!+          $!H@
M                               &X(#)J(           FK
M'1                       Z( '_/           4 $        '/+
M                  'C0&%C0        $]( !P       $Q,8
M            >/ &\9@        .OVP2        DA*
M     %3LD3'$         ^D3[@         OX                     $E
M$@  @         %@,L          Q@                     $5!G
M        ((5PX        ^NH              &M     $"JZ
M DDDDD        / '@              :<@    DDD@          $4<I4,=
MX      $"<[              BO.   $P!>P           @1%KA L
M                  #]*X  #F8^L0Q         %D)_7>?(   !H
M            .?J  $\/14<TP            KH     DIN'H,
M     #M[X  GR0$NEX8           VQD    ":/ \!X               \
M6W   O@U(A?7             $-    '.()2Y #OM]]P         V'H  $R
M?MMB30            I:I   #Q5DO!0 %O/I,         *7L   5HBQ1K(
M           '&L     A  M$ %2P4EH        )-,    (@=Y0]  D$ @
M     1JM   $B((\!  O%OWX        "O55     Q?\   "AF*?      $7
MZ    0!!5\9  Z')\H                !XY@   W]T_=      %!    $$
M^30H@                             %G7C28      )D     &+5E
M           E  $X $(  H  D  !NO=<T      $%@    , !D  ,  $  $
M $$ $H  H  @  !  %  $U "KZ@     $G6    'P L8 $( "D '3  A  &
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M@    %2@B?.    $            %%)\(   $$D     $=BH
M   D                 #; MWE   "%      E6E      @ @ $ D$@
M@!       D@    E:- Z,   #@     !IHA     ' U$E\) $%,&@"@U%
M  $)     E'L8Z   &@      &0'8     ^N]]OQH3T"TBQY#L8 ',W(B;H
M  $( "[H  '^      &Y4L    C#=!H^'PGF"NN+6@*A  SV2(:0    D0%Q
M$(  "M      BR@    '(@                  9V'AQH   $@@7BE   AT
M      )$@    SE                  ',H 8_   $DU(B%   &B@     &
M!'    '@H                   %,"*    $@L&R0   ]X      A(    !
M#\D                  4+@H         (-)(<P       7(    "\DE7WW
MP^_R W"PW  P  D!'30       &UE9!&\              -72222222222;
M272;.    [@0        D0>H SX              TLDDMDDDDDD@LDLDM8
M               E8  QH                    5+ZO$@
M     -/F^>X !D                    ?5_P#9(0                !^
MUQ>,J(!/R                                           'T>(ZR6
M-5@                                             '*
M                                       '0H;
M                                &4)\
M                          QC00
M                   "5]:
M             $MJ@
M        8
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MZD]&5F)O!%07B.4&)@30OG(^%@0"JB02DO=7>!)@(ZN0MF)$AY]IODNT=\?
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M H)#+ZL,0;7"$+*"5A/C"34.R,E5@)4]Y2<8_2H<R@ C#EZ&ZXE*_%F0(<4
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M4J#.(<H\7>A?0.F4P]M,5*8*D,S"FCW/X?**E)P!90 (@"(B(BHB"(^<X%"
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M[4>]FN-U:R#9%'^AQ/P\', 0$#( M<;,&"Y5?LAQ4QX/!J[#IGW*Q(4! /\
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M2KMS_@J"'0&[YPBALI9$,YF"TBR[<T>A^,;85NGA$:-4BLGX@:?CX804 7^
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M529N1B'1KP=.,)&W[KDOU2=)K$H$ LG/#YY;)UY$!)7J -B]$?6@"%$YF$
MR1M*_()A1'3FB#$AC)<2 S=;(;D8,\,RY10:!="W?Y/E9*UBM91*.W,*)& @
ME'>&X2 J$(YKX-W"IR*@&$.V)+;=3T2$6G$NM268F[)T!KK.F!+U86F)!B^$
M-V Y*Z($@5!U!EIXN[,EDE8(**.!KXR&@48MR?U/\%B$ 5"' H+ME].(%&X%
MQ( F-*!+*!P+BZ:M-7?R 4XF)J0A""#:SR!2ZMVU4I3 HYH8FVP<=V+()+[F
MKWQKI#I$(6P1),4PJHG1$?[H.E7#N0$K<PI]W%1H!8I2DR5FLB,)37H!=QZ6
ML;3%[7UUC'%E$<I+O%F8^T#V S(4$WAIW&7CF"L;(Y-QI;BBQFH')F"B!B]1
M+'+J#1#.17C!V0B1!V$V*\$\(=^;TNQ$K/"!S3E1TLH I)AAD>[R!K79B@J5
M%"&8.<28!::C-&L-V3<LY.; -1JE/!O$1+)E,)$"QLLQNG.['=9/W86#(6),
M9)(=$2N<JN/TADG!4SPHWY"#G*U$$1W07Q)[.H/;!)PX]LN#M1M7<64+.=T*
M#)\8!GD-VB3KT1*')%?7)D (P1(+)4!!M..=.JA%)D+:(J,U[!0'Q$,"+',U
MPT8%QH@ 0G4O,'.#V+#_ &TBPK&1"X;I#JQG*XP]H*5A0DI/D\1E!IXR_(,R
M!3#*/$0B=X\ZDC"P[LB(*,>#N9QIHN;^( &U,Y:K\X/P#H,]YEQEL/AE!T,G
M:]S[7]7@MH?0/;]QSTX7O(/PMQ"]-Y?MC=\W^KX:F:8"MYR!^3!B8\3]8:?U
M8_;_ %X'-#N?2;*'\/<T*R]O\+V%&YV\JX?PU;/H?O-^\MY>_*GU^\1FSY(/
MUA8>1/8_H\8S]QY2_P#6/!=GSN=.S]K*W8+S>N#/DY\)CN]S[.>J/V?[\?NA
M]W]>'@\ &FY\C_5\>01/[K\?VG@WPG(O)."_7A>'NY'Y#@_>:W0/!$;_ $_A
MXNWUD\AXTB?YOP?AC^G^_P#T9K=?D]/X<$Y6**)^K^R/ZROS?O3/;F(@V0^V
M@Z&?/>0_>&?)2'[\%I\AQXY;JWA-_(^?Z?%>&\[Z/W\/>IFF;W1?@G\&R:#&
M[<C/ER3 8M-(@"8;C(J)S<":))V5BHF3"%A<,#OX KWI&8@!YSXN$V(E +!(
M0]711 E:7$_&;ZHX+"^HF@.TW,)W,PE "":@B!RC_A&H#=7J&N1FI?2O=D&T
M=Y;E2ST6J>16:T3"B! 4CF&.\+& 4%1F^(BV%+71=&HKI>.>'!:6'UU4QHL8
MBN"9Q%9CBB% VK\C""XN9H4M0@6!"&91QL>)ZF,5.L_=@JLV)^")F:CQ":HC
MN(_3_6+R^\X^X_1C[Y6'S)^<W^I>7U^!UVA4Q'5S[>I?7PPQ]1?I_=X<=7L?
M?\$7TOX']^'@\ &BA'EB_>?:WT+P$53F'V1?@[K\?VGBWS[ZA/JWA>\GZX/F
M/)'C($;_ $_AXNWWVC[$7A(<.;$^GP%O'$=O.-YAQ_=_&X<'16:)Y %O3/;F
M(@SP^V@Z6?/>$_)GDG4_?PK<!=OY'Q_;XKPWE?+C">2O^OX:F:9^4^@_0OUX
MP;"GB\@JR/Q H295)KVDH5Y!3HYUM3I6*7O EFK .1&S"G BSF47(D1XME+U
M(J 96*0MQ>+H_5Z,*:"*FBLE0\Q5&5HXU01SF(+30*Q!F;VHJ&2F+2;=6TWL
M[F0Q>ML36!RP&_EMS  P\Y=9&"8U4I.(_&+=Y3RQ LN,6[Q2%BG/0I@"0 M<
MPS-+&D="B!+()9*QGL:RTL)A:DNE0%-0O9?J#' (:,L2,,/!NA;+;2N[!M.W
MI!(5<2$69>&;&X*8!F#OJ-D[""/!&B1# ?IWM;I H&>L3!8'HB@2+.3=@[TS
MMN9&H 27&5B+*=2DJ"@YLT-%@LKLCK)3$*5&B>F;/T,?7QDDIR'!XU]%RCJZ
MQ+<&.[>B8F+B<,I3?!9!;FY*-&U*VLK$/9FFA9*."51F)5X+Q>(TXATP)3]3
MN)?B@)Z(5:93HY0N9V-F>!1L!RR^/OT(%(;44BRS"IDSEE!<1B4RX#(A3&GZ
M.",% #L8"$0+@*;9, 5A2/1954T&YUA!IO A.)8B1&!WFP9)+7:*/? *FL4%
MF"V]&D3@"EU+E^4@17$E.120/;'-J1"YK9& .AP;T&8 @Y:1D -X'Y".X*=P
M;1CQ+XDJ%PI"$A!]=09>HQ,\2P1LP\)2<Y8Q1 CC+A#P8(2JT:P-LGZ=R1Z.
MK(TTX#)#FUT&14X]QOX74(1(C:RR,%I\FI+%6FSCC"!8:)T/JJ<')A("+6#Q
M2M+L'GJ&/_UF8:":$3[DYQ%P)D-,T7G-CNHG[,,7?M)1)-K,%R'#E[,7%R[Z
ML\DI#HD8L;$&4:I#N"+29PM" O3T<,")S'XS9\TB+0?'' 'Z1Y3!!T'(\(I1
MCH5UUQ?0C';S;#02 X9 [=[3.3UNFTEQ[(OC1##TI2-75,T81):0[.U.*;M+
MP$FZD$7AKEXZXP#\UK0E JT6$7,G)TFZ7BP(D%CU,!,ZR=,#C U6EE%;(=8
MQN5\Q,*1H#N&RH@Q;BU;JVQ.#*]L\HN($TWC_72/T<RDXF)DXR?KBC5!L:)8
M9Z?!<<C'+<SA[G!+,VE_.EPC&= -0HZ+$C<-' >T(8T[<[JVC"K4<&!H&4A'
M1O%0)0ZT)[JR@9PF>:(7V<L$P%"KQ:FGR =PVN@&V# 6 PM6%P#V;P%B1Q9U
M)1:+$, \>9<=!<R(L&L?M'MA/"@9&@O.3HHOJ RU61(#L<Z>8%9PY)3=M!K%
M3965K(@@9828L5TAM1WMA+3T('])L13M"7;E!0%9-3W%F&B"76BJ3D!(!TE!
MVCD-<0*6.H>N!YAS2[HKV'2:Q&/70G)B)B24T8P!\@6D((0Y XP-T;R0U)P1
M(>HZ8JDR3).2.XJ8EASCB4CBDL+(I!P/F5%$9"1,03GF;,3[&[N$OZ5R(/H=
MGGPV5*E2KTOK_P!_RE2I4J5*E2I5VWWOP_FJE2I4J5*E2I4J5!%&CA$2;N'&
M'A]/F%:DDFQ)KP#_ !'=+$;C'F0CL/G.>\J]"LEUNU.,X7PGD2>A*;F=]@PR
MY@5[(U\?(0EQ)50!3:B51D!RL&]98Q.6-9L<P31WCQ-46;-.98<YI?G4<!B%
M*0;4HUT@3.'>_P#:&8!L8U9 *9R!"X4MX@9(6?A@G"16>$AYNMW$^*L((,;?
M@5*G79_>_#^6J5*E2I4J5*E73?V/R<\N?A'RU2I4J5*E2I4J_O?^W!"8HDHZ
M$!J%*PT_;TG7^/P?&LJ5=-_:_)^-4J5*E2IT,*UG05O&2*(XPBJ?SO<;U 3$
M)FI2BPY'Q[.27 >5,YF2769L(3\1NH:)S&"U,%JHC().0,@@)=%A[^K'LANZ
M2W/GL&F0>##QNZ/K4Q,14^Q<-:78DSERJ>6-=6'V#QLS@-+3^11%L,/#)]P)
MYNB*B3"<[/[GX?QJE2I4J5.;Z(<.E4H MHSR?P%]?/( 7>$H.12"_'^?)D,Y
MX?A5T^0EW!7B9"V5ABXNU8N?ZIE 8"B0VKS@X7,=LX,7F5 *49!55P"GS^E)
MH*E,1AYES91A!_FJ7TEBO>C! D^0-@'LTT]61V7><4E?BWG=:*/+)Y5_Z1B4
MJ;L3;*8D)(2F4 ,4HK506WO\Y20!)AE"BH!%5!&H7 ,_FBGW[!3(?+JVV'\L
M>"/HCK!<AM,FQ!:6X^:.?]LJE53G7@UQ$BYQWV):LX "TS5 CPT8-<06 KRP
M;-;DJ/U_Y$*8T&)L.!8FY0&Y(.9$OBV-PUP@;%Q'-@S/I"$,Z]15"WNH2 IL
M#Y7#+!)DTE%+7!/1-G\C8_6B1+%19+I.L/23!?23_!36)Q#USH$WM==D4")"
M*@F0-.X5*7YO6;X9IQ>;X5>'!7@F&REP*):/@O&RD"?_ *4(@%3D(TWM%HL,
MHP%0%Q@E.^A-KQJJ27&E"%>AG]BN(6DAH\73X]5LM>!*"6(VZWH8D==/ 32-
M#2:91]$,<;4+AHF(-[&0L)WY['S%!*@42L$K 7U7$,'6"-?/6#W%=HV/R3WT
MAB<I-A O#Z 1 ("9$HQ FR^% A.5!"Y>\#"H*5OT/\ K(,PG S&Y2U73 :$>
M?S@4!M(RHN42L+^/\&]\--1/NML,8!R=XB*<##1+K?P(0Z?I%:%$60SRG%U1
M/#08<.-RN%,'[%"\4,C.]BQ<S+02!*XH_51\6E"P\8?ET=>$' "880R&EU74
M5&#I]GL$FBJP2QOL5X-VA*,7M  @D@V0D@PFRVN/C02982CGH=&<B:?PP&L1
MZM)@N:IM3HL_S9NDT6,%D(J!#[<0M,A'>RN)UU# :D*1XT"*ZNNMP(1JD!L4
MESB'J2QEZKJF[@#P=+'!A@JC^%1D]P61^;3)89A!&R1E:B_%7"XD*I9UE]3!
M@-D@PD))-G#X0%R*>B:XJ)=OKXJ$S4$KQ%_UXK!+@R2:;$9$X1[G@T+V\Z%Q
M$&X0AI09<0$DXDZ^*C(F#1ES$SZ.OCM3 -LH&V'7I[F !, )$8221L? IS(H
M7-<**\!FD)?,:I'W'Q%&2'H 4/($3L^/%.%)/2IF=O3YB@2H!M6 ]\$T'FDR
MRBDQ),$7&XL^ORH'C6L,9)L?LI7*5BKF:[L[;X-HFJ"YM>RV<*@AVQ85ZK1*
M36T2F,P=#S_S%19#SN$:(Q0%DN)B"#4RK$5HBLBV(";+TT_BX;(71\&4TX=0
MD, W,X!'K0BX,:"9@GKSQ_7Q2=<<S),^28)B/&]+R ,U\V%CP< #0''MN/3Y
ML#%8' \$'FIMF)4867I%QU3T*. ^'#13QBTOA^?X&J](W#F01C!>-W*^>RH2
M<>VGATK=%^B,B,N$@2Y8SF2B#';Y8L+FA0RB,5R* D;*V=@W:&Y)<K8$881)
M[\228:X&3+(9($I:],;0WR5,@9R'!-D(&V)LG*D;-(0:A$(3(C%#>F,6"UH)
M>!4\Q3F ;!2]8,F)RCCD/O" LJ/"*($V9)M3I&@%(^$M3'Z$E6?B*AGCT./I
M##"I*]'#XHC%XD# 64 KVQO #O3PP&(U*!91W.OKKP,A#897V("J9HETER58
MUM *4B&6@!.S  ]AFD#\Q+2\+7X!M,C](8,09$VP[F*Y)I&[D-8B@@H1F3*;
MHIHV1K$@!-O1#R,E+2A:T46WFH.\8G!@H!5L@DF2B#,)AT)CDVI-T<1>BY0Z
MG6AD@.2 8?>FG^402$0PH8BCHL+"V2(12[)>&M&^H5)CANU \+/0FQI<Y!5"
M5'(V1@VJ($BYY+$]>Y,QS\Q RP1>]<E79TO*5-7G[)MH.70H/]Y?WI2DQ\O:
M@O3]T'JN'H$P0Y;72)KC*&4Z5F<6!2, A*[J]B%/&%RC %HK*5$R%F?5SLPB
MU$RI-GVC\-O1W]K:# 7 G(AL);*!'2.DB+BGE%*33:F0-0S;(A?88%()S*^-
M,KRL\<P!Z(C9S<)A;MH>1XL#8"D<*E2_=J?G3J8+-LC1I AP94R( S)+SD@!
M9,<&TK]LJ):,A)(-7,1RZ.^0A%P)_P"AXBE,OS)VJB/7= 4<CE(RPS-!I$P(
MA&OJX=84%(82!H0)!);9J-!(.4EG"%W[-Y0PIR%".)" &!HR U& E8 VTO;5
MMX0HH!"L5=LTG6<+D!$N*($T$:P;";^[-7O4+G1T,,AH5 "N"69(>;R5G(]@
MTD&H(&H9F-Y1(90XDYVL2"(-1% "J/1R(S8JT]DDO#CJ2 Q*5,2L#&LF9<K,
M3),5-(BHDIZY&B9:"16E217%6. @A$(3 (B6H-)#UG!9RPN@-(H)VZ\S41H*
M4( L7\@[8B8P64(<A:[@3/95-TR1""(:7VRT<\8WW(FRBBH$:<24,!E/%R0
M0LQ%$2,JD90D4-4D*&GKD;B!@ +*)2#H @B(K E(@2'DL#@/J3;B0Y+T14%
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M??F1Z,!FX3"P#'B#N^=.>6;31P7%-7B[$T:SE@P^FE&C1WZ._)\:T%0)"6C
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M[4!@1W#<;KEB4U98STOIB]O<Z[$NR6H&H02@;$6$RI0<Q/!P()DL*M0H8$=
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M6 G)'B%@!($@$1%$LK$I'@BB*.?SCJ;UE DW[D@ F&XE_CE?HV%O3F)98$K
M5W"F,U$5L) E-D)) ( ]T$>=M1,4&$1F! 81MR2-C S=_#IIBP%06L T<O&
M$A "J] )7$8('^/"<,IR^D)BU.HF""(J@?8F$@0Z$?I56>N_@)LG()JG:TP5
MJ% E) EL2(IG56MK!4HH85F.(=OL6M@#M)Q=J1T81T)UV,!)A/\ '!4$JO&\
M0PBX*4>S+)ABD2/$$$BP"<;L)$+$J,:,!''L :@20P!*Q4?PN*20%!*,KB2"
M!B%._5 0P8>6H!*6!R'#%4"A42&%D1))=XIFT5+3%*,BQ46%QDRK862>L:;-
M-_XZ)UG!@CSMP02\&=-NA)H8+8A021,F\8?S4':C)EI("-&H6(0XH"#8 -G@
MZPU/A/?),K<^8G)OM_$AUV58=(D2!"&N9( 3Q>3E@@2+!8XY%J7*2 5"'&[M
M&0UM+$GH2$&)<\"R!!!8 *  1*>_B0 J8 M5UA[A+1'Z O:(_A!J^R0F0D=-
MM4@R>B.$N  $) @I)P*OLP!9O+@->V"SDWDP9,$*[P*6? 8166Y[!((@?!$(
M9G_&A^)-"#8#?(@CPDX,1<AZI]8QZ/7 =,"'"!KJ$#Q+U<(*BSAD/<]$#QAT
M\YU//^O;$>?-^>N(\8BZ\^?/&!#9']W_ *\N7'\+C#NYFPA5U4)$@L!Q!8[E
MI8(XM0+2P"21-&&/VA61"H N(WB62WXGJ$LR)<:]%)DEDQP=^/!B'&K<=RR2
MJF\U,E0)PA"12(U+3RD065"555_@U*1XJG[$!,#OP3P7.R;8*VG*++#J)$XT
MA#/N-!G0$],A"O80E8DD)/:-K.1!1 +,$ EA* E+_' B2X"2H52(H\PTC")V
M..N[A!91RDFX, @[ )&&-@)0O*Q,R^ $J&T?"@'C^/\ 66V[W?GSO)8Z^3-O
M\6=NL<XBP;:Y(BDY63T-)BP*)0+,R'-!#)F!0$W !V\-2#&#'(\)!(*BQP@B
M2S4SL5W#6I@3&#!/N*7J">-M4=. SC3HH T05*4<_P ,W<1!24DLD*34R,%H
MP]@F9,A!E4,!LW+40,JO91%PPJ9+$5WM4I0Q4R*=K@+',G,2%>L"5M )@1_C
M8&\6'"7O7GS]=3EX?!?'A?5_B[.WCO&B<[Y;_%(YP19K KIR&&N #*/88 4
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M#;CFC-J16M=,%N>M@=F&DI6L&NEB46)G9Q/3#@?(4)"?60(G6!M3O* ,IW)
MNJC6 [2O* ,IVI NIK1@SX.V@G=2!V21HQQR3YE01ZI [)(T9,[:]RD];[C
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M @-5@^M!(0+HR)5!)@,H&)-4"&(1 KK1.$OD!\2TD8D0 ;H)'M(G!N5EWA8
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M;K 94)"9@.0II#-/!#-"BVL$2&!Y+8NI"T7 L /1S%)*W!$54C105(7;6.A
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MX+'GSY^\Y+DN2Y+DN2^$>7F//OEZX_GQSSD>?/GTRY]L@B-G?&^SD3O(UUR
M:\$+61++G;C.?\4SQD$SY\^:R#&_/GK@>?O^<BJR-Y>^?/GS&>V1C;'O_@TG
M/@Q 1: 95 0H$-+HF+/**B& A$U6,OU9F%6D"C")(H[&/"&Z("R)!A(@(81D
MW7 5L2K2JW98,Z$](QXCJ^O#/O9HMPLK$MVB&D6<:ET,)B21!SJ8G.%W !,
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MB$1I$'YQ\Q*@9=B9!+$J9"B<^DW^[L,=^5=8U(8 &II6_;\8EIL*=5.&TQ:
MHL(R0V1L#&')E1515?DQSG<WY\_CP8Q-BG_#<6&:::-()C8 D,526<J#-029
M:0B-%H#"0X:2*MF;)29N@0!!3$26&5ZNX-#"@LJBY$"PDF&!'!1.R@(&:(U
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M>IJK@2,F9PP, ^+-F30L%<!5&D1%C4$G(AT2I+;2E1*C2V__ $T(A!2X2!A
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MV/7?KUZ83<Q7X3CK/;$)37\V?XP.A?\ >0GKYG\??I.:G!KZ_P!XH(Z(_?\
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M3^US%B&B[3UG ^R,"0  3/4-8A?'PG:#N,W)TQE9AX)@"-#-&\A!R=B7 0$
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M+DN2Y+DI=^G7MCO$AI?6@$J6PG\(H*U2("54-*4  D]S'J*A9_)"@9'A! L
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M\^?,>F$3>=X_'GRY"5ZXJTZPHCM&*,'I^_)_S+V[QOTR=]\EE7;Y<9840:\
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M(0Z520DATW7 4@V$:JP3%,X,!.@C3EBB#(KAQ^H(GOF80"J!D-;LT@A()BP
MZ!SDP[,F18!  11R%8&4$L&H$/F5)3)CO)8P 2[X+%81/0UIDUR+Z*AUTJ0?
MD-"XYA21$*YI )T?:UD##H$%-*Y(7CYCB-- *4P!1SB#5R8B*@4*0F9XR#A4
MCC$V4@PR-B$A@*$Q%+P01)( B)(PIB3P!HT6AI&$,80B(+=49 @C?X"OQK7/
MS8^5'T_F*3J,@@:DYA'98(&&*^@UU(*J!&"Q)#B4'8$^ C9RUC('(H%5L$Q7
M6$3SQJB(0Q%)1B0H(&)C(W).H:=!7D69,FZ"EK;@6,@00RR 0T2"*R"T272*
MV S$$,42S&D 05&/CGQZ1C(*BN!(72RIL&S!ZE$")H! +!+YMHS!#J".!Y,N
MI)(A%5%%+5,EFAKE@A'P00:AA2GB;018LTZNG[9(+U2' F80?9$P=9ZDTB73
M*9HZ&08.)@5A4!(*3,?,='EM\0MZG[R%XR'#3.\AR'.?"'QAQD,#Z^$.H9^
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M4=YG2002 2P-I:2 J"6<*/%("N0+$!23D E,8,)[AAD 0@"$BDF7\F37.0^
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MU7S"$P$J$ZD,*E]I<QFR(8)8"$3@4E!(S&V%\/L^<KD""\ _]-;1BE"!@P*
M3!'ES]YY\_>>?/WA7H@ SU]<H7NJP @A]7]_^H"H;F-)RG&_?[94\1')S_ZK
,]6][-8Y^C]_^0__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2113965d1-pht_electro4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_electro4clr.jpg
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M 0$! 0   1$A #%!46$0<8&1(#! \*&Q4,'1X?%@<(#_V@ , P$  A$#$0
M ?OX          #B4AR*3'$XT3RE4Y2K(                        "U;
MU\87KFBH                      AP19E@.1Q45Y#!8'EM>\WUL<1]J,VH
M]N%M=YK9Y.3<7LTGXO+]^FOG$UD                       +'E7@7)<QD
MFV6OO;ECN4@                    $.O%,(YO7H)V;1,9]K"2L9L&26F6S
MW'Y;M^%YPJ\<<N+/#,C@,.O<5C%]93?K.Z;"X+;_ &:/4
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MD;'ZQT:<<+L]R50 #3]&N$QXAXT)/3M$GPD94;"I $<$C(JF-T9BGUP
M   "D,.YSE+^4\_9V*TASY;Z!FO5M=R;>,3BNF7L@]8PW.J           /@
M_-/W(BKURA1!-04/)1Q3[14 0QSTM]&^@<>SBPV+<+2^B=M76%9 <1$<ID #
MB6X09G-7U=VWFFU.F]3F[$;#<F  .(!0'D'H%@]$ $=$B(JGY-(D@^CJ0
M    *(I GPM:O(SX)M.<=BUW&M!S,B]KU:)_G3<9'[7K'N[59W[B *(%4@
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MWQ3^@N137K>:^[OSMW'Y*_1OYV[<:!]";<\R^CK]0   ".B1$52
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ME$PQ/)(     MF#RP>F)K3>1;J0PG*9HSV*^Q!!(    "RCY1'TGF,\BH
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M#HQ3IINW,>H\-W-(ZOV:@ Z]#Y'_ $;^=VW&@?0FW/,OHZ_5    $=$B(JD
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M:Q6)MU1U/6B*K[%0IL.E11G-3GK6>@;-ZSNWHTU534  Z]#Y'_1OYV[<<_\
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M*W[,4\)="7A^]QB%U[QKD?>$,O<SIKF/W.U[&5 (YN\?IMOW(=UN=]BSGRO
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MK"M8"@@$J@   I )5*%0 6RA= . I*E3D
M   1T2*@D                          <2H     *E
M     ".21D$U*                         %#S3'0
M          1\9X70         "B*I0LTQ>JE*B*I            [1E@
M                      !'1(J"0        !1%F)K2L^E'7ICLUSSHKYS%
MU(                        A-$5IS<\Q&S*>8            (Z1(H2
M     .,.KYS;]$397#X+D,'BE]BL9]L=9N/"WZ>.,56V4^&0R>WR6<XC.29B
MM@D2TO\ FF_$\I          #$3YCH^L*;H         -6T0&=T\"7T;B?7
M           !'1(B*IT"1OBGN      'E5^.N6>UB-,[IN'7F%]+SN\IQ>QY
M1X93(O"\[,48_P"GGYL6V'Y;7/#N<?QN/#V+'-3IK6[3QAMB[D5@
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M,5N;+23H7+=SN?=.SBVR(%BJF,\IJFN^S\RRFPV3"[FO>#1>IWJP
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M&I^S:G\%?HOYR]&SZAY5[I?W!X!]$;N:;EKDQ0%2A5%4U    !'1(B*I
MZ-5&BV\\OX^GGN_S[J7>H]M/]XYOTZ];EC#[/L!@>B=6F=/-DR6J>SY7)*64
M^-O['E'9IIZJ?%]ZL.]KVUY>.Y^JX?9+#V%P %BF,(]?#2CHG&)/PVW;>ZCO
MW95@             "S,>15X_/[IG&MY>=]6SBTRU8)=6?/QZXTTWSY\P;)U
M;9:)V*9L3LG>I1U?X&+,OIJF\T!W//: =0Y%YEQH_P"@GYO^E=G<!LO)(
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M7GM#V2R.RVM8?ITYG0/IG!=3MPQ%[SKQ3-\F^M/$^VY73KTV8#?-JM5W/G6
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M/+:[               "'"F;%NQB[C"$>V9Z8>$XNC)4YSX35/8]Z:@
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MV_E.D73OF+ZG?/OWI>]H    CHD5!(    Z5?GHGN_+;?M:[GZ+U;+;>ZK4
M XS%FFO#[CTC^\]O+]9][QHD6R\LE\/*Y4  '$C;(XK33>>221@=PW)U/?KJ
MH          <)I^*/U!^87V6^9?TO]OPR &HFVZS+V%RDM8S(X5=6FFF\<DR
M"PR>VNF=+R>;BY3/*8K$I10CJDPI'&8Y1/"8\9Y:E;CSW ,KK6X&C]6DS'Y>
M$\WAXSR^-V\T[:@.,()V_E.D?3OF+ZG?/WWI>]8    CHD5!(   %$43@%W8
M:8;MR?NV][N_I74LD\[@    4*@02 H@8%=V.E&]<B]^SRFZFD]4R"CTY
M        X33\4?J'\POLM\R?I?[?AD /@#]%<+G_ %G8?JOR+I&D&\<ERVRS
MDXX;=94PF2]6JH #!#DC.4@ </-A%W9P3L>FPQF]-W/T?KORY[#S+5;<M6_1
MO\O_ $2!QA!6W\ITBZ=\Q?4[Y^^]+WK    $=$B(JD    "SY3$&4P^J6\<I
M]CPR^Y>D])RZUO*I       $1Y3#ZQ[5S:[Y7FX6D]-RKSN;\P
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MZM,"D+$QI7O'*\SQ6Q[4ZYN0'&$";9RO23IWS+]4N!_=UZL   !'1(B*I
M    '"(\R4:Y7"P7G]1P7*ZSW**>C:4=B^KI9WUB[QW1NK?Q:/"2<?L.<XO9
M)9PNU21C,KZ55/(JD            "W%4?WN!S>TSG=@!X]=/6J\/?\ *YY
M%L\"JON([$1=3S1R@.$SQ.".NGIUSZWG1VP >)Z>/7ED?E[ <8CS/3QQJYQ>
M<66:Y3(   $=$B(JD        "U#HS1C?OX^-5;8IDK'K3'8BKUO+WSRPO\
MWK?W[$U7               "B+<QRB>:0.$QRA5(          HBAR2!0HBB
M.:H    1\9^<@        (<:H>-5:HX3'"J;J*1/*8MRJ<X52
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M^0S52GXR%R4<+9*=49*<0^7^6"OEN:<(?2:'?H.H2XTI78+6AL)4ASZ%7D7
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M[F1F1WF,>-)_P?)*MRVK:3#YE;9[7T&MIN(\AXO+:D]#YY:<P@:QKV! E#F
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MR2X4[C1)0%+&H4-=FHU!#4)4'"2L'N?I:Q^%VHD.*1N9J1JQW#DZ7GZ=\/\
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MMG/[RN287O*=O#&*:*(KZ/>*E,=WC'J3'/JV@[4YSN[0K_L;,%,>/RX(Y(\
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M*)H "C,IG?NZP@&M$84\_K"HK(ZP0J:KW8$-/\ZS_O*ACC%48V*(I'"R_F_
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MWM*CYBV;/S759O5H5YE+8UXUPSTA <3VS>[CC30MD[NX\_)0H^9'0K@H2O\
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MOC7M%<,<RA#"WC[G8%(\/$!]]G4Y2O&.O@*49N[]ZWT:#;:J:FFO)'_-4T9
MJUJ\' _FY,O[K40VHQ&80R?$#0[X:0K[Z!'$YRWV3DK5UO ;U]Q3_N_RCBDS
MQL_&%)Y>I'!.A?4]H497C)D<VWV2@T]_R7Y@I4)0@/+0HNP::O)1Y;KJE?A0
MKK*O)M+8<A^$VP.9$TN K%HL$!$!K=)C0HMI&%O'W.P*1X>(#[[>IRE>,=?!
M:PI]./(HL! MS<NB '*H_P!869<W/JA:U$ZT8\JU7!458-) 420XYJ5=9#L'
M+FHYU1&,?W=K2A,G=[)U>A0;5P.]?<4_[O\ *.*3/&S\84GEZD<"*-.N+/9&
MB8+;8."VSQ]3&RKFPHFI4*G#@5$5JGR0\IENJ(6K&ZV,**JZF6^)Q*$#'"G_
M '.P*1X>(#[[>IRE>,=?!P<(C)E7T8-?9$59(<M*-V]?LIY.AL3I6V>2UT*1
MDCK<\  C+>Z.+>UR:V'TKO\ F]"N0^G#_+Z46PU?43V+9@D#,86P[5JN-6?)
M_F"^ERYA7T@D%0/Y5N4_O'4M1H6;@MZ^XI_W?Y1Q29XV?C"D\J. =:X,M/8@
M:FDUVN^<=[YK%=&%#@H*]A;1M#^CE:*UL\EE<.:@86\?<[ I'AXAL=[9?8FO
M9(NS&VT^E08J:^$UO)CD@@8U>D>A.^*'1'TJ[G[!Z%1PL"CO,Z3>FG3Z4?TC
M;C#93Q29XV?C"E<O4C@0MA"\8B&@B/2$)W?KIHASMH.$!PL<$A4_4:#4*8<C
M8#G*!P9_W.P*1X>(ZU(\Q5\5F>-GXPI/+U8$;%"EQC5!S<OM-CTA$BAN3U\3
MI5.!!&Z;IC"HNZ* KII<WVJ*?E%6#/\ N=@4CP_L1,\;/QA2>7J1\I3-A*:#
M$4W3337%KNQ?6.OCEXS%[;UN6%>4A%DFVS5LC[N#O'W.P*1X?V'T)_C9^(*5
M=K . 4U\R8RAU4&<T05J\4C@[0.:!<MN93[R:UQ:Y@O5%N7X1@[P3_Q/0I/@
M_8@[G*,'%PZ"F[S,>RXP66]. 0%>.[![8U_3YZEDP(\0HP?I,+C=]X-[$TSF
M/::?ZD1@04W>F/9<>Z-(]:9N[^\UL/V)C_\ HV%TUQAR5\R;+NTN+J= B#\R
MENDGO72?":#! @/@;V3V7 )[&V/>W^$'G1R[>5^%.A^;<E_QOQ@G.EAY :XB
MJPAJ?2W9-YZ&Q=S( L-,ECQ#X[$(&NK0*#^T42B6@F$.4&N'@]KI3Q)="8X&
M6WQC6:[E%"$UOY)@&P]UXNS*?'$G)F3ME&+1*:*+9;KKOX4Z8.ZV49;:?BOA
MW8FQA 7C_B [5&,/J%W*1!1OUO:ZKW1#*C2(0;'Y:NE1/>V5S^*\FL?^8(C3
MM'4\P3IH[S)CR***-1@6S)U94&?)WYA[-.10<*:_\1U.BE4UQAZ3HZ%>'FZ)
M\L/-IC$D-O4>[E5PG6B!'V;Y[CF_#8<Z:Z%-YT-,83ARUA9+M1T=TZ;%<@(4
M])B>E0%6'&U72*$1 4B'(:^>U;3VL0/\(J1%(;W/])M-[,YSJ(JBF;[328@1
M[H:+#=@3G6J=:)'*VOS,^:*PU2WSW0F$*,LQ&"R=+,/JMCHO4H1GRXP]X+5F
MLYT-UDF]N]VF'A5.7S5$U!%LLB(Z":HYD-D#MKY.9LWVH_\ +?[)Z%%P^B6D
M &((::P<\:E]*L@#F$% <)K!190ZOE5'Y@C3I[SCG%01=-B#='RM'=^9ZN.(
MO PY?=T^972LH7Z"?<:V55&U4W;N;!?NMMVC2O\ X^;NS?U\G4INB]=HC2+5
M>WC<X,%5+*^0*9_=]Y%PS>Z,>2SS5$KZ) @?X[&N$*&D>W5&A"[0; :;OO,=
MIK:3R*\^N&/,H<0@5M&Z=!RU\PL4>[!E&9D1%YRS,C>]"U;%U0YP+"[2J/,D
M7B$P5%?H]^+7,%1;V]"OL,6X(E[N''^ZCNEE8TJ7_P#Z@.?()%U_L GWD'-(
M,JR'FJ#?RR8 ^R2*VZ5M&5U4_P"W,6K%TVTFO-'19F52S\2VK*'M,8>R7>\Z
MTGE5QHI!)C[V>=H_I@<L4)3HQ(B,X][0;/,E"+0V1=.>G\*F?VV>8N92,!TQ
MO>6W;+ENWF;KEQ<?:IA44_=MXW>2[=R/?/\ E3__ *[OHI8+S-%9S^T%"WRW
M6HNG3P#FI[4[]+.E.G"H.<&]I7_5[NYLZRL,/S0[$7]%$.0P628/,&P%HHRD
MV!EA?D;:H$1-3Z*X"J:/Z1%A'>-"UHEVBS)GZUONY3MHYC3+N ,LN"-7Q+\N
M>-,LA.E:VQ#8TMAQ.^T F.)SPR(R'5&EP-!=\;S_ $AF&@*Z:2+:KVCS(?\
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M (<:(;$J*XUOD.0XRXV#5 (2;(U%/C%J*)MPW";MTQJ5O4'-AT=T29H>M05
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M5EI71.X;<;5?RR:BLL*XO,723DQ 916R0(S(HK2MJWDT")I5OR>GO98O4&!
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M3UR*0Y'@1B,7"BP]^VC1F>Z1%0:)FBX$$R0!04[R)3\&+L03G&W&]YJ34CJ
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MVEG="-)NS=-"2&;8P)QX;/Q:FJEA8=T\C*;W+>NM0WCVHH\)US/>W3JVEQY
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M*"JTYU9=ZE4VHF>) RN%GV)Z O5$"<#L9XN2IJVVYHKS)CK():$C$7Z$4*M
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M94J,<MN+Y<6G#D1TA18I25;W8N2!S(51&P34"8<E2G0989!7''#+2(BG*O\
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M)#>K_B\F$@O[RVW32BE;;BVL=^J\C1K\WDIGENS*N'?ZIS\U<<._L*T_J$?
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M$K*LR"U*I=-'.EG7),41!1$V)_J]B07P6'5]QLL</?L*T_J#'L9\O-A7)"-
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MQN#'H@$\JJN:[/!M1$V(B9=[DP%\8'YK<"$)"HG1:EH@@-:?TR?BPG[MG^W
MX3"=AM[%<+@N9*K[E?WL.7R2&EZY4&,A)F,-LRTN[<NLKGWNRB09,=>K@763
M?=@SY$,7UJS'%9UI/KENDC5:+2BH>(46*$U8_0!YX&8'%D(W'"3HS8DYQ+FP
MV C76J<N&66Q !;$ 06P1L$1*>*">*G<]JKA_P#K'OSRQ!^AQ?D0[//-,3BC
M0W)K$Z7(?CNLC40&0Z9(+Y5%0W8EW<L1%!@[@+D=M"W"*X4=_.K*CT5W8HF6
M(,E&BD$>^*1":Z;L+5NMT0AT1<)VGE,^3!SE95'=^G_3?YXFD1$WZIRFI+D-
M=F)\C='%)&D1F*[T#F:>EH,>EH2J=W$>=,BNPF(.],B?10-TR:)I&01%42;Z
M2YXZ\_'5'"5%>1MTVQ>5,NF*9<F&HT=M&F60T-@.P138B8N'T&7\@YBQ?L:V
M?J3'L=?=BKJ-S>.-@ZX+)G5255;1:=)5SQ;G;2QO0A"ZT41O:C9[I$)H5R51
M0.?$N4K)L.JK6B ?1=E-MGO"(@STF!(BBE<\3"-AR K<5Q&=]Y,I3WBI'1.D
MB,FWM)>7&[=AR+>#6K7(<2FP5W:,KGJJ6U4IE@8I0'6!%U$<EDFF.+:'7?-.
M+FXM,Z43/!Q1A.21-YS=S*48=;<4AWSSI+Y,Z+JI2N(<1PM;D>*PP9YYJT"#
MRYT[1=?[G]HQ,6?^O/Y$\)VKAG[Q-_9-W[424R6M<3H;4;='K(U2SQ9]QD:"
M%2:>N=_N6[CQ3(=C0 NGG7$B,?5A.<B;UN(Y<;U+UIIW#MVN[R1H<)=&QD&U
M2I;<+7/F[WN8DW2XO;B+&%%5<M1J1((@T*JFMPE79AAZ[,3++P@9(XS;@T!,
MGCJHCLU[4CK+)#[U-M=G+AFWVV*U&BQZ(VT(Z4VUKEM7NK[$FW2AJU(#37E
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M7(UW @(X2M:U39[/]#<8U2ARD3WU/B7LE4H[BHE4P[ GMDQ(9*BB=>FE51'
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M+-!U(7E R4'-T:;=H.9+S+@_G#*;K7K\H'1W6;E<\MVFWFPFN4P.K>TJX/\
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MV:*-96;3'MG085#A(?AT/X*Q'4ZKT^IK:OJQ_P"Y+I[.:\3&+)RV/IEN:>]
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M"B/,"4;R#J??WW^"+-,<R!]%K&F8P/ #EH?1:Q$4"*(;#(+>B5A#%OZVNQA
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M$H/):'P@$1[#&QRL(4P^6YB@C?1GUK>:J^W_ ##B1HX_YX1T_P!?^9(/]?\
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MI39"*5%HYU"$EY L2;3AT-%P=D:AA5G'00M!7P??=SQ6+77[X^BCO[/T9O\
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MZ.,'G@Q##&S/#S,>D$I-&CUP=LJS!ZIETZIA!VS2Q"#G 1'$IQ;]WM42=G.
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MU-#%3@Z.4IH]U QA20@O0I<0$W83YEP5?6I+R86(;.WR'80T7W?D<)8B[L_
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M-Q#@N9Z(;P_2PUQLD(_ARF'9K\8N >CK\S@11Z'$331M^I;RO1VO(/+.+]L
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M>.#=L'XQH['YIAY/Z)C.L"<ZEQJ?D_?QNLN"+\7_ *P$%H_O#W'T@$@]9W7
MWDPU1*I<$SS!^LB6SKZ^ 1C*Q. 8?T^V3*H)X,O,L7?ZQPOC%4X8<$Y!G+CX
M1D9'@,&"?$SY&(]\ZO@VHY60?T#S@J.U$3SA><J$A%7VX2_2F_"7VCJ^.J8X
M!)5@OHM](8YN2]%^^/+)W!COZXJ@6/VP0C GMK.W!^6_[P0V1_8/]^"Q>,%P
M3EEO7Z&.WI^;'O$_/[+C*1OKR_WD $J?N92C5C!O*-'7>4 BWQNL_#P?J_WG
M[O[^DI-CJ3_GB\T""=G_ !#EDVD\?U1XJB@8B8Z?=9$AQ. 1<3&\>V-R@4\O
MD!K1\ E?@]E W_F##X"4L>^*T$56'VJXX#SIAZO8R0&?/?O]*;\!?:.KX],X
M)A"'3< X=@63Q>NN('0HX7 F(!F,/>U[G&ND'=5@()6M5KNYJE:['0Q\TG/B
M5BIU,CBEI]^YD%4B'N_MS@Q*9<=6$W0D57'EPR9,,$"M$085&(."J?\ K-K9
M/N_&ZS\/!^O_ 'G[/[^D%ILR+!'E&]&SUC"KL*27H*?-Z.,-3&2<2]O7'RDW
M(@;_ &CCS<3\@+O4?K$G>)! <%[XO&)GK\##E\,R?!#D3IDU+XLI[?AFA%61
MLK\@#L61Y<X$FG>=];\GTQOP-]HZOC=8J'"J' AK.N<<+UB2'T9$N()5Z.)D
MC]'$F/=/+]YU?8<6>N"UQWO(7G([Y:LLP S\;K/P\'ZN?N^D2YQU\D= Z/*D
M>>S$2B<&_K4>C)V#?GB$1 2#<=4Z^^-2_<$3B$[\$G)2;;,G6)XI5CA\$^$8
MG9)Z,4;L"/A<8W<J/\/2<FHH02$0=?\ 2Q!;%$P$^>GMG'TIOPM]HZOR8\(/
M*6X&^8)CS36.:*8\AY=UYXR&$/ 6D%]L*0;/K_0&"9"2Q6;WXYAP_6-7$G8Z
M!^SCB]:5Y_VE\L^^3[WY9QN\%^4ZS\/!^KG[OI>SGW?;&!2=$+\P5SS+QA-^
M"Q9A'13R,"?>]/BB#OLXR;CY<77R )0[UBJS*II?BG!RT.5_U^\904L$6GI.
MP?28Q*R[^F-^%OM'5^07A+*8")7VFR>G#J3-$;4OXYZRLK>1I$F2E&P+'IR8
MBUDD5N/R_?*)$/\ /\SU!GYWLAM;?WD-8ZE_]G* 14?B#\JYMK(C\3?0KYL9
M5++\'V>^<R=N>OX+Z,4X#/W#Y.#.=OC=9^'@_5_O/W?2B3#D)')L=SIW,ZS<
M1Q7CA[7]YP4*X:;ZG$\3@R2?#!O->'(,,20GUK^\Y ?@L;1E<KV?_<>9F>1\
M+/&\7H7K'=-RXTP>A%?E/(.CZXA#!S ]05ZXJLN_IC?A+[1U?D<X,W$ASP<Q
M[W<G(Y#H.NH?A)WC%8$?:8]2?.<NE<E=_'*:R$X&+P?LG\P3DRK-G)/2O(*/
MJQ-0V8_1]+@:S[6^WY#K/P\'Z?\ >?N^F@1@:UK!-[."N#*$V[ZNH: CEK%M
M28?%62YJMZX7R\[SOGMG)SRK-N/7!GY%R>[$_?GQ@2P-+:3]0.XR'ZR7_(]I
MQ25W].>%OL'5^ O3*92_O$ 0=M$^TRL(S8<OCM_\VTF]N^3BS==(GOLB!YX8
MO+O3\>W&3D?(GP,)-!_O9Z\X=>?L_P":'&1$TJ.W?^P77>4>5Y</KO)]\!ZI
M=D>>^>G&!WFDF#S('X'6?AX/U_[S]WTXFTJ8W#L.^4X^Q?4562;53Y%VN4Q
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M2_ 3X /#$6<5! ZQ$>Q\6>,@IQ$-)GO?:VNL';%A8$7'Z'[OK/P.L'3;]?\
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ML/CC*@J8<<5.V, FP6)GKK=89<P+<UK_ #(^DG;^F":9U/5?1U+Z&:"S3.!
MX\&$<N()BY4]"@FW5ZX*"68_"+H0@VX;+,T]3?\ (\6\A1W?\R2>CAK^+O$;
MP/\ )HYHQK"X8'9NF%\R$Q:=">8I*FH.A$#@VL=G$.S<-/),:K&)(><C1WQ=
M=L66?@E&LWK>0$;;NPR4)2T2/8SFI\''JQ%4CJ)C#G!R@@Z5?LN)<B*N1R>G
M[Z?QT+K(, W=&(XX/6/R9RYQ<N)SD^O?#S^1SDDLE]TQMO10$RD2A:9!"CS;
M(R2L] \G"*#TSH^7  3-,_W(WT"XE!YLT@:24,NL1:G6RL,T$.$F>8X7<J<@
MY(V?QD<9DQK$!Z8<.5RD9Y.BC\W(E)A_<CZE^@1- _*U:KUES"D=DNQ8Q7*\
ME88$5U?$1$GHN36 )'&3\,?()+-Y:H->ED=RP-3@9K(\I+P"7>NC,9JP=G3P
M!+*R%BS6)'TQ]). \!1D-*'ZLU9'!KP&V3]V"",\CDX))C]0GS[#-S1 +35\
MG(.%Y3@&H5,99+45$2)T]&#2 S?PCZ' !ZX<[GEF(\/Q<0X"YUCNKJ$FR9.T
MPAF]*-_^*%V3'2TW_P"H^E?H6J[.SVR$9TPGVPX90FQD4AZ40^6, G:"#SQJ
M+]&<C0X,DD8"I48OUXD2VXS\LS&'IY2/?'Q#M!!YYV@P!R7KT1G(E)XA/ME<
MT_P31(Z&SS C&-*<D(^<JC"+HH2A#%Q@B<&._@9K(LN\&C(-Y'(X)3%,0CXJ
M4E[*XG>I[2ATQ!:VF9EGA=KN ,0>?^#=8"^?EMK//^V-ZJG>G_,A_+8GI2^<
M"ZZ^_P L]\*%AW][6-?!WO&2/?$R+B38'G^\$\A8/F%]? 76E]AP4H61'>#
MNZ-V_P Q#WJ=/I&&"U:3^G:,NG#\#MD('=WN/?KDP4Y]?+G??/O /^1]6(L=
MIQKOY?"*ZC+,':KN"F.91+M6#(@Y)@H<+0;_ %BEKX$)<5V>38G/AODN*Y\
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M?:1G;_=_GZ<^X[Y]NZ?EE,)8M%XG9[#'N8A&+:6X%]BV<XJ9T6DD@$-%6;+
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M/@2;^HWA7PI.1_ 1D^-".G-D9Q'A'[S_ '_\)__:  P# 0 "$0,1   0
M       @16K0                         4@
M 1 .27LA(                        RP                     1JE>
M/YA5                        6"             !Z <E   4F']E'-U/
M    X$"$             "$?ZK(           ]=V034  7),     V+D  &
M-:1X $H8         $/=Y@           $ # $L@ 6N5H Q  %3E    DD
M -"X        _4FF%H _         A      U2< PFKI0&,IH @     !H+
M      #VC#,B]95@            G4  MB @!RH4D 6-  K@    -
M [#<$I"<=RK            %9L -?X/9#MZ5='^@ !J     ( $D$@]@].LM
M,"%8*L<@           Y.H0G  = \)97X'B "EH    !  #3V00B3"=S[3NT
MI[8           '<K%1@!5DJL+]\ 4XX,&    !H $[[)XK"XK.H>@KFXE
M          #F@RG'YEI;&$SH I8%.P    -        ?<WB7 K#<X
M      ]]:W/S>$UM.<C.W?ID>    !H        +>4[@X-%[
M "16FLF]!G !U-][=34)H    %          #4  $B      $       $A-R
M2D&7\( KHAQ]86C,    $H   G      C8 $E0     $;       &<>0#=S3
M\UW(V!>JPBX@    $   P7       \H5@0     [H      &NT!2X##OC52[
MU ")PM]     H  !H8     :8.=W4     $PP      !N@I@ VQT-E[^8 ?=
M%+     -   VT    H^[?!^/M     W5      $SD&TX$H61QW)X%W( M&
M   (  &WP   &,Q/F,4Q\H   !0X      'G@';.&L@#\V\ BD %=@    %
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M@       7@   [:A/&>6X   %O@    U   V  &TH HK4;034 "JP .$
M  %\W     A=J.@     PJ    $(  &VP R  XL1??7AL &F !C@      +B
MP     PR(F     ' (    !   W^!4@ 5K+_ $F-^&!)D #7       +0
M             2     :   O\ 80 -]*&G#B_&  0 6>       / !)9,#5_
M5]X));)))0    )0  ';@+  ,_[50#_M)@!$ -5P       ))))))):M,6!)
M)))((     *  !BJ)\P!K0KP!(.^@ +  +8             !()(
M     #0  "_ "V )O    -H( !^ *(0
M 2                           ))))))!)))))))))))))))))))) 8))
M))))))))))))-)I))))))))(%)))))))))))))))))))))!))))) !)(9)))
M)))/"E/))))))))))))                             0         +'
M<=0                        &LP             2       ![)PP[[W?
M@          $@         !VA             !1H      (74LV<*#&
M       .P     !:  &F\             :(P     7!@*!NR-@0<
M  !0      2V *P>0            #0X   !2)WX0   !98#(
M     )MP!3[H             :     $PZ0      !C%P              G
MQ<9<%T2@JQ08.)Z     #0      T>  !50  +^1P             "L@(Y!
M#0F*NG6G6FP     :    !TJ^@  5=   !,%@            !V_A?\ !9-8
M.(ZC,,EP     T    'S2D@+.2RT@ "JA             "2"", -5.#;('H
M2"6     &@    ;>&L)*R.#>@ !M4@              7\Q#D)@9>YS@
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M IL               !L9 :._L           T   !Z #)G <  7-#5F*Q
M        "0   #5?-&!OC^(   2     2@   ?C/M@\#  #IIY  1$
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M     "@   3 B833>$*'GMT 2-T          C@   #2?2+<7,    &T
M 4    014 "+O;P\G@ 5,,          'T  "YFPD8RTD;(  #3@    2@
M  6&@  EV6$!\  %8           /   21G""P!A'[   8Y     $     (;
M   1Z4L  "/]@          #4 -.L,FH/@024F!@";@     @   !BC,
M"@( <A*P           B@"*44  #,  '_3D 2*     T     =P/@
M;ZP           $\ *JM@"?591 T.& "4     &@    #>K*<    !8$7R
M          T@#VY8"\ __P!7./F $G0    -      "?7TC=+FL4+)
M      !W $BH$1M)!S4@"DH E5    !H       ^*2'6;] \P
M  1@ <& Y)JJA($ 'D $N8    -        ?-A$ESN'-             ")
M D "-(Z>SI0 $X XA    !H         0?QMX                ?X '
M        = %'     D         4#<(*M
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M4!5 -K0>N.)IU++(59)!W<8("7"!<=9OAP8]CLYNH@>SD=\!-+* (Y2IEM<
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MFI3D1VQA@H'2,GN8,@]0??Q8D6@Q$2A)(2$]8Q /X'<H9<%(4F$JE0@HZ@J
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MB;/]H1D/NH*9EET=HBD84PO5,0JVGS4_4"2^]F0!&!BLBT D4Q/<=&4.  D
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M?LS;P*][]?GW;IC1Z_M\ "?#+/:;L,5LM6.84/,R$)A SA(!6U?@0F-G%Q6
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M?M?\,_!/T?*?K99\C39]O_EX!M'[(^ )@ZA[XB&<\9\I9_%[,*BTE@DX<RP
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M=0\UZSB.2]P2N1B)Z_,2?_4_3A61A0B9H3&E6T8&CMTWLGG&,.E8^@7A)_\
M4_6%?<_,&;*J025?53%&G(T+-TX XQ20 L?PADI"!(HT-F9@ECY8L^1KJ?=_
MQ\)WX'Z^%F3IS<9!"&U@)(S*"MM#B,B14J09'.3941)TSFLB#FJ;+2\0&'=<
M/,Q/0K!*030!.@ABE")"8TXEP84'FDV&,6X!L['.I,-E9#DG727 R: H_P#L
M90H3%>F+2!9&^F$1$1QK&!\NI_N1C/#>=UG=5'J8T.!$1N//$D^:!?0Y>F&A
M0-VVT.<=X-R)YIC1)=NN;ZC:N95 !B!##6#-]?!L3LY/\(FRJP,.9_!UCU15
M5/<2+$2(<<=V$Q#CE 980^"=^K]F,^VO+\'#L\OGCI\G^0KUR9KY&NU]W_3/
M=IE^#^OC=0ID$KE 6884.,')],H )V1,Q:L Z#2&2$ID2(#X)BP!5Y5(/*GW
MP$HBA8/ +0028%C#\4@BPBN(UD5V=^H(Z&&3 LD\%AJC6&."&SWXR>&#\\?W
MAPU-\=\& @IC"UPY.*&-,CQVR"0$TA@5"$X60$>^+0F%!6I[<#=)?GJMCMD"
MC3L[RXTQA!AZ3.O 0E!P(PXC5_BO@!:$L2:20T4JI  92LKJ4\4:>/#R?V9]
MMXP5G9Y_A?/91RH#:PL$P2AD2K:3VV- #;I^6-35J8D2)&B5PP&VD%\@31@+
M2OA&OM$0"V2D(!EB%C@W$:7$/9=(BGB08"$3M5>VC[2MN'$XQ _YC!P:$$O:
M^$J7!_:!5F5F\B&9\[XY@6CBJR2:>]ZM0S#AH<D3D66,+ ]'XBZ5-<4B(XLD
M@F@82N%&PF,$!%$$1Q&Q'8?!=]C_ +S_ .K_ *?PB1(T;]B?OQCQYC1TY*5*
M""[60:) PTDFDZ_+?K99KXT7)J3RL%#$XQ^D,J40DQ,>J$ DR598PXK=8B@$
MF>\^(IIP:#%A/DG%&TQ"X,5<.T:%F@RA9&/N)<A0&5.)^!^#H<$+,@ LPQ&3
MK&#TJ9*W*N[BO(TV @ZN)5*AT;8[S6;!,$E0:HP&*43-7$U&"63+T\K\[P((
M\9Q9XP676/[Q \0-3<$<]L%@&E5-70.E8$P+'J[G'&(C! * L")GN8YTM:@(
MZ<^11G3X  _M+PDCO%DX0GI-2PO(:5D4"\8H@9;B$Q.F63'WF/PHD24SO&N=
MKD&/,=M-UDCA!0[*&_/YX!"I<TQ_Q'#X&+LPQ7@)6 ^7,F3)DR9,F3)C98B4
M1A$D84F:BIUG"]/#."($R@ [I,J# K.2/M>ERX8B.9R!F[ '#(7-$V7 /S.F
MH708R65R25<8;XV/3C"&*T\6M^ R;X#!O@SU$K$4E4*KVY*PO*V2K*A5)8HL
M7XDB4G+L:%$<&L(;*P$  " " - </ES)DR9,F3)DR8HC014WJ$H33@0 :*/E
MCTLLU\;-RD%T@'78F.J+5$T[04+J><)Q 5/V"_)0@5P:V +"6 KN=^"P+T%Q
ML+3Y2X\2E<44QIL+A0'A.)3A)9AWH@%HC@.A&@/@&NKS\ZWHJ!E )*JI* L)
M=\ ;6Q#!R*6S6H1D6ZN"7RR*"A%2_!.\')+JGSYY"! C4*]/\^!)(RCO(V@B
M_P"\/ELHA/[,O3HOG+4L<]<$6PA;:&04L><%_P T,Q,RI#&2PH%6(T00NI[_
M  GEE628MLK&4<@XB$ !!IJ0'I*,#QJB)U) ;L-23@BM8<!L)A=:QT(Z7$DT
ML'3C(AME7FG]_6Q!&:D[BGDQ9IYRY=@#5;%-2#$],"$A#2*LD$+6H,J4@LHD
MB\[Z\]><#9C+=RW*S"Q-[W@,P%J$+,3/G&!12* 1((I!A%;,54N[T-P-^0"N
M,.,8  "@ H ^J)FOC1DU);K"'TC(A(0[.'TP!$XA0 O,A@#($P$]C7MXK,HG
MKS$1'E&!P)V(Z:Z%8'8!\O@0< "  P R#H>WR(G>(.P?/(.AD!HCRKPA,Q<S
M/PKVXD)90%)U1EFU80LDJ^1OX%0* )9T*A3U<$("1 V0)\C+YC-G,73),,X$
MR$9F3K_]L3224MQ3OD'*-&2=<DZGODG4]\DZGODG4]\DZGODG4]\DZGODG4]
M\DZGODG4]\DZGODF2=3WR3J>^2=3WR3J>^2=3WR3J>^2=3WR3J>^2=3WR3J>
M^2=3WR3J>^2=3WR3J9)UR3J>^2=3WR3J>^2=3WR3J>^2=3WR3J>^2=3WR3J>
M^2=3WR3J>^2=3WR3J>^2=3WR3J>^2=3WR3J>^2=3WR3J>^2=3WR3J>^2=3WR
M3J>^2=3WR3J9)UP'=(:D)[.B,$C9DG4]\DR3J>^2=3WR3J9)U,DZGODG4]\D
MZGODG4]\DZGODG4]\DZGODG4]\DZGODG4]\DZF2=<DZGODG4]\DZGODG4]\D
MZGODG4]\DZGODG4]\DZGODG4]\DZGODG4]\DZGODG4]\DZGODG4]\DZGODG4
M]\DZGODG4]\DR3J9)U/?).I[Y)U/?).I[Y)U/?).I[Y)U/?).I[Y)U/?).I[
MY)U/?).I[Y)U/?-_$@V2,()N6:R&W[:J+0L!.4?PSAPX<.'#APX<.'#APX<.
M'#APX<.'#APX<.'#APX<.'#CZ%PX<:-#B X<.'#APX<.'$#<3BE)I  @=>$"
M^P$E$ "  D "OIH$!PX<:("APX<.-"AQHT.'#AQ?'ZCPN$DN84".5)AA0X#"
M0))T'P.!^+S^J+APX<.'#APX<.'#APX<.'#APX<.'#B"VRHB%'00E+B9_F19
M]*L"],CJF4."2!)2!6#OTP69 B69R".9D8=(/YAP#%(N  AD"RB\T!KV-9)*
M $887#K"044P**MG'$I&22 2"$"124D2E>%3D>P1ZKA71#JOZ_DX/40.H8E9
M*JF"RTLR-YBNBEPRS;^B@Q4T@8W?-7!.,:F$EBYK\*4]A46VHKR?XU:BH02R
MP*3%Q@HE0CA$\U>EZX;(T;D%F%8 ^QAC$RYD E+F*J)Q;">GL5@S%1G/V%7]
MX9<BK#FW"9[?F&[LQ%,,I,JZ7.64#*FJHXTB_5)98"3*\=0R!$=M=T%@JXG@
MG9G<7> /2E3"I-1$T94I:W$,X"[V#8C@@A""!4S,;(K-3,8)&H]'H9X 25,X
ME3 6H2QT-8>V)%A+,VC:<WKZ=8EPDT*S*B"4)<75'5(53LI<'4O 1A0@%%5Z
M5IST^DN4!E4@J=4CG3[(P B@HIU)1R)3,T201=BQ>4L!8\8,CC+* 0$'C*<W
MX% (OZQ2:\#1?D(H&1E2. $(YZ!Z/!E_3J^=RI*/I7@]P' @F&2TMIW0B!JI
M@J+VI)=A[ "@8:3R2]B [CP]!QD0 B82T%8)ASJZ&TA^Q!K)@X_7E(+ XDI$
ME!LXDDJ'+T+($XE@X MTW5&R(<;Q5B>\<2-(-QQ%B:"+ P3"5 #&I7EI$0*)
MPKCCP/\ =.48::F N4NG;KTSGI=!*H[R/2FM&3CBB.",TI?.4";& =##/3>4
M%\!*^G21=O%!1O@B"H+PC V<)DZKAPLB?+2!8N19 E1+!F?F.RTI_J_3&(+>
M2$+Y]L&08BM.\@3J12$]]_   @1@H,"P;WES>1*A A*5)\C "0> 8 LDSCR7
M85"4H2)&0\ER<EVB PJMG6W?7&F22$41 (P[$_6$S67MO2*<#AI0@IUDV4I<
M<;FGJ,2 H4S! 45 8:3'S$.(4&P14U8&,-BC"\0J+KR2)]$?A_$HX.#)A0.>
M8K@]\0@**!$K 3"G93AT]K0!*9IKT)@9PBDB@9L-AU,"@'!$<,QQ1+#N\549
M59E $HE !C<8VE$1M-H$KKD3P2;4+*3$PIAD.M!DE4*D3HDX1(*+("-:CLS8
MS +3"3E.<5C%&#K!<X&8MAS$X+]1ZE"*$!$A+@](""24,R*<O^"$CP$L"2&X
M88*+S==608%:5N43I74G F0']SC)*)OZ0P#5^"@PZDK";A8VO SB*%"%B\G,
MQ:E!8M>GO=>?S)A(2PD=FE],DW9Q)OA4+Z33$+)F3UA817:NLG)Y-FDR%Z)^
M!2C:R3I"]IPZS'ZR880I6/:,-HY$UI1D2&FL"XK4G13AJ]8PY/5?R-HIDY4F
M62#$2"$+L?K"9KP@-4Y+3:%&2HL7(L("VDB4E1^3(;=XD@@70ITG]9LTNIVR
MC$ &2PI 7FK-6AT\10H_<[ 1R8!22;\*VCTU7$K3 >J\0A+<I"86'$O2$[E(
MJ"231C/$F&CY#@/5?./Z,6A(%*1(8.0A OO!..>0O0,#')48^6^!50^=D($P
M "H=+(:"( "+$3B5#/N.54I-CV8!TEKL.".G[?X))]DSET.A9)#360QC<B!Q
MXQHNE3T8-<8 ;'0JID0GP &+KT0IT],BR69AA.2 $3O%OJ0(8NR&RLBS*=U=
M+<$3"F,P!;"7-$*LRH*IG4R2< P:"C3ZPF:^8@09EHI=L;QVJRN=A)\"-XAI
M@SF-30@!+P$J,J'6\WJ!]2V<M27C. *07%0RM!A6XF X>9"[GZ =/R\848,D
M1?-4$ W-[466J\,3*K@Q@O ^_L<EP-RJV#,M#Q"!9RA0[(1 G#]<U92J!+ 4
M(J#LE2#->%@$6UALB/?%B5 FYLD+<BDQ2/)FL!@@(85++BSUXRY[0X[NTA"^
MU> R#E67J&>ZF5(R..6PQ527,TEC$IU>CE:9PDD@8<3L(3^%\$4 E9%4)(@E
MR,7V 1I $5-$ZC)AK/%Q&0184 5X#>%^W4!XLP0;ZVP+ )T\ C1"SBPJ2$ %
MA2U;V>&PA4)\^QA.:2.N&H@6A88AE.<C2TT8F[B%C6!)  P+"3LDAVO-!8()
M2*"4R*;G"*76(":!FG5X(DEG^,8/%;9\1I[/7K@5&J4) L0U!^9A3!=$'=CF
M,7H8$P26B$PT-[QX*!$*%(FEF2'IBA,)Y[^:3-?,F-C0TT@$05[XL SS':I?
M/(@@(<G/!NLVZ!54W(9#A#N:\5H3,GH@U$=2QE7GR+Z.H45(PL;/C6.%\LEZ
MOQ_N'E'QZDZ<<HHHSB(%DA(B )XPC.%83@80.<OM7(2I0:.Y8C"B;3DF#&LY
M;9S<-& 93 $'K;[NOUMH7;UX4V:A5D(#_P#6["< (IJ3IF*+"1(*)D9Q%Q')
M1\B\8M0#I#!.HE([.SX1[/QU2*T6B!QDK6=G!$*$#33@CG25*9Y>7 0.-$2B
M1-L@J]?#F.I]_O)^V?()AT 0M'F<<D&R!"W*99& ? 312?-J^(R WFVRE>IL
M(H 6 N!##$+;G \!TOPATT#[L8W;40!WV!/9@R7^:!!5\(2#3$+?TU9<6XC$
M1Q)<KJ$U4RJP P CJ2*!$&"2RZ."[.@;#[I*,3"L2FI^]S>(23S?P9)T''*I
M@_6 &1\PRC:1+HEY7E"28>(XB@YP&:ZN(U"[*:M\O!T)@1]_KD^R2'5 8F!2
M%XF8]:GYA,U\L6*,& X6NM-8J\QT?Y>?EOG$=0-Q0]GX1H,H4W&!3FP<,? R
MU.M78&175( 9,>LA"SGU;*,:N,!+P<HLT!OB ^(MR6J'9V5,I.CT&?[D):(.
MW^@3 P5!A(3T2DO;)(J)X=U^$CY%[CR R$*96,<E[R<7$T&$A.%H-U OQL C
M-X B6$2F$((:(%PC="3HC8CH)R5]8M8I@C5.PH9"5(;_ !YF/6$.4QY3:/*I
MQ,G838TLVJ>>=<LD!#D3(P)H4A0,358-Q$WX)^& I!)!M@CG#8>_&:R,#1+C
M"CU1*BH,4M/2Y-@ED$!$; LM;\.>^3KK.S]$ASDFJ<LK7FD?A+[T$9)61JG,
M5D:, P3Y^VDBIQ%.\,$DPB4)+&89@H]? $GE/E.3G%@T&)CYLEE.%]V4"1X"
M91@!F4-$IDU2!")(&\XDII;1=(10:S3E?]H0BKXO22'KD#%X*8-Q*M;!4F$
M1LP!P5D ,1?2V7?L_:.%X"J G[AH-: 0^5\M]"F0B7)@AE+2LO$8HET(@Q,E
M%WC$ +,>R*ZWZ\ U6K83B)1 159&YFR/7YA,U\HD)H@21@!J3O1O$W<!![)M
MI&HQDAF4C3^J*:)P&'Z-^63YX'(KQ8B@U0F1 01V@K&<.KJ&DD'&A",TLZ">
M=A"Q18#I7V$AA8>8)4>"!A8J<%AL^_;%1D$\("F<0&,T8H?!50J09(.E;3&$
M$K^&8$BEVQ\G2"=$!$-$5B -,LBYF5FW;)6X3A)4FY&@1AM_!\0;FF1IUB?:
M-,T'Z0HPH!.'4A%Y76@8M''Q+-S(C:/N0X2-00WL!"=P.7"%VY[&K8T(!"!"
MIB9+!DC%*(!&E;O% 6:**4+=!(F='RW]6#, E5C;*4OF.11 000A(18NG&!(
M)*P$&TR&YG F0SZU<H=!=G..08S"X(D[0:Z>%]EID5'>8RYTG(AY2>&3J #F
M<E%Y611 MLE *  #+D=Q@^<'@L7P"X62:X-^I-@6-EF.B3J;!?\ 3*@4X'K]
M6H7"H$"Q (E%^U2)D'((;>N3$!8&F25+J4"G/@@B/.(AHIF)1FN2^,Y BFF,
M]$!:FDD[0N'=)802#,P!;'5:+0=@:VG)(/"(=!K.D1$WO&<T_%UZE)#249P4
MQIWC 3Z8LDS,RDV >PGSP$ ($. B((B",@V94 2# R"(9,[7:W=K*WS.73?T
M7$*ZU5K+9A,1Z=^MX $&OF$S7RN8_80>^9D *F+7A6U%,C'L@D8QN7OS ):\
M*2P:%K1&<T>.3J8(C F8@$JIW.1(K9C0WW2-(DD"7<D+OHV8$(!-O?.TB1P"
M@+P%-B/.45,D 80TVM>GK0D0A)9VS)#5P4Z# K#("Z41<4?IAL%NR+HJJP(B
M&KF?UA%=WJ^F7.2MW;^C-")/1Q$!H.SB#623D)&PH=T89E6%#L#"'0R,@9>0
MHY"I)+&H-Q"ZAO-<G0LZL^'41B P$I!;"!OMC!P(@;*W:B00A&U^:AG6B9%W
M+&6>QL?M51"\EWYN139?+1@GI]>QR;5'<L@AD0.?* 5T&<5*;QH:+LF,G<UX
MXM$>BCC()&"33%GD^(4!VC*!L.G[Y)3TK+1:.2D@;,C4HCRD'B0T,U0.5&7D
MFT"Q ^(H7)%3@ K$PL."C)*PP0.EC8%+/@<0+@"!JHE&EG! FU2 @ !:1W8/
MJ (G!614BN4.8E>=\.">^8@01*45!"&$1@WB02!4B$F (/G3 A\9+GL#H@F!
M"1$37J_6#W!OLK?H3^QC/;I8:+W!&H9BX7%SF4<C450)><4J2HKX.Q;@!H#R
M(Q("=0()24Q'.U[G[ G&8.+8NMH- J7C@"E<9RJ$Y*@03*,]\.X &>DBI* 6
M +RS0_@:M_4>"5Q"0D2,&DC,DG:"G%1A<_E234V[Y> D$:AA(KSQD'L!O>@R
M,1X#J?LR\A1'0C]9LC43N>D&$4&9W3\5AHQQ?)OLZP@)1+9#29ZX 7*%&&3D
M$P@"T0[5-I[6#146-NB.& MS.R(PC/.*>&L;@T5KP<B2;;":"QF,$L#B]&"!
M^$:1Q#1AC&B/$K]6+@E#))R@&(@"AJ# 8EWR2O1'*2<D9]U#6SV%C8MF#P0Q
M-7^HP(R&(BJRB7]=0$H(J;CE\L>:%#0WJ0A$7'&<@-;MG1@7+6'.Z&E<LV;M
M#\$L8 ^I,1=S'IC&E$@4/3AHC6%U40@J]3(-G966#'*9<<50'=P6;&Y1D0*Q
MX"@0FB2AO@I7@@PR$WKHD+&%I#U,$&M:7C 2H=3*@1T)9VS9VJHYJZ  " X=
MJ!)'$! <8)$\U^%H[X@%5*Q%MTWM D:  (,:$(Y'K]&3-?)"-++H4750)?3!
M*YC9HB1TO)9.32%M<(Y0A*2X+(J!ZD605&M'A< ZXJAD)60WCWKT<Y"1NR@U
M9O7?RYK $*3A 4"8K<G0R$H&#)EO6E5"NTLR86.(J!3(H,3:D1P$&C%"AQ @
MN0\G)TQ0!16CC3>\ )(8H$\<]<.S!*T=//+A-EP'^F=*3S'^Y8H:Y'3UR5.L
MLZ_-X 59"Z3S.(P+^"B7 ' 1"=W!K !E"0B0@S3 EB"8F%D3*>FA#1S')^0R
M$U%\-72!ASR+0@*2<53@&*L?$D_7"2<-L ,4)<F4H0)DPC 95O"B0 < PLDU
M"9/#"E\O5?P EX*:*$A%2^%!$Y( #-T$J$?$@D$A(* @UVU'U]'5:>0C*=YR
M" )%E%VVRDN\D7<IU!??'>$ XX: H- D2EV2*3%T2Y@34R4"PJ0:F?%)_P#4
MKTQQB4!U%77@Q-&4(*L6R3/1D6=O/I'EXJ0K"6""@JKE0HQ@6:1OQ@*$0S&'
MRV(X_5*0X@R'TY,U\ARTV*MH6CKEV#@AV-^;N#8AN%%#1X%]RD@S1L@,1,Q6
M<-G*'$"1&Q/=-]_")61(@3;3/U],.=4/#;]K#,"RW <^ C' P E>*O7S<(+U
MI@V#$B!%E-40BLH !-P[+.,&0@!HZ<& 6&X?T83,B@3<W=UCR0R!/%Y>1O0*
M:K FOF?K;#I1Z?T& )&E3/%Z3-@G+<+7,7D:@408>\1EL0&ZGF(PBB[F'L>G
MG@R)3"\*.L:<,TSZ>Z[-C<$X(X'?<H\?3<)I"K(S@8;5P""023% H ZL$@8"
M(6$G$ZVICB]6$HA62P?G@(7H3;*@%8!X-1R[7\$$S$Z#PFF09I(3S &AXG2S
M#)V/3H ;A1=P;%D#,S=/?ZYGACTF?%*U*LFY2!,T&'T_#S"Y+(+"4Y&<UQ((
M*(HQ+F8U65.*T]"TQ2AR+L0A?,DB5,/<'!DG%+=#/D-_6& ^Z?PB);0=T%]Z
MR18L<4*N6%J@!0(!D*FT;4..:RA [9 .;0($M<,8&-51,(F120^H)FOD"3ZE
MN.'GC+FY%=S,%[D$=8@L9,D90.2H40RM1U 0G5!$"")ASA64LJ^$H!)(,E+$
MF:(P;_\ _ P$<$1$T9)6\B>=%P%8&*5R86TU@4R")%8"00,@)B?:%R%5=!EH
MC#QDZ!IM#\#A2G(CR>?3") (2>CS[Y"2URUCB].F$-2\X/VX%/T'\F.;CUY5
MN\801E$[;\N<!BFY8M<^>0(!NX['JF15G:(%@@N%WA1?.V@)(,50Z8(03(?R
MB@X$&H7@QGA@F7"EH45)L,7XB,;^3=P:Q!&DQU1S1C@#BYQ0A82YN.DRA2<E
M1R2I-D8DD3B\64&!L=RU'H3:_P![-%U-$0@S1Z!V,P6RV61'^"8JZJ>PB7'+
M"D\Y*4]MU0>N2HW$-2%OOX]9&:?$;%OT1",E(X1RJ:L@.,EJJ@DZH I4 ^ Q
M&Q/;%CB T9Q2DHN^:P3QVO$[^02P4PXLQ2@5 C:*Q*&!U=+;IB*1*2,A8\ $
M1 D1 ""T[G+OY(('4@A9ZN*4Z@WO7/T[];+-?((FDB"=2&3'%=FZBZ[@E))@
MJXO.U7%!/D1+$9-X<F""BVDLDN=_ Z?)PB;MIKD@7ADEJS';J( *MUB7+WU!
M@;K(5I+/$X(0T91.I<>6/'8YC4O;!3P@.*0CIA1@^^U&LT3Z@O3O> R,D!JI
M_& ]7S?\C!J!8>9^9PI6$/2/_,.2FAX.FM:P(1X#N>4Y+)72*Z>3CHK,*,1]
M1I(C9D!) +IO"&K9PW'$B"A4"$N02LOD62XNBGPIB01UU;;WI(@\,A&K$1+>
M#2P[]PSEJ"6Q  !4@E."3#Z(F_DJ(1 81^(94Q/&'LM!!A#@D KTADEE("$)
MWT8!NY=-H_@&AN*;Z5O"#[(#=@A$FQ)A-H3>PIB!42WB%Z-=L0N65/3&,)'
M%@!%A7.! FEA-%99MX @Y!?!2J85PK(* !BU+B5C%I4Q84H66R:/,I:[R)F!
M0DL $02MN8WC<(),A*MR2C.EMYA*>+6)(U@<J\H76FC@B<C5JCR@^H5FOD*$
MZ"^QA DALF-HF>5E 8T)B0@DP:!00=U88C$O)U#5G-_!^ _K!^=#<MT!(1?#
M60H1 BN1.JX\(/6,3N:3G',B:F]!'F,LB*(_+[1A%'!UZ;WAV%2<M_FL4H#[
M[^*C*7DL[>;_ +FSI9Z8X_TZ^?1PD0 CN\5O)6D2)=H8SLP:N&3_ .M8 V8R
M7"2PJ2+\\Y:4@%D#'!58WP7P''FHNF,,H<%)#/*/)1)8!M>)RF7IFP'!0L
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M2_O(A#5RO^\*:I;L?>// C"E/)TR^./4@O\ 6(HJ.@<)A HNDI!WYG(A6GF
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M^GRU9KY1*M&P,.AD)#"3'!3 UZHE,BPX(JZG5-W_ ))P+./-&*(&:\HI8,.
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M)Q,O]]RXB 9#LQ'D!AR1<P*LT#F%1T%$)L642B=4(B&6Z!5@A-$=?5/MW3$
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MALXYR&#D2+;F(X64]?JU"I QG(5#IXK+(^"=&($$W.O7!#0PN@, $D-@RAA
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M?B(G\@^D##[%U9K\WPG'+L$&U>F-65X"4D:$4RRF96LBI5D% 2@"C<25%KB
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MFKAYK!,^G']QC=1.D1^Q^<;2KS' -&3@)1P_K#4I; 2Z!NHIN-8>PL"INM2
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M1"2^<C^W\9(-WD2RRLDF 8J>V*SDO@@C+\X\2&*0=8=0CI[+YXM#X)[PJA"
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M?/?Q]\]\]\OP]\]\]\]\]\]\]\]__D(\#1S!B#8SH>1)Z=<FTNO!(^J;\_\
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MM<Q"2I@92$<9)D63R$B0L--:J42WM39OZ :ZJDV?C>,DR!@T5.*D%$Y7:CE
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M5C8TE(XXR3X%3"$,-*4E(]<#ZA$2D' K)@&)EO HDS=%@W(Q9)FSC#2X7]"
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M"0 U..5$TMB@-S9+<XRY+>?LCF.N;9LY1KZQ4)-X,@)(*%]B,:BJC,_OU9^
M6&"2>CS9YY$,0U-<>G'PBC)O&IZ/_3$<K>Z?[R;?N.3[D\W.Z^^=QSN.=Q[Y
M_P"PY_ZCDC1\W!T&=O\ 3%*;+\,^)TS3.\EU=,L?!<,3I!Z/:/[<.H0V2':'
M[O DNSZ]%.$KCN6:?WD1"(-5*'YO$$@@>0E\T([9Y7W%M/0+Z[QC#U\D'FH<
M.XS]**]!P0UR@[^YK$6<)^O^Y8*;XY]-Y+O^ ##.#"*Q937P""*C)^*!W]",
M8VS\.R.<]'M]?%SSBDC"CUJ^J2.E[R8"9'S_ ,P ""!?S> 0"5GUSF<4EWA!
MH-8%KHGOBEEZ?_(F_P"8_]H " $# P$_$/IHG*V%9/&*;(SJ*,H=/XRWJG(X
M3E\[_E)5'?$L7?;^0$=8E,@$7L&Y[]L/D,")7-%T(8#$U$G(*@H @B$,(%*)
M(AP0X(*B!&94074HM,AX*(A@54$*(E1(L$X1.WCD03''L\R,5 @(9=8Z8 ;<
M\<SBT*!%F$+:(W9B:P9!.4",PA,AI$'#)DKT1*-H08"4W R!$\[.;-GKDQD<
M_P BXDT'?+6>0&WR^ZUAR"X(#W23VWA9)K^-WJ!^_P"\:2'"F'0'(V$&R"29
M).H2D$A4&0:0=34.0N J33$%)$@DM060*("ARX1$@!D#@5&(R9"["V  NU1)
MY)=#-#:"I%L\&"A)T54T\8&66:4E5B5M5>_K,\(@4XEH\R 1TY,GU!)A69>L
M#3?<Q<224UA%@5AV<D @R##4R'DS)06&PR9F?)EM&TA+)58='I&YH/2#@W_(
MCBWMX.?76C(ZT*0+Y"H>^310:MV)V]-8HAV^L?S@SY9Y[RN<G)ZX9K>3U^.9
M:K#!SKDEA(V*1@NGHX$SHW$H$T$(:-UO)P';(NCT 6E<#&3YP4-$U%B((DA"
MY&Q<.=\,AO@[:" F*!(W1$1W\V^,540>Z<D.IG*\#"048Q+634G22\9IM"B8
M="*;@A(T*(J>3HE4@209[D<GJ(S$#$F<I0!D7 8H6-B46B8=I"(1*0;Q$IA\
MM?\ O4XSGM\:QX_O.,H\LY[9^_KC69P3>#N$RJAI-PPPN&%Z.TM[ZE]8Q&%5
MTP/[QC5>+)<2 G?U"]-8=\:R8ZY$,\??ZR"9ZO\ N\AZ94<SCZK\_NO!_/W]
M^OQ,PZ8Z@=H7D)8%"4EBL"@*"DA@P6"LHW Z:%D@2#HPQRHD"0C/+@/ZU-^>
M*3IF?ES;GA!_<XZ:I$!HV8CL!%5IP"Y:!V0T%;@*;A24;5@DF)NZ6A,& #1F
MOB2YK#^L>\SZ_?EDBP[X^]9S'/@^^!VKX8EPN_":EKZ91QYVBU3G$>5"917,
MZXXQ058#:_8]LB7+?(1P0,M.\53:!2* \C+,02A)%>?7#X A6H9[=3%D'CZC
M6<X\8-9OQWD'QC"8!8:!*)/DEQ>.V4P $B))((!IU$RKH $)"!2&RO,DX, -
M#MQDBC634?!YLOXE7>)98ZL6H_+2QG&T@+R1;AQ.ZB(2!G?A%R+&R+@F:+Z2
M/;"5IK 4#/Q09OY9O#7A!MS3Z($WC/&4XRD]).B=M)QE-BW3(>K&V<BP2,S"
MPS4C6\??:)$^18O2,(03 ".?_</J2#H(K3/!@,"BI_UP4/P A>\AF>/HY,YC
MYW:L8>>(@$21$4G1W2AD!.0$) 01RR,.P8*!$&:S\-B@["Y"6 #<<WU_>#L,
M9HGL,1N+R<1-GPJ/ PEK0B)!*9@,J0;P*:RI 11$6I$RT6<.B0O,V)11)(PP
M20E.23'/T)O#7@%9PU>_GM$M&0228BTIB(*S/&,C?;,4-IDI-]NN14B$&1TD
MMG<P/JLA$4$L*@T2TUB1AA0ED(HL3S$PQ$S!J%W ZP4<FX8SD#J^_P#<E>\F
M-FK/_&6V0%K_ /,DDVVBAMOIA!$L49M1:)'C>;JYA\P*'&\IWZR:#; S'MA5
M@8 J38$JIS&+)02CIUE/ZWA @E(FD[/U:L5@O?X4DA8/WV]=8N&\J,F86>0*
MCP<XK2B*10AJ+IMXC@Y1 >P'MTFXP1#QF,CI@ZY;TC[Z?O*4Y<EO[Z^ %]_]
MRI.B<D@0SQ_Y'XSEHQJG?P3A*R%2N60@8HF?5DKA&AV12DS"9$4X!,*H0U_;
MX5F^^4_+-X:^AE*-QDQ\C(W,,8>+7%E"&HE)Y@(J7"'5C*95*-*=4^4:'L#O
M26 4P&SJW@&LB4H")OO%N28C$. K<4K$@8E8X-\8C0F61"@%QJ+LZY ^9+FT
MTQGH*G&D"'$5AET75^ WP6=9ATJ2[//#(.B@(+<H92(A>^.ZJ7F#$1$6@6;4
MP@&9CN>8(D5AC4XQ -)&VP())+)CF*SEZ *1>IA"DA,RUSA*4VA))B.CJG"R
M30F9E *J""$$X_'3WIL&99+OJ@EC(G05VJC^^F,4#*.[!GA,2/&*J.66*+;K
M*R*T%EW4.1Q"$"A85)&";"0J*PD+!RPT[_?&L66?",,Q4[F ,&0K[G$ML*W]
ML.!G!G%C@+9B.[R/>]C\8\HX_&L1-Y%3X5#UPTRO-D]QI\D<8Y-*\%B \,(B
M.[P@Z,46O9$M7,[OX($POEB$&#N8P)2(O+.KY7.&OBDUSXEL9K.[DY-3QXST
MQ6.2X?(!VL</YY\XP=&T +'SQ*X>IB0D2 E\6"$T-B8P>G4)).4&%9L%WCB3
M1=5%RHP#I6*,@4LJ8% $%9$R2 "X1"$JTK!S6MDM&)<"J).L9'76)B$D12V4
MGKG,8SO<&E-@Q>\L9;1!@=DLD +Q"+KH<8L%.%2EXG)HKQ7AQOP0SHK*UK.!
M*:QD A*Q71DFUR$2MHNYGJ"9S@G*-#F.PTFB;Q,;SRB KL(D)1]]@00)>_0>
ML_5!6#>)4NL@1!:AWK$C*6 "0*8YU)B,P"4>+$B "S"U"; A*0&4$Y02$,MD
M">,%X) DQJ(1+K5=>(Y?/CX!LFUZ_P!_K( @2#TO)".,]W G>!(B,#)B<<"0
M,!W.+07G[CODRF[[??&/BDX,%5#T $ZH06BI>&S!<LR(+"D2B&$2? ].HOIC
M6 1Q2:'L\DL]3HPJ*]F2[I_<?*Y//#7PSQD'I^\%Z83OC.(YP'CC[_S>7G9Y
MX#K@^_O_ -S;O]_[G=^_OC.>^5J/ B PJ L2!2-0J65E 3M<1AYPUWQC(IJ>
MXT1!F0ZK(I7D*$&,8;PN3R8-Y>R"1F"BVD((8'2O( @ V%HI"V9NM+"!'2:D
M&XXWC@L@"%+!M$8'^V$#A,)LF'J >N/)*()L+!=&(74LUAK(CPH"T,!"+ ]5
MXW<.A^@<!13AD4EYJ0+4"0-(XG M.@"2FPK T'>\E$8A)C50-A1%Q,B#M.<!
M$UD4R0#"SK!)K-P65 225)30DYKB$-1!(#9RW/;"/G>,HI$6Z%3%1E^OW'U)
M(UO#+%&M@-CB<E6H@/(3S9GS,U/*GGG$ACPVO$)(1$B;5@4B7!!"%H>TR17*
MQ$@YI4C&UY/B$H<SA.-G^C_S\XJSQSRIQE ISDY,:U@IG)8K'C R \^<<I??
M%B68X^^V.EL8]O@D2U-!D")V-S"]"LGS K$P39*3,864,01I^S!GP"'N/91P
M &&O,U>-R#4\W>KCIFW4!_,_*-X:^*"9,C(,C(-\Y&)/A&1<X$>61L)"\4 2
MLN8TF-37HG)H7)81%E8%MR $N+"**$E:*A6%-T#.@FTMHL5#>0[YE%YT2UM9
M,A8?D['.XU,C/$9"4%+R*!)DC")I,6R)6)/  DD+,E*AWC+[L.J!=L%M2QF\
M&*3:[2"8AV<.1N.DD]!#- </'GAM1PJB!8=TM[+?0Y>D!8S$:%E)@YRTL0"
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M4B46PI%Q:*4-BIH5%"F,0B 20$BJ$ RDA4,NI&H4)+L$'$ F"J& )40S!I<
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M2% Q RUQMF$Z2!)$-!1@D2>N*.-,+$4'24><9YW\Q@"\XV -35!M]"_3)!P
MAJ20#6$6PV=<J]M($P+$24 OEE3D0"+G@#$@0DMA#,#K(DSF' B@N:&C (I
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MX:TU!F[D<^62JE-U>Q*6#)8ZR/62NWJ!OA:[WRX%QOF*55$=>/[PR;8:BS8
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MPGWR<E7!Q8WK))R$QB#RSNPL^1?PN&OF&OC"%T:ZS>.KTSI@47"R04%66;&
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MDD'WV\GG %+7[[/8X<8.'(L  !\::@P"< Q7 R(D,D44C(" 4E%6<8%C>@"
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M_P!_K#B)>;CA)2<W[5E4,'I_F-&)#A@_63E1?/-#GV_W(<8AO_G^W\0008K
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MP9' !$;D8D\G 6L4K Q3.B)N=X3"AMR]9.7L8]58]!5[8D01S.$[&^'TR/\
MT&&D()8^YP,),7!S^<Y6>9&#*E<L';OUQ5N>U_K_ #) NY6;R( :(]\1SX,I
MT*@QU+,IET[)A;9M8#;J"#C$<HI':>6M['<.F00Z!+2"!B0 )X6N%(DE,,,L
M,.@8@3& @N@Y>?@-^%'/S<_+Y0WAKYUDA1OOR//\8@R*C%(C8LZ4@3G#J^NF
MC34B@$8)8411H@LA<-Y4*J .+ZU=72B:=\0!W P#0!*@"$\D$Y4H036<G)6.
M\;]L9"(AQ08=X(ZP1)+,[FLU;G'D%#E#;Z9#): _>)(06P4%M],=":<)0)
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M.>^OMK :$?\ !@ 04?P"21B*7W'"2Q3NS\ N4SD?3I"'!PGX!C 0LU@1F_X
M SS@B(XQ9(<2>7C\9U*+_P"8DBTD8V. ![9&1_!]3600G5/JX$?_ "#_ #'_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2113965d1-pc_clinical4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pc_clinical4clr.jpg
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M)87QXI34H.-$9,-%=18V$P$!  (! @,'!0$! 0$!   !$0 A,4%1(&%Q$#!
M4/"!D6"AL='QP>%PH(#_V@ , P$  A$#$0   >_@           !SX*'.GYY
MS2LO@MX]1ABC2^3.G@-12(&>-K"0'D)&4H?TT).F)[S(&HYZ#3DZOF1-)RRC
M9DQQFBOBPC-G,\^QOP9HAIEC\F5,*:V'],";:DA(R1@Y4FQYOJ?H]AB@60
M                        <8B8F+(N4N4R7T6J:[%<&P!*#R$]/B<\#:4L
M@QIZS<PXPF_!!2_S6<OL]IMJ<*S9<EQ41*RHC(F_AS\/](YQM.G9R:*$(X6P
M3LQAIN7R;+F#,>4.=+2WSEZ0,M8LLTU-N3G\?Z4#5HNDV.
M          !JX:1FUY,RJ3T%MG]->"=GI)$0(M ^A\3]$*)V#9<TQ+1(R?,@
MY:!]32@WQ*A)$34@!#B;%IG-([%FFQC3[DG,49PT%-]RDB]2-'W,"38N$SYS
M&-IR1%;GB-F#3HZ*'U                                 * ,Z80O<\
M9@R7 KTS9I.;O$A     *=/V6^:JETE@F&-13=(_I3!<X
M                        ,0<_#8XYKETD++P/>:;&X@(Z4<6R>@AABRPC
M'&OA;)+3=@O(XY'O.OQP .@9OX<9BTS4XOXA!ZSHB;*
M                      \9S /<38F)JV6^0P@YN ><W.-0RK2L#6LZ-%#$
M#+O+3-;"ZC?,XVEI&PYH66N=.CF\467L9DQ)S;/]+@
M                           !'36\VR  !BC*@    %<'G+/
M
M
M                             (I=([5,IQO7D@@\4NL9Q550N&6I:^5V
MN36)'IS:T6R1*;9(
M      /X4W,,6ZO9,UXUWR%@NN9# @   !8\=GVQ&/LZ;08SV&N2'Y2_H
M                                           !\^?C5[)NO6D^:-2*
MHE.-       !:T6R5NQAC;?:'&6POU^>P
M                  :\1_&]'9FP=I'LSI<         +2C&1^ANOV\=ZPC,
M                                            '@Z^CF9CO5;0F%ZY
M;:RS,_E]#<$5Q(H$         /UQ];B8AVGZ X%W7]O35
M                           "%T5DXZXITEH&RXT'Z<]*MG=A].]O]+0
M        !<,1RIU%UD]$)=:9,
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M1RIUEU4]*_=TU8     J._PVW+!,@              !_G-PQYV>6TQ(
M   #$U=?_HJS;Z32CMJP (!;;'/[E?   !R[QMJ=J[',26M<9G).Z\RZJO=6
M6^&3"HD6K=@PK@.FV]/<A;;[R37/7[YY      'YYXU'ROK-SYS]I#BZFV@
M ;BXAVHZ'Z_;Q     "H[_#;<L$R               '^<W#'G9Y;3$@
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M3<          5=)L><D=K_,K%55M  '2C7+?S:S%NQP    J._PVW+!,@
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M4@   <Q<R:Y_3XJMDXAD"O+K8_5QU_WC[T7R/B.?VR[V#;+ON;C[+%[1J:@
M 43.,/<H=I_-8  ;D8@VKZ&:_P"[X   %1W^&VY8)D  !I#E36Z+W>*@
M      ?GJJN:NF6'?+:8D       !B:NO_T59M])I1VU8    &CODAM#&X%>
M@ );DR/;L>K^LO\ >0   %%R6$^GKJ;GC\K^G'T!$ZVV8&JHM>95!]R\?Y6^
MO'T   .0.VWF!5,IQH !/;%-NR^GOJH   !4=_AMN6"9   <<MI?.&N)UA,
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MC8?#WT7NZ*T>;MI_G]=?V^.[V=-7CJBW^GKJ(W<8^  /S$,P=UM3_2H
M         :Z:/9CH333+  $CG=FWC]<=70           *7+=/6 <;]O_+&N
MY! P -V\+[=[\X(W/   %1W^&VY8)D  !QRVE\X:XG6$P )O99?;T2RCZ>JZ
M96FJI+;9'\?KJ^?WT8:LLWLZ+GZ^O[\?;\1:YQK6C).NH  _,0S!W6U/]*@
M            !K1H9FRD-1LG@ 37+,9W1]4]:@ .?9@B2&$+?(F9@CIACH&<
MA"2FP!X2:&./ 8TSQ6Q>)^3:, Y'[7^9M-S#$X &XF(MJ>B&ON\(   J._PV
MW+!,@  ..6TOG#7$ZPF   );:I1CJBAP=;90 ,O27;-T5WAMXB0  _,0S!W6
MU/\ 2H           >"SU6-L%: !KUI;E^G]7,B@ 37+,9W1]4]:@ .71=1H
M07^>LU>-^3E*;@G4(Y@%K&*,:8,UJ-V#3$W5*7!<YTJ .2&U_F;34PQ. !N'
MB+:GHCK[O"   *CO\-MRP3(  #ESD_7>(VB2@          1/-6IO:#5WT5
M          $>A%WD,WM  &NFCN8Z$TURP !))[9=XO6_5X "*'Z,,2$Q!D3\
M$()L94]1C#W$8.=ANF6R1,D!XST'I), <<=OO+.N9# 0 -V<+[=;]X(W0
M%1W^&VY8)D  !1TUQ'>,*RX          !RHVC\Y>J^KGHT           (]
M"+O(9O:  *,U%RE7V%)=YJ3OG&7XM'X1=_K5?%:X"FN\OKIJW]>_X   K8T_
M/4;7$%(^6L9,S!CBA2\3T&IQX38 OL  ^/UU\0-UO(CP=]  !T#P'NYNCAS:
MX   4K(H7[NOO^O'-A6F0Y7HJP!1TUQ'>,*RX          !RHVC\Y>J^KGH
MT           (]"+O(9O:  *QP%-]5_.O/%F[ 0CX4O;C(]7>>F[<Q);=L!N
MAB29Y0C8  '/DJDODU\**-L#3L\I?!K^30E)8)D#?TU;-^@ "JI1CGD!MOY=
M@ #J)K)Z);(8[SP   (%=+#'ZJW_ "^OB W2QX_NI9]:)/*J*YV1:;[1TUQ'
M>,*RX          !RHVC\Y>J^KGHT           (]"+O(9O:  ,%$KIHMY
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MC4@LXL0\!N4YY$N.B3G4IQL>Y_A-#0%QT-<[FN>5&T?G+U7U<]&@
M  !'H1=Y#-[0  /YPTC\FMG8MCF_  #:;T1P1<&S>.P          !6DC@>L
M&3==O=T5F"KK/[^BL]W168*NL]@V";[<8GV:    %1W^&VY8)D  !1TUQ'>,
M*RX       **<7BY^@ !RHVC\Y>J^KGHT           (]"+O(9O:   *9U;
MR1J_Y[YS  'NO%)N?ZIZV2G(-B          &!KK-J#EO5_X??3X.^C]'QW?
M?K[O!WT?H^.[8G'N<[AB.4@   !4=_AMN6"9   4=-<1WC"LN
M<J-H_.7JOJYZ-           "/0B[R&;V@  #Y='WI-Y/;-Q?'=]  _OW\W[
MZ%8,NG:#'&?XY         &"KK-J!EO5\8FJMHRU+<L356T2NUR7<3$.TG[X
M^@   !4=_AMN6"9   4=-<1WC"LN           <J-H_.7U^5WH;G8++P
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M?LIU10>"S2S9&38]VOM4EV7QOGT     5'?X;;E@F0  %'S7$7S^NL
M    "#WN(:I^.F\=I8,S0       !6NP&$.J'I9C, "/0B[R&;V@   #RT'?
MIIY9[(QR#7BZ?2O7W7+.,.Q[@ "SOGG9OK^K#^>0    !$KK&M=<A8*@E\AV
M6I;EB:JVC+4MRQ-5;?Y\=N)IZZ2=55NGB3:#)4]<     *CO\-MRP3(
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M?'=]^ON\'?1^CX[OOU]WOZ*S<3$.TV0Z*T      5'?X;;E@F0
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M!F:    /!5]7NINS^_/(  K78#"'5#TLQF          /@4;]_.N_9Q%.>
M     -BJJU8+).O%N1/)MOQ'*/TX^@    !$*ZV12X63\\_']^>S^<\?QQY>
MSKMZP2[T_':               .4_F-E.TL&9H        K78#"'5#TLQF
M         /R5E]<4S]\51]<1_G@    2#CFUOGF]/CFPOGD
M             #E/YC93M+!F:        *UV PAU0]+,9@            ?P
MC'/$&Y17ZXP7+P@]IG>$JXYG'RE/'/\ 0
M#5^W0CQ\=0       &1^N[9NX38
M
M                         #7?(.#,+66D2ZTR>](1F(
M"*\\0+Z 6O\ '.0                                     ..>WOEE6
M\B@0V#@.;NJ.KWHYQH,>;(GI,:6B:NF4.I)DP         "AOOYU,[?D#?WH
M^])^.?"5<>0NHK<L@DYL.<L"[3^EF$#)P:[E^'C,F;[@
M           T4SAIS$[K&A9\9R%N1B#:G14R)[C&$G*?+F,*;C'U
M  *W^N*5^^ -ENKFBG/P(0?@E!@RQS7DWX-/C,D4+7(*>4Q!_"A2V3H,
M                                           "C3Z&6,4?,F9%#P$^
M/T>DITV1                               (?=XO4DKQCY>WHR=-7W7#
M,MUG27/.DU,B0DC!;I%"5@            &D)&33\L4AIG">D1,&1\]!M&=%
MP                              "H);B_73(>"O=T5F"KK/N5A[:K1NT
MR?6\G96Y;IN\:/E!&_QNH
M           1RX6&,7./XNJMV3IJ^Q8].X9\=L:(L90'O(&9PGY8H
M                                             *F->2UR8&F)>Q[R
MQ2H3)F,,F1PEQYC:4       T9AF .5.-=/@.\N:?1&I[I+_ #$U/4>8\9'"
M/EL%'FRI2Q<Y!3)$!)D?<M0EX               (8<CBSR!DA.@)I*5&; E
M &9)\98AY11M&:@%U&XQN.    #3@I V6,0:SDK)@00SY\2O"VB*GL+6-QP
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MV:U'H,8"Q"FB6&9(T;;&!*L(P?HKT]Y8IERB"^26G0T
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M-($(\YA$7"2^$'))'<8W2#,$XRHAEJ<L,+FY+D20RQL>R]"(LWR[,0<B:_\
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MWB0$?6<F0W3(_P!^R1_CZLP':F6I,8[$N>K2770U3D!M.K99(+=;I9(+M;Y
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MK:QH4DO$FUY]HYI._P"KD[(![4YI*K+DEBUK]*9%DBIAD7L3962#<5+R8RQ
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MY-UL[\1ZAI4V%#<4/V&GEVUIWP?UGBANZWC54.R>D*1FW"HXDU#AK/6IY%E
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MF-:1  '#; 0(C1Z7EE7KU<ZZ>UMO!L0&)RQM6<*\2>413^76CY*&>ZNN,;8
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MWEC1"X51OA5A%4-&G'CV3'WV6^N1M-^6'^YR^4CUP[9'3P>N QG8AIH%3BC
M 5DDV #"31.L]; *UL<U-H:[+F,V"Q.,]"B7EQ>>58*A8(X:.24HKR4(3;A[
M7 4MQ%=C@&0K.%>()?)'Y?95Y.'&.KKSK2 8.?!9PLP)>+:%:S22V!V@P0%8
MKC?B2LC*W*.R$LZC3O)5RAQ<87A&\E.2*LZ$$$F]4;(2[#X0-5I4JZ1'RA23
M$FN_77\'G8(5,ZP 2YKIP'1HL0EL7@3@RHA=JS4=ZCTO+*O7JYUT]K;>#8@,
M3EC:LX5XD\HBG\NM'R4,]U=<8VP!@Y\%G"S!IIF[? NY-@ABMC7$VG@VSY-O
MZM&T27Q'[W1'\A1?Q:.@OD5>Z3LF/OLM]<C:O[[))^Q/*\H!VCAP^Q7[OV0_
M2B4E$%R868)2+3Z>I03DW!S7"DUG WZU&[W2L."JWH4)2F\\>T[:'=*[A-::
MU78QJJK!DI%P:.UR<L";/)I,1_#]\.<:L0"DEK5K7%HL5-JJ 54 :_)UW#G'
M*Q(F&6RK617>3+@\4.U+IK,*T9VCMX&6&'[QTA*ICUQNX?6""L\UJ-E$K=:4
MU+-HR,D_:+N:28"[?R;$&TQ590%3?*)I40VPJL-I,#I5 QNQ-VVY$&,8&(6&
M5*N..):Y1E"ZD'?JB GMJD"&&I!<NHE&3 -I_P#NW!"U.&L-QR%6FO%>>JF5
MIJ:P2Z*H0Q+4E*; F%=58AMGR;?U:-H0P[+L.!L0!4"3UZ<SE>]/9IS.5[T]
MFG,Y7O3V:<SE>]/9IS.5[T]FG,Y7O3V:<SE>]/9IS.5[T]FG,Y7O3V:<SE>]
M/9IS.5[T]FG,Y7O3V:<SE>]/9IS.5[T]FG,Y7O3V:<SE>]/9IS.5[T]FG,Y7
MO3V:<SE>]/9IS.5[T]FG,Y7O3V:<SE>]/9IS.5[T]FG$L9L+#9BMLW*+^+1T
M%\BKW2=DQ]]EOKD;4N4FDA<NXF"@<(-.3JBJ276TO&,1]<G#TC8:(D9%!7,K
M-0]-@&$X*:5R#FM5C*<Q>L1B&,VJPU02.A.6*$)6,(G#[&.=ALQ&B ZF_K=^
M&A'P7KW <48YBH:,UXG):6<AK$5S,R;(=PBV$(_PN*P0R>472U^74F&B[=U>
M.,1$"/PBN*LJJ;Y2F]K%WFS8LEQC6(#-C\&>*MJJ<EI9R&L17,S)LAW"+80C
M_"XK!#)Y1=+7Y=28:+MW5XXQ$0(_"*XJRJIOE*;VL7>;-BR7&-8@,V/P9XJV
MJIV496.7P^U3!S;N%";80C#WKBL$*N4W2W^74GBNW=7CC$1 C\(KB[*JA,3J
M1RQ28R[8A"7![I,$B]7A;-;=N(O.F+BC$G;?DV_JT>@*_BT;!<PUR53#<+ZA
M-2L$WJDWCILF)J$;30SK@091+P:OH<;<3?*+\ 4*5')PBH6$WJMH5+S24MO)
M9#D%+0G)(!$(JK40>+$5^MJ.Q^15[I.R8^^RWUR-K5J^>&0:P<*%8%)W>N(@
MU&FC9RYQ>>X;5;@Q)Q#ACT*E3HO-!0B,8PCIT1-NA*_S M/D6QQ8;KRB8C!I
M/?%9PJQ/2\LJ]>KG73VMMX-B Q.6-JSA7B3RB*?RZT?)0SW5UQC; &#GP6<+
M,"9B82%?F)0@TT,Q**XDF(KJ<]\5G"K$]+RRKUZN==/:VW@V(#$Y8VK.%>)/
M*(I_+K1\E#/=77&-L 8.?!9PLP)F)A(5^8E"#30S$HKB28BNISWQ6<*L3TO+
M*O7JYUT]K;>#8@,3EC:LX5XD\HBG\NM'R4,]U=<8VP!@Y\%G"S!_<-80_OD(
M-MC,2BR)AAS^W5G"K$IURMQ1).^=N^3;^K1Z K^+1L-=^QE/KZ..(0TMQ6M0
M!I$)<"?(1B$K"DQ@+M8-2CA@:3&OM'*LN_VR3<"5H)ET.3,4J7HD(<L@+J;A
M3>,5#"-4O.(EG7UB92[<EW$2[P0TLI4 XTVW>3V]Q.= U0%'=;S[>KY1.G#*
M7N3(<$0%.:-$LELHO0.4\OM0E-:LJDSK!B6EGDG4;<P 6@&](5$:0-5Z,$ $
MI&[&TTD=;:Q9:;F$K>24I2&T3 ;3?22VV ,DU*NIBJ!!!$*)7,<C=FVY^7N\
MFEG4(N.NA*FGXR[;=V'%WR5F!%XUA6OR&6BU+,S1;!;2I"%)>%R"2"D0$0!"
MR(LIK%N:;96&=1*6CR:(A=UK*C=C$=K7D5A, :'\MR>K4S4IR, 74)TZUJ3>
MY0ET-K<BDQJS*CDPV'R*O=)V3'WV6^N1Z!*EF_(J]\F2:T)J"4 Y, ;J0!?Q
MU8DY.BU<UQ;>&<-4"1 1C!OWM6<:\29G1Z76*JFY;!+BJ"S;=L;^"M-F!4M+
MO7KU;LZ>UL@V%1&)L<8K.-6).3HM7-<6WAG#5 D0$8P;][5G&O$F9T>EUBJI
MN6P2XJ@LVW;&_@K39@5+2[UZ]6[.GM;(-A41B;'&*SC5B3DZ+5S7%MX9PU0)
M$!&,&_>U9QKQ">F0E4Z:FY<V2XJ@J%<# -F'DS6>EI'5%3APFL[?\FW]6CT!
M7\6C8/R+*H2LQ=T@@,JX;R:R(B!Q$;M/[7>^P:;2W8#/NW8QA>S:H1AN42^A
M[+1+AC-1=+2:@A2;MU8]F#1F>#T)B704MP0V$H204D);"=&(@]SUA1<I*K3R
M5:@HH6AMQ-X6*NN)6 =T5V8A2:F]9.+<U@Y)Z%I00WDY5X7A4"FLX%8H0HS-
MEXI=EN*N!*$M^Q0@)0(]MDY0J5$4"'G $)=TODT-M>4^$.B2B*_7&)W:/-./
M)NS";KL&F07!"&4H-A2C#MB8C :77'HQEBP3<;O%I5V*5*NWE9B<HDJ& UF(
ME4/9 9T0-QO2!ON [=T@3N7X;#Y%7ND[)C[[+?7(] KLW?5(JSTI.="-W"FQ
M5=M&^4IO:Q=YLV+)<8UB S8_!GBK:JG):6<AK$5S,R;(=PBV$(_PN*P0R>47
M2U^74F&B[=U>.,1$"/PBN*LJJ;Y2F]K%WFS8LEQC6(#-C\&>*MJJ<EI9R&L1
M7,S)LAW"+80C_"XK!#)Y1=+7Y=28:+MW5XXQ$0(_"*XJRJH3,\ 9U28R[8LE
MQ@O" $1&J+9K;MQ%]\WG56GT^D= ?)M_5H] 5_%HV']Y=E6GYTZQT.6IX"YH
M0NQMUNN.'=WJ,:UU%+J;G#,\F<9!*DE93>#B"M14E/=7E$#& "2XIN9E'0PZ
ME#UQ:O(WC"\N*$Q0#4I2+\*\1I.:O=+:')%I3CBB3=NIAFD))-\$% @"<,*<
MDTLM_=M#I.37E::$+UW,T>DNY6CTE^[7"%-7(U6E#2W=7:=Y:UD($#E.*)C=
M%F:.E26Y"]+/2TRZIM+B2NZE:0575A3:7$FZ(C(K%=E'7F'9>9,NZEMU+*E*
M4A2C!,04)O15DQ05956.CK>EEEZP8:TCC"5$NI3:>UT9*16I*7%'A%)5*7Y7
ME4XTAQIJ\N^4JA7Q=T708JRK$JNWH4+Z)N4?@[<*6U*O@X[KB&R4^O3>3N["
M )!T"J\5:<<1PBG/IKO9;_UZ<^FN]EO_ %Z<^FN]EO\ UZ<^FN]EO_7ISZ:[
MV6_]>C?*)R96VVZE=TA@ E!O"-U@*A$8"/0*\G.%%\C)*74WIQQ7:QB5! ^<
ML0K.%>)/*(I_+K1\E#/=77&-L 8.?!9PLP)F)A(5^8E"#30S$HKB28BNISWQ
M6<*L3TO+*O7JYUT]K;>#8@,3EC:LX5XD\HBG\NM'R4,]U=<8VP!@Y\%G"S!R
MUZZK6XBD0XMM-F#.76KME)%[&( N.5K48G?/0/R;?U:/0%?Q:-A_9G9IIB=&
ML=-EI>(N:$(M;:<KC@W-ZDE)22U3:43?*'UI!0FMLM7&PL)4JZ#>R@F*@+(Y
M,XB5G6WE3 N(2S*-,$H5G<H699-F)M1)57$8$<G_ /\ 03&A1,Q!K3+7KBHP
M"25Y!,(U"Z;!16OFIQMILM7M&F4;Y6'+EVX'URZTP_B%PY.1=PT8U:\[=8<U
M1R9Q80HZ)R,15 %2<=R,:J2&HI1\3,RY/J><4E*PA(#*D)2-(E"B3G$W1#-K
MM,X9*8Y9-O/-A*;CB;J&W+ZBZI24B^<W(O@'*K%5)G7$M.)\JVHH;1*,IF;Z
M^T6\J64FX(Y2](M2AC-NJ79:96SR;5[#:W$H)+3B+\<DW+T(B,# BR]91UJ<
M>EIS7.E3HG6F%-+"!;I5%MJ]%-00 JZ:[QP?I^15[I/H26'UG0MJOAH>_JR0
M$&V.4$U7%5%5EM$S.CTNL55-RV"7%4%FV[8W\%:;,"I:7>O7JW9T]K9!L*B,
M38XQ6<:L0OC1:N9S$89O$I8@,DW45ELVJKC9?.2UVJ.U0*A!.*P1A"/4Z#(-
MH0W]6GT!7\6C:@_++4V^FQ224J&\172\JM1V?R*O=)]"4OMPOBR(C X\-EHW
M:*90]#61XY_.O#N&H1LC#WKBQ9@Y'J])9U;W/='NE&W%45$9(Q"E>VQ8;6L#
M$DGK4XAWO32"D0WRD=<BD%*93ONM^-3RDPR-Z^KK(AU:92WG-Y(3U25>YI]C
M:2VKNCEKX3DC?"0:%2C%1] 5_%HZ"^15[I/ZPK^+1T%\BKW2?UAS>O3-ZIIF
M]4TS>J:9O5-,WJFF;U33-ZIIF]4TS>J:9O5-,WJFF;U33-ZIIF]4TS>J:9O5
M-,WJFD0*^G_C@F8;T=Q8B*_V4M:X3V*6M<)[%#,O7-&,1Q]+]<&/BD];]+F^
MGW0_7!N76VX5(0!@P=.G%N^#V:<6[X/9HJ5:0L+)%L,!CC_QC4J<4I+*4QR8
M7E5@0$2,<=X&C;+M[ETQQ:!V@JK=JO55Q@CM%5XC)M.>59$7G#Q2<83C(KSB
MC,5TCK)2G4:K!NB,-*M7K14F%N%68KI%M0*3B-HW#4*QAJM_6^,LC23MTZ,&
MR.&.4GM+^&V%'I>65>O5SKI[6V\&Q 8G+&U9PKQ)Y1%/Y=:/DH9[JZXQM@#!
MSX+.%F!,Q,)"OS$H0::&8E%<23$5U.>^*SA5B<2X;SM\WCZ[ML [:.#];U%A
M12I281%1M!J(WN"C; " PW#) @%PN\8+%YHMH)DALW1!*2(H1FYB8Y)R191:
M4GRR[7*]+VM5^,89(J_P33[+U-@W[$?K>GV7J;!OV(_P_F-7"32L,NJ1'2$1
MNF$87*<Q1\Z?$IS%'SI\2C>JU2J6@L*RK\<U)59=&+]<)_[TY[H_IE_8.?5J
M_7"9<G]8S#<Z7E7TAM1"51K .A/7-/Q6:^:7YBGXK-?-+\Q1IW4L^^_K"ZNZ
MA2% '),:RTFP;OZJ?__:  @! P(&/P+_ .!U"=F&6E8E+2#P1C0@/EQ0[A"C
MU2 .K3R$O,JW[B>LI5,B1JW7O_ITYFWWY\6G,V^_/BT\I(U;CO\ ].GEI>93
MO7%==2:0+Y;4>[0H=6!3U:?8IAEWV*TD\$8_K.4/OA<P.T;RU58##)2?9*%+
MFJI=#:>Z<RCWH@!PJI";FWBG$#<'32BZ#P;7]EFW@,2C?'22N\!P4NZUET.)
M[IO)/>F()Z::!##X1,'M',A5> 1R5'V*C^L-Y52:%G5_VN9W#!L>WP^U!&Z*
M%$T\4RQ][1DHWL:A[,JZ!")5XJEA[VO*1O8TCV)30,ZQ^RS.Z8MGV_:^V &Z
M:7D&*3^KI0LZ2<A4V/WCVHZN(&C&NY!:^3(XYH$PM%9%4=&H84V&^( 5]"#D
MCEZ5PM*K0=[N;8Q3"NV(JH&0=!K#X-1%?L#VW455&[#]6BZZ0EI(B2; *&4U
M+%+)%;MBC[#"G?SL4+:7E5J-%:HG('5\V+L#9>-7 L9)QY-%R!B6<YLGMD&S
MIBM)LK!P="WDU*%$R6OB7)6P.VK3[/NQNY_LJ)?EU!;*A$$5@C]5S-3JPAKJ
MDX@,)W*%%;<@#4CU58SU!@QG]$1;03:<K7<D#OJLO5 5WTB\F SQ=&'H?(\I
MJ]1RFS9OI[E77[:P0$[J]=YHVXTGN5# >O:(@@_JJ9N;,$"P85'$-W_J:J<I
MF:D#-3@2.SC.'>@!L$O+)Y(O)<WL<,:;=Z(%M.52P_VZ:RTPL"NW3^\+!!4!
MFG9!ML%3AP"LT\E)S1^27#AA"D1)N]0=<TB9-WJ'K&GE9.:'R2X<,(4+;@*7
M!@-1V;FMT-G^W-* 4N(M) LC$UJ%@,(T.LI.66Y)B-8A7"VZF-Y6+)!KJMII
MI%J^W?NYR$Q5=O74WE J5=KNIB84=G4(/)6"D+-0@5& %=9,< C"TU?HY7)F
MHU*0<U8Q'U#:-Z((G9(^R3VR%8CZAP[0$S"KI.X3UA2MVKV*NQ2")IB/LT]F
MEUF884K<6D^K2(L]!%RZV*TJ(SS@^3IQ'AGS=.(\,^;IQ'AGS=.(\,^;IQ'A
MGS=.(\,^;IQ'AGS=.(\,^;IQ'AGS=.(\,^;IQ'AGS=.(\,^;IQ'AGS=.(\,^
M;IQ'AGS=.(\,^;IQ'AGS=+J6,KV9\W0+QC9(0RM3:E.)%X78P]LE0ZE.>S7!
M+^8ISV:X)?S%.>S7!+^8ISV:X)?S%.>S7!+^8ISV:X)?S%.>S7!+^8ISV:X)
M?S%.>S7!+^8HN<FI^:#:1BEHDX /(6G!333BU+"<V,*A[5*4QQFZ([-W\N3!
M'+V$WF2=S,QYN8JK,55713#PNO(44D8B*B/T R;"M!W:LE'2)SO:QI>UK,F]
MW+0AX2P8]X*11*H6K^)%SJ*BG@%+C*4H3N"'6V-QY*5IW1'KTRY1M!QM^3]S
M <(I>U5,F]W+HC'VR (=X:$S;"BP.W1E(Z9&;[:[^EK5K1"5NJA$X,)/!2<U
M))2VC8;T:61>;BXE"TK6Z2%0!5E*@8'<B84_+:&"= )-,/;-Y7"+:3,HIC2H
M8UH^\U!=R!RVX*%Q5Y.& *3'#"C6I)5M)=;4'IDWD('*9C,;RE 7T)(0 E1O
M%1JLHIET%+J200;01:/T"=E*Q8M.!:<1]0X#TP4:PDC%I6#"DX4JW1U;1$$'
M:H/M-K&ZD'KTYNVDC"@7#PHNFEZ6F)ILP^$T@X'M)U(4BK133.YY-RW$2I"J
MMUNS=J$PS6VKU*B#B(-1& ^@+WLSUST$G?HCV(ZVR:^/3ZNTEUTA+21$DX *
M9)A(-G(3^\=T]058XT7KB<.C6F[!N%<%$"),<FVR$<<*-3<[,IE^4+NM H*K
MQX1".#I8Q1X3SNBT4PAFI-^*ED '.1DY0,;88*3KDRNXS)F[&$;ZXP2D;]I-
M=T0B/THGF,Y!LQC".G^VC.N=3K0AB90"X51W(* QE-13DUIK-9- ZXGE,Z.W
M<%0-6:C-%8B(WE#NMM+NCT$V>W;JKW49IW3 */=4+KB=+(CWQ%8]L+4;O:UP
M"C^A_4B$M\EF%)4HF-[)*2(&,.UP@T;E&TL+6R%!IU:+SK5ZW1J)JZ8-56;5
M1O6,TC3Z-=^Z50O*M!*J^V@H]U8;:/<O:T^EFD3%2[A#B%7NY7%)LNP%5A%'
M9UP ./.J686142H]?]-^M6KW*G$[G=#UR>KFU6A,Q+J"F5B((P@[;\O,?U#G
MH"][,]<]!)WZ(]B.MLFOCT^KM)U+*'R*3Y4XU#M?:FWUU6"BYF7;0M]2+HO6
M"L$V0.Y:*.,\C:1-N)NEV-<(QAFQ\*D_,3BRMXS#=9WVN#I4U(_(I*VV7+JX
M=K HB3B&0:]['2:3JQ>0MU%5U*P5H"0(!05E!0M%<:*U<^_<:E 'II=V^53#
MVYDQNBJ,=R%')!PA2FS:,,1$=0T$O*H*WE6 >GJV"@F=:0=F^Y[1/C'?JW,/
M0$#0S6I;LO-]Q8VK>':'>R=S#14K.(4W,(-8/ILQ$5&T;0-0SI^RN'R1/:K/
M:;R\'K_95;9\O,?U#GH"][,]<]!)WZ(]B.MLFOCT^KM!4V?MKF2WZJO:]> P
MTO*K4?TF62XL2RC$IB;I.Z+#90HE7G6T&T)4I,=^!HF98J>08BH&O>,11R99
M<\J]&_$)(5$QK2H%-NY5@H;L5OJ,5K-@W3Z@&\*:)C*?.>LVJ["<2>N:^@]#
M-"[,)S'!G)[*<:3TH&!'(YY-?:J&:H8TGKX1L[R:E"@TQ_W!F"7-W$OVWN@K
M!MGR\Q_4.>@+WLSUSL)5MP!3:IAL$&L$%8J-%ZNF)>67(*F5-0#3:" 5W04K
M0D+BG?[-!)Z=*4F;=;1Y))5%*2I-YR*590$(6 X*(<!*7W)G1)24XA>6HDD0
M" #& )C51:]73!=T3B$K\G=R5&[?3EJO)CCNF%='I!$RM;\N@K7!GM0!F>4R
ME5BK)PUU4$M)S )T2RK2,"\@IM2IM=Y$<12HPW*:MDI H0X^TM14N7:63!*E
M1)45&-4 D&%<8U 4EUZPF-"[-<6D(OY.!2S>3=!.*]UX*>UP[H$A[1INITA4
M1:K.3! QV^MQI:EDH2WR=O-$ :K:L>P3OT1[$=;9-?'I]79WE6"BI@<V3DM^
MQ&'?5:>#!LQ*2WME8$C&?4&&@E)0583A4<9]-70JI&>3%)L/;)5W2=WKV&JA
MDIL;J58%IQCU1@.S;G(GDIR7!C0?%SAO0PF@6@Q01$;7\O,?U#GH"][,]<[!
MB;<CHVGD*,+8)4#516M_M+J]*IQ+90A O7KR;RPZLP!];7U*-I /]Q1.JF"8
M9$3757&W_K26G9!I0E6+YNFTJ=*BZ;3;')Q4*4/ZP?4IU!\JL@(0#$B <(<)
MLR@!N T>UE&9::7F*1=#B50 B1&L6Q 6(]U1@O:=[0LN)+J@D.**Q "%\B A
M:5*4>OJ]U27;LHPM"ZA65)4!=RK*\,*2[4R[.LJEQ=(85DN(%D?*(NJP%0O5
M=*!E-9AY"4OE:"@Z4P-J%%Q8)W%Q-?:P$*"8E$K2R&D)@J$<G>)V"=^B?*(S
M1A&*G&(X13C$<(IQB.$4XQ'"*<8CA%&4H6DJTR<(W=F]+R:KBEB[>(-W=3'!
M>%6&K!2[.M*2CNK4'VPJZ1KQC9(E9<7GEJ@/3B%IQ"NF@:K?56M>%1\4=J/5
M)/0YE7LF836VON5>*;%#IV@$+DYM)1,-J@1Z<!M!PBL;,ZM>/VB5J&ZV<WO:
MT[UW:_EYC^H<] 7O9GKG8I:;$7%$ #=-E%2+3\LK6"8^3!7>B+4A10&RK<"\
M>(T@;?TIDF"D.KCG69*2K #@&*B5)6E14*P+T4[\4@=Z5;-._1/DT9HP#%3B
MT< IQ:. 4XM' *<6C@%.+1P"EY*$@[PV:6%C*(BK?/IATJ'1@()M$(H/M>Q5
MN4+LL- O&G*:/2[7J;U(S;?D>[36CAP>VAL/[G,C[6\,GUJ.RJW>@,?1/]YE
M!]M83E#NV^RBWV,175LV9PGR!-QSV"JCWM2_:[7\O,?U#GH"][,]<[%I+"TM
MOZ1-U1L"HU$U'#N4.J];R%S6)O7G6BI&$^4N')(-M\V]2FKI>5\KY:90"+"=
M((=]"(W*:R=D+P<Y:B*A:E.A3%0Q8!$61H[--@_WI6JDJ6+M=^-2B(9_8%-6
MSD_7K$K?"5'/6UH5UG"8*L->_723=KY4WJUY3<$A9"KPRDI, I0%@C720><,
MP^OE:PEYU*$DIT2KR.-<6N"J[QJ&;'!1?*5J6$+4$QP"\3 ;GJ0%@&Q3OT1[
M$=;;$).8G*/2_;#8&X-&LXLWII[$*%^73H%=TV(MX+457>E=$>ZH5/MWY?NT
M5IZ>%/3A0!WF;64O=Q)]MUH[4V)H.'2WH70#FW8QK'=8(TT/E @G/( 1OFN\
M![7?H):92Z5E%[) A")&%0Q4" A^),+$^/\ I_M\F2)Q8B2+4I[)@?8I!-51
MI_<7U%;R;U:HF)*[J8X81(Z5!^8N5N<9FQ,(7KD;N96KM;L(96Y1J;L*T G?
MPCAVA0:$)![+;W.Z1[4V>MNX=FRXHQ?:&B7OHLX4W3OG:OEYC^H<] 7O9GKG
M9:!4P^6(0NWU788H1A0MRSSK;9M"5*2#O@&CDJ%.\K<>"]-I#>J%V&,[]ZDR
MM5]<S,-7;]\WDGNHUDGIC?H)I3SIF@(7[ZKT/91CA-$0=<\EF91R?8]STJ)F
M%OO%]&:HK5>&\8Q%+RJU'8IWZ(]B.MMBYDVJ,!O#T]3912-&[C%G3%G6HZW*
M)0(KK*1 *-D=JEE8DO?_ *=)4-)"0F\D0P" JHE6JGVFV-&(A5MZNOBU8(8:
M"_-,7(UU#S-'9N;F%\K4LE! $$)C%"86F[N%->[64NSTSI9=B\4H$25F!@%&
M .(UW\0QTFWYV4?,Q,"MQ04 @;US]Z  2!"%;TD&5:-L!07@5Y8*5"J&2(X3
M90(B LJ"8>N#MZ&_=%[>KI+I.%$>^)4.H=H<N",VQY1&.H92?;)P=U#9OZK5
MF.HOI]DBH\(/@[5\O,?U#FT.R1ED%MM=T*+A%[)2HU!I4(7A3FS7SKGF*<V:
M^=<\Q3FS7SKGF*<V:^=<\Q3FS7SKGF*<V:^=<\Q3FS7SKGF*<V:^=<\Q3FS7
MSKGF*<V:^=<\Q3FS7SKGF*<V:^=<\Q3FS7SKGF*<V:^=<\Q3FS7SKGF*<V:^
M=<\Q3FS7SKGF*<V:^=<\Q3FS7SKGF*<V:^=<\Q3FS7SKGF*<V:^=<\Q3FS7S
MKGF*?AXX[1<?V^+B^K91[V9ZYZ"3OT1[$=;;&V<(3U36>KLENC/A ;Y],=K0
M)I3B;@4!=(&="-J3W-$(F2L!!CDPP[X-(;!<J[$-K$#"WU:?V]$5R]>= Q"H
MQ!J PXJ:7RMR.9>R=ZR_#VT=VEU-FTORJ!"74;Z/8JKJW$F*?:[*5G28(2Z+
MWL59*O!)VKY>8_J'-H?^\K^J8Z(_YBCWLSUST$G?HCV(ZVUMLX%+'!AV;<J/
M9'K#U>C9?6R!E(5HE58#E)KQ A737LY:=.<XR@G?A7U=I^7F/ZAS:'_O*_JF
M-C)_>FO=IH\]K*>1_8T3+MYM4TAP:.*LCDX<4HF%01HX@X 120FY72!J===J
M)&2E+UQ,*K;ML2JND[,S)FEMRTZ&4A*D D%(,22V:Q6; #"%48TEI-;$^7IA
M *G4B++)7F!4&SI+M6E.D;&$45II9_DZ%E*G A=RI5TD+NPANTF=02"YCE[2
M%%"UJ1<4I";Y;NA .;'+O6C,A22;7I5E.II=0;;&6X80A?NJ0TD1BIQ=0%0!
M)I*LN:9EV=;?2A!<;<N/-P*+ZTI *%@C)"4J!PT;GIC2)GWIE:4I-FC;$%DU
M1"M(;M9%BJL-)>?U?>1K&<=="G1:E#=6C2KM+Q-[)@HPM@ *2NIYBZ=87S]H
M5$KT=V)2OX2[ E))C@B(DT=GI>7GY=4LX@_:!4ZV50O)\FW=4+2G+JPFFM/_
M .5;^IV7_,47,:1H7E$VG'["G&-]\?-TXQOOCYNG&-]\?-TXQOOCYNG&-]\?
M-TXQOOCYNG&-]\?-TXQOOCYNG&-]\?-TXQOOCYNG&-]\?-TXQOOCYNG&-]\?
M-TXQOOCYNG&-]\?-TXQOOCYNG&-]\?-T"PXU$>N5YNB4FT#:TGN4D]2'J[-U
M6 &[WM71LVSVP:OC?;R^K=AT]FTB,2TM:/"O=90VGY>8_J'-H?\ O*_JF-BS
M.0O:)U*X61NJ!A&N$84?GH7=,\M<+87E%4(U1A'%25EIZ6+RI-:E-D.7!E*O
MP<%Q5[*KR5(Q4FI?0W.4S@?C?C=@F[=S1'?JWJ,3$_*:;6,NT$!1<\FNX((+
MS922N&&#B+_;542XN RP< %N(0 &]4*3DSJIE*IUP% ?#M]N"DP4M" G/(JC
MI"GUMM#*ORY,HN0:EE77+J_(V+2NX81PH*5 V$D4D=7ZK9$LN36M3:EO(M5=
M7%:G VB]>1&,4I[4)LH>2E)E&DW4W<TF)4XH>R6HUX1 T.J]8M&8U=>OI 7<
M4VN$+R%05:+4J2I),#48Q85J5A,NAE=\WCI5N*@4^47!&3=*DW$! %Y1SC$*
M:D).XXMQ*BI;FE*0DQN->33<&,F\HBHDTFF=#<Y3-)>SXW;J+EW-$<<:M[9?
M\QT>ZYB1#A/[-D5&P"A6;2>C2A6:11<NO/;64GI&&RFI?"E\*[Y,/W-I^7F/
MZAS:'_O*_JF-DQ(QNZ9Y"(VPO*"8PJC"..CDHY-39<:<4@PEFX1285?:K*!Q
MB5F%ME,8AM9$,=0LW:$23+KQ3;<2I4-^Z#1U<TU,-N-I0>*-V"S %:B1<![0
MW57S55;13STK,)93:2VL ;YA50S3##RY86K"%%(]L!"BA),NO%-MQ"E0W[H,
M*$2LN^X4JNFZA2H'$8"H[E$LLLS2GM$%J262DBN[$ %14B, %Y,35=%$LS3#
MS;R[$J0I).\"*Z%V;EIAIL0B5-K2!&RLC#@V?_,='O*W4^KV=D\K^&KK='SK
M9_S*SWQO#K[*=;QI:/ 5]G:?EYC^H<VA_P"\K^J8V4E][9^L32:#,A>8+[D#
MR!I41>,#?T$3$=M&)MC3\O,Q4F$*K,K2@68\%)J4U*E:IIO7,PIY",ZM7DEP
M!C<3"$; H$[M-9AXWG^0R%X^NTM=-8-NF\WR-Q,#9=T(-V&*-<,=-43>KV)A
MUIF6:@M$PE#+2T\:'O(+N1/&$D:05 &RC+.JI9YXMSSZEHE'0C1J4OR*S%A2
MBC1Y+;MU"4W2# U#6R@$)7RF62NXO2)*@!'*N(B8C*R87@;;::1HE+@_*M1%
MH\I35RGB$OZ:;0RLV(<4WDVXU>$1OB=:UH%H)FVRE*\ZW*,#7!1PX8$C9_\
M,='N'U_J;)[V/J]'S<.Z3]6G932>UT ]U^W:?EYC^H<VA_[ROZIC:>2O2LJ^
MB]>BL+"]Z^TMM1&XHD45.39BZK%4 !4$@8 !4.SLA,!MIV':N)"TF.,>J($8
MZ?V]AIJ7DM)?*6[^4J$ 5%Q;BJA8 0G#"->S_P"8Z)N(A&$:ZK*9[/?I[-,]
MGOT]FF>SWZ>S3/9[]/9IGL]^GLT<22DY> @X-S9.^Q]7H^;AW2?JT[*:5@T
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M"4]T],MRR#H()1-A-3UH7HU%,;J5!2:EK&&->U?+S']0YM&MOO@^K33DTO\
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M:W]5/K^PR/;J7@<<&3>2J[4/M A,0$0<OD&D1,?GU:(\IM9E6>YA=4$J4$_
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MI-&MQTC+=42HDK-JJU*NWBJ PDU]!A0S2\^1N@ON$'>(K'H#_,O_ %JMJN.
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M;#)3Y!$H;*U9)I\A?9TL6>8< !;^ND6,:UA28BM,YJ'(Q2%=N[ZNX_FR5M5
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MCL>CV@/SXTR%+:W16M4H7N8UR[53AUO11K&QN^44 KB^E!FS8@3ZH9D-D6)
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M+(Z<-J9YCGF2ILACT6-RF :O*1J\S<CFHWBG-=W:U4C(&\VKC!KO$&MB*1P
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MBI1;&"BI6045%EQT5%2*+5%3F<?A*!]V1_\ *<?A*!]V1_\ *<?A*!]V1_\
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M\Q[;M(+"<(QG#P/5$5C"W9?:$W+7E]TC'L(U>W7M=ZE[/)3)*\ 0Y6OFQC=
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MCT<8FQNC&HP8A"8T80B&G8P01-1J)_5]TR2D>)*VHY%!.CLE1B->U6JCQO\
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MP+>=.?>Y)#<=+1SYT15CP+J/%9L@G&WNL;KIJO>5>++#L*IX5"F775!C$0,
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M.(&FO1!_;_PN]W[+PV0^-C=4]?;FY,_67F\L?VV/6RUDF=LGNCZ:-G"U\0^
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MN/S9_P!,Y!^5N/S9_P!,Y!^5N/S9_P!,Y!^5N/S9_P!,Y!^5N(TV+CG*E0Y
M948GB]Z_EGCD:4+]A+-XW[",1=%147_]^$NOD,LE/#.2.51QA.'S!.VNV.62
MU5;JGO<?:[;[D#^Z^/M=M]R!_=? JR"R>DDS2O9SXXQCT"-Q7:N:<B_!;[WZ
M0#/+0JL*3E-Y+$>N[:Y_:BN9V:-X^#._^ /_ "_'P9W_ , ?^7X^#._^ /\
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M@\.R25&A0ZLL3+H]:V=XA[.@S*+=A0-2I>YN2!UG(51\_3B?+]H=O6^;F/\
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MCWUEPDP%_M*_P>=4^'^+5UCM"OQ4@ W]K>SO-U^,EW?-;#-8RH@\,S0UA50
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M'AVP485%AR9<"+:1Q.<]C1O<2!-$3N*Y$1_;V_HP*.FC='5UD=L6%%YQY')
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M%=3U0Y.4)C5C4<FK.\EH>;(E*B,64[F '\4W7XQM<3/<P7/US"))#?NAU'M
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M2N#&4#-=I8T5>*8JO@U.TT!U'S8J"TE.!@4Z\#B0)+=!0XHMJZQ?TD&_0T2
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MH$G+Q >!SJA2AU(9&SWO*"QI''9^@XO&^W847OV>0>^70GAN2U@2O2!Q[";
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MVZ'E 2[T!P'8O0\K!D\";@+F 4N:JJEZFZ\,$ *]1!@G1':"$M&5F/->M5P
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MB3N$W_S,9!EP0T(YF1153>YKR1+D3\)#FO$+4M #E;CVMQL*_%<$@C*JX\-
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M' N19K!B!-N%X@;>=C6^,*7_ -]+DNZDZYKKR@M#500 ZH'@K['![-G]T?\
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MG\O8"Z.<_P C 71SG^1\S2M8BH]F\7Q]*M=7W!_+[?C36&_,096(FT+P5T$
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MO,X"UN4E ;<'9/T#UIHS&M,#[1U/7PC^ 8ZV"T-_B&IY/EN)V3] ]::,QK3
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MA[#:'?*%V0BJFEJ([UC;UU,-CIEPA-@-Q: '!L$:'J%!XT$CQEGI8\!>P!>
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M23K;T>/@6. ;\GY81'@/ C5F01Y4'Y' VHE-P*! T3HTW!(UUH8\SYS\V#
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MT>VAY..K\H 9>Y#=<?R+]T]7& *1Y'\+^^/2&3A&]I#N"N$3YST1N[:/I?\
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M\M0)"  =WT,Q>[I2O8J &W=F.]0M]IU](WW'1SKSRU D( !W?0S%[NE*]BH
M;=V8[U"WVG7TC?<=',O+%C:>$7Z 0_HR4]$9 50B<B;')L=#V//YX>2>)0<
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M &_68HPLI$L:4G^#VBA6S"!)-)HY'R_2G__:  P# 0 "$0,1   0
M    $D@ D  $D@D$ $DD$ $ $@ $$   D$
M  D $@ @$ $@$ D$ $$  @D@@@$D@$ D$$                         $
MD@D$D@@DD@D@@ $$@$@@@$D D$$DD
M    $$ @$       $$ @
M  @$$D $$@$@@  $  @@                                       @
M$$$ @D@ D @@ D$ D
M    @
M
M                                                     SK'<=
M                                                $F#;;;;:T@
M                                             ZK;;;;;;;;+
M                                          ?;;;;;;;;;;6
M                                      $@C;;;;;;;;;;?
M                                   'FSS;;;;;;;;;;=
M                                 FVT;;;3M:;;;[,<H   @LH
M            ]MMMMMMMM*   VVVVT^VVUC#(  !M;, !:@    J?X
M         %VVVVVVVVUH  0    .E&VJC     ;K/&;=8     "
M       NVVVVVVVVM  "    4*%C.@      $];;;;      0
M    %VVVVVVVVUH  0   (V-5L         Y;;;?     "
M  NV(@7?^^VM  "   )VVV(          Z;;;.     0               %
MVS(^R3HVULDD0  %VVV*           [;;;(    "                NVP
M[VMVVVMDDE  &%GVR            +;;:8    0               %VVT[/
M0VVUH     P"IW8   #KH'[8  &3;;;    "                NVV='N2V
MVM     !  %0     5 SJ   ';;;H    0   C;;;;;;;;;;;5VVVVVVVVUH
M     P  N    #: '-P   %;;<    "   %;;;;;;;;;;;8NVVVVVVVVM
M  (  %       $      C;;?    0   K;<TS\74H;;;';;;;;;;;;H    '
M   @  $@$@@@ $$@$!;;;@   "   %;;^4SVN>$;;8               (
M$  @D@$D@DD$D$ J;;:    0   K;;RZ? %9;;;               &
M           @ C;;(   "   %;;;4 8?$S;;8                  8   D
M@D@@ D D  ';;8    0   K;;;<K;;6;;;            %;;>  "  $$DD@
M@@ @@ @ ;;;@   "   "))))))))))),            8  0  (  D@DD $$
M$$DD %;;:    0   8           (           #  "8-0X   D $ D D$
M  '3;;8   #)( #           !            8  /+!<    $DD$@@@@
M;;;>    BTGH8           (           #  #   8   @@ $ $ $  "2;
M;H   %   #'V4,H  @   !            8  &                 :0*P
M   0   89SIZ>V26637(           #      $             V#P?
M"   #%H=E#OJWJ3&!            8  %   F            "UVN(    0
M  ZJ"N+??V7R30(           #   ,   8           &%@L(    "   #
M        H  !            8   H  '@          %+P>"     0   8
M         (           #   %@  Y(         !MVNPH    "   #
M      !6VVVVVVVV8  8   !H ]RX        %F3Q%P     0   8
M    )        $  #    & :'XL       BI9BR      "   &VVVVVVVVVV
MVT(        @  8    "X7__ .      .M=KDA@     $
M 0 N   , !   P    ,=_P#_ /Y/   Y8%@L%-      "
M ( +Y+4RP @  8     :_P#_ /\ _P"X!/\ IO!X-X      !
M     $ :X!O7@ 0  ,     "S_\ _P  /_\ _P#ZVNU;       "
M        ( :R/H<0 1))8      R?_I ^_\ _P#]NP5,       !
M        $ /N+ALL 0          ;?\ %JO_ /\ _LX5@       "\
M          @   !(  "           3[_P#_ /\ _P#_ /%<     !H.L
M              0       !            ! O\ _P#_ /T@
M               "        (             (<0!*+
M             ?\ _P#_ /\ _P#_ .0
M
M                              +4               * $
M                           (V )((            _\ \2"0222  "
M                          *1"02"0           23@ " 0"2"0
M                                            " 2"0
M                     1P" "               "" """
M                  !"Q@ "2
M                .0D00 2
M                 2 22"0        7;622 00 " "
M00"0"000     " 02000"        [;P" 2 0020                 0
M     "0    0      0                                   "2  02
M" 0   1)P   " 2                                    "0"2" """
M     < 0 022"0020                                002 2 0 00
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MB80>X_9GE7:^7>P3JP$ P  '. A4"4ND9^$DV)(OJ&*L2_ SBZ<DP,8:ML"
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M][ &['%$<>^>Y5]TROVE^&P9EHHVD0N&[EF(\6N,\N(,Y:&0-:M1"53 3.
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MV[=NW;MV[=NW;_7V_6_E\& _<?>SKD!;!OJ &WG3N\^(-7'(,/(B7<J"X
M $ T < =O='JNQ1<4R=/;7C6/T_ZY9BG=1K'9;8%$VD]L O3P.LZJ\Y&Q ^K
MS:1N #&#H86X$$#1A'-Z(RK' <*V]R22\(  ]S/H^"0P!3H:^2+PC9MZN9I4
M=:<ZOSVX\ /W'WDZW4Q3HBZC@^?C/3K<52&E5("&WPK5]^,EZ[AOP2\]'.C1
M5FOAEW(2BH-)_!IN (JC6M0C5G(Y+3_O>LBW P^UZ+PFN%P=YSQ46&;M?)2*
MJRC#W8^,J<KPL7V%;Q;]6<DI) '2%:75@Z@Y/N"*=;]=GU%,*-4AXS4!?RFN
M^C,<D./A[CP=M(<5]1AQB25B :1AL>E5Y"&94]SXIZZ# KS-QBS:@S:T+6*-
M<190>>LPB#3%(&4*=VFHX0+4%NX^"NC-$.+@%=P:2CJ"4KM-:J 56YH%0S+A
M_P"NVM'0](KKB%#9&%?4#)&F:WIRGT(7N+OH*3%JDJE!5 HOP($"! @0($"!
M @0($"! @:WJNA0#UU+'JOYJB>,DL5-'NMBN421>.9IPM\9P2423KZDG@@!V
M/@2^Z$HVJ)1 "N$EH^P70I#5S1NJEJM2%V[F3%+62S=0=(B'&4'K$=DTSZP^
M.] #5!N:SP*?)$1Y>R&H8HK#+F[A'S'[3.!N$B?73M8&\@.:@BHDIF=?57=Y
M/,NW@/JE5-2%'R,SHS (+)6P!'9C7]2;L<;N@65ZN.0$H,(WD!V[#>"%E93:
MWW<=P%G7@P=_H _:0?64=E)"22-)T0P&=.2,:R2ZB;@''5NF=-P<"C3V!+%X
M-H::%K41+.]8KV8:I^&5506=8,QK@TC'L]K_ %")0CV*($>V"E22%Y"'QHU+
MPTIH /.Q!\-7'GTAV!\/115]%G3:#UB<'VQ5EU'R1EI7ZGR;(WG*V B90ETP
M:#*/4,K"IYM%1A   ).C.J"O:4UDJ9?HI\"<Y)8T@2HH5 JO/OFAG$-<$M+-
M&8C#PN)TJC.D]_S1XP'%V3..9/L0<$.-,_TDXY^J7Z6)ZOR/D@U=63?!8:+J
MYY.OA H0%1#JC"=S[-Y\3M:#P;^9R)3!Y5L".'&1'X1-,,[I/&[\'LN,F%<G
M'=H[Q^(3X0RF 4;3*3AS )APY?3HTK88<D/$._&E&4KGA$=*4W="9'E7R#\*
M"TK<2Y71P&\6=Y:8HDU[*58&26Y@SPN3\$/PT:UC$B@%8%O<D@O"  ,+0-:Z
MR\,E P\M%I-<J,CAD!U&Y#\6^C9\8B;Q _" ;ZB-DEQD$U^;BD9",;X-K<5]
MVR/#P%XFBO(DSY9 TB+Y]5D:>4,!G (9T 1 X0!,=S0+_.P6QO\ [3\E<R.X
M(V)Y9#'2!&IJ@IJOB"<3U*0XL6J T"J/AUQY]%G3:#UB<,97>7>?Y!8JHM3M
M;W+E"CFP!8H#=Z@B D$MSC3:CN-J"@)64HQD_! ('Z[#.?61^<[G8H;)CV+3
M]IV8-H4=.*:$5HPP4"X4,.@BVM,53B\PQ>"DMO)O320;3!T[ETWDRDH+J?)6
MNR[N&(4PU!:>H\0I%(^A&=P*].?BBB]Y7I%QWJ \ OW:B&%256 >UHB>F>/F
MU@H%%IX4W0 *U F <!0UL+\/<>5-:/1M-498BC8[IJ->_'K!PT0B:W)%[T\$
M&WS4)"34>R5(*(BHDA-5)6ZNP*%A%.:YV[P"/I)&E$>,C[%2)Q 7XEMB4.F]
MFF95Z$VB<;4C[0@XEJQ3)!P@8. ,1-.8.:+=9#X?)EPJ_:81KGM;V3?A405%
M%)ISJP/-\><=2^!PYWB6FNTS: ,)8 *"*FVZ/V P;0$^XO:\OL3K.0G**L]>
M?HZ*#A,:/EKCX QCO-V:3?=U@B:'$-"WU24'3QH3#^<5L)4[*9'X*QW*IK!B
MF*BEP!@B.\MH\R8-8''=H("!T),F*-,*&S#9PAF7D/),%RB<K\Y/N>YJ2L#&
M[MN"T+.-A12>..5BG5DN':],\8L'G%0!\V9"V/Q<[*K/'T##M6$ <4J++X!^
M;J%J0HM97,[/99,J2) 2][>8OL"E6&B<%@ !XGF$SP[C(02,>?2?$W'G54XB
M/M9NXA</@.VN] &KXFI@]X:6'T#2D><HO&PDQ@BA=^0 %,=;5YT0)+XH4*%"
MA)B6TP#"DJ$1MWXE,X7L@K4>-3K)XMW>'9'0WIS&2"Z@5%H\-9!&!4'!Z&=,
M@T0!,)+-BA6M62Z+#2OUD)FDZ S3,<AB'=UI+$),!C<Z))/WMUE]H!(,VS&"
M<_A(IO!*P,E$D^',1D-[*S* $W8&&0OP.0^-;ZBDW/&4F/C@7&8D@-UA3ZF"
M:P3@YKV'SL3G+*1_+YA62FZ!RI++:+O C!,X"K+V^G=$WSGC0)L:J(RC&0%A
M;YQNY(1PS,9KPL&21K=*T80&BN@*>S>Y?9;^J@LZL]@+X& LQ$!-"0U1T9K7
MB8@T;JBW:X]?P-SRG.,0'$5;OYOO''''''''''''''''''''''$TJ%QZZS=W
M/=6;]'B)%RW"12H<2:$Z^(,&R4YJ-?$%"8+9GAI&9)A 4X0MA\]\&\93<<>N
MU)$4: P)F',JFI"LW$JRX1)2",QFDS$B!+S=[E4P -I+B(9H8O,108$E-N?<
ME#/#I!(X0;ZX0"!QH_M8?96=V!QF$8!])F9E>*>,N.6>LFT8T\*8RF&2-);G
MB0%,IO:(!N:0!Y'*N]FK$-&VY/\ &74S=4!CL8B1+C[N3XJL& 36#=L3D74,
MA) 84*BVOTIN34(Z;8:R8%2R"B&,8V'<GWTIDIAX!D@)5N 29N8J4OB/!611
M(^N$G4.S]$7-J%R3X >;JG/(O0RC-9!1K=#"\IBL83$A?8ZPN'6",.ICTDQ+
M5-FP08Q_L5^96_L@E6<2)U.[,6Z5NT&-HU0_)6_1NRN<<[]Z?2FB^XU-OV1O
M51R+*QF$<5"5A:T*]C0S<#W;VPJQZ)P_'J@[VVUXTYJM\$W3C44MP"@8 S;D
M5:,%%F)"@Z<F^"+6*7F[W*IB@:07"F?:A)BHAP1%IVE-^9QCOL"#,/3E"HM=
M+6N&<J;4BV*B2U%UD%1P$;<AH"/Y)O3&(\V':7'$QVYAX"G'=\3*7QT!=9 D
MJH:P6D,D 2$D>H'EX@5-PL@W06W"]3Q[E KZV*FN<G/9N</AT)"4PH%[,3%0
M'<+G4[+B 1AY#$_%'< B"1Y/GFU"?6/Z;ZA%#B[JN*<55;5*WU;NVO?#OQD;
MA!2#$6 S9> P3$,':CK!7A3QVTSTVE"",DQZIWE:V%RU&>7O_G;_ -XPJUHH
M#%>UMCL%=ON!.<!("O+Z@]O /KXWK'5&DTPQMH33F'GU%2RW[WV21UK[AV!L
MPJ2]/M#\Q]JA%\[G,K:N M_>&<7#IQABC4B=Q)4@^I+ MB 4*7ZA'C"27MTS
MSF6](Y&__=S5DO&50:9\(/)-RFYMDQ8;.9/H.:$TC @IG71'JZ*Q/2>B)'XY
M):/2-^TNL"IV!?#762J@(4G,7QB/VP"6HK"U*G0/<G!&P7&6:E,: LDHB47<
M;3NJ+BQ+9R3VC-/)!L/9(><<J(:"D\3P\F/Q4)7PRS:!;= \/,F>&BBG>!G]
MF8@<NWYQM0H$CS1ZZ&II9*<^,4>\P=052D */*^XE]U_ADVH CV0 /TN?,B0
MX)8#,J844*K;DC%=7D.C$-S &,6-M<K^U;THQWF5RT'O7N@:^I@VFXB1L(5>
MJ&QD[7$486?'%XG4 7O1##"HV^GX%3?0*B'X^4;Z _W^(J[DL13C+*Y-!,5"
MT9:X YO$N;SX2<9^<%5!T-&['C^8!WM&<<;JVI6%"E?") -N=X!:\F[FG#9W
MJABC)$CCJVP(16]T6VI?#NFS9M[0"Y#8/N3CI4=<'4!95R/<[0M\C.<G @HJ
MAC/LK]0S<BUM3"+,KL<-2RJB>CA>7_-OK?P":Q>7:#Z*..JH&%H%=,/"ZN"*
M' :SQ_2/N(;!<^O>-0%^P >%NUH.D$$Y> _*4)PP@ APR:*>M;\5!>,"MVI.
MXGGX^-:_AVRE\C41Y!P4R)SC/>O@B+C5'O;3K<'P173;QOJO E9Q'FY9/N*^
MCP@:W5VC:IZVYY0$!F@%478$:1%!OPES;-??X,3!7H%76/%;L7,@*BE.== F
M41X,1J2UP!0L]YR8KGV"2I7T ZA@4^ QBC?$2K=:\SB(C@?$?SE"#E50 P=M
M+RA'C(5Y'GC0Y,CUL'*$5!>AX#C24LH3<<S(-!H_20IRHNA9CC<L2H*L89$U
M\A#^8P!^>$_N]UHQ@:13%/G1Q6*3VX,678/#6TB4>GL!9M@[]TFJ8[_;D5C+
MP(%D81Y -%I@9I8S&.",C+069F=&+B0JG-)K:%OR%R$1L?)P.@ +ZG8\>B):
MW/K7<8"0?%F?3FE9$!E[>.$/W=P5X-L P_[U"8+_ !T6/@KXWXZS)-LC'Q#]
MW<%>#; ,-ZAOC$8[8L#/T> 5%S"4U) ,E,R?"!(9K\&!-S:/ 4!&#0=B('H4
M.T+0L+NA%R,DF\WE-D*+8D?42+Y^Y6+HJ@&DP&-4K[5+MHJN[[*2U)S!Z*4A
M P&"J4X&*7J 1-M%X^CCTT..!$)RO0_8!B*6%Y*"U1^*:<FQ=TV_&P5FBG<T
M,I/S_P!-?<+#(%+8T5=EV#=E@A@4"TV ;]$=I+B?A!Y&HV41R+[EQ2[1-0OO
M +=!6/'@#]$$.R<44Y-QR3J$28]);5EX9)]*AC#ZQ4E4BR<.-C\;U\1G@0 N
M^1$)]<3A92PDA_AGCTD 2\E$'#;HQ9@B"(B438CPCV^+MK.V1/U'R7 'QMUG
M^23 ;_V/\U]_CLV$?N[!UU8-!@P'QMUG^23 ;_V/\U]_CLV$?N[!UU8-!@R9
MR<D;-AILI?@BY6F71>+KOECHSSENZ :F64&J=.IY1&MUBLDY;Y(U7L!EH !D
ML_*D7W-?)DMIX HF6H,A,,&!-U9X&IJ@69LN )[)= Y;<P.8AC ^L3\"'!(9
M8OPZ/P (2?TLAI;AC@D%M!07 ,+G!^KH(P,QRX^RO8Z;Y(1C5LMCZ$2B+WP*
M\FO X4P+_.+D)X.$SD3,:4PG!ZXV:<GA'"MHK*.!O\I7F6-4@Q1(7"\=*)HW
M<]RDFVIYC5@%F&;F&X-@&!7Q%R4(JKJB'&09,]4!2;7R)[H2)G  "(44.S%2
M36:"D5LZKQPCDV&LEKJ8[6J(^(!0)R 3B2&! 8_O*9#T_A#'_P#['\ZW_EW'
M<?5*"_?TEKG_ />4R'I_"&/_ /V/YUO_ "[CN/JE!?OZ2US^$:B63FW2D]\D
M6YM=/K=S00US-Q4U+DA Q5&   'R="03<8#V@N@&E7CQ['K1;=""PMB:7$:L
M=)!-@'!B1GP].]&KUQ8^C$:8GUZ3P&<Q"D0P@KXWXZS)-LC'Q#]W<%>#; ,/
M^]0F"_QT6/@KXWXZS)-LC'Q#]W<%>#; ,/\ O4)@O\=%C^LBNFRENX-5?HRN
M;4(]6\Z[@60=(S R-&=\@U)ZX!)X@ ?,1"2N  57%N>$IT7!"B:Y!WP=)UC#
MNJU9'PG*>U[O%3^=0.>8^+P)FI\?F[_V/\U]_CLV$?N[!UU8-!@P'QMUG^23
M ;_V/\U]_CLV$?N[!UU8-!@P'QMUG^23 9M5I$?+]B3!"6@+EIV6DV5[2J_+
M+FUY02SCO([J-LKX'_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /UDAZD@+=4,
M/OX3@YRP6=$I 7H"FHI! HB1$TB.Q'P!PWGK6@ "@ N<TGUHH"R!V)\C@A0]
M*@5*0UPN+I7=G-90VV#11P:FZ>44H"*/JH_!K_,, 5GG_""E5(1B.\?J*S-P
M#2!G]+9H98"=E$V>5M58]7V5GINS*[*\TSS4"D)I/9:ZW^E8H)V$UC]_>4R'
MI_"&/_\ V/YUO_+N.-H4J=B]AN,?T?2YM #L)^MO,C1&)(7*$]J0AR*Y@M %
M$$H N"@D;R9%E2+Q%\H:"TJRG<2%)6/9("LHK1 F0:+$,'%U\]V>7UL ( B"
M(B438CPCU'WZ@4 !56 &U5T >RHQ7 IDJM<")JIXG']/4"&&?C)[[^/!,Y><
MA5O@:T SHP@\M%$9]6X!@!E<H,05R["2XQKA_;M[O34V,*6KA(C5JN$SAT-E
M73'):"1L!4W!6@G-9U/A<-PU4]HU;P$OJP ^=<N7+ERY<N7+ERY<N7+ERY<N
M7+ERXAP [")8-JJJERAA1 "4*,?@2+(N50&0*'SRK%,!RRJ0!<H\)' ME?W&
MC9(+W)+0+1$ I@'A"@)EL'# ()K"N*93TO!!:1AB\/WI81P9-NI:S;@!42E2
MA;C.#D0'QMUG^23 ;_V/\U]_CLV$?N[!UU8-!@P'QMUG^23 ;_V/\U]_CLV$
M?N[!UU8-!@W^17=UD4;_ &<GCV-&CCU&G,8*OTNBE( M$S8#SW$.;?R[D*/F
M-P [[C,OYT*:R3"[%GLTKU>O<OC"%:^0>>>CK\-0["Z,DB\".:.HB3.;P=3W
MGS?SG,\;(5VA1( #@ ( >Y(ZG[@O)6UQ@3?K9DJXP]G]; QE1QGRK[:#4I3>
M=*"KT-D8Y%\/2@J]#9&>5,'%C&B36HL@'=4-X,*&\INO'JH7I-DA<0_BI]=;
MS&,[J042JD-,_P#[RF0]/X0Q_P#^Q_.M_P"7<=Q]4H+]_26N?_WE,AZ?PAC_
M /\ 8_G6_P#+N.X^J4%^_I+7/_[RF0]/X0Q__P"Q_.M_Y=QW[$ [H5K.*A!S
M]^.N[CJ0R0K\SN 'NS]A8K9A^JI@4BTD=SM 5"+HY#>Q=Z;\TV #J8]J"('8
M_9CH:-Z(H:T<<#M@>/\ [?RD%QNK]3URF.'+L$8:;MP-0*F< ".YJ)1AD"KE
M91+NAN_<2\OX83L(+(C_ %FQUL IO$;XH?4NI+(@&F$]X^4U5P4!5PH!S@<^
M(4 ( ,CY\:XUFW&(CE%>D7,IFG&(CA4>L7,KAB /-_CKHATZ:XUA\W -0@%
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M-916UAB 4P,/Z5T)$,F^).Y[L/3P53H"GHDQAH7I+E5LT,VM 8<#D^5#4&I
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MK+#BH-(S7&0UN';V0TJ_81VF/'Q8_P!D+C=[P>,:\@B>]-4>SA$ JP/!P?\
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M4MG@C;=9B@*QC&J@,W(Y?#DPC!\,.^- X\=R+0ZP-N\/">28G R- ZU!G?\
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M J-Y/<![0Y'-A^9(_3N>3[_<GLQ:\=B7T[EQ_B+^"(D1*?T4W0D<J"6! $T
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M6(F;];Y64XS@4@$B8J.J* N^D'D*Z0A0!&!/L<M^X=L4PGP6GG+6?%.R<:D
M9I$=-$=KECU0H[2>-Z !$2B.D1Y'J8D!T&S;D>K#L\Y='N^;Y"WU?7P *F
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M_0Y_T.7GEI7/O!_.2 A,XH![NX"8%3IR2QCA"T4\:C@Y(BH-1A4$ :%^-9)
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MD6.%H/1"/3$RJ#'O$&UU%>F#IPBK24W I0J4[Y5=Y!M2UE1:"U*2B-DP%!%
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M!'B=@QOUN",%8D.;P/=O-^@6CB _ED):+2X-*1P-$=^=*U+#V*4"'PN&^\N
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M9![_ )ODK<8Y(Y[V'"A6A$,1_E+.F%,_"+#Z0(RU-0U0Y$,E3C>O%YS+HDE
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M41$!>R(65Y]NK4XJC'O #6FLMW(__8@R=U.<:"I'@2%.;VRI1.50LI J&;
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MBJ-P;AG$M#Q&XE9=FX%H+* $0( 6B",#K(!A7\.[K<,QXHTV:*I,,8, (\>
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EA-N-_K#Z3V_K.D0V4&0H.*;13R/:5*K?U<88B3H'>#TY_2G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2113965d1-org_genet4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-org_genet4c.jpg
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M]8&V/5(.XM<\ZYM>LFVZ1A7/ZUE'#YW:K3M\N:TO0  !KGM&G;&:ON(
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MW??F_5\[Z[M0                     ',#KO#IZVNX&YM+/O<=,4;F7H7
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M[G(>,S&ONRZCF[7]GP]G==R%B\OC++X3+.%S]+[I^4Q?./R@
M
M
M
M
M
M
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MI]0 "D/0M1%>F3+=1>20 (XI" 1))GBV2\0
M                                                        "B16
MI    %$BM2    *(K0    42*U(    HD5J0   !1(K4@   >1YE2
M                 "%1-)    $*B:2    (68FHD    0J)I(    A4320
M  !"HFD@   4R*<D4@                       "%1-)    $*B:2    (
M68FHD    0J)I(    A4320   !"HFD@   4R*<D4@
M     #^>+Z=^/[PM+T    ?$>ON?(    ^(]?<^0   !\1Z^Y\@   #XCU]S
MY    'Q'K[GR   *"I2SEK.W]>>'_1$BD       6_X                #
MAM])_)_:3B/T$    **C<UM:V    %%1N:VM;    "BHW-;6M@   !14;FMK
M6P    HJ-S6UK8   8XR>)YZ;_S;L-POZ,D4@      "QJ8
M   <*_I+Y2W=X+]*@   "3TC6);!X(    >'BI[^Z8R?L^3SGO6;   HJ-S6
MUK8    45&YK:UL    **C<UM:V   &.,GB>>F_\V[#<+^C)%(       L:F
M                ' ;Z0^5I;YY^I@   !>?&.53^@:8     !L]T_9MY^Y[
MN  !14;FMK6P    HJ-S6UK8    45&YK:UL   ,<9/$\]-_YMV&X7]&2*0
M     !8U,            !A3TK2')8JBS9C8CQ/ ;Z0^5I;YY^I@+G(T\"5+
M< +SXQRJ?T#3 !(5JOZ5U6K04J7S$4-*F -GNG[-O/W/=P  **C<UM:V
M%%1N:VM;    "BHW-;6M@  !CC)XGGIO_-NPW"_HR12       +&I@
M      ,2>F'O49$\S=L,)^XR#Y9?\SP=^D/E:6^>?J82QM5YFS)9"A$&I_J*
M<%Y\8Y5/Z!I@ OK*Y+.FT;%>&1O\1:]@X^E2P=J^N@#9[I^S;S]SW<  "BHW
M-;6M@   !14;FMK6P    HJ-S6UK8   8XR>)YZ;_P V[#<+^C)%(
ML:F             U]]Q>GF;<EY(NR)LGU&P'B> WTA\K2WSS]3";-JO,XWF
M)9-PPU-]1\@O/C'*I_0-, &=MJV2@HTKFO;R*H482VML1:]@P!L]T_9MY^Y[
MN  !14;FMK6P    HJ-S6UK8    45&YK:UL   ,<9/$\]-_YMV&X7]&2*0
M     !8U, ,:YC!W%:7MT65^ (.YM/7S[EZ%Q"W%K-6]T!"W%K-6]T
M . WTA\K2WSS]3    "\^,<JG] TP     #9[I^S;S]SW<  "BHW-;6M@
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MO9N0QFP.J[EM'I6_@      #A[])_*/4#A?T6    /S%4*ZE8@ ?=&EZVMN
M*6G7JJE 3-[6N3)7(  %'2KUE6@    *.E7K*M     4=*O65:   F[VM4U?
M6.,GB>.?9N#[5:9OON      ""N;4=2^%?1(  'AZ\^_GUX^O/MY] #Q]>?V
M'I'K]        . WTA\K2WSS]3       "?T'3+SXORH
M     =)/I+HV8=PR^.,GB>>F_P#-NPW"_HR12      ,#[%JO)GM/ .TOSA]
M4@            8/],>>HE(7U$X]F(*6X5.>!'TA\K2WSS]3       "?T'3
M+SXORH                     =)/I+HV8=PR^.,GB>>F_\V[#<+^C)%(
M    P/L6J\F>T\ [2_.'U2            !JA4BMA]GN1LH@VTISP3^D/E:6
M^>?J8 #U-H/,P$K51E>)U=]1'  $_H.F7GQ?E0        $_=W6;=FV"W[2V
MC*%&\<C?ZZZ?JH         Z2?271LP[AE\<9/$\]-_YMV&X7]&2*0     !
M@?8M5Y,]IX!VE^</JD            "UY2L*$^)5L*65PPX#?2'RM+?//U,
M!]&UGF;0E?L* P'ZBS@ "?T'3+SXORH        #*6=S.9=CSV/\3C,K9[-8
MXPV*UYU#5@        !TD^DNC9AW#+XXR>)YZ;_S;L-POZ,D4@     # ^Q:
MKR9[3P#M+\X?5(                X#?2'RM+?//U, ![F386M*G)LL$  $
M_H.F7GQ?E0         O?)Y&,HT8^C2N"\NK+QF/         '23Z2Z-F'<,
MOCC)XGGIO_-NPW"_HR12      ,#[%JO)GM/ .TOSA]4@
M#@-](?*TM\\_4P       G]!TR\^+\J                     '23Z2Z-F
M'<,OCC)XGGIO_-NPW"_HR12      ,#[%JO)GM/ .X/SE]4@
M   #@?\ 2'REN[P7Z5    'AXJ>_NF !7X#"S6EZJ /#Q4]_=,    >'BI[^
MZ8    \/%3W]TP   !X>*GO[I@ #9+I.QWAF+O'&3Q//3?\ FW8;A?T9(I
M    &!]BU7DSVG@'=7YS^J0               !P?^D?D_M)Q'Z"    %%1N
M:VM;    "BHW-;6M@   !14;FMK6P    HJ-S6UK8    45&YK:UL   ,<9/
M$\]-_P";=AN%_1DBD      8'V+5>3/:> =I?G#ZI                '##
MZ9^2JY     _//O]]>    !^>??[Z\    #\\^_WUX    'YY]_OKP    /S
MS[_?7@   4WKSLCJ.\=8>+=_D4@     # ^Q:KR9[3P#M+\X?5(
M       TNJQS^J^0  ,B_.7#*K%X_I'V;K&?]UVV:2    (68FHD    0J)I
M(    A4320   !"HFD@   4R*<D4@     # ^Q:KR9[3P#M+\X?5(
M         TGJQSTJ^0  ,D?-W"*K%8[I9VGK>PF[[?-)    $+,342    (5
M$TD    0J)I(    A4320   *9%.2*0     !@?8M5Y,]IX!VE^</JD
M       #!7IB/U%Q&2?,XA]1ZFV=.=,ZL<]*OG+D,:RRC"K+%E99LYPOD7YA
M\5T0Z]U/*^T;#-)    $+,342    (5%J93$:][-J(   $:B22    (U$DD
M  #Q1XE8D    3MM=[2Z=O?N# ^Q:KR9[3P#M+\X?5(            &EM2+
M[A#2I"Z(6E+;6G.F56.>E7SF2%PISEY:_P#J!C.71KG.E:]:-IVXW1=\SYNF
MV320   !"S$U$@   "%1IYO_ #/A;USB%%;W0                   &:O,
M]\_F[ZPR\G],#[%JO)GM/ .TOSA]4@               #2>K'/2KYG2.)TO
M2%ARMXS5\]<3N*SM>C?8NJY;VG8YI(    A9B:B0   !"HT[W_F?![J7'(RT
MO@                   ,V7%IWC^<?JS8)/Z8'V+5>3/:> =I?G#ZI  %I7
M^.UYVO2[CM+W)6'SN0L3FJ2I2^21I5J"K1KZ5;5W== VBTK?P       -)ZL
M<]*OD  #)'S=PBJQ6.Z6=IZWL)N^WS20   !"S$U$@   "%1IWO_ #/@]U+C
MD9:7P                   &;+BT[Q_./U9L$G],#[%JO)GM/ .TOSA]4@
M#&V7P>N6WZ1<]E?X/V75,J8/8<69O7JCQ[D*5:V[RQZ2\?[EJAO//-M-%Z*
M      !K34C4JK   %Y\6Y346%GNQTOH65]HV&:2    (68FHD    0J-.]_
MYGP>ZEQR,M+X                   #-EQ:=X_G'ZLV"3^F!]BU7DSVG@':
M7YP^J0 !;%Y84WOQ4^/>/,MA;9O;".JT:RG4^WJAJ4=G]+W[%.<U[*^#V$
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M? SOB<W;M:WQ5D,8        !FRXM.\?SC]6;!)_0"QJ8
M :&U8T.J^0+F+G+VB:,L28L, R1\W<(JL5CA?&4R.0,ME(RA1CJ5'%>!PP[6
M_2WT%]W=Q-1(    A4:=[_S/@]U+CD9:7P[?\K[1T3TW>M#MLTS3G9-6ZO<^
MZ;EFPO\ E5OW-KBI5NF>C=#Y$=%Y;RDZ#R\9;QV4Z/:5T#QF+ N[&8IU=C<+
ML&L^<UV2\5,WXK,X3RF'L.\L><NZ:        ,V7%IWC^<?JS8)/Z 6-3
M             #0VK&AU7R    !DCYNX158K'   #M;]+?07W=W$U$@   "%
M1IWO_,^#W4N.1EI?7;;7G3G1>CCF?O'.K[M,COMJ6ZT'NGR[WSFFW.N[9LO@
MMBU'V/5=4]@U871;W-ST+FZ*%SN1K6V:K9_6LOXW*X-RN%FZ5:JCW1>O%#[\
M:Y9K7P      !FRXM.\?SC]6;!)_0"RZ8                :158TFJ^0
M !\F1/GOB=3C+    =A?HCNRZKS42    (5&G>_\SX/=2XY&6E\
M          !FRXM.\?SC]6;!)_0                 "%1-)    $*B:2
M  (68FHD    0J-.]_YGP>ZEQR,M+X                   #-EQ:=X_G'Z
MLV"3^@%J>                 J)7'Z    "%1-)    $+,342    (5&G>_
M\SX=]DX/24+@                   #*-O<]VOFOZSV!3^@%C4P
M        QU[BT<7C-K,KE    (5$TD    0LQ-1(    A445Q;:HW^,M(
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MTV3T_><2YW7<M8+8@   ,,>F.O47CYFY#&,Q=,,S^9T\JQJ+HVE=R]XW8
M"%1-)    $+,342    (5$TD    0J)I(    A4320   *9%.2*0      !8
MU, !HGTWDF7<#LF-,Q@?#UYP=LNIYXUC;_'UXQ;F]?W"Y_TR[K#)8KSFO;$Z
MENN%=CU;.^L;<   !@_U%X1,!+R+BA;$LT^6D]6-1=&TKN7O&[    0J)I(
M   A9B:B0   !"HFD@   "%1-)    $*B:2   !3(IR12       +&I@ ,99
MG!9-PV=QEF<%:M[CK"RF(O"PR4A1K6?D,;G#6]KQ/G-=DJ5?).'SER6=_6TZ
M@       TGJQJ+HVE=R]XW8   "%1-)    $+,342    (5$TD    0J)I(
M   A4320   *9%.2*0      !8U,   /*8@;JSF[:[^XGUB0 *7W3JO%0
M    :3U8U%T;2NY>\;L   !"HFD@   "%F)J)    $*B:2    (5$TD    0
MJ)I(   %,BG)%(       L:F   &-LO@]?MKTVVKRPS=K>UW399#%.<UZU;W
M'9=P.RT_KQ;]W9;1Z5OX       P/4C"]C8; Y"_  K\!AJC'V0%XYC*90RN
M3    $+,342    (5$TD    0J)I(    A4320   *9%.2*0      !8U,
M ,;9?!X$VG3\IX38,&[+J=1X]RE&XP[L&LYIUW:<.Y_6<_ZMN.T>E;^
M  -#:L:'5?(  O;B?)IS1=0 WOZKTK=OI?00   !"S$U$@   "%1-)    $*
MB:2    (5$TD   "F13DBD       6-3   #P]>?F8'CZ\?4>H.YLYNVNX&Z
MLZ^E6KJ=6OI5@   ,&>F*?43QD;S.(_46Y+>*E.A]6-#JOD  7MQ/DTYHNH
M;W]5Z5NWTOH(    A9B:B0   !"HFD@   "%1-)    $*B:2   !3(IR12
M     +&I@            -*ZD7M".E1$K"(EMC3G1JK&AU7SM5YFVY7A#[-1
MO47MQ/DV^.0R6,,)AZ*G3SMM6R[M]+Z"    (68FHD    0J)I(    A4320
M   !"HFD@   4R*<D4@      "QJ8             #S/0'D>IH;5C0ZKYSG
M"X$WU#P-.?47MQ/DVX3W)5ZUE8S'YLV?8MV^E]!    $+,342    (5$TD
M  0J)I(    A4320   *9%.2*0      !8U,                -#:L:'5?
M(  O;B?)IS1=0 WOZKTK=OI?00   !"S$U$@   "%1-)    $*B:2    (5$
MTD   "F13DBD       6-3                #0VK&AU7R  +VXGR:<T74
M-[^J]*W;Z7T$    0LQ-1(    A4320   !"HFD@   "%1-)    ID4Y(I
M     $;Y                #$7N+%D  )'7<'4XVP OG-Y?*V7RH    A9B
M:B0   !"HFD@   "%1-)    $*B:2   !3(IR12       (OR
M     %+,3TR    (5$TD    0LQ-1(    A4320   !"HFD@   "%1-)
MID4Y(I       %C4P                E/2Y?0    0J)I(    A9B:B0
M !"HFD@   "%1-)    $*B:2   !3(IR12       +&I@
M!%>F3O0    0J)I(    A9B:B0   !"HFD@   "%1-)    $*B:2   !3(IR
M12       +&I@               ! >V6)    "%1-)    $+,342    (5$
MTD    0J)I(    A4320   *9%.2*0      !8U,            !@_TA)CY
M+HB8:8MPV>\3!^V6)    "%1-)    $+,342    (5$TD    0J)I(    A4
M320   *9%.2*0      !8U,            !A#TLN8N1,_"Q9B6,X>)I/;+$
M@   !"HFD@   "%F)J)    $*B:2    (5$TD    0J)I(   %,BG)%(
M   L:F             PQZ79"'E3$["$EEKR@/;+$@   !"HFD@   "%F)J)
M    $*B:2    (5$TD    0J)I(   %,BG)%(       L:F  Q;FL!E+"Y\
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M2    (5$TD    0J)I(   %,BG)%(       L:F  %!5I6U>6%#4I9"Q69
M      %&592'Z5!3%8:&U8T.J^158O'= N7:#T0Z_P!2  '/ZKXM"0
M   N^&\]+U-)    $*B:2    (5$TD   "F13DBD       6-3
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MC2Z[MXJ8Q;4\Y1I^X'UYR!3]^15F'*M/*E/W8OOSD:G[W"M:X    %C4P
M             T-JQH=5\BJQ>.Z!<NT'HAU_J0  Y_5?$+*M/0ARI/@JSW(D
M^"Y(1\KDA8LIP\CQ/<ARD+OAO72]0APEK>1TF\>MY?$C"]6G32URKTLP4O>*
M*GC.U*I;LQAFM3\C(E/W\2UUKTNJN-O .4'#.-X4U+6,R;'GNLW?>VC72O2^
MS E>G<7F<K4O=G>_-W^/6.JGBW?437F87U&::-38NA5     L:F
M       &AM6-#JOD56+QW0+EV@]$.O\ 4@ !S^J^+0D         +OAT!I>P
M     ,65/%L^O(%/+VAGNC5 I*?CSCSZ3-74J            613
M        #16K&BM7R*K%X[?GF.A]".N=0  &BU7Q:D@        !=<-Z:7L
M                       ?_]H " $!  $% NY[ROR"L=K_ /($Q!;-S1-V
MQ76C;S@9B?;W_P"???4MO49&XKPM/49&ZKDZ)^6+!0EH:UL;KN#4+4QI8*M@
MWJE?</TVGJ,C=5R6M?\ \FN*9UDJUN.+U&-(WAT\QD>8HOC52"LI>+UYCU)
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MFU0G=0CZM6?.N[%/*Z5*1FL,>E%Z<ZO?XRM;ZP-(?\F_N%^EW=_@)K;KVY-
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M 0> @\!!X""/3)A/ 0> @\!!X"#P$'@(/ 0> @\! L0GE,TR83P$'@(/ 0>
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M9,]G'\+LH_A-BMZ33A.T*)IK)I(I-TE44G"56K6K9NW;M$58.$<.W#9N\0/
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M0-T0-T0-T0/##C=$#=$#=$#=$#=$#=$#=$#=$#=$#=$"A8>@W1 W1 W1 W1
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M.\N3 D;$*%-N[6_U<**Z(U<:8UDIUYO!SH T?/ I<V[BRU\:-B"EWF=+B:*
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MN[OIIH.,0*_K)Q;-F0LM&2DP-96AC%A$0?%UXVMXIWPN\TRW V>%O"%(^O\
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M'G,E^5MX./:5J>Q[I\LPCL'!Y6-2OB,G-X#Q&C;4G0 N<T-,/JJ8V\^2YT8
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M]3[ZZ?U/OKI_4^^NG]3[ZZ?U/OKI_4^^FW6U:LQIJK).OCU)76-WTWK1[+O
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M<06DERWF7C ,-1][OKC8:8!K<XGB1OUQM@-=!S7:]1!U),S_ )YA<?JB@9?
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M[AEG1Z\8TPQ>.[8:VWCAJ>6T'9U/)$%$ 17X@!V5 5*VYHM*U 6E9> 0K+1
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M-O\ LYWM[Q;46_[YWNW3<MQNVNPVO!VF#98--]UL_393'B!5*7F T%CT5-H
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M9S&#<1$D%+A5S!HBW:[K+-+EF'MU=C5 FG1HRN5;U_(HTH4.Z]=6SNLZA28
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MX&YR8T@0T=)CBD#&Q[=&AVOT<I0:!*)5(^6Z@6KSIVQ?#'4YTDP-L((BW%:
M44&R1SM*XEL?-L"O.GN9ODNCT#O9)#*'/E"*@0SCO;NC(\(A>,U5Q84NZ"JY
MRJJJMZJNE55=:JO/5?-=V5?6L\[+J%2J<>)6!O0=);+ILZHQHNAKG5%P8P'B
M,=JK<)'.X#FXE1=%HM?AYH3,-4'5(\LHGTZHPWO02J92O/*:C%9B$UF!.<[H
M)9N8TKYMW9-[Z)1>]\GOIO+3;RV#O'YFH]K_ -KCNP^CIM6Z;6I?>E:A6WYA
M@S-@23'#-,AAR8\A@44J",(B7.1-;;UU6IV7J1,=4!1I,JHSY^P?&#(G2&#
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M^2_G&WA_Y+^<;>'_ )+^<;/3O]Q'8?!>O0B_^H^C;P_\E_.-O#_R7\XV\/\
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M[W@03\;>"1KV#=@=ST2R*^_"^HS'"OU*/V)BX?0VK'?RVF=CB?8-S.=W0WM
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M!QY3Q/: Y*AMF!*K51A'"W9FT1CM-UZ7VDSYA7'ES#EDR3/6]Y3&>I"/<O\
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MM<V%%1S52Y45 ,145%THJ+:=W0WM N9RN[#_ (M@_'L']'FV+]5/6I]*J/\
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M%LW[GJ?2>+)J8)QV3'% -((XY'(YB,>JO21)C(C;N@JV!#!!KC"2#@CL4T:
MUB/D$03%<K*F1V%'+IT<RF=CB?8-S.=W0WM N9RN[#_BVW6I08=0!C0J G1@
M2PH5J*C2(([",QM1RW+KTV5042E"3H"IT(:=)HDMX+@>\XG66\%P/><3K+>"
MX'O.)UEO!<#WG$ZRW@N![SB=9;P7 ]YQ.LMX+@>\XG66\%P/><3K+,4E-A.=
MM).ET6*Y;DDF1NE6\YJ6\%P/><3K+>"X'O.)UEO!<#WG$ZRW@N![SB=9;P7
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MJ)K6ZT>CTK9&K5"K,R2E-<<(3RZ;4@ Q2(VW>-I7QY %1S4U-^JB6\GU*GG
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MB2PCD1I(G@D ,Q'B,$K5809&.O1S'M6Y;%%E^>X,BB^4@^5J-*-A.TU);6<
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MU&/0-BD>U786)JM^Y66_%47K+?N5EOQ5%ZRW[E9;\51>LL\3\EY?1KVX544
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MC4U+7E=<[SM>S*HE'%-10BBDR/E*V-32L0MD!V <AD),063 !&*Y<]K?:=8
MW@IY;=CZH!RDNL#V*J;AQKIN\J-VG*6PXAP;&SO1Y$X*[NC-$;(1(:J+SQ&1
M#* 2M: V.TX,'%TG;&4U<MY]J='F%N+ 'H"0$%<). ;9;GHEV4&3@V&4@@RZ
M9R[FN:!D:+QP# [66_3$V)GQ:H[1.C.$".:BY:$5+KM#-I6;]FEH@%+ *M;
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MAJ9?<N9>?,_8TJ;^*^!\1A@AC7_YV&]:XX32/!,YBS06E4-2P(90PX *CA1
MDBA Y[@X%J^"W656"W(ZNJW.J"G=#9'Y5!S?\5@H]F.&[8DFI&C32L$O[X,Z
M42$[DM/C1ZP.>6M=!\!J<+F[P#SAAK&XN6_W;E$7I'5 A@7\1?Q7I<K==C%7
MEO"K4EJ"Z7LOQ<EH6OI9O#5D%3XA  TEJW*TB52:,%0Q2W#6M,%5QYI'W#U1
M"&:NA"5#J)P7;;\>T-3RD:W H:"2;AU9&&.R$*32H2\<7.["TMRB#='GW,=4
MM? &!NA>TB$+F6**!\($E,(F<@>67X-;4J"OT[PEY W-36$=IMF2QT,B_B+^
M*]+E;KL8DOU31F%@DH=:/RJ#F_XK!1[,?^2\CIT_#=1NZ]3R.Z*Y*6;6ZL;A
M4H6<,(NF>)\C4LB5N1"JX\TC[AZHA&6*[YI/)"6Y;,M_NW*(O2.J!#]0--51
M%!WZQ+$*'4C"W<P<:X25$EC0E>#2:[A&_J\D0K""RES,WLOSK?@$TX$+YUU$
M\HNP0UN[#DRLAX[P1%A&"%>2[A1>:+Z(<SXUSK+WP(G&*,LVMP4&\)&HS;.\
M1I1B2/\ SU&QXAH\#@G>/:SJ\*F+E)P&18)Z0:KXW#%\I )@G9"-@#/^98JN
M6T#1&%L3T54!>0-HAPEF(X$K3J=,M'(&Q,P2ELVL?&P1"%0 LV0 2@$TK&+J
M5VHKU APEF(8$K1J-D86Q/158%Y@T@..1M.HH090Z3X\M;72^PZ5#&R+T5>R
M4<%4C#1Q#P."=X]K.KPJ<Y];R'@?0I5DE\ZZB>478(:W=C#J0--XV*E;1\45
M:L YT*BB]BI4L76R;Y72L2*8T.$LQ' E:=3I@+OV\&\5S1I#DY:48DC_ ,]1
ML>(:^H9AGI6!IK1FU^Y'",NO9(84H!/"&P"09];;$3#3@ 5KN1:V;@\JB0PE
M@L8J+F.\=/=L;$9HLR_&E]T)0M6*(E)-A]2>\<$P#,^X"MM1XX.(1LR3+6-,
MX$U@<1"'B= %="H+6_C-R6=L9F#MM=X0I0:\?$78JJB6C(C1!:[5 FI<OZXL
MI,)8O,(&"U.X(84  ^,_\,[Z#[HN")OEN(4:@>#%2I?UQ9:82U>00+1D1H$M
M]NJ74!2JU$?B(  #XK%@L-3\B@(D'Q]FJ3'P "B#O,@(4 1P,<R-F29:QIG
MFL#B(0\3H KH5!:W$3#3@ 5KN1:V;^+KG,G\J A23(3C!J?E)@T TI"KP>?
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M;)DR9,F3)DR9&:W"F^2_'9,F3)DRYP;UZL+53A$[7+CC%(59D6AM(446K-J
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M9^A\1'<YP1")$K@/+Z5__P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
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M8Q7,#PI\T6QSKI+FVX( 4NJVFMD3@@HMM6;2M[6# $W_ *?P;=5RP%B!97K
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MM_Y268CI=Y).?A_/^S*@%%,*<W930S8 "%.;LIH9L@C-J$ 4]Y@0X(JJ@@G
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M1811D85'5:$+L@^] 107(321@J2>Q26@F 4EK-LWH^H.9#12$K@XHYUA6R^
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M7I%MQ!N.;9N\L5ZU0REDX#(0;M3>C[*?+GLR@&-W;QWTGZOT^1K>]4_CNP
M  'I^ 0.,M?OXJJJJJLJEJP2^69[Q_N>\?[GO'^Y[Q_N9Q3?/E\Y[Q_N>\?[
MC6Y%*"SEN>-?6>-?6>-?6>-?6>-?6>-?6>-?6>=+PW/&OK/&OK/&OK/&OK/&
MOK/&OK/&OK/&OK/&OK/&OK Y;7\KUGC7UGC7UGC7UGC7UGC7UGC7UGC7UGC7
MUGC7UGC7U@3?A>L\:^L\:^L\:^L\:^L\:^L\:^L *>E"/#9C?9X/RS3RZO@)
M@K^B=./TX_3C]./TX_3C]./TX_3C]./TX_3C]./TX_3CM="A3;YH/RST>3^Y
M6.XV]/+LLL6GP\1>B(V(_)_I?X_X#D9X/R_(V? ='YU6!B405A+ ZRK3K/MV
M/TO\?\!R,\'Y?D;/@.C\Z@HYH7 (V]@+R@XG9^E_CX\[BPF=_-\L.!?)?'[;
MF/$L)-%[Q6>3?E*V.ZHJBX'0#J-40"YYZ*HX0*:M,16J*H,5\N9X/R_(V? =
M'YU6]ELM[+>S]+_'Q[\HU..)<&OFN6-?%^#ZH9+*IIQF*H#8WC+<:\.S*C15
M@L159W+<;@NQ-GWK2[,S(V82@.*_3GL^7,\'Y?D;/@.C]$7Z7^/CH[:/G.5K
M&M9-<NITU$#YNG?F:8K>N*VSI997[Y_?Y<SP?E^1L^ Z/T1?I?X_X#D9X/R_
M(V? ='Z(@     N.8?Q/!7_L\%?^SP5_[/!7_L\%?^SP5_[/!7_L\%?^SP5_
M[/!7_L+.^JX<YX*_]G@K_P!G@K_V>"O_ &>"O_9P,V_*"J_H^'N[K2<+W;W=
MW=W=V=RM?.O=W=W=W<O=W=W=W<O=W=WVB9EP6Z5AOL\'Y?D;/@.C]$7@NCN_
MT3U[OPW0[O\ M[O^S_7N]?<^#\OR-GP'1^B) ,JY#V(OY&=&'1AT8=&'1AT8
M=&'1AT8=& *I9CHPZ,.C#HPZ,.C#HPZ,.C#HP!5#*.C#HPZ,.C#HPZ,.C#HP
MZ,.C#1&3<=&'1AT8=&'1AT8=&'1AT8=& ="D=&'1AT8=&'1AT8=&'1AT8=&
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M/;<]MSVW-[1/W.]W^',_M^GPNC2E^T8[7 ='#_WL]IOE7E?E:^A7.:9Q@YO
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M /0+Z0^^V? %.1K]UG&:?V! HVVQH9JSAN5<%U<$4\M\NKFRR,\QO ^/RCQ
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M ]O K$&IDM73+!>M,H6B".
M
M
M
M
M
M                                   &2   'F+   8&X  "DG   V@(
M  ;F&  $,B                        >P   $5@  $0-   W (  " '
M%@-2  = 0                        8   'S0   $V   #G0   \7@  @
M^#   S4P
M                              (    !     0    %     (    %
M  $@                        '     X    !     H    '     H
M K                         X    '     (    %     X    %    %
M8                        '__ /\ _P#/_P#_ /\ Y_\ _P#_ //_ /\
M_P#Y_P#_ /\ _/\ _P#_ +;        ;;;;;;;;;;;;;;;;;]MMMMNMMMMMM
MMMMMNMMMMMUMMMMNMMMML8       !))))))))))))))))+22222:2222725
MMMMUMMMMNMMMMMUMMMMC        )))))))))))))))))"22225__P#_ /\
M_P#[;;;K;;;;=;;;;;K;;;;&        2222222222222=% 2$D5DDK_ /\
MZ#__ /;;;=;;;;;K;;;;=;;;;8P       "2222222222223!E>PEL!DE?\
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M-=))))))))(222222227_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P";8P      -22222222222222JTU0DDDDDDDDO_P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P VQ@      :DDDDDDDDDDDDDDON]A))9#I)))?
M_P#_ /\ _P#_ /\ ]?-?_P#_ /\ _P#_ /\ _FV,      #4DDDDDDDDDDDD
MDU^\D))+8;%))+__ /\ _P#_ /\ _P#\V[__ /\ _P#_ /\ _P#\VQ@
M :DDDDDDDDDDDDDDDDDA));FU)))?_\ _P#_ /\ _P#_ /HN_P#_ /\ _P#_
M /\ _P#YMC       U)))))))))))))))))"22222222_P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#S;&      !K;;;;;;;;;;;;;;;;:TDDDD
MLDDFDETDDDDNDDDDEDDDDDNDDD+8P      -4DDDDDDDDDDDDDDDDC;;;;;K
M;;;;;;;;;;K;;;;=;;;;;K;;;;&      !J22222222222222222&VVVVTVV
MVVVFVVVVTVVVVVFVVVVTVVVVNP      -222222222222222228DDDOIP
M "    !0    .    !0   !6      !J22222222222222222$DDD_>
M0    *    !P    *    *P      -22222222222222M=]PNORE5P    "
M   !9    &     0    2     (!J2222222222222>Z?B$XR;).     0
M  *L22222222222222222222>8-222222222222222220D@\M#P    "
M!4;;;;;;;;;;;;;;;;;;;;:=!J222%33R2222222222$DDD_>     0    *
MC;;;;;;;;;;;;;;;;;;;;3H-222>2,^^\222222228   .UP    "    !4;
M;;;;;;;;;;;;;;;;;;;:=!J223U_5P[B22222223]MMMM@VVVVX0    *C;:
MM9]]:894IDM7)Q&FS;3H-22222222222222#%<<DDDDDG_\ _P#\(    %1M
MM(5X9M,W8K.KQKF?S)MIT&I)))))))))))))BR#N22SZ23]G#_A     J-MS
M,@(UH1D/NH%NX2<%%MR_^)))))))))))))+E89R2*WR2?]>G\(    %1M"E[
MR&M2EMAMMMMMMMMMIT !)))))))))))))))).20(A23_ /D?X0    *C;A=Q
MH-:3?Z@L;;;;;;;;3H "2222222222222222<DDDDDG_ /\ _P#"    !4:V
M]H7,+5@8GXA;;;;;;;:=  VVVVVVVVVVVVVVVVVK;;;;:VVVVP0    *C;;;
M;;;;;;;;;;;;;;;;;3H                  .    !P    "    !4;;;;;
M;;;;;;;;;;;;;;;:= !;;;;;;;;;;;;;;;;;@    .     0    *AMMMMMM
MMMMMMMMMMMMMMMLH "2222222222222222:    !P    "    !:DDDDFDDD
MDDTDDDDFDDDDE2  22222222222222222*    .     0    *     P
M.    (@    (  "2222222222222L0F10   !P    "    !0    .    !0
M   !6        227."<Z:<2222<,.V*    .     0    *    !P    *
M  *P       "23!THRL322223U!L10   !P    "    !0    .    !0
M!6        2289\>BP822222222*    .     0    *    !P    *    *
MP       "222<MB22R222222210   !P    "    !0    .    !0   !6
M       2223X28QD222222220  ,DF     0    *    !P    *    *P
M     "222>2_8,B2222222<DDD/_ (     @    4    #@    4    5@
M     $DDDRTQ_LDDDDE*K2Y))(?_      !     H    '     H    K
M     ))))))))))))).9KSR4206&     (    %     X    %    %8
M   !)))))))))))))))-.1%*#FP    !     H    '     H    K
M  )))))))))))))))))R220_^     (    %     X    %    %8
M!)))))))))))))))).222'_P    !     H    '     H    K        2
M2222222222222222(   ))     (    %     X    %    %8       &VV
MVVVVVVVVVVVVVVW     X    !     H    '     H    K        ))))
M)))))))))))))     '     (    %     X    %    %8       !)))))
M)))))))))))*     X    !     H    '     H    K        )))))))
M))))))))))@    '     (    %     X    %    %8       !))))))))
M)))))5JO,     X    !     H    '     H    K        ))))))))))
M)))*XG/@    '     (    %     X    %    %8       !)))))))))))
M))6@T,     X    !     H    '     H    K        )).)))))*))))
M))))@    '     (    %     X    %    %8       !))SS(3AE1)))))
M)).     X    !     H    '     H    K        ))("%Q)QQ)))))))
M)EO    VVVVV6VVVV=     X    %    %8       !)),J)))))))))=]K.
M2B   Z2222222227H    '     H    K        )))))))))))))*CFER4
M0  '+0265&VR5R]Q+ SX\/X@ &W MX%;H$     !)))))))))))))]=M>2B
M  _,4PQ%ST# 7O2@%W;R_>0 WX%JUF'MP     )))))))))))))))))R40
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M^JXB5<U22M4E\;;/!8!6$!-^M&P+O*&3AB/SLB%ZPG5A[]1: MBKTE3R1;"
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M+M/8:2(M <#L$MQ0R!&0 +=9G'NBGTJZ+"Z4FQ"<-,@9P"L#$/L#,X0AL
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MB$C? IF"#Q9^H.F(^*@ZV=JR(#GY?3Z@%W2JI,6PCRU>XZU!,P9M>3^]JA<
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ME:K!?=TM;%=L/!?P_;..<FVD0<@ M$:TY=]]G*4A!RYB><1_\ ,H%^&@@D0
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M&C08&-G/)<_4-.&'8[R_8J@HU%*2U$<*,1"(9MCG1Y68&XSY06)3C11""IH
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ML<>X/21$92U.7&*^.L)_@[&#XN47@:/(_GS_ )#6:?4$//R<%]%D83@EP1]
M. VLDD=AR%*M1C$*UBNWRQGLP["<KK&B3"P:=K )MZ@=E#P*-3B0A#D'P1D
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M.16(I66?@9!<[-(55FP:1$KRR46K1E^$RY^YL^ZC1"/(L2G^%M)B)D(R44E
MIMS5X^*58#B+6R KJ52;B/<;8Y/4;5P#('PJB$C?)EK >G*TF:R<M8>0+H-
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MK-YE?SHRZ!_RQ3-K&[ZU[:06*L%1*8B$!.0+"W@7**$61OCAU$Y:JU$:J+5
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MAG.-00;6Z@X("%FU[$B0J9HA1%F&J<C77X/Z#/TW?V_N[&)L*UOP.JK"#;"
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M8A/3@4APP+1B$*M4DA110M%&#I%+_/G5JZWF8PG5I5YH8A2EJ*/-6U^\+V5
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MM-P"UD(7 H!VVII98<"DC5(>2V2;#R)%T&Q E#^1R:6Z;0MHMJW,#/P7@2&
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M[9/MD^V3[9/MD^V3[9/MD^V29"/FZ[;9[9/MD^V3[9/MD^V3[9/MDLN L +
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ML6+%BQ3CN\6+%BQ8L6+%BPCAO^6%BQ8L6+%BQ8<.+%BQ8L6+%BQ8771=["@
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M!Q:F$;L6Y5E,\C40IEGY2)H-XIK*IQ"TM^03*+8"G03+"N6C 'I+:@NU@H*
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MT,(@5LB4C0Y<)"PB4HS7!7PIB^S:[2\6X3"EGQ!/ D .25TLBPZT-!9L&#G
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M +YT5G!.&FE*U2%*Z/8*5*A,3D5H9<#$NX2 6\Y0MSF)=PD MYRA;G,;V@L
M5MMH6VY;VY@- =!P5P7K&]3*;+RESH)#AU0 #D!0'D1766W%S2*L&2I_'-P5
MP7K&]8[$$IU+9:W0!?.BLX.Q+MX2[W8!7U8 #&P 7SR,"ZQ"$*Q@2C&,0$
MH#0<CL2[A(!;SE"W.93+6Z +YTWG++<]0L#0T5JBBL8J'2+0 #C@,;S$5L:P
M7X_U+N%P GX<0"(:  /(,0&\"A,#D5H=+C6\5@"O=M6WQ@&N&KM50"RP=(2
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M5<EM-5Y#>@CSK,6L^X# '.P>1U3HB4E6VW"Q7)J\E([ R16Z/!GK 9@4JJ7
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M9(:&B2MJX(WE< LI$"W@6HBV#"B!>%>( '8B'"U()YP(@N@!!L/9B!0C*A:
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M-\)D9MEM=8V?4'4N#7<+PF,"+B:89?CJ,PMDXPVOQE9N</O',,*0Y_&5MW.
MQRA#$/B=1AR8G&;MBX^+2+1"MNX84G"^L6SZC1W-$J4=W1W-#V42K[BA[*J4
M=S1VT=Q1*OLH_P#DW&N[X_03/=F?KW'[=V;>[.[/7NS7=FNZ=0U]3X_;NS;W
M9W9Z]V:[LUW3J&OJ8=L2BT(6!R+0.[,&#!@P8,&#!BV)&G957]EG=F#!@P8,
M&#!@P<*-G$+K]CNS!@P8,&#!@P8IZM X@Z>[&#!@P8,&#!@Q31(8YA9^#W9@
MP8,&#!@P8,/13L^YW(P8,&#!@P80N6'%E UH+@7D0 K:@+V4KG+#7R-2I4J5
M*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4KY<??\ =]W>-\_EE'@.CNT" U]3
MR/52]U?#QW;N[N[N[\P#Z(IYWMA15O==W=W=W=J)]URM\F^O;W=1([<"JQ;W
M?V[CQOG\LH\!T=V@0&O^4S2%O&^?RRCP'1W:! :^F6W1+Q<MXQ<T0<9ENW7Q
M9J>VGN9 UW,-7D"_J)R<O%3IH&OM$:9+36#;RGG#+OIB\@5_$2[I&7F GX[U
M;QOG\LH\!T=V@0&OIBU@W$J-(H><2E>^P-?#F%N^$NC$W5P;>G<R&CN[6GPC
M(T*D6J;%)CK[I5K!:J Y # "-AR/I*) H&;=N)+54;BQI[0QIDT)A;T"6IC;
M)++0O>K>-\_EE'@.CNT" U],VNY6*<RN<;-W YYG)P^+,UJ\0JJ98:F!ON9
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MK@*.7D%6RJ5DQ RBKRPU8N\L7Z+%</T(P?ERRP'VA-RLR%B&#!:)[?AVET
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34J5*E2I4J5*E2I4J5*AOZG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2113965d1-pc_celltype4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pc_celltype4c.jpg
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M\)&QP9) X4)28G+2(Q0%@K)0\:+"0W,D-&!38[,5<).#H]-$5#7B="4&$P$
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MG8!ZBESK6X412MJC%F0Q7GTZ/Y'['IY              ?-*[P.?>H9,:_N
MB^21,:'"8+)-%]               %$,5EVGZ?)$,EV9$              !
M1%.ZK&PE"1_**4LE<               :42.1E$VHD7B A9Q>)A<DF2S-JX
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M0R=IQEGZ1JV0X;3TJVSV&AKM#G;7-L.IW#Y^TML5FM@^O[/LRUO;+^\+D
M    8_.8H)>I9A7R]S&>(UZ)VG1I8^-P0 Y*_5TS+*GF]EB-^-0 I-S"['O4
MT>1)/8W+     40K8 +:*,4@JQS%.+_,4Y[6=2TV\YP]WZ+/E0#[5V\0)U'Y
MS,KANO6@ D+89/>3I$B[ ,#L@    HBE;5 '2+(.,J!U#D*F7+:^F#.1)3P1
MR7)TO_TDY^LN(-D J^U8_1'V7SSK<V/40!<GG[;:M4W7<QI^]W1Y>P
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M$XS/G=OE-N,DW1>9$   ",&2Q6B/>8XA9F=?&SO6=Q]!.A25VJ5   %$*V
M #\-2\X<UZVI9@T2'U;>-O$%]+2/U/>    ,3W5II&W6/M8>RZ?^$L\5F_3!
M&\M7WX>X  %$4K:H   &/L#M,(X;Z*D'O$6T#A[8LCSIIN:^K(RY[OS   '3
MK36#LVHZ/=UCS'MQ:U[X]/1Y'4KSTP>P@      ?*F%=XBCF^/6RX>O[FNLC
MG38MS     '"IIGW'1-*>YZ!QJ;8M5W;?9HLC   "B%;   !J\F3G[5I,O/0
MV11-.VV&$NB^W\>H     UX;!K/GCD"+K<]/*8F(SWISC26ZO\_8  HBE;5
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M0+U#YR\KB )KX;8?0!H4EYWL<@!K"V74O/=O\8<M*^I6,9BEIBLR !1%*VJ
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M:\^&_P 96#[VLL\5G/49&4O=_P"?H:G]JTS0CO4;9+MKOUZ1+.'?I4 "B%;
M !YV>JN),+Y_5-IL,]$;08<GX?"FBOI'D2+&VZ+=V*SNVJ'9_G+'$M?H (RY
M+%>=F08NCCD<3D6WNO5I%LS95M;P17RF(\K,H0S]*^M&*9KSW8Y$ 412MJ@
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M?LK$;#+*4(/D!O<7BAV62UYP-U1U?+VE3)D*R)W^*0  !9.<U/#6Z19]4^I
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MUKE#->T;'K[TKFC%T@='SFR>U21E^/\ YK2_M?W/*^HR/R_/H.MZ6^IKJO\
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M2LW/I;-->D/GI*JWM= #C^O.V,I@+%SVH67F]4^:_/+\^F=M!F*X,?F0
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M0      *(5L       L?V\(M9/$86O<=9OMYW!Y_65+6\DQC<OFRSO@
M!1%*VJ      !P_/S:GE;=F_\*-FM<_#N>-S5[/)URPRWW3[
M             HA6P                 412MJ@
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M*?BMJ5I>-%TJ@=#WL_FOS4;>^   %%M[3J_'E<EWD          !1"M@
MUN;+I6KS9M0]#,>RORVUY;M70,VTKW#7A*L$POD&*=Y?-W8MG>7M9562J5O
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M(;TD2(<<%D5ISJR%HPN6'5D$S11A4J9CFJ\:,ST925
M                     &,8 W?'4';E(KN&',=W_ADQ7]*2=@I!25+[5%$*
MV#AM?2RXDV6N[EBNKN>+I2EPJUL
M            CIPY,>!.-I8GM^R7)\3,W9VI6GPK:JEUJYMHQY6F/"I*]E2C
M'Z3SQEQBSER0KSEK6[,EO6L&5= L!38G\_54
M                    *;A+SH8>[K^X8GZ^Z     #Y^:]3%W'-=^7/=^8
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MUZD3]QIW\I_WF;3T7MUOIN)*#SFTF,MFMXC]?_V?_P#5>XV,QI0>\'R$O=F
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M(R#-7'Z_71#:W5Q^$2YE!X)#L4Q"1 U62E-J*"#.;E]IMM9RV1?5+#C[9?\
M7O<?%;*2I"J%**!)VC^R22E)4E:>2_[SE;D;UCPJCCC),O3&MHLVR6T)]=X
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M=D6_^$X^_)[Y8L!EN"[SPFX4AIGP*8S.:^M9ER=I]/MPQ96.5]='/)N]PO\
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MAY=2620</"2WV.VIBT9=]KILU$Q-2^0'U"0DKD<IM%M5'[90>BUH:1O+GO\
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M9B( GHS.<+D<(FZQG*)C$I3!=PH7.@>;NWO;"[<CS<W*9'*5LSM07N3.B"#
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MX@*YN40H,A-9*J%(9F EL?*,:M=^<A1:>R/'AW12A3A^07#)+(8@DL/+0AQ
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M366-^62T!5X/T\GSM<I";K7:WA:C%><G2)3I)W\!N7&3BHT:^323E'ER):=
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M+1;C_"@A.6(="#URE:J &,15)+.27P[QZ3,F/5<2.:%I3B/=(F)<?/BY!/K
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M?UG9ZMK9=8]&K](7NFQ*U@3'(RLQ'I.I\&V#6 [UE-O%?@)C[$7M+_%MI/\
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M7\HTJX)AG0%7#V2#^L_HD[F#8SJJMFV%8$QNMG2X,61,KPL6>S6 09+S1O1
MG1TX;R H\4-Q8IM6'6Z;H*\Z5F7'IBA4]?%*ICSS)V<Q6$Q'!8#,UPU)T6LJ
M.*N)8[-/U^C=*P7F),B:P]#T]41G69DMGLTJ6TXS$ FY,F-Y-PTZQAN7=M#H
M_P!VJ#T+72&Y=?4>AZ[T7 E-.N/M28<#L_9(LAM]TC$P%"0B5>==KGCZ>HWO
MWC1@=0\6I@.>GABMJU&&YSL+Z42.TN4./GRCN38]-CI338Z=<=X[E -%5I2F
M]Q1?XIU:1>PD[Q@0\V3',F//LS&C,M1XT=IMB/'8;!IAAAH$;:99:;00:::
M4011,$39'KJ;@^X*E&KHR(_82L/Z)C,* &[SCB@WCNS8[.PH66BIR)/F\9<\
MUY )" I,]10T)"''!I&T3IS<^RJJJJJN*JN]55>=57I5>X1!155=R(F]57O(
MFVJ!-LP);:ZP$A427&@JD3!%3'GVP=;<;5=Z(X! JIW^LB=R*T%N[V'/G>II
MN,NH?WHIXQ#+YN;F&]QE6G?PMF*RURZ8U$YE 8LQ\5KI[J[L*ZP)&QXKA<S+
MJ >*Y15SG]C7\]$_:V.Y?B2V&9424R[&E19+0/QY,=\%;>8?9<0FWF7FR42$
MD5"1<%V$?W7T[E&D/3(CZ%K<HZ;<WN:?%.S8)2&O/$\POP=JLY.E=.2"HXHP
M:4GZ.L>*GA VC00ZM7(Q+7Q0:%!1MK**#NPVC2ZS3])72H=9Z$AR8%5 B2(E
M,DA9:5,9Z.PVXQ6=K7B\ 51KB=;#'9J&.F-/)$9MTU S%2EK4CM7R*I)=M,=
MFX86Z$2KVE$XWX6QZC9TU0,ZA<XG$OFJ>N;N7.*'#=SV@QTG%Q&^J6)[TW;6
M,VJI:FLF7#PR;>77UT.%)M9(JZ0R+%^,RV[.>$GS5"<4EZZ]]=B<=,6VP3$S
M,D$13OJ2[DV)FK!'%YEE.HO#_P"B:W*?MEA[2[)-SXR$D=JS94$5?S"1&H @
MCUU'?W]F)K7,38/#W\CB)F%?"*\_M=PRN&[%?\U=N*+3JMIIVJQ<0"4$P<FX
MXEAE3#N6K*EL9E7/9\W+@R'(SPHOC!G:(5)L_?"N(DG/LS6^L.(DMA<H)J*L
M9%N4US]>QK&T1F2F*IB<?AJ*)YLUV8MJ2PBV==)3%F7$=1ULL/& L.LVZVNX
M@+ P7<J(O\$)QTQ;; 5(S,D$ %-ZD1+N1$V.)4$3+&\3F>*\[T*C&.]D/PO'
M7P;8KO5>=>06VP)QPEP$ %3,E[PB.*JNR'(R5[2_T_7?P\# +BG\I1V19)2)
MI].<^"U[@,X.)_/7;R-;#'#WRL-FY_I#0C^_M@*(*=Y$P3[B<G!G1(TQG^BE
M,-2&]Z8>(Z)CS+LJ6&BZ#$L5)V%"&ID$J])2JKL4@E]LMC<TY<6VGWU55%F1
MP[FO%,-P VZL6>._I*0?M;.2&JT-1US>*]LH".6Z(X*6+U:0-V(J@IUE!MQL
M?A;$!B0&!*)@2*)"0K@0D*[T)%Y&9D*0_#EQG!>CRHKIL2&'@7$'67FB%QIP
M%YE1<4VBZ<]8K[;+Q96(6J506F'"7JMMW8BB-QR5=W:11&_Z1!ZSFPF!(0$B
M$)"J$)"28H0JFY45/8H/ZS^B3V.31Z4)N9;!BS)MNH[!KG.8@C)U@F3&NG'R
M0%SYEQ%'Y]A*?F3))\1^3(<)UUPN;$C)57<B8(G,B;N5MX*[T5!-,R3KE2A@
M0[E16HV0YSJ&*XB2-\-?A; Y>V\^T=3>3,,6ZZ)X0+'M,IQ$[Z&WCLB1=+5)
MX>_G,>E'._BCED4LT7=T+MDB1H\8%PZL=EMD=V.&YL13=F7[O(33S8.MFF!M
MN")@2=XA)%%4V(;+1VG)"E^5]$0FI*8\^66PTU)#'P$FQE4^EM-2%\3L4TYT
M-#Z5=C6G:GB%>\#S>'M;MG)% ]"U9##,66,OHZUR#O52KY;I,&N',+4ATUPY
MN;9V#90I=?-8)0?B38[L62R2;E%QA\0<!<>^G+&H]7G)O--]1EF81*];TS:=
M4.$9KFGP6TW<(US@/FRP3(L6VIYL>QKIK2/19<5Q'&G07<N_G$P),I"N! 2*
MBHBI["OYZ)^UL>QME-?1OBF@@"(IN+O1"/(/6X;>.)+_ )=F9L=\W8;:)Q6
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M*N1L?\O?792WFVO..'7#PAAXR>#G[W>V1F$*$&XG9"^99!??&2=_#<G.NPD
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M]:>JVI#;XL1;NCM9\F@C,MO/<3R6<@7<BK@!!R:Y?;5%;/5NH,A"683 +24
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MK9H(4)S3MEZPWZOLM5?U]S(*UF:GLKUU#<&(J-#'A#@7C&J%U:=J@I_5?9#
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M7>JJN]57PKR4<4AR&%;%)P?@NO-H\\*^%''%]BJ'*IA'Y4:0^PXBNM,B,:2
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M#<)$\)HZVA+[B;)VO4FIWQR;TC+5155S=UD5ROF8!X,/=V$I$*XML/>V-Q(
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MG:B/6S!JKJAPQ&60M]1%S17>=,-INH'&XJ3(S&HG0; '4C*53+LF(V8%>)W
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M\JVP,;,JXAF(RYMJMR&$.-?UTV'8N:C&LC^D+&4#N>S6:8$T^XW; ZZ)AQ<
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M'<;!%)=R8D6W_=['_;X7_MMK<K:.#"2VX8L9)##^962D*>/",\N'$3GVA/\
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M<2E@/^:7GCZ+2. JG4"XA=)E8H!@!_JD0H3[-OP$@$"PJ,O@7BH/8*;-,KH
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M5I-AA5R2%6(  " L!8 P!X5>U6125E1$BS<((124NLIQ;]D%TUX9K-L)^D"
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MW.XZA& JQ,(60$L]-V=.[A6(W;;V6VR.J@5_B'9\-FWGIH2\W9" Z<VGF.K
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M  2T!Q)1?X3>N'DL5VTCVPJV 5K8C22 AX""IV4%5*UQV(8\:IQ8 0D?XLI
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M4$M])>A(A'X@4'9-HJ[T.]GA&V;$K5V+29/1*ICES,FG_A34HZ[Y]A7Q#5+
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MA/SW5WH[_350-C9= Z>= 5+W68I%:,&8^!&U]QV 4'1SA<HSS-$5013=$M+
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M$D%N+J9,L7S4UG+/$=L0PDC 2,K12 J2DPP2W8RT!!2*& P$WR\I:G(UHMZ
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M?4=^W;\]*D>B%CWY]_""XK,6N_.LX\-G'4_8P_3UIZV>+'_3W_T8"/"[SN]
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MHSZDGXG[J_OX3\-ONL6\!ID,)3Q]YN7HZ_6[%ZMQI?\ /O/!G,,U S- 6L/
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M4OP/(5=6LO0970&CT'=]6#I]UM&L+EO/UW?^Z & :=@'ON?U\\^=;^[?IO\
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MOO2)Y;?_  8N9H):U\.>_/SHE$47*=?W/=TZ_/7S8[]6P]<5OTW=U]8-M&F
MP<O!ZZUEP?1L'^ HBU;H_;_IO9%8!HJ3?;V\\CW.$*+"3'F@K(J!;^%N]D_1
MA I&I)2+(V^N^ULMT+_ W'X-Y?IV;T/Z!,O _#AVT)F,*N/KZ;TORE;\UPZ/
MR4H8T(D)W'RCZ$V*'=O''NW['S0 P#3(!_\ H]*2/*_Q&'46:E2P7_8Z?9]Z
M9LXIE@^8[<?CM4VW5\H%8,UFWAW>G-^E&A!L:.'@??0ZUB*?8_[=W]?XKP?4
MR>GNRB,.=) I>7E_'J>\EJ+9U7X^.,=O+;M[V/7:@(=U^N*MM^A_>/BBLAPN
MTW?<V6PJ)GU;YQ_006F?\(>(<CAX-S[,B-ZF[ 76_?\ ]!N%ITXJB;'L+^S)
MTII],0#Y"N]QLAB23"F&?%\IC8^6*]3/E_GO45X^_=RZEL7'MZ-L]J=O+_D#
MHAA*AXN?;^'I\<:QD];]<>U?%)A\E_IJYJY6/K'O6+/AQ-<Q;YQ5G7$7?X?=
M?=I?Y;>T&LN)6!E_AU_+:IBVV-CUS_DD8?6SP_\ KD7.+9KJ?5P,_P .J58]
M03&PP]<=:=U8$YG>_P 4U3%R+-\B3WO%=R7!_'A7A7HK,>DVS7\03X_M #!H
M>,!I62'/+ST_R/R21&$3<3%&CG "_L9^7J;T7QN5)_T\C<WUW7@_1P?2LZG4
M3\U=$?(_#74>CK6#'NK\M?5D#P0-]?\ 1E]JD9_E/3WZUF[_ )X6;Z';GL_)
M43_1N=SP?>N#^:S_ +$GX2NH]'6K@#W5^6L=GLGY\#= <K4P4\N/8W[OPTA5
M3=_S7.DP/H?UCI4Z5[S%X8A?W_ZJ\PGH_15C8_W'L3#VTEX[\DTN#_!(I3T/
MS0'J?FL7[Y/YH6"!T\&1=(_;M^>E7%Z1C_/VXMA[ECH$J*CO?]VA[@H^%-T(
MH@63+<6S%ZG38/3W^O'CIXW/JQ[I6/7EN_&#[J4KE?\ 5(U'<M5AW)C^'X.]
M6DZ+]V/NA!-QX[*3AE^"]<Q>BQ_?:I,^C8[&/]0(9)DM\\T.6$3$ENW@B#=/
M2NUAB?FDA;D=00?<T9LH?HIX1X1U8JPS^ ^7^5D'2_K/Z_V6_B@V^,5]J _4
M4>LORU_Z;2,.BS!'0?\ ;7VEJ_\  ,SV]2K%8Z@_]T#+]FG)\[6R/R_LKZDA
M^YJR/X3;XQ_OA6*V:!@N L9G;K0$[()G'R4;GVT[7VU@ ^W]6OP*M^(I"17_
M /2D-483[U_YM!@A_FHO44VH1,;&$D5_Y]':$8Q<K46J-;E62F6 ;\ 4R+$)
MD0LYTBHIUW_QJK&2%[T4::(WK.FL:'@R7,JSRBT<@/@'Q!W :-Q$R)N.D9O3
MDW&",P)C6+Z14:%13_Q9V:4,]>*Z+X?Y09\?YJ:G0D2#EG+$8'143N$I.P',
M5-3KF#&&)-A&$:#JB9%+%X:34ZS4_P"/)60DRG8BIE@ ;B)N:3I/AC3JQB+:
MZ%26B W4?!G2V)V(!?K28TYO& C@<.DU.LZS_APG[8#'OKU5^J),!&>ZHM45
M&H;* LAP@Z<  F)_FHM4>>FH2,1O/(U_[M $8%J*CS8WJ/) "!W_ +1H07K_
M 'QQX9A#N)*@S#J_GD]"2(/S0C!+ZM_^"Z$%9<= \Z)7MD#LK&DU.L9"TSBS
M_L:6%FQ/W4U/G@G=_P!JZY7V7YKK4U-.DU-6J==JMX)KK5JDC6="^[^J+6,Z
M6TFK5/A]!U5]U1K:MZSHYK%V?EKZ?\Z;Z13_ ,PGH%F#M' K_P "M\>#\GA6
M0;<9Q2P^2PZ(\,<46G$HWT!<=!@G),KC2/!%14>>* DKSRKQUJ!@L9_Z\F0U
M@Q/[H_/9GTG_ )U$0_\ 85T6O3."MYU<T]08D_!1W1H5BI*FK5-&0,_LU_XC
M5N$UIJ:-)T-9_P#DQ;2V0 1U?C7H;]4+(B'$4/:?-<-+ =BZ"<>9A6>__P#3
M")S\Z%6\$UZAS_\ H9^#?Q_]>VGH,&,>W3CS<F,;X]]/X/\ [_7^3__:  @!
M P,!/R'7D)!N]%J]+^%>E_"O2_A7I?PKTOX5Z7\*]+^%>E_"O2_A7I?PKTOX
M5Z7\*]+^%>E_"O2_A7I?PKTOX5Z7\*]+^%>E_"O2_A7I?PKTOX5Z7\*]+^%>
ME_"O2_A7I?PKTOX5(C8FW\>/7Z]RJ$R7C^*]+^%>E_"O2_A7I?PKTOX5Z7\*
M]+^%>E_"O2_A7I?PKTOX5Z7\*]+^%>E_"O2_A7I?PKTOX5Z7\*]+^%>E_"O2
M_A7I?PKTOX5Z7\*]+^%>E_"O2_A7I?PKTOX5Z7\*O?TS\1BW3HML>U>E_"O2
M_A7I?PKTOX5Z7\*]+^%>E_"O2_A7I?PKTOX5Z7\*]+^%>E_"O2_A7I?PKTOX
M5Z7\*]+^%>E_"O2_A7I?PKTOX5Z7\*]+^%>E_"O2_A7I?PKTOX5Z7\*4!W>B
MWCY<L_?RF 4EVU@"YPEZQ3".@%$"DIS!P$VO@/FB-@0QB6DA,"T,99-S55G4
M,Y8W% [7"!9=Q!8F8+%'>L$><[88PV *F%BL^W-(R*$FAQ2I!7C)DG B\&\K
M0FKDGXKND  +*/+XD4* F1D1D A1 :%A'(\/E?3^/7Z]R\IF 4EVU@"YPEZQ
M3".@%$"DIS!P$VO@/FB-@0QB6DA,"T,99-S55G4,Y8W% [7"!9=Q!8F8+%$U
MB626).S$R63,4M,G2*@043224*ST%,' *&0VJ; R4!!]@O8\K<_"I%A.X(!)
MLP@LKIW7<"1L9.$J\S1+"FVYH4L&,$EO,(177)^=S[X38)*7?)]%Y>(QZIR^
M4&XQ;O();(E(OA7(LE#$)(9;AB[3QF>)H1-QT1+=(21XAB"2U!9#'@+*F D1
M,"N@QM(6T#2G<PM $]&B-YL%TGDQ E$EDDICO6[J8P)-2HQ8ND\R3-E'O,H9
MFQ# N!PI.!N-QLC-M@(9M8A@;S5I1 D('0+^5C[^/ERS]_*P[RVF)AC9B'I2
M]21@10Q)+D0,O =?465@':,+W0DU!;2%(?T43%42 U#'%D.0I#-US&\-2A28
M&!!@*YV*PE%Q2H \C[ZP\N#.1>\7.2]$<K$C7WP#N3"B;9"N8)GT 6,S8IF1
MJQNSL!\ <!Y7T_CU^O<O*;#O+:8F&-F(>E+U)&!%#$DN1 R\!U]196 =HPO=
M"34%M(4A_11,51(#4,<60Y"D,W7,;PU;.SD:(2;3:$KB %(*7*=B3<"<PF"6
MTJ(X8<3(?-BQFJ6A+1<.K/2W 6H&&R>S-WP%B9VF@J@D&L$I6[8)O(BFS0OK
MD"P9R !V:1J\'D%$(D(!YX!Y/HO+Q&/5.7RH<J1W0NL<83T5>-N9:&+KFP'"
MF3)F0(@K%(@&Q#BD<M7$8"$FR4)1?P:"6RB7<WY?"^&':XA/@108A>*0[*%+
M7S9!;S(@<.RB9H3-.F39&028MS,6J%X@Z,L(EWA=FU%V4T4R'[  ]UAA*#D[
MRDN.$W&1(&0OY./OXN2TM&I(5@); KP"TA.__@ERY<N7+ERY<N7+ERY<>.C>
M60I!-B\31,A%-LL6,HD6<SF_FW+ERY<N7+ERY<N03 :PYEPA02(W$;(X\0-J
MQ RLJG-#?_?KERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7"A64%9;,/A!-$@
M$JL0&Z[%2_)>^_[ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7 !WZ@TM.H)4
MD8;B)R(__N?WY@_-9WV@_BF!) \(<?-"?SORT?('1G_@H.)N ^6MXIPOX6ET
MC!)  IWA'WHQ/@4!(/0?Q_L_'BR=]FHZAJV/IA8KHSDF^)J9N8_V34ZH'5^\
M/F>E=R4?^@^FL_CB8/B!6? 1PR9*_(Y_2FNI%K\,BSUI! "Z79U]S_K[U8"]
M2DNBSWE3(M9I)'1%/1B^\"F6X<.V\'=UO>D;E2JRKU=_"YPT#:9/AM]5:XUW
MGN25NPX(D]I)\H]*S_IQ0J*@7Z=Z>TBQRU@R^O\ "U?7@1I]+]FJ!"5^I/Q5
MB@(P9^R%1043D^1P.+'\=N@LQT>'H_Z)M/TW=_ZZ5,2;I'OO[K=#PHP%:>,=
MC2B,.?#?_HJ_M<_,G!6$&YV'MN=3\_Z $&:)8FVPVEE@9)21.Q.\^0[;D+E2
MJRY\ *P9H=*.]2C!'A6'Y5OVVNRR%W:C;UN;/Y.UGB?\X520 2O8H$=ZI@.T
MGH:5)<,F2)7+#=EK#L;[JSV=NYX$0;Q^RGD'<>$* >XQZ.3#O0$"?<;?L5AP
M4-(>XR?Y'J DJX*G%=W<_H=<]J567.A<5,!=^*_*2?!^TJX]T8?%WVUB"\PG
MY;T (+&C8"2IF_R0A^2'[JX^G%FCW4.?OE\>ZD5@&AQD<(PGN5>0V,!_7Z<Q
M$O\ E6C"8"NYEWA)F8*#&E$JX^BQP %C7.&/HXO4EU>C"TQRYO W1_*?%:IJ
MX,S(F9[MB]MJ [! ?C3-9*NH_-8[UR?J7U%8M3^EF3\^G/1D81^&^KY+)V/Z
M=,AB8*'B)A/\F8MEP+6);3@'X)1*[W39EST2%IN-XU=@+!O8"'# H/Y*N,.E
MO^_NLYNZZER=R#^:NP=Q]"WR4_LK?;V,&_>]GOL#Y%O;/37O-%EW.>N>L34A
ML#JG;DZ_,/\ B=("E6H&:X)L$V<>Y?6'F^SV-N[\-1\+=RN[GVQY0_PUOEOV
M9*Y$\"Y:;?RQU%C5YB<?P?3X8$23'^.#N3[,7V.XNLPSJ WA?C-PY[61%"'A
MO"+?[B6B+>4/S9H[.3VHQ=^-]. <6<Z[L])-OH+.R&@%9];\G^*!7?TF5\&7
M80"[3]KNNZU&U%$Y#L?YWCDI4/0G:> WZ"]P&)E@^8]F/L]U(,I%2O=?)0$7
M%8CX=_\ ZBY)]J5-^EZCA.W;.B5E2)Z^>2S:L<5<V?T<FWW_ (%!+8*E1=^7
M+IP>_82LI^?/['N;BBY!NI_)N>]$ FT9_KU8-N?.G(R8-^O7\.B(45@&C-R[
M<SET=N&V'_$C?3)\&PO.W&ZO$T8LC+2</I)@&DT8@ "P L 6 L>;*X#.WHV7
MYF"E;'7'U\)9R6TA;5^QT=3?DLX(.H)2)N?X ]H7V?Z.!N]!2$U;?UY7*Z(X
M!)N\YVZC;:[:@3.J";'%[VZW\V(;[1Y'9_\ ,5NCT$V'PES<*07,ZD^L[1FU
M(J=@9!]9+@V N\Z'-<7=-O=EZ1RZ&1EL!3I\D;3V>HG'AM!]0@Q[Q2X]]T/J
MA%%\N2PRI6B-^*B"Y7]%&V)U<_3'Y:MD)Z+.J\=<>$-X -O0X?.&8UN?;RM^
M3F3'L9O_ (!P(2V8D2[96N5B!>HK95NJ[NCAR S$9Y$Y&W79X+P)C)O&0R6Z
M0,J%9&U;7;(33-UQ;BT?)GZ/U4$@_!#$$RG$WK[HQ1( TW7'PIGX?JE?E ]M
MGW/AEL!>@V_&3<4K*A'U_P!.VEYP:_A9_(?E/GH<$#E<5!&J_H+&.CJNG  ;
MJ_0W?M*=K]8X#8-CPC6>O_"L@'Q_?S5E0,R\_%0)(&))9&Y/PU[(M*^92D('
M47^1^4/"D$N1Q0O,IL$WGW=Q@LA<25!F/)+8E)6"=E4_9N4$[*? H*<MIA<F
MRNI(;(GFXM%ARL'[>DT\,I*]70#'B\'[.W3OX.G\<KP&_J:29^ R[_H??C(B
MB#!GW,5<5BX?7GDRXHZ0+/JX\C<W\%NK]H8_1Z'"LFE\FY[EO^ZWED>OSYQQ
MFT8 E?8J5$:/R:;Q>%EA$Z/(+%=$,W)!<S% :A8V40'O]'+8J1*\(;F0R,;A
MN,%/#J5%'JMWQN7!_G/T?9TJZPF?R#]X=GP6&XQZI-N;G$4B$@5OIO=-]L(>
MBQMYQV?/X_U_^NC W!_AU6P;K5J\;;&T/V[LO@-)6_\ #XZK<4CM3-NX<V\6
MX@@$UVXO;;^>VGTOV:H$GGZ[#&\+6]BIGW%@# )QI)(283-2C<N[DP(C8&'@
M.+9I>PN%R#&"]R$)4+3D +L9/^[ $OS8E^;OS\$'>=(W]:\>ZW:: "#&N<2[
MB_G+^Z52MAL' >NM] 5@S0HRV]O[?(*"7#V/M7\4'@,BV03:-N*&5L1C]!H%
M\;7].Z1K-F5E] \;.I(HS+VW'AZG_9;4"Y-'LU@?5GE8?C,;R;:6T^H <;,'
M5YWV94-8YL]D/?0'9CN#=70%=!HL;/9*W@@EF +KJ<.23]!RK8"ZVK/7Z+ZZ
M/8KD6H =V*Y%N:+@$A>5\&]-J=]5,9ELH%K?[2?IC\*!) ]_RO/2A%-@,/1,
MGMH1A'WT>2HECV!U[/\ UX+?[AU?TN8LQ%M(S9WWWXY8V 2X\W _^SE[!=Z%
M ! QV/5]&)[\]?#V_9X\$/E2? _02T!%C%.#ED)R5*SM/-Q=S?J)5G^I/[]5
M"BHBMF*(M/\ >:!E;J/Q_IH48<5KN G) O2Z\H7*J>ZZ6T8'76!]WL[O+/P"
M20+%,YH3+; LFYT?H$AD2XG4:M96/L'X,<D._ELQ;-7@XK=NWQ_%(K!2)6\[
M;/C[7518.7UUP5CPP/@/[RU$4$8.E]3%QRI U=^'?^N>UZ"/)YO;AV]U\4_%
MQ,/]/=B9"*11C[.3D?\ K.A*<]OZ=3[+<("<62/)K C;ZG[3P7@$T?G!W,)?
MDDH0;CS4=3O4F4/;;RLYT,;D[)"'=@.T.^N+N*D:P%]L# 89Q*XYNJ9-&$64
M5.]K=C<)0<IJ!(VEMPHP#"@!V3>[=3/H["C/AX\K&P]]R[9DK. PX?X]/B='
M#@?";CT?^R&&OWA@ED]GV<EM8Y+3V']_+049,U)WQ%EOL,=/,@A_5CVLT\33
M<NP^1/2:2-0J\K==22\?WG89]A0P2&5$J!.4YO")90A5D,SE!\SYRK-BH W9
M;WHM@WO-&2#N_@X.A;PYF)F2&2SP@CL@EZC8!*SU:;Q;K=F<:KG=P9#*Y^;9
MO-2G" >'<-@>F-'[6W%A<R)EL3;>6]%(2(]N^)!1424& 8>0S:8B%H)MEE,L
M'89(FAHR,EN)Q8QJ]&!/4O$[)F6-H9IR>L+T>DT$GGO)ANO3\[4ORA$MUCUV
M,%O(Q6]B?ZW/V%%TJA/7T[Y-)M=_N_U\"&N;U+LD5#U*4<C#]Z%<F3&VS\GO
MYCNT&IDO)/ ?;0$:K %U> W:CKDD+#G[C[FI&\$N#$L.XV,(IT)6"!=4P <K
M8I$L<=N&.Z,Y7FSR*94+U[FU,>I7HOLG/2'3M/.FUSN&Q5V$^"#\L>UVVPR'
M0TQA +]B1L$'NOOY<*2S/[_A>VB2NW]O3Z:EK  ZMJPB7GT$O\TPI&VP'47!
MM'O+E2O5Y!T GA$[#A; W2,3K%Q)2=@EJ _+ J)L=Y:!=T&#$!3(Y2289!5S
M6/&/[%=[(=WWI]P$3@;[)GE@G28#;4HZEGV%[M<J67L$UGDS\TZ>XH]M_9;D
M:Z['YCOPY/QY4Q=SX=WLV]SC20F#"[=9GM,]P\$=8]"[K15> />1_#S!!A9N
M73["^\:$=;A;F$]$+K7C?P9V?%I]US.CH?<M]L9VD"1(%QY0.>2 NG86Y>#(
MT"TAI.Y1B;;VDN>VN&#=N_([?7WT",\M# K1W6*Q4(.Q8TNIC/1R+[ZE)'XJ
M3M>!B"?>*[;R/E&*W./W<![H/>EQE%[_ *X-CR7>(02 A$W$LE02/*!2V3@L
M.VHRMPOO<1-?4!322A)Q.3)MDF'V$QA;Z!"B#*^,OVB^VO?#*N,/:1Y3HJCN
MD\%V+%[JQ+I'J"!M<,_1>^^L6,I\F_T.C [?R:)6P0>5C)<]]GV;UBSG1=]!
MWB_WKWB'XD?ETX03S@PU9?*/>/\ 6I^\9U^E(G5MUNO5=]#Q)MSBWLA[>61.
M%O9L^G19NP.S'Y+JS<B?/Z:,S4'LL/TOERQI,3XA-9U\NZSK:1MA680C@7$]
M:GJ3J#LD'O0W-T!2QTR8X]QY97IHP%GY$9SF;T>4.JX@'@W"#8+DPG!(@03<
M* \[16.(F_1STJ/-1;<)")8@F6WE0XR6W!/O GKH!66.N=SS^%_=+BP2^%^_
M,]:MT:*3X?SOWJ?6;M('P/W?UYB)NWY']Z!S0'S_ -=6S!TI7CB^\2"?NL6,
M>6)#*OL?K1XVK_V_!K[J?A']:=#T^SR\*D)>OK&D+,*/A^ ,8O\ DK\Z?]XZ
MG_7QY>6P[N_CO1_HZ%:^=DL\G@%HL[2WZ6F?<YAHE"SZR![4T<D>-B2E()&P
M2+1Y1\49K\*#V1$Y+Z 9D-^3\.HZ#^= &[A^WF>G&&-!'4_*U=G0!8,'F8Z5
MHD;Z^5F;V2^C2TBV[ 7S%)<:2+O5)#R^[:(;E_-Y:CX#[_UH2^$?!=MI\6_6
MG7!_3^O+5W!]^$/?^5]+=S$^3\"91'\#]:2P2YWP>D'WGRMH9T.)%S\N;Y+?
M'L:26D">,">V_P!>7ERR]@FLB<KW=!,G]E[[?;5H#*;[0/RZ2CROL?OS#MP9
M58C'9MB6*;B;)[@@64@&BM8DHR1' ,WU^^28GVC5/!509B,2<BG4\L"\/0=Q
M=&?./J ?N=8ONA]'\&G4C\+RR=W^H_MIUC#Y(H*<#4/^P'^NE8/D>CIY>!4-
MQ2%HJ8B&:9"D@EGZSN.PIXC?$A"&Q%\C#7H.?9]0- _Z;O*.R6[Y)?<]MH_*
M#5"[Q/8ZZGA#GR6?:G!P6'0EK]1A]S[GRAE+FSL9?FQ&Y.DB%LML;OL2T $&
M-3A8(]W^$TN8V!^5_!YEZL4#!<7YR^],S"=>Y;Z>!&@J 08<[A9:1-!NI/UE
M^5=EL>5%ER1W+'%A9>A:]*K+G25N1W7^RZB0[KVPC[_%T13"G:1^4\O_ ,A\
M?U0B28T78QCM^L-39X.Y9\A'0!N4OG?+#T6D1P6$X?*!3_59?=^HT6F8$.);
MOP!\Z_0-POZT\15E6ZKNN[IV9V(IVM(T^5 3F)Q%1EK%*["8CP>4=+(#S8X=
MZ%0F5GA:UBC=O 6)W?1SGW>-!+X#TY[G]-Z,. D?(9."]!U=JLE;$J P'_A+
M+%](EV^3L6XR'<:J#84LPOM]C8]BVBBYEW_#VB7OYD,?^B?H33#PD[C)6#U#
MLDZP@Q?L!!(<#P&E4 N@DPB):R,",+"9K;H'_84?9 LGD/4 2K@#*TSX("1P
MR$[29NW%1N! (@A$%H<EVZS1/\%"\[/?/7P)K2$89N7[$2O_  5=!L%^_,)M
M9C^1_,3[Z0JS'IW1JQEMCDP/>13*0B=&YHPXF/1/V.CR"F+'_9W=OGC1$7%0
M\"GN9^,=C66"$XS%E[I6@&*!70_]@M:] # 'E,K*.>21Z&$]*A7:)A1Y+V!T
M<;(.S'=Q" <.MLG)<##^GI-###PFA'S*G 2J<27>"^6C#);\ P/9&!#Q6Y#8
MWZ W_!E@J]O0)>7\8-YK(UDQ(-U]$L&6B0@__7NMWEU-G"_)VBW<:8D,'=_5
M8O4.P1YB"0XJ=+%?<V;<D.B,=A]7PSV(:SI/+D(3XJ;]?X,VV8-HPN30-[(=
M[-X''+7-$V5#$7J;G$S9)D0\.7+:P$V,[K8,K8O7(UL(^3GQFD,72=YO0(@@
MY<P.;$(!2"SB!L8N6$@[P3F#7I-1B78]V"E:2TO=TFL@<4,W7,R04\>9*G8^
MTQ\+]G1AT_P#Y.Y\![0JIYR^[Y).-'X (1N(Y$IXV7)^=]#>27QG,'I)Z]/F
MDH*E71H:[[^7;9_'@=6+HB)L@YF8SAL,K6Y5B&(6QQ9 O$EK3Y:EXFX9/HOC
M;03D1 <!GF"^T2MS'@6P ?#AZ\/L])82P1@YZ?9[-*[Y'\$"9UU<A(O/0\SP
MS!( E@ -R]Z(5@9SLL8MEM7 +5:N*0?H[/\ %".FC@8'ADBBV$>P6>RQ^"C'
MY(<;8$>8=*:I>ZSUCH7L%C;0$S9'K'6L8OO70Z'WGP31_&F7W>UHG&G27]P_
M7Y#YS<:_<L;W%7:&B=O=2S\9[E'T 2)A'?7<3D2X_,1MP&U$29\?8?<V>XP$
M*2-LK0VLE\*=F*-.F+NRIVX ZEF@:V=T^<G/VAM4,0=0^F]6Z!S'VJ?)*,;L
M7X#LRJ.[]+VM7CP=ALXG(R: C5L 96H@69[A?V+/"=W@1?.=7#V=6[%M$BDE
M]!RQYIP@'7:^ESJ% GEDCTTDXDW&/ZFYU!MJ8="R)D>2@P ]@\/0R6DT623L
M<O'M<NA%?E) P3.7+VYHH #58&9+67^*WDRJF2U8)6UH>*LUB86\<QFFQVXB
MTCO<MRR31"LNV7OE\0=-;^U7<_LZ[?!1@P$!TUF*1;Z391W.A#*4X!51E5NJ
MMU6ZN=%XP)"0WW;FUX5MI\R[QWE0^CVMG8U"%IQLVQYV(8O@'X(_S L#V$#*
M0!FZH!-4*Q%N%F0F4 DZW@],X\'%2=W@_KT/>,UG Y<O\.#\M_ ".0=<,QW]
MW9(Z&3* '*L![M9[PN\K+_.D>=MC[MP]QN47\/#_ -=')TTFOLY3QOSZF=RT
M!X".:X#-F'<=YE I*"FZ;'N8 W4DM8K'D %O9'R-9ZHEL7H@6Z^6"2[,D&3X
M"P)L-]O;+JP23-(GELKUT;C![;'?*XR#CSBF[=NNSU8T6_<N)P]MGHM.XB$]
M;;CN7U#NHD2R)A&GCV38]FST6YW,J!A!MOIW1L029IMY<OK@P<%2&+([G:7)
MD+W) ZM56(;VC-]OBF%LL- K!FF"3TAX??;-&B!6#5*GW :4-@"5;!2IDE00
MRB,[(=H*$BTME=$6;.7<8$F@\Z09GZR[^!F(+$=)>(]C<-PLEG<1A#8KI689
MB;29/)D'P*(^T&\,EA)$$<B"7*=[W*[,@N5TMU+ >3&=[%\WVW+S(>O2>&A(
M":1<0D1R5N[<?RIOW$_4ON*AF[]OR3[J/!4"0'@C,?2#@^UK71")4KHI:Z#\
M_J>[P_X/[5)W].ZP: E082R5(:!OT</WP]/ B,60CO2[,N MMEV(BP"ZLM+K
M,W"<#D4RD6TN:EV:)0%LLV);(Q%YBD((IZP:X&HL>\"'=^O-(EB,\]Y%<:)-
MNL <CV0._5Y6[OX%KP,&ZV#K^,L M(NP'#8]9=+#=E9;?MT6V>?D9[FVXNY\
M9VIJYF'3D>HV>N@P@?$/0O=:$<&A81R/#X(=K*;,7Y_]M0N8,++E\6;4.;I6
MN0<"3V[C<%CG2B8Y@9I0%@N/PE [C<7%BY>17Z4^ABU[KO 7F,]JR3[C_I[1
MX=AJ.P0R&[V.V32 -^:3O &ZD"4 6EFCF(#Q#8M/< JROFE#@D^1.%0HN ER
MCG5EV)+/0V.P2](0AD29/Y![#, !JP+C=Y,=%.Y(/-M[?'#KP.F7H2B %7?7
MT;:3D.^YZ'GF,'$E&# D ;?X4!7=M_';_IQ-)659*A,5[?V_\3>/-S$/8.#X
MEP3>MG[L#^N[?L 5G(<NPW7U=@K"'>Z[KU?_ "W^!)>]?\7IL.+[0@G%DB;Z
M%,)YVZ+QP]G(7.\*LGFHG Y6KT2]7J([$8D!AJ3:%JH;R%8"+^H$OGWOB_M'
MK&Y@2-FD%HW/WB_)?=9%J?@ZP1Q]DB811LU'#9 MV+66)ZBPM1XDD21.1+)Y
M38RW6"I3[1^#^?AO24O)E>5NO=TW$K_H/2,NPQH%8];\O^)P8"$:;2LVX=.K
MKA[V*%&3-3A' 9CW;.>&YHH!]SRL4;W!MMF?;BV<B*F-;=_ZL=B#0&)^(-UP
M'_1*@Y%][7Z#8VZJK_AE7(W_ */K^  )*TC\ <!Z,/M#>D11G"Y.^'DO#:?+
MF/2BZ]MN[!3,^W_;?\=*O!>L\^>[?C/,R[DA+O=@]O:BV!,$/[D/<GPA_B;,
M5':/# [(D@B*L%6P6['J+ED-+T E7R':7H4;P:>[*F+H3ZU&(V!)AAL!(1&2
MR1XI."-B_P $M!'XQ^#N8E(W-JD^?H[!8U1[YW_AU6XF\'6!8]97=;K=_P B
M<1"XX:GYINK^!SD,[ZNRN]^YA]Z$N[9S^2/>':D\IB&[FQ"?:?%9W>%)]C+7
M>VG]E_H[U9>SVV[;W))(<)K # ;N#^L;'28+U''.7?N_F#_(K)]9U<O=P<(<
M$]6>1N5TT[RX?MZ#3V#>8,S\W.QUIP#"3,[WR[9FG80R0<"8KD^ER3!0D$P\
M*3PP+<JQ5NZ-?Z.]3I'3O\MO8GK2AU>[G0\Q,!FA9;)]AWC_ *N?Y'1B $&R
M(V1,C3[995+K8?<[ESC!67+ 0\2<J+"5LNL*6*8PPE]Q\Z@(;9*/B8^J"('\
MOYHL0 ^C:LL_A_% I6V4/A?!V%A[Y6V%I!M2!#\;Z<VZ;_Z)B._WOP[.52DG
MXV<KLX]L\G@$[E!^&BX'[B_- B%/1Q30K)\[@^"U8L8U- JL&6D(G8S[C&]N
MBS%"3!@+'^:U:.2_>/V0FS2ADLEV\6,V)8]VKGO_ ) [8* CPM,QL"#%[-ID
M7-)/M" 1ON/MQ:V[)\QO>#[UE)=ZR,$]>ZJP^P?X4OW09\$(SUEF7\=:B\CR
MLOX=#_/V7VO(B0B%N#UJ<[HW+8$03 M8D9H4D)"5YRJ1;F;@E1!-Q<70>Y+M
M-LOB!6#+2Y<>;1[-WL-!2^*7R9=Y[*A56P0?ZD8B9&Y2+P#^C)\P;%7KJGZ(
M/=9]U M!L^,R43.![+ ^U7"U]-WV?*KF27=V.7+[O^J,RT%I3G9]Z0DE98$[
M! )*W7#*2Q+B8GLG)WXK,^[T.;[TI^92SF<CY?#V4<7\5\XB_P #]I4/:>K\
M&#\]?]B4\Z0OS6!2Z?L6N#Y?YUZO^*-WY:5"Z.4^IA^*,B:X#\?\!V0<'\TY
M(#U#Z&/JELC]Z.+UNU&Y\M$0[O\ N4B$ID$_.?\ ?",7LTH4 -A$N")EF.:(
MN1-DVQD:] OP4>DOPUE7?'Z"LQWT;JCB'1_^E P3)#'%?^BJZ*T>Z%3KF:\(
M8;B?:O\ T]*#@*2V87Z>':KBBP4INC[T^';V@B/4?ZBZJP".T-),HDR"2-\)
M9\DB_CN$9L"]/(KYD\5'( (!1"XC<2XZ%MZCKPEN""8S!_RK,C(QTYK_ -+^
MJLFD/<"HJ-)A["(6"3=.=%*MG"HW:84QX;0O.&S5@!<VXJ=4Q6%5@;8X%TC_
M $6'#(<P38'/)2"WBVQS(X-CR8JYPOH$C9N(ZT/:3+$$);-MT%X/$98AJQ-V
M-KN=-PD9X2)\4PS_ *@LR5)*&$PWB6.[7JG]TS:MU<K"[XI.L4'7,@2Z44W8
MOP'^%O0,H+B.!S7_ )%:I9!^32?\Z!"$0G<-X)OQ1TD1A/"VEGUYC<KR)/PM
M%4' ,OWY-MJ3"GPM"I)>G/\ P5D3  NQB;M]#Y#PE+60"6D^%/$F!J"2F\R1
MVGKI&PDT^QI'GPP6E_YE>E<?Z7597 U&JRY7+S7/3.?)P>B]/5.3_G3KC; Q
M=TS,[:$X#YQ&)0?"DDY$DL#L>>*(_A,$OM_CQS'C6,P"B9O>UG1#R5":XXZA
M.?\ .QTHVNP.72A T,-T>_DSF.,+L3UZU(T@<-GO_P [9G)I(7R@KTS^JL)S
M^EX5A!#:AX0.CH^- KBH_P#7*N./0_\ S^4;18&;N>VF!D7'/ACS9TW!\U_Y
M!5RESZC^_P#S_K7&GTWEXWQ>M<__ $,8/I[Z<GFF='H?\G__V@ , P$  A$#
M$0  $ *I)))))))))))))(N!@)Y)))))))))))))) .!9))))))))))))))%
M0 *O_P#_ /YMW<FS_P#_ /\ YX" C_\ _P#\V[D^UH?_ /\ _P!A@6?_ /\
M_P#20A4(?_\ _P#U0 *O_P#_ /XXPHX@_P#_ /\ YX" C_\ _P#\<8:3Y/?_
M /\ _P!A@6?_ /\ _P 7_P"%D'__ /\ ]4 #-))))))))I)))))*@("-))))
M))))))))))+!@-I))))))))))))))X"  0               (200
M       !B 0               "202"0             (20"""
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M       &H)      Z"X   "    '_0     !23   8   ##W      I2X
M   %YP !5+;  '6   "   #_    [;H0 &%   &   ,7, !'\<P!68P
M)O !H;8D?  TT   @  )?8 R/^DB  TT  &   *U0 1V@MH '.@     +X@*
M[AY6E0!^J   @  !V0)?Z.[D^  @  &  !<R  &ZH?\ @ 3G     )7@<@$
M <* "+H  (  "] ?/6  !ID"^H !@  5] *90 "3]@1<@    +K@3V,  "!<
M"Y8  (  3L #YP   M, 94 !@  -X D&@  #30!>@    -T"J 000 5( !$
M (  3T ?X0 0"96@=( !@ !1D!L0"02"!<!?\    %H#^: 20 :J@9(  (
M#H [X222""K@1< !@ #.P NB22 09\ !\    -D!? 0 "0!(@5$  (  ?X!?
M<"0 0"*@9< !@ !L@ N"20005L :P    9\#^@"0" "I@=$  (  #T"<@202
M2#J 9( !@  , #NB22"09L 9L    =D"?     -K 9$  (  >4#_ )     2
M8"5  8  31 3H    !9 '9     ? 9[    $5@&6  "  #1 &^    !'0 3
M 8  E> ;J    '[ ?8    '+  ^X   X2 05  "  %2H _H   X? %0  8
M#? $=    O5 C,    #;@'OD  $*T RU  "  "Z0!7I  #7V U0  8  !8 !
M8,  "W0 ;      W0 JA\J<3('BP  "   ZO D_%,B[@ ">  8  '[H"K"MA
MO\X C8     S7 %C;Z2_  7(  "   B0 ''_ /\ ]H =)  !@  !.("0OW5@
M(#AT      #Y@"#N3_@!-<   (   9. #QG?Q@#!4  !@   9]  #7I$ 0-P
M      >]8      9*P   (   >(       :IP  !@   ).$      EN@
M   +_H    6Y9    (   !M!4    ?U<   !@   "EP@    6FT        ,
M_C\  9U+0    (    !I=O  .Y)@   !@     [3@  U?G         ";]7@
M8)*7     (     3I(Z2=)]@   !@    !";'^;?]H          !A=))7Z@
M     (     "69))(6@    !@      :W_\ ZO             !!C9
M  "       '_ !WP      &        J9:P
M@                 &                                     @
M              &>)B%2R'QLW2@        :_H( !-0-S3L)Y*  @
M          &$DL1*3'$+5;P        Q*GP @'^((R<W\>  @    !;CH+KB
MP     'L"<LUOE]F?F]T!M_GKP!N   !D           @    /\ \T!J>(
M   !ZU:TG 0, 2L  0DFY 8 *OA9"SP$T        (                 !
MH?+"H//H?8_YMM/*    <3.18=#+P        8                 #W?Z$
MED0 XU650%*/@                                       $/P:9@ #
M3[@                                             ('$.2N5^LD1@
M                                            ?D     "&@
M  #_V@ ( 0$# 3\0U;S]5B.0JP$)7_=#############################
MF@<7BRL3")X']V(1LA29HLB=_ )BZG<S.<>&P'^^&&&&&&&&&&&&&&&&&&&&
M&&&&&&&&&$C$ %V  )96 T&]3A82$GN84,BG@O<XT*=_DF  V/\ =#######
M######################'U6)X2C"QA/\+=NL6RH27-YS$L&Z5)+7[G[Y,
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M(YN3H>I53E81<O6E<H7@ -<;VOF)=GI8/_X$:9W,E.@>I%\N*B.DH0DJ?S2
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M"+WI0/;60VQ/50ZD>9Z1;1X?LT:4-'1EP34"&HD($)"&9C@ S"2JZ;ACA,
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MR84RT6(@!&H1/JUF=&U$!(KDJU 'S$0D#D1!$T<CKG$NB6*B>&8E2P$0 X>
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M@UJ0(!PVB_*WB5_BWP'/ J5^0QGK=LL4,@ 5#@9$K*&0!W0903Y<RA2W@NB
MU B ;Q2+RD[:XRN I>!';3#MTP,$@*#0!T=T']H!EP1FD+J0=.N+]&,JP?\
M&?-%_:QRIQ'<J1PW0D@0,=NQ7_*-,MI1J%)/>*RPVB@^MNN+ Y">4?)*6MT1
M3WI&$R-[ND-)S(=:@)G3[2<@0-@R+2=YZ:I4"!HP;28E&QK@&"9N,-M7'*7B
M)(LC01!#,:;6T+ '1A?6O@GRZS(@HH(C-IENV*L6Q*+*<L2G1C&&0%)AP0W
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MS%SHDM@.(-G6X#>\ (H(@3"L!H<Z3\"<V@3>(1+!\N8$I<.(<"F^# , %$Q
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MAN)Y=: 4:0(D80B-UJ &>JI+H0$39TMQ!((F1@3C.#<U;2$M 1QE,V39=)J
MC*L6"2MK S2:#0C0J" 41GRKP3,9;85D3R(X:1>I^WGJ9C$AJ1@'W =7<FD8
M"H4Z5+9-:5)5NKH=HIQ=#4F!8%W\I=C+JW$GFD' )!/+(8H28WL 7(9^E>00
M.6%".K-#@QYTPL*W4&6CD!7.REAAY+5*2:@(GR,6ZCAN-F_D0?:<M'Z_$QZ
MAYD.QXHKXB[=H?P<0Y"(%59 8TZYT&PENK!@6U+7&FA[+?-*4EV@%XPKVD)E
MB#S*32ME6C1,:48F\2K:L@,9ZRX#L2KK4+)PRIG#1 :633"A*(:]:=D=)GC\
M9(P]BB8 .BS4V'PQ!EY"?(%.(RH*G) :!CPP"R]S>%0=Z^2=*\8;&/")C",L
M.7@7D1:KBZ">4X&GD]@T2B=!QH8F;+ P$GRZRQ/II4[?+,MV-QTE8K\"WQI0
M/9YM9:<I&*"" NA;+1RL<RN\ L%H$LZ'*)$F//5Z4WR!\D+5OW+/$I($!-L:
M"#SA"0Z5  +K1'2EV(@04L&,DZ@X[MW30)"X2(5*DL60;JXY^PR2P48#?X@2
M!P   >4]"ZH;5+M1)4A"GF9*VO:-"2Y9%$1A+B61,(U%.14M%N +1XP=62##
MEQ!)5R(NB+PUF>GBO*Q% L@EG0EX 5K0,-K!(F -XUBY!"(*,.\12M]R6B<H
M7B14U(",@:DZ")0FE$S7"3>1659L@=\75@Q+0 &C/KY#.,G7( &F>W)C<Q &
ML0$L-;_D8**SC5+*+Y<UQ4"C/DYBC*"(2( MBIXE6^D5Y%1K!_>RX"U(X] P
M!$TDP,D/'-*\(!>,TD =H1-.DN+8[%901PLIM8 N/'BM&O"/J HJ"A#RC8D*
ML)DA9.!&@;\O*R!(1(V-:?>V%[E6;;6X2;E]:(@GH"92CO/3%*@0-"7=("?.
ME]#0B.H1YE64-%WRU,X@(.4@*#2Z>C#I(.TPC/@#42_!V!N07B+-$"^H  S:
MT  C-#J2%V*#"+K>YTL(@B(@B,B-Q$R/BO2> [4%0\"2LS%-Q!L BN "P$
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M% C'@E3<N)] H<W+1$ O,8Q^:(@M$%I)@_Q(2[[X,L%;)#A'D1S%:DD9HS:
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M$+@S*=VQU+G),)0 H<9<$R)OKR@,@$@)0LD,@MQZD\E%MBOSE1$#=GZ6-UW
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ME7"C5SM0*ET0]-=7I^9/?3H2K5GQET"5=&</:B&AB1 B(8FB2',V006<BX7
M4YI%2>& 4B4J4I376N\1U#CI@A*YXD*Y6'G E9X#W8T4P8F-$80D1#1(1!1'
M"4J%W@6UO%[QBA>4'0'P>8!1J- !BKN3!]+4]PV*;?(EO#*^L9>VJ48G4@D&
M.B9'%(!8.E-W>>>TJ]T59R,4J2T]L0NB6D?2<\ [V-H]JB"P%!6IJ9BX"CJ3
M=#6\BWQ^@&Z#I#O8*DN0YGKGX@&]O0I0RJ*7@BN#(AE$$U-A; "0$3&A _VC
M&4B?@N$/13C*MCE<P"53/!6&PH$T0\P#=GZY93R%7*1<;^SA3U5IN+&+Z C
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MJ^;!TXO%VD9KPE"L6&V"C+LJ"J1"54:NA]DSW$*A3(2E'B4F?PN1 RE@1!U
M B,B-Q$LB8?*]<X\$,P^ )Z?J^39&6NN603$!+:9H;EUX2RR=BI*^9&YD"<@
M(5PD"(#0O%52)'AN5&"&F^,QDY%V8&1EIRY&6 2D4N(0@4!3H(90 RA2044@
M!!'=@"J:%Y MB?=7]T,W8,8F;Q5H%67V/&?$8)4TA3K[H3I=K2( %M8.08R
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MX;NL@]<CBI'DM_?'LEWJ3D&TOH/I6?!#01&XD4<S5O\ DE]T&\9AVA(#O/\
M0R?;'RP0=?.AA\P4JX^BKVF\?RD=FX2Z*B&21!9Q L92^@Q-!([&\>19'M;
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M*/1?PV8,8+!CA> @"&Q0THMBU[[!O(;NSRS/F'#&UA*@8R@4EX1P@PLEI,,
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M'LC;E2MQ@JT:JV6> 7["P[F_^)P#8 NKZ^"[4NDK;A)\EP7C(2:B2DO<L=3
M_L 5:G,+OWE>-X(X!Y0A8-[[S!GN1UF@B=NZEWL>V#L$ZF."XP'-Z=6,&[1Z
M"A$2$2R(X3<\DP^2"L&:L6PFP$W,[-D+A6JNGDFDIPEU]P7CI2]_Q/PB;:%'
M:GRC*!3<SW"5[DFR4\-<!*_W;^X_ 5FYC2"1#8+GY5VRKY)1U+;FR;([K(F?
M(,^4.0/7_;-('W= ?REUV-@P&P@*/D^HY !%(%%8:8'A/61&*KX+<5&;_(U@
M0!B$(=T^AOF6#,%&V /)!J1(C"/(ERFA../S.UFS&[&$,\<9'C(NB#OA'0Q(
M0"1/5QR()<J_& W&X]8Q>'/G@@5, 97@J&$W'6V]>7-BQ*T,%<V)L]);<X(:
M2KR@19*'N-J1OB8.!DF?ZAYPMR'F@"(&1,C5\$8'BW ^/D<Q0(!!19TCE')F
M#8&UGAT>2,/DJK86)SN%VW#FPM-HV:9%"\.<V%3C#S1*1USR4"ANJJMWS4)$
MD1GK/?D[<KI#6,HD3]/(PC9!(T61"GEZW_HN;*.(>19$LCXS/DQPR)%_RF;:
M+%@I(DE<' ;!8+ !H35OAA?*$A9%Y<3((=^*+ 4$* !5T "; >:<=B3(<8$^
MS(C>H!$=_P")=WY5A=: #E\?4F?K>8B]"5K@0NSB9!04A44><6#&"[I9]N.J
M78=$[ %5L 75Z%'<,X&&UM."TP$WL>!%(/\ .0LNZC5$&TC\4?.EY[P*@(E[
MK,3+X6#:#;%?8),=H=MYH\I=E^;\:EY$B.YC,"[##T\-Y>0K)PG+9<\Z@6TB
M0(,B'%T,"0 >0,/D-*64;#RFYP5,$*C1\P  $ %@ L 6 QI=LH$(DCMDP-YD
M0GAQRMB 9$PE$7%)@+:GH,BL<)<6 8MD0MR1N)_&BG'8E;SENTZB(Z10 (D)
M50X[P?SHX=L ![V/>7;>BF!]/;=("Z@=<^&9W+&-LY W,"S<08D!#"/K#<;-
M])&RT#8(.\P/_MXC/D!11=@"5_Z+N"]2O70VFW3<>6"P11C%521/S$DQ**P$
M$L7;*@%^%=7>P'A/AXB2$)L#:34V7<6WY/[T<A/($ &!"&"VO-Y0/MHP"RP;
MG)O39V1?X2/IHM.=C\X^P;TI%*R>!XIRB$_Z<(V21$:#F$"O"LYDAO [%!2!
M'K9"9@Q=!B%1N=,B(BP7A]=-XTJG?+%@69V6K@4)!MYLJ8V6;.7Z.HH(@(#
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MD:1F2 NV7L![**&%"<(PGL^(P^,XB2S#C'FT/LL:(M0$3E9+L3%F=HU! J8
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MF@F:1O;]CQ3#XHZ28="(]XG9='<BSF&9&X91;<$F/ 71AMC039!QO*Q@I_\
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M5F;AIW$1-D30S(%'4@GY$]M0-RA^/^VCK-E?1^_,P,)^BECVQH8C(OR_>K<
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M=,3IY9/Q5*EC)9"X-:!W/57T*V4A9*85B=9Q0&1LW]H,8E@F]!&  < 0'L:
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M[PY<2?861P!;248L$&X\\(V#<1&YJE9P H(1&R)9'-#JI*KUF:V]=N$T"-R
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MX75B95I4>@H1$A$LB-Q')HB"VSEUN[LCE+W9H/9TJ%'<^$R-F_FG040 2JX
M+J\5$(#;K)-;-U*HS5F2R;9)989<VKM87GHA@0=B?.3G@6(7(9,P1#$&?U"1
MNF$*BL$4!FX[B")< (@TG+?ZF+H"O#!L"UFV 3*,@!$W$'RL)3 5^MC=P9:=
M(AN)(9V/L1RB2CH   ( "  L 6 P:6$%;EU^@[N^"^'TMN[' &P%@,>28?)D
M4@#(^LF$LVH5'T:8Y\K<EP,D*D A*I DRKLF<2]XZ<9:1#^PCW'"=11Y\H$:
MI@"ZKL4\;[[[".&;RZ$S6%DWY%95=U5=W3[[]6P;K8[J@*;J: V+F>8#D@"
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M2UJ"8Q!8 D68#TJ+%[B^ZGPS-K8*_!>FQ)]U#\)EW ZU#*ES^$W]R/%'P (
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M+[$1A:$1<AAA8J5E\*13BAUP0FA"XDVUX$L/"Q;W;L'B4!6P%#(>ZP\9)0F
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M2FIL!4/NH?5#NZ5#/>A"WK-"8ZTH0<_]U,I5I2(*$L-2.>*A?UM7TM4[N:;
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M>VX)[5CNPL2LW16P1S,"$;\4>RR(.6P6'6XHP@PP54+2,MRPJ55U*3X+MR)
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M$X0%\Q,@!T.8NX)9ZA!?VA,U/)2%^0RC>"#8/*>Q$8+9Q9@38>A3:2BA2)<
M862]M) U/[H"[L%R<&XQ:% 3BR1+B.$=Q_Q+%W%75SD*D;QNFQ.:PB1 @CB
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MY>LCKU). 8) ,*'8QI< -+L2FS.#@.$\R!*)"B!2&2R)"40C0^Y@%!@ *C8
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M2"2%JGZ*!,2;I!0A()0Q?1C)7H$ #@LO/A>"M5KKI48DQV21])G98H8Q)$D
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M;.X*PXF)58)%@F"LDV&4N4MDV+XH)/&^0ZW+41:)M,890+BHF]8)6!"P9.6
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M91W"T .T<'VKE3=)556?\2+R 2(Y$H8-@<RP1@8(%E(3I G0LB61,([)1 &
MV4Q,TD73BE*V-G"2=G<3<81L@^4H);!5S;R5C9 &4MC(,A(2BP&*8)@  2J
M"L!.F9+KV!$F&Z)864"D-N^4(!BU[I#4"J^0L^4C,Q,AKEW:YRVD.PA$9$;B
M)9$N)G3'=1@WP=I,V[LV@!APS8 $%D2)$DB/EO J)[,=!Y>I-J1M$V1OPV)\
M6!9 W4'=XW7X)CNMB@B#RM01Y"B(BMZ2U:.-66,D+!DN!_Q-FE* !$3N7=-1
MO7>?OA+ "=F);A":^:19.K3<  &QV!2)' &1C=;6'"2<D'XLB,)>&$ 4($3Q
M$" I:*8C"Y+I 74+T5+91PANDIN24D5O04(8&#M(ZR N\ZFAA"0"?$&8A="4
M@;E( #@GNJJJ)4*%%5_R)]$ $'(C9*CO?D"%>DOV F&IS8J5H3 DB2P!-XJ8
M.*O@DB"!)O,(8P;7@:"=V+ *W>*R3(P,W,>%\6Q09!$LMB28&).2@7J&%G@M
M&+1(T;4WR6:)$E6(LQ,1C6V8YT&H;SA+UY&A8+83W8W5L2P(D8"6?(?+E@C!
MO.YE[BD9!FDN*RN3J)D, $L@U#H@E[-]@A[>O!22ZHH@L"F +A$"T52@\F8B
M9X@.92MR+I&3@I85/I1[%]([? \$BH"7$;GA7 V1 [JA1*LMB'RB',).,22L
M-U.=X'LARIJ22HJ>595ZNCC/@"IZ!Z"[0YEU) C$S= 8('^0/DA$T.4" 1%$
MB@TL%QKK),+,FP0JE]DXI1)9BFA))?10);!1QUZD$V#88<LWLLU#<%#'$!O0
M'"C#$A2L*V5QUN_<]:;H DDQU)1)DD3D2@X$=/P"DJB5NTSD #@"#  '@Y=@
M @LB<$R$@V,H4F9KD-DR-V7N"#O"@18Q_G-F<5B%WL!4N16X45+S%.4L(RI"
M902(&W@N,Z8'GL!0)<"+O[J+W;T40&[,_ /@JV*#H?V2I%5F0^0#Z4   !8U
M@LH,J0J 78!7@%;#1HR+=98B<66,BW$"BI;  #@"QY3YDY+RZ"8)RY@82@"S
M))*A1+"10"%LWN,[2:A+=8%=@06P!4<%%0ELZ!QA0A+1S>$J)>!0-L&<U456
MO&W"$AM BQ"IO,KE@Q$?(L&>[4#[+<]#%%PYZEE.H\V7RJ^!15=I).;/1;56
M;E%_T)Y. PLM_P#.A:I@N")24(#YL*O&K,ER)#7C!0:@\* (S[8@- NH9S&/
M2R0D)A"!20Y6/$")6 #*K !NK8-VITC!VHLL ;3?IM*"%4NP)+D$B9@>XHY,
M:!2+*P 2JJY5E_U"EF "'",B=Z4B/>RJB2:8LR &\A3!"43*Q 8)E1 RH$'R
MFA!$>$;GOXQIJ(P,X5@2]S;O2A).2;LD3%:) E<@Q=5#P MR2>8U4DB6(GS'
MSAJ"EPB1)%T&0MB&*9ES)0L%!#KYL25EI(E%E"!>"\+DARF0HF!(D$H(B[*#
M8H58-N7+N7EN3>>OAZ4Z5]X,>]+"JY$71X]E=*;%\0@\PVG#"/\ 8%'1 (#D
M$2%C#M4G/IOGM[ #H1!@(I("6&5%ZV#ZHDO'21%D(XQ!E&YAPPC#9&&I^521
M'O#VE'2G@92W%B)8$L 2[?\  =#5"_ :8I?"_ J?25Q,%MIGUNN^T0RV9[OU
MH6=V']ZG7(A0+]![!1Q+ M%A2VQ06]X)QY[_ (&@DA 1.$9'WHR6EYT RJ*"
MJ9E6F8NDA902>/:;%XD5%JSN+\>C:CS(X@'Y_12T]* ??CWGK4$G-Y>^X_ =
M* '>  'L0?\ S+_]@TKTP-)&$QF-J]>?NFD4XY4E]UFBR=Z&]#-323 3+< H
MF,Q&)T:D4"F08J[  X"*F\5/-#.GS9C'4!N5NMK5CI :X8L(C"/#I-NM3BAD
MFMZF\4,DT8_Q6 164NP )56"ZKEI&9T4 @Q4(-D42&FQ5Z&]32VD\"%8!"H0
M 5=0NW:-_2BHB2(P1+(YTEN\5>A??13T;$1('"  1$T4MB"!3&R)$G#(F"&9
MBL%+8[T/Q4MZEF*<4J8J>.:+W_XIHQ7"$0JC(S#H9+F!G 26M9*(:H[Y.%$2
M$LBTS?&@!'?))!I-X0Y[U&>M!%1I:;[1L<,PUED2A4[%0B1J0%A#871E44$6
MTB@@BC_%8%] 8 ' 2Q,220J6 ^15PFR@)+&"Y45%1221X = #<!T^&4S0D)D
M% .N1(@^"5& N,#45%1H*1J &RK!(58+MM#317R<OD6@CLF;3#234;U%YTBH
M/FHJ*@^ZC_ Q;@E*0!2R$Q8RZ85[.@J&4;JMU;K=J;]*FAU=5V/8H%@ E%@#
M&FQ>%&JRJLJMU6ZN:F]"T>:TBA2RIDCK4S.V-$L7(VC$@L9M>UZFH5)K)4E2
M5)4Z25)4U-XJ1J2I*DJ2I*FI-!H(I3EY+740+1O>G4,01"\",AE6I8O4WBI*
MDJ2I*FI\$-((92"2!)$22XCAI\5@C#@ 2KL!/DRXP6(,PP&&&&(LT12  (JV
M ":K@_X),P&!3;N!:82,6ADJHH]+E*@*1$24(D4O46BHJ-5(P2$)$4+!BLD+
M36<6H",PB-S-RHJ'G-,YA@%WX5_[3^4$-S^K5XBD?NH?S0147J'ZJ/S2.U0_
MBD6NM9:O%J!WI&5J$Q4/U72HJ&9J&H9FHT;-XTAMV0AO:CV>1 '*I!3<J*A^
MZ!^ZAJ&H8J'PP^H\*<5_*EJ7[J\=:L8J]&/ [/6B=ZW/>I6_2C_EVISWJB8Q
M(>0Q"(9IH%0') 6!*L2VE6-VNM25)H?:1/4LE!E8%JF7G#@A;()MNM)TDJ2I
M*0EBV!?$  2D!B1+:9^WY^=%<YET$1>:DH1)J32:FE"IJ:DJ2I/*P&\P#>HS
M-V-XJ>A $N3$SB>8=(*@U@J#0:+0 %RF49V1M0O=$YH&.^-8,U!_S#2F1O5(
M+J)AB<PQC2B41 KKQ%0TV9HQ2E3"B3O!0GS<J#N13<J[4- [U#4,4SX%E; $
MBM>FOW6)?? Q-LPUO-7S4,':H::AJ&H?NFD:BY4/U44?_(N73BT#9V1C'->J
M/W2%H&N4:3WBI-<:+%2>(D$$QQ(/WI)S..0(['.B3_Z!H O$;UO4<9J+5OTI
MP=ZNJ';-=L4E1\TA7J7#4G,TWO4?,U'_ ,W\T=.__CWT]1ESG._7GKYN+.=L
-^W73L[_QQ^_;_)__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2113965d1-pht_typical4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_typical4clr.jpg
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M 0$              P$"! 4&!P@)$   !@$!!04&!00! @<! 0 ! @,$!08
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M1"4&@&/#19.$M!,! 0 " 0,"!00# 0$!     1$ (3%!46'P<1"!D:'!(#!
ML5#1\>%@@/_:  P# 0 "$0,1   !]_                           :C=
MUY?JEVOGDOP-EOIYC[/8>MW0
M      PZF25Y@   8HRH     /++VCYR\OO8?!A]TOL;5;CW:^9?LBZ]-T8
M                                        $?4R*O>/T   PJF:5
M  A.QU'\V7UK\)]2^S]HL31;SJ[/2['^;>U>W/A7TUVP
M                         1Y3(*]\^@  #"UIFJ5     UZZGC?Y]OJ#X
MKY:696N!W(-A&9[Y!P_I'IG\V_8,AK0                       35;O*H
M    !USI*           8<S"N3/H   P5:=B@    # 9.)_./]:?"UT<IV=#
M=SY?CK<P7=XU]$>SGCGO\A4                       '74M:@ =]7F
M           !'3M&6/H   PM:9JE0    !H;Z%Y3XZ?0'RSCI\42_C_0/4;Y
MO^O=YH,C[                       !BE+%MN                 CAV*
M5R]:<@  !A:TS5*@    #C-;-EJ?+OKN#F>NV^X/(]YL;DX>AGJWB.RO'>@Q
MO,UTXUNTAN?KY9@[*OMMHLOCY5A:G>=22/ Y6!@,K$QD^'.]7O:^VW/7OR_<
M:3^D>/YO&SHIG:_<WSOU>+YNN[%E\GP]C$<_4['<AWH           &*4L6V
MX                "-*<]+LS6G*   86M,U2H      T!I=>UU+8K;#]AJ]
M&?3/'+#U/0U9N^:KK<<[L#R?<PS9:J+YF!^5C[L69P707;S?75UM]'^5B)*4
MZ3B_2WQOZ&T4]-\7W(\]]:UB[3@ZMW?*=:^*Q]/T5?[;19*')]6?#?I
M       #%*6+;<                !&%.6EV<K3F   ,+6F:I4      :!4
MOO>ZRUJT$3SM;(<3/C>9@9**7]I7@OLXJT*=R.8=FR_!96)DX9NE)'Q5MDF'
MGXV?&SN+FQW+PN&ZSH2P]N.3/XN=@LK"E6#L0           ,4I8MMP
M           $7/JE<_6G.   86M,U2H      T"I?>]UEK5IC*M1-E@32*:[
M<6?*VUC-]D*ECL&&691WQ6^W7?-Q-C\++C=]E3Y$>P6'D:TYV):F//;^/+"I
M;*[FAM7'GQEUN8LNZ%U,I;=D;:QZ2S6'.Q-N==G8JZW&76P.6.QX9<O;=T*T
MDEEU>S1_5$OCDA\MD0DCMK'FP]U*#S,.\\3+DD=\8DCG44@&*4L6VX
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MLM:M ! Y8II'+V*(5+9)([\C0 !7DT5APR@   "#2V3F*\    5S-'8T,@
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MZ;;:%;;68NYV*,!?;=&-- I8]P-=G7#C3@#%*6+;<!IS[)\AW#QWK5R\9[$
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M?@9],_&NSW'^B<%\'Y2[6KK>"]Q_EK[8W$YSK/T    UP5EM;92H
M                !UJK"MNU;]3^9O/+Z'_/D>HORW^F]V<3[0  .F8M0
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M0 8*?&_GP^H/B^(;/47#H>HI7H>3^.>ZOUZ^9OL?;NE?T
M        '3)9:R*H     U]]!\*\P_IS\V@!ZG?+/Z9WAQ'LX
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ME0#:Z6ENBY;>'S7UVX>?Z@            =,E=K(J@    :">]?$FF/L?R0
M!ZK?+/Z6WGQ'LH              KDAE+K24DE:?8  (!5H7;)Z!7Q?I1'3\
M; =KI-(?2O&]D^.]&C&9A6OHNDEF#GUEN>?M#2]'5N[YO$3PX;)UVRW'>@[&
M\AWFL/:>>3+7;K4[N_+I;@;B.Y>NVMX;TGGMEHCI^,NOF^ONKG>I
M     Z9*[615    %.]?Y7Y0?5/YG=.7%  ]6OEG]*[SXCV0
M  5N0FE]JK9-6GV  " 5:%VR>@5\7Z 0?9::9:_<0K8ZF=ZS;@
M           =,E=K(J@   <5T?DO]6_F;3G7^4  #U<^6/TJO3B/8P
M       !6I!J7VPME%:?8  (!5H7;)Z!7Q?IKCF8T!FLH7+QMTM9G:ZYF/&I
M++3@OL.&6C<K'N/&GOG$R?.W<ZGTDTFX\V]WJ;?QLG-6KAQIJ:R8L_9=DZ)]
M#)0V7CS**35W88>UNOS,55F;6O\ F03N*^5Q292E8=)'+8[Y[#):L$P
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M:<@  (!5H7;)Z!7Q?H  !4F1!;>/.  !6\T=93P[*X64
M.F9FUW@   >67T]^=E!]_P"(   #UF^6?TBOCB/80      !4>\YKS#]B\"J
M'><U?W+]GZ>^.?0$[P-H   !6!7U+[@6RRM.0  $ JT+MD] KXOT
M                 Z9*[615   UB](\%\M?IC\_0   /6WY7_1V^N']?
M    @6RU'\\WU-\30W8:R8Z_;73H.LKS-U'O[\N_:<TCE   %7*U[2ZXU)96
MWD  !$JTI>EUP5M                         '&2ZE>V  #!9NJ\8/KO\
MP8=MN9    ]<OEC]&[[XCUX      #S1]=\)\L?9_G;<#A/4;'U6[U=[+SRB
M.CX_U?\ G'Z[]+.$]+^P  "K2NZ27(MEU;>0  &%K3-4J
M              !YR>^_%FE'KWRZ    /77Y;_1B_>(]=       \HO:_G;S
MF]7\,]LOGKZS@NRTNIO;^:Z0^A^37=\_?5>Y_FWKW,   <1Q'.?1^@  ^3Z
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M;;[_ .4[?SG]=\+])O'O>?,_V3Y]W"\_]5P>3@[%<EW?X=VB24J
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M     !^'=HDE*@           #3KU#Y\\M/H;XB      'L9\O?H1L)Q7K
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MOPUUG1NI"Y8OTV*P<[K5I]+=7<_&G$5UJ039*UN-K<X        #\.[1)*5
M          \Y_:OE7SM]G^7        /9_YB^^MB^+]3        Q2GFA27T
M/OBY3$W4'&8VZW-671Z^T<ROZIW[;HY)9J[G8>[^KV$;OMR-*X"^WLT9NRZ.
M26Y>ROQ5TZTR%MW,=2M!CZT[U*CO4KE;:@        ?AW:))2H
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M8(           'M?\R?=VR'%^H#5OL_.?.WU7P_ 9.+N-P'J7H)Y=[;VZ5
M  &*4\SZ2^A]\7*                        #\.]:DBH   $&VF@T]]$\
M6U+] \=UZZ_S;'30             #VT^9?NO9'C/3]2>Y\Q\+_H[Y)R\&7U
M;X\5-C;^>1^]^P_B7T7VP   #@(>ID:@    (6K%Z5GRF<K3Z  !CE,BJ
M           ,U1W%0 /Q2DNFX74KO_'M3^^\@H_I^%XJV@
M>VWS/]T[)<9Z=X/?2OQW1/2<KN'P?J-HZ;HO,+V'Y[X:/?CY"^^-@8)@
M     !7BL,76@MD:GV  #$5IEZ5       '<5_0       "H.AXS0[U/P#4C
MOO(JYW'-                 >W7S/\ <^R?&^F_SU?4OQ)!-CK_ $ \R]GM
M#2]%Y,>W_-L8R];MS\C?>E^:[;_H                      !+JV^DJSE
M      !0'5^>^*7TE\1QK,U@                 'M[\T?<NRG&^F>3WMGS
M?YI>N^$S;7[:7X.RL+5;[7O+UWM'\O?:FQUT8
MQI8]M>4       UZZWSOQ3^C_BB-9FM                  'N!\T_<.RW&
M^F1Z?$\4/H#Y7U"]"\L_#/\ .=AOE\[?67IGH^DS5:
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M4TDVSOB   IGH>5M/2='DX9P    !7FVTEAZG=@    "L]SH+,TV_
M&+)_;7E    !H7Z;X;Y-^W?+^(GQ0                    /=/YM^U=G./
M]' UR*II)MG?$/-/=ZS8/#R8)+':D$F(N9.VL7DBV?P,SRZWVHWIU6QC]]MA
MPR0^2SY4L&&;7'.P[6QYYY#+463C[/X&9JCL,*W\;(S%MW$5Y/!5L\5HP3:Z
M9F/?>)/]EDP35A/#QUI>V)DTKE8\8OMDEE\.EBD\=^3MK2>5#>F)/]JU]-#;
MN-D="ZD$EBVIP,P8LG]M>4    \X_5_G_P K/9_FO@NM
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MT+K>U2OV?BOW2F"OI.8KQBR?VUY0  #S%]?^<_+OU_YZ_%0
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MJUMALEN-NML^"2D<J"9Q7]^EW/2OH]I=H    !BS+6OL 'X>:_L/SIYF>M^
M@                       >\OSE]C[1<AZ&!KD5323;.^(1Z^T8^M*GR(-
MB</*%;31?:L1DLCDD<CCDE\=]!Y>+=V+E9"E8++%UJVV%#+6\T?4NML['FLF
M&41N^W6S-Q+8QYJ]GCJR>#8_"RX-+'E[:\5:X2ZP32*3BJXU<7='LAA98
M &+)_;7E !Y)^T_-7F[ZGX<5                        ]ZOG+[$VDY#T
M$#7(JFDFV=\0                        &+)_;7E /(OVOYJ\WO4?%
M                      />_P"<OL#:;D/0 -<BJ:2;9WQ
M            8LG]M>4XJV^07MGS9YS>G^,
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ML"0Z?49[2Z3O:_49#"P9!J];G]+H^UJM/^4H          /;SU+[EV4W?IH
M             CIVC+'T   :K[2#^4#V?D@           %:9"'&R&%A9[6:
MW/Z31Y[2Z+,:;1][%UV3U^#(=1I\_I-)D-=J,AAX/WAXP
M ]O/4ON793=^F@             "/*=Q7)GT   :K[2#^4#V?D@     .2L>
M<QK.Q@:W.ZK4=_6Z?(8>#G-9K\_I=%F--I.[BZ[*:[!D.GTV?TNF_,3
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M%"YGI=Q^W]\_/-SVP   47K>3\(_)/SY
M       'MYZE]R[*;OTT    ?"E$[+&UQV<5&['$U:W&/2^=%J_M\*OL@
M  !ZL\3N?Z!?.MWV0   47K>3\(_)/SY
M       'MYZE]R[*;OTT  5-@<GIQK/+];MEI-8,W!J._6]?!UF9U^O[NMT^
M=U^)S:_3]J#&^;80     -\^E^B/6GM/ISG   !56)H_,WAOEP
M                         >DO9_1]Q;'L  !USI*           8PD:O*
M   #"UIFJ5
M Q:F25^@   8HRH
M
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M\4MEV9MYKG;D                           5MEQ59G0C9?397*J
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MY_F\_P WG^;S_-Y_F\_S>?YO/\WG^;S_ #>?YO/\WG^;S_-Y_F\_S>?YO/\
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MO121NDM<Z4USI37.E-<Z4USI37.E-<Z4USI37.E-<Z4UR;0(Q;-3'5Q%DD<
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M<,E!':/..>5\8 !,,-&ECFGM6/ZSX8W_ 'G/Q,I\&YT]Q0I=P#D)LX(G,=(
M*L03KBD7=*82BFNKN".T0V)MC)F,IP"[IR;F<O\ W."41,D&ZF3B'Y?;AD@
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MPS]HU;J\!=Y$=778-FS6>+])EOE/_DK<@OX9.+3+("B*4=)%$\:]9J,7$?\
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MJ!C%Y8^T"& %";<% P 5$QBI(?UE1,83(F*/+'PB1CX9(Q<%N<.^A(43&
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M N*3L0E@V>&##6N)+A[BP##W,V&N$B.#;)4<-9ID</,RJF*+KJ^'QWR?A!7
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M51LW6.=FT55Y)GN$(1,H-FY5L2;-T"E:-"(@P8@5=FS<B!"E*BS:-S?A8OL
M98V ?>)O & (#F^3-\>+O%VX(@&%4,("(%P3? 5  XCL J@X!MHYO%VF.(*
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M%<NTR@%PJF&.!<,J4HF6_K\*DGZ,8QDY)U+/.^I'VO[D/:<=TA"[I-TX 'Y
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M@E*; (0,W2[>W8 ]GYYL##$4$Q";I=TH9LP2E'LV!FP S8&; # *4,$I39L
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M;G=F62+G,I8+O.:4P7"HX/\ 5WS3NIWZ+^"*=]N>U,3#:$;&U!C<-J"4</?
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M_2=X'Q7_ -5WABA6HAI<7);M><"-$!E9!3& N\<97[(\,</,=04 4TVQF_\
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MUSX(:W$0'"X)#E'X;HEICE,3BZ'$K(Z+0[D@ K(G<!J!TP')!?:A8D.!Q$-
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MJ8%G*W#Y@W0VKEPE"JP. T?._EA_9V9:V=XW'H)@="]/.,8<[-L8[/U20T$
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MP5+]=OP@+PK%M$',.":!H'>LYJL/P::)K<J]&.WX>MZ/W&_%K@=L %K0\Z!
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M")R0 D*2T+IB4WP'V!IA"@\</%EGSLA@8+2V%!:4T1,H UP0]+!\S!NE&.$
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M:)$:&F $:0!!?B1$MA;KB?&$ :%T#XDW.YKVV#=&@G7X-O?.KZ/W&]_O><X
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MI9;+U,M2R(&\UY <Y;";M%Q4*;[(K2/IM#FCANL+6DWZA;=JL@OJNHYB@//
M1XMP3=33?X_V*FP>/NG;%:N/-JKT,BMGK/QJE(#G$W/:8;_H>6.U/2\%2*'N
M-2A1J5 '.-0I-8"EQT\D4\RXTC3=3*RD.:'Z2FK5?;KBH6U*&:RZ$W;P^S+8
MH^>B*59KOQ"9+AU5<$NT"*%#((TN:KG(LUWE\")&2SM-H8^NQQ</Y:^.V*O9
MY#?=-[=07XDZ2<8S68H&FS,MK.8U[[F@%/GI*"*%?.5*%3-LJ"?AD;S%MNM-
MB=*)!=V;6R]3+2^R<T(+M%O(;H=3>)7AQ4:.[0_U!W6_Z(^\Z&OR30ZNVU%
MLN-Y&F):E.KENT2Y)FGSKKQBN,NTQ7;2X;ZC!;5JKNJ%!V\ANT0^K5J-KUJ;
M@CP$\YOB/S2,A0J^S-,]#5\45*&>JY3^G7"G,)FI=@$/+9A#LKE*[*.>%0JX
MAIF"V(MA")=M2&5,VVE:N\Q1-]I<?+S5INKPX:W)TGLS)4-+K1]\_/&,R:?!
MXC29JK_-52HT$WFPILO%>L]M>HQXWP$QM'-#?Z/7H<$-3A$68W^>-FJ,UF*[
M*3,U2N'F-)!*ZFW;!#AG:^6J9]A5I8X*FC#78!HQBED,JUONLBD$ SVHAYK<
M;89_I?XG1G!7*49-XZD<L/J9![ZN9<$M7^%MG3 JM?0RV6<[KD*]U^T>"Y8R
MV:")5:0XBQ040GP\D9O/O'X--N[Z5J#[O+&7S--/>7.ZQ -ZDWZ8RIH!K75I
M9R@4A18L5GN:U&TPY,)CC\\;;XK,[3KY6I5 )IR."@I=AJTDXX1E*F705C3;
M:@) E"HNF,EFJ:-J5PCK+QN^7;!I]H$>[4QN*+&N<UAM_>J14+:E#-9=";MX
M?9EL4?/1W:FP0RNBR/!YBL?U+A>8DLWCE\45,W)-Q%L5$4K>AC@9K+TZK=/4
M=ZP"F*)I,%.C0(+6WW)><;H9VBV@E8+-O];=E&%B;+8.>IV/XLXQQ6/?!EF^
M\HA,QMLPL0;;;+(S?X?_ "E\[JK-JMOU0_LV3K.69=8-R:M,4,O3;*^@Y0Y5
MNU)!S0R[/Z@6I/,4]7]ZZXKY=[9WUU5RZ>2V']FR==RS+]G!/JZ8IY>K1!K4
M0 UR[/,1"H%JV0,P,G3&:;B'$-]1$^=\.S%7KN*Q2IYB@VI6H]5Q)Z1C=IAN
M?X6\VG*DW3U8J9N2;B+8J(I6]##LEF*8K95V"HAVP,@RB*; ;$/B3G*VFV&9
ME)I3==#\PDLY5(=5DGF:EZ>(Q[Q1ONVB'G(Y=M&O4O<J\P2R#DLS3%;*'!43
M88I.RS12HT>JV_5;<MED/K9;+MIYRH$+YB>8($T[;UC@9K+LJMT]1WK *8I2
M4F#+4;F'>'*M_P \8=6RF5;3S3@DTQ(Y&H@BKD"U34?-,OV<$U:8H9>27@M1
M55; -%EVN,N^C)1JT[%<[=Y;,;N6'9JK0HTF2[]6=0=G5EMO)%L/S"3435+D
MN43*D<<ME :@"KY(&1J4FOE<K2;KU0M2W$7W&/><OE&,S27S&7U$ ^=\/&<H
M,K3N5>JY3]8!8IY?*L%'+TG3 *I72ICWOW9G]0E2=2GJ]%ZI8L9B@]LSZ][E
MTZDC^FR>>LR^)/'&59P_^,0>MUDY+.F/>W95OO ZIF-FVQ#T17K56SU*XTHG
M08/9LE[EF77H3QQ3J9K+MJ9NE<^8CG"6Z=MR0_,9NE3K<2\$7?9-I;99!R62
MHBC1>=[>+B>?]BIL'C[IVQ4[/D7B.69;KL$U:8HY<L3A%I5>M*$T6=,#M'A7
M,EEF\<OBC-,D7WE<>JLVJV_5#<IGJ(KTV'=WI2-5Q6/>Z].F]J)(0H3EQU^*
MR*E+(9<475 A,Q=S+=']/S%(5*8*MWBU/+:89EL_0;7%/JE93^_YJL,SU1HD
MI@AK!8 "$UP[M+AK,NZNG6GBBNVK3%3*5WEQ83<N@_NP")%.A1IMIY2D5#.L
MI^LM_P"\Q[S1RC&YM+PXRZ.HB0ZK4Z[BIY>[0_U!W6_Z(^\Z&YBC[1L<896G
M[TG66W[J],5JF8:*K*_6%VJR^Q+(?V?3H!E$W(ZZU;5&];LBA5I-DJ4!I5;M
M0AV8R^7:S.O"%\Q/]U/GBL<#-Y=E4+?U7<KA:892:P4\M3&ZV_IA[Y)YFI>G
MB,3T,E295TA/$P16]X8*M.OU@J<U_P T@Y"G0:RFN[:J(5M4;V*[;H;7]SI^
M\MN+7%K5TR@)\[XJ9FH&O;6Z[<",.866K9'N.4I"CEB5-I<3RGYV"&>]4&5<
MU3ZKR3TC'GAM:21&I>N).@:8KY>2;C-151+"-%M^KN-R>;H-JMIG=M(Y]/19
M%&C2I)F0#YU]BXHEVDQ2R#S_ +D@&IR#':ZWDBED9$X6*WWX)XXH59$X*8WI
MR61_4*30U6REI*J.B'Y7(T1094.]O3+JP3P11RDDO! "JJV)HLC+/8R5V7UJ
MO5U#1 S@RS)_.F,X=<EXW43"*E+(9<475 A,Q=S+='^3_=C_ "?[L?@2>BGB
M[\_@3\B^*/\ ._O1_G?WOB8X*\5;$O74D?\ K/\ S(_]9_YD?[SB<9//54Y?
MC_\ _]H " $# @8_ N^QI4EK9D8-ZJZ"[^$.3&/PZ%,-UDGR>"$S>7,J7L=_
MA<GWXXV3>',Z1M!M'CO%GRN/963<E,>T(Q/T-@\[2=VX$.[DK;7&!7H&6L.9
MS3;Z3'6&RPV.:;C#<W3L)L</HNQ'C&H@I\K*N9;UJ=-Q&T"SI@N=:X]UW:&1
MF' ._:KDOXK0 "&X6VA)E-LHR]1HD:=PVSM;] X2KO 7@EVDQ4R?^6]DWI-_
M<2NP?*S,!E_#Z,>CN3.L$<2MNT1<-.W7H:.G!F;N=3<'-&L8NT[+AMM[E(BX
M!Z^H1X?E8_+U/9O:6G80D/RM;VC')\]MX@N[1?-FZCMR4*ZG*#:;NM<F-EHM
M<WB5;7] V>7NU>TGW$2-\+O$.?Y6^]97_GM%V#QHU.T'D-B%IH5VEM5MX/=#
MBK,EB_3J;I/0,< 6Y;+B6BP(!\_F?E=)G*3:FV\;#>.0PK.*S8[^(.@'A3O^
MOO='5Z(070_,5/9L:7'8 L'M YIV6RY<9&L6[D<W&Q2I5; (>WMAS2UIW7+:
M@Q.K$+;;O07!E<Y0%.+)^'SWZKHHNKS&E75'-0A!+:;53>6P&#1K,KTZN <P
M@O4H)1:;<%2*H:VHRK1ZS'A'<RP,PVGF#15'&2QGVBJ6WV$\]D,LK>[/*"K(
M137:Y#9C9#:#YZF:?<Q@F>1I3YW%+HJYJG-^ "7L(1[4"HG(<47&&LRU/,2.
M57R;C2 2CG+>FV\02UM9V6:Y#5#%I@[?W;([/-.O593J5 G#M;4!=3ZQG;9;
MH=839I=E64Z]>LSK<-DTNV[H6*N?[.>]I5@LW7-,[%%F*' W'1&7?4)+S18I
M-YL$9C(4<W6H4VL#K"Y+J=B!S?I+']'S%<YFDYJJ;2TRK:I);=<I%H.,5SG/
M>:[VU"; 7R,2\DE VS3']4+_ /:[+55$33_;=;#<I4IYBA5J=7B,EFV6F'9:
MG3KUZM/K\-DTNVT0>T6U/]JV_4=":;K,5"0RBYM6D:OLS4;*'_9-O)<J@"WY
M-5<L+#4IN;SA(_IG:<U',47.P)5278 Z=B(0;8SE/)TZ@E:0#]+4-:7C!1!R
M\[!6X+FR>=,5M363,L=BT<R/Q.(ZPZ#4ID#F-V%T93_0/@K1VA_V;O!2BIM7
MFJ",DGTJ?Y;X;5XXRK:E 2U"T.;8+6[U@_>-,=IYMN8?7_VU1KG<,,8YTMA:
M0XJ@'T1>NWA4?;/I5@-I<\".!GY9Z9<'4R!,=Y>H;[QJ&-T=D/I,-.D:K4:0
M @GI6(+HS67SF:.3RE!0&M0/??:'$3*1: W2$TG.?Z[/O4HRW^@S[HC,Y;,%
MX8*8=NHJ@4AB#I@ORP<:I\YUI31<!T1F_P#5=]V.-E?:',%JWR[JKHY[+8R"
M9LYNKQJ<QLE'XC;@VP8KC<L5ZW9V?]TSDV^QZM:3RRKB;GWJ,(-:OO<+,]8!
M)F!IM2RYQT#G$9.D[/',N<\%@919N7=='M+=>@ DBSY-KF:5.H1])H/AB5@
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M3#FDA71.SK1,\V]$%HB1Q'#Z8GII;IAQ6TQ^)*@.$$TDMTPCCO*L"8BQT'9
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MJSKA*\>%J=ZJF>S%E&DPN/)XSA%7/V\'JTQH8+N?K'63^SE/YOYU3O:7OL8
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MTMC@7%:@&S><H0$VS(8R.9X]:NV="]S963'S6A!:O6OPMLCM-YN#F_XH;G*
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MVP\N-@<80@C;$J$G5 +%M,8J<,8)T0MLNG"-<:-L7%-*6?#.[-[.=^.J/<,
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MM>UR+;;CH:5)7K"QI2*_:>>>_P!]+R&N#B)"BJVW";=%P LBI_K?X6QD'9<
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MDBG@3*_<M9.8P;XD.?2D'+M%.1!QQUT4132'DD*Y%9S&CS3Z^+M!1K>!,V^
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M'-THW475GEGDWHQ3T!+"I.>J](<;=*RN;-:V15 &Y'(J=B>YED0CU7E\1_\
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M:,%A7I,?;K(5\LC8HAKGRD8Y7(B-1VI,;V!O6O@!L]EAA2BNHWG[!9 LV?\
M#QQNV.(<1"E<QNIR_=.+6JU<!N[(_HWE5+WC=(H:;<J2-VPXIGY:\G2W09AX
M[>+F#34N?0WK9#VOM&NI;$<S;D.[BSK+MP0Q&2#JUTR<\)=9(?*THT;!M+K>
MG'[%?2/MJT@[>A[AV[6/?8D 2>^LF[?GUTHISUC5<20R<D9$4?-=IU/36UN2
MIB@\\>;/DVN\U>;>U?(WFV'V+SAVK^\^^YO+]ZZ-.#!L86S+*/#HPR6AMX\Z
M7&C[7;>,3G@&9KQCW,UAEXY=F3-<2K"AE^CBOJ E*R'!W3N-L3<%F(#WCYK
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MP:[@N:+PQ9S20IB5<CT?MK_.'9S)#=)=;@<Z*R7HY"R>5F[1GJRXY8D[;O\
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MQXQ5_P":C_(8\8J_\U'^0QXQ5_YJ/\ACQBK_ ,U'^0QXQ5_YJ/\ (8\8J_\
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M:HB9[4K=W4][M3LM0Q8-U3DD6$>E=UN;0DMV,ERY9PE7--<5[>MFCDS=C<
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MC99N>1JS$42)J&0#&:,^+>/J_0:3_$OTM/\ I%LNZDJA#:DAP([>;.FO9WR
M%FU$8S/K$>K1MS1,\U1%>RBC0:*-G[V]PVV,_+U7DDM['Q3N(#AZJX4OZS&5
MR]*.@5+A_6"L!1-^LF&"W-7@LHW!'2Z]J1)S.G4]P7.6')7U&IR/JX'94TT4
MR,_JJK5R($N2*X,@3LB ,U')U7(BY+GT*GT)GWUO\YF&_6PGT _U'_B#83[9
M/W,)^RAOO;_YJXC?U</XMOT E5'5?.=K".@W,=DZ(![V <=V2H]KBC<7EJGV
M;/H5)_B7Z7G_ $A87L_B&"'6T2+I?).]4'&BC7)<GR#N1N?V.>:\$Q(N+B0I
MY4A<D3H#& BKRHL4>:H*.%%X)]=<W*JJP0F.(0CD8,8VJ][WN7)K6-;FYSG+
MW,1:'3V*6<SF&6:UX$A"$-\B5(E-<WF,'%BC<1W#/2W'G6DL[.1_PR3< 6TK
M 08MM709I(,XD P)TOD3(SPN-V8W76.J.SSS;@<Z(4G92JQEC#1?>Y8$7AFU
M>KS@YYC=P5%X9Z7.SC30$849PC*Q[%54<PC4>UR9HB]9J_06_?6_SF8;]1,)
M] 2-GESS-%GT9<QA&=.3O5]3&4*2XG=_.C(_\5"#COH?LF]SCOH?X;W..^A_
MAO<X[Z'^&]SCOH?X;W..^A_AO<X[Z'^&]SCOH?X;W..^A_AO<X[Z'^&]SCOH
M?X;W..^A_AO<X[Z'^&]SCOH?X;W..^A_AO<X[Z'^&]SCOH?X;W..^A_AO<X[
MZ'^&]SCOH?X;W..^A_AO<X[Z'^&]SCOH?X;W..^A_AO<X[Z'^&]SCOH?X;W.
M.^A_AO<X[Z'^&]SCOH?X;W..^A_AO<X[Z'^&]SCOH?X;W..^A_AO<X[Z'^&]
MSCOH?X;W..^A_AO<X[Z'^&]SCOH?X;W..^A_AO<X[Z'^&]SCOH?X;W..^A_A
MO<X[Z'^&]SCOH?X;W..^A_AO<X[Z'^&]SCOH?X;W..^A_AO<X[Z'^&]SCOH?
MX;W..^A_AO<X[Z'^&]SAS%=#R<BHN2F[O#^!@(W99C$-BY=&;6HU<NCAP^?F
M64M=,>$ AR9=\J,3@QOJO([@GKK@MG/<BF(P0T:WP8QB8C$8-OV+57-WVRK]
M"I/\2_2\_P"D-N4C'*@Y<F;8R43-,^Q,"",B_P ),YA%R]5J>MB+ AC4TN;(
M!$BA:J(I9$DC0A&BN5&HKR/1./##T\R.F2*(4\-J!Q8X2URJJP'D"0Y&QWRF
MD>K6MUIK9JR7+CC]:(&T)T(.WJAKREF!!(BV-?&>=LX\LD,Q8I1%CV"A(-AG
MF;'34NG)=$^+M^DG5QK(!H;R65ZMN"M@2B-).ATT7S=!2/VSEM:XI7&)R\T3
MBNKYCH#W.<V(4XFZG9]7@=J<>XUILD]9,(OT!OWUO\]F&_6PGT"+_7 ?[7[/
M&VO#<SLD4D9\XS'.U$EC0KGQ5RZKA"4C%7U"L];Z'1_XE^EY_P!(;6FY+H+$
MLHN?V*. :*5$Z."N23]?+UL0IXO"P9<:8/N>^1C,,SC]LS&]YUG8PJD6YWTE
MI42[,XX,6PA]@<^4Z')EN&$CQSY+^8Q':D16JJ=& ;J;O\M]LFTW!(C2JVGK
M=O3#!B2TGE;$K[63VX<D<9P$"YJJ/JYY*U<;A#MU-[1;.HVY:7XR6[Z;L:I7
M().6YL5QBO5Y3MX=7JY\<_F$2F<C&.1SG9B0F;].E5X^LW#??Q]'_HC,>''Y
M(S'AQ^2,QX<?DC,>''Y(S'AQ^2,QX<?DC,>''Y(S&3R!>GJ.A"<G^G'!8Z?4
M@!QP*+R,>/#C\D'CPX_)&8\./R1F/#C\D9CPX_)&8\./R1F/#C\D9CB82Y<4
M_,Q]/JX\./R1F/#C\D9CPX_)&8\./R1F/#C\D9CPX_)&8\./R1F/#C\D9CPX
M_)&8\./R1F/#C\D9CPX_)&8\./R1F/#C\D9CPX_)&8\./R1F/#C\D9CPX_)&
M8\./R1F/#C\D9CPX_)&8\./R1F/#C\D9CPX_)&8\./R1F/#C\D9CPX_)&8\.
M/R1F/#C\D9CPX_)&8 XBYO7/4J^KGQ^GI;PE1ME+1L."U.+V$D\Q%DY?8H$(
MB.:O1K:B8-)D/4AY!2',1>DA3/4A'KEDF;GNS^AT?^)_IBP^D#MB"4ME5D2R
M@,8F9#*-KF2(S<N*J>.]=*=TB-^93UJ[@.VAB2H@S +#@37CK6F'SP#/(AGF
MH-D9%1C6OZB<&Y8E4U-*0DEV^)]D, XA0#=!<LXO;45PQL09WS$RSR>KL^&-
MVDLY'9TLMCWU3"R$4JGL)CH2QH_O3'Z.9RG=9V3$[JX:QB:GO5&M3U57HQJ>
MS-$&O%4Z7+FKEXY]+EPB:$X)ZB8[QOL)CO&^PF.\;["8[QOL)CO&^PF.\;["
M8[QOL)CO&^PF.\;["8[QOL)CO&^PF.\;["8[QOL)CO&^PF.\;["8[QOL)CO&
M^PF.\;["8[QOL)CO&^PF.\;["8[QOL)CO&^PF.\;["8[QOL)CO&^PF.\;["8
M[QOL)CO&^PF.\;["8[QOL)CO&^PF.\;["8[QOL)CO&^PF.\;["8[QOL)CO&^
MPF.\;["8[QOL)CO&^PF.\;["8[QOL)CO&^PF.\;["8[QOL)CO&^PF.\;["89
M]L3^>OTZXQR,")F6HA'(QC=2HU,W+P3-RY8G6**O9=?9H#5SZL*/FT*Y.1%:
MIN)')W'/7Z)1_P")_IBP^D,L2=P[:$WF2'.-/K4R8TI79N))BKWC"D=Q<Q<D
M<O%%SX*^/+ :,<:Y/"<;Q$;]5CT1R?,T &XCOXJ='U5Z&I]7"'>/47-N2Z<V
MC17(G5U)Q<J=*_6^J,2Y:LN/!$_<3]DF?;E_&+].KM6"55/V@;[CJJB,&,<>
M7% UZ]5_,(1KER[U1Y?1:/\ Q/\ 3%A](JUR(J+ZN#O)$AD<T;G(I@(3CZJ9
MKP7$^,H@/:&;*$UKV9M1&'(U$1,^A$3 M08S6M^Q1CD1.CN:\(Q@QIT<6MR_
MUKBG+4V4^L*6WY1"5\R1#(0?8Y#N6]\8@W/9J3/+U<0XK)\ANZC7S=F/F-E&
M;-;/CSWJXBRM?:$,^ %J/(JYYOS]3%]:;EO-V/:#<;0+8U-FYU^$2MI.4&)+
MGFR&%3&Z[=66ESNZN-OB,EU:3+>%$=6U\2.EA>3!.$)&F.WFB$X[U?UNOF]^
M>G/)<7HQ3+D=.E'J%36+I<9L&9''2@E-)5&?RHTH4KFH[)O2JKGQQN&5"DGB
M2@PV.#)BF)'.)W:0)J&83FD8N2]Q<;,D6RVEK:7576LBPX0G65Q:25B1W'(U
MI"L4ST<5-2N?FJN[JKC<)H%9?,MMOQ^;)HYE7HM6J]W*&3LC)#D<(1%S*G,1
MS&(JY8G6^ZELQ=A+(DR;F5#Y=9,[1+*P$*H>-WYP8&2,Y36)I7$:I=!O:2;/
MC]JK&7U<D!MH#2Y_,@O:<[2M5C55%7)'=S/$ZRD9\BOAR9I]/%W)BA><FE/5
MT,P3=7Z[2MM@EEE>9ZJM66.-R@&(#3(=$EPU8QIPZ=3FG>J9N]9;,FX9JQ-P
M1)<$0+&LFJ.82&ZQ@M:\YX7)1IU1[V+I7KL[[BJY^CZ),L]U):V&WQG#&B3!
M?J_-7S>=YC7@2D[1)D]5RM<B+UD;B]@#JMS3)>WY4F/-# JAR]0X1S ESAO%
M,48H,=P>L\ZAX.3ATY1]QML=TP:N1/"'G;:,"OO R6J9CHIE.5!-&CFKK1'*
MCN"IFF*^N*&VM;6P AHM33P_.%F4'%.>X7,$S)>6[[+-=*Y)PQ9WR23Q(U*J
M,M8LT"AL(1GKH" L9KB9D.7J,TJY'/14SX+BOJ#5>XZ63;#YE6Z\JVPP3VN:
MKF+&(.3(UM(B=5V2,7U<>E))\Z?+@U$@!(L0LDIQ1 L6R>1D(!B\D&MHDX-T
MHN28#=5PI88IR'&P<U@1R$6.5PGZF@/('DKF\.MT8VAM.JFR8$G<5NQTV5"D
M%C2@U<-XE.UA@/&4?/YBKP7CRE3NX/2_K]-V76-I(TI)"VAXT'GHB)RD$MI6
M@YQ]6>>K-=/=Q<[67=K]ZU+:<T\=MSRR>1($D?)1R"GEJC4YVAS6&>/4J*BY
MYI@I-Q)NJ](*U*LNS9'D6@*R,=L,41LZQF26-"TA=6AB.<OK<4SI[#\^L_U@
M03J6#4Q5E6-BTK!DS!%>\/>-,W4CE145<NGABY5S;&F-0!=)MH=Y#[%+B1V(
MY7F>(9)"9-T\6YZ_6XIB"A*_<=? LY*Q*^[L:I 4TLR%4.09C9)55-:+FNGJ
M9+JTY8\T=DN;NU0':SU]!7^<),.+EJ21*12@&-BIQ[Y7(BHJHB*BX':TY^?$
M(YXUU,<,H3#RY@#"=UF$9FGU45%3@N*L$"_?0[9&-[[9]7+-$OY,C,BC9&*V
M(08PMT,3/FIW[\VNR:B[VHYMS)O:?;1T?"N9K^T26@1TIIA2):9]JR0'!W\1
MV7!41*V>+<\BG!;WMI;W4N3-D^<HU&LAP11:J4]A&0AB%'<]K4Y0TS1R*B9H
MN]:!E[:7NV(FN+4[CDR2&G,.='L(R/;CY;Y#V-?J:]CNKH:YFE')B;77!R2;
M;;EK*J)<DQ"&-)8QRN"8Q2=9Y$74/->*H-%7BN*G>M),L"1*@S!7M(V;)2NE
M07N5&R7PT)V?-O,4;WZ%5-3'_89X@AV]9V4':.WHL:?;28,J3 =8R9;6G' .
MH"#<K5T<I6.[WEF7/HP3(%X:I!+["?<L>J>;;X9'\!TQI><[UM(G:D7-,TXX
MKHB@L[BPM1.D0:V@AI8SCQF-U+):+FB;R=**J+GQ1JY="XNKX(K-C-O9I:UI
MXH@VL9=3FM:H'2>SYD5CLO??L51<E3$JU?!OX%1%@]M\[3ZQ!5\E_/CQ5KX1
MAR#+*GMDR-"M8BL16NZV7'%?6$KMPTI[<:%J7WE8V%'LV.9S&+#,.3(:1I&]
MZ[@UV:(BYKB0D1PF2U 5(KSHK@LD*QW)<5K>LX329:D3CEC:H_URL-P[OM+3
MEW&W63'3:?S>1[51XJY0A6 /D?=%8S[)S-*,5?F;AAWN]]R[8HZV/%AP1T,V
MRC*:P8..LC6.)&GB1K2.-J<HVY]7CB*B[K!.1T&9+JY^X;N*>;;9N+(8O:'O
MC.FM8\J#30F:-R;TXKB6-A1AW#+=-1]/#E#'(TQCR-"CKSRY$WC$#S%Z>''H
M^:S[<OXQ?IP]C*<S4C#,AA>[1VJ8V.8X8^?2G-4.6?'+$B9)>I)$HQ)!B+TN
M*5ZO>OME^BT7^)_IBP^?1_)D'S=ITQQ\UZ<%74K<TZO#'R=:^2?TF/DZU\D_
MI,?)UKY)_28^3K7R3^DQ\G6ODG])CY.M?)/Z3'R=:^2?TF/DZU\D_I,?)UKY
M)_28^3K7R3^DP9G8;%FH;FZR1=+&YITO=K7)J8MO^9SO]Z-AOU/F;:%_XW<8
MA\<T3KQC-Z4X]W$FA<O_  @-G8[PY6E58LBRJ0^_Y+GWLQ[&]Q."^MC=7_>J
M/_/VYCT=[QM1G7;R;3A5A9S /D,KI*P98^NT3'O:W\^:Y/LG(K]*+IRQNF;7
M=HB G;9(.+(* T:0J("DCCGH G*,QI=/,'GI<K-*\,\;LFVF^K?<T<M&L5D"
M>DQ B,^RKBMEM[1;SV<QC .9WB+D]>/J^C&(&R-M^@LJ2"VWOHU>D\\?3#CH
M@&(X9N4[EKJ32WF+TMSTJB[\".3:SB66VY!(4FY"\-C9C=V=B2^4085:$SR(
MH6Y)D)6IW,/V]5I)-=[:N76EQ5MC24D,AO/8"3@HT:9S'&UN8U5<WEKFB8VT
M^!>>DS<5E6O%8_G\D,JNH"#5ABQ[,\V''4(3+'1CNSJY"Y(U%SRQ:5;G\MME
M738"O_@),C$CJ_\ D\S'ZH;JH;=MC4DEC@$BM"^/.$60:2Q5-(,#(7-/DUXT
M*BCRX9IDMQ9WU.RF,:;7=DCISVO+#\YP.7(>&0WF!UN5=.:]=$U9(BICT1?]
MU?\ ^E3L>FA<DS\]26Y^MVW<V:?47'__ %__ &>(>ZKL9V;?L=NC@LLQ1CR0
M0I+0C&HSH$9",<JAZ&HJJA?MLMS7NS]N'JUBV/O5D^"%P9X9<LJR;H4?E,4Q
MT&K2E4C'M8XO65^3L>CRT7<-WN)CK"**5964%\"MC3SF#JKJ\?($)"#,_P!]
MTJYN2LXY-QZ7)1$<HXTN,=Z,R5ZL"MH1R-15:BN5&\.*8#=5PI88IR'&P<U@
M1R$6.5PGZF@/('DKF\.MT8]'$LJ?FYA6$,;G=ZLC0=F2?QD=-'[.)-==Q.VP
M_P!6 R.3SY,?WX7*1C^9$, O!'KPSRQ-;0U88':!.YY$>>0<J-:]6M?(E%.=
M6-5W!NK),;OR1.,NR5?77DU:9KZJY)CT:1 V1MOT%E7:;>^C5Z3SQ]+LD Q'
M#-RG<M=2:6\Q>EN>E47T@!F#O[^+9;;,5!S **]O(*DBM,>,$ZPLE,TFJ.W-
MCD'I1O%,5X_1MNO=,J>6:@?U(M:L[UC:R/Y[IF2I49ZF-:[ELU];/6W)<KZ?
MNBYW3MJKN8P#U]UMN1) V05H(Z+7R# B2GD0?)<B,RZJM15ZJYXDRJ86YQ0[
M2>^7_P"M/84F'?RAC=, V$GBY]/?/ZSU;GT9*L3:M9*2#*M@H6RLEYWYC6E*
MZ.UK.SC*9''4;U>K$4C1MZK55Z9;DJ-HVKK6Q)#&"PD=@GQ#S9=R0=9J8DR*
M%$&T3W<L;5<K&M[KE5R[7KI%$:RH4B J;BP$[6RK&&/'"\TJ(R*=);)**1SN
M+$72O2JHF-QVVU(Q86Q2P1B;HCFA5DVS1(B<R%#*,31O8]A>]:FAO3EK1,>D
MNT'GV.=NR0R/_!S#*LI#\EZ,^5.'BQ 8;2A- EC*,B(YA!O 1KV/:O!6N:N+
M,4=!BE6$NW!SN]52.B" %Q'HBNR'G];!]N;ILO2-%N6SWQR;-I7YQIR*=KQ'
MBP#Q'P2Y/9J=K(BN<S4Q%X8VMM=UQ;;2VBW;L,?G?S:"RM"28XGL'$DGBA.Q
MD@'9AL>D=/LE5<V.14]-(U?8:RCA21>>,TMS1GR[1XY,]'M8YTH@SL<5V7%S
M\^[BJ!:5EM9USJ2 60"C8$EF+K-/VV,PQ0M58QNN[ONKGFU6ZL;:KMB;NO=S
M5<J3'':4EE6RVAI*Q'AYZ$+)58PW-&0BZH[6-:X?2[-$69)B1%GRH\4YH\%I
M$"Z880W/'&:56$0;C.32BY+TXIDV_1RZ_P!)7G8/-$"-('9U08Z%&KI5JV+%
MYT;B-4U9<I,U=IRXMLXOI N*0'*AM?5P6S>R<P V-.]O)N(0OSEZ*J^]=W&]
M*6^VFVEG3 R 0S@AI,?O%"(8<<CB@KPIK>A!N;S"$1JO5%<CFY+5AW34$-;1
M06QJJ.:7-AE@LGE>< B##*C#:\I&H323/3JR7)<TQ5VUQ3=DW=%=8<P_G$Q]
M##DE1Q^]19QJQVJO*B<&KT_POFM[-V#E:GY<_M',SU+GGR^KTX_NK^UX_NK^
MUX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^
MUX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX_NK^
MUX_NK^UX_NK^UX_NK^UX_NK^UX_NK^UX$-.4D&L64*-R4>@SO>94=+Z[E<J%
M")FG/++Z_P!&HO\ $_TS8?24G[R_]S%M_P SG?[T;#?J?2];RYOFVQI[6+;5
ML_L_:^2>,]'*Q\?M$7F#+DGV:<41?HD@<8R1I! %8"0X7/;',YCD$9P=8^<@
MGJBZ=3=666:8C4L<RRG#>8\J8X?)=,E'?J>9PN87EY-TL1-2]5J<57C](,^W
M+^,7Z;CTT NF=:CD+*5%ZP:UP2Q5Z%1["2"DZCO^J=]'HO\ $_TS8?24G[R_
M]S%M_P SG?[T;#?J?,B-_6'<]#V13+GMJV\UND\Y!<):\@_.07*ZG1IU+ZN+
MN?#W5N^VVM0/+31_/M^6R%;W6G3.,P;1BBN@P6OR8N2JK\G([N);V<6+82I(
M84A(_FZ*V86,=X"(*<<3G(U(4,F3S.7-&L15R7&RY5K<>E)]I>SI#1!N9K6T
M<Z0"F%,.8<<Q%+(VZ1LO\V<W-7$9FJ)EBPC-AW\^'5&[+8WM?5]HHH4K/1V>
M18<]B#=S>IJTZ,_LLN.-H"!&LFNWI&M)57S0Q40 ZD':)"3]$QZB>]G><OFY
MKTY8OZD@)ZR-N42[@FO8*.H2PT&I>7%<LIKWR=+>AS6-_C8F7#H&X(%+#@BF
M>>+"KY%=,(5X@^;JX[)!>VV+9).4K&)IUM7)RIQQ&J25FXZ&9/$XU8FXJE:T
M=HQC>8JP"H8[2^](KDSTYHG#$^S.TCP5T*5.,T*-<5PH@'G(T2/>-BD5@^&;
MD3/NX@E-&W!"JY[&<N^EU+F4HY3HW:7U[Y@S%5\T'>/032-1_P!DJ<<$I60;
MVIL.R><(H;VM\W+8P=>CM<#,Q'%"N>::D:JMXY<%R]$1*6WW.:LM+R^$=]]/
MYEK8B ^8U1V[HI5CRQA.Q>4BZD:-&]W%A!%5;FN6U!>3<6-)3.G5E29O$HYT
MKG"T. B+KTH[+)>ZF6*<T4=GN(M^!\JI@[<@K93Y403$>:2D97@48PHO6U*C
MD5%3+JNRO;G;T:[CVD&0M0>-(JV)8[?GN8K^T6\0KR,C1A-3+F==J$5$Z<\M
MM2K.!N-]O< &")2I6<W<%B6,-HSS10N>FN+)>FL;U>G,:]%1.G+<%@T%K$D;
M7BGEW%)8PFP[N,( "'7\T(?E*YZ"5$]\X.[[+-,5J+7;EAP+60&)$O)U0@*1
MTPV2)&6=VE_OC"+I<J-5B*F>>GC@E,.KW%N"SC '*G1=MU2V;ZX!D1P23EYP
M&A0K5S3BJY*F?2F 6U2?GQ#ZF]9JC,$PUTFC20NR>&0%Z9.:OU4S147$2HFQ
M+B9/GPW2X(*J$R:26Y)"1F0HXNT#,2:5_%K=.G).+DQ<V#W3*?\ 5[Y;AWD5
M8,^L32YS5D1D<;PFA4:C5<Y7)EEGB!!)5[FIV6Y>13V-U3/A5EJ9R^]"A2D,
M;6XV::=2-SS3NKB1MB+3;EL;*'8"@3%KJT,F+$:;D96$HZ3$[/7-61DI'HBI
MI7AB=?6 Y)HE>T+C#AL$22Y#2 QF\MAC1Q+D\R9YO3AB%6)%O8([4KPTEM95
M;H=/=D8NE$K);BJXW-7O=3&9JJ)TJB8/MN)3[DG3H=MYIG&AUC)$&OS<)K;"
M=)9+RC5KE(O7<FOWMW5Z,Y.B#N294PY/9)>Y8-.Z1MV.9':'ZYZ&1[FM=W6C
M=JSZN:8JP,#:7TZYC)-KJW;D+SG.D0%;K2<T7-"WLSFIP75QR7+H7'I/W,>1
M;S*"K_5<\:O=K[1 YE:X,Z+'@3#A!$D-G(J&:CFHKVJN:].-O3I 9KQ;EM*B
MI@M",#B"D7(WDBOEH^0-K L1G75BO5.XBXE5"0+Z[F5\=)=JE!6><!U$=6Z^
M;8D4X&@8T:ZG=.E%XXV#YBB[AL*&S;939/FVI0R7C7P'!C1X/,<PQB4TASB3
M!]3E<%7/)/I%GVY?QB_34ZVF+[Q! XSD3+41W!H@LSX<PYG-8WUW8-:V3VNE
M':)B\MN@3&A$T3&C'FNA,FYK_&55^CT/^*?IFQ^DI/WE_P"YBV_YG._WHV&_
M4^9N&U$ND\.JEOC.3AIE/$HHKN''A(>W%-60C]DEEI6'6;R6'<*SL@+*++<)
M^39*BER,T1W?(U$7&[S;@WM^LT5^U+P8H?ZMUE-R9'82N23VB$5Y"9#:YNA>
M'6S[F/\ ]/G]0?\ ^ZT7&X=B[@B31[G!Y_C#@)7R"^?_ #J^4L>:(XQNC+'<
M$Z:W/<GO3.KJZ,>A'=-DR2VCJH6XXEE-!&-(;"=;14C0R':)KG<MSLUX9N5&
MKDBKPQZ4;6 .2D"1Z-9"0C2HY(KI@ QS![8(!FL,V.4C':-:-<J)GEC9ZUX9
MA?-;-O7$L58NBQ=# (G:R05TORE"[1S47)<M.?<QMU*S=GI2W;.@3@V:1[&6
MLFNI"QO?.;<.LZ^&P(W<1KV=[W.XM3I3/='_ '=N_P!&R<>C$;1M1CK/8SW-
MRZJN/&<0RJG_ %CR*J_5QM'_ +K7GXU<>@K_ +P;I_WNSQ?5&[MX>D7:MH*Y
ML)$*'MZ;.!574:23F1Y=:,%9):IY*\'*1S$SRX]\C=F=K+Z1-HM##M'4VZGC
M8DZK2?*D2W5]YYG4AAODN+F(;!(O+?DKT7F9>DJ,^SG[JHX4..W;]]+JB5TR
MP3K2;-$ J//(!$1J>^$76B>HBZ6;(WV3M,S:R;._5*59 A2BLI+F*9I3DD Y
M7:&HYN8]36+K;GIU8])F\:B-(9MX7HVLMOBL3QRQ66\Y&DF+) ,S6$>P(&:,
MW(CFIIS1,\;%1K4:G_J(N341$S=&CN<N2=USESQNU=V[HWMM&)<S V=/8[9E
MS8U79">+(@)/9*Z:5\Z&JZ>C)$S_ (NJ7)JEW2^+:W,VR61NY8_G.<8K(XBS
MQ\AK'.BRU!J:XJ(5[LW+P5,;:MK01W00;6LFR)((Y92US#35%VX@@(XO(9JT
M/5K7*B/Z,>DG<.V(<M];-IZ*MK"$C&C&ORU%C&L)9X(2L:0C4CQ%8S-$>Y5:
MW+/-$IZYFZ_2]?V9)T1Y-N'G++\V2HY47G6/G"MC5[(\-S<W$:15:WCPQZ5G
M9<5NZ=%7UD@R,D^MJQN;[S7_ *7K\;4VKMN'/9<0-PTUC:12U\J*S:T6G<Y)
M/:S%&,;7CU:!\M7([HS1<D7TO $3DED;A(!AT[X3B0C,83AQ][<_/!M@VD&S
M%NZ-7VU(W;[*R28EA)G/FM":*80W1BQ#]HU*[4BKQTH[AG066[VR0ULW8D&D
M=9BCR)PJFSC3.VDK979V%*-KFN1&Z&JCGIP3)%<GIRD55;*$MD';LN'"(!PI
M9P-@EDMD=GRU\RPCCY[6]\[F>JN/1G65#9QR5F\=EK;&)"DQH]=)CZHC8)C&
M&P1)9WO<YJ#5Z:1JN/2 +=C)D5FX+$=Q3RV09$P-K'<,J)!"\ R>_C<30B/T
ML1<\U;W?1#N6RV^/9-,*3N]7U\<#B"@,L8 0PGF#"KHO)+8$=S-""SR7->[E
M](,^W+^,7Z:=M^&=[8%8SDS6L?[U+FD<&01KT:O7;#4;&\>+2([Z0H?\4_3-
MC])2?O+_ -S%M_S.=_O1L-^I\]80 ^DN['061I#CUTFNC6-@R/)7WV&"^E25
MG!!HZK41,D;GPXKG!JX3.7$KXH(<=J\7(*.-HV:W9)J(Y&YN7NKQ^D*W=?;=
M/F^GEU/8.S:N;VHZ&[1VKGIHT99:>6N?J_.6>WNV=@\XL SM?9^U<GD2X\K/
MD<Z/S-7(R[].G#6^HB)["?3#/MR_C%^F988YVMMY[&1(C.EXARN:TLO+--*,
M $FAW<)E@IS/4AC$>4I'=\\A'*][W>NYR_2%#_BGZ:L?I*3]Y?\ N8MO^9SO
M]Z-AOU/F4\FIE=E-*W12UQW\F.?7#ED*D@.F2(S6\Q&IUD1')W%Q(@75V.%,
MBMC/-'=$L#$TRVN>!1I'B&YZ*UO'1JT?999X=N6/;Q'48V.>6P<YP1AT*C7,
M,PS1F"?4Y$Y;FH15<B9<4Q,\RW09CJ\#I,H79YL8[([._.P$N, QQ,[JC:Y$
M543NI@L:MO G+'KGVTA71I\8,>O&@U))D2944,8"#0K=2/<CDSZ,+5T]]'E3
M\G*V.X$V(IM&>KLSIL:..4J(F>0U<NGCT8=6W-\&-.8U'$C#BSYKPZD1S4/V
M")*0#W-<BZ79+DN>(NX)MU$'43M/8YC.8=)2N1SM  QQED$(W0NIJ-U,5%1<
MEQ>6NW]SAC"KXAE/;-KCRC4[N6]S)9:>4 <@[6Z%5K59D32N6>*T5[N,?:3T
M<.V;))7S K8Q"Z ).%'CQ2-824;-W9V^^-3/JZ45<2+>HMHTJNA\SM<EW,BI
M$Y(^:1TH<L8"QVM%ULWM1,N.$%%W$$Q%F1H#1I#LT>^3++R(Z#8Z$UQ!/+PY
MJ9B;FF;DS3!G<SDZ1$=S=/,Y63%7F:/L]'3EW<;?EWV[AV/G<%@^)>%J)-6R
MT\WO>^2_L(8RL@N"Q48UCM*E<G5S<N6)A:.YCRV0&\R9K')A.CBR<O.(.>&,
M1 9,7KY:4]7 ZBMW#&D6!7J,(5CSH[#D3/J DR8H8IGNRZJ->NKN8W?"EV 1
M5E.!DBJ4<"QYAH=;%E2+^8=>S.?K 1$1&9-S:U-#7+FJRWBOFD9!=$;*>ROM
MG,$Z<1 Q6ZD@9.<\KM*HW/2N>K+)<55?.E<F9=G+&K \F03M)@,0I6<P0GB#
MI8[I(K4P\$S<( &'82ZL@G1+%2#F02-#*:1K(;E& 979<Y?>79+I<N2Y,VX+
M<$(EN4C0C -#O"\STS8!D]H5KW'=T(SFZE=U<L^&&0+R[!"F/8TG9T!,EE8Q
M_>.,V%&D]G1V7#7IX8KKJ9<1AU5J<<>!/:ACQC%*(QF(I(XRH%NB._4Y^EK5
M;DJHN+%]7>"E)4PSV$]O99X2BA1FZCR6!D11&DB$G3RD?TIZJ8MN:<"V$*QD
M.2+'C20C!4$?HK'\PS-)7F03E=UE=GTHU,DP.7?V8:X!GJ,.MI2E,]J:G(&/
M&&:070G3I:N6:9].+*QJ;D4N+41WRK)4CS1&BQQC*5QG1#QA2W,T!=EI8N>7
M#$6OC[DBOE3>S]G:L:P&)SI36N"-\DL1D4!5UHBL>]KFNZJHB\,1X]_< @'E
M)J"#E2I)E9GIYKQPP2'A"KDR1[]+55%X\,;M.><.?%A;QM*^H,)D9HDJ! A%
MAL&^,,:2&9'54>[4]V?3]*L^W+^,7Z8FV<MVF-!C%DE7AFK1,5VAF>69"*FE
MJ=URY8G6F;^S:NS5XW_<H %5 )E]BI%52.3N/>OTC0?XI^FK'Z2D_>7_ +F+
M;_F<[_>C8;]3YFWO^^VW/QI\;JD$"-YHVV:?LY7L1SP<Y!,*HG+Q&I&<%5.Y
MPQNW*/\ \&K/3I)/:1P!]X#2A00BM4(VZ61T>\:999=&(7F827-^FV+A(UG1
M%1\"HJFP#YAM^1-" ;7Z] QO$5XWJG!BJW$1M8)6ZFLG679QHXI8S+Y[YAGL
M33VCEC&BN1R^#9ET)C: S^F2IMNSVU>>AK*S9=6*<$X7CY<;33'[;4!>--+T
M*C!9)UDZO#>+(=UL78L*!<S*VT%)JAS=S7[0Y +9D@D8T=OS=;^2U$XYJA%R
MZV-@EF;J3:=Q7WE\7;=E(@]JK4EI.*0@9ZO$L&,U=351QWM1$SX.3ACTEU%@
M3:E_*%LPTZ1O':\<+5FKI0 (-I*CA$"3(0;E<U&=4>A4X_8[ 60$9EB^BB!*
MC\QJ/Y,AA^6PS,^@C&E7)>YGCT\ K0KPG[3E2 1V+K=$:G;+-S$'T*X37O(O
M\'5CT=Q]OR:R3,'NF@=!# 47/K:QI40X)0Q]>&U2.&G*?DY7)GEP7$W^J2/Q
M+\>@&/*".0!TG=+W"*U'C<X*\X>IB\':2C1?K8WDRPYD>NE^BTGG4L01'R.S
MDF)'DR&, $Y2''$3ADQ[NJG!<;7'7;GV;Z1J$%G6QJ.CDUT8>Z:[G&9RI$&,
MP3ID*='7-$*9V:<.KQ1$]/\ "+)CCF2J<98T0AALDR!@VQ.4Q  <Y"&8%'MU
M*U%TYIGTXVVX =$>+!V;.D<IG!C2+"+)D.:G%5)(D:G>JYV>/1>*DM(EJL>T
MGR9#X)$D"CLEP6I'8<K,QBD$Y+_>E7F-T]9$X8]-<ET8+SGO_2$TI7C:]SFP
MXKS16YN1>$<[E>WU'KGCT3O!&")Z7NQI*/:QJ/0\T:&EE1_?(^01V;O5QZ0
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M9KZV-$FT)#C]?\TJ]4$"H34CFD4;^>=FAVG(CW)EZ^:_2E!_BOZ;LOGT9SI
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M=DO?JJ-[N:2K6S.LB9+)K*]>A.&E@QMZ&"$Q$:UO<:G[#[>_Q;].6?S)%=/
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M,./53=$(;S#W'&*YI2MC)X-K456%SSQZ3;+<5M(\VTN^+D+"S9$B2R#"&0;
M1(HW*5PQ:WHT8AIWRY(F*^',J-TT([8C0U5C?TJU]98D+DH&QI?/-JYZ.;I5
M41.LF)5/'J=S;BFUXQDLV[;J%LAUG-;S!MFE4\=HW.'QX:D3N\<TQMFQVJZZ
M)&N+N'VB;7PN]!%,O;*(Y'.::);RBHB,$W)2M8[)VA>M4+)K[\EM=QQR8>V(
MM6IMQM$_-%637\YK([AO32J*3-7(NG/)<K^:,5G$E;9B29MQ26,-(5W&#%CD
MD._-"FY;G.0:M3WS)'<'*W-,19OFS=+:>0Z.(E^M*OF6%).QKGQ)4Q)*YR8K
METD032IJ3JJY..( SMG6DZTZU;5447SE931)EF<(&/8SD\4R<KDU=S/CBU5[
M;&DETD=\RUJ[^$ZNLH4$8^:LTD;4;5&T)TM<Y4[J)FW.$IJG=5;5V,AD:#N&
MRI%C4,DI7*P/+G)((NDKD7)58B)DN>67S2?6_G)AOVJ?N?0INUMM27^<N<L2
MTL@JG+B@0;'&CPS,<N<DCB<I[ND6AZ=]DJ$,9[RE*]Q"E(Y7D(1ZJY[WO<JN
M<][ES55Z?V-VY_B_Z>M/G++[U_V@L-^]L_<^;Z4Z14S=8;.J! STY-EM#%+#
M>NKA[W+&Q?K8MK^:(C4VCZ/S[<:TRO5SK^7".ZYFMX9<SD1F,=G_  \>@/\
MYM,_[3&ZZ7=-G$I[B%N6XGS16#^4:='E\DD>9%U=>Q[0).J@]9%3+ADJ8_\
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M1D_Z.$S/8J[N^_1M*_R4B:D]G'>2?*%_>QEV%7?QEE2\_P#HG1N-+:R"J?\
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M?L?M[_%OTY9_3\+[X;\0_P"A;HAH_EK(JY8]:IJTYQR\=.:9XZUME]2#G_\
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MEO\ O(:$CD_/V0=O;9,UI@\F')$L-L?DR!(CD,PS'<MSLW*C\YB3)!9/8-W
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M3EPTY='TE*\Y]E\W\@G;>W<KL?9M*\WM7:/>>1H[[5PRQ_\ +C_V9Q_\N/\
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M 26\_;Y7">G)@7D=46S#X=A%8'9QI".B4IIBU&TYD!;&U"*V0KMQ-Q</LO\
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MS8;XLRF/J#%6C6*]J#2!.N@7*MV[$$%8 G88Q>JR;XWZ261!0CL*NN9I@8/
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M@/1\C];%=67(#PIYO;"!\38J90-9O_MY_P#;S_[>?_;S_P"WG_V\_P#MY_\
M;S_[>?\ V\_^WG_V\_\ MY_]O/\ [>?_ &\_^WG_ -O/_MY_]O/_ +>?_;S_
M .WG_P!O/_MY_P#;S_[>?_;S_P"WG_V\_P#MY_\ ;S_[>?\ V\_^WG_V\_\
MMY_]O/\ [>?_ &\_^WG_ -O/_MY_]O/_ +>?_;S_ .WG_P!O/_MY_P#;S_[>
M>@F*# J;;WBM)CM2XD2G31^M8*+VJ0]D/J67YLP<+H)0.5=?Y0 _;580-WR.
MY4$):!\K0NW484"[<GW**L6<AI.)#O6[/(KR0PS@"_-Q\@@P<UCX/;V0P (M
M9!<$.F>9 ?V2OJO/PGH^1_\ "]58Z=!Z:R[>YQ?;+[9?;+[9?;+[9?;+[9?;
M+[?P=Z]4/-,DIQRZ:&V47T2UI+H89P*@:^,DH40.#C,DAD%:>!P$DX609$KE
MT[9!<GS,H:%<DCW,U*$3_KGI'\YZ1_.>D?SGI'\YZ1_.>D?SGI'\Y_S6B%F?
M9^/]&'"?L>>DOSGI'\YZ1_.>D?SGI'\YZ1_.>D?SC%L!1(.!729Z1_.>D?SG
MI'\YZ1_.>D?SGI'\YZ1_.>D?SGI'\YZ1_.>D?SGI'\YZ1_.>D?SGI'\YZ1_.
M>D?SGI'\YZ1_.>D?SGI'\YZ1_.>D?SGI'\YZ1_.>D?SGI'\YZ1_.>D?SGK'\
MXTLS8JWZKJ_SI'BP"(;5@"V.<A<?_K2X10F\N7+ERY<N7+E_@P/F,*3G#.KQ
M?P*@J$& !BD32#-$(M'(6VJ9IBXG*(R*I=/29HQ(H(\K@W WFE<RS5!X!C.F
M<2L/4?XRJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJK]%5553)[3
MD(/8_P";]6#&H72%'EQ)X"-''L>N\-E<KE<KE<KE<KE<KE?X+ "O]YNBS\-2
MB#:(DK"B5BW_ .7-_ HWS5"N%XSN@S4PBY7SF%P\::K@^$'7?G&C_(O#[/\
M.@D84PTF7(7M*5,OOE]\OOE]\OOE]\OOE]\OOE]\OOE]_P"%4"0$04WDB:H
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MQ0R;4',K,614PIWHH!,@ $AI,H/Z1J>!VE69V5-O5LX!U-R'%L/Z.;$(Z<9
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MH;PU*DE0QW644U_,>'V<4U&,!*2%/X?KUZ]>O7KUZ]>O7KUZ]>O0Y@0 !5&
M#(CT-E@Y]#/L I#1\6.>X!37B-],!TNTUTVEXI+ERY<N7+ERY<N7+ERY<N7+
M^P1Q['CUSQO=.X?MZUK6M:UK7OSX7/>4/@ ^T?!)IKR"DH*EB\Y&? 83U0L6
M-9G)PVE/&D;-/$;\PCF+UWD+=J*?T@00 ".3A>7L!I'T61B5/6ZM%F5*%B,
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M>WB T=1@KEM$K*DTO1'PR91.UHO2Y(747!V7=Z,CK!T&; K%T/5*;A#)6OT
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MXST'^,]!_C/0?XST'^,]!_C/0?XST'^,]!_C/0?XST'^,]!_C/0?XPW)UR(
M@W,<L/?_ $8@*?3VST'^,]!_C/0?XST'^,]!_C/0?XST'^,Z>52[4MPST'^,
M]!_C/0?XST'^,]!_C/0?XST'^,]!_C/0?XST'^,]!_C/0?XST'^,]!_C/0?X
MST'^,3%9?@Y'Q'0&'P26W81I;P:!7+ERY<N'DY@1&IYZ5YX,>#MI)U_LQFWE
MR0D6_N@I\L6YXTP#'JX_ICNQ@X]C_0X%XZ05FTW\WFWC#1Q7%<<B[OG>0-2T
MT3)2\9C)]Y<.#:KP?%$S""@H#8CFQ"NAU=UPR,-6:PZ/>@2]$ <UKQBQ$2%!
MKV6IT@TS1_FONFBM0E<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7_ RY
MCAT?/^1UF0&578+84%UG)>!3^;P!-*&S.;00)L9XQK A>78#Y.J]EP@-1OD3
MAZ+VN:P7=*".Z"<>KEPW72'ZOUPP/R::<[45PX2(8)1$0W/)_  R[%XBA*B-
M'""UUL!*&TZU@!#6.$.A2&C-.MITZN.F6==?%*NDI"G!((&"8*$8(B(Y3*93
M*93*93*93*93*93*93*93*93*93*93*93(SH-4BAR(WMXPHB9W.^R+$KLA'5
MFH$+U%]L<X1L 4NAP=#_  !8?TS@?NNH=49;RJ&[N+H<:;@#;(2LRUK.Q>N.
M7;@WG8!O82\;.&U'2JG:*#NL\ZP%X-+3DMBKJ?/>N<K2OE9%T333NY30<0'Q
M7Y#%>4H;<*TQJHWNY8&N_L^$:I.D>[#D JQ=CIX5=F.WG:J#1FCGMFB3AJ8X
M*K"_R^*@]>UV3;C B?\ NEC>D2(&4$)![/\ 7%(@%B*QD4HO948OH?H=\-CV
M8]AG+Q4%$RY<N7+ERY<N7+ERY<N/G]$-"T@]!YX<Z,'6$U>"?R'*HT#?6E6B
M=7)TZX3MW5M^>G+ NV;4NQOO@/ADG2<:7KJ";_PD"[\7^OV:ZU &@!>]$<)E
MV1!)%V)!ULPVH"0'KLWWNIBI8[" T(S1T0>=XKMO$>#C:*-5QRY>M)K)&PP)
M>?\ %^)XSL]>9M4TWDVC*)9;L5P $=,J2G1</H7X"\]<,UWGD'JV>P7>G/IG
MTSZ9],^F?3..<]>F&PVY-/M :7A'5]V0('6#\\$+ 3W\ZCRD$O!SF/4KG6\S
MY):H16UT?P8+-8[MW9X =7R?R$$$$$$$$$$$$$$$$$$$$$$$+2T;?&TDNKG/
MY,X?YJN72-[+USXV/(F,1@=Z2)UEYDURVF%B6E;;YP.QH;^>EDC0<[X,/J1$
M*7$';2$ 6], \TY0%[*&GESG=NEWMT*FNI@T]K:^[*O?/'0_Q\!<_P!,]'T_
MQ]<Q6B.'*/I<41]07\@-<R8I-O-'QS='%2D=96YK^GR9@G9V0W1W^G.J)2CP
M<>ZO;!1,FY=\A!R$<GEJ^-$R](MBOQ(WRS2'@NB .:ZWO?7"Q# ZI8$*<YV[
M7E_R\ ?GZ\YP>NO^#KABQ(B-XB0W +7PG=--Y816>G7?)7C#BD,]M#2^Z.(D
M\=YKJH_:YQQVC\]*?"5U[]-/;SP>V=JX+CV7.5 !,$0#Z<:/6X%,!A;/O4>+
M,!>!!&N-$ZR!.T G;('+_P"#@ #KZZ9P>NO\:O\ .E;##07ES9"_9[U^F%ZH
MBTKV*^5 R3&3#M^9[K6"THY(^%=,*UIU%]G9>^+./0RT6I$?#BSHG(+7;KDF
MOOEL](\'RHS#A=T]>[@J,#2D^ 7@)B:"%XA$K ='I@H0P2'1A$X$-?\ Q\$#
MA]/RYP/V# DS3:H+,XIECD=2?ZM/I@+MOA"_.!]\,V&N8^=<K. '?]"$^^+'
MMD;OK9@D7^0]=TPR^C0^<2;W,(C??/JF0J<]9=FE.-=!^1BQ%3LSPZ*APM'M
M&962L[77_P Y @.O73_Z1M 2H7(0>^AE;6<Z#WT,$LZ5.4TPH=ASH2'PLZUE
MT:Z:RX</7T)KQB0Y_?)T?DM6(NS1GO&_0RSX-B_?. =CE7SC?6Y/%#20>"7S
M;@8?^E1K['%*[W1^N#WSN#ET"F#CY??_ .=;0'9 \.T8 *KD]Y4* O5GI\K&
M(XLC;H?6 PN:[NH>]8"O#NP1H;H^Z^"VOSQ_-)]O:H_L6+(5M,(VB/!@/WO3
M._.GW/\ YEM!;R2TT9P!V;@J$$R@8=Q6<D"\1SFSJ-]Y+1;CYUPQQ(>RB#7K
M0Z=,JM=1;-ES757><S2=/'&J^N&E1UX]_P"IS>[.#GULW*2CT[_UST%]V\5T
MJ=G][K5JU:M6K5JU:M6K6V\E&T)-'&<S]EW@RD>H6SHH=/\ #2)$B1(D2)$B
M1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2/\'(D2)$B1(D2)$B1(D2)$B1(D2)
M$B1(D2)$B1(D2)$AHMU/O;B,LH\_K,G 1,@$0$+Y_D>O7KUZ]>O7KUZ]>O7K
MUZ]>O7KUZ*ALW2."F&&?3_['NA"2%CQ2@&KA^SLOK3RSXK_\7-;$DMS:BT4/
MA]:U\@)Z>S0327IZ7_7]'7=KC/37O"3>CR?B=*&^]@IPV+1E*48W_$7@OK[^
MPZ"Y!(*8=]/];+_Q0:BC\Z>4/_$:I4'-T9.N$:A?TGK*AKD9 UZ;=8;IL9(_
M8M:A11%B ?I9-<E]4.(4T"F!Z^;P9/$;LEL/U^J1#>1U):XST<RL?[/4KU2H
MH#GM\QJ462$!-;V H^+^KJ7<S'*4AX-GQY\X\$/W6)(-\].RD^WQGA56.MF>
M7A!+Z!<,"8+)TQD6!MO@8#1[S&$%:%GZ!X)I^M W4"!^U1X%<"[JK('G/^9C
M_P S$M!"C1&[,HH=<8#0Z"0TN5]4E! 7S?%C "6$)8$DQVGB/",N (GP]4J*
M Y[?(;^(+(G@72:0U>>F <S120B<G8QRU*0?%(T. EW^KT0,[W?,>4"/2K87
M%Z/H 6G,3EEFA/S"Z7[/1B2:C-,#OVYRXO+5S$#H!TA7](0YE^^XI\Z+8=EG
MG**QKCJ$?UZ!%R[$;'\(*#(#.,#I)Y:2?<QMS,IM'!]IMLPD\LDM)L4G >_#
MWP]VAA-K90]!RSS,X(0B$.=@4SZTEM8_25 Q*!^)X+)@-B2)4>$&L:#U.-G3
M"#J?B+N@J13%D^PC&_QE%ELK)R@?5'O\53"(J.8EMZH771T8D]!"XB5V&659
MZZ>7""=G(X( Q/G1;#LL\Y16+['K7Z29N\E;/9^'X,J)^2%<8[(V@0#?)[50
MMBC<=#5%1K.=N#9438M/< SHWH$@5,C$NW0C:'!"JZVH8D)P4)3<MN0YZ=@\
M=8I3TI[MX)_"_P"LR@9[I>5",:=(_-"K:J<CP<I@G WM,$(F<+W#5K5#2)R8
M3]<AS)OHA2L#<#&FTII</H7%6J1;G;U";2?!W5D:1=]&A%!65AX8CB2K7*VK
M882YU A, (*F3.9-GC7DY@1%.X2KE0(=?T#:\O(_L^<AU-TJED89H""^P+T)
M.I@C4@.BW+0!V1(EHRD0N:@^K6L?U'O5N-D,4*&;:5_F^5^#:)SFTF[TT68Q
MU<8+GLZ2=AA[ZO-2:PZURZ.1C7<$V*)C<V/:#]AC^TAFJ2>%ANWOK6\)Z(V'
M7 47.(_E\(QX:?Z54_5#O"&OAM15*5R,T"LUD'$;E6XL+ ^<*M='!G3JB%TG
M4#F<K[4_IQ2A5,$34W5F&8;6-R)G?JJ%@: 3RETVL$J4<(C); <P0,1?34.6
ME19\L6].0,%&GVOF"B.F_4$NAYWK@O\ N)&4.9 5=]-<552XJ[G7*SJ"8GP#
M(VVJ<ZSH$F !XTDZ<8VH:(%1-89!Q_9K [%I''7L-])]M@$@X8**R@E"X,BQ
MC&?+16 D5@O0Z..(,N'$#MK(DDR:K&6>B;MW+X$V,HYB&D7) 0P'UQR(,\"0
M1A'5&DKU =X<,%P7%Y2^$..)XR!$,MZY0"FO4W2-@,"JJ%1ZCB%_?D]/YT1>
M)H(-=>.UP?+,# H7W+6]])M8YD/ZO]KD!@BB\5.YVPZF 7![),5@TIJ9LXIV
MJ"MJ0C_*)**0IME@=;&023"J"#*EC&L:6?TM0<W:N1&3V^BFHE'B%I/SI"-U
MJI:$YS\<I0N48M-9!Q&Y5N+"P/Q"'/2_Z_HZ;D<YP KW5[8?F.S/5L+XCOSR
MXW@&/FYPH24 R1MQ,,R\6:3'1FE+'PD(D.[*,<\],%. 5@=\<%89G^3!Q9.O
M 0Q]^U#*]I?>8>CS$"[X%U C2O.A$@@J8-QK1>AG#")L(23'AH\K4DM+#Y9Z
MK66[?(:=7%U'?@/W$<NZT4 CI?CJ()LE4,3F"L&J[N:ZP0-UHU,^L^Q!&8D+
M'X-C<E'6 0/5L+XCOSRX =#J9X435UKD'Y$6)Z;TUY&#_P!1JE0<75MZ9ZK-
M"SX%WS_VX15K[3G=G<5REB?129Z@4Z'@&E6"BA+TS,MJ@,W%H5/A[/%!2U^
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M,J-$H_%0$8T/'H/H:J+.N+UT. X#1_\ 0'[UD5Y!V]R_,')9MWV_</MB*RZ
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M6[/#K$CKR$?<98Y5I;>]YPWP,##V%?\ X@_?</@@#E<NT/*!/]YU%L=3V_\
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MXV$!H5VK*4-N3&X*M <G7&*[A=YM+Y]W0IL\>HS;:O+NLNP'7/5\+)"R;%Z
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MPE#PNOMY_6XJ!=NM[#V^.& IV.=4BGLT7Z"=,\7+X[794=?.(Q6A YX,=/\
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MB2.JO)\,=3K4?'U7O\7WS%Y<WT8#?['I_>^1\,?89&<<O*H%H&G1$C5<T4)
M-(7"I!1V1N-W?A((7=V&]M9PW$X5!Z <,<!9=6W#MUZ4@ZFVJ7J$(:P0X$:+
MR3OQ[H=:M465RH%4J;M1O%WB,X9AT;;%K.=E3!T=M7B(T$Z 9@X[FP"!!R?G
MP"@3J%K"!PAB&W1P;?=^/J??]#4$LK0#'R!W7KTRHY[9'65Y)%;\R7'5)M"-
MEK)Y42ME73/D<J"$ >H@#P[K"EJ"=Y3[+#XQ@N&1X6CH+>KTS#2<Q&6S<=1I
M'DK?! #T)Q7OT38%DQ-=N7VN\<#^B!1Z=<UP:I%RNZ(4.X\!R!$46(SE1V,A
MKNF@%!E+BCP*]=\3Y ZF['K,%:ZX;P(3JR='O%UE1M!//$:>Q<#- &E)5.NZ
M(FKGVO!&C@#DWQIV%33[.3G1!$[73MMYTAGOE(QTC0TPBD-59;BLC4#PIM6
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MB.K!LD#530)O:8^7T#K)TZ;Z9?";8=8"/2+T&BHZ-)1U29-.AQC.V  "7C"
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M$1O@-S[WC?3.=/&)UM25"A0U[I4:(LF8ZW;AM@BI%"5QV:>+C?H.1'@J6!\
M"I-))I\H)>I_D@       !T_?E1Q()^$Y 'LM/\ !MG/P?U6">7<(GTP-VJI
MKW#72U/90CR64Y/(Z9T93<Y<7A.^:ZM<.C@NA5=YI&SP%@=BJSNKRX(A._L\
MOVK6 4C@$ ( = -!_P# 2F)T7<V<KTZ[\3)DR9/\!4</@_K$6._[!(AT0'(F
M6"'!4&OFZ NANF;9I[X$A(BE[@K8XUY';APV0#JZ.[M>5J[^ ,C5.^-":B .
MSN?M:E&T0H&CR(:,J^@Q*(D02B:0>YBPN=']"L;ST [DHG(X:U%!(FQK7.#:
M.0?T&@GT+*@T%:H '+E,IFR:7D!HZO\ BDE^2\V'?@'50Q4\M'=]I.0=!7_"
M UUQQ_8ZXLROP0(21Z 5?D98"9":9T'3-EJP'N"8]VF:C8/S)@0'1CO"](\'
MH,#@7ZGMIZA!%;U"/GV!@TQ\A\IFH ELM,1I($T(<-V7%/$:A#3,M'4(ZC3P
M71FV !L$'B3(+%Z$< PQLH2/+CI>HK1V38K2;Y(8'\O800..FF\%& 8IIY,>
M<ILY^ :F]3;*+SSY5JHC Y)P3U,URG 3>V4I@=R"D0%]8'.)[-!ZHX>8VT)7
M487X4!&F1+4Q)$$MQHDO@P>H*:*D36L%ZP7"*4_'O]NHO&E*(V5-B <@N$[<
MV8I@]?X5URO%V V#KA[[_P"(0G3;E/;2!5&G:)DR9,F3_ !'P=/V.I^@\^12
M@VE! X7E.*2J!<.4!):0X,Y^6*&F%AHC-VW;'&WY/03K&B=(KIPA=32BQ2DR
MC;85VK P:*^(]U'$+LX8B'DFX];BC*J"0J:=+1L7 &]R;.*<K3H6MM.M -\)
MK<I"+-"88B,LQQWX=R%R@(.MZ%P@01.*:3DEO%P"U%N14&HCT6:'X$_'<0MI
M.IUN+K1[T-XYZ"+LS<RPAH_)B65T;4F *P.$%-7C133T\LV;"O6( ID>[)8W
M4A6Y2M)PX;1"4ZNP_,3M'.4["2B@> LQWL=3'I4.G([[]O\ $=K1O([L>/81
M"<,4JJ'*RIJJ7_"@&'.G['4_4AG8'# :S@)9OCC #@& L;_Z#_L[>?\ ,P*#
MJL/K@C$\.^_VY.AN7_#8'P=/V.I^A]XSW!^SL_U\LT>W'L('UY^><:G/VQKP
M5?NPR^_31_ZR$7A!N:T>?MWRQLJ;H_/\8K.VL.JUDA5-;$^V..=F@9[6NA\^
MO& !#C!+:$[-O#SVR9\F!S6O[YPI)7<3ZG]:SH,K]&.XT_-+_P"9M4'%!7\&
M)*VXV(_,ZY0FS%%!Q/=]N2Y2]BFQH>V),Z'GJP+67.P#YO7)E(J)UN5)OK8^
M<XRU@/.TT:_.:;]Z/KU3+Q.A/7WQ'"EYNO?.E]X+._5BC 5-@3W< ;GW_#U_
MF*\411%>8WJ3F<.3)DR9,F3_  "!ASI^QU/T/O&,O+]3U?WD<2,$30X1[ORG
MG/0]V*?GL]HQXM2N/9A9$]I.=3>4&RJ>+PRG*'G0CW_KX>O7HW/IY0,]([X(
M"48^U&!=/5C.6LMS8FG=G&4A=.9WRMAV>ORQ0=GL'UY<_J_V9Z#W^,F$U4)P
M<<:PD;7C:IWCL_OKD!QP; ^9KQC/+Y]'YQ>3A:/,GM,5;D1A0N6/[P)U'W'^
MHX#T305]EY^IO&H-'7+S[_R[* !B?NTPQ* ':A9T6*MFLF3)DR9,G^ @.<?V
M>I^TV7U_.D_8:"=P];P!5Q- ?;_&HB%VQB$QCL#8<)DR9,F3)D_A.%F%Y* K
M';N@J#0'I-LI\V]0FJF]LV[;Z]:YP 7I7->1ZT:[:\8>9=7DH,.8(P&(\)^T
M8<Z?L=3_ #YM6:E%$*(B$.&>F3)DR9,F3)D_@F=<:SJG0>4#Q:ZSZ;N] >^R
M-]5*4=!0 &U70!U5T&2KIX,01&.E1S#%\S,[Q"V1R++ *5JUY>CK?73;"LS!
M(. 5'A-_LF'.G[*K_G4FG>"#@\K1Y3$N&*.@@'0M7D=<F3)DR9,F3)_!<[_8
MG8!Y&GPCY</#VVD&X;7KK-I<3*^I.K015C!QBOM%8W/1# 'OYHSN(65LN9<8
M-_"KJL%NM?( .P0T?LF'.G[#_GE&)S6U5]&@]N^9,F3)DR9,F3)_!L4G:\32
MCYM?>>'-K)3W(?UAI=5"[I12":"T#"N PPE3+ CP#$9S2NFUR-1K6KHSX'8B
M/D%1\@^7[0  $_\ A@            !H! ]?<$N"18YQG+C<K43NJY,F3)DR
M9,F3)_!<*&N?=#]1 ? /R/1Y*$(4 =)$ RW9B,<S@$0\E6:7'&B0[!PRQX!U
M&+E#!U6@_P"Z.N+M2"]U[J54.@SI_DCC^:FY9) K#;YUB,G:6]:M4$YD\ R&
M0R&0R&0R&0R&0R'\*87RJVA=[@;R3J"LJ>62OH/P]E]M'E-'E!F_6"";)TER
MET372K*K_DCC^:U6T;( =$H-54YF3)DR9,F3)DR9,G\,?Q?LOT"9#><*Z6 @
M]@@8MQA1(I$I%1K5F*6ATV4FW0%6-E%,.)3:EHT3@+QU'#*T1JFSLY-]2[1P
M._>LA+2'-URJMJCW:A!IL39\LBZL3G,"FEJ>KJ@3=;I6^AZQUY 5.+S^NCB%
MG.!BAAM<@;A]<+0$!>E.K<^\@XE]C&?$*-"4W(5%RZN(*8U5PHS"KJCDPFW6
MC\U2/4*+PN![R0L(V)O*M$@[ TF"J@1=<$D*/*2.5S*Y\.H=NK>BUG'BM1M&
MSO@* AHY>/;I!=RFNO+O4Q2Q[H&)&94Z2XW @!#85 <G?%T!EBF@00.IS12X
MGG]E6B3E%MO9DNFCH1&M#P:>(F)Q <48$:4M"\5+PY"BD#4K0&HEG(,>!QXK
M+0.FN+Y&R\#D4<0'D1Y#1XG(.9]=_ ''6E20.63!.$1.1'8_V1*(X]\5:[S;
M0"=&E5*B?[DV^DYW(C8PO$>#P"F"D&X*%P:5E!H,C15&U(\#GT#IS"4+*VU0
MI5D<6(#KO?"JJ.C6/3EJ<8&U+ \FX4Z ]V1+725L-#<(V:P8*BCA7G<4M39*
MDB.\]X3Q1@07G*6K12%JA+P(MI;F,G %)PZ&D53"A0I6P1JG4O.2<X+;.]"@
MYB>,?!1M_,HUQ"ET7B[6K,GD+SL"!.(8[=J.<#.I+SJ\/B<?S&%D*M*NW..@
MSMB .]DE?NY,F3)DR9,F3)DR?Q-WCXGQ[Z,\CFIMZE)YX8!H.'1\)AT0$T*W
M!G&=#4Z.O72X$M1/F24%PR)'1)N*H+W&^XV -;)&D(KHX11!EW0&FT0$B(<$
MVFY("G4N@$;14YEF:?H$>1E^3V.#8QCU53DI1[7)8!E)E/5$#'3AQW;8DF"
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M13PP@0=LUFS0TSN@ZSU<=<S6FT<7^_A.0.SQ[9T#!,COF\40,3CIV]L@$8)
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MZ;:1%-_#[T82'W/\C_\ _P#_ /\ _P#^C^$LB(N[:0(V4%U1N(<5DH-'!H
M \ ;KRKDR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)D^-VNKD3C0[
MKIJ0A:#X.TO9#)DM.#L<=J+P*A?8)\!L0(-A"9 :%V1ZWV!7-CXUE"6MG(GE
MVPF#_P B_P %^ 7Y-U&@0\^ AOUHOL =  '0 R9,F3)DR9,F3)DR9,F3)DR9
M,F3)DR9,F3)DR9,F3)DR9/B\&>L.I_8]1(CL1,5E5B*78-OM\%% _ H6VF@=
M8]?3:WF%0CQQ<G<^#B\'5/\ )!_@)GGG6"&KLJ)8R0A"8WU=WIX#7  -&3)D
MR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)D_3\Y?":<+U']L(!)1N
MCR(HI.G;(#@/AIGUT$\,!RA((X0K$+ 5\%^+DYY 5XV!O##BRB<)W/C/)B@6
MXIL:0E;FS3383P5!AI0JD/>U^2_!"CE  <JN@.JY;B$,T48B,1'LB?$6T0"L
M+!06"SF#VSG9Q\(NQ"3RSO / :Y^%'C0_7GC9#?3>\,.+*)PG<_7"EU17B3:
MZ67$DB!*QI')#O)@L:&=>EG63<G&?2JG+.?DUI+K#AS4 '=70>^%^"1FFF(F
MG6,2R+B,0E4(FYO7ZY96#FHBIL0A79W^'_5CE(,+<#!)[)1_0_ODX,.0T!J<
M$@C'414#5\J^T#P !H !DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F
M3)DR9,GZ1C]#R#ZR:=M:3?X9KLMH$XI*D[^AF:_7)EPV[J5*;48<GIP$-"O)
M;VW6-&/+=BM@3=CV3 &1&X.G?1X)TL2)CXQ7K<T 'MJ<'(-: VD]*:\EJ(<M
M -IFSDX!X2>I. *&CEE(.W -P T&3#>)Y_AL/Q<HW"K)E=10!?EV##WM(WB&
MI]P.@T(0-PZE=-ZO0@P4EIVD*C9TWH4B;E1K6X[U=)P.4&]S%UT1N!U##F7C
M5FY7E<7B&IUEWGRDY?8+DK^371EX0O!7!/!+_8B>"Z^K(Y"+7=6>'K=:\3&?
MH0&T/ 42.*R7"@VV;;(2'E>U8-*S2BJ6FGN5T*XU1-O##9'H28Z6.&\HPAH[
M!-Z^).Z<-(PYR.+Z'#&PV53%F"^R;>#L9.[\CTE M;CJM155WRXYJH(.@R'O
MG1Q!K\R)LOO44V\%((,'M%5)-*!(0!(N<0@H"(G4328[=Q0IH+U00:JP!0UA
MO5S\6V>C:9-C0MM<J"+6T*<H.S#8M/#@N@<.A:HJC$]<%O>YT[C9O7&Y<AVD
M2+XE%+IKW-?+_CSL[)=BNGK!R)B?LYD45Z5^QR&PT;>]/79V=R8)7]1)XP"1
M[A:D_H?W@  HG4D!-MGH)JF)U%5*JM=OE7)DR9,F3)DR9,F3)DR9,F3)DR9,
MF3)DR9,F3)DR9,F3)DR9,GZ=C]#W/V"/.HU.)CQ>#TRM:/2<.<"'))2#I0>\
M/8!&-[2-OV1)68H\Q0T-T+K)5.C1 /[DY4$>%?DTC6 %847=[(&.LM&:/O%(
MNY'A.'E$3>$'>I8+KKI;_(NPKR20<^?BFPK0A9:U*?-,AG5UYP3Y'"5#D#NS
MPY]QP[F<^6@5OP;U++;3#!/P'V' 2PAU0BQWOX @U+PIVHON-LI='2]8ZTFS
M:ZRO)S@&=(;\X].?L"81NLPJV@!:J$.4UG5*?^%XDO236:W26J X!8'C6:,%
M[(;04CIO76=(:J#A%"E-P*N(UR#=?314@2/DXD1R[NQELY>L0PQP(V6J :,X
M1VI0D Q6D; W" :<;^!CTP HVCI1-N3N8IBF1470&#R9#4,[:\N#([0A<[&)
MG)N2*!WKH>$>1?!7:$,-:P@B:SA[8$B)1FI"]"W@H/0R_1G!+86"-ISH@,HN
MA<.)75(%4:[C$NR; 7"-;2SD>V3)H0D2NI4 ,=50"67AP^; (I(:&[X PL#"
MU8((+8T+TQWR1%[U\%),7IN-BO0[CAYAK/\ > APUYFZ&P/T#^[QA@ U8(IM
M(#@:A8<-HJ@"O@ ]C)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)
MDR9,F3](Q^R^"5U0&Q8FDB=&Q!X'@X @?3]UIT54Y!J4IM=\S]UV4$IOM,6A
M4]$UH3^ _N0K X2R WO1T62L'K<% KZT&@T 9,F3)DR9,F3)DR9,F3)DR9,F
M3)DR9,F3)DR9,F3)DR9,F3)DR9/T['Z'>[F%UR+]9CBJ/+VZOV,J[I]]O3SF
MMY<H4/?%V+_L</5)KV.5Q]OU:U'Q_K+4+#ISEIGGP<_<3>1H3T"N F7F?OKW
MUE2O-YRC"W:+?_<E[66"I[]L_P"N3#R/>PYUJ>W+D\.R%F=.&$ M;?3X-M#'
M1_9A%]:'HF CE;^EP.E9V2.D&1+ZH+KO\_ZQB3["S7+XQ B] /\ 3SFMY<H4
M/?+DNB_KZ8R.5/SG&J88<>7Q_P"YJ G:*&&-ZR35#06WM[=<T@[T./?MB1,<
M)PZZ^N<B[L70UFX"=(@Y.AN8L]\G> <'G9[O&%%(KI_3-S1.Q(G7C."+=FGN
MX=NJX JX0NT<FB8$(OA;+Y^+^VXK;QW 1ZWM*HP=N156JO*KM7JY,F3)DR9,
MF3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,GZ;C]"#G7 Z]6?Z&>I
M[\+:5M]:T?.L^@975=1R):"I-/>=.##W0X.CK/,R]\+!]\?O?W9=6 ,7Q;_>
M=7M#W8XBX9:ZX<,N?'$D'4^I@TK4VK9VQ'P'XX)Q*WJD,?2TGR(N(J%?TR!:
M9T3# B!.M.=91^._=S]-/RQ"!HC[MGR+]&:\<20_WB>;:?5S]KB[=37CY9UM
M/H)KQGHO/"G@MO5K1\ZRH_"OE6-8>'?1SU'A@Q"U3R<AYPD\FO=M_.?9_P!?
M@'^Y_; L["V<P3C%T"D:V^IXP#@%;P_)_LP%#0WT0Y8T4DG1SWP&M#%Z7GYZ
MQ]'M@79BC-]ERX"D*L1Z:W?;-%+IO;[$W]OB_M 0U.SOJDZE7P:EWQ,F3)DR
M9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)^EX_0Q=,&@ #D
MX 0X\>V+@!&&@(?#4 /!/ATT\<7Y.UU[Y0EHXT =#.?W&N??.@FDOC"H!/.\
M "'&'0B><(@)Y+\.,/<7%XW@&+4'G-X@D>,@_!X 9\$!-C.#1KC*0W-<A[3
MNWW\KMPF !XP!P<XK4'CX * K#@ KDY [/'MA1 5Q6(O&??@+C0 X4L/&:P.
M(>/3.FGCTQ! <"Q#PP./DS?Q?V;I14K5&I.X'76Y,F3)DR9,F3)DR9,F3)DR
M9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)D_3X?H7G6+/S[><5#D'ZF.4=@P<
M%D-M==W#.C_OX(B-!C103G> *#A6$IV<.R;=^>^?1+R<=_;SDJIY],>4A#$Z
M^3=9>O3.(/8W$5 6<G/; 2RJ'/U?EB80NMRW9QB@5XP%S#X$"]$>O+C%,))S
MZ=,5J#SC9!.=\91V<8BA*><XPKNS*<],X@]C</;!!T_OK@+C0?)PZH#SK*)>
MF<X/9O[C^OC;QE R8FHJ*_'O/,V>3_*$GZ'E=?P8T]!K.AUQ=46<&Y!"5)'?
M9[,U#L$=SK]\J_8A/IGVC*<#.;YX<9HGT/[R:)L."O?K];A6 M_#%!"GOKQW
MQ'TOQER*-73EQ9 C4=AH==LFO11RFF!F<_WW"^//?)D*6\L LG?;7"\!5=/;
MIE)V;'9=Z\?3VPI[!0_? W49 GSSY0'V7>'!%T-7>*,Q08#4P)[_ !X9[_?-
M-(='[I@XU-\HCQ_[@4@23763S@TBM/).UU,=4:-^IN*].N=0;YFNNC!(+K;S
MCM8>UR8-0YLUTQ1@J0J'<>P_[Q$12' K[=_-_<?U*!7C#,B]2Y$SBR$L*@YD
MR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)^GD_0
MBJX$^N"(X$^F<BUE?6<59[?%E5R8 76 ^G_<IUA[^7;-5FZJAD$4+R73TXPW
MR)-YL-OP71[8%W0/IA,.J_:?C.>K=^]R\I^*L]LY@V?5G4=E\VW(6@DH[9W[
MYNAY7:^_Q<[UAIJQ$K9.AXS8N]+\B8. ' T8=:*$UTW[X$XVY\Y<&3H5#VR8
MK<U+[XM&D;1W>]RY7K+?EC1 T,9\O;U<8S1DGC-D]PHX&^MSWO>]\#,3BK/W
M']1/SHC/,O*8N!!R'71Q_D@       &OZ G^57]*;T-$UK?#F,XO9,1R.1R.
M1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.1R.
M1R.1R.1R.1_2B?Y5?BB<"57@,UIX"B^B=?N4:P3)DR9,F3)DR9,F3)DR9,F3
M)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR?I!,,_RR)P)5> RA?+-,B:
M-QHJPL$R9,F3)DR9,F3)DP'=X Y?8ZX%9O"_0(]79Q*6$Z<WTCZIAEPXA!]G
MA^63)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,G^!1A^R_P7/(1H V
MJ]C'=#6^8JEL2D-5 $R9,F3)FS5R%5[:N_&>JP>!A(V>HI[GJ>,C+KM%\H;[
M1YPOVP_VP=]DTGY_?'N$/%^$'F ?+/LD%_6"8!X)\4!R+/$%#[DWYW.\M^(T
M^GW84CU"SZAX!\4WE*3Q:O:\GDR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)
MDR9/\ #U_:?X!S&4< *OTRN(&S87ZX@*RW;B:K>O]@=G?%X/O_*YS_N/4/E[
MXOL^/I;>OVWO_EZ?:OODJV>C!\N/&#"QPD'LA^[^ A$G(E'Y./I*3>?D>7GE
MUS3W31]->NSMW\.VY/(?V>K>(4XXGN#L^>1R.1R.1R.1R.1R.1R.1R.1R.1R
M.1R.1R.1R.1SA5\_79Q2"OL/YSJ-[P_WZ^F,D1?QOY_7.G[+^FS;BT"^YG_>
MSG_IK_0X=]@?[3&=J\H?U<U\!^;\&,]&^^*=OR_VN=Q3V_ Q=KZZ?2S$KNN1
MV/R<'B/!/Y?A.9#Z-RRM.K]%V'K"]DPPLQPNWN>CKB<[RY/O?&P>W3(M#HD?
MH_P.*WS[<YWF^!_Y@^=]]>NOK>=$?J_DQ:Z^VNM]>/G>1GW;_@SNN/[+<:"_
M0SN;^!_VYI_TRG*^A^#*-?M'TLR"U_BP(C:18^'D^736=#WN_P!'^?.('IBK
M[>CH=F]F#0P5),.OU9K]<B!6%9<[_P#8?7^\)S7Y'Y_&/[9Y?]?UG" ^1^<F
M73R_XD[KC^S][_I_R6U(>7%A)Y/_ %QQTNJP'M5.T1[9MTNA7;U&_5L#O4@4
M&U@>VU7O]LO9CS7_ %G"OL'^[CE=\W_'G'.//[/WO^G_  Z@AY4 ?7&'J1O_
M *<Y OAOOID8(=S_ '1^V3P_>!][^H8X3>L/M_L_WHR(W_E>G]!3YXQ41^Y?
M[A]LU%_ WU!^^$0#RF%5R+_+''/[7WO^G^4H*Z,\@K /NYYF8@?7"*&=OL*7
MY<YQWLORG$@%WA?3_F'9;H8OS!SZN)LG8J_7_3%_G='U@^V1XOS'SO\ 1/.0
M"!W_ 'S?SP;W>']X\5(4GTO_ ,$=U_:^]_T_O<1%[N/$?S,[WG1_:XD$'?7T
M"_UURJ5['XA]\ @-[17ZS]\ZF/D'Y96YW5V^<]/.*7I\4'SB_0]LBR]@S^S]
M\K@'M^6W[Y%]$N(/SXZ86!&AN?F?_CCNO[2#I(U:LOG-?6P?^S^'^V?]SGY$
M>?T/S^ L.4>%^7EP1.P>GOCSOI_]9]+A\\6YPVF \M_>+->E=\*HGE/S_P#-
MG=?_ *6L=Y#-@@/?/^S?ZS=LOHW)GV@I^4SJ]]V?[PCL#\WX9XM]_P#S*])]
MG_><=\@/S<5)]@?T&?\ 7/YR''UG&$JZ_/\ \_6.$HZ[;?H5SROT</K/NS^L
M+O$^S_O&^@\>K]\;R.UVWSU^W;I^]^+\_P#S58XCU2%4K8Y'UMFL*;3S^+#5
M$=RWW XY[F2^@7VSBU[5N2)ZU\/]7%D"]/7$J\*,^K?JN02GA]X'%-MLWWD7
M_O'K;\YZV_.>MOSGK;\YZV_.>MOSGK;\YZV_.>MOSGK;\YZV_.>MOSGK;\X4
MAG(/7N_::5%* L:"RNX/M_AK5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5
MJU:M6K7^#M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JUN6/)=8BC@6
MC=]_\2__ *@KOU2-4U\!-ZX7L'%[IMG3/(E7P:,LEC.8Y%YOW#=S[?&Q9&-[
M2UUT9=0@-8Y9JB@43$*_8#V7O4%^HCLN@'ZSB%)\CPGW/%ZPZ?7NOA1U<.3@
M(O2K+TUUSSFD$NA$%1Y G9Y%$?V95B78\Y7>X&N+^@LV4="1=[2S4YG(S!E!
M[#6J:L*G!^OR],Y)EC+WC[9]DYOFA=N',\YUM^^C3?\ 6\><,ST.(WY"GN/'
M3]8HA?#/7G^\]>?[PV7/4D4\S>WLFM\YAZ\[9Q V\M:<V[)*B)M'71]>26@&
MC:$:;W'M:NOCT7D?8;U130*%0_:-(,PY0[77Q$$?1IFZ+"G4'SN:HH4%$ .Z
M!5!: H0)?+1-S8B=$MZ,M89Q*%-.Q[B".DOPZ6_?5IO^]Y\?HBUVC@A?/]L&
M),%C+VN/8;=\3A5E$45!B:>$IU_5]<E+D7VTG3G& @ 5A( B4@;NMW$X)S-;
M#F=*"1PFOV:,CI%8%T=\"TZ0O5YK>_BSX>F=_P /5N_P9O2>^5\X1N+^Q$O-
M;R!OW,+(W8T0#BP!$8:C>KP$;4H[9Z@98[%6(:T+UN/T@(VI;H!'#H5VX77T
M7G54E3?1Y*=.XF"H(CA.?D7"4PH[YV.BG"+)HR;C#1YG@'=AG(5*4N&S0%A1
M!J]PKL$N<Q$D5'N\0A4@ X488Q1H*<,I/'O@"L5W@8W'6[/$;IV;$1M74YCQ
M.64_H,HU@)%.5+;PPTE/2 ?!@=+#0&5\X1N+^Q$O-;PE9D 0-4ZD39-Z!*XZ
M8CD ].R -=U7?PH.@E,JO3AHAXC@0X3^U4*B?.D&C'(A@$)_(6';'BX@#A(5
M;P*3T%B2\J$$HWMT3=4=^80X;$.UQWO6*RLX!*$KE'.)L7PS5;0S6R2(WAT=
M6-, <8"AD,;B, '(%T>*RE!& W1OC2P\@A1.$=7.76P8W(5&W1??!:1"M$\N
MB+85=9B7H)XLWYI.-Y<!E4F5,-(T)3Y!UH1SKV!JQ"G3<62RPN/K;L./C2@O
MNG88(,#8!A?<LH:/,P?0BHG!-J  "W&T'9(:V'P"Q$ZC,72D&"K-"TH)-SC$
M9/HCB(51HX'0Q$/<A@)2KLPYMQTQWS4X"]^1LU;!N(71BMI"58%&T7G-1VB>
MRX"?M9)B$>4N=(>Y*]N9RP27,E(@,!3>J*BS0%=\4'Z#^\?CP>V.@A5[6#OL
M[P@7QL-@Z,6B/3OA]HR^]S(#JX( J%0#UI0 &+"WZ2-H):/98@\,;2[D!QPM
MN%HMJ!B"@=!+RD@#>1C%#L(,!,1:\R'[V4VWH3-=4@.]46J6*'@+4AI, XJK
M0G-)T'AN^!=.8*VVUI)J)Y0)6<QU-#7S5CR,#$-*"$#2&QH=1Q\?4NWZ*R;S
MC<=L8;ZP75ID 9IR$@+M#>%L"6<"-T"+R&\&@9YEYJHRJ.$2-HD<&X5[%1/
M3V0QXS2Z>*%R0*!%1J>"Q>MF,#FAG8I@4/K5 .T[3M5I78S61'"[0(!N[ 8Q
M78-#))TL&D2 EZ4THY3=KL"$J[]Z !H9UFS8AT+:'G26' TI[$I-T 4H)RO+
MJL,/2(XPB>5-!AR-Z60,M!0BS!BK^>=Y"6X%$WI$>AT<XJ:%2<P9WL<>;T8X
M6]J")8(Y4Z?,"?;.3Q@A3,%?(B.Z+;4+BE&OZ.,L9:)U#1% W;0Z**E=1#0*
M%A4-]1D>_&*Z==Y"0T?,X*CI:.BX\A:B!:M^E1G?8+R=B]J-P&K74<@[G*C;
M"M-*Q>U@U9<!MP0>&-I=R XX6W"],[_AZMWQX$J^30LME+Q3&AT_7/Z_3G]I
MH+Y!;RG&^<HZ80Z,H#Z*AS6"JQ#)$YMW%;O**&@,2:3K <&Z_P"EVPZP"&P
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M                                          !@   #      +\#
M                                       !"   #@    "_X7@
M                                    #"   "      =F@J22222222
M2222222222222221@     $DDDDDDDDDDEP   "$DDDDDZ/^4DDDDDDDDDDD
MDDDDDDDDDDDDEDDP              "4   "      )?MFVVVVVVVVVVVVVV
MVVVVVVVVVT@                 :   "      ")LB69BX6P1$E5FVVVVVV
MVVVVVVT@                #^   "       ,&D .\?*^D^%_F6VVVVVVVV
MVVVT@                #N   "       *VO8LQ-6F;&I%L6VVVVVVVVVVV
MT@                !<   "       *W&2+*ZAC/677U>I*XU6] @4+VT@
M               #L   "       *V _&BC8Y9C9@^KE,,)U*P:;M6T@
M            #>   "       *UG'JH;2FCWQ;H^G/?!J_MN0A6T@
M         !X   "       *VV\T>VVZVVVVTVVVVVFVVVVVVT@     ?_P#_
M /\ _P#_ /\ _P#_ /P   !;;;;;;:+9N.FS*C[RXSB@I9$RY;;;;;;;3;;
M              &X   (       K5O[[_P"R.AB;E9-G/!;2VVVVVVT@
M            #N@  "       *TVTVVVV[6YVVV5>VVWLVVV6VVT@
M         #Z@  "       *W?ALXB!BSLQ9FUCH^/.>!-82VT@"H
M      !K   "       *UJZ6(3Q[]97UFWP"@EW8=?'VVT@#L
M   !]   "N      *VVVVVVVVVVVVVVT>VVVVVVVVVT@.,
M!\@  2^V     *VVVVVVVVVVVVVVVVVVVVVVVVVTAN(               <@
M  .%90    ;-MMMMMMMMMMMMMMMMMMMMMMMML"-L   ?_P#_ /\ _P#_ /\
M_P#_ /J  '96 O\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M .__ /\ _P#_ /@DP              #*@ "99=/_P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ <      3_P                BX  I?
MGY))))))))))))))))))))))))/      ))/               "\  #JU'M
MMMMOD6MM]MMMMMMMMMMMMMMO     $Z25               C\   @=F]H0=
M5E6+15)MMMMMMMMMMMMMO      ;;?               K<   6-XHZZ*RE^
MM>"]MMMMMMMMMMMMMO     TVVR               \\   6-M\=MMMMMMMM
MMMMMMMMMMMMMMMO    'I))*               .P   6-6Z:I_/3-;PS].<
M#"?MMMMMMMMO    &VVVS               =T   6-1+2.9J0T(S/1M_KM!
MMMMMMMMMK))))W2227   %MMMMMMMMMMM54   6-MMM=MMMVMMMMMMMMMMMM
MMMMMMK))))9)))/        ]3X    ,<   6-MMMMMMMMMMMMMMMMMMMMMMM
MMMO   $    $       &\]"    W4   &?\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ U   !_\ _P#_ .@      !.I/H   &-   (
M                             +MMMMM        V)/>DDDGWDDDLDDDD
MDDDDDDDDDDGP             !Q)))))P      !6V[5MMMMMMMMMMMMMMMM
MMMMMMMMM@             *=MMMMMP       *^G[;;;;;;;;;;;;;;;;;;;
M;;;;:              -;;;;;;         97.9.\FCMN(^KK%<8BYT/_BS>
M_:             !O_\ _P#_ /\ P   6VVVV[&K\YD-^_I4:)P!E.$6JT\%
M U)VFVVVVVVVVVVVVU9))))))8        -&VVVVVVVVVVW6VVVVWVVVVVVV
MV@            #6VVVVVVH        -&^9\_P!\@1CY=\6MB;K-MMMMMMMH
M            "P      "        #1I'E?4.,U?&P0#J15L%MMMMMMMH
M         %MMMMMMMN        #1MMK5MMMMMMM=MKMMMMMMMMMMMH
M      1MMMMMMMJ        #1KL,/S6-U$<?]/:H%MMMMMMMMMH
M  %Z22222224        #1J(#WB@,'IXQ9RXX=MMMMMMMMMH           #
M;;;;;;;;>        #1M*+R!5?5!8=.)/L-MMMMMMMMMH           >DDD
MDDDDDE        #1I^@W3L^0#4"UMMMMMMMMMMMMMH)))))))))N]MMMMMMM
MMMI   %MMMMN1N(U#@':"M.D-MMMMMMMMMMMMMH)))))))+4O_\ _P#_ /\
M_P#_ /\ _0        T;@=04TCB*+BO;;;;;;;;;;;;;:      -"]MMMMMM
MMMMMMM0'^P     \;;;;;;;;;;;;;;;;;;;;;;;;;:@   !LW;;;;;;;;;;;
M;;:06WU    !/))))))-)))')))))))))))))))0  ^Z4DDDDDDDDDDDDDDD
M1 "N/_\ _P#_ /\ _P#_ /\ _0__ /\ S_\ _P#_ /\ _P#\        $NDD
MDDDDDDDDDDDDDDDB'TTYI)))))))))))))))))))))))L        T;;;;;;
M;;;;;;;;;;;;:%ZR:))))))))))))))))))))))))$       $FVVVVVVVVV
MVVVVVVVVVU&*^RMMMMMMMMMMMMMMMMMMMMMMMM4       \VVVVVVVVVVVVV
MVVVVVVU E!RUOMLLN%N5L]MMMM6UMMMNLMM3_P#_ /\ _P#_ /;;;;;;;;;;
M;;;;;;;;;;, '6G*XGDIC(FO4]FE0#.A8WNBP6U0     #'_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#D %6NVA]:,)VX5K6Q6TYRUJ#.NZVU0
M  ?2222222222222222222228 %6VVUVVVVVVUVVVVVVVVVVVVVVU0    "N
MVVVVVVVVVVVVVVVVVVVVVX %6R,S/LRCL 6VW'"<]VC$%QQN>U0    9@
M                  4 %6LVJA=+6=0(C>'2'=U^+^4?HEU0   #@
M               0 %6E=7^@MY84@H*B_"@[S);:VSBU0   ![;;;;;;;;;;
M;;;;;;;;;;;;8 %6V)RDY5^2%BA=DK+Q4S96VVVVU0  -@
M           %6Z[M(OI3>J0+4Y0$7 QS6VVVVU>VW(
M      $ %6@/V\^Z<3M^NW=Q'<=<3VVVVVU0 #T
M   0 %6VVVVVVVVVVVVVVVVVVVVVVVVU0 8
M0 %6VVVVVVVVVVVVVVVVVVVVVVVVU09                          0 &
M22222222222222222222222223S$      <I                  < !MMM
MMMMMMMMMMN'MMMN-MMMMMMMG;;;"*;ZE)SY;;;;;;;;;;;;;;;;(
M      #L   "        2T,%=))))))*JNI)))))))))))+%(
M   !<   "  6'?,RHE)))))))))))))8&)))))))(*YO_D
M#.   #BB!))))))))))))))))))))*2A   >^2__ /\ ^0  !;;;;;;;;;;;
M6X   ,DDDDDDDDDDDDDDDDDDDDDDDDH#DFK_ /\ _P#_ /\ Y
M    &@   R22222222222222222202AD^5?_ /\ _P#_ /\ _P#_ /\ D
M           "4   #))))))))))))*7%+2S+?_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#^0              '    ,DDDDDDJ=[O?6U__ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /D              #"   !XJ7#7]V__ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#D
M      !2   #_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ D       ""?<'9($    #_\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#^0
M /MX.DDDDDDF    /_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#Y   H@)Y#<DDDDDD8    8
M                        $   !)))))))))))T    @
M                                     \    P
M
M
M             6) "H   '   /<    8 &H  &IH  !D^W( (    *27P( S
M   9X   !8V:8+Z_:A6QW&LU<]I26Y22_51ZA_ " /062-@>K /Y5,,[3^R[
MK.O&$D2V9"4P4(X9PX1'9RK+);%&H7:Q%.: " /<0K<@N; /Y3B3+W$3]:#G
M.((+RP                           &D8        Q+
M __:  @! 0,!/Q#_ "QDV=#%8J%2Y\,8P"BNNT1 1%J@1.]7I""/0- (5'\
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M$0-$DF9:A%Z[FM#P,+S=9\%LX$;7!"@5OV(<\("$VXEZ35ZE[1!4>5_E</\
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MH\!REB[UMOPPQ VNQ+X8]T/Z%X;!#:9&1.(B57F$_4)/,<0'JG%SA,QHP_\
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M@MQE;QA/A?WN'_"8P5_ZF??+JG)IUH+#&<O OC9_3_()]])[/@':)G?#DV_
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M!H/YZH/^J/SD3K=W?6]?KBM.:7YS_7\@GWTGL^";HV=L.3;\$&(,,)0X N?
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MQXH+EQ;UQ3:E?MBB4%89GOOP+L(8+\U'P M5?=EA<*%[CQQW&KYL:P!6^P&
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M/BM.($: LAEU?3EY.^_3_(^L=G^=9!/0[PMC=L4]#W?4_P"\]WU/^\]WU/\
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M/@!"$S,Q9MFV#BC#K1< XA:J7J,'&U.$6G7A+ -V"EB[ML\H HP6+?:.>4T
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MSV_?_P SV_?_ ,SV_?\ \SV_?_S/;]__ #/;]_\ S/;]_P#S/;]__,]OW_\
M,]OW_P#,]OW_ /,]OW_\SV_?_P SV_?_ ,SV_?\ \SV_?_S/;]__ #/;]_\
MS/;]_P#S/;]__,]OW_\ ,]OW_P#,]OW_ /,]OW_\SV_?_P SV_?_ ,SV_?\
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MJ,=#7SWQ[X@$<!_=!H670%E9,74!Q.^"L%%O!AQS+:E0F(M0N\:6(8;?<B$
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M52B)%$#WB(BC;?\ RQP_M'7V_<2R&8VCA"E[YTP,3V(  #H  ';X=,&NBJK
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M*IVPMT! &N\EKO&2*JK57:JU5ZKD4=X\;Z[%%RX()P,241,@"Y UJQ@7/5=
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M3<(E2H&L2#!'<BF %MZ0VFJ13+MD=:O-P@F,YU(T%Z4O]*?4^$Y9^\*LD$[
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MHW2?7GW,UM+H[)= +.FGOO"12UK1RYMZ3;?,Q=?60$<I#G "Z.W&=2+4NA>
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M66)2(8C(CF_K<2R3-+A)RD?H0 X!T 2000(9W4"D@6MVFD?YSS^YX% <2-'
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MG;@,-H5->3R#TR=2$J14VNRQFC08[I410H3"ZO4J<9&4Y$0,!&N6O25N*=3
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M%;T(='?C#22[-=_&."W /3!3=NI9U@8H,\5/84E\<Y X%6J>X*GS,=ZO*@(
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M.557W7>&R[@0?19GA?@/H&9JZPA2 X+;#"O%))'LK3%UO0*Q[APOGG#3)<P
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MCDLYNW],;-/EH%[5 O@R5!(');VE$\C,2M4-B4.BO)HWXSM^!H7V%%^0XB!
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M965E965BW]0*@5PDERH%PCN.A2B1RQ9HV#KQ76<NMXH5$JD5D%B<,9%(*+O
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M B*T87?/$QZ@T;P]RN$D$27BHM7>]\'C/<3PJB1%7?7>%(9"AWF;3VJ8 F"
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M.I"O%U)7^=T<Z_L]7M^D$:K@-N5P'4#ZB,!HO=_@SCMZ;3C\]MW^F'H#W/\
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MR4HJ 4 @8=T(T%HQ T!;[697BODAK2A0@""MZ8N!5M0=82Q!0FI3CD 2+8E
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M$MOF3IBR*U6BO.FP\"'B8 " @=C)DM*69P1SVNF:N/(1132* UV"-9UPT4
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M\?\ >1X/[RW/YSP_WGC_ +SQ_P!YX_[SQ_WGC_O/'_>>/^\\/]YX_P"\\?\
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MT8*$(]4RH0)"1:S7/<#O90=874YE4LC0&G@LYP+)6(+,(=BM,YO&2KVD:TJ
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M$"OOR(H$35.3/@ GX7*RQO(-I$DHGH*)<L3L"MNI9]' D6M* >ART9OD8=W
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MNA(J6! <Z[!\C )."*'@%[]!BZ.=8DB*%V;*T%-G+DX;XIH MV; <J)3&/X
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MM5X$>D)B,3M(42AHL>M\?N</U6N08PJ:#;4CP'$(  &B?Y+_ /\ _P#_ /\
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M&"4A&W6W  AQ^^);X,#L@B>$R89*0IPZ#E1=5*"1M((T%VT+E.0J9#():./
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MP=T6B;88X;0 % 7ZX9#(9#(9#(9#(9#(9#(9#(9#(9#(9#(9#(9U/VA9[_\
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8)-<?PORI%OG/Y+A\?_0S#V;_ ,1_/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2113965d1-pht_expsca4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_expsca4clr.jpg
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M ,_A $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M"O&FOTJYC-4 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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ME#ECB\2RA*E5DS>,AY7.N'%T;Z"2,5JSP;PU%2F*6+*M*M$;D7F S<\#VP
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M4N5MT:-1UA)Q2S)B#@/H5B#5 $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M*-<:<W[13"3Y<,35OPB[LJJJ1=1' 5%#34<:>Y7-<U0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! :$ @@\""#]!0'7Y:P%]
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MST4=0WE^X\D[XB:"A\BNKE.*1&-*(Y=UF6V$,4U[B<^&R@F$G"9(%H(T/+Y
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M6HL34XR2RR?L9$XB0ULCW<SJD$\#)K0#E\.6BP2HWV+X&2%4N2M9'.5" @"
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M 'I*/]H?F%^R34Z _A4^TGH]U7V_U&S.]KK?-AA;R*]AV]?V%M'!=36TT,[
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M$C97LEBBD9S5+ *.7V&XZ70[OIWH-TA&YIVFIP:3SP33:.L.F-UWOH_<%O\
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ME.Q"M!7C05^GQ4E35 $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MUHS?;OW/=)^IN$W)/M:TL=T8;^DF2MW/A)L),OCQ<,FEBFMR]KK=A%'.H0G
M)5ECD>OQT1ZM[%ZW]&MB]6]D9G^DNT\[MO#SX^[A#V"2Y=96S;JI#G%SFRR<
MKM2*CB593Y8II8FE<M/YO)/!U)MQS.M62ON8C' UGS$%N).;DMXFA]S*9 ?_
M $;-:'V44K/.B9C?B=7FCS1/Q+W=D>O7>X[IKT^Z@2YSI]TW9!;9C"1ND-I'
MDY([Z._B=!\Q)%6.[):"6-.BQ^'.F"-^VN2U3\3,>:XFAMK>9X^ B(MMHR?W
MZ?DI$P>SFDH$SP7V%LFF_M,V[\*-V/BUVSO#NZZJ[,.-W%<3,M]JSY"T\\31
M21V7+=6QN;.@(8P$%CR02IBJRK4PW94MJ/%YF;B!$^E''^!.#O) ( ;-0MI[
M@#]2O+PIJ63-:#4TN1>(C(#3RNH*TJ#05%?8?!"K[SZ0! $ 0! $!H0VFH&E
M?#A7C1 06Z@;<Q&%K8I[.9DL%[CIF,++J*=ICE#@\$$<A-1J"%6J;P+^5]YY
MR'XG/T_LOT'[G,7W2;%P%I@.EG4E[H\U'81PQ6[LI9P7DUT]\<-M"V)TLL@?
M0N)U6-8.G!FY"7-;\6,TS&.DK<6DSX(A*^2"3R9W$ QO>P^6[D/$M<00K? E
MI-41FM_A(^Z_$V^W>IG:UOC>U]==0C-!=;+L[N2XNHK>SC;9/NK6WAGN7QPM
MH0:M8!\*BM'C@V4O1E\M5QIF9R[0&N#7<7D<-*NC.KM/VY'!95VFFZ-4/-L_
M%<9N\E[\NG&$DN+IUL,<2RW=<S.M0#9WYJ+8O,(.G[54I%-U-V#?RDD8S]\2
MVUG:XCXV/B@(%/B>TL&G#0E,\>)>N%'F>@3^$AV3G-J]KG4^YRX(@S>5Q=Q:
M'EY0YC;:$$CX6UH'^]5AC-M>4Q:G"$:F7E0>P:\:ZU^GVK*:8H/8->.B U0!
M $ 0! $!MR_O;OJ_=! 8GGXLS_(XVI_.UW_<9ECGYD;6G\LCSRK;^+P?VF+]
MPU2LV9C(Q_"X_P#B-3?S5E/Y#9*%FBMS^E+W'IEK(:(0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! >9?^)SZV[2ZQ][
M>(VMM+)QY.'IYCK%]S=P2@M><E9WCPU\4<C^6A>-2&U6.B55P.1A56U5T2,=
M*YF$%G,'_ [R7PEE*_%*PQL(]IKJIXU'[N2,^[\);T=S73#M>ZG[SW?<82UP
M74#(V%SAKN\N\='D8C;P0,<WGF,=U#$8Y75UY>8#QHB2=>5^)F#43IR\%$RX
MK3,X>)G+-N+!REQK:Q'*67PM!U+7^<7/J/952^26"?@,'\Q1R;GQ(O\ ?V#_
M ,,XG_&-G_PRL4HQ]_8/_#6)_P 8V?\ PR$T8^_L'_AK$_XQL_\ AD%&/O[!
M_P"&L3_C&S_X9!1C[^P?^&L3_C&S_P"&048^_L'_ (:Q/^,;/_AD%&/O[!_X
M:Q/^,;/_ (915"C-6YO"25:S,8MY((HW(6CCK[FS$J11D.?/B&,E$.5QL$[3
MS13/O[9Y975Q(=)\(I50Z4Y4R5)UK2A+GJULW:/57I=OOI_N',8N]QNZMM9G
M'7;A>6?*P3XVYM_-,8D>TLB$I<=/!./M)BW&2<50\?;O!Z/8+MX[K>LG1/;-
MXR[V]@-U96YQUU$0Z-QO\OD9Y&M+&M;1I &@5'BJLWG%II+%$H-A;HLM@=7^
ME74G,L,F+V9N[ 9"^B#N1LC+?-V-S\1#F@_#"?%*/EHLR4TI<V3/8G[.^O6U
M^Y?MLZ4=;-J1^5M_=FT<0&0FCA"^SLH87M: YXHR?0:G1$E/Q=AI74[<G'CP
M)"^I=G\]@.W+*7F+R+\=>R3V\!EB<6/E@G=+'*P\KFGXH747>_T^:'1Z_KRS
M#76U."3:3X-4:?VGB[Z[M_W;IOT'UVOV2_*SJ7<MPDUFXS;C-9K.+:,8X?,3
MVUM'-)6.:X:V,4 +G7,P\Y[B-2>9U=5^B[^5;G)VE62CC[E@?SIQ_-:Q6+.I
ME2Q*[X%VN<O$W[^TRH?3ZZ0XSI?T,Q&1L;@W$F[((<C<MU 8XQQ^UK:GF)7Y
ML>MG5%_J'K&[:O+E_+R<%[FS^E#Z0_37;O3STDT4=%-S>LMQNS]LHIO@N)7N
MNG#U0$ 0! <2O*X2O^(&H;[O#]E62K'D(X5XFC^9U*"FE1$/TB.!YQPH5:/+
M%X/#M*34Y4;R["C'O([5]M]RO3?*6=QC8/Z8XFRN)\)D&QQLN7SPPS.BA\T0
MOE-9'  57:/I;ZC;AT#OUO4V;DEMMR:5V%72C:JZ5ID=*>N_HSL'K#T;J-HW
M*S">XV[4I:>Y1*7.HMQCS4;7B:,0/=6VLQL'<>>V9N?&W-KF,9?W%G=VMW%)
M X,MIWQL=&^5C/-:]C*U 7ZA[5N6DWS0V=VT%R,])<@I1DFGFLFEE0_G@ZIZ
M9W;H/>]5TUONFN6]?;O2A.$JK"#\+3=.9-8U*D^TCNQWIVL[[L\IAYIYMB[@
MO;6#,X:29[X&0.N((YYQ&Z=D<98QI)TU77_JAZ9;5ZB[/*SJ$EO-B$G;N)8U
MHVEDZGH#Z;?J'WST4ZACS*3Z1U]V*N6G)M17-%2E3F27:^TN_=\?J0[3P/2#
M';>Z*Y.+)[IZ@XS^%WUK,'285L]LYMTQXCNB\.#I:+RUZ/>A&Y[AU1<U?5=I
MVMMT-S",E_4:>%*KN/T<^I'ZM>G>E.@[6GZ*U%O4;[NMBL'"2?R8RC25:2K5
M-I? QQKRZ?-+=9S*W$MYD9[F6YNYWN?)/?7-[(7\E"725$CZ>*]YV[<80CH=
M-%0TT8I)<(J*S/QYN:B]KM7/?MRN2N[K<N.4L6Y793=:4S7879/3V]/')=;,
MOA.LG5*SFQVQ,=<LO<!A;F)[&WSH)+:=I+)K:G*\ZZKR_P"M_K=9Z7M7NE.G
M9J>]7(\MRXGY:IK@S]$/I4^EN]U-/3>HO6UIV^G[<N?3Z6:XIQE5UCC7,R?L
M5C;+%8VVP^/MHK.QQEM!:6UK#&R..*&WC;%&1R-:TU8T>"\!:B]=U%Z5^])R
MNSDW*3>+;Q/UBTMNWIK4;5F*A;MQ48Q6225%EAD<V/[5&O,C!7S"01R^RE?H
M5'1I/)\"8NDI1>+>?<&CE.L@$(#G<Q-!RM%7<Y)  'O4/'ABRR\N#\2XEBGU
M3._ ['L+WH)TNR#)=S9>*:UW!<X^Z;(;>WF9/$Z(SVUS^J):W4<:KUC]/OI!
M_>[T>L.H(..WVFG;4EFTTZT:Q/$7U7?4)#HG02Z%Z5FKO4VLA*-SE=7",DTT
MVI8/(QPHV18C'33WTSO,NII+B?X3/=W-U.XR"-KM9I"^8T\5[?N2>KU"MV56
M,%1<(I+CV9'YFZ.W;VG;7J==)PO7Y.4OQSG)O!+\6>!=]],OT^+WK;E++K[U
M=Q]UC-K8F\M[O:> O()8_O%T$MM<-F>RXMJAGCKQ7F;UU]9;?3-B?1_3<XW-
M?.+5ZXFO#5-4P9[?^E_Z>9=07X>IG6]J<-)&2EH[$DUR4H^9J2QJL3*/M;=E
MK:V]E:P-MK:Q@AM[>-C0UC88HQ&UK6-#6M:(V^Q>"IW'<N.[<?-=DVW[7WGZ
M7VX1A;^3;\-F,4HON7<;CS1H;RD0N(_6 :Q&O #C\154JUQ\2^\NY*+4^TB(
MX#Z L1.>)J@" (#K>Y<5CL]A,MALE V[L;W&WT,\#N#XY+>2-[36OVFO/%;F
MCOWM+J;>HLOEO1FFG[S#>M6]18N6;BK8E%J2[F8'O=-M3&[&[D^IVUL':_=V
M(L\Q/):V36<L33/>7;Y',^%C*$^P+]2>A]=?W+HO0ZW52Y]2[>,N."1^5/J-
MHK.V>I>Z:+1Q^5HN>+5NE(YO%8)?856^DCN_!;%[M?GMP3&TAS ^4M9WSEL4
M\LS;6!A$)>UE6.=[U\)Z_:#5;GT!&UH_%*WBXTQ257F=@?3/J]-H/47<)ZR+
M@KW*HW.;";PRCDJ=QF5,?YG+(QPD9(UDCC2G-'-0QZCV-*_.EJCID_U'Z.).
M46I8Q_"85OXM3N(VF-A=->W6W:V7<V2EO+P#S@) !%>#D,?F\Q#1%7[)K5:S
M\_-P1O:>-+37[1@P0\\&-=S?&^&UE>Y_V2##%S 4T)H6(J)U+NJ5>+,Q_P#"
M*]N&R][7G57NLR#GMWAL^[@Q%D PUGBR-K )G']6=&LAY/M?I*W*^;,Q7VU!
M)/S&>+$^1SC).P13R.!\DTD:QI.AUTJX)G6BJ^PU7&2BY1>"(V. ^@*Y4U0!
M $ 0! $!H>!UIH=>-/?]2 @SXN<20S1F]9,6F5U/+H6:QCWZA5YG+'_J^!*C
MR*O_ %G$AM];QWD<D$L#[/)7UG=8^V/,Z5D<,\9@DE</WL^6QW-0\:+)'ROL
MXE&Z-/CP/+0]?7M/PO:?Z@N^,CA,A]Y0=5Y8,S-+Y8B\JXN?GKV:+RA'&T&*
M0TJ*UIQ6%8>%9(Y&+<HJ:S?Z"R!NVSGO\&+6+FD,F2QMU++&XQOBCMKN.9Q#
MFT> &M\$1*=5CVGJM^@KU=V3U']-SH1A=F9J#+9;8N &,W5B0]LDT$Y;%1DS
M_,D+2!*' FA-$@VD^)KZA5N.3R?$NK]6>H>TNE'2;?74'=.2&-VYM_;F9N;G
M(3 _J2+"X<(@'%IUF:&C4:I&L*1>,>TIC.:/'K[N]\8/JEWC=P/53; =+@MU
M[HOC92NF,S*6^4OA)*SF?(/C!!H":*>YFY)1K@L:$A[+!76Z<[MW:^.<)LAE
MLYBHL?)7D:'NR-NUX>34 5?X^"C_ %8(E)N2^!ZW'I2[)/2GL)[?]F9S(;=L
M,[9;7M)\S'%=XUAF?/#&^,3F$L/G>7R5YAS4^I0J./*G1FO>E2^Y9HN+G-8%
MLCY!G<'&XAHN!]Z65': ,YJRCE-.%5EKS1Y7F:\4XRYJ8,YXSV#H/^6L3P_P
MC9_\,A%&/O[!_P"&L3_C&S_X9!1C[^P?^&L3_C&S_P"&048^_L'_ (:Q/^,;
M/_AD%&/O[!_X:Q/^,;/_ (9!1C[^P?\ AK$_XQL_^&048^_L%_AK$_XQL_\
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M&2_YR3E8J^T?YS_OE_[:MR_XPR7_ #DG*Q5]H/J?]]&E.M6Y2T>'WAD_S_\
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MZPVF)P[#]H8O'D_5;1"OY0ORBU-?S%QK+GE\6?K=9:5F">?*O@>;]^+*=_\
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M+4![(\1ND&,T<_\ HQF2WCX.^5H0? ^*EYX9!1DUEB:'=6.K&/NK=7.0:_\
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M+60T0@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MA^*V_P#$)Z;_ ,VM_D5^L3S.2L_T48V61_B[O[?%_=%+'!'I'_A@?\CO)?\
M&,?_ "2V40XFO?R7O,G%7-8( @" ( @" (#;E_>W?5^Z" Q//Q9G^1QM3^=K
MO^XS+'/S(VM/Y9'GE6W\7@_M,7[AJE9LS&1C^%Q_\1J;^:LI_(;)0LT5N?TI
M>X],M9#1" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MRV>A]E7J#UE8A/J77Q4K5N<4_DQP:?BCF\2]F U@: T1O(Y(HF@-8V-E0UH
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MS+(/@%22=-=#D@DI<TE7#,P7HN*:MX0;Q787^_EW,F%PY[88HPP L:',F<0
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MKF>1S"[4  'E)&MG.M8Y5,,]/7Q6\^PR<^F?<)T9ZV;(QO4CIIU*VIN/;N4
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MJK[3+/Z6=$>E?1G$PX+I5LG!;1MK>QM<<ZXQF-LK.0PVD$5O'YSX+>%T[S'
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MD9PUPW0>UPA46:)XWK:7;SK]9R5^UJ)P2MZ.])JE%\MK#VT.))YK]7X;,,%
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ME3'"B=#]'O3CT;]/O2W0K3=)Z&W;2SE)1E-MTJ^9KFS7:59@
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MB_UZ^Q[<_>3V3[O@V?DKC(;MZ?V-UG<%A[>U<^2]\FVNY;B-K8X)Y72&/D
M;JH\T:T\1FL22?(W@SRU<A>Y7:&0R^V-Y;6W?B-TX#(WF)RN)=M?,O+)[.YD
MM+<MD=:,J)WQ:&@KX**U2H;/A3=,D9G7X5WT_P#J@W?5]WM;PL\EM3;5U;30
M[9QN3Q]U9S9J&YAL(97^7=VD4D/EL?7[6M%-./!9E+DX\CCFW]QGL*YI! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M10<5KMT7*^.9M1BD^:+Q62/MNK V0\Y?7@.6G*>!IQ5)229=*JK3#B<I05"
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MJ6D44>K6@ZCP4T3Y9)4DOO,4N:57FB83:\HJ*&@J/8:</J5BIJ@" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M@:</H0"@)!(%1P--1]'L0"@K6@J.!\0@-4 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! >;
M/^++_P O#H]_-TW\COU2.;-^W_11C,7G\4']L9^[*/B6>9Z/_P"%U_R-<K_Q
MJS_DMLJPS9@U.2,GX?:?_8_L+,\D:BS9]*"0@" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" (#S9_Q9?\ EX='OYNF_D=^J1S9OV_Z*,9B\_B@_MC/W91\
M2SS/1\_"[?Y&N8_XS9?R2W40XF'59(R@&<3]#/V%E>2--9L^U!(0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!YL_XLO_+PZ/?S=-_([]4CFS?M_P!%
M&,Q>?Q0?VQG[LH^)9YGH^?A=B!V:Y@D@#YFRJ20 *VEOQ)T"B'$PZKRHR?V$
M$FA!T;P(/Z/N65Y(TUFS<4$A $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0'G:_BS^A76.U[H^C_ %L9L_)7O2P6MW&-P6-M<WMO:2,AOVW!OG6\#X[1
MM0:>8]JQ5K)IKW]IR$*NRE'%\3%"N)),@+3'X&WDSMYD+VSMK>TQK77EVZ2X
MN&1.'RUJ)9@8G/%1RJ:=I*5)98'J'?A_NVG,="NPS8N:W/?7;)NHF/CR5SMZ
MYLIK.YM2R&T^6#O-AAG:X^4\:C@I@N9.AKZB=)\JS1?3:^XD;:AL#L?+(:,?
MS&7EC9H X:CXV>U2DJ.Y7#L,-$FXK%G914  FI %3[334_6K%#5 $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ / H"GWKQT Z2]R?3S<W27J_M3'[IVGN
MZTEM+RWOK6":9[#%)'S6ES/;W#[%[?,.K #J?:J.W6"45X8Y=QDMW)0DY)4<
MBT#V\_AV_3:[<^JPZJ;4Z5'+[FL;F:^L,-E[]V1L+6>6=L\?+'=V7E%D+V@A
MN@%*!6:YJ-X1?WEU?G1JE&V7QL+AK+;6-M,1@\9;8ZRQT$,&&V_:0106N.@8
MUK'-9Y+&0TY!44"<L4TI81X=YB;;K1^T[ V1L<MRYP=\N?+U+23"\C5K1QH7
M%11R2FL)D*F:S(R*$ C@0*?0K$&J ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @-.4:&@J.&@T^A .5H/-RCF/C05_+Q0"@K6@K[::_E0"@]@UXZ! :H
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" T) XD"G&I0&J ( @
M" ( @-*@FE14<174(#6HX>SC[D 0&E16E17V5%4 J/:$!J@" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @%0@" ( @
M" (#2H]H_*@-4 0#AQ0! *@\#5 *CVH @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" TJ.%14\ @-4 0! $ 0&E
M1[0@%1[0@-4!I4>T:<?<@%1KJ-./N^E :H @" ( @" ( @" ( @" ( @" (
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MP'$%8+^OZ0U/AL.5E=N?Q*K3[K!*5%,G+8?BCMI1-C_I+VSYVPD-*FRS4=T
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M*2? W[02!_/)/5K_ -ZAX\I H[XM:T5DE!4R3R780ZMU;J^)$U) 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MU[#];7!?+2BXR<7FG0S)U53=4$A $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M)$32ZIC<[]\=7B[S#K[E\VZN/,WBS:=(?RXX]I&%0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M4=[9VE['^]7=M!=1_P"LN(F2L_\ DO"^:E'EDX]CH93DJH" ( @" ( @" (
M@" 'AIQ0'":\!W+S<LSB:@C1W+6@!.@T3N'F58GR^66H;&WXV_:@/B#X\_LU
M55C+ER1/X4?!E@MFR2S/;&V+[<?F!_+S\:ZU5G58IU3*XMY4I]YTC.;S@LG-
MM,:P7)HXF824\LT-:_%KJC\*JGBC/&"?G\K)59#-WN1<3(Y] XZ<Q XGWD>*
MEMM*N;+))5IP(>RO-*'?^[W!_P!Y=1%C@$6-O79L6W/93TYNZ NM;G-@DC]M
M+?#C1>E?I+FEUGO%E_BTL_\ =GFGZIH5Z)L7OV=79_C1A>6#*8ZZCX\D%RZG
ML_5N(]W!>:]WCR=2[C'LU-S_ 'DCTIMLN;8=#/C^4M?[N)FW_ASG193LBRMI
M+-+YD5])'(ULSPUC3Y+A1@<0-6K723;YLF7E7EA+CB9 ,&.@@MH;*'DDM6@F
M4W#&S?%Q;7S ?$*%@_%YED6YHM-K,W'-O!\,4&,>T?#KC+4U%!0?O8KHKIM>
M:AC\#KRUH;)M"_5^&P4CC6I=B+(G^Y^*<TI<<"RA;SX^T^V8O%2M)NMH;;NJ
MUK_R-8<Q]M>>%P_,I@W+)%)02XXD!RG3;IKN2,Q9'ICM*5U'!SC@L(UY:00\
M%PL.8U#OSHU'F\:(CSTHI4)*[O[.^@>[F6!CZ5;;@M[25YNFQ8W&P%[7N)<'
M4LRXG4JG*I25.!DA-QJGYF=8O_3Z[/LA(WSNA>#O;AS1S/;'#"2YHJ27L8P<
M?<$Y(-5BJD\]U>9I%D;UP_3([?,)VJY+JUT4Z=8_8_5G;LK9+.>Q?&7W=LYE
MPZ2"0-A<9'CEX\W @41P4989\1&XYP:K5<&8CG9D;FP[V^WEF2M9+3(XW<]I
M!EK*4/AE9)]ZX^-KV\X8]PD<"= OINC:+>)I<82I]AH;K+ELPKE5'J^[?(=@
M<(1P.(QI'T&SA*X.]_6G_J?Q,D?*O81=8R0@" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @-J9X9&YQ/* .-*H*5XT(29V<L9B#YW'F,
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M^K+_ %/XEH^5>PC:QDA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M])-)4Q7:1-" @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MM;HU=&[[=.C$OMQ3F\:T#;6#2NM>*UY>;!&>'F?N.X@&C1X?%4?7I]*-INO
MG\)K^W/@.7ZJJR^\1\QR8!^LD/LMKG^XN4=A'XBT)ZS>/=D/3U=<T^''WLU/
M']\NKWW'P*[W^EJZH>J5^U^WI[G\!T#]4=NGI3*\LHZO3_[PP=[(_K\X/9:N
M '@*PD+I[K.U\GKG=+?_ &\OXY'=72MUWNCMMNOCIH?[N)F'?AC+LW';[U@Q
MKB2+3*61T.K>>!I &NE5P2IXFL,CE)2:MQ?8S(XZ@V_F]-MW,+W1\^.N0US'
M%CP1;R@4<TAP*Y399_\ W[32I5*Y'XHX?>XM[1?JVG*W+X%E+9-D;5MY_22Y
MRS+1]]D?NN9F2O7UD%Q)RZMEU',%ZUW6\KSA^2C:^;R1YERQRHNX\K;19=KY
MBUDKKL<\N1\TLZOO[2;_ $CO=R-O-X,GSF2:6V[S8-FN;H\K!$2QS1))X-H5
M\QU3:V_Y.F=NU;?B\5%'M[CZCI:YK_S&JC.[-+E\-6^SVF[LW/[@=A\F_);S
MRD5X+FX%C<-^;F:\B9U&:2$#E( 4;KHM$K]IVM+;E:Y56."X9Y%]IUNL>FN*
MYJ9J_P SI+%\2<&RMU[ZFVIN2:;<UQ+=V!A,3W>;SN::<IY2_F'PA?-;KMNR
M1W+3I6$K4ZU6!]-MNOW9[;J*WW\VW2C[:DQ<)N7/S;-EW#)OVYBW%""&6#[2
M6KZ>'Q.]BXO5;;H+>ZK21T<7HG^+F1R>DU^NGMGYIZIK5+A0J0Z&Y_+;CVW)
M<YJZ=<W9=1\C@=0"P"K233FJOANK-)IM!N')I(\MOL/M.F=7J=9H%+5OGN<6
M4H>K+9"Y[+.H\H:#\J_'2<!H.::I&GP_F7R-VM*GU-CS-&(YMS+BVW+TSNFN
MH6;JV^PD'B/OJQ;0T.M%S/2DE'?;<>V$_@:^[5EH'VU7Q,_#:SQ+MG;LH_\
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M*K[/IJ*N=)[C7-.+^\X/=I2ANFG[ZU,P-L?+)(_]O3\R^55:NIN&ZK ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M]UKH;EWGC5-TQXF;3]&:RS84)-.2KAPQ^XE?W:[2O]H]B'4W!9>C;JWQT\K
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M7AA[/Z:\%L[O#Y>X78_O/[V:6E=;,:=A,9S:@T&II_H_(N-3QQ,[RP/M02$
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MBJPZV8ON/;%Y>.3?;^D](KTT\O#F>Q?H1>F> &;;T3(W7$T<+7&&$,+>>1U
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M#6O]1<"E@V;-7S)(^U!(0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MC7PX?EY_ \[ZTB^6S.Y(>!.7R ^GEOI@?V%]/]2MM6?6'4K]JW;?_P )\?\
M3=<^=Z/:+NO7OXCL48:X\&N'AS-#J:&M X&BZ4JT=V4P29$X&QDZ11>^L;#I
MK[0/:H3#RJ\R/X;%9+<-^W%;<Q3,A=%P$Q,(CM[>I #I+@L,30:@ZE<OL'3N
M\]5:UZ'9+;DH^:YE&/OR9@U&IL:2"N:ETGV=I-^#H+U(%K)-R[?, #7<GWEC
M"65 );6NI!XK[N?HOU-!KFU=I3_U1.-6_P"E<J.#KQP9QF]+-\0R-B=CL%(>
M;E#_ +QQM-#0GCXE8WZ-]6N?RXW[2[^>)D_OFDIY'3V,C?\ U4;\MHQ,<9@9
MP6U+1D,8*4%3P-=%,O1?JQ80U5J37[T2BW_0O!PDO<S8EV?O+%V,F1.U<1?6
M\7[_ .5D+%TC&\7.$;*N=RBI6MJ_1[K+1VW?C<M7TDWR*<4\*O\ 07COFBE+
MD<''M='[CBP7%J^,$0VYKI+$;>(&U</M,^S5_P 7BNMY_.MW9V+\7;U,'247
MW885S.8I!Q4H23B\CGQR6P+'B"!KFUHX11APXCB "HJTF@TGB0W<%Z&V>.DJ
M:-W+MOB?#[VMJZ^'#VK?V)TZCT=?VG\33W.G]LO/A@>B]V?7#;GMOZ3SL-6R
M[1PQ!K7ACK8'76NK5])U@J;_ 'E_I^!QFVRY]'&3*DBUNK2=7TII^UU7S!OI
MTES&ZA 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MH_!'&;='DTD8LJ_-2^,UU(.M.%![/>OF).C=.!NJ62:.2I 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M1_A.+T?_ )=4[RX4UP:UO-]G77737W:\5\])-SK^%&Q&3ICF;R%@@" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @-'&@)I51)55"5BR'Y"C[3(
M1DZ&QN013VPN'UZ%,ZDY4[3SJ.^ZS;9][W7F #E_Y4C=2A'VKJ\/#16>2,]?
M$^TI6GAYK>Y!_P!IDI_^+=[U*EV"CYF96WH 7SI^U[JOCB:_)WMARMK6@<R+
MPJ::J&O%CD3*G+"F6)>O:PGB*T ]WA]*AT(;I@@VNH/@I#[3Z0J;#SRY*R=[
M)8S^1[55NE?8_@9(?I1C#?B,K!IZA=)+]HH;O'Y/G-*5\MET!X:T7KGZ>(N]
MZ5=2:=NL5;R_Y+/(7U W?RWJYTA>6#K/_>11C%X9W/CK<>+9;@5_LC]"\=05
M+]]=EZ?\3/8=Q\T+<GE\J'\*(S&ZA ^GZN*R<2CR1]"04:ZM*$ZZZ$E4BW;U
MFFFLU?M_QHLTG;FG^R_@4I[\9+'UEV_</)>^1MR.9W$@,?2A/&@7?_KI>G>O
M;?<_ZIV(?P'S.PPY>:#X2?Q(XX_$?VS7._.X_5H%T'54H?0NKJV\SZ ;\AEX
MR!*PXZ^=(Y_QM>!:RFG(ZH-**,:HG-<KX% 7;9+:-ZL9YUM!(Z&:]NB/-M71
M,@I<EM6N<P--2WZEFEY6^!KP5)TK5E?=R]P?*YH,AYA4THUH)- 7<%CQ-CAC
MF<23XG1,;]ITC#R^RCA4Z\5M;<F]UTZCYG(QSK\J7,5@[5N2-M8=KJ MC<#P
M\&MI71;&_P )1ZAU,'YDH_ ::5=/#MJR/FX(/N\1[--/#Q7%I52? SX4)B=!
M;QT/<MT'E:[E=_2K'"M::'+V.GAQ"^P]/GR]2RKY7;G_  G$=0)2T,%^\OB>
MF]MLAVWL ?'[DQ3A[N:QA_+P7S^HQU$W^_+XF:"7(O81Q82P0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!1!ZBD0N>SGK/&[6NV
MKFNG[6.1W#Z%5\/:9K:_FT1YVFW(Z??((X9C)@:^R^F'M6>5%D6@\^PFUT:>
MZWZQ[9=]G^&1 :^V:$>!JJK--9DMJF!?$RD?-D6^^SM#3_Z.WQK[ULMXT-=2
MIF?$<(T]W'\]/%5<BU7[CEPMU]VG]5'+@2HM8K([GLJ'S-TVS6@5Y7T\/T!^
M5<5O$N7;IO\ >C\3>VY*6MBLE1_ L1>J3";7K?:L _?Y@7>'!T_T>Q>N=S2U
M7TOPO/.$4>2K%V6D^J"S87EO<]7["B-IY&M/^YQ4]WP#Z5Y!T[YK$3UK>?\
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MGP-/YUTE%IP3IA0YS'CF;$[[:2)MG<Q?-1WL\-FVR(K\W-=/$$+.4UK61X'
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M?2GNYEPM[^K-?O/XF6'].*[%^A'9%A+A $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MV_S U!PUVVI-:\MR\<37Q"^DZ@;>ZS?='^%'$:.GY==E7\2Z%R%KF.X@<U>
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M.0U^H_E7 R7*Z/,W4U1/@<A00$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MHM4;2Q[<#M:Q$A $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M727%J*EH>^KR  VFCB5WY?W?T(ZW4-YW?DT&\25;B5'67'[6V?)2L]5;=/\
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M_AS>9J7^SQHK^%K#-&.*=7S/V')4%@@" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M*CS=(\#CKC?-E5$WAH $*A $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M:6L]U;.<.<M-HZ?DU=KRK'154HOVE[DER8NI?[)#F@2,Y02>&NH/N5N3F6'
MU)347B&>9YKR16-W+R&O"@IP]ZC!TJJ21:F9R%) 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MK*BI&N)>\GRUI2/ O^*QJ! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M<C/5[W[=LF\A!!'EVL$;1QK]D5^M9K*?RHURXF#44^:_N*SAJ ?:%F,)J@"
M( @" ( @" ( @" ("SMZM+0=L].'D?8OK[7V<S'?Z2U=3DC9T^;+0$'V8_\
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M;Q=.>I61SFWHGQF?:^8=<9,SV['1$PMN[^[<8_U<0;I11D\ US-.:J^PO?\
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M\CHA<RM/*.:X\MO'6K]?=JK-5>)B;P(3:X."]V]?;AN>>>_B\PQ,YW ?#S4
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MC]- 3[$H37$O\_A/X_-]1GK',.#,4W\[81_44]A5Y3/2X5C $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M;QN:9H@Y\+!R_![5-''!E<5XED<OI5N_?/49US@;6W%C;8ML;[ALL57.9(X
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M9U 8L5%I_KC$/ZBE<"J\DN7(]*A6,(0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MIS-DCW-F08Y6F-^F6OJGE?0D'Z%BIX<<C=<JW:+.AU-U0=>-37Z5C+2J@#4
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MQ-]75-5_#V$LX7\S0Z![9B0UT4S""V1K@"*T) +1Q"IQR\/:6;22KC+L[?\
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MX@U]A*5P9:E'$]F_MVMVV?1#I9 ?TMD;9('LKA+'W>Y7BJ1,,WXF3K4E0@"
M( @" ( @" ( @" (#@.\KG9S@^9'7RY0#X\13AXT3&F&19))Y99G4-^=/]I=
M2]LY3:6\L-:97$9.VD@O([B&)[X^=CFLE@D>QSHWMYB06\"HE'YENL\$(R=N
M24'6*,=[N=[0-Z=M.8O-R;6M[S<_2"\N99@Z"&66;;K)))GEKFQ0<\P  \:
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M_93C'L[93''0[5V^UVGBW$VGC]*Y)>5)9''T\3?$[BK%0@" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MAD+U['-YY+E\US(PU)H(W2D#4KCDN+=9UQ?:9Y2KFJ0I@9-?X-^.)_<-W7S
MMY?(Q0B (+@[SK4R$TUH>;Z*U5ZU=3%E%\V,ZGHC*3&$ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M;W,FL*MJR0&A63F6? PN,DUP;*T=H?AE?5+WA\M-GH<9T\BF#721R9&RO98
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M=I"L5JR-LCCB8&1,9&QHHUC&AC&CV!K0  @/M $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M3=*8$O!^(T9YA!>X\E:> /#13XFZ,C!?K.0@" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M3D-:P/)!U(%1KXC35*R\LG4JHQ6*6)NH2$ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M'3@>)&NO%%&G$AY+L DCH8X#1X(H"W34^\44Y8(ENN9RE) 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0'R/M.^SX</M?V2A$\#7Q/#P^GZT^P@'AX?7P4
MDK,U0@T'#P^K@H8-5(" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" '@?ZO#ZT!\C[/Z/#P^S_Y%/$,?MOL_
MZ!^DJC@?2 ^/#]#C]7_E4CB:GB/L_7Q^I'D1Q/I02%(" ^!]G]#ZOL\?]'UH
M2S[0@( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @"A@T/$</KX_4I / \/KX?6@-/T?T?_ #>* ^E#!H[A
M^CQ_2X?^53Q 'U?4A"-!Q/V?JX_6A)J/JX^'^CB@-!Q/V?JX_6G$'T@" ( @
)" ( @" (#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2113965d1-pht_atx4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_atx4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ M "Z P$1  (1 0,1 ?_$ .,  0  !@,! 0
M       $!@<("0H" P4+ 0$!  (" P$               $" P0%!@<($
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MUPQ< XD?(_WL?+_S$ZEV&RZG\O=PWACMJ<]UW86-X^T?=6Y!)? YD<M;F/$
M.9('L- PN8T&@RNX7+-GN'::S>':A/=Y.DVL[Q6 PJ/R3+XI+57$\N3:- C8
M:/DFA9 ,KBWSV40;R"2C=-Q'NNBYP%8A#]L/1>W>9^ZW]INEBSI7J7:F^).Z
M*!_V.:$EVM[FNT^"]K6.=&0XMD96C?<)'5(/,3=/([8-IO=@W:7KWHO?)##;
M-N+J+[?;W :P1Q1R-#S<1O=(QDS'L$D$FDE_[0,-.MU.G.N&03FFT%D6XS4%
MYNJU5=QD-!:.Z'Y._P!/],M+\9<'=.G^390WC$<AGIR Q<QC)N9(_NBKXPE
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MS9!,!>/H'V@\XUE#5<"BE@!$P@8QNHP\>(W$.%Q^U4E3BL>_B7M"N]FVY8;
M;W3 \*D0N #8S3)Y8X#Z@OQKUCR-D,?FMM'YTY;ZV.7D'GX ?*'>SQ;:U]3V
M+Y_I2]+1YT\D_B)0_DUW1?L6KSSJV(P]6[I"<V[C<#^E<O1NE9A<=*;;<#)^
MWV[O7$PKZGNEZJ,EICIM(&324]_T^PQX(G3(I?WK&XQ41$3%$3#[?,:X2@+1
MW+F"2'$&N?UJ?/<F8\VK;E;BBF'#R (% 0XTP5:GM785FU ; B0/.0QRVM^Q
M,%,%;&E5$@V((<U+>0%E0]7$3<NSR4P5:]RZ'<%&R9FAI%JF]]Q=$>LA< 5?
MW5VF!BD<-^LI@(J4IQ !#L&E 4U'(*(<0K)TEW2Q#K$ 2F[I42F((D^0/0(=
M/4 \A$.%*54:B%\Y+Q5MO:[3<YN8U&Q-B)RMM7LX?97%-6XW*1265>CD+8$P
M&Q ZA][*(</94 ?E!62R=HW"!QX3QG_EA6N16TD S,3OU2MY;YT'_&'^X1\Z
M.8?+_&]/GKT+[.S_ !%H]"Z_K?R_[%7TJ_>O.US:41*(E$2B)1$HB41*(N"@
M&$OL\^?.UO.'"H*+6XWM;\]7,YSG-=(\#>.M-\$Q#(IS%'[Z)>N$\FRY>*=+
M1C]=V]1,C\/C5E$CE3;IB(B7B<QKV"#"^0^\=+.0S/I64.:T5'Q*I_A6E(AB
MVN#0ORPR/ '9S"83J*F<Q66)B<YAL(B(M1YWK*&-8 &@ (USCGS65RX?O+>N
MII[59<P$+%]7VK?;J.!164;^H\LEM$W:(" "*>AR3P+\>+*2GG "'H[L:]%\
MHIS;^9VQR#CN$;?74+S;SCMA=^5F^PG+^S9C_%;7Z%\]I1/VY=(.1'TTB'[$
M'CHOH[:Z]YA,\+KW>F<!NEQ\\CBN>\O)#+T!LC^)VJU_J6!?4)VWO@E-O&@D
MB')_HMI:]N/$;KX1!G'CVAU&M750,!5=J=BX]Y5D^H>K6JT%JOG$2SS?)HV
M:9!(MHU-JQ+(MT0(D0[5D@@8J9;"JH4HV.(EZN0U]!;'TWT[>=.6ES):027C
MH&EY+M).)JXG'A4Y+P3>.H.H+3J"[MH[J=EJV9P9I;J H!1H&&%33-1,-N U
M;)C4J]6R(ZKYED<"P(9VP;&$$'T?D2BZ)DQ2(/49Q'$'CQN6U5NNC.FS?QPL
M@ A=!([!QS:Z, UKR<5DMNKNH?L4DKYR96S1C$#)S9*C+FT*J6,:_P"?OLB@
M(HTQ%2+62<LF[GKA4V[I!1<PIJME"D5 4SI'*'3SN C7 W_1FRPV4UR(I&2Q
MM<1[Y((&1RQJN=LNK-WEO(H#)&]CW-!]RA!.8SP(4\0>NF8O89Q*.7F+@Z:K
MMT"QAF"Q'3DBQ"G,ND)) H]('$0 .@?D&N(<+\===([9%=-@C;<>&YI.K4*"
MG ^[]/$8<MZVZJW*6W,\CH-8(&G2:FN9^+AW<\1QNLP^77GL<AY=R5$CA^R3
M76(B!BI%.(F Q4P,8YND+<+C7GVXVS+.^EMHZF-CZ"N:[WM]RZ[LH[B2FM[:
MX9+32WRHH1V[#<LS.4# KG62#TF +#[ZQ34$#!V@/>VKC(W:+ECCPD:?4X%<
MJ070FG%I]BSF_.(_XB?_  =_G%S_  _Q.7YOSUZOI_\ U-%U+6[E_=M?2LQ%
M>7+L:41*(E$2B)1$HB41*(@\AHBTY]P[<$]P&MI0"P!JIFXV_9SKQ3A^ZK.,
MAW*V2R'^%NOW9M<V?E)IJ[L(\^DV;H"(><.L/KU#@K-QJLM-P\E^RU@XAY?3
M5:*Z[+ /$ MR'[0U'>BM2WEM#/-K^[)L4+]YMUGU+6O;W=MES@1\G#NJ[MY:
MO$7F+LC^6YV_SOI]*Z/YG,\3RYWQA_\ B[GYHG%?.Z5+_6F0IVL!9V9('H,\
M4$!Y=H&K'YIQ>#YC;TS_ .PE/K=7Z5/E;)X_EOLCQ3_VV >I@'T+Z9NRZ1++
M;0=KK\O)QH#I/Q >9B87$HFXAQN I>JNCC(+NI.)"GR;T.P"?E)68>MIA%[-
M.3.Y/X=/2+!N[=&*4AEE&S=0J'>"!  1Z;C8*[/:=6;S9V\=K$Z,Q1-TLU1M
M<0.52*_.NM772NSWEQ)<R->)975=I>YH)XF@-.2\I7;KIRX:.&:P9&JFX<Q;
MLZBT^Y6<)J0Y)%-B5%95,YDTR%E5A$.T1 :V6];[XR42L,(<&O;A& */TZJ@
M9GW L!Z+V9\;HSXQ:YS3C(2?<U:<<</>*C6V@F'MY&,DPDLH77B7J3]F#N7(
MY*5=,Z:@B<3M.LY512#KN-QJC^L=T?!);EEN&2L+31E,#7MX5P5F=([<R:.8
M23E\;@15]<1Z.*]!CHG ,46[=&;GC-VZ9$TDG)XUR0I2%$I $%(X1'H*-@XU
M$G5M[*XO?%#K<:D@.'L<D?2MI$ QDLN@   Z3E_!57,=B$,>AV,*U677;L$.
MX34<"05CD YC@)Q3(0E_:$. !77KR[??7+[IX >\U(&7H7/VMLVSMV6["7,8
M* G-:6?B0NAC]ZNX5K>P+969< \H.8IGV<.=<9(2"3R^A<K$*M [*+,5\2/Y
M_P#@.?$N?X?W_/7L?N_XL^9>=^/)R_N75Z>2SQUY.NZI1$HB41*(E$2B)1$H
MB#1%J$[F&@H[B]<""%K:FY6;E81[R144^SUUL-KI'<IJKW/#!/W>3:SMAO\
MEL9PMP'_ +>9FTA&WF]Z"H?A169Q^7-9>:JLBYE,(W#AP#AZJBB*W_<HQ^):
M%[F8_A_/=N>9H%N%[F^ 9V<O[XE=FZ)E\#K;:)OR=SM3_3-^M=5Z[@-ST/O$
M#?B?M=VT>F!X'SKYR:IA/-9 8UB@:>D#6YV QDC@/KZJ[#YV0B#S3WE@R^U5
M];05UKR/N'77E/L4SL_L+1ZB1]"W7]G_ (L.UK37:KMNP"<U+T[2R?#=*<4Q
MC+XB<RB<@Y6)DXB+9L^Z*1+#)EFJ)5"J%5#O;E @"7JO8/,W&)L;3&2YY!U
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0N86]'KXVHH791$HB41?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2113965d1-pht_stx4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_stx4clr.jpg
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M4F*28Q7P0U,D-!9S%Z+"TH-$5"7QPS4F-B<8"9.S9/_:  P# 0 "$0,1 #\
M]Z4][*YK)K:/]:\\O(3XJ$D'PY\5B<92A_#?B;7)"=;F*X&/MV=3NF73>TU7
M4][]0-K;:DT.PN-6U.QU37=(LKTVMK;27LODVEY>07$I,,+J!HQHNBE"W#RX
M&4ISESR6-<#Y^GS4_P!Z+ZJZ9ZH-;VOZ*];TN;I=L^ZGTJYUBYTZWNV:Y>V4
MUU9W1BD-W+R!LL8-6X%<J.3<JG;S%%)2Q:.L36/WG;U]ZR:WFH:"3A6FE0M)
MS_V7O6E%IU1/-BXTH;5_\3!Z\&-#(K_0F ?^BX#_ /.IRMK$G/%YHUEK^\V>
MO:TF;/#?Z")V-<&/_9<)HXC!W+YM#0T/N4<&QSQ[#MT^6/\ O8FK[5FWII_K
MG+-5CN/@1M?4M'TUML8@^2!MP)6Q7+6M\M@<35M*%%'E8YHS24L*'N5])?JD
MZ9^LSH=M#KUTGU?3]2V_N^R=>6MM;7]G<W5F6EM8KV*WN)WV\P;(TEK^4XC#
M%24%+%?&BPD[;HG[C.3%P_RK.6[F -Q9VEU.!6G\W$Y^0SH&K2JE26=#,J<U
M8?"SYUWS8?WCWU8=!/5]U+Z,=&_V3I>C;(U5^GR75U96]VZ9[)[N,QBMP2'!
MC&$U S4Y,:HUS*+I)'6JW]Z5^8>T@RZIH#HW <@.CP-%12I!\S&I5H_K,\\6
M\%D3?_%-_,-_\Z[?_P"*+?\ [ZL\G>7S%V#_ .*;^8;_ .=MO_\ %%O_ -]3
MD'F(']Z:^88<#JNWS_ZH@_[ZKR,>8N**+OWI+YAAY6_M30*--0W]CP5R_P!M
M[4Y<, IQ["I_\4M\PT@$ZIH!(R=^QX,LO\;V*<CK5/$JNI1HT1'[TS\PT#_A
M7;^/']D08_\ RO!.0GF+L(__ !3?S#?_ #MM_P#XHM_^^IR#S$/_ (IOYAO_
M )UV_P#\46__ 'U.0>8CG'\M#]XC]<OJ'];/1WI%OR^T6^VEO?<$6F:C9P:;
M;6LL,,DL%96S&8.P%105/BR5:454L/?]Q9,^D(QSY+:UNH2&R_ 6L]PWOGB:
M_,JRYZQD_@);=N,91_7X&ITQK'N=/(VCW_A.-*C KI')\N1PDFFG<S9ORR:"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" Q9O3>&@=/-K;DZB[JU+3])TK;NC:GJSSJ5]:Z=!(S3K*:[=&);R6&$
M22"*C16I)6%&GO/,[\]8^5%8=I\DKYY/S.=P>LOUM;RWKTKW3NC:&RMO.EVM
M9Z1HVY]3AL)I=*?>:5>W<C;#4C9W#;YH+B.6E'8"BT<Y)+)^\CJ]]*'I(ZW>
MMSK#H/1CH7M/5-V[SW%/,9;MD-[+:MD>]A,E_?,M[B.V<^:9N,A!=S5]L;IE
MF%'GQ9ZA_1#^Z1^I_=G4)]OZNK6'8.T(FQ.\_3K]NH-E:71/?RRPV3VNEY'.
M%.84(56*[&*16-:H[F7_ +GCZ-+BY_HW537F-A,(GMVPQ/Q;3S!S%E?UE/<H
MT^#*IPR<<3J8^8Q^Z8=;=J;YT#_]1?27;[VE-IEQ/K@U+4/A'V<\$,LS6,=)
M9?K;F5T;6M8UQ)<Z@JF*>.)?<DNP\>O6/I%O7H-U)W-TKZG[=U'0MW;1U.[T
MC5[+4+6ZLWBYM9'0R.A%U! ^:!KQ0/:*&F:TGS8LYRAR>['([7_D\?./ZU_+
M,ZPZ1'%N#5M?Z&[BU6PM=X[.O;Z\GL;73Y;RS9=7ME!-?16]JVWMH:EK&BM%
M**M4=*T7)+X3ZUOIQ]073;U:="]E=?.E.K?MO8W4/;<=YI=T&&$%]W;1B_A+
M3))C;W$CH\S7E11;=>!S<E'/@>9#YC7[K[TB]1>H]=O4+L/<&H3=:-[MGU[0
MMO"L=G+K)$Q^&$C;65SGSN>T5<* ,S4E5/E?Q5.BG"YC3#M/*5;_ +K9\UBZ
M?<^?TBBMX8[NZBM.?4RXR6L<SV6\Q L@&^=$ ZE!FK)R6!A*#]Y,U'_PL'S4
MO_Y4VG_&G_X-,12/:/\ X6#YJ7_\J;3_ (T__!IB*1[6;#O#]V'^9UL79>Z-
M][AZ;6%EH6TM+NM7U63]K-,[;&RMWW%Q-%!\*U\K8V,-2, E6C481DZ)XGGJ
MUS2+C;FN:MH6HLK>:/J%[IEXT'\-U8W,EK.VO\F6(A$8>#H=M'H9^2CZT?F#
M=,M9ZJ^G?:=GKVV]$O6V%Z^XU%MF]MU(.=D$370O,TCHZD-&- 5&WP-<L6JO
M,YE__"P?-3X]*;3_ (T^_P"#53;X!J*XC_X6#YJ7_P#*FT_XT_\ P:8DI'M9
M!W[K!\U,->X=*;0N:QSFC]J?B< 2UO\ N/#F."8BD>T[W?D5_NTW53HAU>B]
M1OK:TI^TMU]/-7LK[86UK>Y^)9<SL\E\EY+/\)& (VL>W!WYPPS*F+S-)J*P
MQE[#W..YKD1VU@TPLCBBMI2XT'E6S>6/$T'X0JX\DJSX\#GYDI+DABHLW:SN
M6L\FVC )C!#WBAQR]]:JP255+/@9<KDG[F2S-]0T$ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M.22J\B+)&OR.>2S1_4::I2O$G0@0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M57#@=TKVMEE;<?F@819!_>5^9D^6+BS]4Q<FU3,U4;X&/8VOC=P P8N5'2O
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M $ 0! $ 0! $ 0! $ 0! $ 0! $!2$,8I1@P[@LJ*61>9M4X!T,;W![F@N&
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M0VN)_LYHY2EF4JK(" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M6:.G++!F92D_X^=#<6TH*9+D\"UKB10! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MEP[S]CRN6TU&'PR69O+:\HYC4T%3WKB8(H @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MBR(J ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MV;JU]I6K"#:^O2PNEM+N6T+XY1I[621N?":$5!6FU0Y\LDZ,MT>GGKA1[O\
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M;[>-PI0-%*  8#W9(FXY"7O*CS1I1IL(CFC%?UM,?T:=BQ&/+)R7$LGS)*7
MU=O +>%L0)(;6A.?O6B%= $ 0! 4WLYZ8TIF.W+O[EB<%/Q*G0TWP,?Q!GKF
M*<E/#E2M%>7&K.GF/EIQ)(=/9%*^7F+B\&H=B!7L&6"U'W51'*Y_$FI/@5+6
MT;:\P:XN#C7'A[$;;=>!*)8\2N8ZG%U0,A3[ZJK!89FJU>)+Y($;HPX@.X\0
MKS>]S,RXJE"9L0:SDK4=^*C>-2X85)?(','5_#6@I@*Y\5J,VDUVDFN>2D^!
M.V)K'.<VOBS' >SWK+=2\*$KX&2 AU2#PJJI--/BB)432XD! T-Y :#N'\:<
MV+8C5)+L(^0SD<V@JX4+J8^U%)EE24G+BRG':1QQ^7GC7F.>?!5S;ES!XJA4
M9"UE"W!W%U*DJ<U<PVV3"(!Y?VBA"<WN\IGEK+F;*,EL'@-#N45J0.-<U5.B
MHS3JY<Q4;"UHY6X#L I4^Y9;JJ,M7S<Q!UNUTHE/812F!J*8JJ32%:JC*4%F
MV"1[VN)#R3RG$"JU.?/3M)#W(<IJ.2C^<'#]&G=3M6*X4!44 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 49KB&  RO#:D- S-2:9#&B#C0ZU?
M7'\QC8/I6LSM71OA]T]4=1ADCM= M[B(C3G2PR>1<W+FSL(<V1OX33+W+VYZ
M:>E.Z]=W?ZR:E9V2#QN-?%1XI8=G$]8^H7J;M'0UE6)-7=XN+W+2?<\7CA])
MY"?F'_-E]2.YM/=L.VWM>/W3N7SX++1])DFL7:3;3&Z;R2.LKYI;Y44O$8T7
MZ#WG;>@O2#:);C9LPN;MR^[S4;<J9T?>CTOL6Y]=>JVYK23NST^RI^_2J]UO
M*J[G0Z.+795QJ]X[<?4;6M5W?N>^D==SW&H:C>SB"69WG%A;<2RAP:Y[@OR/
MU+UYU)U5K)ZC5WY0L-ND(^ZDL:8)TR/T_P!/]'[%TWI(Z7164Y+.4O>;?%UD
MJXLNUNAZ$&\ATNU+:4Q@A)  H,2RJ^H/S'BYS<OVG^)]F4;:5%&-/!%.3:.U
MK@D3:+;O:<RUL;*YG@S@2MJ[J(XPNW%^]+\3F[5F6=N#?[*_ T4O3?8MQ^+1
M7M)XQW+XZ9G\T!>1#<=TMXV]3=3_ &I?B8EH]%->]9M?X8_@:1W2O9-:0VNH
MV[A6ABU2[8!49T:X+S+7474-GX-7=I^T_P 3Q[FT;7<SL0^I?@2MZ6::P V6
MX=RV.=/)U_5F=M/P7#3A0+Y*SUQU78?N:J37?C]YX%[IC8;SI.Q]3-;%T_W%
M:GGTWJGO*Q</P%FXM=/ET/YM+P4& R7RUGU2ZSL)+SX22[8(^*N] =*W75VI
MU[ILN;37]<=$<Q^B]?MZ6ICQB'[;UYS64I^:;X UHODK?K%U9!<MQ6IK_P .
M)X__ )<=-YVE<B_VY&1M)Z\>MK; #=O>HW=+FM<US1-?:M+4QD%AJ^_X%@7E
M1]8]WGCJ=+9EV^Y%$?0.AA_TUZ<>SWFS+&F?,&^:)M[S6:9U\U2Y9<A@N/,9
M<.,S8 !%R\]]X*<HRS7>UZI[5<:_K]KMSIX+/,\2]T1NR5-)N$H)=S9EO;?S
M@?FS[2?!)%U)EU1MHTM8V6'F!8Z@<'!][XJAO'M7>77WI[J8\FKV=4_:.,.D
MNL[.-O=JO]C,SGH'[P!\SS0C;.UNSM-<C@YO.#K2U#KGFXEQNJCEH58=1>DM
M_"YMTK;?'G>!N6S==6:..K5Q_LK$S3H?[RYZR-(A9%N7I!#J,D9:9+B,Q,#P
M"TN;RLNQ2M"%T\[TDU+]URM5[VZ&&NO+"KY2NT\%4S!H7[U!U.M))1N/TXS/
MCE,(867;Q\*(^7SCX;WQ^: ?8NRV+TKU5/+W/RW^R>'/>/4"S+E_TKG7;S')
M#:?[U=TJN^5N\>AFL:&ZC0XV]W(_Q!K><^.XDPK5>'+H3HNZ_P#E-\B_&'_V
M'FV>I.I5%/6;7*#[I5,\[?\ WGST<ZE+9LUC1M;T6.4.^,DD891:.P\MM!(.
M?G)3_P LMMN1KI=TLSEP5$J_:=)=87K7\_27(_6_N,];7_>-/EUZQ%"[6>H%
MYH4[R?-ADTXR^4VHY27?$MKS!<+GI/NDV_Z*_9NKA[T57[3+Z_VFS&NIC=@^
M/N2=#.6W?GK?+9W*/Z'USMHG%S&M;<V+8>;G+14%UW2C2[&J\6[Z1=8P586[
M,X]UR)NQZA],WWRQN7%+OMR1GS1OFD^A?7FE^F]>]HR@-C<0^\AB(\T-+00^
M88^(57QTO3+K&.>F7T3C^)\K'JO8YJJN_6F9AV[ZU/2_NJ2VBT7K+LBY?=AS
MH _7],A#@T FIENVAN!XKX[4=#=3Z9.5W32HNS'V'E6^H-INND+T?IP]IE2R
MZV=(=19;OL^IFQ)FW1<(>7=>A5=RYU'Q]6^]?#W=CW>RVIZ:]A_<E^!YL-PT
M,_AO6O\ %'\2[;;>&TKUO/9[IVY=L.3[;6],G::Y>**Z>,5X<M%K(.D[-U/O
MC)?<=U?L2QC.#7BC<6:QI$G\WJNFOI2O)?6KL\OPRG-8>GU"SA/_  O\#7F6
MWE*/UHUK9X'TY)HG5Q'+(QU1VBA*YN$UFFOH-)IY%0$$5!!':,0LE(H @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" E<]C 7/<UH
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M! $ 0! $ 0&AOM2L].C\VZF;&W(#-Q/8&C%5*KH5*N18NJ[LEE:Z.S'DQN!
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M[ Y5A_>9I+#U3:WJ9U';^]M%=J'3J2.W9M;;39S''M,6C0&QQO;+RS&;E J
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MI[SZ47W==5M<ERKLYWC0]<ZF=C:>O(VK<4KNZ)U?;R+C_LSZ*[7!S6N::M<
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M8Y3)M/26ESF,=7ETV%OYP/8NBIRHXW/YC1R (8ZH,%O[?(B!^IM<$P,5:XE
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MPLW?3;QE>J6FG1YGWQYFO4($ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!3EECA8Z25[6,:"2
M7$# 9YYH*5+(U7=[&-=%I[>=QJ//J*,.5>6M3BC1M1QQR,>7NH23R.EFE=*X
MFKJN/$BE&DTPJI5M89LZT^HV2>\ J*DY4XCAW*TKBQ[#;))GOKB:<>%<OLHF
M669:\>!1X52O$9(F;C5O;3ZL5(D#A^+^33ZU>X-U)_%4XY4PH.*HP(4P\/\
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M?=#=ED! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MNR7]Y^T^WK%5-[7,H0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!!SFL:7.<&M:"YSG$!K0!4DDT  "
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M_J@SPN;<+A;W@;A2;7F4..3YQ1?U2UJ4KC7;97Y3^2_3<IK2QEP6IG^<X.Z
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M"LRR-P5%)GLEG_G[C_;YL.S]8[CQ7)T,E-,_ $P%03V4^M7',+N(!153*OL
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M<<>*]=:Z"MZ^_%9>?<_,S[?9QT]I]MJ'Y4957BFP@" ( @" ( @" ( @" (
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M\Y?D'\X5%.\*+&IJ629)NR#XK8^];6E?-VOKV']KI%YW+RM!+DW/33[+]O\
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M3JFELK_)A^5')Y?'G4( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MG@-J:#(9G^)#GD1(J:# \>/"J%J1:VN)_LJ)!X>),/Q'W?8KQ)P .-#@4#1
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M,_RL]=G[O\YI]%6CM!',W4KSF%<1XHJ5'!>V/62/_P"<IS[;%K\B/7'IE_\
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MOU@@WU:]17">GM8>$$>N?3:*ATA9MKA>N_G/0(O51]Y" ( @" ( @" ( @"
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M^M*Q&OT11ZXZ%]S;)6?[-V?VR/3@O3Q]W" ( @" ( @" ( @" ( @" ( @"
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M.NG=13A<1ZDZ1O5ZWZ@T]?@=L]A"]+'L@( @" ( @" ( @" ( @" ( @" (
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ME1>_.LT[_I1TW<3IY?FU[ZGIKI&V[/J1U,WE/RCVQ+TB>T@@" ( @" ( @"
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M&7O7M+HNRKG0F_R>:5L^&U\FMPTRK3,YDF3",G&L$'=_@F]R]30>'TL^=:7
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MTGMBLH".-%[ITTYW/2*$;>,(2][NJSUVTK?7&H;SFE3Z$>^Y>H#[H$ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M;=P2\:<W+#:\*XT4IA4TJ\LNT]:$M3/-P'G3>_\ 6.^A#E1%(  ^W[D'>3(
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M3@0H'3VK#EYK?]4%]CZ-?+U;H9?YB_,CQM8O^3N>'W%^;\L0-"L9&"M+*<'
M8<UN[C3BOZ86H1OZ6<)?_+?_ '9ZFC.DJ_W_ +SJVZ?QB'J]OEM.4"8>^KR<
MAE0%?SJZQM>5J-1%YJ[+\S/9NBE51\$9Y)',ZHK5QX]Y7T%'RC)$($ 0H0!
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M7L3I2XUT3OL.#E9]J/I?44*]3;5/L5SV,^A&OHI]E" ( @" ( @" ( @" (
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M.2BDLW5T-.B3;^%'(74=&DVSTZTW2IFF'4+SRW28>,B;E+:B@.17[4Z?VO\
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MSOF ZMMZ;2V^D]%-?U4_YJ3R2KRK!]F!X_3.A=RX]?-/D7PU^TUH=@ ,: -
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M)\UK11GYU.',GRU/?>O41]_" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M?7@8+AOTQD?:N5W&'THZ0IS8]AXT/F$Z"]WK?ZLNE;R6S9[&1SG"C2 ZY=Q
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M2/O]U,T!$8&O9P[??PHH^P$%03<,#4<</H0>.8))&.1]B4H T8C#/(U[$[^
M?8LS;FC_ "[$>YU?H"RP_@HS>.7F?RC,N(^DK5:*K)W(KZW*-/TKE!H9&N)K
M0$8$]HP7-OB;2X'$CJEH>W^H&TMT["W?9Q:EMK=.GWMEJ%K.UKF&:6VG@M9A
MYC7@>0^;FRX+6FUFJVW6VMST4W#669IQ:[FFU]-!=L6=5IYZ34Q4M/<BXR3[
MTU]YX,/7OZ.]Y>D/JIK.GW%C=7O3O7=1O;S:FXH;>62UFAGN;N=\$KH[=D5N
M+=C0T5.-%^ZNB_4_1];[%%N:CNMJ"5R#:JJ)*N=77,_(/5'IA+IC>IW=%;?]
M!<DW%K%/%UX84P.M_5;X4>[F#A3@ZHQ!SQ*WN.I;DSR=#I?+MJ*7O%DP37,U
MZ9()YHN0U/)*]C3CV-=1?3]7K;UBL[,Y0E7@VOO/L5C2VKZ5J]&,H<4XI^U%
MP2ZWK36!C=1E:T"@;S/J:4&?,OC7OV^R=%J;G+XO\3SH[+LJK+^FM<W[,?P+
M?NM;U<YZA.>RDD@[ ?SEG_4MYG\6INM?M2_$O^F[/;E5:6S7]B/X&QSZIJ,E
M>:_NO8)Y1V?R^]3^JW%YW[K_ 'I?B:\C;X?#8LJG]R/X&SSWEP:\UY=N_P#K
M,W&G\M94M7+XKMQ_O/\ $/\ IX_#;M?X8_@;3-.YU:W-UPP^*F[N/.IR77G.
M=?VG^)7."^&$:?LHVN9[C4>=/C3.ZD/9VOXH[3S<I/Z65-X<L4EX(T-&AV,T
MAKP-P_L_MU':7!R^ME3N<%AX$"Z)M?UE*YUFK_URP[7:F7S)94'F0C /80?Y
M=?KJ5GR*XXE\R2R*?,Q[7<I',T5-*'O^Y/)IP#G.6!;-[<"KV-82<:GEKW88
M([2[E]*.D87>QLMR0,+O$&MKB>8 5K[1VKQKU[2:6'/J+D(Q\5^)WM6=3?EY
M=N,F_!FNV]H\VZ->M=N:;RNO;J*XF#PT<D++:,R2&1]"V.K1A6E5]<UO5^PZ
M-/DN*<NQ(^;TO3NZWYTG#D@^)=72_;[M5W7K3]08V70MM-F'Q1#?+O98P0\8
M@M'EO;[UZVWWJ[<-TER:9NUI:X)<?IJ?<MGV#2:&+E=2N7^+9A#>FJ7VN;FU
MBXL;OX;3W3F*VAC'*UC8'O8:%IIBT+ZX]=KVJ.[/ZW^)\P[&ES\N/U(N'0=T
MV>EV-O9WTCQ+$/'(0YQ=6@S)KP7LC8NM]!H]#;T.MB^>.<LZGT[=>E[VIU,]
M58DJ/*.1E'1-S6%Z6-MY^=SJ-:*4)KRC](]J^XV.J>G=1'F\]+NH?6I].[Q;
MDZ6_=\3,&T-G;NW_ *U!MG9FBW6N:[< NBL[>.9P %"2^2..0,P<,Z+RO]?Z
M?6>HC]GXG".R;W.33M-&:;;TA>IF[(9%TTN^9SN7Q2RMH0>^W4?4_3</>EJ(
MT7^W:;_[;WZ>*M-OQ+VL/03ZK+T-<.G[X@ZA!=>T(!I7 P<*KQ9];=+0_P!_
M]ATATEU WC:P\2YH/EQ^JFY_%M1L7, :F]9@,/\ 8.]>-/K_ *7BL+OV'F0Z
M,WE_%##Q-^L?EA>IB[>!=Z='8M-*O^)8ZG;AY'#%>/<]2.FX*D)U?A^D\FUT
M1N,G[\:?27##\J?K?,/Z7K<=J>(Y8WTRX_#KQ9>IVR?JQ;_V\3RX="7E@W0W
M2U^4WU-<1\3OAD!J*@6K'4'NML<"O&?JEMB=(V:_3^DV^@[DO]Y3_;P+ML/E
M*:N6C]I]4?*-1SM&G!W9486W:O#N>JEEM^7IJ_3^D0]/9*CN:C[/T%TV_P I
M310!\9U4+G"E?\FD<!7_ ,%]R\67JG=K6.E^W])Y4>@+,5C?Q\/T%PV?RG-@
MPT??=2'7$8%7M^ <W+/'X;N7BW/5+6Y0TM'X_I/)AT)HTZRN_871MGY>G0S;
M.X-(MSISMW7UQJNGV,!)>QOQ%W>0V\3W1FW(<!(X'+BOA-=U]ONXQ=NU_"B_
MI^\^1TO26T:2XKTH\\U]Q[_?E_\ IEV_Z8/3KLG9FGZ#8:/KMQI5I>;@FM((
M(GW<TL,;[;SC#!!4PVY:VA%:A?7H\\OXEUN5UYMGREV4&^6VDK:R2.;ZV<@@
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" Z._GJZ9=W'I@BU1AI8Z;>.^,_P"RQRB/OP*Q+!KM.]EYU/'1
M'BUIK4%K2,*8$!:QJ="H1C1.\N9$@"ASK7N2K8?VC$5H* T4[V,'WH&KC@,_
MN2F *%W5@AYLQ>63AQRN&$9*\0\%3A4]PWH.G=<>C/HG,]W,38W0+JUP;#:@
M#CDBPC7@)NLCE:#4"F(*T8(H*+B.'WJ%X % G4C0^X?>A?81 %3S9>_'Z$=>
M!*=H J">RGUIQ*1J* $5IWT4HZU0(B@-:4!RQR[4[F'W 5P - :]]**O#$B[
M#0-_X9A_NOL"R\ZFG\!O]G'YUY$RA/CJ:<*$*NC5&3CX&P[^N>5QA8?"QM#0
MTS:X?4N;-16&)Q6W;<.;',#E1V/')W8%REG4ZQ.!/J*Z=;"ZS;.U38W4O;UK
MN'0[N&:*'SF1"YLGN9,QLL-T^*29O(Z0NHVE5VVW=-PV76+<-JNNUJ(NN%:/
MQ61C5Z/2:[3O3:R"G::^H\Q7J*^4?NC3M5U"_P"B&Z!KFE2S3S0Z$^)MN;-C
MGS/; )WVP+^0%K:KW/M?K):OV59WRWR7DJ.>=>^E?$]?ZST_M*]*_HI)PX1[
M/L.%5M\NWU2VEU+9/V< YKRTS?&-(=XJ5_F.*^6O^H73%V*EYWV'P,>C=[A>
MDXPI%Y8ESQ?+,]4-\ Y^D1VM<OZ4PC*I_P  O!?J)TQ'#FK]!Y'_ &5O<N-#
M5,^57ZD+BAG=% !3F_6QFF/_ -'[ESEZE=.Q?NX_1^D[V^A=T:_B2_V^HWBU
M^4GUDG =J.ZH]/K2OZIDG*2!AA;+QKGJCM"_EVG+_;Q.ZZ!U+_F7*/P_0;O'
M\H7>50;OJ8(A^<!8!U,NRV7"7JMHZ>[IL?'])N/IY=K5ZC#P_0;G#\HB=KA\
M;U6);4<S!IE<B./PJ\:?JK;=7;TOV_I/+M]!./Q:C[/T%S6WRDMDL+?C^ISY
M2:<X&G.&0&'^Y>*\"7JEK'7ETOV_I//M]%Z>.,KOV&[Q_*AZ2Q._7[VDN *8
M"T>VN K_ .#+QI>J&YOX;%'X_I/(CTAI(YSK]!OEE\K?H1:.!O-1DU -_$.5
M\>=*?^#^U>-/U*WR>$+?+_MXG:/2.V)UN>\BYK7Y;/IHM@/,V_)=4S=\1(VN
M7#R/:O&EZB=1O*5/]O$O_:6R257"OTG _P"8GZ0- Z/=/-K[MZ!;/N7SVCY7
M;KMK=\UR^6U#IJ/+8X.9HCA95<X]>]23;4[U%X?I)<Z5V6%'"WEWG7?H&F[:
MW)M^UU32[=K;CR@R^A=3SK:Y8QK9FR1N!>VDH(Q7AW^I=^OU\R^^5_[=IY%G
M:-LMI<MM8&)]];7-I'+> \K8@X\H\&(#BUM0!F0OBKFIU6H?\>Y.5>]GF*S:
MMJEN,4O!$FW;R#I_T[O]<:PMWAOY[+72:D^?I\,+A#.8Z\KVB9G8L<JK1?:.
M%67[>L'3OH_,8:QZIK;/,<XG]:]UP"^8U\+S4N/:JUCX&DZ1\3BI#%C6A)>Y
M\CCB?$\EQK[RHLSDW7#@;I'ILM](R-D1/,X"G)6IJ,SRE:P*E7Q,\=/^GDIN
M; ,M)KC4;VX@M[.SB8^21\EQ)%$TAC&%U&N>.&2Y2H\%4ZQ5&>G+T.^F6/HA
MMS3-R:EIL$G4#7K:*>_N+FVCF=8PR1VTD#6B6W!:7QYT."\6Y'FPK+ZV>7:]
MS-*O@=D<.FW#SS?#6PY@'%S+2%N+@2<F85)6/*2_M-^+.CGX?45OV+<$Y4#L
MA''CA_):WB5M0C] <Y-4+DT?IMN;7GB/2]*OKDDT:1#<,!K3CY1'$+7(DU@3
MF:6>!?4?IPW^]G/=6%Q;85 >^084%:UC&(6O*;X?83G[RV-7Z&;MTN-\DMG/
M*UE3A(\UY<3@&=@JGE.F2"FEXF*;_0':9,8;X3VTC"1^L$H%3AFX-!R67!+A
MBRJ7-@:)MG9/-!*#V$\?I*RXX!NKJ5H]%CE+2"UPQKEAAAPQK13EH1RKX&EU
M31Q;VSV\HJ]IQI[<L*"B<K:*Y5,L^B7HS9]5O4_L+;>KQN.BFXN-4O7"#S8Q
M+I+X+V$/)C>QCGO905HNMNVJTX'*Y+E@Y+,]C=K;LM+6VM8_YNVMX;=G#P0Q
MMC;_ -2U>:?&FH0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $!TQ_/%;S>CG< X_%VY'T3U[EETJJG:UD
MSQBQ"D,8X"-E?[T>_-3CWG6M%WDPI0BO97#O5XE6)#M;]'VIAF'W$V&#3CGW
M=Z+%U+5Y@T!YB?=3W*<!P-/=4=&VF1G@)X_AD;0X^Q,F96./$]LORYKKXOT0
M]%G$U?%!J#2:UP#;5HXG@M1K3$3JI.F1S-PQJ,32A[/[*O>C/B.%4*\JCL05
MK0B"1D<TI7P"^T =IHC$2-<*?1W=OMJA0#2AIB*U[T&-.\ ?Q!!EX$>7L/L[
M^WV44J"8'F/93ZZIEBLAW&@%/VO"?SO%7Z![E,WW%?P%Z[>BY[J61P!:QKB"
M1V GW8K6>)AO Q7O2Y,UY<N:26@N'LH7<,0N3SH=E1G&[=H+HY@<P'=GZ+O<
MN4OL-P3;.(^^[9[FS&E?QU']_P!B\=XYYG7W:'#O==C(9Y SS&DEP\)<P?B=
MV'BLJ*K5JI>&!9,>BSR8D.=]-33^52JVH+@8;DL\C7,VY</ :'2]]'/ '$95
M[%KE2X(U[U*D3MB<!P+Y@74KXW\,J>Y.6O!$Q)K78&LZL\Q:?97UX]Q  9'.
M17"F(C<$48UI1!U,DZ3Z6.HNLQ^;^S9K:)S0[FD<\&F!R=%7);C:E+)8$<TE
M5LI7_I<UVPYF7-V6RM'B9Y=:'B*^7CDM^2\J8DY^)C;7>B&NZ4Q\@MS<L96K
M@TU(%> CK^;]:CMM&N9/P,,:G86>FW#X+RW?!*PEK@Z)S1489EHKD5S<'3$O
M/5XFV!NF2&@>/%3AG]2SR-BO!9&LCTZT?3E<TU]@IQ^M3E*L<,BQ-[;?L+VR
MN+2]L;;4+&YB?;W=K<0Q3LEMY6/CF ;*Q[03"\C)1D[LSHZ]77H'UGIA-?\
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M%9,!7,>'V_D<T0KV9BG*:'$=GN09E"X-8'4QI1PX8@U^LJX)@]D_RK-0GO\
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M85:=F1:U1F;;=A#H&D,N9&CSYV@N) YG$@<O .PHN<FGD6F.!<NA[:O-R:C
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MH[^_0EI$NB>F+IU8SPM@F%M>2O8UXD%9;ESFNYFX&K*+4/A/#O?S&<OUHY!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MYO+@-+Z3VS9&.DMV  FI+ :TI_L:TH(B;^@RAI>Q;&S:/)M&<P QY&X&G#P
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M<'.5CD>%=KYCJ<C%HYA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0'5]\X?2VZEZ#>K9(\5FW3+EI[ )
M96'MS+PLRX,ZV?C78>'1M2&G*@ IGD*?<H=G\3)VUXFKOR]V2&^_B0'*XDY
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MVO?_ (&-:61X=QUFS+2IS" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M9F%4P$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MZ@HY8#B9I9N*/5-$M+MCPXB-H=XJFK&#O)'U+BW3P*EVYF_:#N1D]I);%]2
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M.>V-Q)<XEQJ2HLBW?C.S=4YA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MA@[<NB ^_5;<+HCG+,^PU\I*$0?+]].L0P V78FGM@A*+(7?C9V0JG,( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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ME;6 Y*1R+<ISX9'8>M',( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M.'VI'(EWXV<]U3F$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M\1!)'>V5S=RU#K<L;4$^(.(QP.!J5I4I1#/(T\\\=K$V:*VDG<,3RR.::U[
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M,CD@J8" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @+/ZA6K;S8>];5XJ)]J;ACXC%VD7C0<.PE1Y%CFC
MYRV[H3:[QWE:\W\UNW<K6X9#]M7V'NHN6%.X\ZE#8!2@Y<.S[\TI4/L)12E
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MT4+OB+5\<C+5SHI'/)=%0'G<SZUSL7)78\SP9JY!*1Q-\T@EQH13$/ >WZ'
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MK:,?K'VT^B]N+7H_TJMP*>5TYV2PCO&VM,KA[461SE\3,EJD" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M^FBT8?QX'VU.DCG.Z5=,G/P<[I]LQSAV..W--)^M:61S>;\3(*$" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @-FW'_S>U[_ /)M4_\ N,Z%69\ZWK8''K#U$>]W,X[JUVI[?\KW]./
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M_P#VG2E>!S7Q4/MH]*V\G3#IPS+DV%L]M.SEV]IP^Y59'-YE^JD" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M+:?4M'%YEY( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M.1J4 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M%!# .6&&*%N7+%&R,4&6# !@A"J@" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ("! <"UP!!!!!%00<""#@00@.F[YD?RLMF^J?2+_
M *D],+6RVAULTVT=*R[LK:"&WW.VU@<RVL)X8K9T;+E[GDF0XN)QQSQ*%<5F
M=[5VGNR^$\?/43IOOKI%O36NGW4G;=[MG=>@7,EM>V-W#<,@F#97Q13VEW-#
M#'="81EYY*\JYU5.\\BCX9,XB^JP ]%=6X@:QH) [*7[5J.9B;K%U.7'3'Q;
M+L"!XFZ'IU.\_ 6_N% %,O VLC&5R7.UR<O/A$CO=XCV=Z2Q)^L8>ZP.:[3I
MV\1&[#'Q5$G'A12(=:8G6-NUKA>SM&(#W<V' N>NJP.398DC#3V9'Z*J/#P#
MJU4I<N%>9H]KFC[U*D*+KF)E#)-$RG$O9AA[<4R525PJ:";6M(MP?-OX6D?R
MV?1^+N4;QH\BFV/W7I/X8'3W1[+:WEGJ1P_5!_%6JX9$PR)8]<UB]E9%I.RM
MXZFZ0@1&QVQKMTUY) H'6]G(TUJIS8EIQ,N;9Z%>I[?OP_\ 4_H=OVZ;=%C8
M'3[8W':M<9'-##S2Z70!Q>/8IS4+&+>1S4Z<?)<^;!U;DM7;9].=_;65XUCX
M[N^OYK$-B>&.\R07.GCD#6O!-<DQ8:IB\CG)L/\ ==_F2[NO;2'?(TS8MI<%
MOQ5W%K-EJ!M0[EYCY;+1Q?R\Y^A6D\N!$X4S.PWI5^YU[DNWVU]U5]5L\43>
M1USI5EH$5Q)(#R.=$'NL8F!H\32>9.1\&9YH+O.QCIG^Z;^A?;-W83]0-0U7
MJ!%;&,W4,K(]/%V6&,OJ8[=W*'EA_OE>3M#N1:HD=C.Q?D!_*PZ?26=QH7II
MT-]Y9AG)=ZA?7%Y*]S SQ/:YK(B26 _A5Y(\3/F3X'.;IEZ&/2AT@E;-L3HA
ML'2Y6-:UDDVW-)OGMY0P-+775E(01R#%51BB.Y-YLY'6NS-GV0 LMJ;:M T
M-%KH6EVX &0'E6K* 46J(S5F_06MM:MY+:W@MV?H011PM_O8VM"$*Z ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M 0! $ 0! $ 0! $ 0! <9O4YZ/O3SZP]DGI]Z@^G6D;\VR;F&[^&NV"WNA-
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? $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm2113965d1-pht_gtx4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_gtx4clr.jpg
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M4F)R@I(S%?!38R06HD,T)1?QPM)SLV0F@T14-9,G=#8W_]H # ,!  (1 Q$
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M0=P=@[^W'M_1-DP3-T_4+BTD?TQ.#3'/*W/[^*_" ?>K=+O,1>.5Z51T)O\
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M\\/SK3HR131&,4?U5]WNYK4$M!(YJ)P<P$>]22I(L:TN3N%00HG1U#54&B@
M1NKJ$J(BH4( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MYSG.]I5,NB5CZ+?PY/P+NY'K T_;^M:CHVI0Z3J\UK,^]DM[N*%EM+)9O?\
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M00T X''Z5&ZW*K(F4*$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MI=1M\V%H(;4]-<,#3PJN2*QS@^;7L.*N2,T\>I:Z?;L;*]XF,KXQ01D$"*O
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MH63=&M=2* ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M */7&W2QR\DBX_\ Y>+\0WJZ?^C*_K_\SW],JY_N]6HY7WDI_AY/Q#6N#?\
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MP_H+\[>9>JY=].>24N:,JV/VSY9Z)AZ=M88\<5%I*]/ SII<,C+(PRRA\AJ
MXD$X\,35?+UBQ2WJER\3Z9!?P>5.JH8!]0?<K0>U';K<.NZUJ<%I<16D[K9K
MY8V.D<(9R VLC#6K."]]\O\ E[#ONKX7BAS)M5MIIW'HWFGK"V/2LL)32<8O
MCK9]Y\5'JH]2VL=V>Z.HQ1SW=WIXO+F**U9+/*QS73SM;1K9I&XA_)?LC9]
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MP1PQ:>25.T\RM*H=5TT$T!U"RJ>0^\1X_(H;>I^PQ_#[-#?P_NVW3_Z.M/\
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M'1EK23P%<Q^=&E2M0J]EBQFD9T![STTKTXUJ1^8JXWJN DVJ<MR@ZZ+V@MP
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MQP>T.&11JCH$ZJI,H4( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MF^Z;".*\J.I\.](=UFV/F[<X]PW"',FEIQ/L"_#R[W6W<WMA91:U?L=JL=O
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M="=4@0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M(H:CFE:W1+\=29 $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MGO\ L\&/:8E@A:*X'(,:14%N#L\?:NJFFZ';54RJ  *#);--UNR*$" ( @"
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M2O=:%5LC'UZ7L=TFCNEP-#R-":%0M&3H0( @" ( @" ( @" ( @" ( @" (
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MYFE*+T:+N.>"4N$4T4A;3J$<C'EM<NH-)I59::='J7O*J@" ( @" ( @" (
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MB_P.2.7'*T91;[FCG6/9(UKV.:]C@'->QP<UP.1:X$@@K@-DR ( @" ( @"
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M"'?" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MN<WEWS!U#R!N8N'3-K)2VC;J\G.ZSI7L/N7S7P(^N! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M6R1.SEC:>1>W\X4Y36I= 0DCXXR#7)X_Z[FFM@7488 .DMH*\0:9^/%1BQ<
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M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M$J\\;LXL<UR\C=(UU+W:':;?%KH>GR:A<'1M2EDO9-4TZ)W6VV%RYSH0V1@
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M_DITC%+#M9XY*DEN,OYV:O\ K"96T[=W3<"VY>"[CC,[P7YP_4+BY_)V5O\
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M":>!.!5N J3X^*"J94&!/NQYH$N!,0:88'FM:7#[B&%17/&GUJ6*34+FG"A
M-<?;1$^+!EBPC:[M5J9'V@Z.G&GQ"N)P67_F]I5_E]R,6L(H/BP('#D%MF%1
M>)F3MR -E]PZYNCM*'^B."XYW:J<D7[K1A]H!ZZX_M'\Q^D5R?8<96Y?0J[*
MBU-+6XK7,8GYOD5(1E;6.7#]!U,<_A*XY4<&6-4T7VBBFC68Z>GXIN-:_$K#
MX42U:':=NOZ-;LW' ],K2/\ &:1FIEMR/C\V'YD<F-5;_L2^P\JN_$38._/<
MB-K?A\VS<!E3JZBOZH^2IN?D/I<WK\K[D?RE\_04/5?KT8Z_,B:J]_XO,[97
M)I3HEA/R2//TKQ'J)#G\G[V*_P!V_L9[;Z3S^5YTV4G9<WWHP%H#W2:+8//Z
M48&'\UK1]2_EGDMFR+_B2_,S^FT76$>^$?L1S@'S9>'YZJ<"ID[<#E4\/K4[
MQW%5K17EXYI3M)5F0^S\OW7O)VMN*])CWIMS'//7=.IQP1W5"QM*Q^H%HSS-
MMG:,X/\ 6[5T!Y.?V]-@>#_LER'6MQUJ=KL(A'%UAOQFG'.M%K@8E=WT+T$-
M+C7X74Z?=6OCFJZNW$--VXD2TTJ,7\\OFRR2O#@$^'[I/45 XG+W+)FA*.J@
MJ>=1ACR5=. =*VT J*NIB:?#7EAFEM.!;:<"90@H*@\1E[T%0@" ("-5R<S=
MUH0*2575<0%JK:M\0)VCX@&GWT\.11U2[BJE;%0FF9Z:Y"E:4SQ&=5FR?<:(
M?"ZOPAU*4\:YYC@K1Z/0EF1,$+L>D=7Y<_!1%JUX$GW6%U13I/"GSJ4$NTA]
MSC(P!!YX5*-5=B.F@^Y1\W*<K,DXM(12H)(XE7E7$M2I]WBQ^ ?%2ONY<E>5
M!.ER<1Q@U# #[$2H0G5 0! $ 0! 2]/Q=7'^2B%K:@#0#6E"5"M\#YR/QQK(
MC6>T]T&X.9?@N]@NORS77R_%5G;P+W*'@_%"2&X9@>[#VKCTN<J[CD60X -S
M-<>6?,I6FN@19;@VKH^\M O]LZ[;1W&G:C$]C^MK7.BDZ'B)\;RUSFT>ZN"E
M7J*GD-W/[5:QVA[B0Z7=V\K]"GGE?HVI=#_*GC=(]Q:7>6UC?+8*9XKZ'Z59
M.7S]LFG?WON/2/4.%?)^Z7&L?M/T,_P4KUE[^'1V)Z"'?=;'4K9Q'%S;ELM?
M>)@NWZHQC#SOO(1X23^E&?)N1Y?+FVF_Z)ZMKY^>SA $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0%E?ZEIVE6[[O4[^STZUC:][[B^N8;2!C6-+WN=+.^-@#&BIQP
M""C>AX:^M/\ &K[0]F[;6-H=E9+?N#O2&.]T^]U**>**RV[J$3KB%LS&NN&B
M^\N6$98&JXY3X1.Q'#QG8^3/U.^NOO-ZBMQW.X.YN^K[7+GJDCL[>WFGL=.M
MK5IE;!;'3X;MUJ\0PR=/V>"QRN3OJ<J:2I"R-!=8W5?ZM,0U[R'..1=2I)/
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M4K]H+Z2ZT5'JJ_2?-(R7%)23:I3L*P8S,L;49_"/=D%BKX,Y5W)$Y:T/MW$
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M%O\ ?;O%N5N\CGRI<M>!A;7.[_<;3]RZQ;V^X'MMX+N5D4?EDAK&S2!K?M\
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M]8]?,/\ _<?<[KADP8?J@?)/0J#P^EVRPMUY=QN+_P#ZC/HL7Q@^M! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M&>W]\^E9?%3ZH$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! ?*=_$V.O;C0/3-I,$\C+74
M-7W6+J%KWB.81V+BWS& ]+^GA4%:CJ<V/X9(^3ZSTBVL61B-@,H&+Z U(IS
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M>NN%?]50WG[V7;XJ^R"/E/I"EC\DXL$52,=QF^N;/I[7Q$^FA $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MG^6YM/G4:7!JOB;BWQ32\"Z9B<<CP_+Q7"['(N_4V<]+KNG>.IQN.+[:0?\
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M.=9,4L*R1T=8VJ<,H==^6\>:.;DE\2I*]"V;<;BBL/W2+;58M.#V2_=FV-X
M'QN#V$.$8I1PJN5KIT\_\SS8GGI2O-'C[3C7^I0V_P#*\F5;>M:<LM4_ [3:
M=Q-_6$DKV37QDDCCB<]^D7#J,C8&,#2YGPD, 7CLO1NAYDHRY.5-OXTM;]IY
M#'UKK^)N4>>K5/@>BMV$O_2!O$&0S27SO-:]CR=/N :/!#OT<B#[EO\ T3I+
MI3Y=$TU[ZX&/]<ZQ^_\ ,JOZCXZ\#/'HYG+.Z-Q'Y-Q']XAN7N=)!+&USG1M
M>ZI<T-Q)7I?JG!/H$&I1?*TK-,]U]*IN/7<D7&2<DW=-?:=+]1X$/>G=K)&R
MBLD5"(GEI!,V3@*'!>6\@OF\I[:C5%7BNX\5ZA-+S;N5RRJZ<&<!LON<=J0L
ML=2T<;DTNW>'V-E..@6;NIKG%ADP^)PX+R'5O+ZZE-YMOF^1N6O>DOWCQO2/
M,$NEP6'/A_F-JG6,7^Z_:=KO^\.F:YJ>HS[AVPW4=(U#[N8M)=/T#3W6M#'T
M/+C0%PQHO&X/*^;98(0V6XY-S"M9T^*NM3R>X\UX-_N,D]]MN?:Y*>Y6G+RZ
M49UJ/?C!O+^]<&GQ6444$D%IIT3F,;;M=$86'J:0'%HH?&B[\NBR?2O]-ED<
MYN2<I/C>K.@NN1_U5=2AB6.$8M1BN%J([CH7=NVM[&UM=QZ=^];BPDN3:WGW
MGR^F.Z>2]I9YGQ=+747B]YY9G+-+)L,GRH32YHTK=>P\SL?-4<6../J$/FY(
M.7+*M**6O$:CW+TI]G^[M%LGV5J)&RM<RZ<#4O+Y&N+7@D$E7!Y?W$<OS]U-
M3R4H[=W@8S=?VLML]MM(.$*UU[ZF.-P:A'JVKWFJQ-$;;ED(;&",XFT<3GB<
MUYW98'M=M#;-UY6[^)X/>9UNMS+<:*25O W\[?/^]>F.ZC)!Z+.Y&!K3X6?6
M%\1ZU'D\_P!>+G$^W=$_B^0:?U)'GU#B)6DT_M%P![IG5^A?<I6Y7_57V'Q"
M#5&OZS^TR-VTURRVYNZSU;4)O(MH8+H.?3JJ]\5(V4J/MNP7@NO[3-ONESVV
M!<V1RC]MSS70MWBV/5(;G,Z8XQE]-+&8=.W[MW<$%A#J=S'H[[::[%U Z-LT
M=RR61WDR@$EK?A=5>K[CHN^V<YRP1>52C&CK1QHKH]KVO7=CN8P6Y:QM.552
MJ=="[UG7=NZ39P6.BZE:7<A>#=3_ '6&LL<AQPI\/0Q<.UV>^W6:6;=8Y1A2
MRJ[-'/NMWL-KM/D[;)&62MW1:-EQNQ^U;W84QL;RTM9+=C'-:R.$S7<D@K(/
MA_:-Z7J=.74</68QRPE)2=[NB[#&_?3\_1F\4XQ4=+*K?VFND&1/"O\ E#&A
M\%[S+4])CH;)>F)_3ORX;7!T$M/^Y-7H?J!&O28/L9[YY ?_ )K-+2GW'0^[
M$?E=R=R X5F!^5TI7E_+4G/H&!]QXCS-'DZ_N(]YV7MY++%HVIB*W@D;(Z)C
MKN0Q]=MU%HJV-WQ/!JNIUR$9;K&W)II/W;W.YT24X[3(E%-6K*UKG9[G8FE7
M<UUK%W)%+%8.M_WMT.8UD@N"/+Z>D=-17@O'8NL;G'"&UQ)ISKR=JIKJ>1S]
M(VV2<MSD::AR_,I9.NFASDVR=LVDDMO8V<?W+6&P&VNS.USH.D R? 145JNK
M#J^^RI2RR?S,5:JFO8=E](V.*,EA@OE9*4==.THWO;/:5FR>:/4_.9:",3P=
M)'4^4?#TNICTNY*X_,'4,C47CIS:/P#Z!T^+:C.\=5VU[SI&XMMZ?I$#YM.G
M\W[OTF?#A)]D8C,+R^QWV;<S4<T:<VAXOJ'3\6S@Y8I5Y=?:7/;20-WSH)K3
MJD...%7,\%CKRKTC-X&_+]NL83T89BQG^*WZ OA[U/M:T/)G\8JW,GI4UN<"
MOW>Y@/LZA,#CPP7!EX'8V[NT?)E;3=4<9 S8WYF^Q<' [7VEX)0"*BA.1SRS
MX)2NAJO:3F8 89_EX)3M)6FA9ZC)UZ=?M&-;6>IR_P R_P /%:Q.FYPR[,V/
M\Z,Y57#E['BG^5GL;_#9R@:AZMK<N^,:[ME[65R:VWZ2:>UP7Z!]:85_TW<\
M9[=?5%'R+TVER[/<;=:0S2^N3/JE7PD^F! $ 0! $ 0! $ 0! $ 0! $ 0!
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MFCZ:^N&-C:__ '$*K+N(NV3(O[S_ !(\.#3Y</\ "OP+1^V-L25Z]!TP@_\
M$K7W_P":XKF6\WBTRY?\3_$XY;7:2UQ8Z_V5^!9OV5L^0D/VYIGM^YV^-?\
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MRBZ76LF*72<U)QT[4=_HD,D>K87*,E?6C/1V/"-G^(W_ &H7P^6K\3[6M#S
M_%PM!<^C[>DU*F"6T<#R)$_TT7!FT3X'9V]IM'Q]V\O[)E#2@I\F')<"KP.R
MD70EH?'G^05O2Y:<>!/YKZ'PS.'T44[T5N]]"C<2 V5V*9VTP'OC?X*UIDQO
MBLT/S(C7\*:XO'+\K/6_^'"U$6_<KU5Z67 >?+HCPPGBTVAJ,?J7W_UDYY=-
MZ)G_ '9X:?1$^.^G#C_,]2P<<>2OTL^M!?##Z>$ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MX7:=?@"G_%9 <5^FMTO^7EX'YDZ8_P#G\;6E3SIV&TP[G[AQ9 :BZ@Y5NG^
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M6>.5.^B/A'IIG4O-OF':5OBG"OM9]B*_/9]B" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MCSHOTUZNQEF]-_*>:/PQADK]!^<O2U<GJ;YQC6W-A^T^U9?G4^[A $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MXTH,<D%$3-8TG#%O',5Y<:BA0=S#:5JX9YXGAED@L1  %2,?T<3SQ0M2;JJ
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M[CE^=3[J$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M1]?7\-=J G[-]\M/ZJFRU#2/AY!]F/'B5J'$X\RI&"XW/I.SH?:M:6.'2Q%
M$ 0! $!$4!Q%1R4"[PJ!4T(X%*5]@K2Q.!@7'+ESQI\Q1U=N)4N/ G:2\T!I
MR% :X8X^Y5Q2[Q6I-T%F(&>0K]=3S4K:C%+U1 !KB'-.(SP/*@S31>)=74K8
M''(_+3@H2ZMP!&3:\_SH*\2;CEGFA"*H" (!XI?4=_ F#B 0,C2ON5\ NTF#
ML@?B KAE3\Z!+L*@<0SER.=<<?8FI*)R[BH0"*')#"=+H"M,10\LT#[@""*C
M) U2S)@:($Z.J(USPS55O$K>J6C)CA0J<MJG))I.O$J]0#6];<#6F-5:+1:,
MQ6^M&&%X.6#LA4</%/B=>!=:UM0B)#CQY<*?,JU55B.5-51K=ZQ+;[_Z:.ZE
MN1]K;U]AG]FW>[P4DO=9K%;*NP^!QY,=]JL9_0UG5F_Y-].!P\%U3MQ? J&4
MDFN!PPY_,AJW AYE:\,ORR2Y2+)3\=<:12>&;#X+&2G+7A5?::A:1O;^!C?B
M'U[W5D8Z.N;/5"'5_5MX#@/8%^F?/6X4?1GRU!JOS/F>RA^?/(G_ /UWS="E
M%'Y/MJ?<TOSL?;0@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MJ^P^[%?GX^O! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M3@9?R^5M'JNZ&WM@RVLQTVT+&-8TDFCPT"3$XGX@N;2W ZE^.I+0@ \#DE>
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M\0!Z09PT7.G7=N/$1NISRE!3G5:TN/DV^(Y^#\>ST62$>;)=1##J/E--,O\
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M3P@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MT4N;[CY;ZWX5G],]]'L2^\\:;<G^SD?HSM;7E24#ZE_1;)\<O _F]@KR1?\
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MRBJ^%JZJ?3W9T(JD" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M_@"JUW37"M4K1 K!U27#/C]"I._B5!(>&7'Q^9$A9E8O(QR^?ZE$6G$J-?0
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M_2NK+_\ ;9?\,OP-+>[-_P#>(KMWYLDM^#6B?'[N<,3XXU67TSJO_P##Y?\
M#+\"_P WM/\ >1^E?B7;=\;//_T8)K_Q=WU*?Z;U7CMLU/[,OP'\WM?]Y'Z4
M7+=Y;2P(U8@'_<'8_*ZJP]AU)6>WR_X9?@;_ )C:ZK)'Z47#-X[4ICJV'C%2
MF?\ .XJ/9;[5X,O^&7X!9MOPG&GBBYCW9MEV6JL\ 6@5K7^=@L_RV\XX<O\
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MAX#JK[Q@@)T 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M8.DZ;9&E,'06[N',Q'DNX\>S:_R<:7]F/X'1GC=:J3^EG,_]&FV"VO[HL/\
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MH['$9_M1CAX,X+@EL^F/_N,7^"/X'2R1:=I23\6=IA[+;(+1U[?813A../\
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M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" T_\ 7FWJ]*?=T?\
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MVGT>+K%/M1V%QHTG\LUPR550VE5T)(P,3Q_PHM"R2C9:%54R$ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! :D>NF#[SZ6>[D7/;5Z?\F"4J/0Y,7QH_.;U$_P"M=8:,0-:U8?Y-
M_/\ F7-2B.6M[EJ 0'%HQ-*"N=,#FI]HU=&1<VH)+NDX84KX)1/45H2@4!<,
MS_@]F2?:&[T)VT./+AR_/5%</0B!Q=\0^3Z$)WHA44Z<G?+3C[#4*A]ILUZ2
M)?)[O:>RN$S9:X?JMB&*N-I2)/0]3W"DDI_1ZB1\I]Z["K[#B(QN+P1D!X>_
MP*E76^@)PT8@C*F..-52$XIF./U*:.A1C7Z/!*=H(J@C2HRRS->>24J0J,;0
MU.'+Y^2%)@",S7W40$^)R&')!>G<3M!+:#&N0]A3BPB?( @U.-12BC9;%=@+
MAU.;U$^(%,Q\Z.V@=2?I<<78D?9R%:YY&F"E:#W:EW;G]HT'#X7T_P G%0+4
MFT!I\_4P<0'-IPQJN/':)N>J.SAM<78GZ/D6B*G YW;+C%J[GC"NE:L,\JV4
MHSXU6\#:WNW:_P!_C_.C.9<VVS+_ (4_RL\'-]1]'<'=\8S&K7IIXF\G.?BO
MZN=(ES=#V<NW!#\J/Y3^8HT\U=0Q*U,K_,S5#U41.?LC0K@M^&*Z94\JSN7S
M_P!88*?I[U'M45]C/I'HK*4?4/IB?%R^XQS:.Z[.S<<*VL&/.D3%_,N&C_M/
M[3^CTG5U78B\ -37PQ6S#94&%'9TS&5*X!!]A.#B!6M:XY?,J2G:5FT&)]WU
MK+N:IP1,TU]RMN)GP+@$BE,2:UR&62FAKN)Q7G4>RB>&A?#0J$UPKASI]2$I
MQ)VD@U^?W*DJ1+Z!I<*_M(^-/TQ7+P6.5RE&$=93BOI:151+F?!,V=VC.RWT
MULKZ-C@A#V--*-<(VG#(8E?T7\A])Q='\G;+888\ON)O^\DSX]US-+<]4R3U
M2=C#G>+NC#M#9&X-S3SAESY,MO9L+AU=4S)H@YOQM/PD<%Y3S;U3'Y?Z#EW7
M,HY6J+OK5&>E[1[O=J-*P6IXVZ?^\-Z;IM[.:Y?)?Z[J+I[BYD<7G[H+KS9&
M]3RXT\EY"_*^[ZCCP8<F?)*LKMMN[K='O\,57&"T6ANOK#-*TZ&QVWMUK&;?
MT:WA%NYC0TSW$L0^]F0MH7TERK5?#>H[W)U'?3W,V^5NR[*'G\6+Y<%!'$"F
M>8Y9+I&[U'3QY_4KH2O <<JCCP4'VDP-""<CG[DK>Q.X@,"*X4S49=4/A=B>
M'MQX)1H72H0-36F9I@KH[A46NA$5)H<2.&6>.>62EZ#PT)JGB*#CQ2EC-O:2
MM)%> PQP/S*FG]8!Q%?<HU8CL3TSIAEXIX:$^PD% *TJ>.*>)63.(ITC+\BK
MX%(FA-1F,_'#!35$;L25%!7$_)3\]4H6A!S00*D@@AS2"06N::BA&.:<TX2C
MEQ-QRPDI)JS33JOK1+.J?PM49D#8^JFPW?H6NBX\HR]<&MQ5HVZ^S%:]>(!Z
M?%?9?,N[Q^=O3_;]?G277]@N7<2XR3M&NKLCP6S@^F]5GMT_^6RNL5P7:;>O
M>20<NMK9/Z,@ZV_,5\7BU)6/8VE[ 7D 8XFOS>ZF2H)_,%*5P]G\BO$$0XY@
MT]U4=&9K6Y4!)!<31O# 'P/CFLV*B/Q @YCW!*KVC5@.XDX<13ZU6DBD030>
M^IY<E&A4CU=)Q]WCS]B:Z Z['-]W[@[*N0*&/>NTG5KGTZ_8'W+[]Z$.N+K,
M.W#I_=/D7JG[F\Z5E[)OV59^G7VRN_OW;C85WQN-F[9E.-?B?HMDYV./$KXE
MN)<VYRO_ (LU]$FCZ5C5,4.^$7]*1W27^K=[OI"XTJNYH1?U;??])1JCL"HH
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" (#7'U;V,&H^G;NI:W(K$_:>KN(\8[&X>WGQ"C.3$J
MS2/S=+X?ZUU\URW'K[ *9-9JMTT?,%RUX'*ZUJ42*$.X8T/S'! ]>X=!>1_.
MK7QZ?>*4HFA>%B&&+3B</=Q]]4)H1JVE /B->?#YLD"T)6L<0#]IPK7A6IPQ
M/@@5&3=!))ITUI05K6@Q]E$X]PI4V!]+4XMN\>AU-"_SP,L<(A1:QOWS,J<M
M.)ZT/;21^-6UKEE7YS4KLWT.'4BYH+2*<L,N*E+U!/DC90J0C3"I]WCS4[BD
M0TD5 _EQ^:B<03M%:'AC0?-FE 3@4^*N(R-,ZX'PR04XDXQ(-<\\,J*=Y=+\
M"8-K4@5;AC6E/=GFJ+LJM:X $C#K:2_^;U?$*#P0=W$OKLV\D_5!&&QAK>L5
M_2+:$^\K*T[R._@4^GGPX\_S42MBU)P. 4(75O3S"*=/PNKQX8(%JB.W1_:=
M6<30![/?BN+%>)S3U.T$BO*N0S6S)S&CU^_..1_=VI!QYUM9![D@Z;C#+A\[
M'^=$G?#E7_"G^5GA)W%8Z/N1O1CL>G4IRT\JW4_YE_5OH,ED\N[&:_W,/RQ/
MY3^:XO%YUZFI?"LCH_[S-6O5)&7=J[&=N!BN81_\L[\R]*]5X<_D+J4/ZB^Q
MGO\ Z/22\^],RK^E+[C$&D.$FDZ=(<:VT(_^29C5?S%C5<T?Z\OM/Z1M63?8
MCE1\(K7+P6EVDU\2-:4(P(X^WP5(50[(#$_(A5J5!ECB>:A4RHVO X#PYJ:A
MVOQ*@]J!%85.(.!_+VYH*<"H*. IQKCBJ+J_ G&&'R'GS3N)WEO=/#6,H<Y8
ML<1D\$KR'1<"W76]IMW\,LT?S(X\SY,$Y<>5_89HN=9&G[3DD8:%T40&-#]@
M5XC-?T\V>VABQ;?#"T5BA^5'QF3>3+.<OZ3^T\Z/5UNR[FT;;FDLD(MKUT[I
MVAQHXL,I%0'8T]B^$>O?4I8,VRZ?C;4/>YN_6A[5Y:P)0R95JS6SLM8OU?=K
MKLRF-FD-%7<^MK *'@OS%UW>S_DG&OQ'MNV@GD55H;8N(JX'@2 ,<J_F7I*5
MJ'DZI:$0:U^CDC5"/L&)\*>]"V0-.D-;CG4^^H5XU9(OM)CB*94_.LJS(K.I
M&H()/Z.?C5*=@IV<24FF>":E[P2>>'L&'YZI;VA)>T@":M=G2OAX)P#^@FH:
M$\,$)55IQ)1XY\497]1-U TPPQPJ<4I0B7$AD.9^1"\>XBT^-/G0C( U^&M/
M'/Q4[RTI[Q,2:T+<N-?J5TT)3BF0Q. XJZW :>#L:9'+Y@H] UQ6I1E,L<,D
M\$CFOCNK)X+:@@-F82!3F O>/)4\FXQ[[HR_RMQ"K7]E5/']0C26/.U24'KX
MF]FDWIU+2--O@?ZVT@:#G4QPL:[&I%:KT)Q<9S@_W9R7T.AY5.J3X-'(8C_&
M/'^3+)5%X$X<*5S'O"J)1O0J T/@/K'RYI9ZF5V\2;J-,OM</9XIW\!]A$.J
M.5?J3C<M28OK7'#\O!%1#A5@N(.)Q/"F:6]@9(Y_S</Y:)XZ$53J=])T[MV@
M^M#_ 'PVL0?9KED5^@/T_+YG4>IX'\,L$OR'QWUEF\&PV.XCK'-'ZY'Z;G8>
MX=<]F^VDSC5SME;:!/LT:R"^*;Z"Q[_/!:+/D_.SZCC=<&)]N&'Y497?BP^[
MZ0NM'4KT(1GX0!EP^4K,G[].!5\-]2HJ @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (#7KU5DCT
M^]TB,_[I:S_[ON5'H;Q_$?FWWS W6-P$F@.Y=P84/_I6ZXU7*<^I0!-0,Q^1
M]N:>(>@+0XFN8_2QX^&62E0Z4'0/LTJXY<*4Q/&F2MVS-"!8&TKC6M1E]:59
M:$>EU 0*''DGV%56#U$]/Z)]G#'VYJ*VA/L,U^G-WD=X-M.=@'/E#<1F3&%J
M->9,C7NOM/8.4$.%?U&&G*K:Y\5V3A*:BJD M$)A3&IH#3A52G:4#'%W'Y^'
M#*B=R!5QKX?1^>JFMT0B!0#"E:T%:\503LI4U-![*\U&DS5&5(V O;C6M<,J
MT'M5K0<:LJ 5J&MH'98\LT&K*Q>T M!I2E!2O&IX*4'@3AH:W =+N.-?9]*F
MK"U[B8L'74G++#+#VH1.Q5:XD@5Y\N2B#^LKPM+9,<^EU?'##V401M)(GVR*
MSZNT_:ZV?3\BX<3K'N.:?Q=YVJ..@Z2:@^%,JGFN1OB9.3TT_P!K<&G'[C?@
M89]5L_Y%G3)CD_\ ?8_S(U&\9K_AS_*SPM[HQ.@[I[ZA>*%E^XT-?TIYN:_J
MOY9DLGE3I\XZ/#'\J/Y5><8N/G_J\)J\<GWLUA]3<?7V;DD KY,T!I3*LK\?
MG7K/J5!Y?)G48\7#[F>Z^D\HX_.G3Y=DG]J,"[6>9MN:2XG.%HK6M:1M7\OI
M*F2<>R<OM9_2=/W$_P"JOL.>  IS3B2K?@3@AN)X(%<K-/Z0P)]^6"NI"H*U
M%,?F4-/0F9AAD#]54U'=H513G\R7":14%23C0\J54"*N8P&7%4M29M:9UIPR
M^=*F7WEAJ!'1&ZOV98_?5P7EO+T^3S!LY=F6/YD<6X7_ "TUQ<7]AW[<,CG;
M5:&@C]E'4 UK1GLIDOZA;)<\</'^%#\J/CFDIKL;^T\V/51U/BVE*20UKKJH
M_P"Z\/<OS+^H#%)=;VLWHZT^L]O\N2KM9<IT+T^-#KO<[J?$/NU#D17HX^U?
MFGKR:QQ3T/:MJ_?-G/;C7W9>Q>M+0[]. ZA@0<N'\JE2.]D1QJ*X$U^9.!:J
M@&0;^7-7O(T66HZKI6CVKKS6+V*QM6BI?(]@( J:@.<VN2FKL&TOBL<1HN^-
MG;DF-MHFNVMY<@T\CS(F/<00#TCS279J4:U,J2>AV8D9$4(SS]RM.PU1UL0K
MS.'T_7FB[B_:1+J5PP%,:\T1/$C53O !S'L]WYZH"&.7'@?Y%1W@$4J<1\BC
M&NA!I(& KRQ",-(CU4)/$41*U!2W<0-0:YTX8!/ H:<#PIFK<.Y%Q&%1CCSQ
M1$5:E1E#;W%!C5AI[""%[]Z:8WE\R_+>CQ9/RGC.L/EVC?>C<+8%R9-CZ"\8
MGIE%:\ND<05Z'NXTWN:.C66?YF>4Q-_*B_ZJ^P[:US2^M*N.68R'R9+@O[#D
MM4B7T'(<L_JKFB)6GB5@X99\AE3FE:"A,'88>[ZU6R4)B^M,/Y?F4K44'504
M I]2OCJ*<2DZ2GV15WM_..2OB7Q)3( : 5KEX_,L75P=1U9XCW+M)YP/]ZMN
M/IR+=8M",?<OT%^G:DNO[^"X[>?Y#XKZZ-8O+NVS/19\?US/TQO2]>/O^P7:
MRYD-7/V;H()Y]&F6K1Q/)?$=VV]]N'+7^8R?G9]6Q?\ AL#_ .!C_(C/9 (H
M<EP5I<WJ2]-'-(& ZJ_)XJ5JT^TTK1:)U3(0! $ 0! $ 0! $ 0! $ 0! $
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M],FSZ/T^7-TW;/\ ^VQ+Z(1/1%>$.V4HQ3J!S%/K1-.*(DU=E5"A $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M:+\#4?BJNT\Q_P 06V;!W]$P_P"&6=F"?\2WD^5?T&_3QF>;TSPI_NM_:C\
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M,/RH]*EZF>3) 2#0C[7U!$K5*VK)$Z$" ( @" ( @" ( @" ( @" ( @" (
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MQ-S%?M5PSR% B?!Z 5<31HZ/>'5^7*BK:]@I4B!TMQP)X9TH>:E;@FH"T/\
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MONQ6V3AW%5L;2Z)PPI-$1F<I!^99DO==>QE5Y+Q/.;\1R*0[][7WC3TMGAO
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M[8+Y>>\$E#UUX#/WA5:,/@3J ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" X3<O_U.:_\ ^I-5
M_P#,9T*M3\W#OFP?],/<1W/=FX:?^V;_ ,4C='<G\5M#%5*#.OC2BM.)D 8.
M)/*@Y<T7>"5W2TD@8',XX888*ZT1-+LGQ(&'.GBIJ-+AU#0$?/[U:7"HB 97
M(?9R-<ZYX5PHLEJ22DM\ASLFW5LZF'"9IX*_:2M%;0]J>UMP+KMEM&X'^<M
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M6=P]][9$"X@FB= 22:?L3)3SA_BU5:IV$J<I6F)QIQY^Y0=Z )PH.HNS.66
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M/^]/;X?J@?)O0IM>F.TAV;C<?G/HS7PX^MD@!ZW$Y"G1\GQ)I[24O4G0H0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M.O;\*/D?HVTO)6/''X5N,WYV?4 O@I]5($T+1SK\P0$4 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M)L:98\JJD" K-J 1F1PRI7Q0$U>'$?-5!4C7$C\LE'H:6IV[841&I71 ^&K
M3CQ+?D7Z\_35N8OH^_VS?\2/+;Z#T?S;'^+BD]+G$]U-(<9-3Z8S22QN2QU,
MS]VFXTYE?HKJ&R_U#H>\VZODEBE]46>LX,_R]QCD_AJ>;78MT-KJW<G2[IXB
MOVWH=#"[ O!G)- :' !?S@Z_CGBE+%.SCEFO^TSZ?MI)^\NQ&=.:]:J=S70C
M3"H&6?O2PTT(5X<T(G5A"M$%"> X8BGOJJ&OH)9)60Q&20]('PM-*ETK\(F
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MF?5.OS\?6 @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M].74X;;K^YZ7.5'GI1=M*'JOF[!S;%9DJ\ID_?>CMOK2"8Q]370O;*0.#V.
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MIVN*$[2  "WJ)K05IQQ4X]@):%PJ/</Y5:T(NPA3(#(UQYT\.%$K0I,XTIQ
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MZKU^=3[0$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MK1QRQ_,CI]4Q?.Z/NL3NI8I_E9\O_<K78-L3:_I<#@R6'7==8[I(:<-1O&C
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M'/Z\T+WLJ-/5PK[U*WHRW*PH6X?#RXUQQ]E%5K;0R^\K,(-*FN=<_&B,EBH
M/;4CI//'%0AVG2,9[D'(-C^+W"F 4XT-_N]YV04K2M*9I?0R7=G;27MW;V<
M+I+F:&)C6M))ZY&M. !.'4LW1=73@>JW:_8FE=O^V6I/U1D;7:KM[4X9C(UK
M'.?>:9)''4N:TU!>L2E/%*&?'\<,D9?0T_N-<JG&6*7PRBX_2J'P;>L?3[W8
MOJ [F;7GZFV,6MWUSIKB3T2QW=]>3$L/PM- XC <%_47TRZSM/,GD;8]4VS3
MR_+2GW<J2N?S+]4^D[SR]ZA[_I^ZBULISKA[)5NVOK^@T7UF^ZWR#J.>./\
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MGTL^T[+9;?I^VCM=K&,<<5P25?HH>O*\6=D( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M96W%PUD;0"XGJ$I;@%X'=^;\&UR/#NM[/YJX<S?WGE]MY<RY\:R;?:8_EO\
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MDN7Q'H?4TS&.*^0]:Z_EZQEI"L=G%^ZOO/I73NE8^EX>1WW,OB9]>Z\$>0"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MXQU) %3BO()45#JMMNK.VJD" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M+W/8:EN;<&I:W.'N-S,]D;#U$,9%(]HZ:@TJ%-+(4;9Q4.T;I[@TQ$@GD?\
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M*\XE16/&2;;JS(*I @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MK<A_-;\9']&G'CG@G>3B"*U_5P]_UYIX&JT]I -;U#@36F9R&*7U)]I$./Q
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MVA(-*D\PN;:I<U7J<>2O(^P_0L7?.F$ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M&F75!9C/,+FVJXG'EM%H^]Q=XZ@0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M6?>"N\=4( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @/F<_B&V#[OZ<'C-^H;G
M9[F6CWCYWK+^)'9P?#(^9@.+G5=QR]PQR6=#DNW<J"@=^7)0._"Y Y4KARIG
MCSS&*+ZQV,C04!S(^:OTU5X4->.I CJ=7,_)P^13@9DGP)6T IQ'#VXYJ]_
MK[%J3-(S<*D^-,O8C)%)7XDKFU;A@"" .>%,^">(OJ;_ /HJW+;2:5NC:<MR
M!>6IMW6EHYV)#S$7^6"ZOR!<69-M-%54N7L-X&,)/3D<:^%%P%>I/TMZC0U
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MRS).D?:5Q5*4]XUMV[;?]-5EKEANO9G[CU@2/CM]8AM^FW%T]Y: _P N$Q,
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MU/N:7=.L$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M_IH61:5C6O\ F[#Y%V=KH<&6E&S[CEVSK! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MU_5!=.'4Z%FB]#L!T]3-/!P\0NQM=#AR4Y7VGVZ+N'6" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M5_QZM^W-Q_S;], 9;.KTO?N("F8!(=>>(5_E'QD1[F3_ '3J-Y^.-ZBKL/\
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M?T="&9\>"FK+IJ 33_ K=D7;Q(N(-*&A/A7^3)7NXA6\ X]0QQIG[\E!5*Y
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M82WLWZE9^$VN;6I_1L8PBU;,R7NH^UQ:,! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M7(CC>I^AE_" 6X9Z5>Z-Q3&XUC2*GGTVL("BK5DE\*/L06CC" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" (#S6_%RB=-Z">]\;6%[CIVFD- ).%_$3@,< LRT.
M3$JS1\-\K@) 0,&L:*5Y"AQ\%QUXG;[R3*O4:NPQI]662H9$'JZN!PKQ]B(-
MD0WJH?T<?A_ESS0H(9T@TK3AB.-%"4)!4$$FE<C2JH5*6T*E<,<SD/Y5*\>
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MR$FI=41"M"]V?45PSBHG8QRK9&U;2?,Q.-17#*GTKB.30ZS ?^?MG3(AWO\
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M^/%$N##?!&"MP8FY)^R8Y/F8[WK1QO4_1/\ X0VU\OT<[XNJ876KV%#SZ+>
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M* XT^I UV:&!]P_8N_\ L;_]H]57.-ZU/T<_X1JU;'Z&=9N0,;G58.H_XD4
M]]*JK5DDZPB?6HJ<80! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! ><_P"*[/\
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M<G^T>M<#B=>!^DK_  E-MY?X?K;FE/O.J5KSZ66Z+4L_@B?5HJ<00! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! >=/XK<9E]"W>M@:7$Z98GI:"XFEXPY $X+,
M[1.7#_F(^&&[QN'\ ,*YXBO!<9V[)TXE(.H2"?9\B>)%9=Q D-H:5#<\<JJ5
MK<,-;3,8\Z_4J4FZL,,:\,JT]J?83B /<.7+W\:J6;H4AA@"?B'Y>S)6EJ A
M7JJ*X88I9$^PG-": Y9^-<O91*NHUU),2ZN1;PSK7QX(ZCO1+U N'3GC7Y,,
MU-5W#P)ZGJI3 Y'V!47KW%$M;P-3QP(]B M)(G T(J>)^3Q2B'&Y93P,=T]8
MH >JH-#44(Q&)Q4HUXD;[#I3^WVD7&^+/?\ J$SK[6],:]NDLDJ8[ 2MZ9 U
MC@6'J:>"-V(X+FYN)W5]"'O>W$&IQ/Z1KD/!0JJBW<P/(.1X'.N'+A1 NTFL
M[<"?KX%DG^T/#W*4^DM>^QI=V1(/JO[\QG*ND#+P:,N-5R.\%VG'"TVT;U,B
MA87.:UH-3DWI+L3G3DL:6-V=RX <UPI\5?8,D+XZ'50#_?[20[ /;-7(TH,L
M%72EB:LVTT*KMH$5HSIEP]Q]Z)EJ^!@N_-=2</LM$CJG.OQ&GB,5>PC9Q&\@
M7:4&1,J3$_J=7,!II[**6K</2^IYP]V WS[@N-2UTE!E4_M!F.2Y%WZF)-&J
M5X")GDBAK@VN>)X\%J_L,=YQ$V7Q<.'/+B%'V<"HMZFAZ#\1S=E[,/8H0Z[N
MX']P7/&LL&.64GU*HS+2VI=,^+28@<1Y4>.7Z X9I7L-&4M _P"0-.H:X2?2
M%Q2U-0^$Y%PZJ8\_G4-5."NM+L9KD73HW,G:X.+XWEC21B*L;0%52:5"<J+3
M6[R66$"20],; &-;5K0*$?$!@_+BJVY?$161KAO*X=(^6,$FE1CE3XQA7!;5
MO S)HP9=7%W9S.DMY"PCJ+FDD@_:YGP6S@9R<6]-+GTMFEZQIQFN6._8W770
M,/5G2N-"$O7N-*2T:L;E]NMT[6LMAZ*+O6[6![&R]4;Y8NMH^'I!:9 X4"XY
MJ]CEC**C<['+W%V/$WK.OP%HKBWH=6G*DG!9Y653C36[.[=E[67U";]A[9]I
M@_7]U7 <?NS6NC9&&=-7&6DC0/C'!9;4(\T]#49<\N6.I[<>C+TF=U^RFH;L
MO=_VK=/BU.**9C_,:/NL-FV.2ZE,XCC\ORHXG',5HN'^8C5.)V(XJ)U-%_Q!
M?6Q-K>OS^G/T^ZV-P1/EELM^;I=&+R)I#[F%T$9?-,R,Q$])H O(8G[O-/4Z
MF5^]RK1'GQM+9&D[1@,D4<5UJ]P?.NKQ[&%PGE(?*6!S:MK)7)<4\CF[:",%
M&[U.WNJ2:FI_+W!<1R5+>8$B @$LCO+26< TZX([ACYF^^,%5!VOQ/HCVKZJ
M?2IHWH=MMJ7%SH+]?BT*YLW;7=I&GNU!U_+8&!KS?.'WFHN,5XUXLT\S;K8[
M?/!0[F?/ 2'W%_,QGEQ7&HW]Q RM>B">[EE@:/!L3@%Y!'5X@NZ0,SU.:T
MESG.-&M:!4DDG *D.<U':N[M%L+75M;VWJNF:1J#2ZRU"[L;R""=H%>HOF@8
MQH(RQQ4JJ\M;EOQ.D7UHV)D]Q$*M=;W'6!^C6)U#X@JD->]##?[60!\5Q,0?
M^VE<J5$D<25?I++2:#=VL'B!%3WM ^M:>E$15<J'=P74./'.@XE8X]YR45"J
MTX4;^7'BB^HR]+E<.%2"*TI3$A6I*HFPKS'O"MGX%)Z  N;[O#@<TK6R!*!@
M<:#"N%?8@(EE!6OS?RJ5O0%0#B10GA6JA:4U)QC@$H:3L<3KA_LSAS::?/\
M0J9O3N,![B_J[DUK^REQI_,?P6EH<4J)GZ6O\)O UGX<6AW %#/J<]?Z#;89
MHM22^%'U+*F @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MO'4X9H_4"_A8+(VWX6':V8YW%]JIK3]4VGRYJ+4LZ<JH?2<M'&$ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0&AWXEUK+>>C+O%!$QTCW:/"0QK2XD-F#C@*G
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MJ%K6 X##$,!PHHYMW'+'5&,[QD<5]=,CBC;&UYZ6^6RH%3QI5:6E3.NNA;5
M(I0'@  ,O8*9)W%KVD:G]:IXX4]F2J#*C7X $GCC4J6U%+%PTCGBB1**MBNT
M@G'[7/G]62H)G&C>DG%Q R\?J0LK:G+WS VTL*9D/J?<>"KOX$BNPZ?KPI;.
M-:_ 03X4/#P"S>O<';4P+KU/+N:&HZ'8^T/^M;1QRN?J5_PO=E]W_"=[*S4I
M]XNM9->?2ZT"(DM$?1*J8" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MU;J.J-I2FJZE0UK6MY,N'5G<:[2T !%,P,CE6O@J_K +@1AF./M\"G&Y.)$
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M*\2XTQ/BL7.6@&)!IC[?R&256HJCKUT[IWMM>GZEU7_)1D;:9M-MY_\ S2>
M.J/IE)X<,L<<U%V%O2A@S4W@ZE*T-Z:2$<^H$G#PP6I?49][FH<)NEH=I1:!
MTGRW5S/Z)/L6%]1K74\[^[9<+JX:3U E]&TI^OQ\"%R)I''*S-2;UI\^0TH*
MG"N6)X\5OAWF.\X>=Q!J,"/KHIH70XQ[C6IP8,OYV7O%"H1'4=WR :)=GJR?
M#7 XXFG!:6IF5''N.K.N/]71=/ZC*_Y(\%KC0E72AT\FS&NV3KQ_EVX;*2ZE
M?B+:MP\2B=F8XU17AG$KGR5!J]U,<2T$])\/A6DRZJIR<VX9- MHQ;0AUQJH
M='%<NQ^[@?"ZC7'&H5YFB/4X6ST'5=9N?N^F,DU*\E)>8C(X$%Q#G8FI !*B
MIQ857IJ<ZSM;O><]#M-^Z\WOFP;P_2 JLN433C(Y6P[$:U=/'WO5XK5Q(+XR
MQA=P)H.FI4YXHGRV=RLO3SH0H[4]3-T:8M#"SD1E'S6?FVH;>+O.R6O8K85H
M]LCK9T_3P,CA7+^;S4>:5"K#%:G:AH-KLZPGU#9;KO0M3M(S/!<6=W/"2^!O
MF@.; Z+JJZ,9J++-7J7E5TCM_<GUTZEZ@/2+J/8/N3J=S/O+9=_8Q[<^\RRR
M/N&"[#9"'2W,I=1AY+EF^>:DE1DYTH.+U.(VO,7[?VQ= !YL7:9<=.%)/N+K
M:4QGA1_E4]ZZ\J\W>;3]U-'NCJOXG^PG>EUG;O2=MVT7<.316Z*ZP\B+R+<"
MQ^XOEZ?-\HN>WXJ]-:KH+:S^;S-^Z=OYT>6O$\1F]9?<ROPEN[R[O'TR:ZZG
M?.YH&0#2^B[QUO J88C,Y$>T?F0BL8"[H=LI]>D9K.A3_==8M+RTU".@)$DM
MG.+F-M W/K8%5+@9<$[Q/I"]*WJ3VUZA_3'MCM=NO?\ :=O>XVU=/&E;E@O&
MPTU2R9;V]FQS)9YP&]-N2<!P7C,N-X\C;7N,[F*?-#^N8S]4_>OL1V'["7'I
MM].&K6NZ-T[X>]W<S=5I'%&#+&^9[ XQ/;Y@ZA3(YKDP8N=J5*07UF)R45R+
MXF>.MO&(6!@S)+W'G(_XI#XU<5WK:'"ZEV<#CB@K:I2\AC9#*.JIX%[BSW,)
MZ1\B5"TOJ6MV^CHF#&M2>%*5^7!")4+(.ZY'_#^K0^Z@X"E4-'0MZS^9/;VP
MP\DCJ/.I)R6X''*QP>'34MX-XYX#Y%JSN]2'6-QZ_;:#:.ED>/,<T^6W"I<0
MX-%*UJ7*I-D;2)NW';J^[B3?WAW>9K30?,#[&P)>PWC0YISI5H *US1BJ*[,
MQ4IW=D;J;?.UMI6L-K:VEG8P1M:UC#!#-([IZ15SRT.Q#>*X92<G<Y8Q4=%<
MYZ\W[M^:%\;3!@W MM(P'8> HLZ&FS!^[?W-JS9+F$1MD%7"5K6QG ..,;<L
MUI-HRVGXF*XY?M-:X5C-"10X GACF M\:F:=AROWQEW!$&G^IJ#[_P#"JU:^
M@5;G7=?<1;N)R+:'Y_J4#N8(UPX2#FYH!Y_$5I''(_5R_AL[?[O^$7Z;F_Z2
M+7)<J?:EM&\A7[*(S-49[OJF0@" ( @" ( @" ( @" ( @" ( @" ( @" (
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MV-K\K55H9G\1[B*F @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M(2(&^8/A/2UN&*4<E96-*L6JNYA'1)I]?W5?ZM.YTA;/.QSRXNK\;FM%234
M'FM&5=UXF7M)LI+*T)<"U\SG$$C[8J#Q R"S5:FDJ'';BH("!D!54KHC!NK_
M -;#C4&ZMQ3VS@9K2..1^MS_  _T7D_A2>EN/*FVKWY[UY1:$G\1[-*F @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MV'6C 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 6M[8V>I6D]CJ%K;WU
ME=1/AN;2[ACN+>>*1I:^.6&5KXY&.::$$$(#YWO7)^!_MO?6I:]W=],NJ?W.
MW9;PW&J2=O601OL=U:E/)++=00WCH'&R=-+.7-:!0 4KDN.4.*.>.7A+Z3YG
MM\;&W;VUW=KNP]]Z#=;9W;MRX=;ZMI-Y'-&&.$DD;9;6>:*(7;9C&7? #18:
MIXG86G:=/?1HH3094I^1S17L1_23G@*YUP4+1TL,J _$?DKS]B=Y>[@84[I;
MRW!V[OM,W/'9RWNSY'AFN>4'N=8ASBR-_0S$@TJ5:&&Z':!%LCO#MVWOK:XA
MF/EMEL=0MWLBNK*?I#VF3RRZ9W3*\8$\%35F=>M-V:]V^N1H7<4R7.@.(CTG
M>#(WOZH@0QK9H&TZ/+:VE7>U%>Y%;P+O=/=+:-A]S?97T&LV?VKRXM9&/=9L
M)):71Q2.-2,2"M0BFWVD;[-#R@];_=+2-Z[IT/3-OW1NK'36R>;)0M^)XE^$
MCJ/V25R0@XWDC@R23^$TMM[RG31U".(-*$5IR*YN;B<6E69Y[6=[]S=N]1MY
MK*^F=8L>SS(72/<TM#F5%#(!DQ1QC/Q-0G*+JSUQ[.^H;;/<6QMHI;V*'53&
MP/A>]C27EL8)JZ4\7+AR8W$[$)*6FILK'*R0!\;VN! +'-(((<,\*C)<5T;T
M52;J<*8]3A7'*E?;FI86*L7Q21BN'4,*9XH5?6:*;8!;ZZ]XBF<5M3'/]CC[
M%R?NG"_\[N-ZWNZ7OQS>_P!_Q'Z%Q\#EX7(UJ35OLQ\$+WG5=1/3O#:1&)Z;
MO_:E6_'0CUN;/;><X[8E<T=0Z'U;SPYYY*+B:1@G5RQVIO;0LK*36I-?BK[E
M;T,Z4[3C]SU.E/IB!$?=\!K\H6:E>AYW]VA_:IZ&D8+Z'.I_:>]<D=#CDZFI
MNIM\M[AU8]6)IS)I]"U]AFOT' 3@5Y$YG/*E$86MBA^E6M*Y89T&*A=+'7-T
ML#]"NZ_KP_[;VCFG'N,R5BE;Q]>CP_\ 8CASHRE:U2M"*VIDO:8!VOI@ I\5
MQ\5>3AA1<;^(W!UB<PYIH1Q_(K.ALXV=E:T]_P U.*$1Q<K YM,O%N!SKB1F
MG&I$GQ.,FLV/^WU4/\[V>*H=CJVI[:M;P.ZHVDD' @','F#S1,C2XF*==[=P
MR]9B@8/M4+8P"*UQP9G1;4[F'CC2AV'MAK]]LBX_<.K.>[1IY VTF>7.%J2]
MH(^(BH<1[D?O7XA>[;]TVI:]D\;)(G-?'(T.:YI!!:X!PQ!Y%8J<G?P.H;@V
MK;:F8[^'^S:C!5T%W& UW4 3\0: 7U/-2K3L&E)4)-+UN[MF"PUUA$C"&1WE
M/ZYHH!45^&E%;,BK6YS%_IMAJML^WN8(+JUGC+7,>R.0EKFT-'.#NDD.45BT
MJNXP?>]D;#3+L:QLG4KG;.KQO=)#(V26:'J<>IP\@ 1D5 &6%%OYG!HXWCXQ
ML=FTC6.Z>C4M]8@;N>,4:+JK;8] ( <6X'(54;BRKYB5S(=GN2:>)CKO3/ND
MI%7Q>87=)PPJ"LNG TF_:73M9&<5J''F,S[3FK6Y5V%+[S?SU =Y,1K@?'QY
M *597<D8(XG%L0,\]:.K4BIX]7#%$*]A=Q6Y!\R3XY,"*G >&/ZJH[RE>W?E
MP7+83^T$$M7C]#X'9<S@B(WP6I@O23)) ^65[I)G2W/4]Q)+OVAIF>"Y7W''
M5T[RVT5W^L=5&8:YGA2M/E1D6IS]T06,)RZOSK*5[:FK5[RH0T@4QP&&(I@%
MH'3-T;6@UN+S&-#;F+XXW-P<'-J10@5Q*E>PRZ/4Z5&V_MF^3J,;A)'\+)@#
M5S6X \*8-4IV!)Z<#G[/<NN:9$8[.^D;$ *-=UO/+B[FI0U5Z%&YW+O768W:
M?#?3^3. V:-C9(R\'#"0.^' K46XZ&6ZN]SGMM;,AT_HO-1!FO">MK9"7EA)
MZB2]P/54J6X%4>/$R%TU  X%@IR (I\E%5;Q+5U.PZJ.F&P%:_ :X4_1*<0[
M'0MQ#^SEQ=B13+V\O8JM: PEJ>-W9CGJ>GCY;M@6CCXGZ\?X&$)@_#"],<1%
M"W:DAI[9JCYBD=!DISVT/7%4XP@" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @/-/UZ?AM]I_6-M74]6MK*RV?WHL+-S]I]P;*UB$]O<PQRD6U_;,B+
M+R.]+NASG@N;6JS*-;K4Y<>5PM^Z?&7WO[']S/3SW%U?MEW8VO>;;W'I<@\B
M5\<TNF:K92F0V5_;ZF88[-YO+9@EZ6N/3U47$ZIT9V523K&\3$3L2<*%OVOH
M"+Q+Q!%:8UI[J(+(HWEG8ZI97.EZE;17FGWC#'<VLK&O;(QS2TT+VN#2&N*>
M(UL:E;J[:;P[-ZK-O;M/+/?[/;(9]7VB'R/^ZL+C)(Z)] 7BC*T&62*NO R_
M==C,NP>Y.S>\.WY+&Z9"^6>)]OJ>C7@9#=12!HBE$8G)F80YYH0%;<"JC5S5
M7NGZ?-U]M+^[WQV=DN-3V],]\^N[3FEEN2R"LDDWE22-)(\MIH&K2OKJ3E<6
MW'0U0W3V]V=WHTZYU/:#3HN[K!K_ -Y:+=5AF-U&'>:&"=O6ZLI.07+')3W<
MET<,\:?O0U-(-PZ!K.T]2GTS6;2>VGAD<SK?&]K7=+G-Z@YS&@@]/!<C5JK0
MXKQ="QM[\95P_P .2B8<:G?=K[QUC;-Y#?Z3?2VTL4C'@,D>,&N#OLA[1DT+
M5>948NM#TZ[#^KBTU)MKHF[;D1W%(H&7$KAB3Y3,>J;'-<4\;5T<T,E;/4]"
M-*UBQU:WCNK&XBN89FL>QT<C'8.:'#[)=^L%P-',Z4.<BJV6/]'XVU&=<11*
MBIHUH;3'ZZMT%OZ4-L3[H<>:W^X<*7\:BU-XYH3UB>M0Z22C:TI1QS7'6IS,
MB!0U!H3X?G2A>)UC5@/[V[1.1 O*C/-I]R5?L'8;.[: ;M69S7?$&OJ*9@MI
M[L$U\!PL8&UCK.JR8_"V5U<L/B)]N2T[W,KN+#7G..DS2M=U4C(Z2*5)81X9
M46'5&J/V'GIW9ZOO%U)7$.DZVT'PU+Z4/%<D51''+0U(U =4[W..!)I_E'#!
M:1C3Q.$FJT5+<LG5SRX<$!:CI)/4:$\?RP6:E:[-3@MS'_4EW3]>''W\E2.C
M1-:_%HS.%(30^UF5$K?O!D+:%#M?3 #AUW'#+X@N)UYF:A7D.9<:DD>'T*/0
MV6<C:CF/DY)4E2R=#7+$G\N:76A=2@Z$Y<1^7/DFO B5"UE@\,3X^SQ2G#@2
MR9Q-W;,,;BY@R/+.B-*MR?:8WW!%:MC>)&-!Q(. (()H0>&.."W$C[U8;1[I
MP[?N8](UN8OT][VQP73B3Y%7!H!J_&JTX\484TK/0V1M+JUU"VANK*:*YMY6
MAS'1R,?4. .(:YU,^*XSEK:O MKK3X+EI#V"IKCA7E6M*@@H5'#?<;VS_P!Z
M2N#<:--75_FU.2EZ]Q*=A49J5TRC;FT+P#_6##.E<$;15V/4BZ^M3@Z,@\<'
M9X)Q%]"47%F[*(G^B[ZU&EJ4G\T#_>]K4T^T>?L\%5V(FJ*S+>XEQGDZ6D_U
M8P.6./S*^)*+VE\R.*!M&@- QJ:5RYG')2R+1*Y8SWKWDQVXH,G2^&.%%:7(
MWQ1:2BEM<\28)JGB?V;U>*1##>D#^Q]0S$MU_MW'V+D9Q\/$L]"<YVH:OA1W
M5'7$'C\B2IQ"I6QS\_Z&.(.(IEE0U4J6J+@5J"!6@'APP1M<2@-K49$)4G?P
M+>?3K:Y%)HVNX5H!@I2IJI:-T#3AG'0#(4'OX%6G82Z9REO96MLT.AB9'_.Z
M03AARJ$5K%JM-2_#<Q7VX(J(E;5(/J"P5K61G"E/B'RU1"E78[+K9:8].#10
MLCQ][?'V*M$N8[W(YSH<,J8C#E1%2O>5UI8PIJ'^_P#3FM_]+Z8"/;?1#C[5
MK@<:U/U^?P2HO)_#2]-# .D#:0('M>TJ1^$F2O.ZGJVM& @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" U%]7GHT[2>L'M[>[/W_ *-:,UF*&=^W
M=TPV\+=3T?4)(A'%.ZX$+I[B",#^K)H.'&N7%2U-PFX.VA\7/K ]%W=[T9[[
M=M;?VF7>J[1U:YN1LGN':V\LUCN&VADG<8K[R+9EOI+K.", >:6EZXZ4LSMQ
MG&2K'VFH@#@!49^(I[CQJLVJ6E24 BM< :8\J*]Z'$BV0L#A\+F.!:Z.1@?&
M]KL'!S'5::@\0E Z&N/<SL;+=WYW[VKN7;>WA;=5U=Z?;DMM]9\LOE>P11M;
M%$2&T\41BEZJS*O:KOM!KUQ)M+>5M^X-VZ>?N=U;7[2V"[<"('.8;ES8I1)0
MY YJZFE*IUOO7Z9['>$PWMVTNF;7WG9-?=F.S#?N^L.:U\_0YD,8B'6:#%5-
M*TM#,H5O&S-'M>LM)[B&YV'W1T8;2[@V?7;0:C-"(X;Y\75%'(V=\;8SYCL5
MI2<+*\3+C&:H[3-)NY?:C<G;;4IH;RVDN=-#B;>_A:Z2%\=7])ZV1]&+0N5.
MMS@E!Q=#'%O<N::]1\:D^.%.8R5K0E;G9+'4Y()&2P2NAFB(<Q[7%A!!J".E
MP.:VI<"7K;0W2[&^J37MEW5KIFM7,EWIKG,9U22./0P&-N;YAATM*S*$9778
M<D<K5I:'K1V_[F[>WW86=]IM];OEE\MSHQ+%U N\O#I\QQP+EUY+EMP.Q7FH
M:TZ20SUU:\0/ADMX,:UK^QQYI^YWF'_G7T-W)GO,G2QQ:P2/)&8^T>:SXG)W
M%4 TJ79989J5X#@=7U<TW7M!Q/VA=BE,\"%> [$;-[:+AM:<@T#F.I@#6@Q]
MB6J7@8+U8-CU*9X/]9*:^T.IEC2JI*WJ66NM<=)DZF_ (G4%0,V'EBN.IIZ4
M//'NP!YES7'XGT&5,9./'!<J..9J1J=//<*]0_6RX\O:M(PC@Y&G//PKED.?
M%1H71;5%,\\_=DA;'";C_P"1+NK:4?%C7/'EPHJC,E1=Q-: .T:+J'^:)K7+
MX?#.JGVCP,@[1_\ J8TW_'N,>?Q#@N-_$S6/X3GO+J" .7Y8E9=#93,?C7PR
M^M6A.XI&,#,?E\JE.TFMBDZ(G+\OG2A4K]Q:/A%",LJ.SY<*J@X2]91C^(H1
M_L?:HOM)JZ=AA+=\S@7 8#'C_C>"Y(ZG'+L,!:K*Z0O:ZKZGB:$8NR-*BA*Y
M$<4NTO=J=R-U;'NXW65W+>:8P_'ITCW.ZFDMJ ]\F% $:3"DUX&TFT?4-M'7
M716>KC]S7[J,H_XF.?1@^V7](J2N*4&M-#FCDB]=3-5IJVDZBT/L]3LYFD5
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MOI>%E7AYMU7_ "G+>AQ^!P^W?]_:QRZHZ?*M.@5*G9)14Q@\21\[5+E6ER[
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MX=GIP9T]--G6V&6<<1R4CH,JI,]-UHXP@" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M M;VRL]2M+BPU"UM[ZRNHG0W-I=PQW%M<0O%'QS03-?'(QPS#@0@/FL_$?\
MP=GW USO?Z3])C9J<;;G5-T]K("R*+<'PW5Y?7EE<"V/W<Q.)<(VXG "JXW&
MFAV(94U2>I\T=U:W5C<75C?6=UIU[8W5Q9WFGW]O-9WEK=6LKX;F*2UN61W
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MQ=S!F=:$5+GJ*L&;:CD5[,TNW;L3<?;[6W:=K5E-&V.8B.<,>Z-[/,/2X/\
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MT<?&I^QY^$W'Y7H"].K,J;)T\TY5MH#]:L="Y?C/1E4XP@" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M*#@=SV#<FZVU".GH?#-.)8ZCJ:/,HWJ&;:K$]2XW6-SN SQQ'+)9-DU<*T!
M_1(!Z:\B03B4*&U;P/LH<??CDA"7I=GP\:#Z4!$M %2^-O\ C2,;])0-%C/>
M64!/GW43 VM2U['?0[P3P)IJ<0_<>AM-/OM2*U 833W@\5KEEV&7*-;G%WV[
M-'M&=;I3+A4-##^?P3DD7FB=,O-^02AS;;1?O0-?M.Z:X4XE7D[69C/N,7[E
MB_O)5SMOQV;@>H2-D:2*5-: &N)55N))75T=799.M@(I&]/0*#.E!AX9+DJC
MC:X%ZV-IX!WB?'P)5LD4W)]"/8S2>_O=_5]KZOK#M"@T32M0U"&Z;&9/-?:6
M7WML9:UCZ=9%,L%Q99-1JCEQ1K(Y74 (]4U>U&+=/U74=.8__2,L;R:U9(1P
M+VQ ^]<>IMVN6I/+'PYH*G";CMOO>D7, :'N< YHI7&,%V&'@K%TE4DJ4J=8
MT/:NJ:KI]O?.D;;PRE[&ASP"T1NZ<CBN?Y4I7X''S([7!V_LV%KM0W#%!'AU
MT:QU :$TIG0+7R;>\Z#F.YZ3<=K]BC]ZQEFX=5A:?)ZP QDU/A=T.^$@/:"M
MI8<2JWS2)5OP,7[MWCJV\]0^^:C(8X&%PMK5E6Q1Q@O#6B-KNC[)'!<$IN;;
M>AM(ZR3D:5^;P6:?0%V%*:V9/'Y<E>DD$$8$%IKS5#=3D8;G[NQK?+;)TCI#
MC0&@ 'S+7S**QFB;N#?/!JQC8R?TL'*+)(<A3ENKJ4!KY21X"E/G3FEQ+1%+
MKD-:$C+$'\BL5?L%D0QK4@]7$]1P]WB%:5\ 2^P5KG7^52[9JM=2;&E&X'\N
M>&2OB8:6K(X#Q^9*]I;G4-R?U;O84UH'J8ADI^_=L@\=W;9'O.N6M/G6T<3[
M5J?LU?AHL,?HB]/['"A&P]%-,L#I]J1APS1:%R?&;VJG&$ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MBH 0/M%<E9TI6Q*+7B6IEG>#USS/I3 R/X_TE'J"ETT%<2#S).7@4K])2:A
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M1].MR/88K=A"IFK.=:QC&AC&M8UN :UH:T#D   $!,@" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M?VSP,P?L\JDG/BMZF.'<<!*2P=.1X>.(/C12G:*]FA;$NK\6? 88>\(*_20
MJ*!*6(U:@.'%H]KFX?.A2D9H6&CYHVY9O;]%5":7+"?6=+MRX/NF5: 2 0?;
M^DI5%HDSBY=WZ%"#2Y8YV&!<!\W4K5!T9Q[][0$EUI8W-T<>GR(99>K@/ZL.
MS4;)6Y2CU[=NI2QV^D[/W7>22'IC;8;;UF]JXX"GW:TDKB0G-V!NAFK8_IK]
M77=&Y@MMD=G-]WTMTYHMVW>U]PV#'>86!G[2?2PT ]84JRJ,GX&^_;W\!K\6
MSNG91ZGIGI]N+.PG#'QSW^LFP%) US2X7-BWI^%]<56GP)\/Q&VG;O\ A:_Q
M'=X7<,6_['3=@V\KF"6YCUZRU,PM<YG4[RX[1U2P.)]RG*^P+D_I'IUVF_@Y
M'.M+/4>ZOJIO'71Z'7&C6&VK:X;BV-SV27$EI!TT)<T4JM<C(YQ5M4>D_9S^
M%-_#ZV5):3=S=/U#N?-;])D?,Z/2Q,0(^HEL=L\#J+3\JO+VF7-4LKF]VU?X
M?W\*G9[[:72?3)H3KBU+71W%[J%U<RN<PM(=("&1.-6C]$!7DB3YDC>_M9Z'
M_2IV9CBC[?\ 9+86DB%K61.FVYI-_(P-:QK2V2[LY7AS1&*&M:A6B$LDI69L
M?:[4VM8T^Y;:T"SZ0 /NNCZ=;T R \JV90"BIFK.:B@AA%(88HAE2*-D8IRH
MT (0JH @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @,/=\NP_;#U%=
MO]9[:=U]LV6Y=L:U Z*:&XBC%U;2=+A'<6-V8WS6D\9=4.817(U&"C2>I8R<
M75:GQ8>OC\-[NGZ)]P7FO64.H;Z[':E>32:9NVQL9YI]M-G=-<,TRZL;2U+W
M?<XBR,O<:4%:T7$TX^!W(3C/2S/+W<@9YVB.JU_4\NC>TAP <["I;4-=2E1F
M#@5GO9KCWF?-L1E^B7#3GY+2?<P'@E0M68.UOS)-7?'TD,CD< ]PZ0X=;L23
M0!::=+D;O8M]:FM[737RSWMA#^R=U"2]M6.'P']%\H)S67J70\\N\&YMN074
MY?K5H\@RU9'+"^A_:4Q9(:KDC1(XFU[#3/5M[;?9.]S;QDAJZ@JT XG^=Q5<
MDC%3J5QONTD)99V<]XZM/[/'),3RH(NLDX#Y5.8M2V_?^[KUS6:=LC>-P7X,
M=:;7URY:XGB'063P<2%$Q>MT9$VGV:]2O<::.WV?VD[@7LD[VMB,NS]RVT3R
M\M:T>:_2RRA+QC59YNT*+E=:&^G:/\$C\5?O<8)=K>G^^@TZX8V3]X:KJ4ND
ML;"X1'S)/OM@P1@-E&=%?>H*<OQ&^6ROX6#\0W<T<#]Y3:=LZ27I\Z./6;2_
M\BO3U4++-P=T]1^1.62X$KCIJ;T]H/X.O?&JL9>]V/5#)H8^!S],L=!M]0E/
MV"Z,/?8QL(^T"2Y.63?8B.4?$](^TO\ "6^BO:<EJ_N=N+5.Y@A=$Z9LMI!I
M8GZ#&7@^5 ^G7TG_ "EKD#R1? ]*-G?P_GX5NR;6VM]+]-&AS2V\;&NNKZ_N
M;F>9[&M!DD^%D=7%M<&A:Y(F?FS6AN#VL_#B]%W9J6WGV%V%V+ILELYKH776
MBZ?J726%A:?[;;2UQC"<D41Y)O4VWL]D;+TYK&:?M#:]@R, 1ML] TFU;&!0
M ,;!:,#  !2BT9JSL<,$-NP1P0Q0,&3(8V1L'L:P-"$*J ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ZWNW9^VM]Z!J>U]VZ-I
M^O:'J]G<V-]I^HVL%W!+;W43H)@UL\<C62&-YHX .'!"IM71\=_XJ?X4%_Z9
M&ZSZ@NQ5IJ&J=B+6XN-6W3LG3K*XU'4.WS)9G2RW>GPVMM-?:M;ZC>7#6AK<
M8\LJ+AE#ENM#M8\O.N5VE]I\_6L>J3>]CYVV^UW83N1O"]F @BO9MF[JT]CI
M*&,5\RP#0 \!8KV:FTZ6./VWZ6/Q?/4U?]7:STW:UH^GZD]HCFU!]WIYC9*X
M!CC]ZLVEM!.T^%%OWI6XF&Y+P-E-H_PWGXL?=6\A/=C6(=AV\[F>:^WW#!>^
M0R5S?,K%%"ZIC$CL/YJ*,J&>:'&5S>_8/\'+N74K2VO^Y'J_OK>]F:'W=E;:
M"V^DC>6M<Y@=-9QQN <XBO4KR.E*F'.*MJC<;M=_"(^EO;-S;R=R.Z6L=QX(
MWL=/!+I%MIOGM:6%S>J.)Q;U!I^57Y?>%DBN!Z?]L/X>#\+'ME9V+;3T\Z;K
M.J6HC=)J6K:A-.^6:/I/6(F111AI<RM""KR+B9^;*M58WZV+Z /2!VXMK>UV
MIV*V%90VH:V$3[?TN]<T,# VK[FTD<ZG0,UKE0>6;U9LGI?;?M[HEO#::/L7
M9^F6\#6LBAL-M:-:,8&@ $-@LHQU4&)S*42,59VNVLK.S;T6EI;6K*4Z;:"*
M!M,,.F)C13!4A<H @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" M;RRLM1MI;+4+2UO[.=O3/:7EO%=6TS:@],L
M$['Q2-J,B"@.NQ["V+$[KBV7M.-V?5'MS1V.KSJVS!2B%6<[::5IE@ +'3;"
MR R%I9V]N![/)C8@J7Z ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm2113965d1-pht_cuvette4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_cuvette4clr.jpg
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M$A @,$ Q$P<A,A1!(A4C,T,T4"07"!$  @$"! $%"@D*!04!     0(#$00
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M3=-;1/9K)[QN       FAYQPO6359C/>3PJFBS :WJ[WK+K)G*=Z9RU&\@
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MQ=3W%T6\.E84\^ _#L5BK^#P5H5KR5S?DR]+%+:VL++P<=J]<G9^[CM[W<Q
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M', *#\Q((J"*$',$=!&'NMN&1J[VO1SDQ$G/4>;!5LF'*.<=XX?N:$!9B=(
M%23ER>$X26]NGAKF;:)!J'1JE+$5ZA@%;02,/ESL\Q\3'1Y,4C1$'0BA1X@/
MS<R)2"YY>(HR?O. 16O3AHKF%EZ&I57K\UAD<>HLYF'SG'"7[4A3''GTO=L.
MM81\U>;5TG\['X/+_%Y/!W\<W@_./__:  @! 0,!/R'^FZS>'1O*8Q-V%M\6
M&DLX; MKBK-113OBCJ-](K$\K<)=;RNX'6%F$5=^%9>#M[HH/6\7F+S@2H"0
M1L>I*ZF!-X@"LJ3.MTF$:A@8(Q <V'URLJ52;>+1F67C/*7OQ(%@?'0L7%@Q
MVN-G-5P]93CUIY1;4TC%);$4\L9O2J,O8KP:PY[?E-3&D&]&X:X<96/B'1N[
M"GW7I[I*I*^:?.='O**F+>"!Y!-U4?TTY@^.1X4;@G@=E2':#+?P0;0@CKZ1
MLZP+1!B&I@NXM"3C,JTU%FK.:S*YG273H+T5U',N'G,9X*>J+9L\EP\^K%*I
M.CU:RPW/V1;ZL9WI"\6S ]@^F8"V.\^1LI.M(5:9O"><"!U-=8WUHB#_ *Y=
M0VVHF<<WCZ5D,KV#"WP45IW0,%<;])Z21]LMU_B"]<R#@]HM%^\3&.K;0]A6
M-6=85S.< K+C2X.]0%%1*1R>A" 1W@VMY!6.GY5_-!:*S[;>T"2HI>D+8MZF
M:C):H'K!RM@->27+P9Y(P,T+$['VX.M6LF\2Y*C8&(QF2H"Y:@=UQDO)-#91
MV%?FY.C!1O<,UWMR!Y"O[YJLMBV,UC3WCPP!6,:4FRWKJ<+8+#NZ4PO+<H4B
MA:)1(3H+HH)[W<L9*\K#R<):\*W9&RY8)"ZNU(M'"FH@6,:H*@XHMWXJK])M
MF'7$JS5.&:=C.WB=O8?<BPC ^I@-:#*5<NDD1+@+H:YQ&X_PPN+X+G('D>*S
MG&<5VE^@^6/F%[<:2WY[>415S5C3'P@!#1,,'8CA)6-B&5)6<B,L(4-I@@&1
MIV.1(:$P:I<6Z,%]D$P[1T6 CA.D>Q7'*GJ*K]R&20KZZQB4IHHP -4 1TG(
MK\'['9%^YZ[\62O;UK]W ]?Q.('I &IR95#03T)/P1U>+_G93%XG#+=-5V*&
M.LIFH-\ ZI!0EX(F"K.SEEH+-T)Z=Y@0;MB.F"^)@/T<"F:SNHC>%W>'AIN]
MD6POXZF[RE]IIAMH6^TR[NCM-2_</99U3S@9>L!82X2;]2@7O0O-F65C2K%+
MX-88CIBUMX]8;I*!2XZ7B41Y51[$+H[KNJ[0M8WY3_Q(/@?0AWH>;P@[*W*)
M3R7/Q#;W2#&+#7KN,=1<Z&6G@#\D#^(Q=AP#QOV*/8GWQ*RK9PS8(0PC^]?9
M&NO:<(MD:1ZI\G\:F]86K=K>_P!K@MT>R@G"XQQ<O$10EYR?DH%*AY!X>,;.
MH_7'?#O*N.)\A_L,'5S[,7CS@Y53VE7_ $@;U^(%=/"&I:""E>#[R^=@_$LL
M:'GPI@!._P!T]FL_! \>1\1HRJHI.D!+85<!ECT"'"Q&)9RJCG\0V WL$<B(
M&ZG!-4*#Z*L6\K%1V>;&*O1H$;V'FN&@W;"YRQPY;A".=5Q7G<4+$I,]6+Z4
MG3$'N'>-8:Q^9C.TX^<%?A["40,P2ZFU#PY?9<_?/:Q^YL'*]88AZ?C$?]^:
M_4VI?C@K??:"BW*O7,NT Y6_9WAUW+U@(RAE3,8B;%R!1KE]0:HG,$LY8=PW
M6Z%''+A6S;A<,6FN]7,?F;5IYF@>7HW\[*7+(0DBV\4E=N/6.7J_[-*#4J9)
MN5,D;C.H%8\"'88?R3>LJ#\GP](W!&^C/R?F;/5^'BLSZQ,3]Q+)F"WLP9\H
M7NB0(*,8L"1; V$ FCB"YL,#Q"90:&LLI%[A5G<C9DLFZOR3D-7F^;Y#JUF^
MT!6M=4.S0+OCTF4Q*SV1A",R0BM.5YXP>GL$T(ACSE?P!N</OF6>/LA_#J<D
MS7/7_A(*[CWW7V:CO[W67?KG]3\2:)D#N^)2N=8Z7WR14!H&KJ]7Q<&;=<+5
M;]0EL8")MG@#+D1B!H" D6_T-V,9&*FMU)KP61@6G<P6MUTIU:^PG2O4<LUP
MLV*O4OIZ4Y[V0PQ#4N'\=O2:>-RA\%IM0T\YCK>JN:X>0IY'>#R :\O/3_B:
M$0UY#\YGXD6IQB??XE-C&_W-F^LL<+COL768I/@N/3VI:9JK3*D3D4.J=E@"
MUMF6'@]P"S]'&(F/3ILFPEW7*,[YYKO&LCA*]N%Z'X@@44W5'9H>[/M>DX?Q
M_26U=X\Y9MZ,K.3"NHH<7?N'+7L9C47;% ,7-([,,9,0>]LHZ!F[J Y6CN4X
M.5A]9:Z5:?+/<![B3N-\:._*GXG]PV??#,2F_J1V"6?J&4/]1LTTI0-PU #Z
M.[0;E05HNE)AJM=TVTMZ:E^=IE ./)<O HZ$S,S(M;'S@W$@59%DP:SX_P#3
M<8!*<(RP UIRWBJER]WYFZ\ZERY94\E;*L$+)3K%KF2K,8F8-T<M^'.:[R]<
MH6Q79SSR*=/.$GD(7_%:&@7L?*;/,?R0F04?,1X>_P#LV/.:/G++'@<V_F85
MVQCC=5 (4*XJQG);!I!PNA-- 14 47 \9UG_ +H!@3FT9T=1M7&GV@P;EFCJ
MPX2J-8)9#RN1SZ<[FH3>+S&M+&N0,),:+7F4^M%K?>2A8[02.9*Y9OB?G<[9
M')^&?HC%,H57ELYTJ#B\<=>W7,^_VFCS)\U>]PGS15#?%4![%0]1@_,:V8-K
MIYO$NK'J7[8_,Q] : Q[XE]+J[5HS\CD(EDK-B<AKZX1#BJ=K7Z++&;IRJ6;
M"*LL,AO3F%@@T  \@Q]2J_KCNP\CDZ,$$U%MQ;"J,#7K3#'!^V^(CYC;IKF=
M/3YCRS-SN4;'S,:S!@\MK=&764"X,/SN4UPU*A1KO!V5=K>4OS+;75+\^4PL
M6X"#R#']$XSP0AA18B2]6Q6+4N-'1XO'0H0;@I2EB&QL\XZ+CP.V1.4J4.SC
M>95:N%3AWV&'K-D/6PO?GT,"%> F]$2OZPPEH4:VT]I\WG'H>**31"W7*G/"
MN38: .;&^D-J!W60S;MQ$+XHW_:]M^W_ .<^_3C7]C__V@ ( 0(# 3\A_I[&
M?(FX_P"/FIH/G,L?$?\ 88^!WG_8K9?M\,VK>KYE8#O@_BHDC>C_ %/5D;/<
M^NH;E)]7:U_WGI/QN6_(3(O^T>H%WS\W"**])LCB5(NTX=3@6/OI,NQ]8,[(
M-PQ+EM>K%8HZ*>>OUR)FF/:48Q]\19F%EH,2H^L?X353]?\ (?3<IU2B"Z_/
M^0#_ (2AD[X2S6G3<";KJT114VQ:Y=E.ND!F7 \<NU8\&+R\'?T:6)3C"H\0
MFC;[[S,2 [Z/,4KM#0:+XQUGYE,_[,V/V'$SWJIQ$ZG63T.?CB7.&]3X5+OS
M!^4^P$791,!KIGWB)F5XEYOP4RQX+E^%2O')J";)UW [VF5]\OS,OF)OR _4
MXW PI_[/RSH#I_.*R]'27E)3P9EO!I%<=N/X ;8NJEY>+&8ERR62X^"KWX+K
M/AO!N7+ED=S/AM-OZ$[?!I]/M_0G<N7].<_T!W]%\#P['@_4MRF._IF_#OX/
MU(WX;/IFYI_"/IQX.W\B5+0<.J5\!;&GT#,OJ;F"X]D0+X@7*K/@=P+C%/A(
M*L#_ "WCK^;Q.7E&KP5\C+%.7R0Z'5^!U*1,Q.(/F!^GT_D^%<5UF?Q? 3>-
M1:8<FOK[<;KX_F6+BR\[I0?TZP<(7S&^)9OP@!7]A+B*6,"O_J/_V@ ( 0,#
M 3\A_IH;2:KC.2OE +8N['2-??:8]SWC>:NV/U'_ )GQ &4[Y$#LWY_H#,_P
M07%3%E.B_*.PGA1L+U1QCDQ@J:?PR]E44.H@87FH@VJV_;Z[AM,\/U[P',9K
M, I/3_V;5^_6/*8[:Y;8GDU\2YJ=/^FHK0O+?X"5JGO/:A?^$4 S3 1?L/ &
M93PJU]*]W(RN)-#-M?GIKVC:1E$4-CSW[PC%WO,$GMA1,QP_^0NFWS9\R"_F
M Z'H2V&(@X&;0\_P7CQJ5*9;Q*B13J+=95,>E> G7<#T3HGTB[/Q#I6OXA4K
MPZ2O':!<I*^C4(ZE2F&OY<?2G?T./HOAQ_*?"O#;^@^)-II_!_AM]#CZ)*AX
M=/XGCM_5Z?P8>+O^IO-/XGCM] ^A65ENI;PU_@P\=O"N@@G=YQ$:=Q:E_P <
M3$:N->!?\M/X/\-H[/.4HT#S<$I$KSGZC0XR1(#<MX4-P>);]:_Q5STGDR98
ME/A8>&WZV_T+KP.R6O\ 4KAF74M+17]@8&(8O_U/_]H # ,!  (1 Q$  !
M       "'M/,@       <)80H/(L"2    0ZH:LQXE %R  ")P&\7*/HP"/(
M!0.<#Q?*PR@5AK 4*;R-U:UB["NQ@]CTF0 ?;\H5_P"XGI<-;2Y)F=E,;)CC
MH6,)S!+#38%9)38:M@2-R7.G];YH[U$EI1B0_A@)+!$RD%%V:3#G%;[2&QMA
M Y*G(+T %O;IX_!11D_    '+DF>SO#8     #EXB0+D0       !!N$E@
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M0]$*("XHMJ$532ZD%=U<1C(.= U 4-74;#\S [>EWS8-[EU8I<NI;T^Z9E=
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M-H*R!)#& ^//VG"]1!46 I9T()3S9'^C/?"VIULE%.6V//.ELS'D ="NU7F
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C:R0[&H.*F>L8%'%SJU%MQ5W_ %Z<,"53!L7+,']LU_9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm2113965d1-pht_flowas4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_flowas4clr.jpg
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ML<'1X?%P_]H # ,!  (1 Q$   ']_      89HO.V+%K41OEJ3/0
M           ,$U9&KQ:U@TQWD]LJT9.[AV#UL_H                  &"<
MEQ=F3K7/TQLW6Q*SS6M,=2]S#N'?D *0K*A4H5* J            8QQK%WM
M>9H]<%JE_-YVCT<^M>;>,Y=[7IY_HSVL50>33.<6*QY@30]H]3,IV;(GT
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M/?(V0-%E$DF=7W+Z#S.R^QB^??!URN/1#<[X'-YK;$I;-FL5+,]#A]$?2>?
M\FKT@ZUBE)GQ-?)M]YV_M6\   4.=8[ZEY^C8M==\V\)3I6H (REN ^+OEO.
MO"9]$>MA4B\7TY5+^-F?OWU/DPO.=$\'=2+PN:;-+5M.)92*[O[F3LGJX_<O
M"*K:QRFLMFZ4&LUMM=XJ  "ASS);3O*V8>31%UG;?4R=5]?')65 *'+</:#\
MC?$99BLO?'B;Z4LB.4AWF[Z6+O7OXOGSPM\QF1-;6^/:D+WH9]WUYYOT.6Y=
MJ5 -<XWR;5FND4(#G$_TFH !0YCFZ<_\C3G8[V([0V:^5T=-]W#NGI996\5
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M*V@"$HQYC8;3KW*-AZ3CFE>=UT_%J@N/;UD>J],Y%K?G['[N*<[4
M$?2;]HR9  6R$JBJ3L-WN8SY5,.KQ,9TSKU9F$95D#S<S\77*::6^M=/\37(
M=YE+5Z)[>+8>]*@        H8=)\6KXA?A>LNS/F&'")HU7CTE38M'/W"]+.
MNUOG.7*9O'@UN&3SFY='5.734\T[]LI,]J5          !YAX+419HN=)RI4
M,6%$W4143?A<,>4S:*0U#C;:>]=>[\OQ)_9/SG]/?S+[/ZB\'V*%2H
M        !CPAZ)ZX!(0_%G3.1UC\T_OOEN<>GYGZW?E_W>3$@
M    ".B,^9] %LA:Q+S-^6&CEV_)UK!L]%0                8=6794%LU
MFD229>ZH                  !'4CU+.M(USFD+)2P
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MMHB%140"8S<FQ-'@1BG$.(:/.UKGU1*)10]US:H[G[22X[.44* IQS-6U$(
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MAJ:I=NZBPYQ[3GYM?PL:&MO,XG<ZQPK!>+%BQ!"HB!=!:*,AVM7/@NK#W5>
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M^":-1H2KES!XY\U@1S# O,#Y-IQ,>L)94QKKP89:;4S@1.1\QVA[S3QNNW]
M!1N9CD5%R>W1HWY@LIJ$V4>8G6WE2RF9#B<2O$IE,I@-RR*;&IAW9+JMPAC4
MID<=N0F3>J\IM(:/$7GGSB*A*S$.)DJAI0A+/!F=Z0QFF<LREZ_,]&/-/@!&
MD02G4[4[$(U9JI:A/7\W/Z6%BSX//*DCM$MATP#<;#P"H_,?N1H91,S,+1ZK
M5*X##\H@*9O$[Z\V7EN#9XU.\;D*BQ99:AB%N-2)A9"%(,[*+4TEU*\MQUC@
M^2 B*C7@HI\Z77FU\%KV\G,\+2$\V 44B6[)G$)W-NH HUY[8O%-1O$0KBEZ
M0Z$0HP:^",L+,=O-;9YM+\=8:?%@#WESP[^/?PRC!X98 4?H4*EH#N PADQ
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M@                  !YBLQ  0@H@            $U#_?\ %- :T
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M1<D\,BT;Q!D@               RW$I0*8                #@ /P]D
M              $ @0                   'LB
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M3W\5*D&*XH"J5I#ICW@.T:SBHSB69/@Y:6+5*@%#1MTN+L*9;%,&AB)3-1Y
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MM1<(8 &KS7BRS:U:M0 &@*MBP0F:Y&,:\K@KX"Y8TI+Q2 .&\Q&8J#SZR6
M%UD45W^/=A9(4&+* '(I*CC:!N_IPN!7F9V>O31?\P ,HS-Z7Z6JQ.,5(BH%
M4B+ H09<!^"(D,%Z$<]^@1*OWY_.)8E]6 +_ *PDOBT9"T#YPMRAC.,OO_[
MHV.R^VH^P?P!J\TT>8[3B)5B*I1*&PSE@6\/FJ@E3IK@+2I.U)=53MT0J"B^
M>I)Y.W(P$ TD&A"*O($T 4)*642,[H)HP^=[J1S>\,C;H4N.5%7*W$8)(K3>
M8*706$ DI@2L?!@*8!C0H>LP*61H0@LJT\A9\)B@;P'P+LPRN=!0N;HQ$#S"
M0UK?X"=%9'8YF4X[KJQ<;U,V^37I]8\'O+B?L9P#TV9&]D#<8'L @"U%2C>?
M%KY]:@(C8<,IN7I4B"(5@T%<&:,6^!39,E2,.I["&(A&_<GJU#(#-,+1(W1Q
M.B"AX@LK/$!QM>AE529;PQZH@@*: %8]H8 O'660=^8%Z%WCBO?4-$&L=^7O
M*P1,K7WIIZP^APDI,E4.XQM'%L<K&FL2%.D(O&5OS J4P.5_5=E"V^NK1L3F
ML7'7+;4U%ZDHE=T<$?+6B(,#!),,K9IPI"M>=UZ); > !NAB1A4 9H^?G.WN
M^!J5I4B4V4 WQ&)=SV$07-.64;("@*JL%=#!X:EAGMTX>L0HD7H85*N71EDB
MACM?Q#*A,(LKL**+2E@H\QU0P!>!7&HM&(SN]+G@0#I,S6\JWSC>RIGDMR$%
M2S$*[@_)MN]Q*Z5G,/(??M"X"_\ V,,C5< X9-#1'5)$1&9A(.#'\P"&JN5
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M,UV8X&BF$2K/_9?7!?\ LPF08Z]S^_O&)69%_EQ\2OIU+FF&)>L;@,%8&H-
MA7I8',)GWCBQQU*0AL?U-A0]@6YU@R].9=8TR=.(#F2!:*9=6F+BP=8:^A!%
MJFO7KBHU=R/N2 '!,E?YZ_[\LJ<#!C_?^Q0%U3C'2+'7_O@AVR?Z@1K4"[A'
M8Z,PCN^\S"HI%2@>\-NX<_,V1,.__86H$?M4RP,H '"5SKXYOBH: Y%_G^^D
M,%;B/K;CK#7ZFPQ^@T_$7L#*RZI\U_=0D%,&[8[L*;J7>XU6,3-W%9DSTB4!
MP/>K_J8YB;C(?YZ_F T$UBW.LAB)+<0*PB7<F2!&"? Y@1"Y?N%"SN;Z2AQ
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MJ<W@.\_0JZ-0< 805;)T(!DT1+GX/]W$"]_^PP45"0HA%;2=:"?<3^XJ4"9
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm2113965d1-tbl_patype4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-tbl_patype4clr.jpg
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MLP4!9RO+Z.+Z?.%("D14Q%@\;GG>/W<3U>12"@$4A0YGB]?"]ODF0L5, %(
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MA0,_QO!_1QNO7G )@*0!-01%*QN[=,  20  4GGN[;PH! 4  BD8W=^F$*
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M(LE)6!*!"*K''KK?A]>BZP%(D$4@ 09[G6AZS-1 D@ $@SK&]$WB2!2)!!)
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MKLU[SB1N_;GYRS9F_'IH_;FE7.'<NG!EM.LT7GNY;SKW3)!4>/7C5>>W(L(
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M,J59ZY<8YZVSIB%(H4CEN\=,0*0*3G7I+YJ$ +1<:O/3G,L62J,%Y=-Z[82
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MH^=4W-[S^K@0!*(JC<MWKI@%$I"D4A8*/RZ7CK@ !  *0M&YZO/7F(!,I2%
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M %X<<RP 2N58NJ;R 4A2  9_SZ>BM'WS_.WAVT>S6?V/\WO_ ,K]-<_D_=*
M0>,N>YUHF\ #-<ZZ\\]=RNN/=8 ,YY]-&Z<P 7JSSU;JWC>  ,ZY[T7I@ O
MCH]RZ=TNO/[U@ S#&M-W/) !A^-Y]B]L.N)L +GO/>A=.8 2](>73LYO&A;R
M68BO9)F>-Z1TP ,RQKK_ )UW)ZX]B %RO%U3>0 .KG/=L-WZ8 $F58UJF\@%
M(  !0.?3CU]:YZ;<]]F]9?L?YK;OC_JKC\K[H  B7/,ZT3> !\^6O1<=0 #.
M>?31NG, %H.;?K%@ 2YUC6B],  M!S;]K( &8XUINY* "CYMOKDV  9[SWH7
M3  +G^;H&H0!+[$S/&](Z8 'S)?A%PL  RSGK4^F0 ,_SK0-0@ DRK&M4WD
M   #/^?3C&C;P   )DBT1&>9UHF\@!"@ !G//>C=,     (SG&]&Z8     S
M'-TW4D  D@  SW&]"W@    3'D9IG6D;R    !E?.ZIT@    $F58UJF\B98
ML   % Y[Z_\ O\URZ\I6 @)*B ""F\]W/>)J H()6(7):9RW=.N8)A4! )6
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M0J#T]0&=/4 =.T =.T =/4 =/4 =/4 =/4 =/4 =/4 =/4 =/4 ;#1.H>GJ
M.GJ .GJ .GJ .GJ .GJ .GJ .GJ .GJ .GJ .GJ "MZ@-MJ@T2+0.GJ .GJ
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M:[Y7;7I\*APUJ#"X-M>G^'5OWN)1_P!SAW5Z>XG_ *3AESM?TYPZY^_Q+?\
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M# P,# P,# P,!<F!@8&!@8&!@8&!F# P,# S!@8&!@8& @P,#,&!@8&!@8&
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M;';';';';';';';';';';';';';';';';';';'^@_P!!VQVQ_H/]!VQ_H/\
M0=L?Z#MC_0=L?Z#_ $';';';'^@_T';';';';';'^@_T';'^@[8[8[8[8[8[
M8[8_T';';'^@[8[8[8[8_P!!VQVQVQVQVQVQVQVQVQVQVQVQVQ_H.V.V.V.V
M/]!_H/\ 0?Z#MC_0=L?Z#_0=L=L?Z#_0=L?Z#MC_ $'^@_T'^@[8[8[8_]H
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M)%E1WU]['Z'P5<^&7%/B)Y\3^O$5WN&7+B'Q$=Y2.TX' X' X' X' X' X'
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M87YM7\X_5+F]JG/*9T*E,QD*'>F$L4)I;93F5OD*&Q4^Z849*AFA"VPF]?\
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MF3)DR9,F3)DR9&R],F3)DR9,F3)DR*&Q1467@5S4P9@/ (F22: U: :0;<^
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M.11(AE>&!$SIB8ABD*-FXP]Z20^4:7_XROZX^ZRWUY;Y?=)_T4GZUC/=</\
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MORITHF.\H0Q?&"RL/&4&U0D"S%;ZPJ0,]_3?)6(X\!L46>L%BA_LN<VFH/\
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MC_NTN[-?5?[Y*#X [LA\+#["'<8N_P#Z=T@L/Z)5"W_^Y;4:S3,!@-?=GNF
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M&("871.4K4Q0-96K\/Z<_P"AUJ_#^G/^AUJ_#^GO^AUS##^GO^AUJ_#^GO\
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M\D5#-W+$@4MMX51QVSN&")ZJE\W>92PH$:=9,131>F(Y!N:6%#YAL@;^2RL
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MT]_I<;[I,?5?\1.@]T4^[B'K-Q[H'PU ^CDOUC>Z8/\ O IZGDO=<6?>U_\
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MX/:DA[(K5T'M20]D4X3<,8A-$YVH*'1D7JBI2\L0M$B:D8D0QOA,%1'U!O\
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M0"-UEDE :N%5"@90;,W;W[*A6JC1Y"/QQ:KAV586L'R8G)#.Y,@<JX0"U62
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M6/\ )_\ )LJTBW$RUY5"-\1&D$%%2KE427;INUF &S8F"T>]6$X_!+S$6!<
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M3BX2?9XD1F7F-3S4,M#MV<[AO.*2DDM(.3DL?MDDGQN3CRG(J"I1)WJPBOC
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MXM:EC-#1XM:EC-#1XM:EC-#2XM:EC-#2XM:EC-$2XM8;*2)CR%5F#D4 K5(
M4)U<]-=/P<I;P6UJ6,T-'BUJ6,T-'BUJ6,T-'BUJ6,T-+BUJ6,T-'BUJ6,T-
M+BUJ6,T-+BUJ6,T1+BUJ6,T-+BUJ6,T-'BUJ6,T-'BUJ6,T-'BUB(%(F/."6
M(G:2=YJD-Q,&C 0(7)D* F&M2QFB)<6M2QFAI<6M2QFAI<6M2QFAI<6M2QFA
MH\6M2QFAH\6M2QFB)<6M2QFB)<6M2QFB)>"M2QFAI>"M2QFB)>"E5D(I@BLF
MHT,FHFV3*<AN5H92F +0&HCZ@W_4J1FY 3@SC&JKI?-@!E3%3#(DB41 #+*G
ML*4.^8:2E#8@CL*BX(#AOAY.";RW)TCA>10E7SLQ'!W5VS.@A= AA$ $;*(*
MTG&X8D62CM!WR..0G&,LFD!!;R+4SXR3ADFN%OT1@O%&H/$6(\7,#M95LX5&
M)+!,V5IDUED $CQ)050*GFKPY+*3*L];)BJ!!3 52C>!4;J1N#;P5#9"CW_<
M(GZFGNF^=*JZ?R"W)(J*:7#/Y-W9;FFR9S% "(DX:J@V$23 3&I(SI-))R*9
M17214%9)-00X1$UA(F*I2CW[ MW.'/2ZGJB3W;F+BD>5HQAA3F9/.6,FKFZ
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M0P9]#<(HARY ,]P;10W_ )U$223(DFF0J:::90(1-,@72)D*6PI4R%"P #(
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M&Z1+&&QY:,+$+%H7/;.,^84Z50  RK#M#%"Z5[_69ECW;QZ&?S*SG+L*7#-
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MJYB)D!6VK)"1KKSQG\##5*&8TW3-4N#89R1)3OK77D_M=&1I,+T-<$G$YM!
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MFNKC2%LA+LE8F"J'>98*NJS")W=,LQ@"7@.P#*0A7;;,KH8D0+YB8#L0E>4
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M4E=3\'K0S,,$&<8?02X$E?:@->&C9O2W@! <@X3,7U@4U%65+WOTJ.QQHS^
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MXQE1EDC,"^%:512,)FK)1JI$:Z5-6!AQK+V?I:A2^9@$X(!:)%-@13&=8$
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MZ"@(H& HINQF)0X%:LB!%(X- -/ON) QE6R?-= 3 ,$JMBVU)'>E6*)9%/X
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M94J5*B9=O#JI4J5*E2I4J5*\*-2O"I3*E2O"I4J;YSE4J5*E2I4J5*E>#0]
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M&PFF=MX8'BK.Z+A;KY[NL-RQ ("I$:"8L P*@8@-!8.NBM*WRV1L XC<[,&
M@94$OXY1NGWMMUSEK\Y%NT^UD8T-,==<YJ.^G!:$"O?Q@-T7*-'8]J_9LXR^
M8U%J)+! 9@B!::-6H!.6QC,//JW<4)9Q&FA[+87=!69&3.9?"7><Z& IP?P]
M"F%56S,5D%Q8EB]FKFX'V9,Q'#?9^&M7(B?JHDV9)9P=C?V=DY>B#%:_%750
M9<H""7<J,=K+B*J]<HP *D-8T10'V>]&%!6-2_2DVB,_#+.#L>WD",M4J/\
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M8Z "Q:-DKQ\5*ASG\9.6[7(+.]Y!'J-7N3B$2**(4"6ABF4NDQ4+-"48UL&
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MTK$D-UID%@CH2O<DUPCI.CI%=YJ<?LD*B=)L4-2N5(@:X*XC^&B$M\YC ZM
MMRF="%'J*WSDT7!R-U]+ZGYH0)N9GLC/FAL-OB[MP\()OBZ;-JPV$S0[&PAX
M38LB!(#G#*IK8LD:47DH0?SJBBZ5#EAYI?>0^WFK].EZ7E*%/W9L= 4#J_@!
M,0)1@@@M:H7MEE],DO/A%A9@$P:V?/+( HNBJRMW@>?_ -!,% 7#Q891*H+(
M!T-CVK][.%@2"</;4;'0XFG$+-(S%.[O@ B@B54']W%8#.0M+2R8$I10] 1Y
MZQ\6FBJI?3&S]\O%1L;U%B89N3%U$Q:<0R"E"V(BSX@LDH%7N'!*C*, \_\
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MH8EOP(-;6,&FA2\@S?2#C.G0*9KM4M4(::2$)A4;7D0+QBE0(-+ B"6,!CW
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M -G?V=IH;;ABB)-.(X2(C.]:PC<,+MT#:]OX1AY[-G.7L7'1SP8]YX^/'/\
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MY3%TT&E/0&7)HO;J=RNA+#;1J4NF3;]Q>PS8K%P:K3@<T;57H% 9:U8MU.!
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M+9F9E_\ ::QU_P#A,^''_P LU@C6W !25\"GB"1K9@*2DI*2GB 64\"GB%/
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M4A=L/:>),!BE?N&@P82RC&9W<+G&ZE7"!V&\[[!T)W88.)-8!%PTA5IYGO"
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MQAP)3 VO[VCC=(M_C@O&V&T6TBX&FT_S\FC-7O"KS->8)+B:ID%776/P. *
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M)?F2_,]Y?F>\OS/>7YGO+\SWE^9.\]Y;F>\OS/>7YGO%&LUFOW\+U=2T2O\
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ML22';+95=0?+23#(\:S;3?*<3B7'U@     $ @@4  @$   $P D   I
M! D  @ H   @ H D @   @  $&H     ! 6M$@ @"/@Z$(#,D3 E$.(B(% :
M(#0%HC  %   A)M ' %@ <&H     ! #;)@ @31LC @&AM) E$F?8 % >0%H
M$(   > H B(1 " D@@D"QD X  ! (#-  @@J@:!@'S\F E%4E" % VH$@$H0
M  K ( #'? $ !E  "3P'<  ! P,>H @6M_[!0&-2[ M 7JOX% RQ/@%@4@ 1
M H @=; % %L@ &4@@@  ! #G^( @GHD9 0"61. U ?B8P% ;2P8$( I6- (
M,B! $  ,@@&H     ! \]Q( @BV$1$@!#,M U$,(  % @G@(%HGC9H @ +;\
M   $$, &P     $ #U4  @ $* $@ BA  D "8Y % $T" %H !R@ H A@0 $
M$G@ "@%D0L@@(@%DEEDD,/-Y;AB(D,D@@ D4DH@LO$DTE-B,DT+E (DT@9$(
M@*?M>8F@6"0EFPUT@ @@AN@DV@@ZD&PTFRD$&AD#FF $@DD!$@@ PD@D&D%8
M!_ID)"))0))!Y)))))Q)-P))X)-RR)")($T)/A)ICY(]IE\\)%)S;>)(?2'L
MJ! ))WQ)/Y),))((),1))>)/<A) ),]0\)9)KHI)GAD#L)F)))N!(,-I\])2
M))B!),I).!)(X$LT))8)*RL)'))22!+9)R"1)IA&2 )H) R2)-\U,MR2DR22
M2N5"R02B1:V2222O27>R6W222V3TY;R:22ZR632206B[S69XM:/[ >$MMTV%
MXD_1)SD\DDD*1#LD$A#\-@J0 \"(]\]%,(\.0ECDBE,D7$#NY- %,"(KN@@U
M0 $U ?AL%]F%VY()D)C/I&0D_P#N+"1'.)P* 8_P;*8)+8<0)90DD:S!#=J0
M"7B;L%"*1#*?RJ21@B:(#(5,K* *5R6 *_(49[(=83+=1902$9S(#.L&"=<D
M'=2(-X=54#9 (,!]((98AY".J8ZS*#QQ*/(Y:4PG"_4'V*ZIT*\'VFE0]0RT
ME/V@7JE/J4DU8HJMTE$@3-T 7UK H0$EI9L,E=MLL-EMLLLM,EELSE5ELDFL
MIMDLEMLDL,E(EEILDE]DDLMG=L,-EH6,B""20B3\>"2>28B22*1$QR2:"3(
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MW4T18_SF:*D?IZ71+V_9[7_W?YVV);YZ[)7C/;0_Y>97Z/Y'SSY'9>^_?_\
MV&O_V@ ( 0$# 3\0.F:"K.H  'A4Y^P2C4J(>$8.XWIX8.#<O;X5'!:(*QHN
MG2D,-[AN 0&@;%2#4W&]OP:*VI4J5(K BSCEA0QS2XRS/$\+4WT]O'1JT<SQ
MM6H?$^-B4<'Z1\KTW"BRE2.XA>E:G"5$J)&5PN^6XV*D&*; T30BUK%STCS7
MVGE+#H6U=U7B^>OR5*M:I1PP:D2:4,8&6P>Z"#0,^-2+]B;1+4@U"/0O&Y<H
M.:)I*HY=4D&_<H]D";@8+G^!M>+%J5*F]WSV1<P;!L6J5[BN&9*''\E2+%6U
M!<7#4.A:6S^MSE$FPE0OK.N7D-BIA@[G?W^#)A6U)IV:X-F;1$$$#HA"@+$%
MU:(#H*O'$2BN'"T'"A%E P7%0'%7A:-&OA269&<\$G$@$752WPJ$6B/%$XB8
M!I3HJ9K7I.:,+@:%VXX%34PQ=Y,5AOE4Z^>QO#F;&H,G'D*4>);( A/0NN11
M^$8%8S$PJJ_0(@89#"F%KVD9NFUP0*$4!>:@-Q$6A+JLP=C0&UQA0 )F*'M$
M!H\5BLASX\+I\5#Q6Z"2P$^6%F16J0^:IG)?N;UA0EX5G1ZC00H"QNIT334Y
MU[[&0B+?VD)NX122 64UEH%W&/1X0'QX2H1PC:ZS2,A5IV$4,:J0L5'?;^A)
M61:0D:'5CJD48!QFE3'#6DE VYV*H35X>_3B7JQ*)5+=7]W@0$3@*2\2A\3*
M2- IXN/%[+-U>[^_$JX)*+!M>@!E(*5-!2Q^K!?0MB-TD&=>@LA>Y M BO
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M"P4J3FD$ %X&\Y318;@,1!@SOY6%+P@PQU2M3& D>*U8S3V;%@6.ZLTBKEG
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MEY7[/\1.XV-<:2X+G'398FM3?:&>E'ZIB>Y1LIT:]=80,C7VHGV<;[:(FB0
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M>H"TQE/4'PX=#PJ*&O[/3-<(9DW<)BFJ,4D'$+=L@+@08(U#!PAX&#PUO/\
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MZ4F L"% H2KER$6@ #2&LX[8&NKW=C[._!IL:9F6#=Q2$K"6MH8QYV-"AB@
M-DUC\M/L_P V4\U6HO:&^<$12$NS[$^$OK-2"-GV+W/^S=W(V<@K%/+0#JQ8
M<8D'BV.4$ZM11GEYY_ /\O#^-\+]=3R@H!RC+F"%U:TM,;ZKEU7.NKX5OR[S
MA7@+/?N"M\K924 )TN:82#(08F&=>%L9,4U4N[2#J75[*C:K4W@6Z:LJL  C
M4*BT#@@"@-FZ'LOI#T(^(>G6-<@ZB_V.^_NQYNPRBDJ%^NT'F ?"EB!--Z]C
M&SZ^$S_<[]77GF6<GO\ $LYGQ+.9+.'Z9??T?B49P;XCZZ2FXRSBUW'XEF<C
MVOGVEG,[9O\ 4IN/Q&:8U+X -KRH@57O/\EG/RS?ZEG7T?B+;1[_ !+._8?B
M6=?1^)9S.W'TEG.N]G\EG/SS7ZEG.^PO\EG6NS\0X!UB'H77C0>/6(O75_<I
MS_<LYG;C+-QEG7T?B8=4.]_$LYUW'XF.3W^)9S(H<?W+.OH_$$O_ !^)R:^$
MCE*K,.66<_9^)3<9?,>_Q+.3W^)9U]'XEFX_$LYUWOXEG^YJ6<_W+.==Q^)9
MN,KJC5G-8KXUQ8S5.5Y'+$$>)YW+-Q^)9SKO<LX#ROXG TNKP^LN^:ZW3+*N
M^>,_$IN/Q+.9[_$LYWVM_D$LSQ,9OTJ($4"MOFUXXVJ6<Z[W\2SOV'XEG7T?
MB4'6O)^(ISMXT++Z/H_$LYUWL_DLZ^C\2RKNO6_U"GC7<?B6<_.FOUPB![&K
M*X9XW49_+UHWT8<B^C\2SF=LWZ5+.==[/Y+X%OD_$OOZ/Q"NW<3^2G/]RSKZ
M/Q+.3W^)9SOM?Q+.?K$:PY]3@;JE:QQKCN/\&8J[/1^(H<?W*<Y9R>_Q%#B>
M_P 2S<93G^Y9N/Q*;C+.?[EE(-K@H>/0@4]7AQ+OJ01XGG+.==Q^)CD]_B6<
MGO\ $X%_N6<&_)EG,[<99N,IS]F6;C+.8]K^(RG)C@>(B&J6UW@0SE!=>&AC
MY'7P^<OS/ZQOG^O!T+\6>7#QITNU/%_\)\_X>9;736_4'!A+E@44W51F^W[C
M?/\ 7BZS'XS^<;[?OP3,_P 'XIDPX?ERK9<@JKMR0EI12#<W?;_E6CE4W[_<
M;]_";Y_J-\N'2T/GYCYZ;/\ %_S'C[]RG?O]Q_D1%V+>%7^7-!([!:J+.C5W
MNYDY9;_&DW^_7@S:^_\ >#G';^49H'E>;_78YNLS6WOM+H?U3#DY==]+E)AT
M85UPK34_SOY^"9OG^O%BS'"T,\F_ZG.O\+\W^_4;Y_N-+5O$%L*FBSNJ6L+U
M[T>&;/\ H\-]S\:][3X3,? DYZ[O"=\OU;PW<[SO[SGZ,G!GN?!ADO"NL,GR
MR\,2>>;N/Q/AIF^?Z@X4=SH1XTKC^;_J;Y?OP?\ ?;]Q_N1,+ BJ*][!K6KD
M3_8_O&;Q7U[OQ_\ /P_'XR;?_P#?AV/Q_ANGOGIM^B/ @MLA40"V]6D'X[P^
M;MWA>O:=WGF^?[CY[ZWAFQ_/R?/_ -I?CYR?;ME0*BP$H"S_V@ ( 0(# 3\0
M2)6:B]$^O3Z]/JWQ/JWQ/JWQ!/C3Z]/IT^O?$^G?$^K?$[WV?$9@Z 54RK66
M?5I]>GU;XGU[XGU9\3ZY\03X4^K?$^K?$^K3ZU!-#H%!6<:8#F$1QE[)]6GU
MSXGUZ?7I9\28OYOB?7I]4^)=\3XB'QOB=^[)3:,H<",8+3NLO^-/KT^M3Z]/
MJWQ/KT^K3ZM'_$3ZU/HGQ QA( (V9&IDX_9\3ZM\3Z]#_ ?$^B?$%^%\3Z]/
MK4^O3ZM/KTN^)+008A5BPYT!VGUJ?7OB?7)]>^)]6GUZ?5OB<STWQ/K4^O3Z
M]%)4C@Y]HF   JO%:UGU[XGUZ?7I]6^)]6^)]6^)](^)],GU2?7I]>^)4T)0
M&"^QDL=PGUZ?7OB?6I].GU3XGUZ?7I]6^)]6^)] ^)]&^()\2  #=0:7!C *
M!U9]>GU[XGUZ?2/B?7OB?5OB?7I]>C_BI]>^)]:C*F@ (V,,XC0_4G%VY(%H
M!@<"N-(,S5U'&,%:6FF:S50<ZC57%AZNM3%O'W>L<5Q"EZRFZJ5R&*X>#6QN
MSDF/ ]06NAR.JZ 6O E@?M,H6UHXIJ%WB6?0+(: +'%5:!75VX[Z@!@5!Q+*
MXQ==].J :IFB9JHVFB#:,-04+A5!XPC#D! 6!,(B(F$V%B9OQPBG43!@(XLN
M7RAI[&E$Z(E(@B9C1T4!$(1!!1'*59<%CXASP!U<0.2S#+"DG &JKI\XRU%&
MB&84EE %F12DR3,UUTG''@QU\"M30I4"V@4"E0H-8S>@*P;HS+PX+*1,2D,D
MH,*-<VZ\:]L/O5MM3D -&32@U2 ^7G!JH(>(SKJBQ A$;$<B)8B9$:J*!S--
MU7;5B%<3B>%SW7]D=?$ "R*  6JN@!:N EAFA$<JJ RXR=43#'="K4ZJ],WI
M'*AM&-3$HHLSBLU& 4P@0ML-!I\T/&(S"DLL "954FB^)K/-["Z^\BM&4 :#
M+0T98?0 &RKJFW V!%(EC / BT.\]6&0@G&,4-,KH*!8LM@5EYY,G]96+4<1
MMT.+!R.0L!8B81$1,.I-/#V+]DW?R?%/K7Z M6N1+:F9IG"H)LA004SF9;30
M$+K0.5TLP.CBE-HJZ H;+#)EC!&U6%586#4!A.C,T7SEG5TU/&.2XF96.OBW
MQ77P?"XU91J&HI8<O(JXT=D+H8>0T$>&(\K*C+:"V+HYP^5!MJT<4+BZJ^,2
MFO&G#Q0E>!7'2?L LCIQ5W:S>D'M6.Z3B6#7<A1J]++1: :' H:I##C6$"Q-
M$1$>3+=/$U#:'?I!X](%2,@9-+@XR^WD0+&OA"&8I>2HJSD^.1Q@*2@@,W%Q
MFHH:9W1R7*QF@%1B7DU$$W-<IE-'G>K88 60*RK<,1$"M3@9'P5EH)ZBQQI7
M0*YB[S<2I7%T\,><W9R>%143=#! RT*LH+PBWH2$R/#6I:SHN#F,0! 6H!(L
M*A3R.<U-ZB>"$!'?#T8WX4V"!59%@'?<:N,X"I".D"C<PK@<C:E-E$RKGPNM
M-?!8Z^'&*P56ST4'0.-=F4MQ,]?DI4H\(P);"QEK@EB#E@Y8*0O-5539A1 Q
M!ZM(;4JNE<* 6%)F'"N+<L^X W$46\*U<OE N&'P(7@:>!@:7+(44%"#B<2L
M*%/('(T-H:=TM1G*P*KES@@P,+XR]SR.90$HJ@.2HI/A**@%,:H6K0107*MH
M4-@#+#'+,I^=:+2V(L(9.(AX>2O^R/C;P@K7&T=0/O8N#Y1=E,@*Q6 48[D(
M]=Y@7+6EFDOR&R\PD$JBKBYBC2A$.8:V EH#F7\:%F2 +94P/(> >D OK-7%
M#%LU\'?:E=0)0P":Y4,!\*HR(&(B*HLEXQ=8S*E0.XJ&V:4OZ$C*8 .(Z$IR
MT0*I()[Z:R@*+TC*G&U VKS>H<$HP1*:@7/9/V3=_)\*Q<'0D 55= &5ERAH
MLZ890F"5* 4";:JL76$7 56U'+(>!.Q*$EJ&DLA*V6OM $)8*%"WB,B_'6%1
M!-4HP6%:/$QNHZ^&:QK+<Q@("S]&@6WJF-ENY"R^<7:U3F/I2QI/=;1247.-
M8P1O3!?!8"RR@L.8K8UPVD&SC,_J2JG"^%(SPBX E4YE@N6M+\(U& &=ZY#4
M7@-\.2TV6^^X!?6I0X!46Y2% Y  J*B&=,5X!<,10B[G\TMEMW+QF=1EM:XE
MG5S+76,>7"7R\=V<GCDXRV*>\M=66RV]<3'GL+=7@R\=9:ZPTKZELMEOGX'*
M<9[+!UQ"I;PET7QEIGC+>$SY2WC+I5OC[K^R.OC?"*NLMTX17C+6*NKX&M<(
M>#KT\;3BRW7C,R[7QE\I;K,K&QZ3V+]DW/R?#,%,FLMEI+2WG+?+P)I$Q.^6
MDQ6=?&W28*O$MYRTV-6RA(K>LZC!33$5=?!PX\9A&H B"4!3'0P=#!TL'2P=
M'!TL%G#!T\'0P=#!T,%'# L""V2*4LM=PC3I@Z&#H8.E@Z6#H8.A@Z.#H8+^
M&#H8#IQAM1&49=AS10YNA4S6#H8.E@Z6#I8.E@Z6#H8.A@Z>!Y. #A@J#R"T
M8EB7:<*4F;L@/#!T, '#!T,'2P=+ U56#IX*.&#H8.E@6'P4)ZVM=AEF:P=#
M!T<'0P=+ <G!::;@Z&#I8.E@Z6 Y& )9'C2+G#5-:W?"=+!TL!Q3!T\'0P&I
M6!Y.#IX.A@ X8%S3 -=@1@53]L2&I9:[A.A@X%8.C@Z6#I8.E@Z6!IJL'3P8
M--P8--P/YL5E*]&8#D*'-T('#!DTP=#!AJL'0P=+!T,'2P=+!TL'0P!<,!^S
M0Q#L."EJRDIUKH8.G@Z&#H8.C@Z&##58.E@PU6#IX.A@ I7,7@%M#/&<#_@O
M8O\ XN!_XSK^3/Y7\CB<NW_ I!S2+B:3M.'7PM5.&V%:XC4LF+KCXK6:Q#3Q
MX>+1?BT2JA3-5KAMC;7&IBHZ1TN8B O;6BX-Y9P\1'E+/+8U>.\[;-"YP'F;
M=3K,^.NP^+M'CHG+M_P6KY?N-UC69XRFL2P[+-<\X.>TZ30CS?H@\)Q\=3M-
M+QX>/Q_9.-0UG5\,P;\0V!2O,?V2\PZQ\+6V]#VFE9T\33S96<[#KX.D=_EL
MKW30=O'ALB5.-^"\#2&NPZ_@8.?%TG G>4RF4\93IQG#\6EWC7'PX36:,-0;
M:OS/Q MIG&,O&)J7MFCS/V1O3C*C"])GA#W;=Z'K_(6SC',;CJG'.UH>TQ,<
MX:>/#AK#8=?!TCO\MG]A.9MU<T:-)YYFDIO,X[#XE<91XDO&9CQT;])P)A)9
M<-9K,W,ZYQ^+2[D-BX'G_P VG297W_A!B\(Y\*(DS#XFGCP[\2>DOM/2'AJ;
M:J2C1_DJO#I*;FF.U@NTTRO28\IKI,'>-WL.O@Z1W^6SI=R:';;X> </'5_!
MPEXE3CX=/'1.7;_@Q1G6G*\*G.<*YJ.W<$XWX89@C3 HDQ\1IXEX;YB.>)?-
M*<\1YDLTO]0'+AXFPM/!4ZDZF93G*10<TS?EM:D5%,IS97FQA08V -;#KX.D
MMGOI >"^!$*+BQ^*YF9/PZ^-NPZ3EV_X>TJ=O&]N[+._ ,5.-PEV*@6FWCRE
M'(@#PQ,<I7(2B]"<*-/$UV<\9UE37A/+\/>8@Q\MEU\:\#B/!PE<'8X;.DOP
MOILNSGA+N<.FRX+G [?E==ACK,<8?BQ.D[?C7G+YQT_'>?"OQ%7<TRQTZW'9
M==G5S!O/"8TF.'X;QX:3A^*[C,;.C?I#83)<ZY.>DZQ.N3KDZI.N3J$ZY.N>
M\ZY'GDHQ*9U2=4G7)P[(\V.O'7)UCWG6]WQ.L3JGO%0*6WSENB>\ZY.N3KDZ
MY.N2O5)URIUR=<G)2'/)8 F)U2#\3WG6CKQUR=8N=8ASR=8G7/>=<BI)1.H>
M\ZI[SJDZY.L3E).4GO.O'7)U2=<G7/><1+JYU"=<G6)U2H<XG5/>=8AHV3KD
MZ_N^)UBYUR%@DZY.N3KGO.<DZQ*]4G7*G7CKDZY.N1(299U"=2.J3K$ZY.N3
M/J3KDZY.N3J$ZI+#)8U.N3KDZI.N3JDZY.N3KDZY.M[IUR($E!/9)1%@M4:Z
M\I? <M]82'BE%5>7E>D TW\7I"DOAX42B42B(5/;>%$KPH\:)1X43@.;^I1*
M/&B42B42I1X.D$52B42B42B4<I1*/"B>RE$HE'A1*/"B4>%$HCN=V42C8HV*
M)1,$R-RB42C:H_!5;%'C1/V_T2CQHE'A1*)1*)1*^7,^V_4-+!YI;4<[Z:[\
M8P8$O,Q 2R^'O'6!YV7 "B@Z>'ZV'2:?;9;BU(O:]X_J&FSD51 -JS:WKIM(
MV)??:]ELZW!BI9+B#2@L'8_E^W9%:$CO+K6:J'89H[ &T! %H3IX:J"#>Q?S
M]E-LGFE\? *Y$&QJ[WZ/'C %J!-5#VEQ(M0( 7D;'NDP[+]0XK;1>:\JK,H*
MF_3>IDBH'! Z]L?,M2JNWKP==93)E5X[2\Y<]]]9@%+ZXXUVX[L5<4>+I-/M
MLX$OWF(;/N']0TV;:-?@PYMQY.7WKLNDU'K_ #9N6>N+]"4T:;.?:AIL:5%M
M_(+;:GRZ=(0O#?'NP0#6?-E*HTV+I;]=ATEW+%G/'?6"Q;%R^K)B^IB6V.0\
MM(:2K\=+RV+<Q7^RUVK+^:^?.'.1P_413HI7+K*URKKLUKK,>-Z2L\^L&JX0
M&O _F_G#RHG>^-_W9U=_]&QN^3.Y'];^O64WO?SWZR@W";Y7O<OMTK#3Q]TG
ML7ZF"M0*_DL -+QZ^L%MHX-QE'@/#U3^U.4Z]MR(HR5C3?MYU CD2\!@FB*O
MQ=)I]MJC3:\I;^H:;*#MIM]=JCU@!IL^RAIL47*)1I,EUG9W/-V:1!RQ!@!I
M#Q9H;\-A!UE'@@ZP**--CR^RI "42C)KLZN_^C8QQE$HB$I@!IL>Z3V+]0;%
MAQSOT@QMU-/7XE04'^??G+$NJ]>G2,T=*^?F$X5V&$N7+)9%Q%1[2Y9+)9+)
M<N62Y<O,PNYL'A+ERR62Y9+\+EQ;Q/<RY9X+EDLEDLEDLED5OM+)9+)9!\.-
MRY9+/!=S7R/W+)<LEDLEG@N7+ERQF([?R#<N7+ERY9+EDLED9YLLE\I9+/!9
M+EDLEDLE\IK?7^B62R7+EDOG+)<N62YGVX:P M4<I]&2E</RAJ?KCJ?KGT9.
M5[<I_C*_7*?Y$I_D1^CB4^.!6EFE$I]4I]<^K)3_ "(#_,E)'^42M_RE/JE/
M\R4_S( $L.')?Y*?7'Z*4^J/^61'URGU1^CFY$H_$2E_'$?Y$I?\R +@NAR'
M^ROURM_S)7_(E/\ ,E6GIDW,G,]N4?'*_P"9*?5,F?3@VM1R("OCE#7VY7I^
M4I_D2SXR4_S)]"2G^)*?5*_7$_7&K^9 /([='.I7_(E+_D2C_G*?7*?7*Z>V
M2NGMDI_F2G^9$?YDI]4HM8^Q"KRR^$YGIDK_ )$IP]N4^N?1DY7ID17QP_RR
M4_S)3_,GT9 !9@[864^N4_S(C_,E*^*'^&2OTRO'VY1^,E/KF#XY7_**?YR^
M*+#0Y'S*?YDW,E?KE#XR4_R)3_*?1DI_F2['MDI]<^KA7K2:HGMGZE1FGATF
M/ "4^&OA[1LUFI4J=./@;0!*E7IIX)LZC8%<I4X7M>W_ *;/6?J)4#9W/=VJ
MX&Q?AJ\R>P2MCAX5C9]T_;QOP,^+LX/<_6PK$KCPE)X5L/U<]B_4TRNE>2M>
MD"% UMU@OGK!.D)XZ#E=]LPMM0TYE%=ZF*5L)PTO;VF8$@I>!3&7KB%5UG:-
M['LFPFR"V]0X>>/U,(5D2DY/[7"5!B)%WH:/6%M=T'\?B@>B/LL)JN-](D$N
MK#V*TR.>\;9K*?8?=B75>6NQK.$@?%U@+&!H;&O/]0 &@\E9+GO@.<5=62NJ
M<N'D><;E5@=E^3"KU_W['L_Z;)0474>-Z/Y45UKI=ID[CYE^4:KWE;R7C/=Y
MRQ->=YRN//A!S'P-6_5V QM-0U=<W'33K+?0MKLM%2WCAOZFIU:<\P+YH:>L
M4548O5:=<YTCFUO]-C5YD]DV$5%IB+2K@J^3/K'[-":'(EUKCWX<8G5U7]-G
M.K=:4[!  3-(MUS63VN,4*O0JHU6IZZP:=%-")C37/MF>R/ULV\Q^HSXJ^HV
MEQHT.!O<5EH,EO55=$ Y:2[&[86[<-^[VT@C5YG2XZ:Z=>_DZO%FO-O8]_GM
MDJY[=6ZW?[C<%EV67O8GE ;4,Z=5=*Q HT;H[ML'"/8UN^_Z@P>-K^[L\H8-
M);U?.5L^W;%3KM>J:=DBU1;7E$>8K8]F)&D<91SKF[;XVMQPTBBB@QRPD, -
M [_O8QW&K9RZ=R7T:<G>XWGN9X:-:*<%(MS&]77F%U?/G @(G4,]%KV\2N,-
M?"#O,</!.-K^:0A:0K5,<FDLZ.(<M)7,TR6%#7"[F1*XZH6<:&KZU**):^!;
MEQ=9>DUAX>U_I'8"Z*KZ'W'@A2N*4Y0%H'D41 ,E&U<<BUHZ%$P)Q5F[8TS=
MXA:7IYJ_M?!T\#=[NQKAT@U853+8MN&[X\X/Y0I2O,1SQYRH#H*Q9CDU5G>*
MY!T!^G8U'?:2[4BW7+SB:&FGJ:1=51MX#3H-2]CW#]I?C<KJ6G5'.N1&GEI
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MM8)ZAP+?EB9=K^I7B^-[&GA[)MNSO'5+_#7AIG;0KPO8TW3^FS5S2&R3]/\
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M'BD4$Y>(5PPGK-32[ M#3%464Z056PM7&R>]7$!FXOS>^-#UES8IF#12^O\
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M$^LGU!/JI]43ZG_8_P"9_L%:-K6-6O\ )];/J"?73ZB?4?[/KI]=/K#YG+]
MG&]@GUDNQ[)'.:ZL=)]9/K9]7_L^LE>OH$^DGUA/K"5_!/K"?6$*P2N)"O\
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MJ>&><KPKPP<(-[#,U]91L]9<OPKP'I>#F5L,X2B4E> ^U^_!+@5*ACP94X5
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M04AD4(C2(XE>+AF"\3?.T3:[PUIX,-% ;PD%I<%:&*:B\39J7<$FQ2<*@8L
M6B4JKAUJ01,-C3F%*K5MW/(J@5[(,4P+@34(S5C*0YHX JI0"/UO*8"BB\J+
M'-'.YCK. R7@*50*)<OP;F_^?QM,U+6E-!L\"#1CR,R_ J3@5F@LR^4.2V-P
MQUJZ4('EU7)/&D9FP2)F,8#5 JG9T0)=15UL]=IJ0#>@,5<(\O%$82I:H%H
MP7*OM%3PPK'AJ=XARRU>,KRKPJX!!%!1H )!WF6M$C3 7$;0F-TB, 511@]#
M4':8:=.640E8H4J"K.0P0L-*'IM3U+!:E*"T@<_"]'J?N>U2#GKX50F@-BP&
M9[5"4/<HZP2**68EV3+G**R&=6ME%>"8D4,Z4,:,%<$8"Z*5N C4PU5U2C"9
M,JW"K34%+\)#HN$T,XP44<8V+IXLT'B=1:HLSH^A/9S5A]@L2KC(A5Y J/\
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M']DKP&IQN*]YJ>'67*QB:QJ_/3O$%+CW.<2;,NAKSA>G7D'Z/ ('")4]L_;
MN9=8G*=YMUUEF[Q]M+XM<+C45L-WB[-%QE[W,6NK?GOY2FRS+>0<O<EVS*3M
M+^6_<<!"_!YPU/89]8_$^N9]8SZQ^(IQZ#\1_P QGU3'3*.S/I&<OT'XF/\
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MJ7Z>$53D)R/6GV?^033PFYWA7R)L8_V_\A_O>!V3U(L:]6<GPG>B=_ _MO\
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M%W=@VOK3@'K3[*?91)QZTP7[T^R9]M/MH<*+YS[J6:^M.9ZT^^GV43Q[T?\
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M17??J ?'\)N7PFY_"5;K]2W+W=)???R.YOY.Y[N4P]/K\0@%;U^)O_P@[O\
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
